Search by Patent Identification
Patent | Data | Compounds | HGNC (for human-derived proteins) | Patent Title | Organization | Deposition | Downloads |
---|---|---|---|---|---|---|---|
US11028054 | 35 | 35 | HGNC:2867 | 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | Merck Patent GmbH | 11/29/21 | 2D 3D TSV |
US11021493 | 720 | 180 | HGNC:934 HGNC:2529 HGNC:933 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | Amgen Inc. | 11/29/21 | 2D 3D TSV |
US11026923 | 606 | 195 | HGNC:8775 HGNC:8774 HGNC:8776 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. Lundbeck A/S | 11/29/21 | 2D 3D TSV |
US11028101 | 3 | 3 | HGNC:10894 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD | 11/29/21 | 2D 3D TSV |
US11028093 | 867 | 209 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC.; CELGENE CORPORATION | 11/29/21 | 2D 3D TSV |
US11021475 | 37 | 37 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | Bristol-Myers Squibb Company | 11/29/21 | 2D 3D TSV | |
US11021511 | 20 | 6 | Cyclic dinucleotides as sting agonists | Janssen Biotech, Inc. | 11/29/21 | 2D 3D TSV | |
US11028083 | 163 | 148 | HGNC:23393 HGNC:18241 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | Board of Regents, The University of Texas System | 11/29/21 | 2D 3D TSV |
US11026937 | 134 | 134 | HGNC:18368 | Heteroaryl inhibitors of PAD4 | Padlock Therapeutics, Inc. | 11/29/21 | 2D 3D TSV |
US11028067 | 15 | 8 | HGNC:12437 HGNC:4623 | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | Oblique Therapeutics AB | 11/29/21 | 2D 3D TSV |
US11028058 | 12 | 12 | HGNC:263 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. | 11/29/21 | 2D 3D TSV |
US11021478 | 24 | 24 | HGNC:1232 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL | 11/29/21 | 2D 3D TSV |
US11028066 | 97 | 97 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research, Inc. | 11/29/21 | 2D 3D TSV |
US11021467 | 405 | 135 | HGNC:8978 HGNC:8980 HGNC:8977 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences, Inc. | 11/29/21 | 2D 3D TSV |
US11026936 | 57 | 34 | HGNC:8810 | Piperidinyl-propanone derivatives | Merck Patent GmbH | 11/29/21 | 2D 3D TSV |
US11028041 | 36 | 18 | HGNC:5253 | Second generation GRP94-selective inhibitors | University of Kansas | 11/29/21 | 2D 3D TSV |
US11026958 | 41 | 41 | HGNC:1960 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | Merck Sharp & Dohme Corp. | 11/29/21 | 2D 3D TSV |
US11021481 | 837 | 837 | HGNC:6863 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. | 11/29/21 | 2D 3D TSV |
US11028085 | 837 | 823 | HGNC:6863 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | Nimbus Saturn, Inc. | 11/29/21 | 2D 3D TSV |
US11028092 | 124 | 60 | HGNC:8795 | Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors | Merck Sharp & Dohme Corp. | 11/29/21 | 2D 3D TSV |
US11028080 | 44 | 44 | Substituted pyrimidines as LRKK2 inhibitors | DENALI THERAPEUTICS INC. | 11/29/21 | 2D 3D TSV | |
US11028051 | 14 | 7 | Tetrahydroquinoline-based bromodomain inhibitors | St. Jude Children''s Research Hospital | 11/29/21 | 2D 3D TSV | |
US11028075 | 182 | 92 | HGNC:10597 | Therapeutic compounds and methods of use thereof | Genentech, Inc. | 11/29/21 | 2D 3D TSV |
US11021463 | 202 | 145 | HGNC:6371 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. | 11/29/21 | 2D 3D TSV |
US11021515 | 404 | 207 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. | 11/29/21 | 2D 3D TSV | |
US11028064 | 146 | 76 | HGNC:6307 | Tricyclic heterocyclic derivatives and uses thereof | AUCKLAND UNISERVICES LIMITED | 11/29/21 | 2D 3D TSV |
US11028104 | 83 | 42 | HGNC:12008 HGNC:20692 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN; FORSCHUNGSVERBUND BERLIN E.V. | 11/29/21 | 2D 3D TSV |
US11028090 | 505 | 504 | HGNC:13575 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | Dong Wha Pharm. Co., Ltd.; Korea Research Institute of Chemical Technology | 11/29/21 | 2D 3D TSV |
US11020398 | 376 | 303 | HGNC:1133 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ArQule, Inc. | 11/28/21 | 2D 3D TSV |
US11020381 | 174 | 169 | HGNC:10597 | Biaryloxy derivatives as TTX-S blockers | RaQualia Pharma Inc.; XuanZhu Pharma Co., Ltd. | 11/28/21 | 2D 3D TSV |
US11021457 | 150 | 150 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD. | 11/28/21 | 2D 3D TSV | |
US11020397 | 70 | 44 | HGNC:12805 HGNC:17989 | Compounds and their use for reducing uric acid levels | Acquist LLC | 11/28/21 | 2D 3D TSV |
US11020395 | 154 | 154 | HGNC:339 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. | 11/28/21 | 2D 3D TSV |
US11020380 | 410 | 396 | HGNC:2348 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. | 11/28/21 | 2D 3D TSV |
US11021454 | 44 | 27 | HGNC:12805 | Type of aryl benzofuran amidated derivative and medical use thereof | CHINA PHARMACEUTICAL UNIVERSITY | 11/28/21 | 2D 3D TSV |
US11014905 | 114 | 36 | HGNC:3023 HGNC:5286 | 2,6-disubstituted pyridine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. | 11/22/21 | 2D 3D TSV |
US11014923 | 152 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 11/22/21 | 2D 3D TSV |
US11014911 | 1035 | 649 | HGNC:1780 HGNC:1771 HGNC:4617 HGNC:1777 HGNC:1722 HGNC:1773 | CDK2 inhibitors | Pfizer Inc. | 11/22/21 | 2D 3D TSV |
US11014912 | 68 | 68 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED | 11/22/21 | 2D 3D TSV | |
US11014920 | 36 | 36 | HGNC:3530 | Factor XIIa inhibitors | Merck Sharp & Dohme Corp. | 11/22/21 | 2D 3D TSV |
US11014930 | 78 | 78 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 11/22/21 | 2D 3D TSV |
US11014909 | 81 | 72 | HGNC:3020 | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc. | 11/22/21 | 2D 3D TSV |
US11013718 | 9 | 9 | HGNC:29079 | LSD1 inhibitors and medical uses thereof | Constellation Pharmaceuticals, Inc. | 11/22/21 | 2D 3D TSV |
US11014929 | 126 | 126 | HGNC:6863 | Pyrazolopyrimidine compounds and uses thereof | Incyte Corporation | 11/22/21 | 2D 3D TSV |
US11014913 | 855 | 800 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics, Inc. | 11/22/21 | 2D 3D TSV | |
US11014926 | 35 | 30 | HGNC:7110 HGNC:7111 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | eFFECTOR Therapeutics, Inc. | 11/22/21 | 2D 3D TSV |
US11013745 | 80 | 80 | Triazolopyrimidine, triazolopyridine compounds, and the composition thereof for treating PRC2-mediated diseases | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES; SUZHOU SUPLEAD LIFE SCIENCES CO., LTD. | 11/22/21 | 2D 3D TSV | |
US11014963 | 205 | 205 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | Hoffmann-La Roche Inc. | 11/22/21 | 2D 3D TSV | |
US11008338 | 48 | 25 | HGNC:934 HGNC:933 | C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp. | 11/15/21 | 2D 3D TSV |
US11008314 | 623 | 156 | HGNC:1133 HGNC:6193 HGNC:6171 HGNC:12434 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | Corvus Pharmaceuticals, Inc. | 11/15/21 | 2D 3D TSV |
US11008336 | 22 | 8 | HGNC:10259 HGNC:10258 | Compounds useful for inhibiting RORγt | Eli Lilly and Company | 11/15/21 | 2D 3D TSV |
US11007200 | 16 | 8 | HGNC:8157 | Cycloalkyl-diamines for the treatment of pain | MediSynergics, LLC | 11/14/21 | 2D 3D TSV |
US11008301 | 42 | 21 | HGNC:3827 HGNC:3826 | Piperidinone formyl peptide 2 receptor agonists | Bristol-Myers Squibb Company | 11/14/21 | 2D 3D TSV |
US11008312 | 373 | 372 | Pyridazine derivatives as RORc modulators | Genentech, Inc. | 11/14/21 | 2D 3D TSV | |
US11008308 | 435 | 425 | HGNC:29232 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. | 11/14/21 | 2D 3D TSV |
US11008304 | 85 | 85 | HGNC:6857 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 11/14/21 | 2D 3D TSV |
US11000525 | 30 | 15 | HGNC:7218 HGNC:12015 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | ASTRAZENECA AB | 11/08/21 | 2D 3D TSV |
US11001596 | 70 | 14 | HGNC:5383 HGNC:5382 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | Eli Lilly and Company | 11/08/21 | 2D 3D TSV |
US11001586 | 178 | 89 | HGNC:7027 HGNC:12446 | Alkyl pyrrolopyrimidine analogs and methods of making and using same | The University of North Carolina at Chapel Hill | 11/08/21 | 2D 3D TSV |
USRE48547 | 6 | 6 | HGNC:6027 | Aminopyrimidinecarboxamides as CXCR2 modulators | Syntrix Biosystems Inc. | 11/08/21 | 2D 3D TSV |
US11001575 | 923 | 900 | HGNC:6871 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. | 11/08/21 | 2D 3D TSV |
US11000528 | 26 | 11 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV | 11/08/21 | 2D 3D TSV | |
US10995099 | 93 | 65 | HGNC:85 HGNC:84 | Compounds and their uses as ACC inhibitors | Nanjing Ruijie Pharmatech Co., Ltd. | 11/08/21 | 2D 3D TSV |
US11000515 | 25 | 25 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | Shy Therapeutics LLC | 11/08/21 | 2D 3D TSV | |
US11001555 | 22 | 22 | Difluoroketamide derivatives as HTRA1 inhibitors | Hoffman-La Roche Inc. | 11/08/21 | 2D 3D TSV | |
US11001583 | 16 | 16 | Dihydropyrrolopyridine inhibitors of ROR-gamma | Vitae Pharmaceuticals, LLC | 11/08/21 | 2D 3D TSV | |
US11001600 | 13 | 13 | HGNC:2771 | Disubstituted compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. | 11/08/21 | 2D 3D TSV |
US11001568 | 170 | 44 | HGNC:29012 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. | 11/08/21 | 2D 3D TSV |
US11001578 | 188 | 92 | HGNC:6371 HGNC:6357 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED | 11/08/21 | 2D 3D TSV |
US11001589 | 51 | 51 | HGNC:3650 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB | 11/08/21 | 2D 3D TSV |
US11001595 | 32 | 14 | HGNC:3763 HGNC:2861 HGNC:6307 HGNC:8804 HGNC:3236 | Pyrimidine compounds and pyrimido indole compounds and methods of use | Duquesne University of The Holy Spirit | 11/08/21 | 2D 3D TSV |
US11001572 | 40 | 10 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pyrimidine derivative, method for preparing same and use thereof in medicine | TBA | 11/08/21 | 2D 3D TSV |
US11001561 | 146 | 146 | HGNC:9644 | Pyrimidinone derivatives as SHP2 antagonists | Merck Patent GmbH | 11/08/21 | 2D 3D TSV |
US11001563 | 81 | 81 | HGNC:550 | SSAO inhibitor | TBA | 11/08/21 | 2D 3D TSV |
US10995070 | 15 | 15 | HGNC:84 | Acetyl-CoA carboxylase modulators | Monsanto Technology LLC | 11/04/21 | 2D 3D TSV |
US10994015 | 521 | 108 | HGNC:3430 HGNC:3431 HGNC:3236 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC.; YALE UNIVERSITY | 11/04/21 | 2D 3D TSV |
US10995072 | 124 | 57 | HGNC:3538 | Inhibitors of protease-activated receptor-2 | Heptares Therapeutics Limited | 11/04/21 | 2D 3D TSV |
US10995088 | 309 | 162 | HGNC:6833 HGNC:6834 HGNC:2671 HGNC:6664 HGNC:6666 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL | 11/04/21 | 2D 3D TSV |
US10995073 | 253 | 218 | HGNC:8605 HGNC:270 | PARG inhibitory compounds | Cancer Research Technology Limited | 11/04/21 | 2D 3D TSV |
US10995084 | 192 | 116 | HGNC:16709 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. | 11/04/21 | 2D 3D TSV |
US10995090 | 21 | 19 | HGNC:7056 | Substituted dihydrobenzofuran glycosidase inhibitors | Asceneuron SA | 11/04/21 | 2D 3D TSV |
US10995089 | 92 | 92 | HGNC:6871 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE DE MONTPELLIER | 11/04/21 | 2D 3D TSV |
US10988455 | 108 | 53 | HGNC:262 HGNC:263 | 1,2,4-triazine-4-amine derivatives | Heptares Therapeutics Limited | 11/01/21 | 2D 3D TSV |
US10988502 | 64 | 32 | HGNC:6561 HGNC:6563 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB | 11/01/21 | 2D 3D TSV |
US10988458 | 71 | 70 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 11/01/21 | 2D 3D TSV |
US10988459 | 91 | 77 | Bicyclic lactams and methods of use thereof | Genentech, Inc. | 11/01/21 | 2D 3D TSV | |
US10988445 | 310 | 136 | Compounds | AstraZeneca AB | 11/01/21 | 2D 3D TSV | |
US10988482 | 108 | 99 | HGNC:17967 | IRAK4 inhibitor and use thereof | BEIJING HANMI PHARMACEUTICAL CO., LTD. | 11/01/21 | 2D 3D TSV |
US10988507 | 2 | 2 | Immunomodulators | bristol-myers squibb company | 11/01/21 | 2D 3D TSV | |
US10987354 | 24 | 23 | Inhibitors of influenza virus replication and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. | 11/01/21 | 2D 3D TSV | |
US10988451 | 457 | 440 | MCL-1 inhibitors | Gilead Sciences, Inc. | 11/01/21 | 2D 3D TSV | |
US10988481 | 66 | 20 | HGNC:8153 HGNC:8154 HGNC:8156 | Potent and selective mu opioid receptor modulators | Virginia Commonwealth University | 11/01/21 | 2D 3D TSV |
US10988462 | 37 | 37 | HGNC:11036 | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof | Japan Tobacco Inc. | 11/01/21 | 2D 3D TSV |
US10988478 | 551 | 532 | HGNC:17967 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | Genentech, Inc. | 11/01/21 | 2D 3D TSV |
US10988463 | 79 | 55 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | Pfizer Inc. | 11/01/21 | 2D 3D TSV | |
US10988487 | 242 | 204 | HGNC:6059 | Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | Merck Sharp & Dohme Corp. | 11/01/21 | 2D 3D TSV |
US10988476 | 635 | 140 | HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:1777 HGNC:1774 HGNC:1773 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. | 11/01/21 | 2D 3D TSV |
US10981917 | 230 | 229 | HGNC:9462 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | Daewoong Pharmaceutical Co., Ltd. | 10/27/21 | 2D 3D TSV |
US10981916 | 25 | 25 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC | 10/27/21 | 2D 3D TSV | |
US10981926 | 3 | 1 | HGNC:7978 HGNC:644 | Substituted thiohydantoin derivatives as androgen receptor antagonists | Janssen Pharmaceutica NV | 10/27/21 | 2D 3D TSV |
US10981914 | 16 | 11 | HGNC:15631 HGNC:6018 | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Companay | 10/27/21 | 2D 3D TSV |
US10981904 | 67 | 61 | 1,3,4-thiadiazole compounds and their use in treating cancer | Cancer Research Technology Limited | 10/26/21 | 2D 3D TSV | |
US10980781 | 21 | 18 | HGNC:12630 | 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use | Purdue Research Foundation | 10/26/21 | 2D 3D TSV |
US10980815 | 468 | 113 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Aminopyrimidinyl compounds | Pfizer Inc. | 10/26/21 | 2D 3D TSV |
US10981887 | 50 | 25 | HGNC:3467 | Benzothiophene estrogen receptor modulators | G1 Therapeutics, Inc. | 10/26/21 | 2D 3D TSV |
US10981910 | 237 | 236 | HGNC:19679 | Biaryl kinase inhibitors | Bristol-Myers Squibb Company | 10/26/21 | 2D 3D TSV |
US10981882 | 19 | 19 | HGNC:6059 | Compound for inhibiting IDO, a manufacturing method and a use thereof | Shanghai JOYU Pharmatech Ltd. | 10/26/21 | 2D 3D TSV |
US10981881 | 16 | 8 | HGNC:7967 | FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. | 10/26/21 | 2D 3D TSV |
US10981905 | 154 | 49 | HGNC:10593 HGNC:10585 HGNC:10596 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 10/26/21 | 2D 3D TSV |
US10981911 | 840 | 210 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | Janssen Pharmaceutica NV | 10/26/21 | 2D 3D TSV | |
US10981896 | 43 | 22 | HGNC:16870 HGNC:1925 HGNC:1470 HGNC:9377 HGNC:14311 HGNC:6871 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 10/26/21 | 2D 3D TSV |
US10981899 | 9 | 5 | HGNC:21285 | Inhibitors of soluble adenylyl cyclase | Cornell University; Tri-Institutional Therapeutics Discovery Institute | 10/26/21 | 2D 3D TSV |
US10981898 | 89 | 85 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED | 10/26/21 | 2D 3D TSV | |
US10980794 | 334 | 329 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. | 10/26/21 | 2D 3D TSV | |
US10981906 | 110 | 51 | HGNC:6190 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. | 10/26/21 | 2D 3D TSV |
US10981893 | 35 | 30 | HGNC:6371 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. | 10/26/21 | 2D 3D TSV |
US10981879 | 189 | 164 | HGNC:7218 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | Bristol-Myers Squibb Company | 10/26/21 | 2D 3D TSV |
US10980809 | 132 | 95 | HGNC:6307 HGNC:9829 HGNC:1097 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED | 10/26/21 | 2D 3D TSV |
US10975062 | 135 | 135 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | TBA | 10/20/21 | 2D 3D TSV | |
US10975057 | 94 | 92 | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT | Janssen Pharmaceutica NV | 10/20/21 | 2D 3D TSV | |
US10975068 | 453 | 441 | 6-aminopyridin-3-yl thiazoles as modulators of RORγT | Janssen Pharmaceutica NV | 10/20/21 | 2D 3D TSV | |
US10975066 | 25 | 25 | HGNC:11138 | Bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL | 10/20/21 | 2D 3D TSV |
US10975080 | 72 | 71 | HGNC:9644 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG | 10/20/21 | 2D 3D TSV |
US10975030 | 28 | 28 | HGNC:5253 | Grp94 selective inhibitors and uses thereof | University of Kansas; University of South Florida | 10/20/21 | 2D 3D TSV |
US10975075 | 471 | 134 | HGNC:8978 HGNC:795 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | Merck Patent GmbH | 10/20/21 | 2D 3D TSV |
US10975058 | 8 | 4 | HGNC:4840 HGNC:1133 | Imidazolyl kinase inhibitors and uses thereof | Dana-Farber Cancer Institute, Inc. | 10/20/21 | 2D 3D TSV |
US10975084 | 185 | 185 | HGNC:18039 | KDM5 inhibitors | Merck Sharp & Dohme Corp. | 10/20/21 | 2D 3D TSV |
US10975049 | 22 | 22 | Nicotinyl alcohol ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof | Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD | 10/20/21 | 2D 3D TSV | |
US10973817 | 147 | 146 | HGNC:1925 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED | 10/20/21 | 2D 3D TSV |
US10975037 | 228 | 225 | Phenyl substituted pyrazoles as modulators of RORγt | Janssen Pharmaceutica NV | 10/20/21 | 2D 3D TSV | |
US10975091 | 290 | 150 | HGNC:6656 | Pyridine derivative | Astellas Pharma Inc.; KOTOBUKI PHARMACEUTICAL CO., LTD. | 10/20/21 | 2D 3D TSV |
US10975064 | 27 | 27 | RIP1 inhibitory compounds and methods for making and using the same | Rigel Pharmaceuticals, Inc. | 10/20/21 | 2D 3D TSV | |
US10975081 | 18 | 16 | HGNC:18618 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 10/20/21 | 2D 3D TSV |
US10975056 | 659 | 645 | HGNC:2976 | Substituted pyridines as inhibitors of DNMT1 | GlaxoSmithKline Intellectual Property Development Limited; Cancer Research Technology Ltd. | 10/20/21 | 2D 3D TSV |
US10968216 | 332 | 297 | HGNC:2867 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; THE BROAD INSTITUTE, INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION | 10/09/21 | 2D 3D TSV |
US10968163 | 97 | 34 | HGNC:3560 HGNC:3557 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | The Research Foundation for the State University of New York | 10/09/21 | 2D 3D TSV |
US10968188 | 153 | 114 | HGNC:8803 HGNC:76 HGNC:6342 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1st Biotherapeutics, Inc. | 10/09/21 | 2D 3D TSV |
US10968198 | 35 | 35 | HGNC:7097 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | Yale University | 10/09/21 | 2D 3D TSV |
US10968199 | 30 | 29 | HGNC:6857 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 10/09/21 | 2D 3D TSV |
US10968242 | 106 | 35 | Cyclopentane-based modulators of STING (stimulator of interferon genes) | Pfizer Inc. | 10/09/21 | 2D 3D TSV | |
US10968213 | 375 | 107 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Company Limited | 10/09/21 | 2D 3D TSV |
US10968223 | 155 | 155 | HGNC:550 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | Proximagen, LLC | 10/09/21 | 2D 3D TSV |
US10968227 | 45 | 45 | HGNC:4596 | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | Vanderbilt University | 10/09/21 | 2D 3D TSV |
US10966985 | 52 | 13 | HGNC:10261 | Macrocyclic compounds as ROS1 kinase inhibitors | Array BioPharma Inc. | 10/09/21 | 2D 3D TSV |
US10968215 | 227 | 189 | HGNC:3527 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 10/09/21 | 2D 3D TSV |
US10966980 | 1100 | 273 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrrolo[2,3-d]pyrimidine derivatives | Pfizer Inc. | 10/09/21 | 2D 3D TSV |
US10968221 | 13 | 13 | HGNC:29079 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors | Incyte Corporation | 10/09/21 | 2D 3D TSV |
US10967060 | 22 | 22 | HGNC:6059 | Synergistic combination of immunologic inhibitors for the treatment of cancer | The University of Chicago | 10/09/21 | 2D 3D TSV |
US10968236 | 184 | 91 | HGNC:6192 HGNC:12440 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 10/09/21 | 2D 3D TSV |
US10966987 | 23 | 23 | HGNC:6307 | Therapeutic compounds and uses thereof | Kala Pharmaceuticals, Inc. | 10/09/21 | 2D 3D TSV |
US10968172 | 90 | 90 | USP30 inhibitors | Mitobridge, Inc. | 10/09/21 | 2D 3D TSV | |
US10961236 | 249 | 63 | HGNC:8975 HGNC:8977 HGNC:8976 | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor | AstraZeneca AB | 10/04/21 | 2D 3D TSV |
US10961241 | 73 | 66 | Chemical compounds | AstraZeneca AB | 10/04/21 | 2D 3D TSV | |
US10961242 | 81 | 80 | HGNC:3357 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LegoChem Biosciences, Inc. | 10/04/21 | 2D 3D TSV |
US10961198 | 66 | 66 | HGNC:7967 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. | 10/04/21 | 2D 3D TSV |
US10961237 | 146 | 145 | HGNC:1133 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. | 10/04/21 | 2D 3D TSV |
US10961228 | 198 | 66 | JAK1 selective inhibitors | ASTRAZENECA AB | 10/04/21 | 2D 3D TSV | |
US10961249 | 21 | 21 | Modulators of the sigma-2 receptor and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 10/04/21 | 2D 3D TSV | |
US10961233 | 46 | 45 | Oxazole derivatives for use in the treatment of cancer | LIFEARC | 10/04/21 | 2D 3D TSV | |
US10961256 | 3 | 3 | HGNC:10894 | PRMT5 inhibitors | CTXT PTY LTD | 10/04/21 | 2D 3D TSV |
US10961247 | 365 | 180 | HGNC:1133 HGNC:6193 | Pyrazolopyrimidine derivatives as kinase inhibitor | Daewoong Pharmaceutical Co., Ltd. | 10/04/21 | 2D 3D TSV |
US10961252 | 34 | 34 | HGNC:1037 | Quinazoline and indole compounds to treat medical disorders | Achillion Pharmaceuticals, Inc. | 10/04/21 | 2D 3D TSV |
US10961200 | 522 | 512 | HGNC:6535 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; VANDERBILT UNIVERSITY; THE UAB RESEARCH FOUNDATION; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 10/04/21 | 2D 3D TSV |
US10961232 | 603 | 569 | HGNC:882 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 10/04/21 | 2D 3D TSV |
US10960005 | 122 | 119 | HGNC:29079 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. | 10/04/21 | 2D 3D TSV |
US10954228 | 149 | 145 | HGNC:6535 | 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE UAB RESEARCH FOUNDATION; VANDERBILT UNIVERSITY; NATIONAL INSTITUTES OF HEALTH, UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES | 09/28/21 | 2D 3D TSV |
US10954253 | 76 | 75 | HGNC:12761 | 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor | SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD. | 09/28/21 | 2D 3D TSV |
US10952995 | 27 | 27 | HGNC:6863 | Azaindoles as inhibitors of HPK1 | Genentech, Inc. | 09/28/21 | 2D 3D TSV |
US10954216 | 119 | 90 | HGNC:171 | BMP-signal-inhibiting compound | RIKEN; THE UNIVERSITY OF TOKYO | 09/28/21 | 2D 3D TSV |
US10954244 | 11 | 11 | HGNC:6307 | Compounds and uses thereof | Kala Pharmaceuticals, Inc. | 09/28/21 | 2D 3D TSV |
US10954240 | 60 | 60 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | Merck Sharp & Dohme Corp. | 09/28/21 | 2D 3D TSV | |
US10954241 | 320 | 108 | HGNC:6307 HGNC:9967 | Heterocyclic compounds as ret kinase inhibitors | Cancer Research Technology Limited | 09/28/21 | 2D 3D TSV |
US10953012 | 420 | 239 | HGNC:2459 | Heterocyclic compounds for the inhibition of pask | BioEnergenix LLC | 09/28/21 | 2D 3D TSV |
US10954237 | 56 | 19 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK inhibitors containing a 4-membered heterocyclic amide | Theravance Biopharma R&D IP, LLC | 09/28/21 | 2D 3D TSV |
US10947254 | 1048 | 261 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | Theravance Biopharma R&D IP, LLC | 09/28/21 | 2D 3D TSV |
US10952992 | 100 | 97 | HGNC:9665 | Methods of treating intraocular pressure with activators of Tie-2 | AERPIO PHARMACEUTICALS, INC. | 09/28/21 | 2D 3D TSV |
US10954214 | 449 | 444 | HGNC:6819 | Pyrazole derivatives as MALT1 inhibitors | Janssen Pharmaceutica NV | 09/28/21 | 2D 3D TSV |
US10954225 | 28 | 15 | Selective NR2B antagonists | Bristol-Myers Squibb Company | 09/28/21 | 2D 3D TSV | |
US10954217 | 86 | 43 | HGNC:8157 | Sigma receptor binders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 09/28/21 | 2D 3D TSV |
US10954243 | 22 | 22 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. | 09/28/21 | 2D 3D TSV | |
US10954193 | 147 | 134 | HGNC:6943 HGNC:992 HGNC:990 | Substituted indole Mcl-1 inhibitors | Vanderbilt University | 09/28/21 | 2D 3D TSV |
US10953005 | 1229 | 556 | HGNC:9967 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array Biopharma Inc. | 09/28/21 | 2D 3D TSV |
US10947203 | 176 | 88 | HGNC:7968 | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor | ST. JUDE CHILDREN''S RSEARCH HOSPITAL | 09/26/21 | 2D 3D TSV |
US10947218 | 616 | 87 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG | 09/26/21 | 2D 3D TSV | |
US10947196 | 8 | 4 | HGNC:285 HGNC:286 | Beta adrenergic agonist and methods of using the same | CuraSen Therapeutics, Inc. | 09/26/21 | 2D 3D TSV |
US10947230 | 162 | 54 | HGNC:3690 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR inhibitors | Incyte Corporation; Incyte Holdings Corporation | 09/26/21 | 2D 3D TSV |
US10947226 | 23 | 23 | Bicyclic pyridone lactams and methods of use thereof | Genentech, Inc. | 09/26/21 | 2D 3D TSV | |
US10945994 | 17 | 3 | HGNC:11708 HGNC:6059 | Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body | Pfizer Inc.; iTEOS THERAPEUTICS | 09/26/21 | 2D 3D TSV |
US10947229 | 48 | 12 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Dimethyl amino azetidine amides as JAK inhibitors | Theravance Biopharma R&D IP, LLC | 09/26/21 | 2D 3D TSV |
US10947243 | 391 | 79 | HGNC:11390 HGNC:4617 HGNC:3765 | Heteroaryl SYK inhibitors | Boehringer Ingelheim International GmbH | 09/26/21 | 2D 3D TSV |
US10947215 | 458 | 449 | Heteroaryl compounds and their use as therapeutic drugs | Dong-A Socio Holdings Co., Ltd. | 09/26/21 | 2D 3D TSV | |
US10947222 | 72 | 72 | HGNC:16940 | Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | Merck Sharp & Dohme Corp. | 09/26/21 | 2D 3D TSV |
US10947210 | 164 | 135 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. | 09/26/21 | 2D 3D TSV | |
US10947252 | 558 | 547 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | Janssen Pharmaceutica NV | 09/26/21 | 2D 3D TSV | |
US10946019 | 33 | 33 | HGNC:10477 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | TBA | 09/26/21 | 2D 3D TSV |
US10947234 | 36 | 12 | HGNC:10894 | PRMT5 inhibitors | Merck Sharp & Dohme Corp. | 09/26/21 | 2D 3D TSV |
US10947241 | 26 | 26 | Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same | Seoul National University Hospital | 09/26/21 | 2D 3D TSV | |
US10947223 | 72 | 18 | HGNC:2529 HGNC:933 | Substituted oxazines as beta-secretase inhibitors | Amgen Inc. | 09/26/21 | 2D 3D TSV |
US10946017 | 22 | 11 | HGNC:11584 | Tank-binding kinase-1 PROTACs and associated methods of use | ARVINAS OPERATIONS, INC. | 09/26/21 | 2D 3D TSV |
US10947251 | 76 | 38 | HGNC:10597 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. | 09/26/21 | 2D 3D TSV |
US10946023 | 1073 | 391 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. | 09/26/21 | 2D 3D TSV | |
US10945978 | 12 | 6 | HGNC:7966 HGNC:7965 | Treatment and diagnosis of melanoma | The Rockefeller University | 09/26/21 | 2D 3D TSV |
US10947239 | 8 | 1 | HGNC:8778 | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound | Janssen Pharmaceutica NV | 09/26/21 | 2D 3D TSV |
US10941129 | 26 | 26 | Benzyl phenyl ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof | Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD | 09/20/21 | 2D 3D TSV | |
US10941160 | 505 | 499 | HGNC:13575 | Bromodomain inhibitors | Celgene Quanticel Research, Inc. | 09/20/21 | 2D 3D TSV |
US10941151 | 50 | 29 | HGNC:11526 HGNC:11527 HGNC:11528 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | Ogeda SA | 09/20/21 | 2D 3D TSV |
US10940139 | 25 | 25 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | Shy Therapeutics LLC | 09/20/21 | 2D 3D TSV | |
US10941162 | 32 | 8 | HGNC:8978 HGNC:8980 HGNC:8975 HGNC:8977 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. | 09/20/21 | 2D 3D TSV |
US10941115 | 196 | 72 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6524 HGNC:6876 | Kinase inhibitors | Oxular Acquisitions Limited | 09/20/21 | 2D 3D TSV |
US10941146 | 31 | 31 | Methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC.; CORNELL UNIVERSITY | 09/20/21 | 2D 3D TSV | |
US10941138 | 193 | 88 | HGNC:1399 | Quinoline and isoquinoline derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. | 09/20/21 | 2D 3D TSV |
US10934296 | 665 | 131 | HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | Merck Sharp & Dohme B.V. | 09/12/21 | 2D 3D TSV |
US10934297 | 286 | 143 | HGNC:4617 HGNC:3091 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | Samumed, LLC | 09/12/21 | 2D 3D TSV |
US10934303 | 124 | 28 | HGNC:3474 HGNC:3473 HGNC:3471 HGNC:3467 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION; KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL; KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION | 09/12/21 | 2D 3D TSV |
US10933063 | 258 | 214 | HGNC:6735 HGNC:1133 HGNC:6171 HGNC:11719 HGNC:3236 HGNC:6524 | Bruton's tyrosine kinase inhibitors | Suzhou Baijibugong Pharmaceutical Technology Co., Ltd. | 09/12/21 | 2D 3D TSV |
US10934285 | 61 | 61 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG | 09/12/21 | 2D 3D TSV | |
US10934310 | 484 | 472 | HGNC:1133 | Inhibitors of Bruton's tyrosine kinase and method of their use | Janssen Pharmaceutica NV | 09/12/21 | 2D 3D TSV |
US10934288 | 241 | 236 | HGNC:6863 | Pyrazolopyridine compounds and uses thereof | Incyte Corporation | 09/12/21 | 2D 3D TSV |
US10934305 | 54 | 32 | HGNC:10852 HGNC:10850 | SHMT inhibitors | The Trustees of Princeton University | 09/12/21 | 2D 3D TSV |
US10934302 | 294 | 288 | SHP2 phosphatase inhibitors and methods of use thereof | Relay Therapeutics, Inc. | 09/12/21 | 2D 3D TSV | |
US10934304 | 88 | 87 | HGNC:6871 | Spirocyclic compounds | Recurium IP Holdings, LLC | 09/12/21 | 2D 3D TSV |
US10934294 | 124 | 60 | Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors | Merck Sharp & Dohme Corp. | 09/12/21 | 2D 3D TSV | |
US10927106 | 45 | 44 | HGNC:3091 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS | 09/06/21 | 2D 3D TSV |
US10927120 | 50 | 45 | HGNC:1771 HGNC:1773 | CDK inhibitors | GI Therapeutics, Inc. | 09/06/21 | 2D 3D TSV |
US10927110 | 31 | 31 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED | 09/06/21 | 2D 3D TSV | |
US10927076 | 96 | 48 | HGNC:5258 HGNC:5253 | HSP90B N-terminal isoform-selective inhibitors | University of Kansas | 09/06/21 | 2D 3D TSV |
US10927111 | 79 | 62 | HGNC:9829 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. | 09/06/21 | 2D 3D TSV |
US10927079 | 74 | 69 | HGNC:8031 | Intermediate compound of novel tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. | 09/06/21 | 2D 3D TSV |
US10927123 | 36 | 35 | HGNC:288 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | Arena Pharmaceuticals, Inc. | 09/06/21 | 2D 3D TSV |
US10927128 | 113 | 112 | HGNC:575 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. | 09/06/21 | 2D 3D TSV |
US10927105 | 323 | 248 | HGNC:17038 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 09/06/21 | 2D 3D TSV |
US10927086 | 86 | 48 | HGNC:6059 | Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | Merck Sharp & Dohme Corp. | 09/06/21 | 2D 3D TSV |
US10925881 | 14 | 7 | Treatment of conditions associated with hyperinsulinaemia | Tensha Therapeutics, Inc. | 09/06/21 | 2D 3D TSV | |
US10925840 | 52 | 26 | HGNC:285 HGNC:286 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | The USA, as represented by the Secretary, Department of Health and Human Services; SRI International | 09/06/21 | 2D 3D TSV |
US10919884 | 8 | 8 | HGNC:2771 | Amide compounds for treatment of immune and inflammatory disorders | Achillion Pharmaceuticals, Inc. | 09/02/21 | 2D 3D TSV |
US10918640 | 19 | 18 | HGNC:3553 | Azetidine derivatives | Vernalis (R&D) Ltd. | 09/02/21 | 2D 3D TSV |
US10919859 | 57 | 56 | HGNC:4498 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 09/02/21 | 2D 3D TSV |
US10919843 | 18 | 9 | HGNC:4910 | Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity | Emerald Health Pharmaceuticals Inc. | 09/02/21 | 2D 3D TSV |
US10919885 | 926 | 463 | HGNC:10571 HGNC:21088 | Compounds and uses thereof | Yumanity Therapeutics, Inc. | 09/02/21 | 2D 3D TSV |
US10919856 | 36 | 18 | Cyclohexene compounds and use thereof | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. | 09/02/21 | 2D 3D TSV | |
US10919862 | 9 | 6 | Fused imidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT | 09/02/21 | 2D 3D TSV | |
US10919902 | 46 | 23 | HGNC:4852 HGNC:4853 | Hetero-halo inhibitors of histone deacetylase | Alkermes, Inc. | 09/02/21 | 2D 3D TSV |
US10919914 | 6 | 3 | HGNC:8978 HGNC:8977 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. | 09/02/21 | 2D 3D TSV |
US10919901 | 5 | 5 | HGNC:7029 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | Incyte Holdings Corporation; Incyte Corporation | 09/02/21 | 2D 3D TSV |
US10919899 | 20 | 12 | HGNC:1133 HGNC:6171 HGNC:11719 HGNC:12434 | Imidazopyrazine compounds, preparation methods and uses thereof | DONGGUAN ZHENXING-BEITE MEDICINE TECHNOLOGY CO., LTD. | 09/02/21 | 2D 3D TSV |
US10919852 | 416 | 407 | Immunomodulator compounds | ChemoCentryx, Inc. | 09/02/21 | 2D 3D TSV | |
US10918642 | 68 | 68 | HGNC:3255 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | Nerviano Medical Sciences S.R.L. | 09/02/21 | 2D 3D TSV |
US10919890 | 4 | 1 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV | 09/02/21 | 2D 3D TSV |
US10919913 | 67 | 56 | HGNC:6973 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | Boehringer Ingelheim International GmbH | 09/02/21 | 2D 3D TSV |
US10918645 | 91 | 51 | HGNC:6192 | Substituted tricyclic heterocyclic compounds and use thereof | LIFEARC; SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD. | 09/02/21 | 2D 3D TSV |
US10919869 | 50 | 49 | HGNC:2867 | Thiazole derivative and applications | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY | 09/02/21 | 2D 3D TSV |
US10919858 | 71 | 70 | HGNC:17989 | Thioacetate compounds, compositions and methods of use | Ardea Biosciences, Inc | 09/02/21 | 2D 3D TSV |
US10919895 | 66 | 37 | HGNC:15631 HGNC:6018 | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Company | 09/02/21 | 2D 3D TSV |
US10919911 | 81 | 80 | HGNC:6857 | Tricyclic ASK1 inhibitors | TERNS, INC. | 09/02/21 | 2D 3D TSV |
US10913710 | 100 | 99 | HGNC:8788 | Benzene disulfonamide for the treatment of cancer | Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V | 08/30/21 | 2D 3D TSV |
US10913735 | 14 | 14 | HGNC:11138 | Bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL | 08/30/21 | 2D 3D TSV |
US10912773 | 302 | 107 | HGNC:8775 HGNC:8774 HGNC:8776 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. Lundbeck A/S | 08/30/21 | 2D 3D TSV |
US10913740 | 112 | 16 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK kinase inhibitor compounds for treatment of respiratory disease | Theravance Biopharma R&D IP, LLC | 08/30/21 | 2D 3D TSV |
US10913744 | 54 | 20 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. | 08/30/21 | 2D 3D TSV | |
US10913745 | 49 | 47 | HGNC:10548 | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | Hoffmann-La Roche Inc. | 08/30/21 | 2D 3D TSV |
US10913742 | 110 | 110 | HGNC:497 | Oxadiazolones as transient receptor potential channel inhibitors | Genentech, Inc. | 08/30/21 | 2D 3D TSV |
US10913711 | 189 | 59 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 08/30/21 | 2D 3D TSV | |
US10912774 | 144 | 67 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. | 08/30/21 | 2D 3D TSV |
US10913746 | 124 | 111 | HGNC:9922 | Substituted 4-phenylpiperidines, their preparation and use | The Trustees of Columbia University in the City of New York | 08/30/21 | 2D 3D TSV |
US10913733 | 54 | 50 | HGNC:7056 | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp. | 08/30/21 | 2D 3D TSV |
US10913753 | 410 | 219 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. | 08/30/21 | 2D 3D TSV | |
US10905688 | 302 | 111 | HGNC:8775 HGNC:8774 HGNC:8776 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | H. Lundbeck A/S | 08/22/21 | 2D 3D TSV |
US10906896 | 132 | 42 | HGNC:77 HGNC:76 HGNC:6342 | Compositions and methods for inhibiting kinases | Inhibikase Therapeutics, Inc. | 08/22/21 | 2D 3D TSV |
US10906900 | 62 | 14 | HGNC:11138 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE D''ORLEANS; UNIVERSITE DE TOURS; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) | 08/22/21 | 2D 3D TSV |
US10906905 | 88 | 52 | HGNC:6307 HGNC:6876 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 08/22/21 | 2D 3D TSV |
US10906920 | 68 | 65 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 08/22/21 | 2D 3D TSV | |
US10906878 | 7 | 7 | HGNC:1133 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. | 08/22/21 | 2D 3D TSV |
US10906888 | 205 | 198 | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme | Pfizer Inc. | 08/22/21 | 2D 3D TSV | |
US10905687 | 20 | 20 | Substituted piperazines as ROR-gamma modulators | ESCALIER BIOSCIENCES B.V. | 08/22/21 | 2D 3D TSV | |
US10906915 | 372 | 370 | HGNC:8783 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO Pharma A/S | 08/22/21 | 2D 3D TSV |
US10906890 | 112 | 103 | HGNC:339 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. | 08/22/21 | 2D 3D TSV |
US10899772 | 34 | 34 | HGNC:17967 | IRAK4 modulators | Genentech, Inc. | 08/16/21 | 2D 3D TSV |
US10899774 | 71 | 71 | HGNC:17967 | IRAK4 modulators | Genentech, Inc. | 08/16/21 | 2D 3D TSV |
US10899741 | 9 | 4 | HGNC:6307 HGNC:10020 HGNC:6876 | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 08/15/21 | 2D 3D TSV |
US10899755 | 32 | 32 | HGNC:6863 | Benzothiazole compounds and uses thereof | Incyte Corporation | 08/15/21 | 2D 3D TSV |
US10899764 | 56 | 33 | HGNC:11708 HGNC:6059 | Imidazo isoindole derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD.; SHANGHAI HENGRUI PHRMACEUTICAL CO., LTD. | 08/15/21 | 2D 3D TSV |
US10899769 | 268 | 124 | Imidazopiperazinone inhibitors of transcription activating proteins | Board of Regents, The University of Texas System | 08/15/21 | 2D 3D TSV | |
US10899753 | 110 | 110 | HGNC:1133 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. | 08/15/21 | 2D 3D TSV |
US10899735 | 432 | 427 | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. | 08/15/21 | 2D 3D TSV | |
US10899756 | 28 | 23 | HGNC:8784 HGNC:8785 | Phosphodiesterase inhibitors and uses thereof | The Trustees of Columbia University in the City of New York | 08/15/21 | 2D 3D TSV |
US10899738 | 386 | 378 | HGNC:7010 | Piperidines as menin inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 08/15/21 | 2D 3D TSV |
US10898481 | 73 | 38 | HGNC:262 HGNC:263 HGNC:264 | Pyrazine compounds and uses thereof | TBA | 08/15/21 | 2D 3D TSV |
US10894048 | 73 | 49 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Antitumor drug for intermittent administration of FGFR inhibitor | Taiho Pharmaceutical Co., Ltd. | 08/14/21 | 2D 3D TSV |
US10894797 | 52 | 51 | HGNC:9644 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | Nikang Therapeutics, Inc. | 08/14/21 | 2D 3D TSV |
US10894789 | 334 | 165 | HGNC:4849 HGNC:4848 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB; EOLAS THERAPEUTICS, INC. | 08/14/21 | 2D 3D TSV |
US10894784 | 652 | 648 | HGNC:11584 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT | 08/14/21 | 2D 3D TSV |
US10894052 | 36 | 35 | Heterocyclic inhibitors of ATR kinase | Board of Regents, The University of Texas System; ChemPartner Corporation | 08/14/21 | 2D 3D TSV | |
US10894038 | 20 | 19 | HGNC:17989 | Indolizine derivatives, composition and methods of use | SHANGHAI FOCHON PHARMACEUTICAL CO. LTD.; FOCHON PHARMACEUTICALS, LTD. | 08/14/21 | 2D 3D TSV |
US10894788 | 199 | 161 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. | 08/14/21 | 2D 3D TSV | |
US10894782 | 132 | 120 | HGNC:12666 | Modulators of P97 AAA ATPase activity | University of Pittsburgh—Of the Commonwealth System of Higher Education | 08/14/21 | 2D 3D TSV |
US10894803 | 4 | 4 | HGNC:5467 | Multi-functionalized polysaccharide compounds and use thereof for targeting the cation-independent mannose 6-phosphate receptor | NANOMEDSYN; Centre National de la Recherche Scientifique; Universite de Montpellier | 08/14/21 | 2D 3D TSV |
US10894807 | 103 | 102 | HGNC:3788 | PSMA imaging agents | Siemens Medical Solutions USA, Inc. | 08/14/21 | 2D 3D TSV |
US10894794 | 3 | 3 | HGNC:3009 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as antidiabetics | King Abdulaziz University | 08/14/21 | 2D 3D TSV |
US10894786 | 141 | 46 | HGNC:1778 HGNC:1733 | Substituted pyrazole derivatives as selective CDK12/13 inhibitors | Aurigene Discovery Technologies Limited | 08/14/21 | 2D 3D TSV |
US10889546 | 85 | 74 | HGNC:1232 HGNC:14661 | Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof | Jiangsu Hengrui Medicine Co., Ltd. | 08/09/21 | 2D 3D TSV |
US10889610 | 25 | 22 | HGNC:6561 HGNC:6563 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB | 08/09/21 | 2D 3D TSV |
US10889589 | 161 | 157 | HGNC:8031 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | Array BioPharma Inc. | 08/09/21 | 2D 3D TSV |
US10888561 | 14 | 14 | HGNC:9843 | CGRP receptor antagonists | Heptares Therapeutics Limited | 08/09/21 | 2D 3D TSV |
US10889569 | 62 | 32 | HGNC:897 HGNC:895 HGNC:896 | Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 08/09/21 | 2D 3D TSV |
US10889581 | 120 | 40 | HGNC:934 HGNC:2529 HGNC:933 | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use | Amgen Inc. | 08/09/21 | 2D 3D TSV |
US10889552 | 29 | 29 | HGNC:5253 | Dihydroxybenzamide compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | ONCOZEN CO.. LTD. | 08/09/21 | 2D 3D TSV |
US10889568 | 96 | 95 | HGNC:12338 | Inhibitors of TRPC6 | Boehringer Ingelheim International GmbH | 08/09/21 | 2D 3D TSV |
US10888567 | 78 | 78 | HGNC:6059 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | Auckland UniServices Limited | 08/09/21 | 2D 3D TSV |
US10889591 | 69 | 69 | HGNC:8795 | PDE9 inhibitor and use thereof | Nanjing TransThera Biosciences Co. Ltd. | 08/09/21 | 2D 3D TSV |
US10889571 | 217 | 215 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | Terns, Inc. | 08/09/21 | 2D 3D TSV | |
US10889555 | 279 | 268 | Sulfonamide compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 08/09/21 | 2D 3D TSV | |
US10889564 | 52 | 52 | HGNC:2867 | Tetrahydroindazoles and medical uses thereof | Genase Therapeutics B.V. | 08/09/21 | 2D 3D TSV |
US10889579 | 51 | 17 | HGNC:934 HGNC:2529 HGNC:933 | Thiazine derivatives as β-secretase inhibitors and methods of use | Amgen Inc. | 08/09/21 | 2D 3D TSV |
US10889592 | 39 | 21 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. | 08/09/21 | 2D 3D TSV | |
US10889595 | 7 | 7 | HGNC:933 | [1,3]thiazin-2-amine compound, application, and pharmaceutical composition | TETRANOV PHARMACEUTICAL CO., LTD. | 08/09/21 | 2D 3D TSV |
US10888550 | 33 | 33 | HGNC:6819 | Pyrazole derivatives as MALT1 inhibitors | Janssen Pharmaceutica NV | 08/08/21 | 2D 3D TSV |
US10881668 | 12 | 6 | HGNC:13575 HGNC:1105 | Acetamide thienotriazolodiazepines and uses thereof | Dana-Farber Cancer Institute, Inc. | 08/01/21 | 2D 3D TSV |
US10882857 | 17 | 17 | HGNC:3357 | Bicyclic compounds as ATX inhibitors | Hoffmann-La Roche Inc. | 08/01/21 | 2D 3D TSV |
US10882838 | 177 | 61 | HGNC:2160 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY | 08/01/21 | 2D 3D TSV |
US10882844 | 48 | 48 | Compounds useful as immunomodulators | Bristol-Myers Squibb Company | 08/01/21 | 2D 3D TSV | |
US10882835 | 27 | 27 | HGNC:29079 | KDM1A inhibitors for the treatment of disease | Imago Biosciences, Inc. | 08/01/21 | 2D 3D TSV |
US10882859 | 12 | 3 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Kinase inhibitors | TOPIVERT PHARMA LIMITED | 08/01/21 | 2D 3D TSV |
US10882829 | 88 | 22 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pharmaceutical compounds | Sareum Limited | 08/01/21 | 2D 3D TSV |
US10882833 | 17 | 16 | Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof | Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD | 08/01/21 | 2D 3D TSV | |
US10882866 | 148 | 137 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH | 08/01/21 | 2D 3D TSV | |
US10881652 | 2116 | 812 | HGNC:9967 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array Biopharma Inc. | 08/01/21 | 2D 3D TSV |
US10882855 | 56 | 19 | HGNC:3528 HGNC:3529 HGNC:3535 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. | 08/01/21 | 2D 3D TSV |
US10882853 | 12 | 8 | HGNC:6307 HGNC:7029 | Tyrosine kinase inhibitor and application thereof | LaNova Medicines Limited | 08/01/21 | 2D 3D TSV |
US10870635 | 36 | 25 | HGNC:934 HGNC:2529 HGNC:933 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. | 07/26/21 | 2D 3D TSV |
US10870651 | 52 | 40 | HGNC:3697 HGNC:1780 HGNC:16870 HGNC:1771 HGNC:16627 HGNC:11283 HGNC:9410 HGNC:19007 HGNC:9967 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Dana-Farber Cancer Institute, Inc. | 07/26/21 | 2D 3D TSV |
US10870660 | 278 | 138 | HGNC:3023 HGNC:3024 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. | 07/26/21 | 2D 3D TSV |
US10870641 | 855 | 825 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics, Inc. | 07/26/21 | 2D 3D TSV | |
US10870639 | 27 | 18 | HGNC:3765 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO.. LTD. | 07/26/21 | 2D 3D TSV |
US10870625 | 10 | 10 | HGNC:2861 | Zwitterionic propargyl-linked antifolates useful for treating bacterial infections | UNIVERSITY OF CONNECTICUT | 07/26/21 | 2D 3D TSV |
US10875847 | 13 | 9 | HGNC:6190 HGNC:6192 HGNC:6193 | Aminopyrazoles as selective janus kinase inhibitors | Intervet Inc. | 07/25/21 | 2D 3D TSV |
US10875829 | 6 | 2 | HGNC:11050 HGNC:11048 HGNC:11049 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB | 07/25/21 | 2D 3D TSV |
US10864192 | 4 | 4 | HGNC:108 | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions | Aristea Translational Medicine Corporation | 07/25/21 | 2D 3D TSV |
US10869871 | 96 | 91 | HGNC:5154 | Compositions and methods of modulating short-chain dehydrogenase activity | CASE WESTERN RESERVE UNIVERSITY; THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 07/25/21 | 2D 3D TSV |
US10874634 | 43 | 23 | HGNC:20581 HGNC:2603 | Compounds and methods for inhibiting CYP26 enzymes | Queen''s University at Kingston | 07/25/21 | 2D 3D TSV |
US10875867 | 202 | 90 | HGNC:8772 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | Boehringer Ingelheim International GmbH | 07/25/21 | 2D 3D TSV |
US10875851 | 183 | 174 | HGNC:3530 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. | 07/25/21 | 2D 3D TSV |
US10875852 | 156 | 151 | HGNC:1133 | Heteroaromatic compounds as BTK inhibitors | Boehringer Ingelheim International GmbH | 07/25/21 | 2D 3D TSV |
US10874687 | 12 | 3 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. | 07/25/21 | 2D 3D TSV | |
US10870618 | 46 | 30 | HGNC:4852 HGNC:4854 HGNC:4853 | Histone deacetylase inhibitors and uses thereof | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 07/25/21 | 2D 3D TSV |
US10874683 | 39 | 26 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | Emory University | 07/25/21 | 2D 3D TSV | |
US10874669 | 32 | 16 | HGNC:3023 HGNC:3024 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY | 07/25/21 | 2D 3D TSV |
US10869929 | 22 | 22 | Phosphonate linkers and their use to facilitate cellular retention of compounds | MERCK SHARP & DOHME CORP. | 07/25/21 | 2D 3D TSV | |
US10874675 | 34 | 34 | HGNC:23357 | Pteridine dione monocarboxylate transporter inhibitors | THE SCRIPPS RESEARCH INSTITUTE | 07/25/21 | 2D 3D TSV |
US10875863 | 26 | 25 | HGNC:10020 | RIPK2 inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK | 07/25/21 | 2D 3D TSV |
US10875864 | 120 | 102 | HGNC:6251 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 07/25/21 | 2D 3D TSV |
US10875832 | 3 | 3 | Substituted pyrimidines for treating bacterial infections | FORGE THERAPEUTICS, INC. | 07/25/21 | 2D 3D TSV | |
US10874640 | 138 | 136 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. | 07/25/21 | 2D 3D TSV | |
US10875854 | 35 | 34 | Triazolopyridines | Hoffmann-La Roche Inc. | 07/25/21 | 2D 3D TSV | |
US10870623 | 23 | 23 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | Hoffmann-La Roche Inc. | 07/25/21 | 2D 3D TSV | |
US10865384 | 119 | 47 | HGNC:2453 HGNC:2452 HGNC:6876 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | Agency for Science, Technology and Research; National University of Singapore | 07/18/21 | 2D 3D TSV |
US10865208 | 231 | 229 | HGNC:16935 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 07/18/21 | 2D 3D TSV |
US10864248 | 3 | 3 | Dab2 inhibitors for the prevention and treatment of cystic fibrosis | TRUSTEES OF DARTMOUTH COLLEGE | 07/18/21 | 2D 3D TSV | |
US10865182 | 17 | 17 | Difluoroketamide derivatives as HtrA1 inhibitors | Hoffmann-La Roche Inc. | 07/18/21 | 2D 3D TSV | |
US10864201 | 57 | 57 | Heteroaromatic compounds as Vanin inhibitors | Boehringer Ingelheim International GmbH | 07/18/21 | 2D 3D TSV | |
US10865206 | 15 | 15 | HGNC:1778 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Syros Pharmaceuticals, Inc. | 07/18/21 | 2D 3D TSV |
US10864202 | 75 | 75 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research, Inc. | 07/18/21 | 2D 3D TSV |
US10865186 | 25 | 12 | HGNC:8154 HGNC:8156 | Opioid agonists and uses thereof | Nektar Therapeutics | 07/18/21 | 2D 3D TSV |
US10865195 | 7 | 7 | HGNC:10548 | Pet imaging agents | Novartis AG | 07/18/21 | 2D 3D TSV |
US10851050 | 39 | 39 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY | 07/13/21 | 2D 3D TSV | |
US10849881 | 117 | 116 | HGNC:10548 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | Hoffmann-La Roche Inc. | 07/13/21 | 2D 3D TSV |
US10849901 | 159 | 140 | Arf6 inhibitors and methods of synthesis and use thereof | Navigen, Inc.; The University of Utah Research Foundation | 07/12/21 | 2D 3D TSV | |
US10851083 | 186 | 185 | Benzoimidazoles as prolyl hydroxylase inhibitors | Janssen Pharmaceutica NV | 07/12/21 | 2D 3D TSV | |
US10849883 | 380 | 377 | HGNC:2771 | Benzopyrazole compounds and analogues thereof | BioCryst Pharmaceuticals, Inc. | 07/12/21 | 2D 3D TSV |
US10851091 | 62 | 21 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Benzoxazepin oxazolidinone compounds and methods of use | Genentech, Inc. | 07/12/21 | 2D 3D TSV |
US10851116 | 188 | 43 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Bicyclic amines as novel JAK kinase inhibitors | LEO Pharma A/S | 07/12/21 | 2D 3D TSV |
US10851105 | 96 | 12 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 07/12/21 | 2D 3D TSV |
US10849982 | 64 | 64 | HGNC:2717 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 Therapeutics, Inc. | 07/12/21 | 2D 3D TSV |
US10851110 | 95 | 92 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 07/12/21 | 2D 3D TSV | |
US10851102 | 162 | 52 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | Theravance Biopharma R&D IP, LLC | 07/12/21 | 2D 3D TSV |
US10851089 | 32 | 30 | HGNC:7158 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | Foresee Pharmaceuticals Co., Ltd. | 07/12/21 | 2D 3D TSV |
US10851080 | 31 | 31 | HGNC:8031 | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds | Array Biopharma Inc. | 07/12/21 | 2D 3D TSV |
US10851092 | 6 | 3 | HGNC:9967 | Pyridine compound | Daiichi Sankyo Company, Limited | 07/12/21 | 2D 3D TSV |
US10851082 | 434 | 227 | HGNC:7110 HGNC:7111 | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) | Northwestern University | 07/12/21 | 2D 3D TSV |
US10851108 | 7 | 7 | HGNC:6255 | Substituted bicyclic heterocyclic compounds | Bristol-Myers Squibb Company | 07/12/21 | 2D 3D TSV |
US10849898 | 122 | 118 | HGNC:29079 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. | 07/12/21 | 2D 3D TSV |
US10858342 | 226 | 112 | HGNC:2592 HGNC:2591 | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases | Boehringer Ingelheim International GmbH | 07/11/21 | 2D 3D TSV |
US10857082 | 27 | 26 | Diarylalkanes as potent inhibitors of binuclear enzymes | Unigen, Inc. | 07/11/21 | 2D 3D TSV | |
US10858323 | 12 | 3 | HGNC:4852 HGNC:14064 HGNC:4854 HGNC:4853 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC | 07/11/21 | 2D 3D TSV |
US10858359 | 6 | 6 | HGNC:9644 | Heterocyclic ring derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. | 07/11/21 | 2D 3D TSV |
US10858373 | 106 | 53 | HGNC:17038 | Heterocyclic spiro compounds as MAGL inhibitors | Pfizer Inc. | 07/11/21 | 2D 3D TSV |
US10858344 | 20 | 20 | HGNC:3078 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 Therapeutics (NI) Limited | 07/11/21 | 2D 3D TSV |
US10858364 | 15 | 3 | HGNC:3432 HGNC:3430 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:11719 HGNC:12434 HGNC:3236 | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | Acerta Pharma B.V. | 07/11/21 | 2D 3D TSV |
US10858362 | 311 | 111 | HGNC:8775 HGNC:8774 HGNC:8776 | Imidazopyrazinones as PDE1 inhibitors | H. Lundbeck A/S | 07/11/21 | 2D 3D TSV |
US10858355 | 37 | 34 | HGNC:8978 | Inhibitors of phosphatidylinositol 3-kinase gamma | AstraZeneca AB | 07/11/21 | 2D 3D TSV |
US10858368 | 22 | 22 | HGNC:5302 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION; PRAEVENTIX, LLC | 07/11/21 | 2D 3D TSV |
US10858326 | 5 | 5 | HGNC:17734 | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof | PURDUE PHARMA L.P. | 07/11/21 | 2D 3D TSV |
US10858356 | 80 | 80 | HGNC:4324 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | Chugai Seiyaku Kabushiki Kaisha | 07/11/21 | 2D 3D TSV |
US10858316 | 146 | 98 | HGNC:6943 | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 07/11/21 | 2D 3D TSV |
US10858365 | 518 | 119 | HGNC:268 HGNC:262 HGNC:263 HGNC:264 | Triazolo-pyrimidine compounds and uses thereof | TBA | 07/11/21 | 2D 3D TSV |
US10858366 | 71 | 41 | Tricyclic compounds useful to treat orthomyxovirus infections | Novartis AG | 07/11/21 | 2D 3D TSV | |
US10844038 | 134 | 16 | HGNC:11283 HGNC:8980 HGNC:8979 HGNC:6877 HGNC:8978 HGNC:6735 HGNC:4037 HGNC:6871 HGNC:3942 HGNC:8977 HGNC:9967 HGNC:3765 HGNC:6171 HGNC:11393 HGNC:12841 HGNC:9617 HGNC:3432 HGNC:6844 HGNC:4840 HGNC:3697 HGNC:6845 HGNC:1079 HGNC:6846 HGNC:1057 HGNC:1133 HGNC:6847 HGNC:16627 HGNC:1097 HGNC:6342 HGNC:3955 HGNC:6840 HGNC:2444 HGNC:6842 HGNC:6524 HGNC:6843 | 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions | SABILA BIOSCIENCES LLC | 07/06/21 | 2D 3D TSV |
US10844056 | 73 | 63 | HGNC:5253 | Fused amino pyridine as HSP90 inhibitors | Curis, Inc. | 07/06/21 | 2D 3D TSV |
US10844067 | 255 | 86 | HGNC:6307 HGNC:9967 | Heterocyclic compounds as RET kinase inhibitors | Cancer Research Technology Limited | 07/06/21 | 2D 3D TSV |
US10842803 | 100 | 100 | HGNC:11491 | Imidazopyridines Syk inhibitors | KRONOS BIO, INC. | 07/06/21 | 2D 3D TSV |
US10844057 | 52 | 13 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Process for preparing JAK inhibitors and intermediates thereof | Theravance Biopharma R&D IP, LLC | 07/06/21 | 2D 3D TSV |
US10844062 | 94 | 92 | HGNC:6307 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | Incheon University Industry Academic Cooperation Foundation; Samjin Pharmaceutical Co., Ltd.; Bamichem Co., Ltd. | 07/06/21 | 2D 3D TSV |
US10844069 | 438 | 146 | HGNC:7027 HGNC:12446 | Pyrrolotriazine compounds as TAM inhibitors | Incyte Corporation | 07/06/21 | 2D 3D TSV |
US10842799 | 110 | 107 | HGNC:6871 | Serine/threonine kinase inhibitors | GENENTECH, INC. | 07/06/21 | 2D 3D TSV |
US10844032 | 286 | 271 | HGNC:990 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | Vanderbilt University | 07/06/21 | 2D 3D TSV |
US10844077 | 44 | 22 | HGNC:4840 HGNC:1133 | Thiazolyl-containing compounds for treating proliferative diseases | Dana-Farber Cancer Institute, Inc. | 07/06/21 | 2D 3D TSV |
US10844044 | 364 | 359 | HGNC:12757 | WDR5 inhibitors and modulators | Vanderbilt University | 07/06/21 | 2D 3D TSV |
US10836763 | 48 | 12 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 5 to 7 membered heterocyclic amides as JAK inhibitors | Theravance Biopharma R&D IP, LLC | 06/30/21 | 2D 3D TSV |
US10836764 | 164 | 55 | HGNC:5295 HGNC:5294 | 5-HT2C receptor agonists and compositions and methods of use | Arena Pharmaceuticals, Inc. | 06/30/21 | 2D 3D TSV |
US10836773 | 6 | 6 | HGNC:7056 | 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds | Eli Lilly and Company | 06/30/21 | 2D 3D TSV |
US10836758 | 75 | 73 | HGNC:10597 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 06/30/21 | 2D 3D TSV |
US10829489 | 98 | 57 | HGNC:8810 | Bicyclic heterocyclic derivatives | Merck Patent GmbH | 06/30/21 | 2D 3D TSV |
US10836743 | 110 | 58 | HGNC:6833 HGNC:6834 HGNC:29079 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 06/30/21 | 2D 3D TSV |
US10836720 | 24 | 13 | HGNC:6153 | Inhibitors of integrin alpha 5 beta 1 and methods of use | The Regents of the University of California | 06/30/21 | 2D 3D TSV |
US10836768 | 205 | 47 | HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Ogeda SA | 06/30/21 | 2D 3D TSV |
US10836742 | 15 | 15 | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals | Neomed Institute | 06/30/21 | 2D 3D TSV | |
US10836741 | 13 | 12 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | Valo Early Discovery, Inc. | 06/30/21 | 2D 3D TSV | |
US10836728 | 22 | 11 | HGNC:711 HGNC:8156 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | Mebias Discovery, Inc. | 06/30/21 | 2D 3D TSV |
US10836769 | 56 | 55 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. | 06/30/21 | 2D 3D TSV | |
US10835536 | 52 | 50 | HGNC:3689 | Therapeutic agent for FGFR inhibitor-resistant cancer | Taiho Pharmaceutical Co., Ltd. | 06/30/21 | 2D 3D TSV |
US10829488 | 46 | 22 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 06/29/21 | 2D 3D TSV | |
US10828301 | 51 | 51 | HGNC:11491 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. | 06/28/21 | 2D 3D TSV |
US10829480 | 296 | 153 | HGNC:8155 HGNC:8156 | 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives | GRUENENTHAL GMBH | 06/28/21 | 2D 3D TSV |
US10829478 | 698 | 150 | HGNC:7160 HGNC:195 HGNC:7159 HGNC:220 HGNC:221 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV | 06/28/21 | 2D 3D TSV |
US10829492 | 73 | 50 | HGNC:6192 HGNC:8031 HGNC:8032 HGNC:8033 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. | 06/28/21 | 2D 3D TSV |
US10829446 | 156 | 155 | Aryl sulfonohydrazides | MONASH UNIVERSITY; The Walter and Eliza Hall Institute of Medical Research | 06/28/21 | 2D 3D TSV | |
US10829481 | 189 | 189 | Benzimidazole derivatives as modulators of ROR-gamma | Vitae Pharmaceuticals, LLC | 06/28/21 | 2D 3D TSV | |
US10829487 | 150 | 149 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | Boehringer Ingelheim International GmbH | 06/28/21 | 2D 3D TSV | |
US10829493 | 69 | 23 | HGNC:6342 | Compositions and methods for treating KIT- and PDGFRA-mediated diseases | Blueprint Medicines Corporation | 06/28/21 | 2D 3D TSV |
US10828299 | 7 | 7 | HGNC:11491 | Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine | KRONOS BIO, INC. | 06/28/21 | 2D 3D TSV |
US10829438 | 7 | 7 | Neprilysin inhibitors | Theravance Biopharma R&D IP, LLC | 06/28/21 | 2D 3D TSV | |
US10829500 | 5 | 5 | HGNC:933 | Pyridyl-triazabicycles | Hoffmann-La Roche Inc. | 06/28/21 | 2D 3D TSV |
US10829502 | 125 | 82 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Pyrimidinones as PI3K inhibitors | Incyte Corporation; Incyte Holdings Corporation | 06/28/21 | 2D 3D TSV |
US10829491 | 22 | 22 | HGNC:1133 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD | 06/28/21 | 2D 3D TSV |
US10828300 | 248 | 244 | HGNC:1133 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | Celgene CAR LLC | 06/28/21 | 2D 3D TSV |
US10829448 | 121 | 111 | Substituted benzoimidazoles as modulators of ROR-γ | Vitae Pharmaceuticals, LLC | 06/28/21 | 2D 3D TSV | |
US10829490 | 71 | 9 | HGNC:1780 HGNC:1771 HGNC:1777 HGNC:1774 HGNC:1773 HGNC:1775 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. | 06/28/21 | 2D 3D TSV |
US10828290 | 327 | 108 | HGNC:19310 HGNC:8987 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | Incyte Corporation; Incyte Holdings Corporation | 06/28/21 | 2D 3D TSV |
US10829496 | 29 | 27 | HGNC:17967 | Thienopyridines and benzothiophenes useful as IRAK4 inhibitors | Bristol-Myers Squibb Company | 06/28/21 | 2D 3D TSV |
US10829483 | 103 | 103 | HGNC:17989 | Thiophene, manufacturing method thereof, and pharmaceutical application of same | CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD.; CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.; CSTONE PHARMACEUTICALS | 06/28/21 | 2D 3D TSV |
US10822352 | 718 | 703 | HGNC:2771 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. | 06/21/21 | 2D 3D TSV |
US10822319 | 2 | 2 | Crystal of DPP-IV long-acting inhibitor and salt | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.; CENTAURUS BIOPHARMA CO., LTD. | 06/21/21 | 2D 3D TSV | |
US10822334 | 60 | 30 | HGNC:3430 HGNC:3236 | ErbB receptor inhibitors | TBA | 06/21/21 | 2D 3D TSV |
US10822348 | 937 | 789 | Inhibitors of Bruton's tyrosine kinase and methods of their use | Janssen Pharmaceutica NV | 06/21/21 | 2D 3D TSV | |
US10822345 | 64 | 63 | HGNC:6221 | KV1.3 inhibitors and their medical application | 4SC AG | 06/21/21 | 2D 3D TSV |
US10822331 | 4 | 1 | HGNC:882 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 06/21/21 | 2D 3D TSV |
US10822341 | 148 | 37 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | Pfizer Inc. | 06/21/21 | 2D 3D TSV |
US10822342 | 12 | 12 | HGNC:6853 | Pyrazolopyrimidine derivatives as NIK inhibitors | Janssen Pharmaceutica NV | 06/21/21 | 2D 3D TSV |
US10822338 | 75 | 74 | HGNC:263 | Substituted aminoquinazoline compounds as A2A antagonist | Merck Sharp & Dohme Corp. | 06/21/21 | 2D 3D TSV |
US10821115 | 969 | 797 | Compounds that inhibit Mcl-1 protein | AMGEN INC. | 06/20/21 | 2D 3D TSV | |
US10815234 | 116 | 115 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. | 06/14/21 | 2D 3D TSV | |
US10815244 | 10 | 10 | HGNC:3236 | Isoidide derivatives and methods of making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 06/14/21 | 2D 3D TSV |
US10815241 | 10 | 10 | HGNC:7010 | Optically active azabicyclo ring derivative | Sumitomo Dainippon Pharma Co., Ltd. | 06/14/21 | 2D 3D TSV |
US10813932 | 120 | 31 | HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:20790 HGNC:6874 HGNC:6876 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors | Respivert Limited | 06/13/21 | 2D 3D TSV |
US10815215 | 268 | 215 | HGNC:2867 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGELLSCHAFT; THE BROAD INSTITUTE, INC.; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; THE GENERAL HOSPITAL CORPORATION | 06/13/21 | 2D 3D TSV |
US10815229 | 1146 | 325 | HGNC:10593 HGNC:10585 HGNC:10596 | Benzenesulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 06/13/21 | 2D 3D TSV |
US10815213 | 190 | 140 | HGNC:1133 HGNC:3236 | Bruton's tyrosine kinase inhibitors | Pfizer Inc. | 06/13/21 | 2D 3D TSV |
US10815208 | 4 | 4 | Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative | Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD | 06/13/21 | 2D 3D TSV | |
US10815206 | 95 | 90 | RIP1 inhibitory compounds and methods for making and using the same | Rigel Pharmaceuticals, Inc. | 06/13/21 | 2D 3D TSV | |
US10813930 | 107 | 107 | HGNC:3690 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | Incyte Corporation; Incyte Holdings Corporation | 06/13/21 | 2D 3D TSV |
US10813942 | 17 | 17 | HGNC:742 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | Pfizer Inc. | 06/13/21 | 2D 3D TSV |
US10806718 | 605 | 192 | HGNC:8775 HGNC:8774 HGNC:8776 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. Lundbeck A/S | 06/11/21 | 2D 3D TSV |
US10807988 | 790 | 396 | HGNC:8155 HGNC:8156 | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | Grünenthal GmbH | 06/11/21 | 2D 3D TSV |
US10807989 | 571 | 289 | HGNC:8155 HGNC:8156 | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | GRÜNENTHAL GMBH | 06/11/21 | 2D 3D TSV |
US10807982 | 105 | 104 | HGNC:13575 | Bromodomain inhibitors | Celgene Quanticel Research, Inc. | 06/11/21 | 2D 3D TSV |
US10806724 | 59 | 59 | HGNC:4594 | Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use | Merck Sharp & Dohme Corp. | 06/11/21 | 2D 3D TSV |
US10807985 | 169 | 124 | Compositions useful for treating disorders related to kit | Blueprint Medicines Corporation | 06/11/21 | 2D 3D TSV | |
US10807952 | 101 | 101 | HGNC:2771 | Compounds for treatment of immune inflammatory disorders | Achillion Pharmaceuticals, Inc. | 06/11/21 | 2D 3D TSV |
US10807993 | 63 | 51 | HGNC:6251 | Dihydrochromene derivatives | Sumitomo Dainippon Pharma Co., Ltd. | 06/11/21 | 2D 3D TSV |
US10807980 | 220 | 156 | Dihydropyrrolopyridine inhibitors of ROR-gamma | Vitae Pharmaceuticals, LLC | 06/11/21 | 2D 3D TSV | |
US10807986 | 522 | 200 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 06/11/21 | 2D 3D TSV |
US10807944 | 144 | 42 | HGNC:4852 HGNC:14064 HGNC:13315 HGNC:4854 HGNC:4853 | HDAC inhibitor compounds and methods of treatment | University of Florida Research Foundation, Inc.; The Scripps Research Institute | 06/11/21 | 2D 3D TSV |
US10807994 | 99 | 97 | HGNC:12761 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. | 06/11/21 | 2D 3D TSV |
US10807966 | 27 | 16 | HGNC:10251 HGNC:10252 | Heterocyclic compounds as kinase inhibitors | Translational Drug Development, LLC | 06/11/21 | 2D 3D TSV |
US10807956 | 210 | 101 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. | 06/11/21 | 2D 3D TSV |
US10806785 | 205 | 191 | Immunomodulator compounds and methods of use | Incyte Corporation | 06/11/21 | 2D 3D TSV | |
US10807974 | 309 | 161 | HGNC:6833 HGNC:6834 HGNC:80 HGNC:6666 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | The Institute of Cancer Research: Royal Cancer Hospital | 06/11/21 | 2D 3D TSV |
US10806794 | 28 | 28 | Protease inhibitors having enhanced features | Nektar Therapeutics | 06/11/21 | 2D 3D TSV | |
US10807971 | 68 | 17 | HGNC:16672 HGNC:3009 | Pyrrolidinone compounds | Eli Lilly and Company | 06/11/21 | 2D 3D TSV |
US10806720 | 76 | 51 | HGNC:644 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | University of Tennessee Research Foundation | 06/11/21 | 2D 3D TSV |
US10807991 | 122 | 42 | HGNC:3167 HGNC:3165 HGNC:14299 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie B.V.; AbbVie, Inc. | 06/11/21 | 2D 3D TSV |
US10807959 | 266 | 260 | HGNC:12757 | WDR5-MLL1 inhibitors and modulators | Vanderbilt University | 06/11/21 | 2D 3D TSV |
US10800755 | 217 | 38 | HGNC:3023 HGNC:5286 HGNC:6251 | 2,6-disubstituted pyridine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. | 06/01/21 | 2D 3D TSV |
US10800739 | 37 | 20 | HGNC:270 HGNC:272 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. | 06/01/21 | 2D 3D TSV |
US10799507 | 607 | 155 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors | Leo Pharma A/S | 06/01/21 | 2D 3D TSV |
US10800725 | 60 | 20 | Arylpropionyl-triketone antibacterial agents | TBA | 06/01/21 | 2D 3D TSV | |
US10800778 | 120 | 40 | Beta-lactamase inhibitor compounds | Entasis Therapeutics Limited | 06/01/21 | 2D 3D TSV | |
US10800786 | 33 | 32 | HGNC:10548 | Bicyclic compounds as ATX inhibitors | Hoffman-La Roche Inc. | 06/01/21 | 2D 3D TSV |
US10800783 | 433 | 218 | HGNC:1771 | CDK2/4/6 inhibitors | Pfizer Inc. | 06/01/21 | 2D 3D TSV |
US10800761 | 113 | 105 | HGNC:6863 | Carboxamide compounds and uses thereof | Incyte Corporation | 06/01/21 | 2D 3D TSV |
US10799494 | 22 | 22 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | TBA | 06/01/21 | 2D 3D TSV | |
US10799605 | 13 | 7 | HGNC:8039 | Conjugate comprising a neurotensin receptor ligand and use thereof | 3B Pharmaceuticals GMBH | 06/01/21 | 2D 3D TSV |
US10800776 | 45 | 25 | HGNC:4594 HGNC:6251 | Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 06/01/21 | 2D 3D TSV |
US10800779 | 138 | 138 | HGNC:29079 | Heterocyclic compounds as LSD1 inhibitors | Incyte Corporation | 06/01/21 | 2D 3D TSV |
US10800768 | 271 | 266 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 06/01/21 | 2D 3D TSV | |
US10800769 | 265 | 122 | HGNC:1925 | Heterocyclic inhibitors of ATR kinase | Board of Regents, The University of Texas System; ChemPartner Corporation | 06/01/21 | 2D 3D TSV |
US10800774 | 64 | 32 | HGNC:1925 | Heterocyclic inhibitors of ATR kinase | Board of Regents, The University of Texas System; ChemPartner Corporation | 06/01/21 | 2D 3D TSV |
US10800804 | 26 | 12 | HGNC:6561 HGNC:6563 | Hybrid galactoside inhibitor of galectins | TBA | 06/01/21 | 2D 3D TSV |
US10800744 | 41 | 41 | HGNC:3827 | Imidazole derivatives as formyl peptide receptor modulators | ALLERGAN, INC. | 06/01/21 | 2D 3D TSV |
US10800765 | 63 | 62 | HGNC:4502 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. | 06/01/21 | 2D 3D TSV |
US10800792 | 937 | 912 | HGNC:1133 | Inhibitors of Bruton's tyrosine kinase and method of their use | Janssen Pharmaceutica NV | 06/01/21 | 2D 3D TSV |
US10800757 | 96 | 94 | HGNC:12338 | Inhibitors of TRPC6 | Boehringer Ingelheim International GmbH; Hydra Biosciences, LLC | 06/01/21 | 2D 3D TSV |
USRE48253 | 9 | 9 | HGNC:12576 | Methotrexate adjuvants to reduce toxicity and methods for using the same | Tosk, Inc. | 06/01/21 | 2D 3D TSV |
US10800784 | 246 | 123 | HGNC:8809 HGNC:8810 | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof | JAPAN TOBACCO INC. | 06/01/21 | 2D 3D TSV |
US10800746 | 22 | 11 | HGNC:897 HGNC:895 | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT | 06/01/21 | 2D 3D TSV |
US10800775 | 14 | 7 | HGNC:6190 | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same | ACLARIS THERAPEUTICS, INC. | 06/01/21 | 2D 3D TSV |
US10800764 | 23 | 6 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | Janssen Pharmaceutica NV | 06/01/21 | 2D 3D TSV | |
US10800785 | 97 | 85 | HGNC:1133 | Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors | Shanghai Fochon Pharmaceutical Co., Ltd.; Fochon Pharmaceuticals, Ltd. | 06/01/21 | 2D 3D TSV |
US10800753 | 7 | 7 | HGNC:23 | Tetrahydrothiophene-based GABA aminotransferase inactivators and analogs thereof for treating neurological disorders | Northwestern University | 06/01/21 | 2D 3D TSV |
US10800767 | 82 | 36 | HGNC:11799 HGNC:11796 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. | 06/01/21 | 2D 3D TSV |
US10799518 | 188 | 179 | HGNC:3827 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | ALLERGAN, INC. | 06/01/21 | 2D 3D TSV |
US10793561 | 2 | 2 | HGNC:262 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. | 05/14/21 | 2D 3D TSV |
US10793528 | 150 | 75 | HGNC:8156 | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | GRÜNENTHAL GMBH | 05/14/21 | 2D 3D TSV |
US10793556 | 178 | 34 | HGNC:8155 HGNC:8156 | 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | GRUENENTHAL GMBH | 05/14/21 | 2D 3D TSV |
US10793564 | 145 | 144 | HGNC:6161 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. | 05/14/21 | 2D 3D TSV |
US10793552 | 3 | 3 | HGNC:550 | Amino pyrimidine ssao inhibitors | ELI LILLY AND COMPANY | 05/14/21 | 2D 3D TSV |
US10793582 | 85 | 84 | HGNC:17929 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION | 05/14/21 | 2D 3D TSV |
US10793567 | 30 | 15 | HGNC:4852 HGNC:4853 | Bicyclic inhibitors of histone deacetylase | Rodin Therapeutics, Inc. | 05/14/21 | 2D 3D TSV |
US10793579 | 370 | 361 | HGNC:17967 | Bicyclic-fused heteroaryl or aryl compounds | Pfizer Inc. | 05/14/21 | 2D 3D TSV |
US10793566 | 134 | 123 | HGNC:6735 HGNC:1057 HGNC:1133 HGNC:3236 HGNC:6524 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 05/14/21 | 2D 3D TSV |
US10793576 | 128 | 126 | HGNC:1133 | Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof | CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.; CHENGDU HIGHBRED PHARMACEUTICAL CO., LTD. | 05/14/21 | 2D 3D TSV |
US10793563 | 532 | 502 | HGNC:19687 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH; VERTEX PHARMACEUTICALS INCORPORATED | 05/14/21 | 2D 3D TSV |
US10793514 | 38 | 19 | HGNC:10943 | Glutamine transport inhibitors and methods for treating cancer | Vanderbilt University | 05/14/21 | 2D 3D TSV |
US10793565 | 4 | 4 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 05/14/21 | 2D 3D TSV | |
US10793535 | 51 | 45 | Heterocyclic glutaminase inhibitors | Calithera Biosciences, Inc. | 05/14/21 | 2D 3D TSV | |
US10793568 | 340 | 336 | HGNC:7967 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. | 05/14/21 | 2D 3D TSV |
US10793575 | 89 | 59 | HGNC:1133 | Oxoisoquinoline derivatives | CARNA BIOSCIENCES, INC. | 05/14/21 | 2D 3D TSV |
US10792283 | 7 | 7 | HGNC:8977 | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors | HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD. | 05/14/21 | 2D 3D TSV |
US10793545 | 22 | 22 | HGNC:17967 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | Bayer Pharma Aktiengesellschaft | 05/14/21 | 2D 3D TSV |
US10793591 | 16 | 15 | Substituted nucleosides, nucleotides and analogs thereof | Janssen BioPharma, Inc. | 05/14/21 | 2D 3D TSV | |
US10793580 | 310 | 310 | HGNC:8783 | Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors | LEO Pharma A/S | 05/14/21 | 2D 3D TSV |
US10793529 | 4 | 4 | HGNC:9602 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. | 05/14/21 | 2D 3D TSV |
US10793549 | 63 | 59 | Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.; YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. | 05/14/21 | 2D 3D TSV | |
US10793574 | 218 | 217 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 05/14/21 | 2D 3D TSV | |
US10787452 | 579 | 555 | HGNC:882 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED | 05/11/21 | 2D 3D TSV |
US10787435 | 57 | 56 | HGNC:6857 | ASK1 inhibitor and preparation method and use thereof | Fuijan Cosunter Pharmaceutical Co. Ltd. | 05/09/21 | 2D 3D TSV |
US10787434 | 9 | 9 | HGNC:10894 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY, LTD | 05/09/21 | 2D 3D TSV |
US10787459 | 13 | 3 | HGNC:10548 | Bicyclic compounds as ATX inhibitors | Hoffmann-La Roche Inc. | 05/09/21 | 2D 3D TSV |
US10787419 | 92 | 90 | Cannabinoid receptor mediating iminopyrazole compounds | The United States of America, as represented by the Secretary, Department of Health and Human Services | 05/09/21 | 2D 3D TSV | |
US10787457 | 78 | 78 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 05/09/21 | 2D 3D TSV |
US10787436 | 82 | 40 | HGNC:1780 HGNC:1771 HGNC:1778 HGNC:6881 HGNC:1722 HGNC:6112 HGNC:6850 HGNC:1779 HGNC:1774 HGNC:6886 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Dana-Farber Cancer Institute, Inc. | 05/09/21 | 2D 3D TSV |
US10787453 | 2 | 2 | HGNC:9922 | Octahydropyrrolopyrroles their preparation and use | The Trustees of Columbia University in the City of New York | 05/09/21 | 2D 3D TSV |
US10787472 | 23 | 23 | HGNC:10582 | Prodrugs of pyridone amides useful as modulators of sodium channels | Vertex Pharmaceuticals Incorporated | 05/09/21 | 2D 3D TSV |
US10787450 | 255 | 253 | HGNC:10252 | Spiro-fused cyclic ureas as inhibitors of rock | Bristol-Myers Squibb Company | 05/09/21 | 2D 3D TSV |
US10787438 | 40 | 18 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | Pfizer Inc. | 05/09/21 | 2D 3D TSV | |
US10787425 | 105 | 105 | HGNC:5154 | Thiazolidinedione derivative and use thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION CHOSUN UNIVERSITY | 05/09/21 | 2D 3D TSV |
US10781209 | 196 | 93 | HGNC:13575 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | Incyte Corporation | 05/03/21 | 2D 3D TSV |
US10781212 | 4 | 2 | 2,6-diamino pyridine compounds | Eli Lilly and Company | 05/03/21 | 2D 3D TSV | |
US10781180 | 4 | 4 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. | 05/03/21 | 2D 3D TSV | |
US10781202 | 10 | 10 | HGNC:8781 | Azetidinyloxyphenylpyrrolidine compounds | Eli Lilly and Company | 05/03/21 | 2D 3D TSV |
US10781182 | 12 | 6 | HGNC:7463 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. | 05/03/21 | 2D 3D TSV |
US10781185 | 149 | 108 | HGNC:17270 | Heterocyclic compounds for the inhibition of PASK | BioEnergenix LLC | 05/03/21 | 2D 3D TSV |
US10781181 | 216 | 108 | HGNC:6371 HGNC:6357 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED | 05/03/21 | 2D 3D TSV |
US10781211 | 677 | 260 | HGNC:17038 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 05/03/21 | 2D 3D TSV |
US10781204 | 378 | 163 | HGNC:6192 HGNC:12440 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 05/03/21 | 2D 3D TSV |
US10781200 | 140 | 137 | HGNC:6371 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. | 05/03/21 | 2D 3D TSV |
US10780095 | 30 | 25 | HGNC:15836 | Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 05/02/21 | 2D 3D TSV |
US10780092 | 156 | 151 | HGNC:4685 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | Merck Sharp & Dohme Corp. | 05/02/21 | 2D 3D TSV |
US10780090 | 537 | 352 | HGNC:30660 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | Millennium Pharmaceuticals, Inc. | 05/02/21 | 2D 3D TSV |
US10780082 | 18 | 3 | HGNC:427 | Macrocycle and composition comprising thereof | Shenzhen TargetRx, Inc. | 05/02/21 | 2D 3D TSV |
US10780078 | 21 | 7 | HGNC:8153 HGNC:8155 HGNC:8156 | Mu opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; FRIEDRICH-ALEXANDER-UNIVERSITÄT; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 05/02/21 | 2D 3D TSV |
US10781171 | 288 | 287 | HGNC:4501 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | Epics Therapeutics | 05/02/21 | 2D 3D TSV |
US10766893 | 768 | 242 | HGNC:8775 HGNC:8774 HGNC:8776 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. Lundbeck A/S | 04/26/21 | 2D 3D TSV |
US10766881 | 246 | 83 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | Array Biopharma Inc. | 04/26/21 | 2D 3D TSV | |
US10766883 | 18 | 9 | HGNC:6190 HGNC:6192 | Aminopyrazoles as janus kinase inhibitors | Merck Sharp & Dohme Corp. | 04/26/21 | 2D 3D TSV |
US10766894 | 52 | 13 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG | 04/26/21 | 2D 3D TSV |
US10766884 | 294 | 137 | HGNC:1773 | Cyclin dependent kinase inhibitors | Pfizer Inc. | 04/26/21 | 2D 3D TSV |
US10766897 | 213 | 155 | HGNC:6251 HGNC:550 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC | 04/26/21 | 2D 3D TSV |
US10766864 | 106 | 106 | HGNC:8156 | Morphinan derivatives for the treatment of neuropathic pain | Nektar Therapeutics | 04/26/21 | 2D 3D TSV |
US10766903 | 245 | 243 | HGNC:12630 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | ALMAC DISCOVERY LIMITED | 04/26/21 | 2D 3D TSV |
US10766858 | 25 | 19 | HGNC:10597 | Substituted benzamides and methods of use thereof | GENENTECH, INC.; XENON PHARMACEUTICALS INC. | 04/26/21 | 2D 3D TSV |
US10766878 | 63 | 33 | HGNC:497 | Sulfonylcycloalkyl carboxamide compounds | Genentech, Inc. | 04/26/21 | 2D 3D TSV |
US10765676 | 43 | 43 | HGNC:8031 | Trk-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. | 04/26/21 | 2D 3D TSV |
US10766902 | 96 | 96 | HGNC:12761 | Wee-1 inhibiting pyrazolopyrimidinone compounds | ALMAC DISCOVERY LIMITED | 04/26/21 | 2D 3D TSV |
US10774065 | 22 | 22 | HGNC:9644 | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | NOVARTIS AG | 04/25/21 | 2D 3D TSV |
US10772893 | 488 | 432 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT | 04/25/21 | 2D 3D TSV | |
US10774070 | 79 | 39 | HGNC:9967 | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors | BLUEPRINT MEDICINES CORPORATION | 04/25/21 | 2D 3D TSV |
US10774051 | 1232 | 1204 | HGNC:8537 | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. | 04/25/21 | 2D 3D TSV |
US10774068 | 200 | 123 | HGNC:11408 HGNC:11406 | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 | THE SCRIPPS RESEARCH INSTITUTE; UNIVERSITÄT BREMEN | 04/25/21 | 2D 3D TSV |
US10774069 | 4 | 3 | HGNC:6666 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | PHARMAKEA, INC. | 04/25/21 | 2D 3D TSV |
US10774054 | 16 | 8 | HGNC:7967 | FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. | 04/25/21 | 2D 3D TSV |
US10774102 | 106 | 106 | HGNC:6563 | Galactoside inhibitor of galectins | Galecto Biotech AB | 04/25/21 | 2D 3D TSV |
US10774053 | 706 | 352 | HIV protease inhibitors | Gilead Sciences, Inc. | 04/25/21 | 2D 3D TSV | |
US10774052 | 194 | 191 | HGNC:3691 | Heteroaryl compounds and uses thereof | Celgene CAR LLC; Sanofi | 04/25/21 | 2D 3D TSV |
US10752635 | 54 | 54 | HGNC:6863 | Indazole compounds and uses thereof | Incyte Corporation | 04/25/21 | 2D 3D TSV |
US10774063 | 26 | 24 | HGNC:10289 | Materials and method for inhibiting replication protein A and uses thereof | Indiana University Research and Technology Corporation | 04/25/21 | 2D 3D TSV |
US10774085 | 105 | 105 | HGNC:8031 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA INC. | 04/25/21 | 2D 3D TSV |
US10774071 | 762 | 381 | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. | 04/25/21 | 2D 3D TSV | |
US10774056 | 197 | 71 | HGNC:4852 HGNC:6251 HGNC:4854 HGNC:4853 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. | 04/25/21 | 2D 3D TSV |
US10774092 | 345 | 343 | HGNC:12558 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; YALE UNIVERSITY | 04/25/21 | 2D 3D TSV |
US10759805 | 43 | 43 | HGNC:6871 | Compounds that are ERK inhibitors | Merck Sharp & Dohme Corp. | 04/19/21 | 2D 3D TSV |
US10759799 | 40 | 20 | HGNC:4617 HGNC:3091 | Indazole containing macrocycles and therapeutic uses thereof | Samumed, LLC | 04/19/21 | 2D 3D TSV |
US10759813 | 222 | 220 | HGNC:7154 | Neprilysin inhibitors | Theravance Biopharma R&D IP, LLC | 04/19/21 | 2D 3D TSV |
US10759812 | 26 | 15 | HGNC:85 HGNC:84 | Thienopyrimidine derivative and use thereof in medicine | Sunshine Lake Pharma Co., Ltd. | 04/19/21 | 2D 3D TSV |
US10759793 | 318 | 106 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | Almirall, S.A. | 04/18/21 | 2D 3D TSV | |
US10759794 | 172 | 77 | HGNC:6283 HGNC:6278 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | BAYER PHARMA AKTIENGESELLSCHAFT | 04/18/21 | 2D 3D TSV |
US10759787 | 43 | 33 | Benzofuran derivative, preparation method thereof and use thereof in medicine | Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. | 04/18/21 | 2D 3D TSV | |
US10759796 | 139 | 138 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. | 04/18/21 | 2D 3D TSV | |
US10759792 | 26 | 26 | CaMKII inhibitors and uses thereof | The Johns Hopkins University | 04/18/21 | 2D 3D TSV | |
US10759777 | 138 | 138 | HGNC:8846 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Synchronicity Pharma, Inc. | 04/18/21 | 2D 3D TSV |
US10758530 | 28 | 20 | HGNC:10435 HGNC:10431 HGNC:10430 HGNC:10432 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS | 04/18/21 | 2D 3D TSV |
US10759766 | 58 | 32 | HGNC:6307 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. | 04/18/21 | 2D 3D TSV |
US10759769 | 46 | 46 | HGNC:12524 | Glucosylceramide synthase inhibitors for the treatment of diseases | TBA | 04/18/21 | 2D 3D TSV |
US10759791 | 104 | 24 | HGNC:7872 | Mammalian and bacterial nitric oxide synthase inhibitors | Northwestern University | 04/18/21 | 2D 3D TSV |
US10759788 | 6 | 2 | HGNC:6251 HGNC:6255 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD.; SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. | 04/18/21 | 2D 3D TSV |
US10758542 | 530 | 232 | HGNC:8031 HGNC:12440 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharma Inc. | 04/18/21 | 2D 3D TSV |
US10758539 | 7 | 7 | HGNC:6307 | Therapeutic compounds and uses thereof | Kala Pharmaceuticals, Inc. | 04/18/21 | 2D 3D TSV |
US10745383 | 8 | 8 | 1,3,5-triazine derivative and method of using same | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. | 04/13/21 | 2D 3D TSV | |
US10744128 | 140 | 66 | HGNC:4617 HGNC:3091 | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | Samumed, LLC | 04/13/21 | 2D 3D TSV |
US10744125 | 24 | 6 | HGNC:268 HGNC:262 HGNC:263 HGNC:264 | Adenosine A3 receptor modulators | Palobiofarma, S.L. | 04/13/21 | 2D 3D TSV |
US10745392 | 57 | 19 | HGNC:10593 HGNC:10585 HGNC:10596 | Benzenesulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 04/13/21 | 2D 3D TSV |
US10745401 | 582 | 190 | HGNC:3023 HGNC:5286 | Condensed lactam derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. | 04/13/21 | 2D 3D TSV |
US10745399 | 334 | 57 | HGNC:8978 HGNC:795 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | Merck Patent GmbH | 04/13/21 | 2D 3D TSV |
US10745388 | 16 | 16 | HGNC:6863 | Indazole compounds and uses thereof | Incyte Corporation | 04/13/21 | 2D 3D TSV |
US10745380 | 2 | 2 | HGNC:10894 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD | 04/13/21 | 2D 3D TSV |
US10745410 | 18 | 18 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | ZENJI RESEARCH LABORATORIES | 04/13/21 | 2D 3D TSV | |
US10745364 | 424 | 420 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | Lycera Corporation; Merck Sharp & Dohme Corp. | 04/13/21 | 2D 3D TSV | |
US10745420 | 101 | 96 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | Board of Regents, The University of Texas System; ChemPartner Corporation | 04/13/21 | 2D 3D TSV | |
US10744104 | 41 | 40 | HGNC:7154 | Neprilysin inhibitors | Theravance Biopharma R&D IP, LLC | 04/12/21 | 2D 3D TSV |
US10744117 | 5 | 5 | HGNC:9236 | PPARG modulators for the treatment of osteoporosis | The Scripps Research Institute; The University of Toledo | 04/12/21 | 2D 3D TSV |
US10752581 | 86 | 75 | HGNC:429 HGNC:433 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | Eastern Virginia Medical School; The Regents of the University of California Santa; The United States of America Department of Health; Thomas Jefferson University | 04/11/21 | 2D 3D TSV |
US10752632 | 6 | 6 | HGNC:7056 | 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds | Eli Lilly and Company | 04/11/21 | 2D 3D TSV |
US10752598 | 20 | 20 | Aryldiazepine derivatives as RSV inhibitors | Enanta Pharmaceuticals, Inc. | 04/11/21 | 2D 3D TSV | |
US10752616 | 136 | 46 | HGNC:9864 HGNC:9866 HGNC:9865 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | King''s College London | 04/11/21 | 2D 3D TSV |
US10752604 | 35 | 20 | HGNC:11037 HGNC:11036 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. | 04/11/21 | 2D 3D TSV |
US10752613 | 21 | 15 | HGNC:12805 HGNC:17989 | Compounds and their use for reducing uric acid levels | Acquist LLC | 04/11/21 | 2D 3D TSV |
US10752588 | 28 | 27 | HGNC:3023 | Dopamine D2 receptor ligands | The Broad Institute, Inc.; Massachusetts Institute of Technology | 04/11/21 | 2D 3D TSV |
US10752623 | 196 | 62 | HGNC:10593 HGNC:10585 HGNC:10596 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | Xenon Pharmaceuticals Inc. | 04/11/21 | 2D 3D TSV |
US10752631 | 37 | 12 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Heterocyclic compounds as FGFR inhibitors | Guangzhou Innocare Pharma Tech Co., Ltd. | 04/11/21 | 2D 3D TSV |
US10752626 | 25 | 25 | Iso-citrate dehydrogenase (IDH) inhibitor | SHANGHAI METON PHARMACEUTICAL CO., LTD | 04/11/21 | 2D 3D TSV | |
US10752592 | 113 | 38 | HGNC:8156 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED | 04/11/21 | 2D 3D TSV |
US10752596 | 153 | 152 | Nitrogen-containing heteroaryl compound and pharmaceutical use thereof | JAPAN TOBACCO INC. | 04/11/21 | 2D 3D TSV | |
US10751335 | 60 | 28 | HGNC:8156 | Signaling-biased mu opioid receptor agonists | THE SCRIPPS RESEARCH INSTITUTE | 04/11/21 | 2D 3D TSV |
US10752615 | 526 | 148 | HGNC:1133 HGNC:6171 HGNC:11719 HGNC:12434 | Spirocyclic containing compounds and pharmaceutical uses thereof | GB005, Inc. | 04/11/21 | 2D 3D TSV |
US10751339 | 55 | 14 | HGNC:8979 HGNC:8978 HGNC:6251 | Substituted aminopyrimidine compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD.; CALITOR SCIENCES, LLC | 04/11/21 | 2D 3D TSV |
US10738015 | 84 | 42 | HGNC:8155 HGNC:8156 | 1,3-diaza-spiro-[3.4]-octane derivatives | GRÜNENTHAL GMBH | 04/04/21 | 2D 3D TSV |
US10738063 | 246 | 64 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | Pfizer Inc. | 04/04/21 | 2D 3D TSV | |
US10738007 | 130 | 97 | HGNC:10251 HGNC:10252 | Amide compounds as kinase inhibitors, compositions and methods of treatment | Translation Drug Development, LLC | 04/04/21 | 2D 3D TSV |
USRE48150 | 34 | 33 | HGNC:6857 | Apoptosis signal-regulating kinase inhibitors | Gilead Sciences, Inc. | 04/04/21 | 2D 3D TSV |
US10736881 | 141 | 96 | HGNC:4852 HGNC:13315 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI Pharma, Inc. | 04/04/21 | 2D 3D TSV |
US10738053 | 42 | 4 | HGNC:1373 HGNC:10548 | Bicyclic compounds as dual ATX/CA inhibitors | Hoffmann-La Roche Inc. | 04/04/21 | 2D 3D TSV |
US10738048 | 152 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 04/04/21 | 2D 3D TSV |
US10738074 | 43 | 29 | Cyclic di-nucleotide compounds as STING agonists | Merck Sharp & Dohme Corp. | 04/04/21 | 2D 3D TSV | |
US10738052 | 205 | 204 | HGNC:7029 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION | 04/04/21 | 2D 3D TSV |
US10738026 | 17 | 11 | HGNC:10597 | Isoquinoline derivatives and use thereof | Purdue Pharma L.P. | 04/04/21 | 2D 3D TSV |
US10736890 | 75 | 37 | HGNC:8156 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED | 04/04/21 | 2D 3D TSV |
US10738056 | 517 | 508 | Pyrazolopyrimidinone compounds and uses thereof | Aduro BioTech Inc. | 04/04/21 | 2D 3D TSV | |
US10738009 | 160 | 158 | HGNC:10582 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 04/04/21 | 2D 3D TSV |
US10736974 | 64 | 35 | HGNC:3788 | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy | THE JOHNS HOPKINS UNIVERSITY | 04/04/21 | 2D 3D TSV |
US10738057 | 246 | 118 | HGNC:8978 HGNC:8977 | Tertiary alcohols as PI3K-γ inhibitors | Incyte Corporation | 04/04/21 | 2D 3D TSV |
US10736883 | 326 | 315 | HGNC:339 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. | 04/04/21 | 2D 3D TSV |
US10723742 | 270 | 242 | HGNC:29079 | Biphenyl compound or salt thereof | Taiho Pharmaceutical Co., Ltd. | 03/30/21 | 2D 3D TSV |
US10730902 | 10 | 5 | HGNC:6561 HGNC:6563 | 1,1 ′-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins | GALECTO BIOTECH AB | 03/28/21 | 2D 3D TSV |
US10730889 | 403 | 380 | HGNC:30092 | Amido spirocyclic amide and sulfonamide derivatives | FORMA TM, LLC; Genentech, Inc. | 03/28/21 | 2D 3D TSV |
US10723734 | 237 | 230 | HGNC:19679 | Biaryl kinase inhibitors | Bristol-Myers Squibb Company | 03/28/21 | 2D 3D TSV |
US10722495 | 51 | 51 | HGNC:6863 | Cyanoindazole compounds and uses thereof | Incyte Corporation | 03/28/21 | 2D 3D TSV |
US10722597 | 33 | 4 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Cyclodextrin-panobinostat adduct | MIDATECH LTD. | 03/28/21 | 2D 3D TSV |
US10722489 | 10 | 10 | HGNC:8923 | D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof | Peking University | 03/28/21 | 2D 3D TSV |
US10723705 | 206 | 204 | HGNC:13315 | Heterocyclic compounds and uses thereof | Incyte Corporation | 03/28/21 | 2D 3D TSV |
US10723709 | 26 | 6 | HGNC:2536 HGNC:2537 HGNC:2545 | Protease inhibitors | MEDIVIR AB | 03/28/21 | 2D 3D TSV |
US10723723 | 220 | 173 | HGNC:6255 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | Bristol-Myers Squibb Company | 03/28/21 | 2D 3D TSV |
US10730882 | 34 | 34 | HGNC:10436 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED | 03/27/21 | 2D 3D TSV |
US10730880 | 867 | 199 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | Array BioPharma Inc.; Celgene Corporation | 03/27/21 | 2D 3D TSV |
US10730877 | 3210 | 841 | HGNC:15633 HGNC:15631 HGNC:15632 | 4-Azaindole compounds | Bristol-Myers Squibb Company | 03/27/21 | 2D 3D TSV |
US10730868 | 104 | 95 | HGNC:3540 | Bicyclic heteroaryl substituted compounds | Bristol-Myers Squibb Company | 03/27/21 | 2D 3D TSV |
US10730870 | 267 | 140 | HGNC:12687 | Compounds and methods for the enhanced degradation of targeted proteins | ARVINAS OPERATIONS, INC.; YALE UNIVERSITY | 03/27/21 | 2D 3D TSV |
US10730865 | 49 | 49 | Compounds for modulating aquaporins | APOGLYX AB | 03/27/21 | 2D 3D TSV | |
US10730860 | 3 | 2 | HGNC:13575 | Diaminopyrimidine benzenesulfone derivatives and uses thereof | Dana-Farber Cancer Institute, Inc. | 03/27/21 | 2D 3D TSV |
US10730881 | 28 | 28 | HGNC:620 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE, INC. | 03/27/21 | 2D 3D TSV |
US10730866 | 84 | 72 | HGNC:10597 | Indole derivatives and use thereof | Purdue Pharma L.P. | 03/27/21 | 2D 3D TSV |
US10730874 | 328 | 296 | HGNC:6371 | Inhibitors of plasma kallikrein and uses thereof | Shire Human Genetic Therapies, Inc. | 03/27/21 | 2D 3D TSV |
US10730875 | 135 | 31 | HGNC:6190 HGNC:6192 HGNC:12440 | Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | JN Therapeutics | 03/27/21 | 2D 3D TSV |
US10729680 | 63 | 63 | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT | 03/21/21 | 2D 3D TSV | |
US10730832 | 130 | 130 | Aliphatic prolinamide derivatives | ORION OPHTHALMOLOGY LLC | 03/21/21 | 2D 3D TSV | |
US10729684 | 24 | 12 | HGNC:10597 | Alkynyl dihydroquinoline sulfonamide compounds | AMGEN INC. | 03/21/21 | 2D 3D TSV |
US10729695 | 29 | 29 | HGNC:320 | Amino, amido and heterocyclic compounds as modulators of RAGE activity and uses thereof | The Research Foundation for the State University of New York; New York University | 03/21/21 | 2D 3D TSV |
US10730856 | 12 | 12 | HGNC:9596 | Benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT | 03/21/21 | 2D 3D TSV |
US10730849 | 95 | 51 | Benzo[b]thiophene compounds as STING agonists | Merck Sharp & Dohme Corp. | 03/21/21 | 2D 3D TSV | |
US10730863 | 435 | 427 | HGNC:7967 | Bridged bicyclic compounds as farnesoid X receptor modulators | Bristol-Myers Squibb Company | 03/21/21 | 2D 3D TSV |
US10729710 | 17 | 6 | HGNC:3023 HGNC:3020 | Catecholamine prodrugs for use in the treatment of Parkinson's disease | H. Lundbeck A/S | 03/21/21 | 2D 3D TSV |
US10717746 | 178 | 86 | HGNC:1780 | Chemical compounds | ASTRAZENECA AB | 03/21/21 | 2D 3D TSV |
US10730853 | 36 | 17 | HGNC:5184 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. | 03/21/21 | 2D 3D TSV |
US10717737 | 116 | 115 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 03/21/21 | 2D 3D TSV |
US10717733 | 462 | 116 | HGNC:6834 HGNC:550 HGNC:6666 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | Pharmaxis Ltd. | 03/21/21 | 2D 3D TSV |
US10717734 | 176 | 44 | HGNC:6834 HGNC:550 HGNC:6666 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | Pharmaxis Ltd. | 03/21/21 | 2D 3D TSV |
US10716791 | 42 | 17 | HGNC:18367 HGNC:18368 | Inhibitors of peptidyl arginine deiminase (PAD) enzymes and uses thereof | University Health Network | 03/21/21 | 2D 3D TSV |
US10730826 | 181 | 68 | HGNC:2531 HGNC:2538 HGNC:2527 HGNC:2536 HGNC:2547 HGNC:2537 HGNC:2545 HGNC:2535 | Ketone inhibitors of lysine gingipain | CORTEXYME, INC. | 03/21/21 | 2D 3D TSV |
US10717708 | 62 | 31 | HGNC:3827 HGNC:3826 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | Bristol-Myers Squibb Company | 03/21/21 | 2D 3D TSV |
US10730850 | 106 | 106 | HGNC:550 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | Boehringer Ingelheim International GmbH | 03/21/21 | 2D 3D TSV |
US10717738 | 29 | 29 | HGNC:3529 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. | 03/21/21 | 2D 3D TSV |
US10717742 | 148 | 137 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH | 03/21/21 | 2D 3D TSV | |
US10730833 | 9 | 9 | HGNC:348 | Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them | Wisconsin Alumni Research Foundation | 03/21/21 | 2D 3D TSV |
US10730830 | 51 | 25 | HGNC:3165 HGNC:14299 | Tetrahydronaphthalene derivative | ONO PHARMACEUTICAL CO., LTD. | 03/21/21 | 2D 3D TSV |
US10717764 | 402 | 207 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. | 03/21/21 | 2D 3D TSV | |
US10729691 | 118 | 59 | HGNC:11005 | Treatment of infectious diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC | 03/21/21 | 2D 3D TSV |
US10711036 | 87 | 87 | HGNC:6819 | MALT1 inhibitors and uses thereof | Cornell University; Dana-Farber Cancer Institute, Inc.; Children''s Medical Center Corporation | 03/15/21 | 2D 3D TSV |
US10711006 | 65 | 28 | HGNC:4840 HGNC:3697 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:2444 HGNC:3765 | Selective Bruton's tyrosine kinase inhibitor and use thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. | 03/15/21 | 2D 3D TSV |
US10711007 | 49 | 49 | HGNC:10894 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | Prelude Therapeutics Incorporated | 03/15/21 | 2D 3D TSV |
US10711020 | 881 | 783 | Tricyclic sulfones as RORγ modulators | Bristol-Myers Squibb Company | 03/15/21 | 2D 3D TSV | |
US10709688 | 40 | 16 | HGNC:3559 HGNC:3557 | Agent for treating synucleinopathy | Tohoku University; National University Corporation Okayama University | 03/14/21 | 2D 3D TSV |
US10710980 | 616 | 88 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | Novartis AG | 03/14/21 | 2D 3D TSV | |
US10709712 | 2614 | 1072 | HGNC:9829 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG | 03/14/21 | 2D 3D TSV |
US10709695 | 2 | 2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 03/14/21 | 2D 3D TSV | |
US10709718 | 28 | 28 | HGNC:2843 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof | Metabasis Therapeutics, Inc. | 03/14/21 | 2D 3D TSV |
US10710994 | 297 | 150 | HGNC:497 | Oxadiazole transient receptor potential channel inhibitors | Genentech, Inc. | 03/14/21 | 2D 3D TSV |
US10711004 | 455 | 275 | HGNC:497 | Oxadiazole transient receptor potential channel inhibitors | Genentech, Inc. | 03/14/21 | 2D 3D TSV |
US10710986 | 657 | 656 | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. | 03/14/21 | 2D 3D TSV | |
US10710967 | 299 | 294 | HGNC:9599 | Pyrimidine derivative | ASKA PHARMACEUTICAL CO., LTD. | 03/14/21 | 2D 3D TSV |
US10710978 | 234 | 59 | HGNC:11403 HGNC:11408 HGNC:18174 HGNC:11406 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC.; FONDAZIONE CENTRO SAN RAFFAELE | 03/14/21 | 2D 3D TSV |
US10709719 | 42 | 10 | HGNC:3167 HGNC:3165 | Substituted bicyclic compounds | Bristol-Myers Squibb Company | 03/14/21 | 2D 3D TSV |
US10709709 | 212 | 203 | HGNC:10894 | Substituted carbonucleoside derivatives useful as anticancer agents | Pfizer Inc. | 03/14/21 | 2D 3D TSV |
US10676499 | 33 | 17 | HGNC:3287 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG | 03/11/21 | 2D 3D TSV |
US10676464 | 43 | 43 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University Of The Commonwealth System of Higher Education | 03/11/21 | 2D 3D TSV | |
US10676458 | 17 | 11 | HGNC:4498 | Antidiabetic bicyclic compounds | Merch Sharp & Dohne Corp. Rahway | 03/11/21 | 2D 3D TSV |
US10676467 | 113 | 58 | HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | Washington University | 03/11/21 | 2D 3D TSV |
US10676457 | 130 | 129 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 03/11/21 | 2D 3D TSV |
US10676465 | 188 | 94 | HGNC:4324 | GLP-1 receptor agonists and uses thereof | Pfizer Inc. | 03/11/21 | 2D 3D TSV |
US10676479 | 360 | 118 | HGNC:17101 | Imidazolepyridine compounds and uses thereof | Novartis AG | 03/11/21 | 2D 3D TSV |
US10676470 | 36 | 34 | Inhibitors of lysine gingipain | CORTEXYME, INC. | 03/11/21 | 2D 3D TSV | |
US10676469 | 383 | 182 | HGNC:8154 HGNC:8156 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE | 03/11/21 | 2D 3D TSV |
US10676485 | 106 | 53 | HGNC:6943 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Inc. | 03/11/21 | 2D 3D TSV |
US10676460 | 56 | 3 | HGNC:9077 HGNC:11283 HGNC:11584 HGNC:14552 HGNC:17967 HGNC:12434 HGNC:11724 HGNC:6735 HGNC:2451 HGNC:5465 HGNC:4617 HGNC:2459 HGNC:6112 HGNC:2457 HGNC:3767 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:6171 HGNC:11390 HGNC:12440 HGNC:1079 HGNC:1771 HGNC:1133 HGNC:6860 HGNC:7972 HGNC:6524 HGNC:1775 | Quinazolines as potassium ion channel inhibitors | Bristol-Myers Squibb Company | 03/11/21 | 2D 3D TSV |
US10676476 | 30 | 14 | HGNC:3430 HGNC:5253 | Small-molecule HSP90 inhibitors | Sloan-Kettering Institute for Cancer Research | 03/11/21 | 2D 3D TSV |
US10676446 | 190 | 190 | HGNC:3357 | Bicyclic quinazolinone derivatives | Hoffmann-La Roche Inc. | 03/10/21 | 2D 3D TSV |
US10676434 | 200 | 178 | HGNC:1133 | Carbazole derivatives | Bristol-Myers Squibb Company | 03/10/21 | 2D 3D TSV |
US10675286 | 612 | 109 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. | 03/10/21 | 2D 3D TSV |
US10676433 | 355 | 196 | HGNC:5992 HGNC:8537 | Indole derivatives and their use in neurodegenerative diseases | Merck Patent GmbH | 03/10/21 | 2D 3D TSV |
US10676438 | 16 | 10 | HGNC:6251 | KCNQ2-5 channel activator | Ono Pharmaceutical Co., Ltd. | 03/10/21 | 2D 3D TSV |
US10676431 | 270 | 127 | HGNC:3827 HGNC:3826 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | Bristol-Myers Squibb Company | 03/10/21 | 2D 3D TSV |
US10675268 | 284 | 169 | HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | Somatostatin receptor subtype 4 (SSTR4) agonists | Centrexion Therapeutics Corporation | 03/10/21 | 2D 3D TSV |
US10675284 | 37 | 37 | HGNC:6190 HGNC:8977 | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | Incyte Corporation | 03/10/21 | 2D 3D TSV |
US10703751 | 36 | 7 | HGNC:6192 HGNC:6193 | Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof | Leo Pharma A/S | 03/08/21 | 2D 3D TSV |
US10703741 | 26 | 16 | HGNC:18368 | Covalent inhibitors of PAD4 | Padlock Therapeutics, Inc. | 03/08/21 | 2D 3D TSV |
US10702504 | 21 | 21 | HGNC:11812 | Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. | 03/08/21 | 2D 3D TSV |
US10703733 | 457 | 445 | MCL-1 inhibitors | Gilead Sciences, Inc. | 03/08/21 | 2D 3D TSV | |
US10702498 | 27 | 15 | HGNC:8154 HGNC:8156 | MU opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN-NÜRNBERG; THE BOARD OF TRUSTEES OFTHE LELAND STANFORD JUNIOR UNIVERSITY; THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 03/08/21 | 2D 3D TSV |
US10703749 | 843 | 289 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 03/08/21 | 2D 3D TSV |
US10708263 | 5 | 1 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV | 03/08/21 | 2D 3D TSV | |
US10703740 | 14 | 14 | HGNC:13575 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | Neomed Institute | 03/08/21 | 2D 3D TSV |
US10703755 | 351 | 337 | HGNC:15631 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. | 03/08/21 | 2D 3D TSV |
US10696692 | 374 | 308 | HGNC:30092 | Amido-benzyl sulfone and sulfoxide derivates | TBA | 03/02/21 | 2D 3D TSV |
US10696672 | 157 | 152 | HGNC:6161 | Amino acid compounds and methods of use | Pliant Therapeutics, Inc. | 03/02/21 | 2D 3D TSV |
US10696682 | 44 | 44 | HGNC:1771 | CDK inhibitors | G1 Therapeutics, Inc. | 03/02/21 | 2D 3D TSV |
US10696661 | 70 | 69 | HGNC:11305 | Compounds | Exonate Limited | 03/02/21 | 2D 3D TSV |
US10696638 | 48 | 43 | HGNC:10251 HGNC:10252 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE | 03/02/21 | 2D 3D TSV |
US10695334 | 98 | 57 | HGNC:6371 HGNC:11830 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | Boehringer Ingelheim International GmbH | 03/02/21 | 2D 3D TSV |
US10696678 | 154 | 64 | HGNC:1722 | Kinase inhibitor, and preparing method and pharmaceutical use thereof | GAN & LEE PHARMACEUTICALS | 03/02/21 | 2D 3D TSV |
US10696665 | 61 | 23 | HGNC:5382 | Mutant IDH1 inhibitors | Eli Lilly and Company | 03/02/21 | 2D 3D TSV |
US10695337 | 794 | 388 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | Incyte Holdings Corporation; Incyte Corporation | 03/02/21 | 2D 3D TSV | |
US10695347 | 84 | 40 | HGNC:427 | Pyrimidine derivative and use thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. | 03/02/21 | 2D 3D TSV |
US10696660 | 91 | 36 | HGNC:10251 HGNC:10252 | Rho kinase inhibitors | Kadmon Corporation, LLC | 03/02/21 | 2D 3D TSV |
US10696689 | 23 | 23 | HGNC:11331 | Somatostatin modulators and uses thereof | CRINETICS PHARMACEUTICALS, INC. | 03/02/21 | 2D 3D TSV |
US10696655 | 125 | 125 | HGNC:2348 | Therapeutic compounds and uses thereof | GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. | 03/02/21 | 2D 3D TSV |
US10689373 | 308 | 149 | HGNC:4849 HGNC:4848 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 02/22/21 | 2D 3D TSV |
US10689345 | 273 | 269 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Mission Therapeutics Limited | 02/22/21 | 2D 3D TSV | |
US10689401 | 50 | 25 | HGNC:934 HGNC:933 | C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp. | 02/22/21 | 2D 3D TSV |
US10689705 | 212 | 71 | HGNC:3690 HGNC:3689 HGNC:3688 | FGFR3 fusion gene and pharmaceutical drug targeting same | Chugai Seiyaku Kabushiki Kaisha | 02/22/21 | 2D 3D TSV |
US10689346 | 302 | 246 | HGNC:6371 | Human plasma kallikrein inhibitors | BioCryst Pharmaceuticals, Inc. | 02/22/21 | 2D 3D TSV |
US10688100 | 52 | 13 | HGNC:10261 | Macrocylic compounds as ROS1 kinase inhibitors | Array BioPharma Inc. | 02/22/21 | 2D 3D TSV |
US10688093 | 708 | 647 | HGNC:4037 | Methods, compositions, and uses of novel Fyn kinase inhibitors | TBA | 02/22/21 | 2D 3D TSV |
US10689357 | 43 | 43 | HGNC:736 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof | NORTHEASTERN UNIVERSITY | 02/22/21 | 2D 3D TSV |
US10689398 | 91 | 89 | HGNC:8157 | OXA-Diazaspiro compounds having activity against pain | ESTEVE PHARMACEUTICALS, S.A. | 02/22/21 | 2D 3D TSV |
USRE48059 | 122 | 64 | Piperazine-substituted benzothiophenes for treatment of mental disorders | Otsuka Pharmaceutical Co., Ltd. | 02/22/21 | 2D 3D TSV | |
US10689327 | 30 | 15 | HGNC:4595 HGNC:4594 | Prodrug amino acid derivative | TAISHO PHARMACEUTICAL CO., LTD. | 02/22/21 | 2D 3D TSV |
US10689339 | 69 | 69 | HGNC:2545 | Pyrrolidine derivatives | Hoffmann-La Roche Inc. | 02/22/21 | 2D 3D TSV |
US10689362 | 508 | 124 | HGNC:8804 HGNC:6342 HGNC:3765 | Quinoxaline compounds as type III receptor tyrosine kinase inhibitors | Development Center for Biotechnology | 02/22/21 | 2D 3D TSV |
US10689399 | 23 | 23 | HGNC:9213 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | Gilead Sciences, Inc. | 02/22/21 | 2D 3D TSV |
US10689369 | 149 | 127 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp. | 02/22/21 | 2D 3D TSV | |
US10689376 | 39 | 39 | HGNC:3356 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc.; The University of Utah | 02/22/21 | 2D 3D TSV |
US10689414 | 404 | 206 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. | 02/22/21 | 2D 3D TSV | |
US10689367 | 327 | 233 | HGNC:339 | Triazole pyridyl compounds as agonists of the APJ receptor | AMGEN INC. | 02/22/21 | 2D 3D TSV |
US10689390 | 18 | 18 | HGNC:13575 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer | JUBILANT BIOSYS LIMITED | 02/22/21 | 2D 3D TSV |
US10689395 | 14 | 14 | HGNC:13575 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | JUBILANT BIOSYS LIMITED | 02/22/21 | 2D 3D TSV |
US10669240 | 500 | 242 | HGNC:3091 | 5-substituted indazole-3-carboxamides and preparation and use thereof | Samumed, LLC | 02/21/21 | 2D 3D TSV |
US10669246 | 153 | 115 | HGNC:8803 HGNC:76 HGNC:6342 | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | 1ST Biotherapeutics, Inc. | 02/21/21 | 2D 3D TSV |
US10669268 | 343 | 306 | HGNC:10548 | Bicyclic derivatives | Hoffmann-La Roche Inc. | 02/21/21 | 2D 3D TSV |
US10669289 | 209 | 104 | HGNC:9542 HGNC:9545 | Boronic acid derivatives | MERCK PATENT GMBH | 02/21/21 | 2D 3D TSV |
US10669245 | 37 | 37 | HGNC:2528 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB | 02/21/21 | 2D 3D TSV |
US10669285 | 43 | 43 | HGNC:10548 | Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | Hoffmann-La Roche Inc. | 02/21/21 | 2D 3D TSV |
US10669276 | 48 | 48 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE INC. | 02/21/21 | 2D 3D TSV | |
US10669271 | 94 | 30 | HGNC:7794 HGNC:9644 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 02/21/21 | 2D 3D TSV |
US10669279 | 372 | 104 | HGNC:8780 HGNC:8781 HGNC:8783 | Imidazopyridazine compounds | Pfizer Inc. | 02/21/21 | 2D 3D TSV |
US10669243 | 10 | 10 | Isoxazole carboxamides as irreversible SMYD inhibitors | EPIZYME, INC. | 02/21/21 | 2D 3D TSV | |
US10669296 | 8 | 4 | LXR agonists and uses thereof | Rgenix, Inc. | 02/21/21 | 2D 3D TSV | |
US10669265 | 142 | 72 | HGNC:6307 HGNC:8804 HGNC:9437 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. | 02/21/21 | 2D 3D TSV |
US10669267 | 65 | 39 | HGNC:8537 | Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists | Axxam S.P.A. | 02/21/21 | 2D 3D TSV |
US10669273 | 42 | 36 | HGNC:6059 | Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO | Peking University | 02/21/21 | 2D 3D TSV |
US10683294 | 67 | 67 | HGNC:1338 | 5-5 fused rings as C5a inhibitors | ChemoCentryx, Inc. | 02/16/21 | 2D 3D TSV |
US10683295 | 59 | 29 | HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | Ogeda SA | 02/16/21 | 2D 3D TSV |
US10683291 | 3 | 3 | HGNC:3165 | Heterocyclic compounds for the treatment of disease | OPPILAN PHARMA LTD. | 02/16/21 | 2D 3D TSV |
US10683290 | 84 | 80 | Tricyclic compounds as anticancer agents | Bristol-Myers Squibb Company | 02/16/21 | 2D 3D TSV | |
US10683309 | 84 | 42 | HGNC:12008 HGNC:20692 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN; FORSCHUNGSVERBUND BERLIN E.V. | 02/16/21 | 2D 3D TSV |
US10668071 | 105 | 100 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT | 02/15/21 | 2D 3D TSV | |
US10667515 | 17 | 17 | (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using | Iowa State University Research Foundation, Inc. | 02/15/21 | 2D 3D TSV | |
US10683279 | 71 | 68 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 02/15/21 | 2D 3D TSV |
US10683289 | 23 | 23 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 02/15/21 | 2D 3D TSV |
US10682352 | 117 | 100 | HGNC:5382 | Compound having mutant IDH inhibitory activity, preparation method and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 02/15/21 | 2D 3D TSV |
US10669227 | 24 | 9 | HGNC:7175 HGNC:7176 HGNC:7166 HGNC:7159 | Curcumin analogues as zinc chelators and their uses | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 02/15/21 | 2D 3D TSV |
US10669234 | 193 | 147 | HGNC:12513 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED | 02/15/21 | 2D 3D TSV |
US10668167 | 176 | 62 | HGNC:7978 HGNC:644 HGNC:3467 HGNC:8910 | Glucocorticoid receptor agonist and immunoconjugates thereof | AbbVie Inc. | 02/15/21 | 2D 3D TSV |
US10683287 | 96 | 45 | HGNC:934 HGNC:933 | Heterocyclic derivatives and their use in the treatment of neurological disorders | Novartis AG | 02/15/21 | 2D 3D TSV |
US10669235 | 336 | 55 | HGNC:8803 HGNC:3763 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3688 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED | 02/15/21 | 2D 3D TSV |
US10668051 | 56 | 56 | HGNC:25896 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA | 02/15/21 | 2D 3D TSV |
US10668033 | 4 | 4 | HGNC:9602 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 02/15/21 | 2D 3D TSV |
US10668067 | 135 | 135 | HGNC:10597 | Pyridine sulfonamides | AMGEN INC. | 02/15/21 | 2D 3D TSV |
US10668094 | 92 | 21 | Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure | Yeda Research and Development Co. Ltd. | 02/15/21 | 2D 3D TSV | |
US10669239 | 74 | 68 | HGNC:8031 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. | 02/15/21 | 2D 3D TSV |
US10660877 | 2542 | 841 | HGNC:15633 HGNC:15631 HGNC:15632 | Pyridyl substituted indole compounds | Bristol-Myers Squibb Company | 02/08/21 | 2D 3D TSV |
US10662159 | 204 | 60 | HGNC:3553 HGNC:17038 HGNC:21398 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | MAKSCIENTIFIC, LLC | 02/07/21 | 2D 3D TSV |
US10660876 | 90 | 89 | HGNC:2771 | Amino compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. | 02/07/21 | 2D 3D TSV |
US10662184 | 150 | 83 | HGNC:10593 HGNC:10585 HGNC:10596 | Benzenesulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc. | 02/07/21 | 2D 3D TSV |
US10660898 | 27 | 27 | HGNC:8972 | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC | 02/07/21 | 2D 3D TSV |
US10662187 | 134 | 124 | HGNC:6735 HGNC:1057 HGNC:1133 HGNC:3236 HGNC:6524 | Bruton's tyrosine kinase inhibitors | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 02/07/21 | 2D 3D TSV |
US10662156 | 94 | 90 | HGNC:6819 | Guanidine derivative and medical use thereof | Toray Industries, Inc. | 02/07/21 | 2D 3D TSV |
US10662189 | 84 | 78 | HGNC:8781 | PDE4 inhibitor | SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD. | 02/07/21 | 2D 3D TSV |
US10662186 | 650 | 137 | HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:1777 HGNC:1774 HGNC:1773 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. | 02/07/21 | 2D 3D TSV |
US10654833 | 96 | 90 | HGNC:6857 | ASK1 isoindolin-1-one inhibitors and methods of use thereof | Hepatikos Therapeutics, LLC | 02/01/21 | 2D 3D TSV |
US10654857 | 68 | 7 | HGNC:10555 | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | Hoffman-La Roche Inc. | 02/01/21 | 2D 3D TSV |
US10654835 | 207 | 69 | Compounds and methods for inhibiting JAK | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | 02/01/21 | 2D 3D TSV | |
US10654856 | 20 | 17 | HGNC:15631 HGNC:15632 | Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. | 02/01/21 | 2D 3D TSV |
US10654855 | 73 | 73 | HGNC:391 | Protein kinase B inhibitors | AstraZeneca AB | 02/01/21 | 2D 3D TSV |
US10654836 | 40 | 10 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pyrimidine derivative, method for preparing same and use thereof in medicine | Zhejiang Hisun Pharmaceutical Co., Ltd. | 02/01/21 | 2D 3D TSV |
US10654866 | 44 | 21 | HGNC:3467 | Selective estrogen receptor degraders | Eli Lilly and Company | 02/01/21 | 2D 3D TSV |
US10654853 | 147 | 145 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED | 02/01/21 | 2D 3D TSV | |
US10654860 | 35 | 31 | HGNC:10252 | Tricyclic rho kinase inhibitors | Bristol-Myers Squibb Company | 02/01/21 | 2D 3D TSV |
US10653688 | 302 | 143 | HGNC:4617 HGNC:3091 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | Samumed, LLC | 01/31/21 | 2D 3D TSV |
US10654831 | 85 | 14 | HGNC:1780 HGNC:1771 HGNC:1774 HGNC:1773 HGNC:1775 | Antiproliferative pyrimidine-based compounds | G1 Therapeutics, Inc. | 01/31/21 | 2D 3D TSV |
US10654814 | 240 | 127 | HGNC:4852 HGNC:14064 HGNC:13315 HGNC:4854 HGNC:4853 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB | 01/31/21 | 2D 3D TSV |
US10653701 | 103 | 52 | HGNC:6307 HGNC:1133 HGNC:6193 HGNC:3689 HGNC:3236 HGNC:3688 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. | 01/31/21 | 2D 3D TSV |
US10647665 | 39 | 33 | Biaryl urea derivative or salt thereof and preparation process and use for the same | Fudan University | 01/25/21 | 2D 3D TSV | |
US10647719 | 107 | 5 | HGNC:10555 HGNC:1373 | Bicyclic compounds as dual ATX/CA inhibitors | Hoffmann-La Roche Inc. | 01/25/21 | 2D 3D TSV |
US10647706 | 40 | 14 | HGNC:6026 HGNC:6027 | Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies | GALDERMA RESEARCH & DEVELOPMENT | 01/25/21 | 2D 3D TSV |
US10647694 | 45 | 40 | HGNC:427 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ARROMAX PHARMATECH CO., LTD. | 01/25/21 | 2D 3D TSV |
US10647700 | 14 | 14 | EZH2 inhibitor and use thereof | TARAPEUTICS SCIENCE INC. | 01/25/21 | 2D 3D TSV | |
US10646575 | 3 | 3 | HGNC:2717 | Heterocyclic degronimers for target protein degradation | C4 Therapeutics, Inc. | 01/25/21 | 2D 3D TSV |
US10646492 | 366 | 342 | HGNC:8977 | Heterocyclylamines as PI3K inhibitors | Incyte Corporation; Incyte Holdings Corporation | 01/25/21 | 2D 3D TSV |
US10647720 | 614 | 333 | HGNC:6192 HGNC:11491 | Pyrimido-pyridazinone compounds and methods of use thereof | Asan BioSciences, LLC | 01/25/21 | 2D 3D TSV |
US10647727 | 66 | 47 | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors | Merck Sharp & Dohme Corp. | 01/25/21 | 2D 3D TSV | |
US10647686 | 82 | 50 | HGNC:11396 HGNC:11395 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY | 01/25/21 | 2D 3D TSV |
US10647713 | 620 | 601 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 01/25/21 | 2D 3D TSV | |
US10647708 | 46 | 46 | HGNC:10894 | Tetrahydroisoquinoline derived PRMT5-inhibitors | CTXT PTY. LTD | 01/25/21 | 2D 3D TSV |
US10639286 | 194 | 172 | Alkoxy compounds for disease treatment | ACUCELA INC. | 01/18/21 | 2D 3D TSV | |
US10640498 | 69 | 68 | Compounds | MISSION THERAPEUTICS LIMITED | 01/18/21 | 2D 3D TSV | |
US10640533 | 114 | 19 | HGNC:2524 HGNC:24059 HGNC:9537 | Epoxyketone compounds for enzyme inhibition | CENTRAX INTERNATIONAL, INC. | 01/18/21 | 2D 3D TSV |
US10640486 | 86 | 85 | HGNC:1133 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | Boehringer Ingelheim International GmbH | 01/18/21 | 2D 3D TSV |
US10640495 | 646 | 615 | HGNC:8031 | Heterocycle derivatives having TrkA inhibitory activity | Shionogi & Co., Ltd. | 01/18/21 | 2D 3D TSV |
US10640503 | 158 | 158 | HGNC:29079 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | Incyte Corporation | 01/18/21 | 2D 3D TSV |
US10639284 | 329 | 312 | HGNC:17635 | Immunomodulator compounds | ChemoCentryx, Inc. | 01/18/21 | 2D 3D TSV |
US10640491 | 20 | 20 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. | 01/18/21 | 2D 3D TSV |
US10640534 | 402 | 205 | Therapeutically active compositions and their methods of use | Agios Pharmaceuticals, Inc. | 01/18/21 | 2D 3D TSV | |
US10633384 | 113 | 113 | HGNC:10555 | Diazaspirocycloalkane and azaspirocycloalkane | Hoffmann-La Roche Inc. | 01/12/21 | 2D 3D TSV |
US10632126 | 676 | 168 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 01/10/21 | 2D 3D TSV |
US10633379 | 264 | 130 | Bromodomain inhibitors | AbbVie Inc. | 01/10/21 | 2D 3D TSV | |
US10633389 | 1029 | 1023 | HGNC:23393 | CARM1 inhibitors and uses thereof | Epizyme, Inc. | 01/10/21 | 2D 3D TSV |
US10632122 | 116 | 115 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | University of Washington | 01/10/21 | 2D 3D TSV | |
US10633345 | 302 | 248 | HGNC:6371 | Human plasma kallikrein inhibitors | BioCryst Pharmaceuticals, Inc. | 01/10/21 | 2D 3D TSV |
US10632171 | 152 | 130 | HGNC:6932 HGNC:4479 | Melanocortin receptor-specific peptides | Palatin Technologies, Inc. | 01/10/21 | 2D 3D TSV |
US10633348 | 39 | 16 | HGNC:4840 HGNC:1133 HGNC:4195 HGNC:7972 | Methods to treat lymphoplasmacytic lymphoma | Dana-Farber Cancer Institute, Inc. | 01/10/21 | 2D 3D TSV |
US10633375 | 111 | 107 | HGNC:3529 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | Jinagsu Hengrui Medicine Co., Ltd; Shanghai Hengrui Pharmaceutical Co., Ltd. | 01/10/21 | 2D 3D TSV |
US10633388 | 19 | 14 | HGNC:4421 | Pyrazolopyrimidone derivatives and methods of use thereof | Shanghai Hengrui Pharmaceutical Co., ltd.; Jiangsu Hangrui Medicine Co., Ltd. | 01/10/21 | 2D 3D TSV |
US10633373 | 123 | 72 | HGNC:6307 HGNC:8804 HGNC:9437 | Pyridyl benzothiophenes as kinase inhibitors | Allergan, Inc. | 01/10/21 | 2D 3D TSV |
US10604514 | 334 | 150 | HGNC:4617 HGNC:3091 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | Samumed, LLC | 12/21/20 | 2D 3D TSV |
US10604534 | 38 | 19 | HGNC:934 HGNC:933 | C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp. | 12/21/20 | 2D 3D TSV |
US10604535 | 251 | 240 | Compounds, compositions and methods | Denali Therapeutics Inc. | 12/21/20 | 2D 3D TSV | |
US10604531 | 11 | 11 | HGNC:3527 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED | 12/21/20 | 2D 3D TSV |
US10604536 | 59 | 54 | HGNC:8772 | Substituted cyclopropanes as PDE-10 inhibitors | Sunovion Pharamaceuticals Inc. | 12/21/20 | 2D 3D TSV |
US10604508 | 11 | 11 | HGNC:1133 | 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same | CrystalGenomics, Inc. | 12/20/20 | 2D 3D TSV |
US10603310 | 14 | 12 | HGNC:933 | 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors | H. Lundbeck A/S | 12/20/20 | 2D 3D TSV |
US10618929 | 21 | 20 | HGNC:15631 | 3-substituted 5-amino-6H-thiazolo[4,5-D]pyrimidine-2, 7-dione compounds for the treatment and prophylaxis of virus infection | Hoffmann-La Roche Inc. | 12/20/20 | 2D 3D TSV |
US10618900 | 52 | 27 | HGNC:4597 HGNC:4593 | 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 12/20/20 | 2D 3D TSV |
US10618914 | 79 | 43 | HGNC:11364 HGNC:11362 | 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity | University of Pittsburgh—Of the Commonwealth System of Higher Education | 12/20/20 | 2D 3D TSV |
US10603330 | 131 | 65 | HGNC:663 HGNC:664 | Arginase inhibitors as therapeutics | Mars, Incorporated | 12/20/20 | 2D 3D TSV |
US10618886 | 36 | 17 | HGNC:5184 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. | 12/20/20 | 2D 3D TSV |
US10604489 | 172 | 171 | HGNC:8156 | Compounds for the treatment of pain | Alkermes, Inc. | 12/20/20 | 2D 3D TSV |
US10603320 | 9 | 3 | HGNC:10258 | Compounds useful for inhibiting ROR-gamma-t | Eli Lilly and Company | 12/20/20 | 2D 3D TSV |
US10618884 | 16 | 1 | HGNC:427 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | 12/20/20 | 2D 3D TSV |
US10618912 | 55 | 18 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:427 HGNC:10261 HGNC:11397 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. | 12/20/20 | 2D 3D TSV |
US10618903 | 287 | 262 | HGNC:17967 | Heteroaryl substituted aminopyridine compounds | Bristol-Myers Squibb Company | 12/20/20 | 2D 3D TSV |
US10618916 | 68 | 68 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 12/20/20 | 2D 3D TSV | |
US10604504 | 262 | 222 | HGNC:1133 | Indole carboxamide compounds | Bristol-Myers Squibb Company | 12/20/20 | 2D 3D TSV |
US10618913 | 114 | 37 | HGNC:8775 HGNC:8774 HGNC:8776 | Macrocycles as PDE1 inhibitors | H. Lundbeck A/S | 12/20/20 | 2D 3D TSV |
US10618897 | 168 | 161 | HGNC:2730 | Spiroindolinones as DDR1 inhibitors | Hoffmann-La Roche Inc. | 12/20/20 | 2D 3D TSV |
US10604502 | 112 | 111 | HGNC:29079 | Substituted 5-cyanoindole compounds and uses thereof | Novartis AG | 12/20/20 | 2D 3D TSV |
US10618902 | 256 | 249 | HGNC:3691 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | Celgene CAR LLC; Sanofi | 12/20/20 | 2D 3D TSV |
US10618910 | 58 | 29 | Tricyclic heterocycles as BET protein inhibitors | Incyte Corporation | 12/20/20 | 2D 3D TSV | |
US10597383 | 35 | 35 | Bicyclic proline compounds | Genentech, Inc. | 12/14/20 | 2D 3D TSV | |
US10597387 | 19 | 8 | HGNC:4840 HGNC:1133 HGNC:7972 | Methods to treat lymphoplasmacytic lymphoma | Dana-Farber Cancer Institute, Inc. | 12/14/20 | 2D 3D TSV |
US10597399 | 40 | 39 | HGNC:270 | Substituted triazolopiperazine PARP inhibitor, preparation method therefor and use thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 12/14/20 | 2D 3D TSV |
US10597382 | 16 | 15 | HGNC:6857 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 12/14/20 | 2D 3D TSV |
US10596172 | 747 | 259 | HGNC:1079 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:3236 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | Celgene CAR LLC | 12/13/20 | 2D 3D TSV |
US10597366 | 413 | 325 | HGNC:12680 HGNC:3374 | Aryl ethers and uses thereof | Peloton Therapeutics, Inc. | 12/13/20 | 2D 3D TSV |
US10596184 | 158 | 76 | HGNC:8978 HGNC:8977 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | Incyte Corporation | 12/13/20 | 2D 3D TSV |
US10617673 | 8 | 8 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | Jenrin Discovery, LLC | 12/13/20 | 2D 3D TSV | |
US10617706 | 43 | 42 | HGNC:17768 | Compounds for cancer chemotherapeutic sensitization | REGENTS OF THE UNIVERSITY OF MINNESOTA; THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 12/13/20 | 2D 3D TSV |
US10597367 | 724 | 191 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | 12/13/20 | 2D 3D TSV | |
US10610125 | 24 | 5 | HGNC:5382 HGNC:6541 HGNC:6535 | Methods and compositions for cell-proliferation-related disorders | Agios Pharmaceuticals, Inc. | 12/13/20 | 2D 3D TSV |
US10617692 | 4 | 4 | HGNC:6192 | Pyrrolopyrimidine comprising cyclopentyl substituent | CENTAURUS BIOPHARMA CO.; CHIA TAI TIANQING PHARMACEUTICAL GROUP CO.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. | 12/13/20 | 2D 3D TSV |
US10597377 | 268 | 258 | HGNC:11331 | Somatostatin modulators and uses thereof | CRINETICS PHARMACEUTICALS, INC. | 12/13/20 | 2D 3D TSV |
US10617676 | 596 | 594 | HGNC:4586 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV | 12/13/20 | 2D 3D TSV |
US10617680 | 423 | 397 | HGNC:2348 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. | 12/13/20 | 2D 3D TSV |
US10617654 | 78 | 26 | HGNC:286 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | The USA, as represented by the Secretary, Department of Health and Human Services; SRI International | 12/13/20 | 2D 3D TSV |
US10590106 | 12 | 6 | HGNC:6307 | Certain chemical entities, compositions, and methods | NeuPharma, Inc. | 12/08/20 | 2D 3D TSV |
US10590105 | 56 | 56 | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | Bristol-Meyers Squibb Company | 12/07/20 | 2D 3D TSV | |
US10611727 | 18 | 18 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | UNIVERSITAT DE BARCELONA; FUNACIÓ INSTITUT DE RECERCA BIOMÉDICA; IPROTEOS S.L. | 12/07/20 | 2D 3D TSV | |
US10611730 | 212 | 212 | HGNC:13628 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | Janssen Pharmaceutica NV | 12/07/20 | 2D 3D TSV |
US10610539 | 14 | 14 | Cardiac glycoside analogs and their use in methods for inhibition of viral infection | The John Hopkins University | 12/07/20 | 2D 3D TSV | |
US10590130 | 121 | 63 | HGNC:6251 | Chemical compounds | AstraZeneca AB | 12/07/20 | 2D 3D TSV |
US10590114 | 215 | 161 | HGNC:18618 | Compounds, compositions, and methods | Denali Therapautics Inc. | 12/07/20 | 2D 3D TSV |
US10611770 | 26 | 26 | HGNC:427 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. | 12/07/20 | 2D 3D TSV |
US10590075 | 29 | 29 | Cyanopyrrolidine derivatives as inhibitors for DUBs | MISSION THERAPEUTICS LIMITED | 12/07/20 | 2D 3D TSV | |
US10611751 | 15 | 15 | HGNC:3020 | Dopamine D1 receptor positive allosteric modulators | Eli Lilly and Company | 12/07/20 | 2D 3D TSV |
US10590109 | 85 | 24 | Heterocyclic compounds used as FGFR inhibitors | Nanjing InnoCare Pharma Tech Co., Ltd. | 12/07/20 | 2D 3D TSV | |
US10611763 | 116 | 114 | HGNC:17071 | Histone demethylase inhibitors | Celgene Quanticel Research, Inc. | 12/07/20 | 2D 3D TSV |
US10611777 | 156 | 69 | HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED | 12/07/20 | 2D 3D TSV |
US10611728 | 246 | 97 | HGNC:6251 HGNC:8157 | Isoindoline compositions and methods for treating neurodegenerative disease | COGNITION THERAPEUTICS, INC. | 12/07/20 | 2D 3D TSV |
US10590139 | 60 | 60 | HGNC:8031 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | Array BioPharma Inc. | 12/07/20 | 2D 3D TSV |
US10611766 | 279 | 95 | HGNC:1133 HGNC:3236 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | Loxo Oncology Inc. | 12/07/20 | 2D 3D TSV |
US10590132 | 289 | 159 | HGNC:6251 | Selective estrogen receptor down-regulators | AstraZeneca AB | 12/07/20 | 2D 3D TSV |
US10590077 | 7 | 7 | HGNC:18083 | TRPV4 antagonists | GlaxoSmithKline Intellectual Property Development Limited | 12/07/20 | 2D 3D TSV |
US10590140 | 785 | 438 | HGNC:11048 | Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. | 12/07/20 | 2D 3D TSV |
US10570125 | 40 | 16 | HGNC:2160 HGNC:2159 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | Centrexion Therapeutics Corporation | 11/30/20 | 2D 3D TSV |
US10570116 | 153 | 53 | HGNC:270 HGNC:11941 HGNC:15677 | 1,4-dicarbonyl-piperidyl derivatives | Merck Patent GmbH | 11/30/20 | 2D 3D TSV |
US10568884 | 22 | 22 | Compounds and compositions as protein kinase inhibitors | Array BioPharma Inc. | 11/30/20 | 2D 3D TSV | |
US10570167 | 249 | 149 | HGNC:8021 | Ectonucleotidase inhibitors and methods of use thereof | Calithera Biosciences, Inc. | 11/30/20 | 2D 3D TSV |
US10570155 | 21 | 8 | HGNC:9829 HGNC:1097 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 11/30/20 | 2D 3D TSV |
US10570118 | 43 | 40 | HGNC:1133 | Isoquinolones as BTK inhibitors | Boehringer Ingelheim International GmbH | 11/30/20 | 2D 3D TSV |
US10570123 | 100 | 51 | HGNC:10251 HGNC:10252 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 11/30/20 | 2D 3D TSV |
US10570140 | 42 | 42 | HGNC:29652 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | Prelude Therapeutics Incorporated | 11/30/20 | 2D 3D TSV |
US10570077 | 7 | 7 | HGNC:3467 | Substituted (4'-hydroxyphenyl)cyclohexane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform | Marquette University; Concordia University Inc. | 11/30/20 | 2D 3D TSV |
US10570121 | 412 | 114 | HGNC:3527 | Substituted dihydroisoquinolinone compounds | Pfizer Inc. | 11/30/20 | 2D 3D TSV |
US10570156 | 42 | 42 | HGNC:8772 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. | 11/30/20 | 2D 3D TSV |
US10570141 | 14 | 7 | HGNC:1777 HGNC:1773 | Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. | 11/30/20 | 2D 3D TSV |
US10568876 | 141 | 138 | HGNC:16940 | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | Merck Sharp & Dohme Corp. | 11/30/20 | 2D 3D TSV |
US10568888 | 26 | 13 | HGNC:8781 HGNC:8783 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | vTv Therapeutics LLC | 11/30/20 | 2D 3D TSV |
US10584127 | 26 | 11 | HGNC:4586 HGNC:6251 HGNC:2625 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | Rugen Holdings (Cayman) Limited | 11/29/20 | 2D 3D TSV |
US10584111 | 25 | 22 | HGNC:4597 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | Heptares Therapeutics Limited | 11/29/20 | 2D 3D TSV |
US10577368 | 81 | 61 | HGNC:268 HGNC:262 HGNC:263 | A3 adenosine receptor agonists | The United States of America, as represented by the Secretary, Department of Health and Human Services; Saint Louis University | 11/29/20 | 2D 3D TSV |
US10584120 | 58 | 58 | HGNC:9753 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | National Health Research Institutes; Academia Sinica | 11/29/20 | 2D 3D TSV |
US10577374 | 360 | 356 | HGNC:1133 | Bruton's tyrosine kinase inhibitors | Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. | 11/29/20 | 2D 3D TSV |
US10584104 | 18 | 18 | HGNC:17989 | Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. | 11/29/20 | 2D 3D TSV |
US10584121 | 10 | 10 | Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp. | 11/29/20 | 2D 3D TSV | |
US10584116 | 51 | 51 | HGNC:497 | Heterocyclic sulfonamide derivative and medicine containing same | EA Pharma Co., Ltd. | 11/29/20 | 2D 3D TSV |
US10568874 | 8 | 8 | HGNC:17635 | Indane-amines as PD-L1 antagonists | ChemoCentryx, Inc. | 11/29/20 | 2D 3D TSV |
US10583140 | 12 | 12 | Ingenol analogs, pharmaceutical compositions and methods of use thereof | GlaxoSmithKline Intellectual Property Development Limited | 11/29/20 | 2D 3D TSV | |
US10584114 | 82 | 41 | HGNC:9967 | Inhibitors of RET | BLUEPRINT MEDICINES CORPORATION | 11/29/20 | 2D 3D TSV |
US10577383 | 78 | 37 | HGNC:7218 | Macrocyclic inhibitors of myeloperoxidase | Bristol-Myers Squibb Company | 11/29/20 | 2D 3D TSV |
US10584098 | 12 | 12 | Quinolone-3-diarylethers | Oregon Health & Science University | 11/29/20 | 2D 3D TSV | |
US10584132 | 20 | 12 | HGNC:10852 HGNC:10850 | SHMT inhibitors | The Trustees of Princeton University | 11/29/20 | 2D 3D TSV |
US10584103 | 224 | 211 | HGNC:8039 | Small molecule agonists of neurotensin receptor 1 | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | 11/29/20 | 2D 3D TSV |
US10584135 | 348 | 174 | HGNC:3023 HGNC:3024 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED | 11/29/20 | 2D 3D TSV |
US10577373 | 1366 | 1143 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. | 11/29/20 | 2D 3D TSV | |
US10583137 | 116 | 56 | HGNC:1165 HGNC:28923 | Triazole DAGLα inhibitors | THE SCRIPPS RESEARCH INSTITUTE; LEIDEN UNIVERSITY | 11/29/20 | 2D 3D TSV |
US10584134 | 79 | 69 | HGNC:17961 | Use of physiological cooling active ingredients, and agents containing such active ingredients | SYMRISE AG; BASF SE | 11/29/20 | 2D 3D TSV |
US10561662 | 73 | 73 | HGNC:19995 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | Takeda Pharmaceutical Company Limited | 11/22/20 | 2D 3D TSV |
US10562893 | 49 | 22 | HGNC:6171 HGNC:11719 HGNC:12434 | Benzimidazoles derivatives as Tec kinases family inhibitors | GB005, INC. | 11/22/20 | 2D 3D TSV |
US10562890 | 16 | 15 | HGNC:10471 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 11/22/20 | 2D 3D TSV |
US10562861 | 41 | 14 | HGNC:6251 HGNC:15631 HGNC:15632 | Carboxylic acid compounds | Sumitomo Dainippon Pharma Co., Ltd. | 11/22/20 | 2D 3D TSV |
US10562853 | 189 | 63 | HGNC:3023 HGNC:5286 HGNC:277 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS; UNIVERSITE JAGELLONE | 11/22/20 | 2D 3D TSV |
US10562888 | 6 | 1 | HGNC:3682 HGNC:3690 HGNC:3689 HGNC:3688 | Crystalline FGFR4 inhibitor compound and uses thereof | Eisai R&D Management Co., LTD. | 11/22/20 | 2D 3D TSV |
US10562878 | 1149 | 222 | HGNC:11050 HGNC:11049 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. | 11/22/20 | 2D 3D TSV |
US10562844 | 14 | 14 | HYPDH inhibitors and methods of use for the treatment of kidney stones | Wake Forest University Health Sciences; UAB Research Foundation | 11/22/20 | 2D 3D TSV | |
US10562850 | 103 | 100 | HGNC:6371 | Human plasma kallikrein inhibitors | BioCryst Pharmaceuticals, Inc. | 11/22/20 | 2D 3D TSV |
US10562902 | 175 | 164 | HGNC:17967 | IRAK4 inhibitor and use thereof | Beijing Hanmi Pharmaceutical Co., Ltd. | 11/22/20 | 2D 3D TSV |
US10562900 | 131 | 57 | HGNC:6307 HGNC:3690 HGNC:3689 HGNC:3688 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | Shanghai Haihe Pharmaceutical Co., Ltd.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 11/22/20 | 2D 3D TSV |
US10562910 | 9 | 9 | HGNC:7967 | Nitrogen-containing tricyclic compounds and uses thereof in medicine | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED | 11/22/20 | 2D 3D TSV |
US10561656 | 9 | 5 | HGNC:8775 HGNC:8774 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. | 11/22/20 | 2D 3D TSV |
US10562882 | 43 | 41 | Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions | Takeda Pharmaceutical Company Limited | 11/22/20 | 2D 3D TSV | |
US10562854 | 32 | 16 | HGNC:1232 HGNC:12680 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. | 11/22/20 | 2D 3D TSV |
US10561657 | 26 | 23 | HGNC:6192 | Pyrrolopyrimidine compound | Centaurus Biophrama Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd. | 11/22/20 | 2D 3D TSV |
US10562891 | 435 | 427 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. | 11/22/20 | 2D 3D TSV | |
US10561655 | 27 | 27 | HGNC:9644 | SHP2 inhibitors and uses thereof | SYNBLia Therapeutics, Inc. | 11/22/20 | 2D 3D TSV |
US10562916 | 209 | 206 | HGNC:8772 | Substituted quinoxalines as PDE-10 inhibitors | Sunovion Pharmaceuticals, Inc. | 11/22/20 | 2D 3D TSV |
US10562887 | 182 | 177 | HGNC:10252 | Triazolones and tetrazolones as inhibitors of ROCK | Bristol-Myers Squibb Company | 11/22/20 | 2D 3D TSV |
US10577367 | 528 | 508 | HGNC:17967 | IRAK4 inhibiting agents | BIOGEN MA INC. | 11/21/20 | 2D 3D TSV |
US10550117 | 11 | 11 | HGNC:6853 | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use | Genentech, Inc. | 11/20/20 | 2D 3D TSV |
US10577353 | 28 | 27 | 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO.5) LIMITED | 11/20/20 | 2D 3D TSV | |
US10577360 | 308 | 153 | HGNC:8156 HGNC:1399 | Arylamide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. | 11/20/20 | 2D 3D TSV |
US10577354 | 6 | 6 | Bis-pyridazine compounds and their use in treating cancer | Cancer Research Technology Limited | 11/20/20 | 2D 3D TSV | |
US10577352 | 67 | 37 | HGNC:3236 | Cot modulators and methods of use thereof | Gilead Sciences, Inc. | 11/20/20 | 2D 3D TSV |
US10577361 | 69 | 33 | HGNC:3023 HGNC:3024 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED | 11/20/20 | 2D 3D TSV |
US10550140 | 43 | 43 | HGNC:2771 | Ether compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals, Inc. | 11/20/20 | 2D 3D TSV |
US10576087 | 116 | 58 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. | 11/20/20 | 2D 3D TSV | |
US10550102 | 161 | 159 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG | 11/20/20 | 2D 3D TSV | |
US10550127 | 20 | 20 | HGNC:4498 | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes | Boehringer Ingelheim International GmbH | 11/20/20 | 2D 3D TSV |
US10550118 | 56 | 24 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK inhibitors containing a 4-membered heterocyclic amide | Theravance Biopharma R&D IP, LLC | 11/20/20 | 2D 3D TSV |
US10550114 | 65 | 21 | HGNC:391 | Kinase inhibitors and their use in cancer therapy | TECHNISCHE UNIVERSITÄT DORTMUND | 11/20/20 | 2D 3D TSV |
US10577330 | 196 | 28 | HGNC:6160 HGNC:6161 HGNC:6163 HGNC:6141 HGNC:6156 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | Saint Louis University | 11/20/20 | 2D 3D TSV |
US10577336 | 169 | 87 | HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | Boehringer Ingelheim International GmbH | 11/20/20 | 2D 3D TSV |
US10544150 | 223 | 221 | HGNC:11528 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | Ogeda SA | 11/20/20 | 2D 3D TSV |
US10550125 | 10 | 5 | HGNC:2459 HGNC:2457 | Prodrugs of imidazotriazine compounds as CK2 inhibitors | Bristol-Myers Squibb Company | 11/20/20 | 2D 3D TSV |
US10550105 | 855 | 803 | Pyridazinones as PARP7 inhibitors | Ribon Therapeutics Inc. | 11/20/20 | 2D 3D TSV | |
US10577308 | 216 | 36 | HGNC:10588 HGNC:10596 | Sodium channel modulators | The Florey Institute; The University of Melbourne | 11/20/20 | 2D 3D TSV |
US10576064 | 115 | 107 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH | 11/20/20 | 2D 3D TSV | |
US10577363 | 985 | 980 | Substituted piperidine compounds | EPIZYME, INC. | 11/20/20 | 2D 3D TSV | |
US10550096 | 5 | 3 | HGNC:10894 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD | 11/20/20 | 2D 3D TSV |
US10556883 | 18 | 9 | HGNC:195 HGNC:7155 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT | 11/13/20 | 2D 3D TSV |
US10556902 | 124 | 122 | HGNC:7056 | Glycosidase inhibitors | Asceneuron SA | 11/13/20 | 2D 3D TSV |
US10556885 | 634 | 302 | HGNC:4617 HGNC:3091 | Isoquinolin-3-YL carboxamides and preparation and use thereof | Samumed, LLC | 11/13/20 | 2D 3D TSV |
US10556892 | 65 | 37 | HGNC:736 | Piperazinyl methanone NAAA inhibitors | The Regents of the University of California; Fondazione Istituto Italiano di Technologia | 11/13/20 | 2D 3D TSV |
US10556908 | 120 | 119 | HGNC:29079 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | Incyte Corporation | 11/13/20 | 2D 3D TSV |
US10556914 | 100 | 100 | HGNC:4507 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | ABBVIE INC.; ABBVIE DEUTSCHLAND GMBH & CO. KG | 11/13/20 | 2D 3D TSV |
US10555944 | 1229 | 556 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Eli Lilly and Company | 11/13/20 | 2D 3D TSV | |
US10556900 | 75 | 71 | HGNC:8031 | TrkA kinase inhibitors, compositions and methods thereof | Merck Sharp & Dohme Corp. | 11/13/20 | 2D 3D TSV |
US10538491 | 153 | 153 | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators | Vanderbilt University | 11/09/20 | 2D 3D TSV | |
US10538523 | 3 | 3 | HGNC:4076 | 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain | PFIZER LIMITED | 11/09/20 | 2D 3D TSV |
US10538528 | 107 | 46 | HGNC:391 HGNC:10430 | 5H-pyrrolo[2,3-D]pyrimidin-6(7H)-one derivative | Taiho Pahrmaceutical Co., Ltd. | 11/09/20 | 2D 3D TSV |
US10538497 | 213 | 208 | HGNC:6059 | Compounds as indoleamine 2,3-dioxygenase inhibitors | Merck Sharp & Dohme Corp. | 11/09/20 | 2D 3D TSV |
US10538496 | 192 | 188 | HGNC:19086 | Methods using HDAC11 inhibitors | FORMA Therapeutics, Inc.; H. Lee Moffitt Cancer Center and Research Institute, Inc. | 11/09/20 | 2D 3D TSV |
US10537571 | 140 | 66 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. | 11/09/20 | 2D 3D TSV |
US10538517 | 40 | 39 | HGNC:3688 | Quinolone derivatives as FGFR inhibitors | Principia Biopharma, Inc. | 11/09/20 | 2D 3D TSV |
US10538508 | 126 | 61 | HGNC:17432 HGNC:1936 | Substituted amino triazoles useful as human chitinase inhibitors | OncoArendi Therapeutics S.A. | 11/09/20 | 2D 3D TSV |
US10550091 | 176 | 87 | HGNC:7968 | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor | St. Jude Children''s Research Hospital | 11/07/20 | 2D 3D TSV |
US10550100 | 455 | 114 | HGNC:7160 HGNC:195 HGNC:7159 HGNC:221 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV | 11/07/20 | 2D 3D TSV |
US10548313 | 35 | 34 | Acetyl-CoA carboxylase modulators | Monsanto Technology LLC | 11/07/20 | 2D 3D TSV | |
US10550080 | 137 | 49 | HGNC:10593 HGNC:10597 | Acyl sulfonamide NaV1.7 inhibitors | Bristol-Myers Squibb Company | 11/07/20 | 2D 3D TSV |
US10550073 | 35 | 25 | HGNC:2623 HGNC:6876 | Benzamide derivative | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 11/07/20 | 2D 3D TSV |
US10550089 | 124 | 62 | HGNC:3538 | Inhibitors of protease-activated receptor-2 | Heptares Therapeutics Limited | 11/07/20 | 2D 3D TSV |
US10544132 | 133 | 130 | HGNC:6973 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED | 11/07/20 | 2D 3D TSV |
US10548897 | 8 | 8 | KSR antagonists | Icahn School of Medicine at Mount Sinai | 11/07/20 | 2D 3D TSV | |
US10544136 | 207 | 163 | HGNC:3167 HGNC:3165 | Modulators of sphingosine phosphate receptors | The Scripps Research Institute | 11/07/20 | 2D 3D TSV |
US10550099 | 297 | 182 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | Forma Therapeutics, Inc. | 11/07/20 | 2D 3D TSV | |
US10548896 | 122 | 119 | HGNC:29079 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | Celgene Quanticel Research, Inc. | 11/07/20 | 2D 3D TSV |
US10544143 | 3210 | 878 | HGNC:15633 HGNC:15631 HGNC:15632 | 4-azaindole compounds | Bristol-Myers Squibb Company | 11/02/20 | 2D 3D TSV |
US10544152 | 10 | 9 | HGNC:5295 | 5-HT2CR agonist analogs | The Board of Regents of The University of Texas System; University of Houston System | 11/02/20 | 2D 3D TSV |
US10544146 | 4 | 1 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. | 11/02/20 | 2D 3D TSV | |
US10544151 | 11 | 11 | HGNC:6307 | Compounds and uses thereof | Kala Pharmaceuticals, Inc. | 11/02/20 | 2D 3D TSV |
US10544141 | 90 | 76 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. | 11/02/20 | 2D 3D TSV | |
US10544133 | 168 | 150 | HGNC:17967 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | Bristol-Myers Squibb Company | 11/02/20 | 2D 3D TSV |
US10533001 | 238 | 213 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11491 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. | 11/02/20 | 2D 3D TSV |
US10544128 | 732 | 235 | HGNC:4617 HGNC:3091 | Isoquinolin-3-yl carboxamides and preparation and use thereof | Samumed, LLC | 11/02/20 | 2D 3D TSV |
US10544130 | 1497 | 489 | Metallo-beta-lactamase inhibitors | Merck Sharp & Dohme Corp. | 11/02/20 | 2D 3D TSV | |
US10544147 | 185 | 117 | HGNC:8977 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | Merck Sharp & Dohme Corp. | 11/02/20 | 2D 3D TSV |
US10533010 | 416 | 376 | HGNC:6943 HGNC:992 HGNC:990 | Substituted indole Mcl-1 inhibitors | Vanderbilt University | 11/02/20 | 2D 3D TSV |
US10544126 | 111 | 107 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 11/02/20 | 2D 3D TSV | |
US10532048 | 12 | 12 | HGNC:1113 | Tetrahydroisoquinolin-1-one derivative or salt thereof | Seldar Pharma Inc. | 11/02/20 | 2D 3D TSV |
US10544095 | 38 | 38 | HGNC:11708 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | Pfizer Inc.; iTeos Therapeutics | 11/01/20 | 2D 3D TSV |
US10544117 | 30 | 30 | HGNC:5302 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University—Of The Commonwealth System of Higher Education | 11/01/20 | 2D 3D TSV |
US10543221 | 20 | 13 | Beta-lactamase inhibitors, formulations, and uses thereof | University of South Florida; The Regents of the University of California | 11/01/20 | 2D 3D TSV | |
US10544120 | 343 | 331 | HGNC:19679 | Biaryl kinase inhibitors | Bristol-Myers Squibb Company | 11/01/20 | 2D 3D TSV |
US10544106 | 98 | 96 | HGNC:1133 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. | 11/01/20 | 2D 3D TSV |
US10544104 | 437 | 141 | HGNC:4840 HGNC:11283 HGNC:76 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR CO | 11/01/20 | 2D 3D TSV |
US10543207 | 74 | 73 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. | 11/01/20 | 2D 3D TSV | |
US10544075 | 8 | 4 | HGNC:11799 HGNC:11796 | Derivatives of sobetirome | OREGON HEALTH & SCIENCE UNIVERSITY | 11/01/20 | 2D 3D TSV |
US10543198 | 75 | 75 | HGNC:29079 | Inhibitor of lysine specific demethylase-1 | Celgene Quanticel Research, Inc. | 11/01/20 | 2D 3D TSV |
US10543199 | 18 | 5 | HGNC:427 | Macrocycle and composition comprising thereof | Shenzhen TargetRx, Inc. | 11/01/20 | 2D 3D TSV |
US10543194 | 6 | 6 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. | 11/01/20 | 2D 3D TSV | |
US10544110 | 36 | 35 | HGNC:644 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—Of the Commonwealth System of Higher Education | 11/01/20 | 2D 3D TSV |
US10544113 | 206 | 201 | HGNC:5302 | Thiazolidinone compounds and use thereof | National Health Research Institute; Regents of the University of Minnesota | 11/01/20 | 2D 3D TSV |
US10543183 | 12 | 6 | HGNC:7966 HGNC:7965 | Treatment and diagnosis of melanoma | The Rockefeller University | 11/01/20 | 2D 3D TSV |
US10543213 | 122 | 118 | HGNC:29079 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | Celgene Quanticel Research, Inc. | 11/01/20 | 2D 3D TSV |
US10526325 | 98 | 57 | HGNC:8810 | Bicyclic heterocyclic derivatives | Merck Patent GmbH | 10/25/20 | 2D 3D TSV |
US10526329 | 367 | 214 | HGNC:3357 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV | 10/25/20 | 2D 3D TSV |
US10526336 | 212 | 98 | HGNC:4849 HGNC:4848 | Fused heteroaryl derivatives as orexin receptor antagonists | Merck, Sharp & Dohme Corp. | 10/25/20 | 2D 3D TSV |
US10526330 | 112 | 16 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK kinase inhibitor compounds for treatment of respiratory disease | Theravance Biopharma R&D IP, LLC | 10/25/20 | 2D 3D TSV |
US10525036 | 90 | 58 | HGNC:6877 HGNC:6871 | Spirocyclic compounds | Recurium IP Holdings, LLC | 10/25/20 | 2D 3D TSV |
US10513534 | 17 | 11 | 2′-chloro nucleoside analogs for HCV infection | IDENIX PHARMACEUTICALS LLC; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE DE MONTPELLIER | 10/24/20 | 2D 3D TSV | |
US10513522 | 84 | 41 | HGNC:6190 HGNC:6192 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | Incyte Corporation; Incyte Holdings Corporation | 10/24/20 | 2D 3D TSV |
US10512634 | 132 | 40 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB | 10/24/20 | 2D 3D TSV |
US10513493 | 31 | 31 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 10/24/20 | 2D 3D TSV |
US10513512 | 7 | 7 | HGNC:3023 | Flavanone derivatives, and preparation method and use thereof | Xuanwu Hospital of Capital Medical University | 10/24/20 | 2D 3D TSV |
US10513523 | 249 | 246 | HGNC:4571 | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | Janssen Pharmaceutica NV | 10/24/20 | 2D 3D TSV |
US10513499 | 22 | 22 | HGNC:19288 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES Pharma S.r.l. | 10/24/20 | 2D 3D TSV |
US10513518 | 46 | 38 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp. | 10/24/20 | 2D 3D TSV |
US10512644 | 125 | 47 | HGNC:8153 HGNC:8154 HGNC:8156 | Oligomer-opioid agonist conjugates | Inheris Pharmaceuticals, Inc. | 10/24/20 | 2D 3D TSV |
US10513524 | 10 | 5 | HGNC:8795 HGNC:8775 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | H. LUNDBECK A/S | 10/24/20 | 2D 3D TSV |
US10513514 | 34 | 32 | HGNC:20001 | Piperidine compounds as PCSK9 inhibitors | SHENZHEN SALUBRIS PHARM CO LTD. | 10/24/20 | 2D 3D TSV |
US10513507 | 13 | 11 | HGNC:12630 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | FORMA Therapeutics, Inc. | 10/24/20 | 2D 3D TSV |
US10513520 | 6 | 6 | HGNC:4912 | Sulfamide and sulfamate inhibitors of hHint1 | Regents of the University of Minnesota | 10/24/20 | 2D 3D TSV |
US10519167 | 3 | 3 | HGNC:10894 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD | 10/19/20 | 2D 3D TSV |
US10519153 | 34 | 11 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Fused imidazo-piperidine JAK inhibitors | Theravance Biopharma R&D IP, LLC | 10/19/20 | 2D 3D TSV |
US10519177 | 802 | 696 | Heterocyclic compounds and uses thereof | Plexxikon Inc. | 10/19/20 | 2D 3D TSV | |
US10519118 | 167 | 165 | HGNC:29079 | KDM1A inhibitors for the treatment of disease | Imago Biosciences, Inc. | 10/19/20 | 2D 3D TSV |
US10517849 | 9 | 9 | HGNC:29079 | LSD1 inhibitors and medical uses thereof | Constellation Pharmaceuticals, Inc. | 10/19/20 | 2D 3D TSV |
US10517872 | 30 | 15 | HGNC:17967 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | Merck Patent GmbH | 10/19/20 | 2D 3D TSV |
US10519163 | 252 | 89 | HGNC:7027 HGNC:12446 | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation | 10/19/20 | 2D 3D TSV |
US10517878 | 110 | 106 | HGNC:6871 | Serine/threonine kinase inhibitors | GENENTECH, INC. | 10/19/20 | 2D 3D TSV |
US10517858 | 327 | 107 | HGNC:19310 HGNC:8987 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors | Incyte Holdings Corporation; Incyte Corporation | 10/19/20 | 2D 3D TSV |
US10512632 | 603 | 190 | HGNC:8775 HGNC:8774 HGNC:8776 | 1 H-pyrazolo[4,3-B]pyridines as PDE1 inhibitors | H. Lundbeck A/S | 10/18/20 | 2D 3D TSV |
US10508119 | 51 | 49 | HGNC:436 | Pyrazole derivatives useful as 5-lipdxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB | 10/18/20 | 2D 3D TSV |
US10508120 | 1366 | 1156 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. | 10/18/20 | 2D 3D TSV | |
US10508115 | 134 | 73 | HGNC:15631 HGNC:6018 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Company | 10/18/20 | 2D 3D TSV |
US10508104 | 531 | 514 | HGNC:339 | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists | Bristol-Myers Squibb Company | 10/12/20 | 2D 3D TSV |
US10501438 | 16 | 16 | HGNC:13575 | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals | Neomed Institute | 10/12/20 | 2D 3D TSV |
US10508103 | 138 | 51 | HGNC:11892 | Benzimidazole-linked indole compound acting as novel divalent IAP antagonist | MEDSHINE DISCOVERY INC. | 10/12/20 | 2D 3D TSV |
US10508109 | 306 | 303 | HGNC:17287 | Bicyclic compound and use thereof for inhibiting SUV39H2 | ONCOTHERAPY SCIENCE, INC. | 10/12/20 | 2D 3D TSV |
US10501436 | 207 | 36 | HGNC:171 HGNC:1076 HGNC:172 HGNC:175 | Compounds and methods of use | Medivation Technologies LLC | 10/12/20 | 2D 3D TSV |
US10500194 | 30 | 30 | Covalent small molecule DCN1 inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 10/12/20 | 2D 3D TSV | |
US10501473 | 12 | 12 | Fused heterocyclic ring compounds and method of treating retinal disease using same | THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) | 10/12/20 | 2D 3D TSV | |
US10501467 | 122 | 66 | HGNC:270 HGNC:272 HGNC:15677 HGNC:273 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors | BEIGENE, LTD. | 10/12/20 | 2D 3D TSV |
US10501440 | 42 | 26 | HGNC:6371 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | Boehringer Ingelheim International GmbH | 10/12/20 | 2D 3D TSV |
US10508105 | 148 | 117 | HGNC:4596 | Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | Vanderbilt University | 10/12/20 | 2D 3D TSV |
US10508102 | 28 | 13 | HGNC:11892 | Inhibitors of cellular necrosis and related methods | President and Fellows of Harvard College; Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences | 10/12/20 | 2D 3D TSV |
US10508099 | 951 | 303 | HGNC:4617 HGNC:3091 | Isoquinolin-3-yl carboxamides and preparation and use thereof | Samumed, LLC | 10/12/20 | 2D 3D TSV |
US10501452 | 149 | 37 | HGNC:3023 | Lactam compound derivative and application thereof | NHWA PHARMA. CORPORATION | 10/12/20 | 2D 3D TSV |
US10508107 | 58 | 20 | HGNC:6251 HGNC:17734 HGNC:11049 | Morpholine derivative | Hoffmann-La Roche Inc. | 10/12/20 | 2D 3D TSV |
US10501451 | 28 | 15 | Selective NR2B antagonists | Bristol-Myers Squibb Company | 10/12/20 | 2D 3D TSV | |
US10501411 | 555 | 283 | Substituted benzamides | Hoffmann-La Roche Inc. | 10/12/20 | 2D 3D TSV | |
US10501458 | 72 | 37 | HGNC:11708 HGNC:6059 | Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors | Iomet Pharma Ltd.; Merck Sharp & Dohme Corp. | 10/12/20 | 2D 3D TSV |
US10501449 | 69 | 68 | HGNC:6255 | Substituted nitrogen containing compounds | Bristol-Myers Squibb Company | 10/12/20 | 2D 3D TSV |
US10501435 | 18 | 5 | HGNC:4177 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | Northwestern University | 10/12/20 | 2D 3D TSV |
US10508108 | 131 | 121 | Tricyclic compounds as inhibitors of mutant IDH enzymes | Merck Sharp & Dohme Corp. | 10/12/20 | 2D 3D TSV | |
US10501466 | 33 | 33 | HGNC:12757 | WDR5 inhibitors and modulators | Vanderbilt University | 10/12/20 | 2D 3D TSV |
US10507215 | 42 | 14 | HGNC:6833 HGNC:6834 HGNC:404 | Compounds for the treatment of addiction | Amygdala Neurosciences, Inc. | 10/02/20 | 2D 3D TSV |
US10508088 | 214 | 193 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Methods using HDAC11 inhibitors | FORMA Therapeutics, Inc. | 10/02/20 | 2D 3D TSV |
US10494380 | 32 | 31 | HGNC:2623 | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | Shionogi & Co., Ltd. | 10/02/20 | 2D 3D TSV |
US10508086 | 253 | 218 | HGNC:8605 HGNC:270 | PARG inhibitory compounds | Cancer Research Technology Limited | 10/02/20 | 2D 3D TSV |
US10507209 | 33 | 11 | HGNC:3432 HGNC:3430 HGNC:3236 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. | 10/02/20 | 2D 3D TSV |
US10508098 | 13 | 13 | HGNC:12630 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | FORMA Therapeutics, Inc. | 10/02/20 | 2D 3D TSV |
US10493060 | 92 | 59 | HGNC:6877 HGNC:6871 | Spirocyclic compounds | Recurium IP Holdings, LLC | 10/02/20 | 2D 3D TSV |
US10508083 | 266 | 256 | HGNC:4849 | Substituted piperidine compound and use thereof | Takeda Pharmaceutical Company Limited | 10/02/20 | 2D 3D TSV |
US10494376 | 120 | 118 | HGNC:10894 | Tetrahydroisoquinoline derived PRMT5-inhibitors | CTXT PTY. LTD. | 10/02/20 | 2D 3D TSV |
US10479795 | 816 | 404 | HGNC:8978 HGNC:8977 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | Incyte Corporation | 09/26/20 | 2D 3D TSV |
US10479803 | 38 | 29 | HGNC:6190 HGNC:8977 | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors | Incyte Corporation | 09/25/20 | 2D 3D TSV |
US9975885 | 182 | 31 | Broad-spectrum non-covalent coronavirus protease inhibitors | PURDUE RESEARCH FOUNDATION | 09/25/20 | 2D 3D TSV | |
US10479788 | 156 | 155 | HGNC:12401 | Compounds that inhibit MPS1 kinase | Cancer Research Technology Limited | 09/25/20 | 2D 3D TSV |
US10479794 | 202 | 66 | HGNC:8772 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | Boehringer Ingelheim International GmbH | 09/25/20 | 2D 3D TSV |
US10478426 | 8 | 7 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC | 09/25/20 | 2D 3D TSV | |
US10479798 | 32 | 32 | HGNC:3009 | Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 09/25/20 | 2D 3D TSV |
US10479784 | 603 | 576 | HGNC:882 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED | 09/25/20 | 2D 3D TSV |
US10478424 | 2922 | 955 | HGNC:15633 HGNC:15631 HGNC:15632 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | Bristol-Myers Squibb Company | 09/24/20 | 2D 3D TSV |
USRE47740 | 6 | 6 | HGNC:6027 | Aminopyridinecarboxamides as CXCR2 modulators | Syntrix Biosystems Inc. | 09/20/20 | 2D 3D TSV |
US10487111 | 12 | 12 | HGNC:10906 | IBAT inhibitors for the treatment of liver diseases | Albireo AB | 09/20/20 | 2D 3D TSV |
US10487086 | 77 | 77 | HGNC:3529 | Macrocycles as factor XIa inhibitors | Bristol-Myers Squibb Company | 09/20/20 | 2D 3D TSV |
US10485800 | 204 | 202 | HGNC:6850 | Mixed lineage kinase inhibitors for HIV/AIDS therapies | The University of Rochester; Board of Regents of the University of Nebraska | 09/20/20 | 2D 3D TSV |
US10487087 | 38 | 25 | HGNC:4324 | Positive allosteric modulators of the GLP-1 receptor | Vanderbilt University | 09/20/20 | 2D 3D TSV |
US10487092 | 126 | 124 | Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT | 09/20/20 | 2D 3D TSV | |
US10485803 | 106 | 42 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrimidine compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 09/20/20 | 2D 3D TSV |
US10487083 | 60 | 15 | Small molecule inhibitors of the JAK family of kinases | Janssen Pharmaceutica NV | 09/20/20 | 2D 3D TSV | |
US10478423 | 74 | 37 | HGNC:6342 HGNC:3765 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. | 09/20/20 | 2D 3D TSV |
US10487084 | 22 | 13 | HGNC:15631 HGNC:6018 | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Company | 09/20/20 | 2D 3D TSV |
US10472354 | 838 | 389 | HGNC:8534 | 1,3-thiazol-2-yl substituted benzamides | Bayer Aktiengesellschaft | 09/14/20 | 2D 3D TSV |
US10472358 | 196 | 86 | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | Incyte Corporation | 09/14/20 | 2D 3D TSV | |
US10472324 | 9 | 9 | 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives | ALGIAX PHARMACEUTICALS GMBH | 09/14/20 | 2D 3D TSV | |
US10472364 | 86 | 80 | HGNC:8021 | Ectonucleotidase inhibitors and methods of use thereof | Calithera Biosciences, Inc. | 09/14/20 | 2D 3D TSV |
US10472344 | 12 | 7 | HGNC:3529 HGNC:6357 | Factor XIa inhibitors | Merck Sharp & Dohme Corp. | 09/14/20 | 2D 3D TSV |
US10472367 | 5 | 5 | HGNC:7029 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | INCYTE INCORPORATION; INCYTE HOLDINGS CORPORATION | 09/14/20 | 2D 3D TSV |
US10464947 | 570 | 277 | HGNC:13575 | Tricyclic heterocycles as BET protein inhibitors | Incyte Holdings Corporation; Incyte Corporation | 09/09/20 | 2D 3D TSV |
US10464911 | 88 | 76 | HGNC:4852 HGNC:14064 | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | Chong Kun Dang Pharmaceutical Corp. | 09/08/20 | 2D 3D TSV |
US10464927 | 98 | 49 | HGNC:1777 HGNC:1773 | 2,4-disubstituted pyrimidines as CDK inhibitors | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. | 09/08/20 | 2D 3D TSV |
US10464928 | 3 | 3 | HGNC:550 | Amino pyrimidine SSAO inhibitors | Eli Lilly and Company | 09/08/20 | 2D 3D TSV |
US10463675 | 468 | 113 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Aminopyrimidinyl compounds | Pfizer Inc. | 09/08/20 | 2D 3D TSV |
US10457703 | 240 | 234 | HGNC:7967 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | Enanta Pharmaceuticals, Inc. | 09/08/20 | 2D 3D TSV |
US10464907 | 29 | 29 | Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY | 09/08/20 | 2D 3D TSV | |
US10464902 | 10 | 10 | HGNC:6307 | Multi-tyrosine kinase inhibitors derivatives and methods of use | Ontogenesis, LLC | 09/08/20 | 2D 3D TSV |
US10464918 | 11 | 11 | HGNC:11331 | Process of making somatostatin modulators | CRINETICS PHARMACEUTICALS, INC. | 09/08/20 | 2D 3D TSV |
US10463663 | 68 | 66 | HGNC:2671 | Pyridazinone compounds and their use as DAAO inhibitors | Takeda Pharmaceutical Company Limited | 09/08/20 | 2D 3D TSV |
US10464919 | 346 | 184 | HGNC:270 HGNC:19297 HGNC:11940 | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | Je Il Pharmaceutical Co., Ltd. | 09/08/20 | 2D 3D TSV |
US10457637 | 170 | 120 | HGNC:5981 | Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) | GALDERMA RESEARCH & DEVELOPMENT | 09/07/20 | 2D 3D TSV |
US10457678 | 10 | 10 | HGNC:195 | Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis | Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite; Universite Claude Bernard Lyon 1 | 09/07/20 | 2D 3D TSV |
US10457681 | 16 | 11 | HGNC:15631 HGNC:6018 | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor | Bristol_Myers Squibb Company | 09/07/20 | 2D 3D TSV |
US10457686 | 14 | 7 | HGNC:2160 HGNC:2159 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | Hoffmann-La Roche Inc. | 09/07/20 | 2D 3D TSV |
US10457685 | 76 | 38 | HGNC:2160 HGNC:2159 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | Hoffmann-La Roche Inc. | 09/07/20 | 2D 3D TSV |
US10457684 | 30 | 15 | HGNC:2160 HGNC:2159 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | Hoffmann-La Roche Inc. | 09/07/20 | 2D 3D TSV |
US10450301 | 191 | 190 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals, Inc. | 08/31/20 | 2D 3D TSV |
US10450313 | 162 | 54 | HGNC:3690 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR inhibitors | Incyte Holdings Corporation | 08/31/20 | 2D 3D TSV |
US10450298 | 7 | 6 | HGNC:3357 | PET Imaging agents | Novartis AG | 08/31/20 | 2D 3D TSV |
US10450297 | 341 | 328 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer, Inc. | 08/31/20 | 2D 3D TSV | |
US10450321 | 14 | 7 | HGNC:2160 HGNC:2159 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | Hoffmann-La Roche Inc. | 08/31/20 | 2D 3D TSV |
US10450296 | 510 | 168 | HGNC:19310 HGNC:8987 | Heterocyclic compounds useful as Pim kinase inhibitors | Incyte Corporation | 08/30/20 | 2D 3D TSV |
US10457672 | 128 | 128 | HGNC:15983 | γ-diketones as Wnt/β-catenin signaling pathway activators | Samumed, LLC | 08/24/20 | 2D 3D TSV |
US10323028 | 67 | 55 | 1,3,4-thiadiazole compounds and their use in treating cancer | AstraZeneca AB | 08/24/20 | 2D 3D TSV | |
US10442759 | 21 | 21 | 1-sulfonamido-4-aryloxy compounds, and preparation method and medicinal application thereof | CHINA PHARMACEUTICAL UNIVERSITY | 08/24/20 | 2D 3D TSV | |
US10457647 | 40 | 40 | HGNC:1133 | Amino pyrimidine derivatives | Novartis AG | 08/24/20 | 2D 3D TSV |
US10323037 | 118 | 118 | HGNC:1133 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. | 08/24/20 | 2D 3D TSV |
US10435408 | 19 | 19 | HGNC:5302 | Azepine derivatives as 5-HT7 receptor modulators | Korea Institute of Science and Technology | 08/24/20 | 2D 3D TSV |
US10377755 | 15 | 15 | HGNC:990 | BCL-2 inhibitors | Newave Pharmaceutical Inc. | 08/24/20 | 2D 3D TSV |
US10442772 | 248 | 182 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT | 08/24/20 | 2D 3D TSV | |
US10457669 | 927 | 912 | HGNC:6871 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. | 08/24/20 | 2D 3D TSV |
US10307425 | 116 | 115 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | University of Washington | 08/24/20 | 2D 3D TSV | |
US10376513 | 368 | 348 | HGNC:8977 | Heterocyclylamines as PI3K inhibitors | Incyte Holdings Corporation | 08/24/20 | 2D 3D TSV |
US10457675 | 96 | 86 | HGNC:14065 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation, Inc. | 08/24/20 | 2D 3D TSV |
US10329260 | 302 | 298 | HGNC:6371 | Human plasma kallikrein inhibitors | BioCryst Pharmaceuticals, Inc. | 08/24/20 | 2D 3D TSV |
US10457677 | 471 | 137 | HGNC:8979 HGNC:8978 HGNC:795 HGNC:3942 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | Merck Patent GmbH | 08/24/20 | 2D 3D TSV |
US10323013 | 21 | 21 | HGNC:3449 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 08/24/20 | 2D 3D TSV |
US10441590 | 9 | 2 | HGNC:5302 HGNC:5301 HGNC:3023 HGNC:5286 HGNC:5294 | Methods for treating pulmonary hypertension | Reviva Pharmaceuticals, Inc. | 08/24/20 | 2D 3D TSV |
US10399948 | 138 | 60 | Negative allosteric modulators of metabotropic glutamate receptor 3 | Vanderbilt University | 08/24/20 | 2D 3D TSV | |
US10456385 | 31 | 31 | HGNC:1960 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. | 08/24/20 | 2D 3D TSV |
US10399980 | 544 | 539 | HGNC:12607 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA Therapeutics, Inc. | 08/24/20 | 2D 3D TSV |
US10442808 | 127 | 124 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | Novartis AG | 08/24/20 | 2D 3D TSV | |
US10329300 | 80 | 80 | HGNC:3430 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. | 08/24/20 | 2D 3D TSV |
US10442810 | 438 | 145 | HGNC:7027 HGNC:12446 | Pyrrolotriazine compounds as TAM inhibitors | Incyte Corporation | 08/24/20 | 2D 3D TSV |
US10301261 | 220 | 104 | Substituted indoles as modulators of ROR-gamma | Vitae Pharmaceuticals, LLC | 08/24/20 | 2D 3D TSV | |
US10441581 | 2116 | 815 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array Biopharma Inc. | 08/24/20 | 2D 3D TSV | |
US10456394 | 62 | 18 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 08/24/20 | 2D 3D TSV |
US10457654 | 393 | 239 | HGNC:10597 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. | 08/24/20 | 2D 3D TSV |
US10442819 | 556 | 509 | Tricyclic compounds as inhibitors of mutant IDH enzymes | Merck Sharp & Dohme Corp. | 08/24/20 | 2D 3D TSV | |
US10442803 | 546 | 273 | HGNC:13575 | Tricyclic heterocycles as bet protein inhibitors | Incyte Corporation | 08/24/20 | 2D 3D TSV |
US9951068 | 213 | 154 | HGNC:6251 HGNC:550 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN LIMITED | 08/19/20 | 2D 3D TSV |
US10428066 | 213 | 155 | HGNC:6251 HGNC:550 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC | 08/19/20 | 2D 3D TSV |
US10428044 | 491 | 480 | HGNC:1148 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | Bayer Pharma Aktiengesellschaft | 08/17/20 | 2D 3D TSV |
US10428063 | 47 | 46 | 4H-pyrrolo[3,2-C]pyridin-4-one derivatives | Bayer Pharma Aktiengesellschaft | 08/17/20 | 2D 3D TSV | |
US10435406 | 8 | 5 | HGNC:8154 HGNC:8156 | 6,7-cyclicmorphinan derivatives and use thereof | Purdue Pharma L.P. | 08/17/20 | 2D 3D TSV |
US10428108 | 98 | 93 | Difluoroketamide derivatives | Hoffmann-La Roche Inc. | 08/17/20 | 2D 3D TSV | |
US10428068 | 73 | 62 | HGNC:5253 HGNC:1735 | Fused amino pyridine as HSP90 inhibitors | Curis, Inc. | 08/17/20 | 2D 3D TSV |
US10428028 | 43 | 15 | HGNC:4852 HGNC:4854 HGNC:4853 | HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. | 08/17/20 | 2D 3D TSV |
US10428083 | 23 | 6 | HGNC:268 HGNC:262 HGNC:263 HGNC:264 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT | 08/17/20 | 2D 3D TSV |
US10426135 | 104 | 104 | Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | Pfizer Inc. | 08/17/20 | 2D 3D TSV | |
US10428024 | 85 | 52 | HGNC:8810 | Piperidinyl derivatives | MERCK PATENT GMBH | 08/17/20 | 2D 3D TSV |
US10428087 | 125 | 82 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Pyrimidinones as PI3K inhibitors | Incyte Corporation | 08/17/20 | 2D 3D TSV |
US10428074 | 130 | 69 | HGNC:6190 HGNC:6192 HGNC:6193 | Pyrrole heteroaryl ring derivative and method of use thereof | Jiangsu Hengrui Medicine Co., Ltd. | 08/17/20 | 2D 3D TSV |
US10428076 | 247 | 231 | Soluble guanylate cyclase stimulators | Merck Sharp & Dohme Corp. | 08/17/20 | 2D 3D TSV | |
US10428104 | 118 | 117 | HGNC:10894 | Substituted nucleoside derivatives useful as anticancer agents | Pfizer Inc. | 08/17/20 | 2D 3D TSV |
USRE47636 | 27 | 27 | HGNC:2528 | Substituted spirocycles | Boehringer Ingelheim International GmbH | 08/17/20 | 2D 3D TSV |
US10435415 | 152 | 43 | HGNC:6192 HGNC:1133 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | Bristol-Myers Squibb Company | 08/17/20 | 2D 3D TSV |
US10435407 | 170 | 169 | HGNC:2730 | Triaza-spirodecanones as DDR1 inhibitors | Hoffmann-La Roche Inc. | 08/17/20 | 2D 3D TSV |
US10435414 | 215 | 214 | HGNC:8979 | Tricyclic PI3K inhibitor compounds and methods of use | Genentech, Inc. | 08/17/20 | 2D 3D TSV |
US10435400 | 122 | 57 | HGNC:3236 | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD. | 08/16/20 | 2D 3D TSV |
US10435396 | 47 | 47 | HGNC:17967 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | Bayer Pharma Aktiegesellschaft | 08/16/20 | 2D 3D TSV |
US10435392 | 28 | 13 | Bipyrazole derivatives as JAK inhibitors | Incyte Corporation | 08/16/20 | 2D 3D TSV | |
US10434101 | 94 | 47 | HGNC:3236 | Heterocyclic compounds and uses thereof | Celgene CAR LLC | 08/16/20 | 2D 3D TSV |
US10435355 | 26 | 13 | HGNC:3553 | Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments | The Regents of the University of California | 08/16/20 | 2D 3D TSV |
US10435361 | 318 | 118 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 | Kinase inhibitors | Topivert Pharma Limited | 08/16/20 | 2D 3D TSV |
US10434085 | 15 | 14 | HGNC:6859 | Non-aromatic difluoro analogues of resorcylic acid lactones | University of North Carolina at Greensboro | 08/16/20 | 2D 3D TSV |
US10435398 | 70 | 33 | HGNC:4849 HGNC:4848 | Oxazole orexin receptor antagonists | Merck Sharp & Dohme Corp. | 08/16/20 | 2D 3D TSV |
US10435405 | 241 | 235 | HGNC:6863 | Pyrazolopyridine compounds and uses thereof | Incyte Corporation | 08/16/20 | 2D 3D TSV |
US10435369 | 304 | 268 | Tricyclic sulfones as ROR gamma modulators | Bristol-Myers Squibb Company | 08/16/20 | 2D 3D TSV | |
US10434112 | 188 | 179 | HGNC:3827 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | ALLERGAN, INC. | 08/16/20 | 2D 3D TSV |
US10435379 | 9 | 9 | HGNC:6018 | [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | SANTEN PHARMACEUTICAL CO., LTD. | 08/16/20 | 2D 3D TSV |
US10421756 | 152 | 74 | HGNC:4852 HGNC:4853 | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase | Rodin Therapeutics, Inc. | 08/12/20 | 2D 3D TSV |
US10421760 | 61 | 20 | HGNC:6190 HGNC:6192 HGNC:6193 | Pyrrolo[2,3-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. | 08/12/20 | 2D 3D TSV |
US10420768 | 72 | 22 | HGNC:4586 HGNC:6251 HGNC:2625 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | Rugen Holdings (Cayman) Limited | 08/12/20 | 2D 3D TSV |
US10421747 | 35 | 7 | HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Quinoxaline derivatives useful as FGFR kinase modulators | ASTEX THERAPEUTICS LTD | 08/12/20 | 2D 3D TSV |
US10421750 | 47 | 47 | HGNC:8157 | Substituted morpholine derivatives having activity against pain | ESTEVE PHARMACEUTICALS, S.A. | 08/12/20 | 2D 3D TSV |
US10421742 | 516 | 252 | HGNC:6371 HGNC:3529 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT | 08/12/20 | 2D 3D TSV |
US10421722 | 9 | 9 | HGNC:10936 | Sulfur-containing compounds targeting vesicular acetylcholine transporter | Washington University | 08/12/20 | 2D 3D TSV |
US10421743 | 3 | 3 | HGNC:10894 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD | 08/12/20 | 2D 3D TSV |
US10421765 | 101 | 99 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | Board of Regents, The University of Texas System | 08/12/20 | 2D 3D TSV | |
US10414734 | 32 | 27 | 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT | 08/02/20 | 2D 3D TSV | |
US10413562 | 298 | 295 | HGNC:1133 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH | 08/02/20 | 2D 3D TSV |
US10414761 | 375 | 111 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Company Limited | 08/02/20 | 2D 3D TSV |
US10414797 | 100 | 23 | HGNC:7173 HGNC:7174 HGNC:7176 HGNC:7155 | Gelatinase inhibitors and use thereof | Iproteos S.L | 08/02/20 | 2D 3D TSV |
US10413545 | 98 | 97 | HGNC:3594 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | Janssen Pharmaceutica NV | 08/02/20 | 2D 3D TSV |
US10413550 | 137 | 136 | Isoxazole compounds as inhibitors of heat shock proteins | The Institute of Cancer Research | 08/02/20 | 2D 3D TSV | |
US10414731 | 16 | 16 | HGNC:3529 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT | 08/02/20 | 2D 3D TSV |
US10414765 | 104 | 48 | HGNC:6283 HGNC:6278 | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same | BAYER PHARMA AKTIENGESELLSCHAFT | 08/02/20 | 2D 3D TSV |
US10399985 | 41 | 41 | HGNC:8772 | (Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders | Hoffmann-La Roche Inc. | 07/27/20 | 2D 3D TSV |
US10407409 | 426 | 417 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | Takeda Pharmaceutical Company Limited | 07/27/20 | 2D 3D TSV | |
US10407446 | 78 | 13 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11393 HGNC:11390 HGNC:12401 | Amino-triazolopyridine compounds and their use in treating cancer | AstraZeneca AB | 07/27/20 | 2D 3D TSV |
US10406136 | 18 | 9 | Composition for suppressing neuraminidase activity comprising geranylated flavonoid derived from Paulownia tomentosa as active ingredient | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY | 07/27/20 | 2D 3D TSV | |
US10407441 | 14 | 7 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | Dana-Farber Cancer Institute, Inc. | 07/27/20 | 2D 3D TSV | |
US10399973 | 27 | 27 | HGNC:550 | Compounds I | BENEVOLENTAI CAMBRIDGE LIMITED | 07/27/20 | 2D 3D TSV |
US10407431 | 34 | 34 | HGNC:15631 | Compounds and compositions as toll-like receptor 7 agonists | Novartis AG | 07/27/20 | 2D 3D TSV |
US10407423 | 40 | 23 | HGNC:2976 HGNC:14129 | Compounds as inhibitors of DNA methyltransferases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA | 07/27/20 | 2D 3D TSV |
US10399967 | 143 | 139 | HGNC:6001 | Compounds for inflammation and immune-related uses | PRCL RESEARCH INC. | 07/27/20 | 2D 3D TSV |
US10399976 | 220 | 153 | Dihydropyrrolopyridine inhibitors of ROR-gamma | Vitae Pharmaceuticals, LLC | 07/27/20 | 2D 3D TSV | |
US10398702 | 108 | 27 | Dimeric compounds | Hoffmann-La Roche Inc. | 07/27/20 | 2D 3D TSV | |
US10399961 | 15 | 15 | HGNC:6371 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | Boehringer Ingelheim International GmbH | 07/27/20 | 2D 3D TSV |
US10398706 | 9 | 7 | Heteroaryldiazepine derivatives as RSV inhibitors | Enanta Pharmaceuticals, Inc. | 07/27/20 | 2D 3D TSV | |
US10399979 | 92 | 23 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Janus kinase inhibitors and uses thereof | Purdue Research Foundation | 07/27/20 | 2D 3D TSV |
US10399991 | 64 | 64 | HGNC:6221 | Kv1.3 inhibitors and their medical applications | 4SC AG | 07/27/20 | 2D 3D TSV |
US10399974 | 57 | 57 | HGNC:12401 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | Cancer Research Technology Limited | 07/27/20 | 2D 3D TSV |
US10399958 | 21 | 21 | HGNC:9235 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | Mitobridge, Inc. | 07/27/20 | 2D 3D TSV |
US10399989 | 279 | 96 | HGNC:1133 HGNC:3236 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | Loxo Oncology, Inc. | 07/27/20 | 2D 3D TSV |
US10407433 | 124 | 111 | HGNC:9922 | Substituted 4-phenylpiperidines, their preparation and use | The Trustees of Columbia University In The City of New York | 07/27/20 | 2D 3D TSV |
US10399987 | 98 | 49 | HGNC:11773 | TGF beta receptor antagonists | Bristol-Myer Squibb Company | 07/27/20 | 2D 3D TSV |
US10399939 | 40 | 40 | HGNC:3467 | Tetrahydronaphthalene estrogen receptor modulators and uses thereof | Genentech, Inc. | 07/27/20 | 2D 3D TSV |
US10399945 | 74 | 68 | HGNC:8031 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. | 07/27/20 | 2D 3D TSV |
US10406157 | 4 | 2 | HGNC:4515 | Tetrahydropyridopyrazine modulators of GPR6 | Takeda Pharmaceutical Company Limited | 07/27/20 | 2D 3D TSV |
US10398703 | 23 | 23 | HGNC:6307 | Therapeutic compounds and uses thereof | Kala Pharmaceuticals, Inc. | 07/27/20 | 2D 3D TSV |
US10407422 | 9 | 9 | HGNC:7218 | Triazolopyridine inhibitors of myeloperoxidase | Bristol-Myers Squibb Company | 07/27/20 | 2D 3D TSV |
US10399972 | 70 | 66 | Tricyclic compounds as inhibitors of mutant IDH enzymes | Merck Sharp & Dohme Corp. | 07/27/20 | 2D 3D TSV | |
US10392391 | 570 | 547 | HGNC:882 | Compounds useful as inhibitors of ATR kinase | Vertex Pharmaceuticals Incorporated | 07/20/20 | 2D 3D TSV |
US10392402 | 22 | 11 | HGNC:10251 HGNC:10252 | Heterocyclic compounds as kinase inhibitors | Translational Drug Development, LLC | 07/20/20 | 2D 3D TSV |
US10392376 | 131 | 119 | Heterocyclic inhibitors of ATR kinase | Board of Regents, The University of Texas System | 07/20/20 | 2D 3D TSV | |
US10392346 | 187 | 72 | HGNC:11491 HGNC:11283 HGNC:4616 | Kinase inhibitors | Topivert Pharma Limited | 07/20/20 | 2D 3D TSV |
US10392405 | 25 | 25 | HGNC:17635 | Macrocyclic immunomodulators | ChemoCentryx, Inc. | 07/20/20 | 2D 3D TSV |
US10391089 | 334 | 330 | HGNC:29652 | PRMT5 inhibitors and uses therof | Epizyme, Inc. | 07/20/20 | 2D 3D TSV |
US10392392 | 120 | 103 | HGNC:6251 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | Tolero Pharmaceuticals, Inc. | 07/20/20 | 2D 3D TSV |
US10385022 | 323 | 323 | HGNC:19680 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. | 07/13/20 | 2D 3D TSV |
US10383871 | 19 | 19 | HGNC:3553 | Azetidine derivatives | Vernalis (R&D) Ltd. | 07/13/20 | 2D 3D TSV |
US10383880 | 247 | 237 | HGNC:8846 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity | 07/13/20 | 2D 3D TSV |
US10385066 | 36 | 35 | HGNC:2843 | Compounds as diacylglycerol acyltransferase inhibitors | GlaxoSmithKline LLC | 07/13/20 | 2D 3D TSV |
US10383850 | 23 | 23 | Indazole and indole derivatives as inhibitors of retinoic acid related orphan receptor gamma (ROR gamma) for the treatment of immune-related diseases | ORCA PHARMACEUTICALS LIMITED | 07/13/20 | 2D 3D TSV | |
US10377772 | 63 | 63 | HGNC:18618 | Macrocyclic LRRK2 kinase inhibitors | Oncodesign S.A. | 07/13/20 | 2D 3D TSV |
US10377763 | 48 | 23 | HGNC:4849 HGNC:4848 | Morphinan derivative and medical usage thereof | UNIVERSITY OF TSUKUBA | 07/13/20 | 2D 3D TSV |
US10385031 | 171 | 56 | HGNC:4852 HGNC:4854 HGNC:4853 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC | 07/13/20 | 2D 3D TSV |
US10385036 | 35 | 35 | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | Pfizer Inc. | 07/13/20 | 2D 3D TSV | |
US10377768 | 112 | 91 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | Lycera Corporation | 07/13/20 | 2D 3D TSV | |
US10383835 | 72 | 25 | HGNC:3401 | Treatment of inflammatory disorders in non-human mammals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 07/13/20 | 2D 3D TSV |
US10385052 | 28 | 7 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Tricyclic compound and JAK inhibitor | Nissan Chemical Corporation | 07/13/20 | 2D 3D TSV |
US10377770 | 457 | 419 | Tricyclic compounds and compositions as kinase inhibitors | Novartis AG | 07/13/20 | 2D 3D TSV | |
US10377742 | 493 | 490 | HGNC:9377 | AMPK-activating heterocyclic compounds and methods for using the same | Rigel Pharmaceuticals, Inc. | 07/06/20 | 2D 3D TSV |
US10370370 | 89 | 58 | HGNC:5297 HGNC:1960 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | Axovant Sciences GmbH | 07/06/20 | 2D 3D TSV |
US10370368 | 11 | 9 | HGNC:6713 | Aryl acylsulfonamides as BLT1 antagonists | Merck Sharp & Dohme Corp. | 07/06/20 | 2D 3D TSV |
US10370338 | 50 | 25 | HGNC:15631 HGNC:15632 | Benzazepine dicarboxamide compounds with tertiary amide function | Hoffmann-La Roche Inc. | 07/06/20 | 2D 3D TSV |
US10377729 | 5 | 5 | HGNC:12405 | Bis-furan derivatives as transthyretin (TTR) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (FAP) | BSIM Therapeutics, S.A. | 07/06/20 | 2D 3D TSV |
US10370379 | 25 | 25 | HGNC:8031 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION | 07/06/20 | 2D 3D TSV |
US10370352 | 7 | 7 | HGNC:6857 | Cyclobutyl-imidazolidinone compounds | ELI LILLY AND COMPANY | 07/06/20 | 2D 3D TSV |
US10377717 | 104 | 104 | HGNC:7967 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. | 07/06/20 | 2D 3D TSV |
US10370388 | 85 | 82 | HGNC:338 | Heterocyclic compounds and methods of their use | NOVARTIS AG | 07/06/20 | 2D 3D TSV |
US10370375 | 84 | 28 | Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors | Elanco Tiergesundheit AG | 07/06/20 | 2D 3D TSV | |
US10377746 | 20 | 20 | Indolin-2-one derivatives | Hoffmann-La Roche Inc. | 07/06/20 | 2D 3D TSV | |
US10370339 | 48 | 47 | N-Methylbenzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT | 07/06/20 | 2D 3D TSV | |
US10370337 | 5 | 5 | Oxy-cyanoquinolinone PDE9 inhibitors | Merck, Sharp & Dohme Corp. | 07/06/20 | 2D 3D TSV | |
US10370336 | 6 | 5 | Phenyl-cyanoquinolinone PDE9 inhibitors | Merck Sharp & Dohme Corp. | 07/06/20 | 2D 3D TSV | |
US10377744 | 62 | 55 | HGNC:3402 | Potent soluble epdxide hydrolase inhibitors | Eicosis, LLC | 07/06/20 | 2D 3D TSV |
US10369153 | 249 | 142 | HGNC:6190 HGNC:6192 HGNC:6193 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED | 07/06/20 | 2D 3D TSV |
US10370360 | 160 | 40 | HGNC:6342 HGNC:2730 HGNC:2731 | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof | The Board of Regents of the University of Texas System | 07/06/20 | 2D 3D TSV |
US10377753 | 634 | 628 | HGNC:4586 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV | 07/06/20 | 2D 3D TSV |
US10376531 | 17 | 17 | HGNC:742 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | Pfizer Inc. | 07/06/20 | 2D 3D TSV |
US10370333 | 169 | 163 | HGNC:438 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE | 07/06/20 | 2D 3D TSV |
US10370387 | 196 | 96 | Tricyclic fused thiophene derivatives as JAK inhibitors | Incyte Holdings Corporation | 07/06/20 | 2D 3D TSV | |
US10376502 | 20 | 20 | Alkylated imino sugars exhibiting glucosidase inhibition and their method of use | TBA | 06/29/20 | 2D 3D TSV | |
US10364255 | 43 | 41 | Heteroaromatic compounds as Vanin inhibitors | Boehringer Ingleheim International GmbH | 06/29/20 | 2D 3D TSV | |
US10364242 | 3 | 1 | HGNC:3553 HGNC:736 HGNC:735 | Modulation of N-acylethanolamine-hydrolysing acid amidase (NAAA) for disease treatment | Fondazione Istituto Italiano di Tecnologia | 06/29/20 | 2D 3D TSV |
US10364238 | 188 | 92 | HGNC:6371 HGNC:6357 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | Kalvista Pharmaceuticals Limited | 06/29/20 | 2D 3D TSV |
US10364234 | 5 | 2 | HGNC:6251 HGNC:6255 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | Jiangsu Hengrui Medicine Co., Ltd. | 06/29/20 | 2D 3D TSV |
US10376504 | 6 | 6 | Substituted quinolinones as PDE9 inhibitors | Merck Sharp & Dohme Corp | 06/29/20 | 2D 3D TSV | |
US10376514 | 304 | 300 | HGNC:8775 | Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones | Dart NeuroScience (Cayman) Ltd | 06/29/20 | 2D 3D TSV |
US10336729 | 95 | 95 | HGNC:550 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | Boehringer Ingelheim International GmbH | 06/21/20 | 2D 3D TSV |
US10336739 | 253 | 250 | HGNC:339 | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists | Bristol-Myers Squibb Co. | 06/21/20 | 2D 3D TSV |
US10357546 | 20 | 10 | HGNC:7175 HGNC:7176 | Acceleration of diabetic wound healing | University of Notre Dame du Lac | 06/21/20 | 2D 3D TSV |
US10336733 | 50 | 46 | HGNC:6713 | Aryl acylsulfonamides as BLT1 antagonists | Merk Sharp & Dohme Corp. | 06/21/20 | 2D 3D TSV |
US10358446 | 67 | 16 | HGNC:6735 HGNC:1057 HGNC:1133 HGNC:6524 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO., LTD. | 06/21/20 | 2D 3D TSV |
US10336724 | 38 | 19 | HGNC:2671 | D-amino acid oxidase inhibitors and therapeutic uses thereof | SyneuRx International (Taiwan) Corp. | 06/21/20 | 2D 3D TSV |
US10336755 | 23 | 23 | HGNC:1133 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | Beijing Innocare Pharma Tech Co., Ltd. | 06/21/20 | 2D 3D TSV |
US10336775 | 181 | 174 | HGNC:7056 | Glycosidase inhibitors | Asceneuron SA | 06/21/20 | 2D 3D TSV |
US10358451 | 19 | 13 | HGNC:11708 HGNC:6059 | Heterocycles useful as IDO and TDO inhibitors | Hangzhou Innogate Pharma Co., Ltd. | 06/21/20 | 2D 3D TSV |
US10336727 | 237 | 79 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 06/21/20 | 2D 3D TSV |
US10336734 | 12 | 3 | HGNC:6192 HGNC:19297 HGNC:11283 HGNC:427 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. Lee Moffitt Cancer Center and Research Institute Inc | 06/21/20 | 2D 3D TSV |
US10358436 | 643 | 201 | HGNC:11393 HGNC:11390 HGNC:3765 | Kinase inhibitors and method of treating cancer | University Health Network | 06/21/20 | 2D 3D TSV |
US10357493 | 402 | 201 | HGNC:4852 HGNC:14064 | Metalloenzyme inhibitor compounds | Selenity Therapeutics (Bermuda), Ltd. | 06/21/20 | 2D 3D TSV |
US10336774 | 68 | 64 | HGNC:9644 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | Novartis AG | 06/21/20 | 2D 3D TSV |
US10336754 | 22 | 8 | HGNC:6371 HGNC:3529 | Pyrimidinones as factor XIa inhibitors | Bristol-Myers Squibb Co. | 06/21/20 | 2D 3D TSV |
US10336762 | 1932 | 935 | HGNC:11892 HGNC:17967 | Pyrrolo[1,2-b]pyridazine derivatives | Gilead Sciences Inc | 06/21/20 | 2D 3D TSV |
US10336759 | 26 | 26 | HGNC:6190 | Salts and processes of preparing a PI3K inhibitor | Incyte Corporation | 06/21/20 | 2D 3D TSV |
US10336731 | 14 | 14 | HGNC:6059 | Substituted 1H-indole-2-carboxamide compounds as indoleamine-2,3-dioxygenase inhibitors | Merck Sharp & Dohme Corp | 06/21/20 | 2D 3D TSV |
US10358416 | 288 | 286 | HGNC:4501 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | Epics Therapeutics | 06/21/20 | 2D 3D TSV |
US10336741 | 56 | 18 | HGNC:3528 HGNC:3529 HGNC:3535 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | Ono Pharmaceutical Co., Ltd | 06/21/20 | 2D 3D TSV |
US10336761 | 682 | 341 | HGNC:11773 | TGFβ receptor antagonist | Bristol-Myers Squibb Co. | 06/21/20 | 2D 3D TSV |
US10336752 | 15 | 11 | HGNC:12440 | TYK2 inhibitors, uses, and methods for production thereof | Nimbus Lakshmi, Inc. | 06/21/20 | 2D 3D TSV |
US10336757 | 25 | 25 | HGNC:1735 | Treatment of neurodegenerative diseases through inhibition of HSP90 | Sloan-Kettering Institute for Cancer Research | 06/21/20 | 2D 3D TSV |
US10358435 | 116 | 66 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | Merck Sharp & Dohme Corp | 06/21/20 | 2D 3D TSV | |
US10358449 | 5 | 5 | HGNC:3009 | Xanthine derivative | Jiangsu Tasly Diyi Pharmaceutical Co, LTD. | 06/21/20 | 2D 3D TSV |
US10351548 | 11 | 11 | HGNC:8816 | 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of PDK1 | International Society for Drug Development S.R.L. | 06/12/20 | 2D 3D TSV |
US10351563 | 236 | 233 | HGNC:19679 | Biaryl kinase inhibitors | Bristol-Myers Squibb Co. | 06/12/20 | 2D 3D TSV |
US10351575 | 161 | 158 | HGNC:8031 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | Array BioPharma Inc | 06/12/20 | 2D 3D TSV |
US10351570 | 11 | 10 | HGNC:6307 | Compounds and uses thereof | Kala Pharmaceuticals, Inc. | 06/12/20 | 2D 3D TSV |
US10351558 | 215 | 212 | HGNC:3551 | Factor IXa inhibitors | Merck Sharp & Dohme Corp | 06/12/20 | 2D 3D TSV |
US10351547 | 267 | 263 | HGNC:11331 | Somatostatin modulators and uses thereof | CRINETICS PHARMACEUTICALS, INC. | 06/12/20 | 2D 3D TSV |
US10343992 | 273 | 268 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited | 06/09/20 | 2D 3D TSV | |
USRE47493 | 273 | 267 | HGNC:3309 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 06/09/20 | 2D 3D TSV |
US10344000 | 39 | 35 | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp | 06/09/20 | 2D 3D TSV | |
US10344025 | 605 | 595 | GLS1 inhibitors for treating disease | The University of Texas System | 06/08/20 | 2D 3D TSV | |
US10344004 | 1 | 1 | Inhibitor of the mutated isocitrate dehydrogenase IDH1 R132H | Bayer Pharma Aktiengesellschaft | 06/08/20 | 2D 3D TSV | |
US10344034 | 19 | 13 | HGNC:4421 | Pyrazolopyrimidone or Pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof | Shanghai Hengrui Pharmaceutical Co., Ltd | 06/08/20 | 2D 3D TSV |
US10342794 | 7 | 7 | HGNC:11491 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | Gilead Sciences Inc | 06/08/20 | 2D 3D TSV |
US10016430 | 30 | 15 | HGNC:7218 HGNC:12015 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | AstraZeneca AB | 06/01/20 | 2D 3D TSV |
USRE46942 | 106 | 38 | HGNC:270 HGNC:11941 HGNC:272 HGNC:15677 | 4-piperidinyl compounds for use as tankyrase inhibitors | Novartis AG | 06/01/20 | 2D 3D TSV |
US10017516 | 326 | 67 | HGNC:171 HGNC:1076 HGNC:172 HGNC:175 | BMP inhibitors and methods of use thereof | The Brigham and Women's Hospital, Inc. | 06/01/20 | 2D 3D TSV |
US10017501 | 84 | 42 | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences Inc | 06/01/20 | 2D 3D TSV | |
US10017502 | 22 | 18 | Benzoxazinone amides as mineralocorticoid receptor modulators | AstraZeneca AB | 06/01/20 | 2D 3D TSV | |
US10016438 | 200 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 06/01/20 | 2D 3D TSV |
US10016439 | 11 | 11 | HGNC:4079 | Fused imidazole compounds | Ono Pharmaceutical Co., Ltd | 06/01/20 | 2D 3D TSV |
US10017504 | 140 | 68 | HGNC:4849 HGNC:4848 | Piperidine isoxazole and isothiazole orexin receptor antagonists | Merck Sharp & Dohme Corp | 06/01/20 | 2D 3D TSV |
US10016420 | 14 | 14 | HGNC:3357 | Substituted pyridazines for the treatment of pain | Inhibitaxin Limited | 06/01/20 | 2D 3D TSV |
US10017468 | 277 | 276 | HGNC:4501 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | Ogeda SA | 06/01/20 | 2D 3D TSV |
US10336710 | 12 | 12 | HGNC:17989 | Benzimidazole derivatives, preparation method therefor, and applications thereof | TBA | 05/31/20 | 2D 3D TSV |
US10336721 | 35 | 35 | HGNC:7097 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | Yale University | 05/31/20 | 2D 3D TSV |
US10329302 | 370 | 361 | HGNC:17967 | Bicyclic-fused heteroaryl or aryl compounds | Pfizer Inc | 05/31/20 | 2D 3D TSV |
US10329291 | 53 | 27 | HGNC:934 HGNC:933 | C5-C6-carbocyclic fused iminothiadiazine dioxides as BACE inhibitors, compositions, and their use | TBA | 05/31/20 | 2D 3D TSV |
US10335399 | 59 | 59 | HGNC:4594 | Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use | TBA | 05/31/20 | 2D 3D TSV |
US10335392 | 43 | 41 | HGNC:11892 | Cyclic compounds useful as modulators of TNF α | Bristol-Myers Squibb Co. | 05/31/20 | 2D 3D TSV |
US10329286 | 11 | 11 | FXR (NR1H4) modulating compounds | Gilead Sciences Inc | 05/31/20 | 2D 3D TSV | |
US10329299 | 436 | 107 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals Inc | 05/31/20 | 2D 3D TSV |
US10329307 | 74 | 70 | Heterocyclic compounds as inhibitors of platelet aggregation | Universite de Montreal | 05/31/20 | 2D 3D TSV | |
US10329303 | 52 | 52 | HGNC:23357 | Heterocyclic inhibitors of monocarboxylate transporter | The Scripps Research Institute | 05/31/20 | 2D 3D TSV |
US10336717 | 549 | 510 | HGNC:933 | Inhibitors of beta-secretase | Vitae Pharmaceuticals, LLC | 05/31/20 | 2D 3D TSV |
US10335409 | 178 | 86 | Inhibitors of hepatitis C virus | Gilead Pharmasset LLC | 05/31/20 | 2D 3D TSV | |
US10329320 | 66 | 61 | Neuroactive steroids, compositions, and uses thereof | Sage Therapeutics, Inc. | 05/31/20 | 2D 3D TSV | |
US10335401 | 95 | 94 | HGNC:7045 | Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity | Shionogi & Co., Ltd | 05/31/20 | 2D 3D TSV |
US10336684 | 60 | 53 | HGNC:19061 | Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators | Bristol=Myers Squibb Company | 05/31/20 | 2D 3D TSV |
US10329294 | 290 | 280 | HGNC:17967 | Pyrazolopyrimidine inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 05/31/20 | 2D 3D TSV |
US10329295 | 163 | 162 | HGNC:17967 | Pyrrolotriazine inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 05/31/20 | 2D 3D TSV |
US10329282 | 123 | 123 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | Beijing Tide Pharmaceutical Co., Ltd | 05/31/20 | 2D 3D TSV | |
US10335402 | 23 | 23 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders | Takeda Pharmaceutical Co., Ltd | 05/31/20 | 2D 3D TSV | |
USRE47451 | 45 | 9 | HGNC:2730 HGNC:2731 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | Hanmi Pharm. Co., Ltd | 05/31/20 | 2D 3D TSV |
US10011588 | 308 | 149 | HGNC:4849 HGNC:4848 | 1,2-substituted cyclopentanes as orexin receptor antagonists | Takeda Pharmaceutical Co., Ltd | 05/26/20 | 2D 3D TSV |
US10011627 | 18 | 9 | HGNC:11037 HGNC:11036 | C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof | YOUNGENE THERAPEUTICS CO., LTD | 05/26/20 | 2D 3D TSV |
US10011599 | 101 | 99 | HGNC:6840 | Compounds and compositions as inhibitors of MEK | Novartis AG | 05/26/20 | 2D 3D TSV |
US10011568 | 40 | 21 | HGNC:11526 HGNC:2637 | Cyclohexyl pyridine derivative | Kissei Pharmaceutical Co., Ltd | 05/26/20 | 2D 3D TSV |
US10011595 | 242 | 120 | HGNC:4849 HGNC:4848 | Ethyldiamine orexin receptor antagonists | Merck Sharp & Dohme Corp | 05/26/20 | 2D 3D TSV |
US10011607 | 111 | 111 | HGNC:4596 | Ethynyl derivatives | Hoffman-La Roche Inc | 05/26/20 | 2D 3D TSV |
US10011593 | 16 | 13 | HGNC:6307 HGNC:8804 HGNC:9437 | Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors | Allergan Inc | 05/26/20 | 2D 3D TSV |
US10011611 | 44 | 4 | HGNC:4852 HGNC:14064 HGNC:19086 HGNC:14068 HGNC:13315 HGNC:4853 HGNC:18128 | Histone deacetylase inhibitors and methods for use thereof | Reaction Biology Corp | 05/26/20 | 2D 3D TSV |
US10011604 | 60 | 60 | HGNC:8031 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | Array BioPharma Inc | 05/26/20 | 2D 3D TSV |
US10010547 | 147 | 147 | HGNC:1925 | Pharmaceutical compounds | Cascadian Therapeutics, Inc. | 05/26/20 | 2D 3D TSV |
US10011571 | 26 | 3 | HGNC:6190 HGNC:3763 HGNC:6192 HGNC:1057 HGNC:6193 HGNC:6171 HGNC:11584 HGNC:12440 HGNC:3767 | Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. | 05/26/20 | 2D 3D TSV |
US10010539 | 216 | 108 | HGNC:4848 | Pyrazole, triazole and tetrazole orexin receptor antagonists | Merck Sharp & Dohme Corp | 05/26/20 | 2D 3D TSV |
US10005769 | 79 | 78 | HGNC:3092 | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors | 4SC AG | 05/18/20 | 2D 3D TSV |
US10005792 | 140 | 135 | HGNC:10894 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. | 05/18/20 | 2D 3D TSV |
US10005788 | 52 | 24 | HGNC:7027 HGNC:12446 | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation | 05/18/20 | 2D 3D TSV |
US10005768 | 136 | 135 | HGNC:10597 | Carboxamide derivatives and use thereof | Purdue Pharma LP | 05/18/20 | 2D 3D TSV |
US10004738 | 49 | 48 | HGNC:933 | Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines | H. Lundbeck A/S | 05/18/20 | 2D 3D TSV |
US10005735 | 104 | 40 | HGNC:2240 HGNC:16889 | Inhibitors of RPN11 | California Institute of Technology | 05/18/20 | 2D 3D TSV |
US10005783 | 105 | 105 | HGNC:8031 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Array BioPharma Inc | 05/18/20 | 2D 3D TSV |
US10005762 | 159 | 80 | HGNC:6656 | Pyridine derivatives | Astellas Pharma Inc | 05/18/20 | 2D 3D TSV |
US10005756 | 77 | 76 | HGNC:16672 | Pyrrolidinone derivatives as MetAP-2 inhibitors | Merck Patent GmbH | 05/18/20 | 2D 3D TSV |
US10005739 | 214 | 213 | HGNC:2730 | Quinazolinone and isoquinolinone derivative | Chugai Seiyaku Kabushiki Kaisha | 05/18/20 | 2D 3D TSV |
US10005782 | 218 | 200 | HGNC:1133 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BeiGene, Ltd | 05/18/20 | 2D 3D TSV |
US10004755 | 149 | 40 | HGNC:7027 HGNC:12446 HGNC:3765 | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | University of North Carolina at Chapel Hill | 05/18/20 | 2D 3D TSV |
US10329256 | 159 | 43 | HGNC:6833 HGNC:6834 HGNC:29079 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | Oryzon Genomics, S.A. | 05/11/20 | 2D 3D TSV |
US10323042 | 246 | 64 | HGNC:8781 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | Pfizer Inc | 05/11/20 | 2D 3D TSV |
US10323060 | 37 | 34 | HGNC:7967 | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof | Enanta Pharmaceuticals Inc | 05/11/20 | 2D 3D TSV |
US10000483 | 117 | 27 | HGNC:1079 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:11719 HGNC:7972 HGNC:3942 | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof | Dana-Farber Cancer Institute Inc | 05/11/20 | 2D 3D TSV |
US9999624 | 8 | 8 | HGNC:933 | Combination Alzheimer therapy using anti-N3pGlu Abeta antibodies + a BACE inhibitor | Eli Lilly and Company | 05/11/20 | 2D 3D TSV |
US10000507 | 426 | 142 | HGNC:19310 HGNC:8987 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | Incyte Corporation | 05/11/20 | 2D 3D TSV |
US10000487 | 21 | 13 | HGNC:7110 HGNC:7111 | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers | eFFECTOR Therapeutics Inc | 05/11/20 | 2D 3D TSV |
US10323032 | 332 | 111 | HGNC:8537 | P2X7 Modulators | Janssen Pharmaceutica NV | 05/11/20 | 2D 3D TSV |
US9999619 | 794 | 387 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | Incyte Holdings Corporation | 05/11/20 | 2D 3D TSV | |
USRE47437 | 55 | 24 | HGNC:1232 HGNC:12680 HGNC:14661 | Prolyl hydroxylase inhibitors and methods of use | Akebia Therapeutics, Inc. | 05/11/20 | 2D 3D TSV |
US10000468 | 22 | 21 | HGNC:4515 | Pyrazines as modulators of GPR6 | Takeda Pharmaceutical Co., Ltd | 05/11/20 | 2D 3D TSV |
US10323038 | 290 | 143 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. | 05/11/20 | 2D 3D TSV | |
US10000476 | 229 | 150 | HGNC:7160 HGNC:195 HGNC:7173 HGNC:7163 HGNC:7175 HGNC:7176 HGNC:7155 HGNC:7166 HGNC:7159 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | Kaken Pharmaceutical Co., Ltd | 05/11/20 | 2D 3D TSV |
US10328074 | 61 | 61 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | Boehringer Ingelheim International GmbH | 05/11/20 | 2D 3D TSV | |
US10328054 | 69 | 69 | Substituted pyrrolidines as mGluR5 antagonists | Hua Medicine (Shanghai) Ltd. | 05/11/20 | 2D 3D TSV | |
US10328053 | 138 | 135 | HGNC:10905 | Substituted pyrrolizine compounds and uses thereof | Gilead Sciences Inc | 05/11/20 | 2D 3D TSV |
US10323036 | 218 | 217 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 05/11/20 | 2D 3D TSV | |
US10329273 | 24 | 22 | HGNC:7045 | Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors | Bristol-Myers Squibb Co. | 05/11/20 | 2D 3D TSV |
US10328077 | 121 | 118 | HGNC:29079 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | Celgene Corporation | 05/11/20 | 2D 3D TSV |
US10000475 | 14 | 14 | HGNC:10597 | Triazine carboxamides as sodium channel blockers | Purdue Pharma LP | 05/11/20 | 2D 3D TSV |
US10329280 | 3 | 3 | HGNC:6307 | Urea derivatives and uses thereof | Kala Pharmaceuticals, Inc. | 05/11/20 | 2D 3D TSV |
US10322118 | 24 | 21 | HGNC:3402 | Compounds and methods for inhibiting Cif virulence factor | Dartmouth College | 05/10/20 | 2D 3D TSV |
US10323016 | 48 | 24 | HGNC:19680 | Imidazol- or 1,2,4-triazol-derivatives and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE | 05/10/20 | 2D 3D TSV |
US10323000 | 355 | 196 | HGNC:5992 HGNC:8537 | Indole derivatives and their use in neurodegenerative diseases | Merck Patent GmbH | 05/10/20 | 2D 3D TSV |
US10322143 | 63 | 61 | HGNC:220 HGNC:221 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO | 05/10/20 | 2D 3D TSV |
US10322108 | 46 | 46 | N-benzoate group substituted benzopyrroline-2-one derivative and use thereof | Beijing Hanmi Pharmaceutical Co., Ltd. | 05/10/20 | 2D 3D TSV | |
US10322140 | 24 | 13 | HGNC:2637 HGNC:3537 | Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists | TBA | 05/10/20 | 2D 3D TSV |
US10323019 | 18 | 6 | HGNC:6190 HGNC:6192 HGNC:6193 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | Eli Lilly and Company | 05/10/20 | 2D 3D TSV |
US10323022 | 648 | 638 | HGNC:8031 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | Array BioPharma Inc | 05/10/20 | 2D 3D TSV |
US10323018 | 229 | 227 | HGNC:30092 | Quinazoline and quinoline compounds and uses thereof | Millennium Pharmaceuticals Inc | 05/10/20 | 2D 3D TSV |
US10323023 | 19 | 19 | HGNC:10252 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | Beijing Tide Pharmaceutical Co., Ltd | 05/10/20 | 2D 3D TSV |
US10323029 | 995 | 365 | HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 | Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders | The Scripps Research Institute | 05/10/20 | 2D 3D TSV |
US10323020 | 15 | 13 | HGNC:283 | Substituted piperidinyl tetrahydroquinolines | Bayer Pharma Aktiengesellschaft | 05/10/20 | 2D 3D TSV |
US10323021 | 206 | 114 | HGNC:6251 | Triazoles as NR2B receptor inhibitors | JANSSEN PHARMACEUTICALS, INC. | 05/10/20 | 2D 3D TSV |
US9994571 | 22 | 11 | HGNC:8154 HGNC:8156 | 10-substituted morphinan hydantoins | Purdue Pharma LP | 05/07/20 | 2D 3D TSV |
US9993478 | 104 | 32 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 HGNC:6876 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors | Respivert Ltd | 05/05/20 | 2D 3D TSV |
US9993465 | 57 | 10 | 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof | Georgetown University | 05/05/20 | 2D 3D TSV | |
US9994552 | 278 | 138 | HGNC:6342 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION | 05/05/20 | 2D 3D TSV |
US9994546 | 130 | 129 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 05/05/20 | 2D 3D TSV |
US9994525 | 16 | 16 | H3 antagonists containing phenoxypiperidine core structure | Richter Gedeon Nyrt. | 05/05/20 | 2D 3D TSV | |
US9994547 | 150 | 149 | HGNC:11584 | Heteroarylamide inhibitors of TBK1 | Takeda Pharmaceutical Co., Ltd | 05/05/20 | 2D 3D TSV |
US9994550 | 8 | 8 | HGNC:3594 | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | 3-V Biosciences, Inc. | 05/05/20 | 2D 3D TSV |
US9994590 | 59 | 54 | HGNC:8772 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | Sunovion Pharmaceuticals Inc | 05/05/20 | 2D 3D TSV |
US9994576 | 33 | 33 | HGNC:1133 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | Principia Biopharma Inc | 05/05/20 | 2D 3D TSV |
US9993479 | 43 | 43 | HGNC:8031 | Trk-inhibiting compound | Ono Pharmaceutical Co., Ltd | 05/05/20 | 2D 3D TSV |
US9988392 | 21 | 13 | HGNC:8154 HGNC:8156 | 7-beta-alkyl analogs of orvinols | Purdue Pharma LP | 04/30/20 | 2D 3D TSV |
US9987274 | 135 | 47 | HGNC:11526 HGNC:11527 HGNC:11528 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Ogeda SA | 04/30/20 | 2D 3D TSV |
US9987255 | 48 | 24 | HGNC:4849 HGNC:4848 | 5,5-bicyclic oxazole orexin receptor antagonists | Merck Sharp & Dohme Corp | 04/25/20 | 2D 3D TSV |
US9987253 | 8 | 8 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | Jenrin Discovery Inc | 04/25/20 | 2D 3D TSV | |
US9988375 | 36 | 33 | Inhibitors of lysine gingipain | CORTEXYME, INC. | 04/25/20 | 2D 3D TSV | |
US9987259 | 31 | 31 | HGNC:1960 | Pharmaceutical composition comprising pyridone derivatives | SK Biopharmaceuticals Co. Ltd | 04/25/20 | 2D 3D TSV |
US9987278 | 41 | 41 | Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof | FUJIFILM Corporation | 04/25/20 | 2D 3D TSV | |
US9987252 | 5 | 5 | Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals Inc | 04/25/20 | 2D 3D TSV | |
US9987276 | 467 | 239 | HGNC:1079 HGNC:6193 HGNC:6171 HGNC:3236 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | Celgene CAR LLC | 04/25/20 | 2D 3D TSV |
US9981963 | 29 | 29 | HGNC:1974 | 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors | Janssen Pharmaceutica NV | 04/18/20 | 2D 3D TSV |
US9981944 | 245 | 124 | HGNC:11773 | GDF-8 inhibitors | Rigel Pharmaceuticals, Inc | 04/18/20 | 2D 3D TSV |
US9981901 | 75 | 73 | HGNC:3449 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. | 04/18/20 | 2D 3D TSV |
US9981975 | 438 | 146 | HGNC:7027 HGNC:12446 | Pyrrolotriazine compounds as tam inhibitors | Incyte Corporation | 04/18/20 | 2D 3D TSV |
US9981909 | 592 | 296 | HGNC:5301 HGNC:11050 HGNC:5295 HGNC:5294 | Serotonin receptor modulators | Janssen Pharmaceutica NV | 04/18/20 | 2D 3D TSV |
US9981925 | 150 | 74 | HGNC:391 HGNC:10436 | Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors | Merck Patent GmbH | 04/18/20 | 2D 3D TSV |
US9981950 | 116 | 116 | HGNC:6251 | Triazoles as NR2B receptor inhibitors | JANSSEN PHARMACEUTICALS, INC. | 04/18/20 | 2D 3D TSV |
US9981973 | 20 | 10 | HGNC:11708 HGNC:6059 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NewLink Genetics Corporation | 04/18/20 | 2D 3D TSV |
US9980929 | 73 | 73 | Trifluoromethylpropanamide derivatives | Hoffman-La Roche Inc | 04/18/20 | 2D 3D TSV | |
US10314832 | 18 | 17 | HGNC:2514 | β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators | Samumed, LLC | 04/15/20 | 2D 3D TSV |
US10308635 | 23 | 23 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | Takeda Pharmaceutical Co., Ltd | 04/15/20 | 2D 3D TSV | |
US10308629 | 47 | 40 | HGNC:1148 | 1H-pyrrol-3-amines | Bayer Pharma Aktiengesellschaft | 04/15/20 | 2D 3D TSV |
US10307427 | 23 | 18 | HGNC:6857 | Apoptosis signal-regulating kinase inhibitors | Gilead Sciences Inc | 04/15/20 | 2D 3D TSV |
US10308636 | 80 | 80 | HGNC:2843 | Aromatic heterocyclic compound | Mitsubishi Tanabe Pharma Corporation | 04/15/20 | 2D 3D TSV |
US10308660 | 171 | 170 | HGNC:9644 | Compounds and compositions for inhibiting the activity of SHP2 | Novartis AG | 04/15/20 | 2D 3D TSV |
US10308607 | 3 | 3 | HGNC:4006 | Fucosidase inhibitors | HORIZON ORPHAN LLC | 04/15/20 | 2D 3D TSV |
US10308628 | 10 | 10 | HGNC:338 | Heterocyclic compounds and methods for their use | Novartis AG | 04/15/20 | 2D 3D TSV |
US10308644 | 271 | 267 | Heterocyclic compounds as immunomodulators | Incyte Corporation | 04/15/20 | 2D 3D TSV | |
US10308615 | 344 | 163 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | Pfizer Inc | 04/15/20 | 2D 3D TSV | |
US10308663 | 3 | 3 | HGNC:9636 | Inhibitors of PTP4A3 for the treatment of cancer | University of Virginia Patent Foundation | 04/15/20 | 2D 3D TSV |
US10308648 | 15 | 15 | HGNC:1778 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Syros Pharmaceuticals, Inc. | 04/15/20 | 2D 3D TSV |
US10314827 | 21 | 18 | HGNC:441 | Methods of use of cyclopamine analogs | Infinity Pharmaceuticals Inc | 04/15/20 | 2D 3D TSV |
US10308620 | 74 | 74 | HGNC:1950 | Muscarinic M1 receptor positive allosteric modulators | Suven Life Sciences Limited | 04/15/20 | 2D 3D TSV |
US10308667 | 168 | 167 | HGNC:32311 | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors | Boehringer Ingelheim International GmbH | 04/15/20 | 2D 3D TSV |
US10308645 | 86 | 43 | HGNC:4849 HGNC:4848 | Piperidine oxadiazole and thiadiazole orexin receptor antagonists | Merck Sharp & Dohme Corp | 04/15/20 | 2D 3D TSV |
US10308654 | 32 | 18 | HGNC:1722 | Preparation and use of kinase inhibitor | CHANGZHOU LONGTHERA PHARMACEUTICALS INC. | 04/15/20 | 2D 3D TSV |
US10308605 | 14 | 14 | Proton pump inhibitors | Takeda Pharmaceutical Co., Ltd | 04/15/20 | 2D 3D TSV | |
US10308659 | 246 | 121 | HGNC:2160 HGNC:2159 | Pyridine derivatives | Hoffmann-La Roche Inc | 04/15/20 | 2D 3D TSV |
US10307414 | 35 | 34 | HGNC:1133 | Pyridinyl and fused pyridinyl triazolone derivatives | Takeda Pharmaceutical Co., Ltd | 04/15/20 | 2D 3D TSV |
US10308634 | 22 | 22 | HGNC:17967 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | Bayer Pharma Aktiengesellschaft | 04/15/20 | 2D 3D TSV |
US10307413 | 679 | 673 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme Inc | 04/15/20 | 2D 3D TSV | |
US10307426 | 36 | 16 | HGNC:6190 HGNC:6192 | Therapeutic compounds and compositions, and methods of use thereof | Genentech Inc | 04/15/20 | 2D 3D TSV |
US10308614 | 304 | 238 | Therapeutic compounds and uses thereof | Genentech Inc | 04/15/20 | 2D 3D TSV | |
US10308637 | 319 | 310 | HGNC:6863 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. | 04/15/20 | 2D 3D TSV |
US10308662 | 114 | 28 | HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 | Thienopyranones as kinase and epigenetic inhibitors | Signal Rx Pharmaceuticals Inc | 04/15/20 | 2D 3D TSV |
US10308652 | 64 | 60 | HGNC:11892 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | Bristol-Myers Squibb Co. | 04/15/20 | 2D 3D TSV |
US9975876 | 63 | 31 | HGNC:4849 HGNC:4848 | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists | Merck Sharp & Dohme Corp | 04/10/20 | 2D 3D TSV |
US9974785 | 36 | 36 | HGNC:5301 | Aromatic heterocyclic derivatives and pharmaceutical applications thereof | Sunshine Lake Pharma Co., Ltd | 04/10/20 | 2D 3D TSV |
US9975862 | 12 | 2 | HGNC:3023 HGNC:5286 | Arylpiperazine derivatives and methods of utilizing same | Reviva Pharmaceuticals Inc | 04/10/20 | 2D 3D TSV |
US9975858 | 10 | 10 | HGNC:10597 | Benzimidazole derivatives and use thereof | Purdue Pharma LP | 04/10/20 | 2D 3D TSV |
US9975854 | 3 | 3 | HGNC:8154 | Benzomorphan analogs and use thereof | Purdue Pharma LP | 04/10/20 | 2D 3D TSV |
US9975902 | 13 | 11 | HGNC:9257 | Compounds for the inhibition of cyclophilins and uses thereof | Merck Patent GmbH | 04/10/20 | 2D 3D TSV |
US9975861 | 11 | 4 | HGNC:933 HGNC:4617 | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer''s disease | FONDAZIONE ISTITUTO ITAIANO DI TECNOLOGIA | 04/10/20 | 2D 3D TSV |
US9975874 | 86 | 44 | HGNC:6371 HGNC:3529 | Factor XIa inhibitors | Merck Sharp & Dohme Corp | 04/10/20 | 2D 3D TSV |
US9975882 | 212 | 63 | HGNC:1079 HGNC:1133 HGNC:11719 HGNC:12434 | Heteroaromatic compounds as BTK inhibitors | Boehringer Ingelheim International GmbH | 04/10/20 | 2D 3D TSV |
US9975907 | 123 | 80 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Pyrimidinones as PI3K inhibitors | Incyte Holdings Corporation | 04/10/20 | 2D 3D TSV |
US9969723 | 53 | 50 | HGNC:4498 | 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient | HYUNDAI PHARM CO., LTD | 04/06/20 | 2D 3D TSV |
US9969687 | 122 | 122 | HGNC:1610 | Compounds useful as CCR9 modulators | Norgine B.V. | 04/06/20 | 2D 3D TSV |
US9969724 | 53 | 53 | HGNC:3551 | Factor IXa inhibitors | Merck Sharp & Dohme Corp | 04/06/20 | 2D 3D TSV |
US9969749 | 169 | 166 | HGNC:17967 | Inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 04/06/20 | 2D 3D TSV |
US9969726 | 724 | 190 | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof | Sanford-Burnham Medical Research Institute | 04/06/20 | 2D 3D TSV | |
US9969738 | 28 | 6 | HGNC:11526 HGNC:11527 HGNC:11528 | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders | Ogeda SA | 04/06/20 | 2D 3D TSV |
US9969700 | 8 | 8 | HGNC:8535 | P2X4 receptor antagonist | Nippon Chemiphar Co., Ltd | 04/06/20 | 2D 3D TSV |
US9968610 | 15 | 10 | HGNC:6251 HGNC:2625 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | Rugen Holdings (Cayman) Limited | 04/06/20 | 2D 3D TSV |
US9969686 | 9 | 9 | HGNC:348 | Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them | Wisconsin Alumni Research Foundation | 04/06/20 | 2D 3D TSV |
US9969743 | 260 | 130 | HGNC:3023 HGNC:3024 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | Southern Research Institute | 04/06/20 | 2D 3D TSV |
US9963460 | 3 | 1 | HGNC:8153 HGNC:8154 HGNC:8156 | Morphinan derivative | University of Tsukuba | 03/30/20 | 2D 3D TSV |
US9963444 | 117 | 117 | HGNC:736 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof | Northeastern University | 03/30/20 | 2D 3D TSV |
US9963434 | 220 | 220 | N-arylmethyl sulfonamide negative modulators of NR2A | Luc Therapeutics, Inc. | 03/30/20 | 2D 3D TSV | |
US9963446 | 26 | 26 | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | Genentech Inc | 03/30/20 | 2D 3D TSV | |
US9963456 | 40 | 40 | HGNC:1373 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 03/30/20 | 2D 3D TSV |
US9962388 | 45 | 45 | HGNC:15631 | Pyrrolopyrimidine compounds used as TLR7 agonist | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | 03/30/20 | 2D 3D TSV |
US9963443 | 13 | 13 | Radiolabeled compounds | Takeda Pharmaceutical Co., Ltd | 03/30/20 | 2D 3D TSV | |
US9963439 | 46 | 18 | HGNC:2637 HGNC:20581 HGNC:2603 HGNC:2622 HGNC:2623 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | University of Washington Through its Center for Commercialization | 03/30/20 | 2D 3D TSV |
US9963453 | 45 | 43 | HGNC:8157 | Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators | LABORATORIOS DEL DR. ESTEVE S.A. | 03/30/20 | 2D 3D TSV |
US9962398 | 60 | 15 | HGNC:1373 HGNC:1383 HGNC:1371 HGNC:1368 | Sulfonamide compounds for inhibition of metastatic tumor growth | Welichem Biotech Inc. | 03/30/20 | 2D 3D TSV |
US9962362 | 18 | 12 | HGNC:3521 HGNC:9642 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | Children''s Hospital Medical Center | 03/30/20 | 2D 3D TSV |
US10301320 | 27 | 25 | HGNC:5154 | Compositions and methods of modulating 15-PGDH activity | University of Kentucky Research Foundation | 03/26/20 | 2D 3D TSV |
US10301305 | 252 | 63 | Heteroaromatic derivatives and their use as pharmaceuticals | Mutabilis | 03/26/20 | 2D 3D TSV | |
US10301323 | 183 | 61 | HGNC:4852 HGNC:4854 HGNC:4853 | Histone deacetylase inhibitors | BioMarin Pharmaceutical Inc | 03/26/20 | 2D 3D TSV |
US10301291 | 31 | 31 | HGNC:6872 | Imidazole derivative having JNK inhibitory activity and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. | 03/26/20 | 2D 3D TSV |
US10301317 | 373 | 365 | HGNC:6871 | Inhibitors of ERK and methods of use | Kura Oncology Inc | 03/26/20 | 2D 3D TSV |
US10301288 | 61 | 15 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 | Kinase inhibitors | Topivert Pharma Limited | 03/26/20 | 2D 3D TSV |
US10301336 | 33 | 33 | HGNC:2771 | Phosphonate compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 03/26/20 | 2D 3D TSV |
US10301286 | 79 | 33 | HGNC:6932 HGNC:6929 HGNC:6931 | Piperazine derivative | Astellas Pharma Inc | 03/26/20 | 2D 3D TSV |
US10301306 | 185 | 180 | HGNC:10021 | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | Bristol-Myers Squibb Co. | 03/26/20 | 2D 3D TSV |
US10301297 | 63 | 62 | HGNC:1133 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | Guangzhou Innocare Pharma Tech Co., Ltd. | 03/26/20 | 2D 3D TSV |
US10301284 | 141 | 139 | HGNC:6371 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. | 03/26/20 | 2D 3D TSV |
US10301278 | 58 | 54 | HGNC:9644 | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 | Novartis AG | 03/25/20 | 2D 3D TSV |
US10300056 | 14 | 14 | HGNC:9843 | CGRP receptor antagonists | Heptares Therapeutics Limited | 03/25/20 | 2D 3D TSV |
US10301272 | 844 | 306 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | Phenex Pharmaceuticals AG | 03/25/20 | 2D 3D TSV | |
US10301280 | 257 | 153 | HGNC:6342 | Compounds and methods for kinase modulation, and indications therefor | Plexxikon Inc. | 03/25/20 | 2D 3D TSV |
US10300051 | 61 | 61 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 03/25/20 | 2D 3D TSV |
US10301269 | 41 | 41 | HGNC:3827 | Imidazole derivatives as formyl peptide receptor modulators | Allergan Inc | 03/25/20 | 2D 3D TSV |
US10300066 | 119 | 118 | HGNC:1133 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd | 03/25/20 | 2D 3D TSV |
US10300067 | 53 | 53 | HGNC:644 | Tetrahydropyridopyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 03/25/20 | 2D 3D TSV |
US10301253 | 203 | 87 | HGNC:29079 | Therapeutic compounds and uses thereof | Genentech Inc | 03/25/20 | 2D 3D TSV |
US10300048 | 73 | 53 | HGNC:3553 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | UNIVERSITAT BERN | 03/25/20 | 2D 3D TSV |
US10300060 | 43 | 43 | HGNC:8031 | Trk-inhibiting compound | Ono Pharmaceutical Co., Ltd | 03/25/20 | 2D 3D TSV |
US10300058 | 50 | 18 | HGNC:3236 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd | 03/25/20 | 2D 3D TSV |
US10300074 | 114 | 40 | HGNC:13702 | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy | Sanford Burnham Prebys Medical Discovery Institute | 03/25/20 | 2D 3D TSV |
US9957268 | 196 | 88 | 1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins | Incyte Corporation | 03/23/20 | 2D 3D TSV | |
US9956214 | 208 | 103 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | University of Washington Through its Center for Commercialization | 03/23/20 | 2D 3D TSV | |
US9957261 | 118 | 59 | 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives | Hoffman-La Roche Inc | 03/23/20 | 2D 3D TSV | |
US9957235 | 248 | 139 | Benzimidazol-2-amines as mIDH1 inhibitors | Bayer Pharma Aktiengesellschaft | 03/23/20 | 2D 3D TSV | |
US9957263 | 371 | 184 | HGNC:13575 | Bromodomain inhibitors | AbbVie Inc | 03/23/20 | 2D 3D TSV |
US9957276 | 44 | 44 | HGNC:1771 | CDK inhibitors | GI Therapeutics, Inc. | 03/23/20 | 2D 3D TSV |
US9956208 | 4 | 4 | HGNC:1133 | Compounds for the treatment of cancer and inflammatory diseases | TBA | 03/23/20 | 2D 3D TSV |
US9957264 | 938 | 423 | HGNC:6190 HGNC:6192 | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | Merck Sharp & Dohme Corp | 03/23/20 | 2D 3D TSV |
US9957265 | 226 | 75 | HGNC:6190 HGNC:6192 | N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors | Merck Sharp & Dohme Corp | 03/23/20 | 2D 3D TSV |
US9956192 | 42 | 21 | HGNC:4852 HGNC:14064 | Selective histone deactylase 6 inhibitors | H. Lee Moffitt Cancer Center and Research Institute Inc | 03/23/20 | 2D 3D TSV |
US9951056 | 63 | 61 | HGNC:1133 | Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | Beijing Innocare Pharma Tech Co., Ltd. | 03/18/20 | 2D 3D TSV |
US9951063 | 147 | 147 | HGNC:4540 | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | IDORSIA PHARMACEUTICALS Ltd | 03/16/20 | 2D 3D TSV |
US9951077 | 118 | 116 | HGNC:1133 | Aminopyridazinone compounds as protein kinase inhibitors | Jiangsu Hengrui Medicine Co., Ltd. | 03/16/20 | 2D 3D TSV |
US9951027 | 390 | 346 | Benzimidazol-2-amines as MIDH1 inhibitors | Bayer Pharma Aktiengesellschaft | 03/16/20 | 2D 3D TSV | |
US9951071 | 443 | 219 | HGNC:6371 HGNC:3529 | Dihydropyridone P1 as factor XIa inhibitors | Bristol-Myers Squibb Co. | 03/16/20 | 2D 3D TSV |
US9951026 | 13 | 13 | HGNC:3357 | Heterocyclic vinyl autotaxin inhibitor compounds | PharmAkea Inc | 03/16/20 | 2D 3D TSV |
US9951086 | 310 | 305 | HGNC:17967 | Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments | Bayer Pharma Aktiengesellschaft | 03/16/20 | 2D 3D TSV |
US9949975 | 25 | 25 | HGNC:933 | Inhibitors of beta-secretase | Vitae Pharmaceuticals Inc | 03/16/20 | 2D 3D TSV |
US9951048 | 488 | 236 | HGNC:4617 HGNC:3091 | Isoquinolin-3-yl carboxamides and preparation and use thereof | Samumed, LLC | 03/16/20 | 2D 3D TSV |
US9951014 | 113 | 35 | HGNC:7872 HGNC:7873 | Mammalian and bacterial nitric oxide synthase inhibitors | Northwestern University | 03/16/20 | 2D 3D TSV |
US9949951 | 29 | 28 | HGNC:6059 | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | iTeos Therapeutics | 03/16/20 | 2D 3D TSV |
US9951035 | 6 | 3 | HGNC:7175 HGNC:7176 | Selective matrix metalloproteinase inhibitors | University of Notre Dame du Lac | 03/16/20 | 2D 3D TSV |
US9951029 | 63 | 63 | HGNC:3765 | Styryl quinazoline derivatives as pharmaceutically active agents | Vichem Chemie Kutató | 03/16/20 | 2D 3D TSV |
US9951033 | 23 | 23 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO | 03/16/20 | 2D 3D TSV | |
US9944601 | 159 | 43 | HGNC:6833 HGNC:6834 HGNC:29079 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | Oryzon Genomics, S.A. | 03/12/20 | 2D 3D TSV |
US9944646 | 114 | 109 | HGNC:8977 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | Incyte Holdings Corporation | 03/12/20 | 2D 3D TSV |
US9944606 | 9 | 5 | HGNC:2160 HGNC:2159 | Cannabinoid receptor modulators | Arena Pharmaceuticals Inc | 03/12/20 | 2D 3D TSV |
US9944643 | 8 | 8 | HGNC:3529 | Factor XIa inhibitors | Merck Sharp & Dohme Corp | 03/12/20 | 2D 3D TSV |
US9944647 | 138 | 138 | HGNC:29079 | Heterocyclic compounds as LSD1 inhibitors | Incyte Corporation | 03/12/20 | 2D 3D TSV |
US9944645 | 205 | 205 | HGNC:7029 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Incyte Corporation | 03/12/20 | 2D 3D TSV |
US9944618 | 940 | 167 | HGNC:6251 HGNC:11050 HGNC:2637 HGNC:2625 HGNC:11048 HGNC:11049 | Inhibiting neurotransmitter reuptake | Mayo Foundation | 03/12/20 | 2D 3D TSV |
US9943516 | 19 | 17 | HGNC:17967 | Inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 03/12/20 | 2D 3D TSV |
USRE46792 | 103 | 103 | HGNC:8783 | Oxazole compound and pharmaceutical composition | Otsuka Pharmaceutical Co., Ltd | 03/12/20 | 2D 3D TSV |
US9944624 | 126 | 61 | HGNC:17432 HGNC:1936 | Substituted amino triazoles useful as human chitinase inhibitors | OncoArendi Therapeutics SA | 03/12/20 | 2D 3D TSV |
US10294221 | 63 | 57 | 1, 3, 4-thiadiazole compounds and their use in treating cancer | AstraZeneca AB | 03/10/20 | 2D 3D TSV | |
US10294230 | 48 | 11 | HGNC:4586 HGNC:6251 HGNC:2625 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | Rugen Holdings (Cayman) Limited | 03/10/20 | 2D 3D TSV |
US10294218 | 165 | 150 | HGNC:1780 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | VIROSTATICS SRL | 03/10/20 | 2D 3D TSV |
US10294227 | 332 | 21 | HGNC:11283 HGNC:12841 HGNC:9617 HGNC:8803 HGNC:4840 HGNC:6735 HGNC:3697 HGNC:4037 HGNC:1057 HGNC:76 HGNC:6342 HGNC:3955 HGNC:3942 HGNC:9967 HGNC:6524 | Compounds | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH | 03/10/20 | 2D 3D TSV |
US10292975 | 2 | 2 | Compounds as rearranged during transfection (RET) inhibitors | GlaxoSmithKline | 03/10/20 | 2D 3D TSV | |
US10294217 | 35 | 27 | HGNC:1950 | Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators | Suven Life Sciences Limited | 03/10/20 | 2D 3D TSV |
US10294229 | 444 | 398 | HGNC:17967 | Heteroaryl substituted aminopyridine compounds | Bristol-Myers Squibb Co. | 03/10/20 | 2D 3D TSV |
US10294212 | 277 | 273 | HGNC:27269 HGNC:6059 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. | 03/10/20 | 2D 3D TSV |
US10292981 | 53 | 47 | HGNC:6001 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED | 03/10/20 | 2D 3D TSV |
US10294259 | 6 | 3 | HGNC:11037 HGNC:11036 | Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | Tianjin Institute of Pharmaceutical Research | 03/10/20 | 2D 3D TSV |
US10294214 | 80 | 80 | HGNC:6932 | Positive allosteric modulators of human melanocortin-4 receptor | Vanderbilt University | 03/10/20 | 2D 3D TSV |
US10294223 | 197 | 129 | HGNC:3689 HGNC:3688 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | Principia Biopharma Inc | 03/10/20 | 2D 3D TSV |
US10294226 | 60 | 15 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Small molecule inhibitors of the JAK family of kinases | Janssen Pharmaceutica NV | 03/10/20 | 2D 3D TSV |
US10294246 | 271 | 135 | HGNC:9542 HGNC:9545 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | Merck Patent GmbH | 03/10/20 | 2D 3D TSV |
US10292985 | 72 | 36 | HGNC:11773 | TGF beta receptor antagonists | Bristol-Myers Squibb Co. | 03/10/20 | 2D 3D TSV |
US9938265 | 43 | 33 | 1,3,4-thiadiazole compounds and their use in treating cancer | AstraZeneca AB | 03/02/20 | 2D 3D TSV | |
US9938276 | 164 | 81 | HGNC:4849 HGNC:4848 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | Merck Sharp & Dohme Corp | 03/02/20 | 2D 3D TSV |
US9938268 | 34 | 34 | HGNC:11393 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | Merck Patent GmbH | 03/02/20 | 2D 3D TSV |
US9938222 | 129 | 116 | HGNC:19061 | Cyclopropanecarboxylic acid GPR120 modulators | Bristol-Myers Squibb Co. | 03/02/20 | 2D 3D TSV |
US9938267 | 694 | 668 | Heterocyclic inhibitors of glutaminase | Calithera Biosciences Inc | 03/02/20 | 2D 3D TSV | |
US9938272 | 109 | 34 | HGNC:9475 HGNC:3528 HGNC:3535 | Hydrazine compound as blood coagulation factor Xa inhibitor | North China Pharmaceutical Company., Ltd. | 03/02/20 | 2D 3D TSV |
US9938274 | 44 | 22 | HGNC:6307 HGNC:7029 | Naphthyridine compounds, medical combinations and use thereof | NANJING NATINEFY PHARMATECH CO., LTD. | 03/02/20 | 2D 3D TSV |
US9938257 | 57 | 25 | HGNC:6190 HGNC:6192 HGNC:11393 HGNC:11390 HGNC:3765 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC | 03/02/20 | 2D 3D TSV |
US9938289 | 9 | 9 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC | 03/02/20 | 2D 3D TSV | |
US9938290 | 52 | 13 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | Karus Therapeutics Limited | 03/02/20 | 2D 3D TSV |
US10287286 | 262 | 260 | HGNC:14660 | Compounds | Takeda Pharmaceutical Co., Ltd | 02/29/20 | 2D 3D TSV |
US9931340 | 68 | 66 | HGNC:2671 | Pyridazinone compounds and their use as DAAO inhibitors | Takeda Pharmaceutical Co., Ltd | 02/29/20 | 2D 3D TSV |
US10285983 | 70 | 70 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | Samumed, LLC | 02/27/20 | 2D 3D TSV | |
US10285982 | 66 | 66 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | Samumed, LLC | 02/27/20 | 2D 3D TSV | |
US10287274 | 43 | 43 | HGNC:5302 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 02/27/20 | 2D 3D TSV |
US10287270 | 3 | 3 | HGNC:550 | Amino pyrimidine SSAO inhibitors | Eli Lilly and Company | 02/27/20 | 2D 3D TSV |
US10287301 | 719 | 698 | HGNC:2771 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals Inc | 02/27/20 | 2D 3D TSV |
US10287293 | 45 | 22 | Bicyclic heterocyclic compounds as PDE2 inhibitors | Merck Sharp & Dohme Corp | 02/27/20 | 2D 3D TSV | |
US10287292 | 184 | 129 | HGNC:23692 | CXCR7 antagonists | ChemoCentryx, Inc. | 02/27/20 | 2D 3D TSV |
US10287258 | 37 | 37 | HGNC:2528 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | AstraZeneca AB | 02/27/20 | 2D 3D TSV |
US10287278 | 40 | 14 | HGNC:6026 HGNC:6027 | Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies | Galderma Research & Development | 02/27/20 | 2D 3D TSV |
US10285988 | 30 | 30 | HGNC:15983 | Compounds for treatment of fibrosis diseases | CUREGENIX, INC. | 02/27/20 | 2D 3D TSV |
US10287300 | 130 | 64 | HGNC:28426 | Heterocyclic derivatives as modulators of kinase activity | Merck Patent GmbH | 02/27/20 | 2D 3D TSV |
US10287268 | 8 | 4 | HGNC:4840 HGNC:1133 | Imidazolyl kinase inhibitors and uses thereof | Dana-Farber Cancer Institute Inc | 02/27/20 | 2D 3D TSV |
US10287279 | 42 | 39 | HGNC:433 | Inhibitors of human 12/15-lipoxygenase | THE CHILDREN'S HOSPITAL CORPORATION | 02/27/20 | 2D 3D TSV |
US10287267 | 951 | 304 | HGNC:4617 HGNC:3091 | Isoquinolin-3-yl carboxamides and preparation and use thereof | Samumed, LLC | 02/27/20 | 2D 3D TSV |
US10287250 | 110 | 35 | HGNC:8156 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED | 02/27/20 | 2D 3D TSV |
US10285989 | 371 | 197 | Pyrimidinone amide compounds as PDE2 inhibitors | Merck Sharp & Dohme Corp | 02/27/20 | 2D 3D TSV | |
US10287272 | 149 | 126 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp | 02/27/20 | 2D 3D TSV | |
US10287305 | 266 | 261 | HGNC:4849 | Substituted piperidine compound and use thereof | Takeda Pharmaceutical Co., Ltd | 02/27/20 | 2D 3D TSV |
US10287253 | 52 | 51 | HGNC:15631 | Substituted pyrimidines containing acidic groups as TLR7 modulators | APROS THERAPEUTICS, INC. | 02/27/20 | 2D 3D TSV |
US10287295 | 605 | 303 | HGNC:11773 | TGF-β inhibitors | Rigel Pharmaceuticals, Inc | 02/27/20 | 2D 3D TSV |
US10280166 | 126 | 125 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | Samumed, LLC | 02/24/20 | 2D 3D TSV | |
US9932329 | 28 | 14 | HGNC:6171 HGNC:12434 | Benzimidazole derivatives as RLK and ITK inhibitors | Principia Biopharma Inc | 02/24/20 | 2D 3D TSV |
US9932325 | 215 | 166 | Compounds, compositions, and methods | Denali Therapeutics Inc. | 02/24/20 | 2D 3D TSV | |
US9932332 | 2 | 2 | HGNC:7967 | FXR (NR1H4) modulating compounds | Gilead Sciences Inc | 02/24/20 | 2D 3D TSV |
US10280171 | 183 | 98 | HGNC:3255 | Heterocyclic inhibitors of PTPN11 | The University of Texas System | 02/24/20 | 2D 3D TSV |
US10280184 | 71 | 69 | HGNC:1133 | Heterocyclic kinase inhibitors | AbbVie Inc | 02/24/20 | 2D 3D TSV |
US9932350 | 108 | 101 | HGNC:17967 | Inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 02/24/20 | 2D 3D TSV |
US10280167 | 39 | 39 | Purine derivatives for the treatment of viral infections | Janssen Ireland | 02/24/20 | 2D 3D TSV | |
US9932327 | 10 | 5 | HGNC:1780 HGNC:1771 | Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof | The Council of Scientific & Industrial Research | 02/24/20 | 2D 3D TSV |
US9931338 | 7 | 7 | HGNC:11491 | Syk inhibitors | Gilead Sciences Inc | 02/24/20 | 2D 3D TSV |
US9932341 | 125 | 112 | HGNC:8977 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders | Incyte Corporation | 02/24/20 | 2D 3D TSV |
US10278968 | 15 | 15 | Combination therapy with glutaminase inhibitors | Calithera Biosciences Inc | 02/21/20 | 2D 3D TSV | |
US10278929 | 41 | 36 | HGNC:12405 | Identification of stabilizers of multimeric proteins | The Board of Trustees of the Leland Stanford Junior University | 02/21/20 | 2D 3D TSV |
US10280160 | 31 | 26 | HGNC:1884 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | Flatley Discovery Lab LLC | 02/21/20 | 2D 3D TSV |
US10280164 | 16 | 16 | HGNC:6863 | Pyrazolopyridone compounds and uses thereof | Incyte Corporation | 02/21/20 | 2D 3D TSV |
US10280144 | 213 | 213 | Pyridazine derivatives as RORc modulators | Genentech Inc | 02/21/20 | 2D 3D TSV | |
US10280165 | 40 | 40 | Pyridopyrimidinones and methods of use thereof | Genentech Inc | 02/21/20 | 2D 3D TSV | |
US10280150 | 297 | 183 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. | 02/21/20 | 2D 3D TSV | |
US10280174 | 3 | 2 | HGNC:1133 HGNC:3236 | Salt of fused pyrimidine compound and crystal thereof | Taiho Pharmaceutical Co., Ltd | 02/21/20 | 2D 3D TSV |
US10278975 | 186 | 172 | HGNC:6871 | Serine/threonine kinase inhibitors | Genentech Inc | 02/21/20 | 2D 3D TSV |
US10280149 | 220 | 219 | HGNC:13610 | Therapeutic compounds and uses thereof | Genentech Inc | 02/21/20 | 2D 3D TSV |
US10278962 | 24 | 11 | HGNC:11177 HGNC:11178 | Tricyclic analogues, preparation method and uses thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 02/21/20 | 2D 3D TSV |
US10273234 | 26 | 26 | HGNC:3357 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. | 02/20/20 | 2D 3D TSV |
US10273222 | 604 | 163 | HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. | 02/20/20 | 2D 3D TSV |
US10272074 | 477 | 475 | HGNC:7978 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute | 02/20/20 | 2D 3D TSV |
US10273211 | 24 | 5 | HGNC:3763 HGNC:6307 HGNC:11390 HGNC:3767 HGNC:7029 HGNC:9967 HGNC:3765 | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | Exelixis Inc | 02/20/20 | 2D 3D TSV |
US10272079 | 361 | 180 | HGNC:11073 | NHE3-binding compounds and methods for inhibiting phosphate transport | ARDELYX, INC. | 02/20/20 | 2D 3D TSV |
US10272095 | 87 | 83 | HGNC:2874 | NRF2 regulators | GlaxoSmithKline | 02/20/20 | 2D 3D TSV |
US10272077 | 14 | 14 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck Sharp & Dohme Corp | 02/20/20 | 2D 3D TSV | |
US10272087 | 50 | 8 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pteridines as FGFR inhibitors | Astex Therapeutics Ltd | 02/20/20 | 2D 3D TSV |
US10273225 | 22 | 21 | HGNC:4515 | Pyrazines as modulators of GPR6 | Takeda Pharmaceutical Co., Ltd | 02/20/20 | 2D 3D TSV |
US10273223 | 391 | 389 | HGNC:3527 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme Inc | 02/20/20 | 2D 3D TSV |
US10273244 | 348 | 173 | HGNC:3023 HGNC:3024 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | Indivior UK Limited | 02/20/20 | 2D 3D TSV |
US10273230 | 16 | 15 | HGNC:19061 | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof | Piramal Enterprises Limited | 02/20/20 | 2D 3D TSV |
US10273214 | 78 | 39 | HGNC:4588 HGNC:4587 HGNC:4586 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | Emory University | 02/20/20 | 2D 3D TSV |
US10273259 | 881 | 804 | Tricyclic sulfones as RORγ modulators | Bristol-Myers Squibb Co. | 02/20/20 | 2D 3D TSV | |
US9890168 | 32 | 15 | HGNC:3236 | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 02/16/20 | 2D 3D TSV |
US9890171 | 200 | 130 | HGNC:2592 | Aldosterone synthase inhibitors | Boehringer Ingelheim International GmbH | 02/16/20 | 2D 3D TSV |
US9890124 | 46 | 23 | HGNC:15631 HGNC:15632 | Benzazepine sulfonamide compounds | Hoffmann-La Roche Inc | 02/16/20 | 2D 3D TSV |
US9890162 | 156 | 52 | HGNC:19310 HGNC:8987 | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | Incyte Corporation | 02/16/20 | 2D 3D TSV |
US9890156 | 152 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 02/16/20 | 2D 3D TSV |
US9890160 | 3 | 3 | HGNC:550 | Compounds I | Proximagen Limited | 02/16/20 | 2D 3D TSV |
US9890166 | 638 | 168 | HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 | Imidazopyrrolidine derivatives and their use in the treatment of disease | Novartis AG | 02/16/20 | 2D 3D TSV |
US9890185 | 468 | 169 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 | Urea derivatives useful as kinase inhibitors | Respivert Limited | 02/16/20 | 2D 3D TSV |
US9926281 | 1937 | 451 | HGNC:7160 HGNC:195 HGNC:7155 HGNC:7166 HGNC:7159 HGNC:221 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | Galapagos NV | 02/10/20 | 2D 3D TSV |
US9926301 | 28 | 13 | Bipyrazole derivatives as JAK inhibitors | Incyte Corporation | 02/10/20 | 2D 3D TSV | |
US9926306 | 34 | 33 | Inhibition of MCL-1 and/or BFL-1/A1 | Dana-Farber Cancer Institute Inc | 02/10/20 | 2D 3D TSV | |
US9926330 | 55 | 53 | HGNC:17967 | Inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 02/10/20 | 2D 3D TSV |
US9926299 | 34 | 34 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Centaurus BioPharma Co., Ltd | 02/10/20 | 2D 3D TSV |
US9926282 | 826 | 401 | HGNC:10251 HGNC:10252 | Phthalazinones and isoquinolinones as rock inhibitors | Bristol-Myers Squibb Co. | 02/10/20 | 2D 3D TSV |
US9926318 | 58 | 53 | HGNC:3357 | Tetracyclic autotaxin inhibitors | PharmAkea Inc | 02/10/20 | 2D 3D TSV |
USRE47351 | 11 | 11 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists | Gilead Sciences Inc | 02/07/20 | 2D 3D TSV | |
US10266528 | 23 | 22 | HGNC:1133 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | Merck Patent GmbH | 02/07/20 | 2D 3D TSV |
US10266537 | 116 | 27 | HGNC:6613 HGNC:3763 HGNC:11724 HGNC:6735 HGNC:4037 HGNC:3386 HGNC:5960 HGNC:6859 HGNC:9829 HGNC:3689 HGNC:6873 HGNC:7027 HGNC:3767 HGNC:2730 HGNC:7029 HGNC:3688 HGNC:2731 HGNC:6192 HGNC:8031 HGNC:12841 HGNC:9617 HGNC:8803 HGNC:4840 HGNC:3430 HGNC:6307 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:3395 HGNC:77 HGNC:1097 HGNC:76 HGNC:3393 HGNC:3955 HGNC:3236 HGNC:2444 HGNC:1974 HGNC:6524 | 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof | St. Chuan University | 02/07/20 | 2D 3D TSV |
US10265310 | 158 | 71 | HGNC:3827 HGNC:3826 | 6-membered cyclic amines or lactames substituted with urea and phenyl | GRÜNENTHAL GMBH | 02/07/20 | 2D 3D TSV |
US10266550 | 64 | 26 | HGNC:11986 HGNC:11989 | Bacterial topoisomerase I inhibitors with antibacterial activity | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 02/07/20 | 2D 3D TSV |
US10259818 | 114 | 109 | HGNC:8977 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | Incyte Corporation | 02/07/20 | 2D 3D TSV |
US10266560 | 65 | 64 | HGNC:7967 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | Enanta Pharmaceuticals Inc | 02/07/20 | 2D 3D TSV |
US10259776 | 16 | 13 | HGNC:4685 | Branched 3-phenylpropionic acid derivatives and their use | Bayer Intellectual Property GmbH | 02/07/20 | 2D 3D TSV |
US10266513 | 190 | 134 | HGNC:1133 HGNC:3236 | Bruton's tyrosine kinase inhibitors | Pfizer Inc | 02/07/20 | 2D 3D TSV |
US10266491 | 200 | 168 | HGNC:1133 | Carbazole derivatives | Bristol-Myers Squibb Co. | 02/07/20 | 2D 3D TSV |
US10266496 | 160 | 118 | HGNC:12805 HGNC:17989 | Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof | Sunshine Lake Pharma Co., Ltd | 02/07/20 | 2D 3D TSV |
US10259816 | 26 | 26 | HGNC:427 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. | 02/07/20 | 2D 3D TSV |
US10266542 | 19 | 18 | HGNC:3527 | EZH2 inhibitors | Mirati Therapeutics Inc | 02/07/20 | 2D 3D TSV |
US10266535 | 56 | 29 | HGNC:1133 HGNC:3765 | Inhibitor of FLT3 kinase and use thereof | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES | 02/07/20 | 2D 3D TSV |
US10259786 | 8 | 4 | HGNC:3023 | Psychotropic agents and uses thereof | LB PHARMACEUTICALS INC. | 02/07/20 | 2D 3D TSV |
US10266526 | 956 | 932 | HGNC:20982 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme Inc | 02/07/20 | 2D 3D TSV |
US10266548 | 211 | 187 | HGNC:1148 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | Bayer Intellectual Property GmbH | 02/07/20 | 2D 3D TSV |
US10259811 | 517 | 258 | HGNC:11584 HGNC:14552 | Tank-binding kinase inhibitor compounds | Gilead Sciences Inc | 02/07/20 | 2D 3D TSV |
US10266515 | 202 | 144 | HGNC:6371 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. | 02/07/20 | 2D 3D TSV |
US10265307 | 324 | 106 | HGNC:19310 HGNC:8987 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | Incyte Corporation | 02/07/20 | 2D 3D TSV |
US10266493 | 71 | 70 | HGNC:17989 | Thioacetate compounds, compositions and methods of use | Ardea Biosciences, Inc. | 02/07/20 | 2D 3D TSV |
US10266549 | 345 | 343 | HGNC:12558 | ULK1 inhibitors and methods using same | Salk Institute | 02/07/20 | 2D 3D TSV |
US9918985 | 181 | 155 | Compounds and their use as BACE inhibitors | AstraZeneca AB | 02/04/20 | 2D 3D TSV | |
US9920047 | 375 | 109 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Co., Ltd | 02/04/20 | 2D 3D TSV |
US9920032 | 510 | 168 | HGNC:19310 HGNC:8987 | Heterocyclic compounds useful as pim kinase inhibitors | Incyte Corporation | 02/04/20 | 2D 3D TSV |
US9920031 | 261 | 218 | HGNC:1133 | Indole carboxamide compounds | Bristol-Myers Squibb Co. | 02/04/20 | 2D 3D TSV |
US9920038 | 62 | 30 | HGNC:4849 | Methyl oxazole orexin receptor antagonists | Merck Sharp & Dohme Corp | 02/04/20 | 2D 3D TSV |
US9920054 | 104 | 104 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | Pfizer Inc | 02/04/20 | 2D 3D TSV | |
US9920053 | 130 | 35 | HGNC:6251 HGNC:11050 HGNC:11048 HGNC:11049 | N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system | CHRONOS THERAPEUTICS LIMITED | 02/04/20 | 2D 3D TSV |
US9920060 | 80 | 79 | HGNC:3430 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 02/04/20 | 2D 3D TSV |
US9918974 | 2 | 2 | Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors | GlaxoSmithKline | 02/04/20 | 2D 3D TSV | |
US9918969 | 16 | 14 | HGNC:3529 | Substituted oxopyridine derivatives and use thereof as factor XIa/plasma | Bayer Pharma Aktiengesellschaft | 02/04/20 | 2D 3D TSV |
US9918990 | 226 | 111 | HGNC:13575 HGNC:1103 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | Incyte Corporation | 02/04/20 | 2D 3D TSV |
US9914735 | 391 | 78 | HGNC:11491 HGNC:11390 HGNC:4617 HGNC:3765 | Heteroaryl Syk inhibitors | Boehringer Ingelheim International GmbH | 01/30/20 | 2D 3D TSV |
US9914707 | 30 | 30 | HGNC:6307 | Naphthylamide compound, preparation method and use thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 01/30/20 | 2D 3D TSV |
US9914731 | 293 | 156 | HGNC:7029 | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | IGNYTA, INC. | 01/30/20 | 2D 3D TSV |
US9914736 | 114 | 113 | HGNC:8031 | TrKA kinase inhibitors, compositions and methods thereof | Merck Sharp & Dohme Corp | 01/30/20 | 2D 3D TSV |
US9914740 | 420 | 404 | HGNC:10252 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | Bristol-Myers Squibb Co. | 01/30/20 | 2D 3D TSV |
US9914721 | 22 | 11 | HGNC:4849 HGNC:4848 | Use of benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS Ltd | 01/30/20 | 2D 3D TSV |
US9908875 | 45 | 45 | HGNC:6857 | Apoptosis signal-regulating kinase inhibitors | Gilead Sciences Inc | 01/27/20 | 2D 3D TSV |
US9908845 | 68 | 65 | HGNC:12680 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. | 01/27/20 | 2D 3D TSV |
US9908886 | 266 | 132 | HGNC:7110 HGNC:7111 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | Agency for Science, Technology and Research | 01/27/20 | 2D 3D TSV |
US9908899 | 143 | 48 | HGNC:4852 HGNC:4854 HGNC:4853 | Histone deacetylase inhibitors | BioMarin Pharmaceutical Inc | 01/27/20 | 2D 3D TSV |
US9908865 | 511 | 154 | HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 01/27/20 | 2D 3D TSV |
US9907800 | 460 | 198 | HGNC:11393 HGNC:11390 HGNC:11397 HGNC:3765 | Kinase inhibitors and method of treating cancer | University Health Network | 01/27/20 | 2D 3D TSV |
US9908872 | 19 | 8 | HGNC:1133 HGNC:4195 HGNC:7972 | Methods to treat lymphoplasmacytic lymphoma | Dana-Farber Cancer Institute Inc | 01/27/20 | 2D 3D TSV |
US9908897 | 306 | 84 | HGNC:6251 HGNC:11050 HGNC:11048 HGNC:11049 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED | 01/27/20 | 2D 3D TSV |
US9908895 | 196 | 88 | HGNC:6190 HGNC:6192 | Tricyclic fused thiophene derivatives as JAK inhibitors | Incyte Corporation | 01/27/20 | 2D 3D TSV |
US10246444 | 134 | 32 | HGNC:3432 HGNC:3430 HGNC:3236 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC | 01/21/20 | 2D 3D TSV |
US10246442 | 135 | 135 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | Janssen Pharmaceutica NV | 01/21/20 | 2D 3D TSV | |
US10253018 | 41 | 41 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | Enanta Pharmaceuticals Inc | 01/21/20 | 2D 3D TSV |
US9896418 | 68 | 65 | HGNC:12680 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. | 01/21/20 | 2D 3D TSV |
US9903855 | 20 | 5 | HGNC:5960 HGNC:11584 HGNC:14552 HGNC:1974 | Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS | The Regents of the University of California | 01/21/20 | 2D 3D TSV |
US9896444 | 175 | 101 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | Novartis AG | 01/21/20 | 2D 3D TSV | |
US10246453 | 1146 | 330 | HGNC:10593 HGNC:10585 HGNC:10596 | Benzenesulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc | 01/21/20 | 2D 3D TSV |
US9902722 | 237 | 234 | HGNC:19679 | Biaryl kinase inhibitors | Bristol-Myers Squibb Co. | 01/21/20 | 2D 3D TSV |
US10251892 | 856 | 186 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 01/21/20 | 2D 3D TSV |
US10246462 | 92 | 88 | HGNC:1605 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. | 01/21/20 | 2D 3D TSV |
US9896458 | 251 | 243 | Compounds, compositions and methods | Denali Therapeutics Inc. | 01/21/20 | 2D 3D TSV | |
US10253017 | 22 | 9 | HGNC:7856 HGNC:263 HGNC:264 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | Palobiofarma, S.L. | 01/21/20 | 2D 3D TSV |
US10246466 | 54 | 18 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:427 HGNC:10261 | Diaryl macrocycles as modulators of protein kinases | TP Therapeutics, Inc. | 01/21/20 | 2D 3D TSV |
US9895376 | 116 | 57 | Fused tricyclic compounds as Raf kinase inhibitors | BeiGene, Ltd | 01/21/20 | 2D 3D TSV | |
US9896436 | 329 | 106 | HGNC:29012 HGNC:13606 HGNC:17071 HGNC:18039 HGNC:20672 HGNC:13610 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 01/21/20 | 2D 3D TSV |
US10246456 | 686 | 509 | HGNC:17967 | IRAK4 inhibiting agents | BIOGEN MA INC. | 01/21/20 | 2D 3D TSV |
US10253004 | 54 | 53 | HGNC:4498 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 01/21/20 | 2D 3D TSV |
US10246457 | 56 | 28 | HGNC:1133 | Indazole and azaindazole Btk inhibitors | Merck Sharp & Dohme Corp | 01/21/20 | 2D 3D TSV |
US10252984 | 51 | 51 | HGNC:4545 | Inhibiting G protein coupled receptor 6 kinase polypeptides | Mayo Foundation | 01/21/20 | 2D 3D TSV |
US9902719 | 31 | 31 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research Inc | 01/21/20 | 2D 3D TSV |
US9902741 | 68 | 46 | HGNC:8031 | Macrocyclic compounds as TRK kinase inhibitors | Array BioPharma Inc | 01/21/20 | 2D 3D TSV |
US10251893 | 230 | 227 | HGNC:15983 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | Novartis AG | 01/21/20 | 2D 3D TSV |
US9896435 | 31 | 31 | HGNC:8031 | N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | Array BioPharma Inc | 01/21/20 | 2D 3D TSV |
US9902709 | 13 | 13 | HGNC:6307 | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. | 01/21/20 | 2D 3D TSV |
US10253015 | 169 | 85 | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. | 01/21/20 | 2D 3D TSV | |
US9902726 | 5 | 4 | HGNC:8154 HGNC:8156 | Pyridone-sulfone morphinan analogs as opioid receptor ligands | Purdue Pharma LP | 01/21/20 | 2D 3D TSV |
US9902714 | 35 | 7 | HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Quinoxaline derivatives useful as FGFR kinase modulators | Astex Therapeutics Ltd | 01/21/20 | 2D 3D TSV |
US10246467 | 67 | 57 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | Boehringer Ingelheim International GmbH | 01/21/20 | 2D 3D TSV | |
US9902710 | 169 | 168 | HGNC:8772 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | Exonhit Therapeutics, SA | 01/21/20 | 2D 3D TSV |
US9896452 | 703 | 365 | HGNC:4849 HGNC:4848 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. | 01/21/20 | 2D 3D TSV |
US10251889 | 530 | 232 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:12440 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharm Inc. | 01/21/20 | 2D 3D TSV |
US10253019 | 1854 | 609 | HGNC:6192 HGNC:11584 HGNC:14552 | Tank-binding kinase inhibitor compounds | Gilead Sciences Inc | 01/21/20 | 2D 3D TSV |
US9896447 | 46 | 46 | HGNC:8031 | TrkA kinase inhibitors, compositions and methods thereof | Merck Sharp & Dohme Corp | 01/21/20 | 2D 3D TSV |
US10238658 | 120 | 32 | HGNC:4840 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:6874 HGNC:6876 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors | Respivert Limited | 12/30/19 | 2D 3D TSV |
US10239843 | 681 | 620 | HGNC:8605 HGNC:270 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | Cancer Research Technology Limited | 12/30/19 | 2D 3D TSV |
US10246425 | 16 | 16 | HGNC:10593 | 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds | Parion Sciences Inc | 12/30/19 | 2D 3D TSV |
US10246432 | 25 | 22 | HGNC:4597 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | Heptares Therapeutics Limited | 12/30/19 | 2D 3D TSV |
US10239883 | 665 | 132 | HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | Merck Sharp & Dohme B.V. | 12/30/19 | 2D 3D TSV |
US10239868 | 43 | 43 | HGNC:5302 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 12/30/19 | 2D 3D TSV |
US10239840 | 22 | 22 | Benzoazepine derivatives | ViiV HEALTHCARE UK LIMITED | 12/30/19 | 2D 3D TSV | |
US10238638 | 48 | 48 | Benzothiazole and benzothiophene compounds | Universite de Montreal | 12/30/19 | 2D 3D TSV | |
US10245267 | 2564 | 1057 | HGNC:9829 | Biaryl amide compounds as kinase inhibitors | Novartis AG | 12/30/19 | 2D 3D TSV |
US10238743 | 98 | 49 | HGNC:934 HGNC:933 | C5-C6-fused tricyclic iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | TBA | 12/30/19 | 2D 3D TSV |
US10239870 | 462 | 190 | HGNC:3023 | Dopamine D3 receptor antagonists | Indivior UK Limited | 12/30/19 | 2D 3D TSV |
US10239838 | 106 | 53 | HGNC:4849 HGNC:4848 | Heteroaryl orexin receptor antagonists | Merck Sharp & Dohme Corp | 12/30/19 | 2D 3D TSV |
US10246419 | 13 | 12 | HGNC:7965 | Liver X receptor (LXR) modulators | RALEXAR THERAPEUTICS, INC. | 12/30/19 | 2D 3D TSV |
US10238633 | 584 | 357 | HGNC:2528 HGNC:2536 | Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C | Boehringer Ingelheim International GmbH | 12/30/19 | 2D 3D TSV |
US10239835 | 142 | 141 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B | CADENT THERAPEUTICS, INC. | 12/30/19 | 2D 3D TSV | |
US10239887 | 97 | 75 | HGNC:1953 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | Vanderbilt University | 12/30/19 | 2D 3D TSV |
US10239881 | 26 | 25 | HGNC:10020 | RIPK2 inhibitors and method of treating cancer with same | University Health Network | 12/30/19 | 2D 3D TSV |
US10239882 | 86 | 86 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | Dart NeuroScience (Cayman) Ltd | 12/30/19 | 2D 3D TSV | |
US10239869 | 405 | 243 | HGNC:10593 HGNC:10597 | Sulfonamide compounds as voltage-gated sodium channel modulators | LUPIN LIMITED | 12/30/19 | 2D 3D TSV |
US10239861 | 60 | 58 | HGNC:8638 | Therapeutic compounds and uses thereof | Genetech, Inc | 12/30/19 | 2D 3D TSV |
US10239876 | 170 | 169 | HGNC:3020 | Triaza-spirodecanones as DDR1 inhibitors | Hoffman-La Roche Inc | 12/30/19 | 2D 3D TSV |
US10246426 | 240 | 240 | HGNC:1395 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS Ltd | 12/30/19 | 2D 3D TSV |
US10245275 | 158 | 76 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED | 12/30/19 | 2D 3D TSV | |
US10246429 | 755 | 248 | HGNC:934 HGNC:2529 HGNC:933 | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | Amgen Inc | 12/30/19 | 2D 3D TSV |
US10227299 | 295 | 287 | HGNC:1148 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | Bayer Pharma Aktiengesellschaft | 12/27/19 | 2D 3D TSV |
US10233156 | 57 | 57 | HGNC:85 | 9-membered fused ring derivative | Shionogi & Co., Ltd | 12/27/19 | 2D 3D TSV |
US10233178 | 24 | 8 | HGNC:6833 HGNC:6834 HGNC:29079 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | Oryzon Genomics, S.A. | 12/27/19 | 2D 3D TSV |
US10226452 | 45 | 45 | HGNC:735 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | University of California | 12/27/19 | 2D 3D TSV |
US10233188 | 433 | 221 | HGNC:1771 | CDK2/4/6 inhibitors | Pfizer Inc | 12/27/19 | 2D 3D TSV |
US10227357 | 1107 | 650 | HGNC:6342 | Compounds and methods for kinase modulation, and indications therefor | Plexxikon Inc. | 12/27/19 | 2D 3D TSV |
US10231967 | 323 | 159 | HGNC:620 | Compounds and their use as BACE inhibitors | AstraZeneca AB | 12/27/19 | 2D 3D TSV |
US10227360 | 50 | 49 | HGNC:19061 | Compounds for use as GPR120 agonists | Piramal Enterprises Limited | 12/27/19 | 2D 3D TSV |
US10227329 | 268 | 130 | HGNC:9967 | Compounds useful for treating disorders related to RET | BLUEPRINT MEDICINES CORPORATION | 12/27/19 | 2D 3D TSV |
US10227314 | 13 | 13 | HGNC:2501 | Cystathionine-gamma-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. | 12/27/19 | 2D 3D TSV |
US10227373 | 6 | 6 | Enantiomers of the 1′,6′-isomer of neplanocin A | Auburn University | 12/27/19 | 2D 3D TSV | |
US10227334 | 8 | 8 | HGNC:3467 | Estrogen receptor modulators and uses thereof | Genentech Inc | 12/27/19 | 2D 3D TSV |
US10233187 | 49 | 47 | HGNC:7967 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. | 12/27/19 | 2D 3D TSV |
US10233189 | 78 | 76 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 12/27/19 | 2D 3D TSV |
US10227310 | 6 | 6 | HGNC:32311 | Ghrelin 0-acyl transferase inhibitors | Eli Lilly and Company | 12/27/19 | 2D 3D TSV |
US10227312 | 46 | 46 | HGNC:12524 | Glucosylceramide synthase inhibitors for the treatment of diseases | BioMarin Pharmaceutical Inc | 12/27/19 | 2D 3D TSV |
US10227342 | 400 | 99 | HGNC:3236 | Heteroaryl compounds for kinase inhibition | ARIAD Pharmaceuticals Inc | 12/27/19 | 2D 3D TSV |
US10226449 | 595 | 337 | HGNC:3594 | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V Biosciences, Inc. | 12/27/19 | 2D 3D TSV |
US10231957 | 21 | 21 | HGNC:17071 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 12/27/19 | 2D 3D TSV |
US10233190 | 160 | 157 | HGNC:6059 | IDO inhibitors | NewLink Genetics Corporation | 12/27/19 | 2D 3D TSV |
US10227341 | 146 | 145 | HGNC:1133 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. | 12/27/19 | 2D 3D TSV |
US10227327 | 27 | 11 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | Universitetet | Oslo | 12/27/19 | 2D 3D TSV | |
US10227343 | 112 | 109 | HGNC:4596 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | Vanderbilt University | 12/27/19 | 2D 3D TSV |
US10233152 | 161 | 158 | HGNC:29079 | LSD1 inhibitors | Mirati Therapeutics Inc | 12/27/19 | 2D 3D TSV |
US10227331 | 1137 | 369 | Metallo-β-lactamase inhibitors | Merck Sharp & Dohme Corp | 12/27/19 | 2D 3D TSV | |
US10231963 | 109 | 39 | HGNC:8156 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED | 12/27/19 | 2D 3D TSV |
US10227346 | 104 | 104 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | Pfizer Inc | 12/27/19 | 2D 3D TSV | |
US10227350 | 167 | 129 | HGNC:8980 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences Inc | 12/27/19 | 2D 3D TSV |
US10227336 | 32 | 16 | HGNC:4849 HGNC:4848 | Pyrazole orexin receptor antagonists | Merck Sharp & Dohme Corp | 12/27/19 | 2D 3D TSV |
US10227295 | 48 | 24 | HGNC:4852 HGNC:14064 | Selective histone deactylase 6 inhibitors | H. Lee Moffitt Cancer Center and Research Institute Inc | 12/27/19 | 2D 3D TSV |
US10226464 | 150 | 75 | HGNC:7794 | Small molecule NF-κB inhibitors | ImmuneTarget, Inc. | 12/27/19 | 2D 3D TSV |
US10233173 | 647 | 642 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | Janssen Pharmaceutica NV | 12/27/19 | 2D 3D TSV | |
US10227338 | 181 | 136 | HGNC:10593 HGNC:10597 | Substituted benzenesulfonamides as sodium channel blockers | Daewoong Pharmaceutical Co., Ltd. | 12/27/19 | 2D 3D TSV |
US10233160 | 150 | 75 | HGNC:391 HGNC:10436 | Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors | Merck Patent GmbH | 12/27/19 | 2D 3D TSV |
US10233182 | 245 | 243 | HGNC:3357 | Substituted spirocyclic inhibitors of autotaxin | X-Rx, Inc. | 12/27/19 | 2D 3D TSV |
US10227332 | 8 | 4 | HGNC:2160 | T-type calcium channel modulator and uses thereof | UTI LIMITED PARTNERSHIP | 12/27/19 | 2D 3D TSV |
US10233177 | 25 | 25 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | TBA | 12/27/19 | 2D 3D TSV | |
US10227340 | 27 | 26 | HGNC:17967 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | Bristol-Myers Squibb Co. | 12/27/19 | 2D 3D TSV |
US10227359 | 58 | 28 | HGNC:13575 | Tricyclic heterocycles as bet protein inhibitors | Incyte Corporation | 12/27/19 | 2D 3D TSV |
US9872852 | 297 | 292 | HGNC:17635 | Compounds useful as immunomodulators | Bristol-Myers Squibb Co. | 12/19/19 | 2D 3D TSV |
US9873693 | 331 | 307 | Methods of treatment using pyridinonyl PDK1 inhibitors | Sunesis Pharmaceuticals Inc | 12/19/19 | 2D 3D TSV | |
US9873683 | 43 | 43 | HGNC:8535 | P2X4 receptor antagonist | Nippon Chemiphar Co., Ltd | 12/19/19 | 2D 3D TSV |
US9873709 | 1144 | 774 | HGNC:6190 HGNC:6192 | Triazolopyridine compounds, compositions and methods of use thereof | Genentech Inc | 12/19/19 | 2D 3D TSV |
US9867826 | 100 | 47 | HGNC:391 | Heterocycles as modulators of kinase activity | Merck Patent GmbH | 12/12/19 | 2D 3D TSV |
US9868726 | 123 | 72 | HGNC:6307 HGNC:8804 HGNC:9437 | Pyridyl benzothiophenes as kinase inhibitors | Allergan Inc | 12/12/19 | 2D 3D TSV |
US9868720 | 93 | 92 | HGNC:6851 | C-linked heterocycloaklyl substituted pyrimidines and their uses | Genentech Inc | 12/10/19 | 2D 3D TSV |
US9868738 | 102 | 51 | HGNC:934 HGNC:933 | Diazine-fused amidines as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 12/10/19 | 2D 3D TSV |
US9868744 | 23 | 19 | HGNC:3020 | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc | 12/10/19 | 2D 3D TSV |
US9868729 | 216 | 214 | HGNC:11491 | Inhibitors of protein kinases | Portola Pharmaceuticals Inc | 12/10/19 | 2D 3D TSV |
US9867833 | 197 | 185 | HGNC:6871 | Serine/threonine kinase inhibitors | Genentech Inc | 12/10/19 | 2D 3D TSV |
US9868748 | 113 | 110 | Thiazolopyrrolidine inhibitors of ROR- γ | Vitae Pharmaceuticals Inc | 12/10/19 | 2D 3D TSV | |
US9862688 | 47 | 7 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:76 HGNC:12440 | Hydrophobically tagged janus kinase inhibitors and uses thereof | Dana-Farber Cancer Institute Inc | 12/03/19 | 2D 3D TSV |
US9862730 | 405 | 393 | HGNC:3540 | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | Bristol-Myers Squibb Co. | 12/03/19 | 2D 3D TSV |
US9861612 | 9 | 7 | Indolyl-containing RORγt inhibitors | ORCA PHARMACEUTICALS LIMITED | 12/03/19 | 2D 3D TSV | |
US9862726 | 40 | 20 | HGNC:8154 HGNC:8156 | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans | Purdue Pharma LP | 12/03/19 | 2D 3D TSV |
US9862679 | 189 | 58 | Potent and selective inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH | 12/03/19 | 2D 3D TSV | |
US9862711 | 91 | 13 | HGNC:8978 HGNC:8984 HGNC:8975 HGNC:3942 HGNC:8974 HGNC:8977 HGNC:8976 | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | Novartis AG | 12/03/19 | 2D 3D TSV |
US9862721 | 13 | 13 | HGNC:3357 | Tetrahydrocarboline derivative | Ono Pharmaceutical Co., Ltd | 12/03/19 | 2D 3D TSV |
US9862707 | 103 | 83 | HGNC:8031 | TrkA kinase inhibitors, compositions and methods thereof | Merck Sharp & Dohme Corp | 12/03/19 | 2D 3D TSV |
US9856252 | 107 | 106 | HGNC:10894 | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | Cancer Therapeutics CRC Pty Ltd | 11/21/19 | 2D 3D TSV |
US9855269 | 345 | 340 | HGNC:6866 | Aminoquinazoline and pyridopyrimidine derivatives | Genentech Inc | 11/21/19 | 2D 3D TSV |
US9856239 | 42 | 38 | HGNC:17989 | Carboxylic acid compound, method for preparation thereof, and use thereof | InventisBio Shanghai Ltd. | 11/21/19 | 2D 3D TSV |
US9856263 | 41 | 39 | HGNC:3020 | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc | 11/21/19 | 2D 3D TSV |
US9856220 | 125 | 124 | HGNC:8772 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG | 11/21/19 | 2D 3D TSV |
US9856257 | 68 | 68 | HGNC:16672 | Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2) | Sanofi | 11/21/19 | 2D 3D TSV |
US9856274 | 42 | 42 | HGNC:8772 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | Sunovion Pharmaceuticals Inc | 11/21/19 | 2D 3D TSV |
US9856250 | 58 | 57 | HGNC:1395 | Substituted tropane derivatives | Toa Eiyo Ltd | 11/21/19 | 2D 3D TSV |
US9855229 | 11 | 11 | Treatment of respiratory disorders using ROR-gamma inhibitors | GLENMARK PHARMACEUTICALS S.A. | 11/21/19 | 2D 3D TSV | |
US9849138 | 10 | 5 | 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties | The Regents of the University of Michigan | 11/14/19 | 2D 3D TSV | |
US9850203 | 128 | 122 | HGNC:3357 | Autotaxin inhibitor compounds | PharmAkea Inc | 11/14/19 | 2D 3D TSV |
US9850225 | 378 | 375 | HGNC:17635 | Compounds useful as immunomodulators | Bristol-Myers Squibb Co. | 11/14/19 | 2D 3D TSV |
US9845313 | 167 | 151 | HGNC:10597 | Cycloalkane derivatives | Daiichi Sankyo Company, Limited | 11/14/19 | 2D 3D TSV |
US9850245 | 24 | 21 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 11/14/19 | 2D 3D TSV |
US9845310 | 772 | 485 | HGNC:339 | Intermediates for preparing triazole agonists of the APJ receptor | Amgen Inc | 11/14/19 | 2D 3D TSV |
US9845308 | 66 | 62 | Isoindoline inhibitors of ROR-gamma | Vitae Pharmaceuticals Inc | 11/14/19 | 2D 3D TSV | |
US9844553 | 19 | 10 | HGNC:2592 HGNC:2591 | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | Merck Sharp & Dohme Corp | 11/14/19 | 2D 3D TSV |
US9844535 | 28 | 27 | HGNC:6080 | SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors | Indiana University Research and Technology Corporation | 11/14/19 | 2D 3D TSV |
US9845333 | 164 | 47 | HGNC:4848 | Substituted 2-azabicycles and their use as orexin receptor modulators | TBA | 11/14/19 | 2D 3D TSV |
US9850258 | 152 | 43 | HGNC:6192 HGNC:1133 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | Bristol-Myers Squibb Co. | 11/14/19 | 2D 3D TSV |
US9850277 | 402 | 207 | Therapeutically active compositions and their methods of use | Agios Pharmaceuticals Inc | 11/14/19 | 2D 3D TSV | |
US9850257 | 26 | 13 | Tricyclic heterocycles as BET protein inhibitors | Incyte Corporation | 11/14/19 | 2D 3D TSV | |
US9840503 | 33 | 10 | HGNC:7027 HGNC:12446 | Heterocyclic compounds and uses thereof | Incyte Corporation | 10/31/19 | 2D 3D TSV |
US9840501 | 242 | 121 | Morpholin-pyridine derivatives | Hoffmann-La Roche Inc | 10/31/19 | 2D 3D TSV | |
US9840508 | 90 | 18 | HGNC:11526 HGNC:11527 HGNC:11528 | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders | OGED SA | 10/31/19 | 2D 3D TSV |
US9840498 | 95 | 32 | HGNC:8978 HGNC:8975 HGNC:8977 | Substituted quinazolin-4-one derivatives | Novartis AG | 10/31/19 | 2D 3D TSV |
US9834554 | 41 | 41 | HGNC:1133 | BTK inhibitors | Merck Sharp & Dohme Corp | 10/28/19 | 2D 3D TSV |
US9834513 | 249 | 125 | HGNC:6371 HGNC:6357 | Benzylamine derivatives | Kalvista Pharmceuticals Limited | 10/28/19 | 2D 3D TSV |
US9834543 | 16 | 12 | HGNC:10597 | Indazoles and use thereof | Purdue Pharma LP | 10/28/19 | 2D 3D TSV |
US9833448 | 14 | 14 | HGNC:16709 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck Sharp & Dohme Corp | 10/28/19 | 2D 3D TSV |
US9834548 | 407 | 129 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyridazine compounds as JAK inhibitors | Portola Pharmaceuticals Inc | 10/28/19 | 2D 3D TSV |
US9834551 | 220 | 109 | HGNC:6193 HGNC:6171 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC | 10/28/19 | 2D 3D TSV |
US9834564 | 209 | 209 | HGNC:8772 | Substituted quinolines as PDE-10 inhibitors | Sunovion Pharmaceuticals Inc | 10/28/19 | 2D 3D TSV |
US9833457 | 26 | 13 | HGNC:8783 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | vTv Therapeutics LLC | 10/28/19 | 2D 3D TSV |
US9834565 | 58 | 29 | Tricyclic heterocycles as bet protein inhibitors | Incyte Corporation | 10/28/19 | 2D 3D TSV | |
US10221182 | 98 | 19 | HGNC:4586 HGNC:6251 HGNC:2625 | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists | Rugen Holdings (Cayman) Limited | 10/27/19 | 2D 3D TSV |
US10221172 | 65 | 64 | HGNC:4596 | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | Vanderbilt University | 10/27/19 | 2D 3D TSV |
US10221173 | 451 | 159 | HGNC:6251 HGNC:3467 | Chemical compounds | AstraZeneca AB | 10/27/19 | 2D 3D TSV |
US10221177 | 261 | 248 | HGNC:497 | Inhibiting the transient receptor potential A1 ion channel | Hydra Biosciences Inc | 10/27/19 | 2D 3D TSV |
US10221163 | 1497 | 492 | Metallo-beta-lactamase inhibitors | Merck Sharp & Dohme Corp | 10/27/19 | 2D 3D TSV | |
US10221174 | 46 | 22 | HGNC:6943 HGNC:990 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | The Regents of the University of Michigan | 10/27/19 | 2D 3D TSV |
US10221197 | 528 | 147 | HGNC:8978 HGNC:8980 HGNC:8977 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences Inc | 10/27/19 | 2D 3D TSV |
US10221178 | 83 | 82 | HGNC:8977 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | Merck Sharp & Dohme Corp | 10/27/19 | 2D 3D TSV |
US10221195 | 46 | 44 | HGNC:438 | Pyridine compounds | Daiichi Sankyo Company, Limited | 10/27/19 | 2D 3D TSV |
USRE47267 | 31 | 25 | HGNC:6027 | Pyridinecarboxamides as CXCR2 modulators | Syntrix Biosystems, Inc. | 10/27/19 | 2D 3D TSV |
US10221175 | 42 | 42 | HGNC:1950 | Substituted pyrrolo[3,4-e]indolizines, imidazo[1,2-a]pyrrolo[3,4-e]pyridines, pyrrolo[3,4-e][1,2,4]triazolo[1,5-a]pyridines and pyrrolo[3,4-e][1,2,4]triazolo[4,3-a]pyridines as positive allosteric modulators of muscarinic acetylcholine receptor M1 | Vanderbilt University | 10/27/19 | 2D 3D TSV |
US9828368 | 146 | 64 | HGNC:4849 | Oxazole orexin receptor antagonists | Merck Sharp & Dohme Corp | 10/24/19 | 2D 3D TSV |
US9828396 | 92 | 92 | HGNC:2771 | Alkyne compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 10/22/19 | 2D 3D TSV |
US9828348 | 10 | 10 | HGNC:10597 | Benzimidazole derivatives and use thereof | Purdue Pharma LP | 10/22/19 | 2D 3D TSV |
US9828339 | 224 | 224 | HGNC:1952 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD | 10/22/19 | 2D 3D TSV |
US9828343 | 199 | 93 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 10/22/19 | 2D 3D TSV |
US9828369 | 167 | 166 | HGNC:16940 | Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | Merck Sharpe & Dohme Corp. | 10/22/19 | 2D 3D TSV |
US9828378 | 257 | 69 | HGNC:8978 HGNC:8972 HGNC:8975 HGNC:8977 | Kinase inhibitors and methods of use | Intellikine LLC | 10/22/19 | 2D 3D TSV |
US9828374 | 94 | 47 | Substituted pyrazino[2,2-a]isoquinoline derivatives | Hoffmann-La Roche Inc | 10/22/19 | 2D 3D TSV | |
US9828381 | 88 | 88 | Substituted pyrazolopyrimidines and method of use | AbbVie Deutschland GmbH & Co. KG | 10/22/19 | 2D 3D TSV | |
US10214477 | 210 | 56 | HGNC:6833 HGNC:6834 HGNC:29079 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | Oryzon Genomics, S.A. | 10/20/19 | 2D 3D TSV |
US10214524 | 20 | 19 | 2-heteroaryl carboxamides | Bayer Intellectual Property GmbH | 10/20/19 | 2D 3D TSV | |
US10214516 | 14 | 14 | 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 10/20/19 | 2D 3D TSV | |
US10214478 | 11 | 11 | Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof | TBA | 10/20/19 | 2D 3D TSV | |
US10214545 | 36 | 18 | Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders | Bayer Pharma Aktiengesellschaft | 10/20/19 | 2D 3D TSV | |
US10214509 | 35 | 18 | HGNC:10593 HGNC:10597 | Amino-substituted heterocyclic derivatives as sodium channel inhibitors | Almirall, S.A. | 10/20/19 | 2D 3D TSV |
US10214536 | 76 | 76 | HGNC:11584 | Amlexanox analogs | The Regents of the University of Michigan | 10/20/19 | 2D 3D TSV |
US9822124 | 255 | 85 | HGNC:19310 HGNC:8987 | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors | Incyte Corporation | 10/20/19 | 2D 3D TSV |
US10214537 | 824 | 774 | HGNC:8977 | Bicyclic heteroaryl amine compounds | Bristol-Myers Squibb Co. | 10/20/19 | 2D 3D TSV |
US10214528 | 152 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 10/20/19 | 2D 3D TSV |
US10214546 | 213 | 174 | HGNC:1133 | Btk inhibitors | Merck Sharp & Dohme Corp | 10/20/19 | 2D 3D TSV |
US10214507 | 138 | 137 | HGNC:8846 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Reset Therapeutics, Inc. | 10/20/19 | 2D 3D TSV |
US10220048 | 100 | 97 | HGNC:9665 | Compositions and methods for treating ocular diseases | Aerpio Therapeutics Inc | 10/20/19 | 2D 3D TSV |
US10213407 | 9 | 9 | Compounds and methods for inhibiting production of trimethylamine | The Procter & Gamble Company | 10/20/19 | 2D 3D TSV | |
US10220040 | 9 | 9 | Compounds, compositions and methods useful for cholesterol mobilization | Cerenis Therapeutics Holding SA | 10/20/19 | 2D 3D TSV | |
US9822074 | 99 | 94 | HGNC:7045 | Dihydropyridinone MGAT2 inhibitors | Bristol-Myers Squibb Co. | 10/20/19 | 2D 3D TSV |
US10214512 | 386 | 227 | HGNC:3529 HGNC:6357 | Factor XIA inhibitors | Merck Sharp & Dohme Corp | 10/20/19 | 2D 3D TSV |
US10214492 | 511 | 238 | HGNC:10924 HGNC:10922 | Heterocyclic inhibitors of MCT4 | Vettore, LLC | 10/20/19 | 2D 3D TSV |
US10214535 | 32 | 16 | HGNC:4849 HGNC:4848 | Hydroxmethyl piperidine orexin receptor antagonists | Merck Sharp & Dohme Corp | 10/20/19 | 2D 3D TSV |
US10214544 | 155 | 154 | HGNC:3540 | Imidazopyridazine and imidazothiadiazole compounds | Universite de Montreal | 10/20/19 | 2D 3D TSV |
US9822068 | 26 | 13 | HGNC:3553 | Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments | University of California | 10/20/19 | 2D 3D TSV |
US10221129 | 293 | 288 | Inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 10/20/19 | 2D 3D TSV | |
US9822103 | 94 | 92 | HGNC:3527 | Inhibitors of lysine methyl transferase | Bristol-Myers Squibb Co. | 10/20/19 | 2D 3D TSV |
US10221161 | 192 | 94 | HGNC:6371 HGNC:6357 | Inhibitors of plasma kallikrein | Kalvista Pharmaceuticals Limited | 10/20/19 | 2D 3D TSV |
US10221160 | 12 | 4 | HGNC:2637 HGNC:2623 HGNC:2621 | Metalloenzyme inhibitor compounds | Mycovia Pharmaceuticals, Inc. | 10/20/19 | 2D 3D TSV |
US9820989 | 119 | 88 | HGNC:6307 HGNC:8804 | Method of treating conditions with kinase inhibitors | Allergan Inc | 10/20/19 | 2D 3D TSV |
US10214533 | 23 | 7 | HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders | Ogeda SA | 10/20/19 | 2D 3D TSV |
US10213421 | 10 | 10 | HGNC:1604 | Pharmaceutical formulations comprising CCR3 antagonists | Alkahest, Inc. | 10/20/19 | 2D 3D TSV |
US10214519 | 354 | 327 | HGNC:8980 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences Inc | 10/20/19 | 2D 3D TSV |
US9822120 | 64 | 32 | HGNC:1133 | Protein kinase inhibitors | Pharmascience Inc | 10/20/19 | 2D 3D TSV |
US10214518 | 8 | 6 | HGNC:9602 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals Inc | 10/20/19 | 2D 3D TSV |
US10221156 | 6 | 6 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 10/20/19 | 2D 3D TSV | |
US10214511 | 56 | 3 | HGNC:9077 HGNC:11283 HGNC:11584 HGNC:14552 HGNC:17967 HGNC:12434 HGNC:6735 HGNC:2451 HGNC:5465 HGNC:4617 HGNC:2459 HGNC:6112 HGNC:2457 HGNC:3765 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:6171 HGNC:11390 HGNC:12440 HGNC:1079 HGNC:1133 HGNC:1771 HGNC:6860 HGNC:11719 HGNC:7972 HGNC:1774 HGNC:6524 HGNC:1775 | Quinazolines as potassium ion channel inhibitors | Bristol-Myers Squibb Co. | 10/20/19 | 2D 3D TSV |
US10213433 | 373 | 370 | HGNC:990 | Solid dispersions containing an apoptosis-inducing agent | AbbVie Inc | 10/20/19 | 2D 3D TSV |
US10214534 | 44 | 44 | Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C | Bristol-Myers Squibb Co. | 10/20/19 | 2D 3D TSV | |
US10213416 | 11 | 11 | HGNC:735 | Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | University of Chicago | 10/20/19 | 2D 3D TSV |
US10213427 | 107 | 107 | HGNC:3690 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | Incyte Corporation | 10/20/19 | 2D 3D TSV |
US9822102 | 357 | 143 | HGNC:6371 HGNC:3529 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | Bayer Pharma Aktiengesellschaft | 10/20/19 | 2D 3D TSV |
US10221142 | 124 | 118 | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp | 10/20/19 | 2D 3D TSV | |
US10214515 | 36 | 9 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Substituted pyrazoles as inhibitors of fibroblast growth factor receptor | Zhejiang Hisun Pharmaceutical Co., Ltd | 10/20/19 | 2D 3D TSV |
US10221146 | 424 | 411 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | Lycera Corporation | 10/20/19 | 2D 3D TSV | |
US10221162 | 788 | 507 | HGNC:339 | Triazole agonists of the APJ receptor | Amgen Inc | 10/20/19 | 2D 3D TSV |
US10214527 | 94 | 65 | HGNC:7218 | Triazolopyridine inhibitors of myeloperoxidase | Bristol-Myers Squibb Co. | 10/20/19 | 2D 3D TSV |
US10214530 | 118 | 57 | HGNC:12008 HGNC:20692 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN | 10/20/19 | 2D 3D TSV |
US9815850 | 266 | 255 | Compounds, compositions and methods | Denali Therapeutics Inc. | 10/14/19 | 2D 3D TSV | |
US9815836 | 74 | 33 | HGNC:17967 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | Merck Patent GmbH | 10/14/19 | 2D 3D TSV |
US9815840 | 24 | 24 | HGNC:7029 | Protein kinase inhibitor containing pyrrolopyridazine derivative | The Asan Foundation | 10/14/19 | 2D 3D TSV |
US9815842 | 127 | 126 | HGNC:6819 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | Novartis AG | 10/14/19 | 2D 3D TSV |
US9815861 | 12 | 12 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 10/14/19 | 2D 3D TSV |
US9815846 | 228 | 227 | HGNC:8031 | TrkA kinase inhibitors, compositions and methods thereof | Merck Sharp & Dohme Corp | 10/14/19 | 2D 3D TSV |
US9815832 | 184 | 92 | HGNC:8781 HGNC:8783 | Azabenzimidazole compounds | Pfizer Inc | 10/13/19 | 2D 3D TSV |
US9815790 | 48 | 23 | HGNC:2160 HGNC:2159 | Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists | Janssen Pharmaceutica NV | 10/13/19 | 2D 3D TSV |
US9815819 | 87 | 76 | HGNC:2771 | Complement pathway modulators and uses thereof | Novartis AG | 10/13/19 | 2D 3D TSV |
US9814715 | 14 | 7 | HGNC:7966 HGNC:7965 | Liver X receptor modulators | Vitae Pharamceuticals, Inc. | 10/13/19 | 2D 3D TSV |
US9815796 | 1267 | 689 | Pyrimidone carboxamide compounds as PDE2 inhibitors | Merck Sharp & Dohme Corp | 10/13/19 | 2D 3D TSV | |
US9815834 | 91 | 91 | HGNC:3688 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | Principia Biopharma Inc | 10/13/19 | 2D 3D TSV |
US9815820 | 30 | 7 | HGNC:10251 HGNC:10252 | Rho kinase inhibitors | Kadmon Corporation LLC | 10/13/19 | 2D 3D TSV |
US9814704 | 167 | 166 | HGNC:6850 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | The University of Rochester | 10/13/19 | 2D 3D TSV |
US9809582 | 68 | 24 | HGNC:8781 HGNC:1952 | Aminoester derivatives | Chiesi Farmaceutici S.p.A. | 10/07/19 | 2D 3D TSV |
US9809568 | 7 | 7 | HGNC:18618 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | Merck Sharp & Dohme Corp | 10/07/19 | 2D 3D TSV |
US9809572 | 16 | 1 | HGNC:427 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | 10/07/19 | 2D 3D TSV |
US9808445 | 32 | 30 | HGNC:3551 | Factor IXa inhibitors | Merck Sharp & Dohme Corp | 10/07/19 | 2D 3D TSV |
US9809545 | 25 | 25 | HGNC:3551 | Factor XIa inhibitors | Merck Sharp & Dohme Corp | 10/07/19 | 2D 3D TSV |
US9809574 | 248 | 248 | HGNC:990 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier | 10/07/19 | 2D 3D TSV |
US9809583 | 31 | 31 | Oxazolidine-based compound and selective androgen receptor agonist comprising same | DONG-A ST CO., LTD | 10/07/19 | 2D 3D TSV | |
US9809561 | 424 | 422 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | Merck Sharp & Dohme Corp | 10/07/19 | 2D 3D TSV | |
US9802907 | 47 | 44 | HGNC:12805 | 2-aryl selenazole compound and pharmaceutical composition thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. | 10/01/19 | 2D 3D TSV |
US9802947 | 18 | 9 | HGNC:2536 HGNC:2545 | 3-oxo-tetrahydro-furo[3,2-b]pyrrol-4(5H)-yl) derivatives II | GRÜNENTHAL GMBH | 10/01/19 | 2D 3D TSV |
US9802924 | 43 | 43 | HGNC:5302 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 10/01/19 | 2D 3D TSV |
US9802944 | 68 | 34 | HGNC:10555 | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | Hoffmann-La Roche Inc | 10/01/19 | 2D 3D TSV |
US9801889 | 200 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 10/01/19 | 2D 3D TSV |
US9802928 | 48 | 24 | HGNC:934 HGNC:933 | C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 10/01/19 | 2D 3D TSV |
US9802960 | 484 | 476 | HGNC:8974 | Heteroaryls and uses thereof | Millennium Pharmaceuticals Inc | 10/01/19 | 2D 3D TSV |
US9802945 | 23 | 23 | HGNC:4076 | Imidazopyridazine derivatives as modulators of the GABAA receptor activity | Pfizer Inc | 10/01/19 | 2D 3D TSV |
US9802915 | 262 | 215 | HGNC:1133 | Indole carboxamide compounds | Bristol-Myers Squibb Co. | 10/01/19 | 2D 3D TSV |
US9802920 | 20 | 20 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Hoffman-La Roche Inc | 10/01/19 | 2D 3D TSV |
US9802904 | 64 | 62 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | The United States of America, as represented by the Secretary, Department of Health and Human Services | 10/01/19 | 2D 3D TSV | |
US9802939 | 77 | 77 | HGNC:3529 | Macrocycles as factor XIa inhibitors | Bristol-Myers Squibb Co. | 10/01/19 | 2D 3D TSV |
US9802918 | 324 | 107 | HGNC:19310 HGNC:8987 | Pyridineamine compounds useful as Pim kinase inhibitors | Incyte Corporation | 10/01/19 | 2D 3D TSV |
US9801872 | 35 | 34 | HGNC:1133 | Pyridinyl and fused pyridinyl triazolone derivatives | Takeda Pharmaceutical Co., Ltd | 10/01/19 | 2D 3D TSV |
US9801888 | 129 | 129 | HGNC:3942 | Pyrimidine compounds as mTOR and PI3K inhibitors | Development Center for Biotechnology | 10/01/19 | 2D 3D TSV |
US9801878 | 34 | 32 | HGNC:8772 | Quinoline derivatives as PDE10A enzyme inhibitors | H. Lundbeck A/S | 10/01/19 | 2D 3D TSV |
US9796719 | 321 | 219 | HGNC:3357 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | Galapagos NV | 09/24/19 | 2D 3D TSV |
US9796741 | 168 | 167 | HGNC:2771 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 09/23/19 | 2D 3D TSV |
US9796664 | 27 | 11 | HGNC:4852 HGNC:4854 HGNC:4853 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BioMarin Pharmaceutical Inc | 09/23/19 | 2D 3D TSV |
US9796729 | 36 | 33 | HGNC:2843 | Compounds as diacylglycerol acyltransferase inhibitors | GlaxoSmithKline | 09/23/19 | 2D 3D TSV |
US9796710 | 47 | 44 | Dihydropyrrolopyridine inhibitors of ROR-gamma | Vitae Pharmaceuticals Inc | 09/23/19 | 2D 3D TSV | |
US9796702 | 52 | 23 | HGNC:2592 HGNC:2591 | Dihydroquinoline pyrazolyl compounds | Hoffmann-La Roche Inc | 09/23/19 | 2D 3D TSV |
US9796700 | 349 | 344 | HGNC:6877 | ERK inhibitors and uses thereof | Celgene CAR LLC | 09/23/19 | 2D 3D TSV |
US9796680 | 41 | 31 | HGNC:4177 | Glucocerebrosidase modulators and uses thereof | Alectos Therapeutics Inc | 09/23/19 | 2D 3D TSV |
US9796720 | 31 | 31 | HGNC:7978 | Imidazole-derived modulators of the glucocorticoid receptor | Bristol-Myers Squibb Co. | 09/23/19 | 2D 3D TSV |
US9796706 | 505 | 173 | HGNC:6881 HGNC:6872 HGNC:6886 | Inhibitors of Jun N-terminal kinase | Imago Pharmaceuticals Inc | 09/23/19 | 2D 3D TSV |
US9796672 | 170 | 93 | HGNC:8157 | Isoindoline compositions and methods for treating neurodegenerative disease | COGNITION THERAPEUTICS, INC. | 09/23/19 | 2D 3D TSV |
US9796742 | 135 | 61 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 | Kinase inhibitors | Respivert Limited | 09/23/19 | 2D 3D TSV |
US9795611 | 60 | 59 | HGNC:8031 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | Array BioPharma Inc | 09/23/19 | 2D 3D TSV |
US9796723 | 60 | 60 | HGNC:8031 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | Array BioPharma Inc | 09/23/19 | 2D 3D TSV |
US9796707 | 36 | 36 | HGNC:11305 | Piperazine derivatives for treating disorders | The University of Nottingham | 09/23/19 | 2D 3D TSV |
US9795602 | 9 | 9 | HGNC:9213 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | Gilead Sciences Inc | 09/23/19 | 2D 3D TSV |
US9795608 | 15 | 15 | HGNC:1133 | Protein kinase inhibitors | Pharmascience Inc | 09/23/19 | 2D 3D TSV |
US9796725 | 125 | 122 | HGNC:30661 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | Millennium Pharmaceuticals Inc | 09/23/19 | 2D 3D TSV |
US9796732 | 42 | 42 | HGNC:3942 | Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. | 09/23/19 | 2D 3D TSV |
US9796708 | 1363 | 1352 | HGNC:1780 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | AbbVie Inc | 09/23/19 | 2D 3D TSV |
US9795606 | 35 | 35 | HGNC:7027 | Pyrrolopyrimidine compounds for the treatment of cancer | University of North Carolina at Chapel Hill | 09/23/19 | 2D 3D TSV |
US9796687 | 18 | 18 | HGNC:8791 | S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 | Consejo Superior de Investigaciones Cientificas | 09/23/19 | 2D 3D TSV |
US9796716 | 127 | 124 | HGNC:1133 | Selective inhibitors of Tec and Src protein kinase families | Pharmascience Inc | 09/23/19 | 2D 3D TSV |
US9796724 | 517 | 232 | HGNC:8031 HGNC:12440 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharma Inc | 09/23/19 | 2D 3D TSV |
US9796704 | 1540 | 275 | HGNC:3763 HGNC:3430 HGNC:6307 HGNC:3386 HGNC:3395 HGNC:3236 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. | 09/23/19 | 2D 3D TSV |
US10208016 | 23 | 23 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | Takeda Pharmaceutical Co., Ltd | 09/21/19 | 2D 3D TSV | |
US10208024 | 246 | 83 | HGNC:3690 HGNC:3689 HGNC:3688 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | Array BioPharma Inc | 09/21/19 | 2D 3D TSV |
US10208044 | 3 | 3 | HGNC:85 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC | 09/21/19 | 2D 3D TSV |
US10208011 | 50 | 25 | HGNC:4485 | Benzothiophene estrogen receptor modulators | G1 Therapeutics, Inc. | 09/21/19 | 2D 3D TSV |
US10208081 | 137 | 133 | HGNC:7967 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | Enanta Pharmaceuticals Inc | 09/21/19 | 2D 3D TSV |
US10206907 | 633 | 322 | Compounds useful for the treatment of degenerative and inflammatory diseases | Galapagos NV | 09/21/19 | 2D 3D TSV | |
US10208056 | 240 | 97 | HGNC:19682 HGNC:1779 | Condensed tricyclic compounds as protein kinase inhibitors | FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO) | 09/21/19 | 2D 3D TSV |
US10208000 | 19 | 19 | Eis inhibitors | University of Kentucky Research Foundation | 09/21/19 | 2D 3D TSV | |
US10208040 | 34 | 11 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Fused imidazo-piperidine JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 09/21/19 | 2D 3D TSV |
US10208019 | 434 | 246 | HGNC:4324 | GLP-1 receptor agonists and uses thereof | Pfizer Inc | 09/21/19 | 2D 3D TSV |
US10208023 | 23 | 7 | HGNC:10597 | Heterocyclic inhibitors of the sodium channel | TBA | 09/21/19 | 2D 3D TSV |
US10208039 | 147 | 146 | HGNC:17071 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 09/21/19 | 2D 3D TSV |
US10208066 | 156 | 68 | HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 | Imidazopyridazine compounds and their use | Hutchison MediPharma Limited | 09/21/19 | 2D 3D TSV |
US10208060 | 10 | 10 | HGNC:1232 | Inhibitors of HIF prolyl hydroxylase | Merck Sharp & Dohme Corp | 09/21/19 | 2D 3D TSV |
US10207999 | 226 | 119 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research Inc | 09/21/19 | 2D 3D TSV |
US10208064 | 36 | 36 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | WuXi AppTec (Shanghai) Co. Ltd | 09/21/19 | 2D 3D TSV |
US10207991 | 170 | 93 | HGNC:8157 | Isoindoline compositions and methods for treating neurodegenerative disease | COGNITION THERAPEUTICS, INC. | 09/21/19 | 2D 3D TSV |
US10208068 | 46 | 46 | HGNC:3529 | Macrocycles as factor XIa inhibitors | Bristol-Myers Squibb Co. | 09/21/19 | 2D 3D TSV |
US10208043 | 31 | 31 | Methods for inhibiting fascin | Cornell University | 09/21/19 | 2D 3D TSV | |
US10208027 | 4 | 1 | HGNC:882 | Processes for preparing ATR inhibitors | Vertex Pharmaceuticals Inc | 09/21/19 | 2D 3D TSV |
US10208020 | 126 | 62 | HGNC:17432 HGNC:1936 | Substituted amino triazoles useful as human chitinase inhibitors | OncoArendi Therapeutics SA | 09/21/19 | 2D 3D TSV |
US10208021 | 21 | 21 | HGNC:3529 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | Bristol-Myers Squibb Co. | 09/21/19 | 2D 3D TSV |
US10208047 | 36 | 35 | HGNC:1133 | Tertiary alcohol imidazopyrazine BTK inhibitors | Merck Sharp & Dohme Corp | 09/21/19 | 2D 3D TSV |
US10206931 | 611 | 311 | HGNC:2348 | Therapeutic compounds and uses thereof | Genentech Inc | 09/21/19 | 2D 3D TSV |
US10208071 | 189 | 187 | HGNC:3827 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | Allergan Inc | 09/21/19 | 2D 3D TSV |
US9789094 | 21 | 21 | HGNC:6059 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | Incyte Holdings Corporation | 09/09/19 | 2D 3D TSV |
US9790230 | 212 | 106 | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives | Hoffmann-La Roche Inc | 09/09/19 | 2D 3D TSV | |
US9790229 | 360 | 356 | HGNC:1133 | Bruton's tyrosine kinase inhibitors | Sunesis Pharmaceuticals Inc | 09/09/19 | 2D 3D TSV |
US9790233 | 21 | 19 | HGNC:5154 | Compositions and methods of modulating 15-PGDH activity | Case Western Reserve University | 09/09/19 | 2D 3D TSV |
US9789116 | 96 | 91 | HGNC:5154 | Compositions and methods of modulating short-chain dehydrogenase activity | Case Western Reserve University | 09/09/19 | 2D 3D TSV |
US9789100 | 132 | 45 | Compounds as rearranged during transfection (RET) inhibitors | GlaxoSmithKline | 09/09/19 | 2D 3D TSV | |
US9789110 | 55 | 55 | HGNC:16940 | Diacylglycerol acyltransferase 2 inhibitors | Pfizer Inc | 09/09/19 | 2D 3D TSV |
US9790212 | 110 | 72 | Enhancer of zeste homolog 2 inhibitors | GlaxoSmithKline | 09/09/19 | 2D 3D TSV | |
US9790221 | 574 | 287 | HGNC:17967 | Heteroaryl compounds as IRAK inhibitors and uses thereof | Merck Patent GmbH | 09/09/19 | 2D 3D TSV |
US9790228 | 640 | 194 | HGNC:8979 HGNC:8978 HGNC:8972 HGNC:8977 | Heterocyclic kinase inhibitors | Intellikine LLC | 09/09/19 | 2D 3D TSV |
US9790203 | 25 | 25 | HGNC:8772 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Inc | 09/09/19 | 2D 3D TSV |
US9790174 | 318 | 118 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 | Kinase inhibitors | Respivert Limited | 09/09/19 | 2D 3D TSV |
US9790209 | 47 | 17 | HGNC:11491 HGNC:11283 HGNC:4616 | Kinase inhibitors | Respivert Limited | 09/09/19 | 2D 3D TSV |
US9790196 | 12 | 4 | HGNC:6833 HGNC:6834 HGNC:29079 | Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae | Oryzon Genomics, S.A. | 09/09/19 | 2D 3D TSV |
US9790235 | 133 | 130 | HGNC:6887 | MK2 inhibitors and uses thereof | Celgene CAR LLC | 09/09/19 | 2D 3D TSV |
US9791447 | 30 | 10 | HGNC:17927 HGNC:30402 HGNC:23116 | Methods of identifying SENP1 inhibitors | City of Hope | 09/09/19 | 2D 3D TSV |
US9790201 | 119 | 113 | Piperidine and azepine derivatives as prokineticin receptor modulators | Takeda Pharmaceutical Co., Ltd | 09/09/19 | 2D 3D TSV | |
US9790180 | 126 | 41 | HGNC:4852 HGNC:4854 HGNC:4853 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC | 09/09/19 | 2D 3D TSV |
US9790217 | 174 | 85 | HGNC:2592 HGNC:2591 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | Hoffmann-La Roche Inc | 09/09/19 | 2D 3D TSV |
US9789082 | 100 | 20 | HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | Somatostatin receptor subtype 4 (SSTR4) agonists | Centrexion Therapeutics Corporation | 09/09/19 | 2D 3D TSV |
US9790198 | 102 | 98 | HGNC:4498 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | Janssen Pharmaceutica NV | 09/09/19 | 2D 3D TSV |
US9790220 | 49 | 25 | HGNC:4849 HGNC:4848 | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | Takeda Pharmaceutical Co., Ltd | 09/09/19 | 2D 3D TSV |
US9790158 | 24 | 12 | HGNC:14063 HGNC:13315 | Substituted tropolone derivatives and methods of use | University of Connecticut | 09/09/19 | 2D 3D TSV |
US10202412 | 19 | 16 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | Atea Pharmaceuticals, Inc. | 09/02/19 | 2D 3D TSV | |
US10202369 | 883 | 393 | HGNC:2596 HGNC:2637 HGNC:2625 HGNC:8534 HGNC:2622 HGNC:2623 | 1,3-thiazol-2-yl substituted benzamides | Bayer Aktiengesellschaft | 09/02/19 | 2D 3D TSV |
US10202365 | 79 | 39 | HGNC:9967 | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors | BLUEPRINT MEDICINES CORPORATION | 09/02/19 | 2D 3D TSV |
US10202411 | 20 | 15 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC | 09/02/19 | 2D 3D TSV | |
US10202377 | 207 | 115 | 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | Samumed, LLC | 09/02/19 | 2D 3D TSV | |
US10202383 | 46 | 46 | HGNC:3009 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | Boehringer Ingelheim International GmbH | 09/02/19 | 2D 3D TSV |
US10202370 | 154 | 153 | HGNC:6342 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE | 09/02/19 | 2D 3D TSV |
US10202368 | 88 | 88 | HGNC:23692 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS Ltd | 09/02/19 | 2D 3D TSV |
US10202399 | 34 | 34 | HGNC:2671 | Dihydroxy aromatic heterocyclic compound | Takeda Pharmaceutical Co., Ltd | 09/02/19 | 2D 3D TSV |
US10202388 | 53 | 43 | HGNC:11708 HGNC:6059 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd | 09/02/19 | 2D 3D TSV |
US10202390 | 29 | 28 | HGNC:6266 | Heteroaryl substituted aminopyridine compounds | Bristol-Myers Squibb Co. | 09/02/19 | 2D 3D TSV |
US10202373 | 49 | 49 | HGNC:8974 | Heteroaryls and uses thereof | Millennium Pharmaceuticals Inc | 09/02/19 | 2D 3D TSV |
US10202367 | 71 | 62 | Heterocyclic compounds and methods of use thereof | The United States of America, as represented by the Secretary, Department of Health and Human Services | 09/02/19 | 2D 3D TSV | |
US10202381 | 147 | 145 | HGNC:17071 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 09/02/19 | 2D 3D TSV |
US10202418 | 29 | 20 | HGNC:9958 HGNC:2529 | Hydroxy-ethylene derivatives for the treatment of arthrosis | Merck Patent GmbH | 09/02/19 | 2D 3D TSV |
US10202362 | 4 | 2 | HGNC:2528 HGNC:6710 | Inhibitors of leukotriene A4 hydrolase | Celtaxsys, Inc. | 09/02/19 | 2D 3D TSV |
US10202350 | 187 | 81 | HGNC:10924 HGNC:23357 | MCT4 inhibitors for treating disease | Vettore, LLC | 09/02/19 | 2D 3D TSV |
US10202403 | 19 | 18 | Macrocyclic benzofuran compounds for the treatment of hepatitis C | Bristol-Myers Squibb Co. | 09/02/19 | 2D 3D TSV | |
US10202375 | 36 | 26 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | Redx Pharma PLC | 09/02/19 | 2D 3D TSV | |
US10202371 | 151 | 19 | HGNC:8978 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 | Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors | Novartis AG | 09/02/19 | 2D 3D TSV |
US10202404 | 128 | 127 | Polycyclic pyridone derivative having integrase inhibitory activity | Shionogi & Co., Ltd | 09/02/19 | 2D 3D TSV | |
US10202389 | 125 | 120 | HGNC:12469 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | Millennium Pharmaceuticals Inc | 09/02/19 | 2D 3D TSV |
US10202379 | 784 | 388 | HGNC:11535 | Substituted polycyclic carbamoyl pyridone derivative prodrug | Shionogi & Co., Ltd | 09/02/19 | 2D 3D TSV |
US10202360 | 382 | 361 | HGNC:2348 | Therapeutic compounds | Celgene Quanticel Research Inc | 09/02/19 | 2D 3D TSV |
US10202354 | 120 | 120 | HGNC:13610 | Therapeutic compounds and uses thereof | Genentech Inc | 09/02/19 | 2D 3D TSV |
US10202378 | 434 | 200 | Therapeutic compounds and uses thereof | Genentech Inc | 09/02/19 | 2D 3D TSV | |
US9783488 | 107 | 107 | HGNC:14063 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation Inc | 08/20/19 | 2D 3D TSV |
US9783501 | 80 | 80 | HGNC:10582 | Substituted quinolines as modulators of sodium channels | Vertex Pharmaceuticals Inc | 08/20/19 | 2D 3D TSV |
US9783543 | 38 | 19 | HGNC:7110 | Aminoimidazopyridazines | Bayer Pharma Aktiengesellschaft | 08/19/19 | 2D 3D TSV |
US9783530 | 84 | 40 | HGNC:3529 HGNC:6357 | Factor Xla inhibitors | Merck Sharp & Dohme Corp | 08/19/19 | 2D 3D TSV |
US9783573 | 132 | 66 | HGNC:592 | IAP antagonists | Bristol-Myers Squibb Co. | 08/19/19 | 2D 3D TSV |
US9783527 | 470 | 356 | HGNC:10582 HGNC:10597 | Indazole ureas and method of use | AbbVie Inc | 08/19/19 | 2D 3D TSV |
US9783556 | 68 | 22 | HGNC:11491 HGNC:11283 HGNC:4616 | Kinase inhibitors | Respivert Limited | 08/19/19 | 2D 3D TSV |
US9783524 | 48 | 10 | HGNC:427 HGNC:3236 | Protein tyrosine kinase modulators and methods of use | Betta Pharmaceuticals Co., Ltd | 08/19/19 | 2D 3D TSV |
US9783551 | 11 | 9 | HGNC:9642 | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | Glaceum Inc. | 08/19/19 | 2D 3D TSV |
US9783511 | 263 | 255 | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease | Lycera Corporation | 08/18/19 | 2D 3D TSV | |
US9783500 | 109 | 18 | HGNC:7872 HGNC:7873 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | Northwestern University | 08/17/19 | 2D 3D TSV |
US9783499 | 24 | 24 | HGNC:7029 | Quinoline derivatives and their applications | Shenyang Pharmaceutical University | 08/17/19 | 2D 3D TSV |
US9782415 | 530 | 232 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharma Inc | 08/17/19 | 2D 3D TSV |
US9777004 | 61 | 33 | Amino-substituted imidazopyridazines | Bayer Intellectual Property GmbH | 08/13/19 | 2D 3D TSV | |
US9777020 | 185 | 185 | HGNC:8031 | Furo-3-carboxamide derivatives and methods of use | AbbVie Inc | 08/13/19 | 2D 3D TSV |
US9777008 | 310 | 306 | HGNC:29652 | PRMT5 inhibitors and uses thereof | Epizyme Inc | 08/13/19 | 2D 3D TSV |
US9777010 | 124 | 111 | HGNC:9922 | Substituted 4-phenylpiperidines, their preparation and use | Columbia University | 08/13/19 | 2D 3D TSV |
US9777017 | 196 | 90 | HGNC:6190 HGNC:6192 | Tricyclic fused thiophene derivatives as JAK inhibitors | Incyte Holdings Corporation | 08/13/19 | 2D 3D TSV |
US9776995 | 524 | 366 | HGNC:10593 HGNC:10597 | Bicyclic sulfonamide compounds as sodium channel inhibitors | Amgen Inc | 08/12/19 | 2D 3D TSV |
US9776990 | 146 | 73 | HGNC:13575 | Isoindolone derivatives | AbbVie Inc | 08/12/19 | 2D 3D TSV |
US9777000 | 173 | 158 | HGNC:8772 | Pyrazole derivative | Mochida Pharmaceutical Co., Ltd | 08/12/19 | 2D 3D TSV |
US9776991 | 211 | 206 | HGNC:3402 | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | Sanofi | 08/12/19 | 2D 3D TSV |
US9777003 | 544 | 269 | Tricyclic heterocycles as bet protein inhibitors | Incyte Corporation | 08/12/19 | 2D 3D TSV | |
US9775839 | 42 | 41 | HGNC:11491 | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors | Merck Sharp & Dohme Corp | 08/11/19 | 2D 3D TSV |
US9775844 | 440 | 109 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals Inc | 08/11/19 | 2D 3D TSV |
US9776974 | 122 | 119 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research Inc | 08/11/19 | 2D 3D TSV |
US9776988 | 32 | 8 | HGNC:6307 HGNC:3690 HGNC:3689 HGNC:3688 | Pyrazolylbenzo[d]imidazole derivatives | Celon Pharma S.A. | 08/11/19 | 2D 3D TSV |
US9771369 | 502 | 253 | HGNC:6342 | Compounds and methods for kinase modulation, and indications therefor | Plexxikon Inc. | 08/06/19 | 2D 3D TSV |
US9771375 | 159 | 156 | Indazole compounds useful as ketohexokinase inhibitors | Janssen Pharmaceutica NV | 08/06/19 | 2D 3D TSV | |
US9771353 | 39 | 14 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 | Kinase inhibitors based upon N-alkyl pyrazoles | Topivert Pharma Limited | 08/06/19 | 2D 3D TSV |
US9771379 | 28 | 28 | HGNC:933 | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides | Pfizer Inc | 08/06/19 | 2D 3D TSV |
US9771376 | 56 | 51 | HGNC:10593 HGNC:10597 | N-substituted benzamides and methods of use thereof | Genentech Inc | 08/06/19 | 2D 3D TSV |
US9771359 | 37 | 33 | HGNC:12716 | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II | Medifron DBT Inc. | 08/06/19 | 2D 3D TSV |
US9771366 | 28 | 20 | HGNC:10435 HGNC:10431 HGNC:10430 HGNC:10432 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGN | 08/06/19 | 2D 3D TSV |
US9771320 | 334 | 293 | Carbocyclic sulfone RORγ modulators | Bristol-Myers Squibb Co. | 08/05/19 | 2D 3D TSV | |
US9771329 | 122 | 119 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research Inc | 08/05/19 | 2D 3D TSV |
US9771316 | 35 | 17 | HGNC:11063 | Phenoxyalkylamine compound | Osaka University | 08/02/19 | 2D 3D TSV |
US9763922 | 595 | 308 | HGNC:13575 HGNC:2348 | Therapeutic compounds and uses thereof | Genentech Inc | 07/30/19 | 2D 3D TSV |
US9765057 | 34 | 14 | HGNC:4849 HGNC:4848 | 3-ester-4 substituted orexin receptor antagonists | Merck Sharp & Dohme Corp | 07/29/19 | 2D 3D TSV |
US9765037 | 344 | 136 | HGNC:4840 HGNC:11283 HGNC:76 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | University of Washington Through its Center for Commercialization | 07/29/19 | 2D 3D TSV |
US9765038 | 62 | 23 | HGNC:3236 | Heteroaryl compounds and uses thereof | Celgene CAR LLC | 07/29/19 | 2D 3D TSV |
US9765054 | 75 | 74 | HGNC:14063 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation Inc | 07/29/19 | 2D 3D TSV |
US9765056 | 173 | 173 | HGNC:990 | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier | 07/29/19 | 2D 3D TSV |
US9765068 | 193 | 193 | HGNC:10894 | PRMT5 inhibitors and uses thereof | Epizyme Inc | 07/29/19 | 2D 3D TSV |
US9765060 | 118 | 113 | HGNC:8977 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences Inc | 07/29/19 | 2D 3D TSV |
US9765029 | 40 | 37 | HGNC:10597 | Pyridine compounds as sodium channel blockers | Purdue Pharma LP | 07/29/19 | 2D 3D TSV |
US9765058 | 20 | 19 | HGNC:1148 | Substituted benzylpyrazoles | Bayer Pharma Aktiengesellschaft | 07/29/19 | 2D 3D TSV |
US9765070 | 81 | 39 | HGNC:6371 HGNC:3529 | Substituted oxopyridine derivatives | Bayer Pharma Aktiengesellschaft | 07/29/19 | 2D 3D TSV |
US9765040 | 15 | 15 | Therapeutic agent for pain | Astellas Pharma Inc | 07/29/19 | 2D 3D TSV | |
US9765092 | 444 | 442 | HGNC:12008 | Tricyclic piperidine compounds | Actelion Pharmaceuticals Ltd | 07/29/19 | 2D 3D TSV |
US9763957 | 206 | 201 | HGNC:10548 | Autotaxin inhibitors | Novartis AG | 07/26/19 | 2D 3D TSV |
US9763952 | 568 | 262 | HGNC:8975 HGNC:8977 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | Novartis AG | 07/26/19 | 2D 3D TSV |
US9765018 | 65 | 65 | HGNC:6059 | IDO inhibitors | Bristol-Myers Squibb Co. | 07/26/19 | 2D 3D TSV |
US9763943 | 43 | 43 | HGNC:8031 | Trk-inhibiting compound | Ono Pharmaceutical Co., Ltd | 07/26/19 | 2D 3D TSV |
US9758480 | 44 | 44 | HGNC:3529 | 1-(cycloalkyl-carbonyl)proline derivative | Sumitomo Dainippon Pharma Co., Ltd | 07/22/19 | 2D 3D TSV |
US9758508 | 11 | 11 | HGNC:1133 | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same | CrystalGenomics, Inc. | 07/22/19 | 2D 3D TSV |
US9758505 | 35 | 35 | HGNC:11708 | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | iTeos Therapeutics | 07/22/19 | 2D 3D TSV |
US9758524 | 664 | 132 | HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | Merck Sharp & Dohme B.V. | 07/22/19 | 2D 3D TSV |
US10202344 | 88 | 67 | HGNC:10597 | Aryl substituted indoles and the use thereof | Purdue Pharma LP | 07/22/19 | 2D 3D TSV |
US10201527 | 144 | 95 | HGNC:4852 HGNC:4774 HGNC:13315 | Benzimidazole derivatives: preparation and pharmaceutical applications | Mei Pharma Inc | 07/22/19 | 2D 3D TSV |
US9758537 | 116 | 116 | HGNC:2771 | Compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 07/22/19 | 2D 3D TSV |
US9757383 | 30 | 15 | HGNC:286 HGNC:1952 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | Almirall, S.A. | 07/22/19 | 2D 3D TSV |
US10202340 | 49 | 17 | HGNC:12524 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | The Regents of the University of Michigan | 07/22/19 | 2D 3D TSV |
US9758495 | 7 | 7 | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer | Amgen Inc | 07/22/19 | 2D 3D TSV | |
US9757369 | 28 | 27 | HGNC:4617 | Heterocyclic GSK-3 allosteric modulators | Consejo Superior de Investigaciones Cientificas (CSIC) | 07/22/19 | 2D 3D TSV |
US9758517 | 21 | 21 | HGNC:17071 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 07/22/19 | 2D 3D TSV |
US10202330 | 54 | 18 | HGNC:6833 HGNC:6834 HGNC:29079 | Lysine specific demethylase-1 inhibitors and their use | Oryzon Genomics, S.A. | 07/22/19 | 2D 3D TSV |
US9757364 | 370 | 71 | HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Naphthyridine derivative compounds | Astex Therapeutics Ltd | 07/22/19 | 2D 3D TSV |
US9758483 | 160 | 159 | HGNC:10582 | Pyridone amides as modulators of sodium channels | Vertex Pharmaceuticals Inc | 07/22/19 | 2D 3D TSV |
US9758538 | 157 | 153 | HGNC:8979 | Pyrimidine derivatives | Pfizer Inc | 07/22/19 | 2D 3D TSV |
US10201546 | 769 | 362 | Quinolinyl modulators of RORγt | Janssen Pharmaceutica NV | 07/22/19 | 2D 3D TSV | |
US10201545 | 102 | 102 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. | 07/22/19 | 2D 3D TSV | |
US10202339 | 353 | 350 | Therapeutic compounds and compositions | Agios Pharmaceuticals Inc | 07/22/19 | 2D 3D TSV | |
US9758523 | 20 | 20 | HGNC:29079 | Triazolopyridines and triazolopyrazines as LSD1 inhibitors | Incyte Corporation | 07/22/19 | 2D 3D TSV |
US9751886 | 33 | 10 | HGNC:934 HGNC:933 | 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE) | Janssen Pharmaceutica NV | 07/11/19 | 2D 3D TSV |
US9751873 | 161 | 138 | Aryl sultam derivatives as RORc modulators | Genentech Inc | 07/11/19 | 2D 3D TSV | |
US9751885 | 801 | 224 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Co., Ltd | 07/11/19 | 2D 3D TSV |
US9751856 | 6 | 6 | Ethynyl derivatives | Hoffmann-La Roche Inc | 07/11/19 | 2D 3D TSV | |
US9751854 | 484 | 477 | HGNC:8974 | Heteroaryls and uses thereof | Millennium Pharmaceuticals Inc | 07/11/19 | 2D 3D TSV |
US9751888 | 236 | 58 | HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals Inc | 07/11/19 | 2D 3D TSV |
US9751881 | 118 | 115 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 07/11/19 | 2D 3D TSV |
US9751837 | 187 | 70 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 | Kinase inhibitors | Respivert Limited | 07/11/19 | 2D 3D TSV |
US9750744 | 68 | 47 | HGNC:8031 | Macrocyclic compounds as Trk kinase inhibitors | Array BioPharma Inc | 07/11/19 | 2D 3D TSV |
US9750748 | 14 | 14 | HGNC:2671 | Pyridazinones as DAAO enzyme inhibitors | Takeda Pharmaceutical Co., Ltd | 07/11/19 | 2D 3D TSV |
US9751832 | 42 | 21 | HGNC:4852 HGNC:14064 | Selective histone deactylase 6 inhibitors | H. Lee Moffitt Cancer Center and Research Institute Inc | 07/11/19 | 2D 3D TSV |
US9751843 | 148 | 148 | HGNC:2097 | Substituted uracils and use thereof | Bayer Pharma Aktiengesellschaft | 07/11/19 | 2D 3D TSV |
US9751850 | 11 | 11 | HGNC:497 | TRPA1 antagonists | AbbVie Inc | 07/11/19 | 2D 3D TSV |
US9744173 | 132 | 114 | HGNC:933 HGNC:2625 | 2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | Pfizer Inc | 07/05/19 | 2D 3D TSV |
US9745284 | 120 | 59 | HGNC:4849 HGNC:4848 | 2-pyridyloxy-4-ether orexin receptor antagonists | Merck Sharp & Dohme Corp | 07/05/19 | 2D 3D TSV |
US9745265 | 128 | 126 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp | 07/05/19 | 2D 3D TSV | |
US9745289 | 262 | 62 | HGNC:2592 HGNC:2591 | Aldosterone synthase inhibitors | Boehringer Ingelheim International GmbH | 07/05/19 | 2D 3D TSV |
US9745304 | 64 | 32 | Amidoimidazopyridazines as MKNK-1 kinase inhibitors | Bayer Pharma Aktiengesellschaft | 07/05/19 | 2D 3D TSV | |
US9744252 | 20 | 20 | HGNC:6138 | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA | 07/05/19 | 2D 3D TSV |
US9745307 | 46 | 45 | HGNC:6871 | Compounds that are ERK inhibitors | Merck Sharp & Dohme Corp | 07/05/19 | 2D 3D TSV |
US9745328 | 898 | 885 | HGNC:3650 | Flap modulators | Janssen Pharmaceutica NV | 07/05/19 | 2D 3D TSV |
US9745321 | 142 | 140 | HGNC:8977 | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof | Shanghai Yingli Pharmaceutical Co., Ltd | 07/05/19 | 2D 3D TSV |
US9745317 | 28 | 23 | HGNC:3020 | Heterocyclic compounds and their use as dopamine D1 ligands | Pfizer Inc | 07/05/19 | 2D 3D TSV |
US9745310 | 199 | 198 | HGNC:4597 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK Biopharmaceuticals Co. Ltd | 07/05/19 | 2D 3D TSV |
US9745324 | 83 | 44 | HGNC:934 HGNC:933 | Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 07/05/19 | 2D 3D TSV |
US9745282 | 100 | 47 | HGNC:2592 HGNC:2591 | Indoline compounds as aldosterone synthase inhibitors | Merck Sharp & Dohme Corp | 07/05/19 | 2D 3D TSV |
US9744148 | 96 | 90 | HGNC:6368 | Kallikrein 7 inhibitors | SIXERA Pharma AB | 07/05/19 | 2D 3D TSV |
US9745291 | 277 | 274 | HGNC:29652 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme Inc | 07/05/19 | 2D 3D TSV |
US9744172 | 287 | 286 | HGNC:7027 | Pyrazolopyrimidine compounds for the treatment of cancer | University of North Carolina at Chapel Hill | 07/05/19 | 2D 3D TSV |
US9745287 | 36 | 22 | HGNC:10597 | Pyrimidines and use thereof | Purdue Pharma LP | 07/05/19 | 2D 3D TSV |
US9745311 | 266 | 89 | HGNC:3690 HGNC:3689 HGNC:3688 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | Incyte Corporation | 07/05/19 | 2D 3D TSV |
US9745283 | 328 | 169 | HGNC:7029 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. | 07/05/19 | 2D 3D TSV |
US9738626 | 7 | 7 | HGNC:9595 | Antagonists of prostaglandin EP3 receptor | Pfizer Inc | 07/01/19 | 2D 3D TSV |
US9737516 | 44 | 18 | Bicyclic heterocycles as bet protein inhibitors | Incyte Corporation | 07/01/19 | 2D 3D TSV | |
US9738641 | 20 | 10 | HGNC:6371 HGNC:6357 | Bicyclic inhibitors | Kalvista Pharmaceuticals Limited | 07/01/19 | 2D 3D TSV |
US9737544 | 120 | 24 | HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Compounds | Astex Therapeutics Limited | 07/01/19 | 2D 3D TSV |
US9738658 | 36 | 36 | HGNC:2843 | Compounds as diacylglycerol acyltransferase inhibitors | GlaxoSmithKline | 07/01/19 | 2D 3D TSV |
US9738637 | 297 | 93 | HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. | 07/01/19 | 2D 3D TSV |
US9738630 | 17 | 16 | HGNC:3527 | Inhibitors of lysine methyl transferase | Bristol-Myers Squibb Co. | 07/01/19 | 2D 3D TSV |
US9737522 | 17 | 17 | NMDA receptor modulators and uses related thereto | Emory University | 07/01/19 | 2D 3D TSV | |
US9738632 | 20 | 18 | HGNC:7978 | Phenyl and benzodioxinyl substituted indazoles derivatives | AstraZeneca AB | 07/01/19 | 2D 3D TSV |
US9738668 | 30 | 9 | Phosphonate derivatives and methods of use thereof in the treatment of Alzheimer's disease | University of Kansas | 07/01/19 | 2D 3D TSV | |
US9737542 | 111 | 111 | HGNC:19679 | Pyrrolotriazine kinase inhibitors | Bristol-Myers Squibb Co. | 07/01/19 | 2D 3D TSV |
US9738676 | 7 | 7 | HGNC:8780 | Selected macrolides with PDE4-inhibiting activity | Basilea Pharmaceutica AG | 07/01/19 | 2D 3D TSV |
US9737525 | 20 | 17 | HGNC:10886 | Small molecule activators of NRF2 pathway | The General Hospital Corporation | 07/01/19 | 2D 3D TSV |
US9738628 | 36 | 21 | Substituted 1H-indazol-1-OL analogs as inhibitors of beta catenin/Tcf protein-protein interactions | University of Utah Research Foundation | 07/01/19 | 2D 3D TSV | |
US9738640 | 16 | 8 | HGNC:6833 HGNC:6834 | Substituted benzamide derivatives as in vitro MAO-B inhibitors | NTZ Lab Ltd | 07/01/19 | 2D 3D TSV |
US9738649 | 771 | 379 | HGNC:12716 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | Janssen Pharmaceutica NV | 07/01/19 | 2D 3D TSV |
US9738655 | 635 | 318 | HGNC:6371 HGNC:3529 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | Bristol-Myers Squibb Co. | 07/01/19 | 2D 3D TSV |
US9730929 | 33 | 33 | HGNC:7110 | Substituted aminoimidazopyridazines | Bayer Intellectual Property GmbH | 06/26/19 | 2D 3D TSV |
US9732104 | 43 | 43 | HGNC:2771 | Ether compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 06/24/19 | 2D 3D TSV |
US9732037 | 63 | 21 | HGNC:7872 HGNC:7873 | 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors | Northwestern University | 06/23/19 | 2D 3D TSV |
US9732060 | 560 | 555 | HGNC:8534 | Aminotriazine derivative and pharmaceutical composition comprising the same | Shionogi & Co., Ltd | 06/23/19 | 2D 3D TSV |
US9732094 | 901 | 326 | HGNC:6251 HGNC:9413 | Arylquinazolines | Merck Patent GmbH | 06/23/19 | 2D 3D TSV |
US9732075 | 1982 | 990 | HGNC:4849 HGNC:4848 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS Ltd | 06/23/19 | 2D 3D TSV |
US9732088 | 116 | 39 | HGNC:934 HGNC:2529 HGNC:933 | C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 06/23/19 | 2D 3D TSV |
US9732103 | 16 | 16 | HGNC:2771 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 06/23/19 | 2D 3D TSV |
US9732061 | 76 | 38 | HGNC:2160 HGNC:2159 | Cinnoline derivatives useful as CB-1 receptor inverse agonists | Janssen Pharmaceutica NV | 06/23/19 | 2D 3D TSV |
US9732087 | 30 | 30 | HGNC:17383 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | Janssen Pharmaceutica NV | 06/23/19 | 2D 3D TSV |
US9732093 | 691 | 353 | HGNC:3650 | FLAP modulators | Janssen Pharmaceutica NV | 06/23/19 | 2D 3D TSV |
US9732066 | 239 | 237 | HGNC:9599 | Heterocyclic derivative and pharmaceutical drug | Nippon Shinyaku Co. Ltd | 06/23/19 | 2D 3D TSV |
US9730939 | 366 | 326 | HGNC:8977 | Heterocyclylamines as PI3K inhibitors | Incyte Holdings Corporation | 06/23/19 | 2D 3D TSV |
US9732063 | 194 | 72 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 | Kinase inhibitors | Respivert Limited | 06/23/19 | 2D 3D TSV |
US9732044 | 8 | 8 | HGNC:644 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | Galderma Research & Development | 06/23/19 | 2D 3D TSV |
US9732072 | 30 | 29 | HGNC:10894 | PRMT5 inhibitors and uses thereof | Epizyme Inc | 06/23/19 | 2D 3D TSV |
US9732097 | 26 | 26 | HGNC:6190 | Process for the synthesis of a phosphoinositide 3-kinase inhibitor | Incyte Corporation | 06/23/19 | 2D 3D TSV |
US9730940 | 387 | 370 | HGNC:8977 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | Merck Sharp & Dohme | 06/23/19 | 2D 3D TSV |
US9732085 | 36 | 33 | HGNC:3529 | Pyridinone and pyrimidinone derivatives as factor Xia | Ono Pharmaceutical Co., Ltd | 06/23/19 | 2D 3D TSV |
US9730931 | 144 | 67 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pyrimidine FGFR4 inhibitors | Eisai R&D Management Co., Ltd | 06/23/19 | 2D 3D TSV |
US9730934 | 33 | 11 | HGNC:3432 HGNC:3430 HGNC:3236 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | Xuanzhu Pharma Co., Ltd | 06/23/19 | 2D 3D TSV |
US9730937 | 1155 | 377 | HGNC:9829 HGNC:1097 | RAF kinase modulator compounds and methods of use thereof | Ambit Biosciences Corporation | 06/23/19 | 2D 3D TSV |
US9732092 | 23 | 23 | HGNC:10966 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | Gilead Sciences Inc | 06/23/19 | 2D 3D TSV |
US10196387 | 88 | 87 | HGNC:13575 | Carbazole compounds useful as bromodomain inhibitors | Bristol-Myers Squibb Co. | 06/16/19 | 2D 3D TSV |
US10196396 | 240 | 174 | HGNC:268 HGNC:262 HGNC:263 | Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof | HANDOK INC. | 06/16/19 | 2D 3D TSV |
US10196436 | 116 | 57 | HGNC:3691 HGNC:3688 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION | 06/16/19 | 2D 3D TSV |
US10196393 | 56 | 6 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK inhibitors containing a 4-membered heterocyclic amide | THERAVANCE BIOPHARMA R&D IP, LLC | 06/16/19 | 2D 3D TSV |
US10196404 | 3 | 1 | HGNC:6943 | MCL-1 inhibitors and methods of use thereof | AstraZeneca AB | 06/16/19 | 2D 3D TSV |
US10196390 | 466 | 233 | HGNC:6192 HGNC:12440 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi, Inc. | 06/16/19 | 2D 3D TSV |
US10196391 | 120 | 119 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | Hoffmann-La Roche Inc | 06/16/19 | 2D 3D TSV | |
US10196374 | 50 | 24 | HGNC:7978 HGNC:11892 | 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators | AstraZeneca AB | 06/14/19 | 2D 3D TSV |
US10196354 | 127 | 127 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp | 06/14/19 | 2D 3D TSV | |
US10196381 | 41 | 41 | HGNC:270 | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD | 06/14/19 | 2D 3D TSV |
US10196353 | 10 | 10 | HGNC:8910 | Chemical compounds | GlaxoSmithKline | 06/14/19 | 2D 3D TSV |
US10196378 | 44 | 9 | HGNC:11283 HGNC:76 | Inhibitors of BCR-ABL mutants and use thereof | The Regents of the University of Michigan | 06/14/19 | 2D 3D TSV |
US10196365 | 22 | 11 | HGNC:3430 HGNC:3236 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | ARROMAX PHARMATECH CO., LTD. | 06/14/19 | 2D 3D TSV |
US10196369 | 103 | 102 | HGNC:3128 | Spirocyclic EBI2 modulators | Sanford Burnham Prebys Medical Discovery Institute | 06/14/19 | 2D 3D TSV |
US10196373 | 93 | 86 | HGNC:11364 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO | 06/14/19 | 2D 3D TSV |
US10196383 | 8 | 4 | HGNC:4849 HGNC:4848 | Substituted quinazoline compounds and preparation and uses thereof | Sunshine Lake Pharma Co., Ltd | 06/14/19 | 2D 3D TSV |
US10196385 | 3 | 3 | HGNC:20088 | Tetrahydropyranyl benzamide derivatives | Eli Lilly and Company | 06/14/19 | 2D 3D TSV |
US10196382 | 6 | 6 | bis-Pyridazine compounds and their use in treating cancer | AstraZeneca AB | 06/14/19 | 2D 3D TSV | |
US9724347 | 120 | 32 | HGNC:4840 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:6874 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors | Respivert Ltd | 06/12/19 | 2D 3D TSV |
US9725459 | 175 | 89 | HGNC:2536 HGNC:2545 | 3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I | GRUNENTHAL GMBH | 06/12/19 | 2D 3D TSV |
US9725446 | 32 | 15 | HGNC:8816 HGNC:11584 HGNC:14552 | 7-azaindole derivatives | Merck Patent GmbH | 06/12/19 | 2D 3D TSV |
US9725465 | 406 | 201 | HGNC:6342 HGNC:3765 | Biaryl acetamide compounds and methods of use thereof | Ambit Biosciences Corporation | 06/12/19 | 2D 3D TSV |
US10189849 | 50 | 45 | HGNC:1771 HGNC:1773 | CDK inhibitors | G1 Therapeutics, Inc. | 06/12/19 | 2D 3D TSV |
US10195181 | 48 | 38 | HGNC:16807 | Carboxamide derivatives | Novartis AG | 06/12/19 | 2D 3D TSV |
US9725433 | 164 | 146 | HGNC:3763 HGNC:6307 | Compounds as tyrosine kinase modulators | Allergan Inc | 06/12/19 | 2D 3D TSV |
US10189853 | 42 | 15 | HGNC:8803 HGNC:6307 HGNC:3236 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | Duquesne University of the Holy Spirit | 06/12/19 | 2D 3D TSV |
US9725445 | 668 | 296 | HGNC:6190 HGNC:6192 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | Merck Sharp & Dohme Corp | 06/12/19 | 2D 3D TSV |
US9725426 | 44 | 44 | HGNC:2501 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. | 06/12/19 | 2D 3D TSV |
US9725436 | 51 | 17 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) | 06/12/19 | 2D 3D TSV | |
US10189859 | 236 | 91 | HGNC:10597 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | Nektar Therapeutics | 06/12/19 | 2D 3D TSV |
US10195178 | 99 | 98 | HGNC:4498 | GPR40 agonists in anti-diabetic drug combinations | Janssen Pharmaceutica NV | 06/12/19 | 2D 3D TSV |
US10195201 | 75 | 32 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | Merck Sharp & Dohme Corp | 06/12/19 | 2D 3D TSV | |
US9725442 | 422 | 338 | HGNC:4502 | Heterocyclic derivative having PGD2 receptor antagonist activity | Shionogi & Co., Ltd | 06/12/19 | 2D 3D TSV |
US9724435 | 232 | 99 | HGNC:3023 HGNC:11050 HGNC:8156 HGNC:11049 | Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders | The University of Mississippi | 06/12/19 | 2D 3D TSV |
US9725441 | 199 | 93 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 06/12/19 | 2D 3D TSV |
US9725434 | 62 | 31 | HGNC:4849 HGNC:4848 | Hydroxy-substituted orexin receptor antagonists | Merck Sharp & Dohme Corp | 06/12/19 | 2D 3D TSV |
US10188639 | 3 | 3 | HGNC:9236 | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone | DeuteRx, LLC | 06/12/19 | 2D 3D TSV |
US10195186 | 101 | 49 | HGNC:11186 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. Lundbeck A/S | 06/12/19 | 2D 3D TSV |
US10189791 | 5 | 5 | HGNC:7873 | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole | Dartmouth College | 06/12/19 | 2D 3D TSV |
US9724352 | 7 | 7 | HGNC:8979 | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 06/12/19 | 2D 3D TSV |
US9725439 | 29 | 20 | HGNC:3236 | Quinazoline derivative and preparation method therefor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | 06/12/19 | 2D 3D TSV |
US9725443 | 31 | 31 | RORγ modulators | Bristol-Myers Squibb Co. | 06/12/19 | 2D 3D TSV | |
US9725435 | 16 | 16 | HGNC:3529 | Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors | Bristol-Myers Squibb Co. | 06/12/19 | 2D 3D TSV |
US10196346 | 26 | 26 | HGNC:4910 | Substituted acethydrazide derivative, preparation method and use thereof | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | 06/12/19 | 2D 3D TSV |
US10189854 | 347 | 343 | HGNC:8781 | Substituted pyrimidine compounds | Gruenenthal GmbH | 06/12/19 | 2D 3D TSV |
US9725449 | 371 | 292 | Tricyclic compounds as anticancer agents | Bristol-Myers Squibb Co. | 06/12/19 | 2D 3D TSV | |
US9725430 | 18 | 12 | HGNC:3521 HGNC:9642 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN HOSPITAL MEDICAL CENTER | 06/12/19 | 2D 3D TSV |
US10189796 | 9 | 9 | HGNC:6018 | [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof | Santen Pharmaceutical Co., Ltd | 06/12/19 | 2D 3D TSV |
US9663479 | 6 | 6 | HGNC:1403 | γ-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders | Novassay S.A. | 06/04/19 | 2D 3D TSV |
US9663475 | 31 | 28 | HGNC:2529 | 2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors | Merck Patent GmbH | 06/04/19 | 2D 3D TSV |
US9663502 | 580 | 573 | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease | Lycera Corporation | 06/04/19 | 2D 3D TSV | |
US9663522 | 43 | 40 | 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp | 06/04/19 | 2D 3D TSV | |
US9663503 | 18 | 18 | HGNC:1925 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | Cancer Research Technology Limited | 06/04/19 | 2D 3D TSV |
US9663530 | 136 | 67 | 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives | Hoffmann-La Roche Inc | 06/04/19 | 2D 3D TSV | |
US9663496 | 493 | 492 | HGNC:9377 | AMPK-activating heterocyclic compounds and methods for using the same | Rigel Pharmaceuticals, Inc | 06/04/19 | 2D 3D TSV |
US9663526 | 468 | 113 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Aminopyrimidinyl compounds | Pfizer Inc | 06/04/19 | 2D 3D TSV |
US9663498 | 53 | 53 | HGNC:5301 | Aromatic heterocyclic compounds and their application in pharmaceuticals | Sunshine Lake Pharma Co., Ltd | 06/04/19 | 2D 3D TSV |
US9663470 | 177 | 176 | HGNC:5208 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | Vitae Pharmaceuticals Inc | 06/04/19 | 2D 3D TSV |
US9663523 | 56 | 56 | HGNC:13575 | BET protein-inhibiting 5-aryltriazoleazepines | Bayer Pharma Aktiengesellschaft | 06/04/19 | 2D 3D TSV |
US9663508 | 431 | 308 | HGNC:10593 HGNC:10597 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | Amgen Inc | 06/04/19 | 2D 3D TSV |
US9663519 | 33 | 33 | HGNC:882 | Compounds useful as inhibitors of ATR kinase | Vertex Pharmaceuticals Inc | 06/04/19 | 2D 3D TSV |
US9663515 | 16 | 16 | Dihydropyrrolopyridine inhibitors of ROR-gamma | Vitae Pharmaceuticals Inc | 06/04/19 | 2D 3D TSV | |
US9663527 | 4 | 4 | HGNC:3529 | Factor XIa inhibitors | Merck Sharp & Dohme Corp | 06/04/19 | 2D 3D TSV |
US9663476 | 18 | 17 | HGNC:11056 | Glycine transporter-1 inhibitors | Amgen Inc | 06/04/19 | 2D 3D TSV |
US9663494 | 9 | 9 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Hoffmann-La Roche Inc | 06/04/19 | 2D 3D TSV |
US9663543 | 33 | 33 | HGNC:2771 | Phosphonate compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 06/04/19 | 2D 3D TSV |
US9663525 | 125 | 119 | HGNC:12477 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | Millennium Pharmaceuticals Inc | 06/04/19 | 2D 3D TSV |
US9663513 | 257 | 224 | HGNC:8772 | Pyrimidine PDE10 inhibitors | Merck Sharp & Dohme Corp | 06/04/19 | 2D 3D TSV |
US9663506 | 315 | 292 | HGNC:4594 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | Merck Sharp & Dohme Corp | 06/04/19 | 2D 3D TSV |
US9663511 | 44 | 21 | HGNC:3169 HGNC:14299 | Sphingosine 1-phosphate receptor antagonists | Arroyo BioSciences, LLC | 06/04/19 | 2D 3D TSV |
US9663528 | 23 | 22 | HGNC:10966 | Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections | Gilead Sciences Inc | 06/04/19 | 2D 3D TSV |
US9663510 | 28 | 28 | HGNC:12401 | Substituted triazolopyridines and their use as TTK inhibitors | Bayer Pharma Aktiengesellschaft | 06/04/19 | 2D 3D TSV |
US9663529 | 96 | 96 | HGNC:10252 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | Bristol-Myers Squibb Co. | 06/04/19 | 2D 3D TSV |
US9663463 | 21 | 21 | HGNC:8156 | 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose | Sanwa Kagaku Kenkyusho Co., Ltd | 06/03/19 | 2D 3D TSV |
US9663465 | 50 | 26 | HGNC:5299 HGNC:108 | Acetylcholinesterase inhibitors and promnesiant serotonin 5-HT4 receptor agonists, their methods of preparation and the pharmaceutical compositions containing the same | UNIVERSITE DE CAEN | 06/03/19 | 2D 3D TSV |
US9662330 | 243 | 240 | HGNC:10436 | Aminopyrimidine derivatives for use as modulators of kinase activity | Merck Patent GmbH | 06/03/19 | 2D 3D TSV |
US9662339 | 296 | 295 | HGNC:6710 | Benzodioxane inhibitors of leukotriene production for combination therapy | Boehringer Ingelheim International GmbH | 06/03/19 | 2D 3D TSV |
US9662310 | 68 | 66 | HGNC:2300 | Cyclopropanecarboxylic acid derivative | Daiichi Sankyo Company, Limited | 06/03/19 | 2D 3D TSV |
US9662327 | 402 | 393 | Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer | Agios Pharmaceuticals Inc | 06/03/19 | 2D 3D TSV | |
US9663469 | 319 | 307 | RORγ modulators | Bristol-Myers Squibb Co. | 06/03/19 | 2D 3D TSV | |
US9663460 | 209 | 209 | HGNC:1603 | Sulfur derivatives as chemokine receptor modulators | Allergan Inc | 06/03/19 | 2D 3D TSV |
US10189845 | 867 | 207 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | Array BioPharma Inc | 05/29/19 | 2D 3D TSV |
US9636336 | 248 | 55 | HGNC:1952 | Aminoester derivatives | Chiesi Farmaceutici S.p.A. | 05/29/19 | 2D 3D TSV |
US9637499 | 10 | 10 | HGNC:8780 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | Leo Pharma A/S | 05/29/19 | 2D 3D TSV |
US9637486 | 28 | 28 | HGNC:1133 | Btk inhibitors | Merck Sharp & Dohme Corp | 05/29/19 | 2D 3D TSV |
US9637484 | 20 | 20 | HGNC:17989 | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | Shanghai Hengrui Pharmaceutical Co., Ltd | 05/29/19 | 2D 3D TSV |
US9636335 | 44 | 43 | HGNC:5299 | Heteroaryl compounds as 5-HT4 receptor ligands | Suven Life Sciences Limited | 05/29/19 | 2D 3D TSV |
US9637488 | 37 | 33 | HGNC:8978 | Heterocyclic compounds as inhibitors of class I PI3KS | TBA | 05/29/19 | 2D 3D TSV |
US9637455 | 21 | 21 | Heterocyclic sulfone RORγ modulators | Bristol-Myers Squibb Co. | 05/29/19 | 2D 3D TSV | |
US9636339 | 64 | 32 | HGNC:2592 HGNC:2591 | Phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors | Hoffman-La Roche Inc | 05/29/19 | 2D 3D TSV |
US9636338 | 48 | 23 | HGNC:2592 HGNC:2591 | Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase | Hoffmann-La Roche Inc | 05/29/19 | 2D 3D TSV |
US9637487 | 34 | 34 | HGNC:1133 | Purinone compounds as kinase inhibitors | Pharmacyclics LLC | 05/29/19 | 2D 3D TSV |
US10189841 | 544 | 538 | HGNC:12607 | Purinones as ubiquitin-specific protease 1 inhibitors | Forma Therapeutics Inc | 05/29/19 | 2D 3D TSV |
US9636337 | 315 | 292 | HGNC:4594 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | Merck Sharp & Dohme Corp | 05/29/19 | 2D 3D TSV |
US9637472 | 391 | 389 | HGNC:3527 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme Inc | 05/29/19 | 2D 3D TSV |
US9637496 | 1033 | 378 | HGNC:4849 HGNC:4848 | Substituted 7-azabicycles and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 05/29/19 | 2D 3D TSV |
US9637493 | 47 | 45 | Substituted pyrrolopyrimidines as HDM2 inhibitors | Merck Sharp & Dohme Corp | 05/29/19 | 2D 3D TSV | |
US10189840 | 40 | 40 | HGNC:11892 | Substituted tricyclic heterocyclic compounds | Bristol-Myers Squibb Co. | 05/29/19 | 2D 3D TSV |
US9636330 | 15 | 15 | HGNC:3357 | Tetrahydrocarboline derivative | Ono Pharmaceutical Co., Ltd | 05/29/19 | 2D 3D TSV |
US10189838 | 117 | 114 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | Hoffman-La Roche Inc | 05/26/19 | 2D 3D TSV | |
US10189835 | 22 | 21 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. | 05/26/19 | 2D 3D TSV | |
US10189831 | 182 | 181 | Non-nucleoside reverse transcriptase inhibitors | Merck Sharp & Dohme Corp | 05/26/19 | 2D 3D TSV | |
US10189836 | 398 | 189 | HGNC:6190 HGNC:6192 | Therapeutic compounds, compositions and methods of use thereof | Genentech Inc | 05/26/19 | 2D 3D TSV |
US10188615 | 195 | 171 | HGNC:10294 HGNC:9864 HGNC:9866 HGNC:9865 HGNC:10477 | Alkoxy compounds for disease treatment | ACUCELA INC. | 05/25/19 | 2D 3D TSV |
US10188653 | 55 | 55 | HGNC:16940 | Diacylglycerol acyltransferase 2 inhibitors | Pfizer Inc | 05/25/19 | 2D 3D TSV |
US10189819 | 87 | 86 | HGNC:3551 | Factor IXa inhibitors | Merck Sharp & Dohme Corp | 05/25/19 | 2D 3D TSV |
US10189794 | 194 | 192 | HGNC:3691 | Heteroaryl compounds and uses thereof | Celgene CAR LLC | 05/25/19 | 2D 3D TSV |
US10188756 | 189 | 27 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 | Imaging histone deacetylases with a radiotracer using positron emission tomography | The General Hospital Corporation | 05/25/19 | 2D 3D TSV |
US10189829 | 145 | 139 | HGNC:1133 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. | 05/25/19 | 2D 3D TSV |
US10189805 | 8 | 8 | HGNC:10943 | Metabolism probes for therapy and diagnosis | Vanderbilt University | 05/25/19 | 2D 3D TSV |
US10188758 | 8 | 5 | HGNC:11050 HGNC:11048 | Organic compounds | Intra-Cellular Therapies Inc | 05/25/19 | 2D 3D TSV |
US10188627 | 67 | 32 | HGNC:9235 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | Mitobridge, Inc. | 05/25/19 | 2D 3D TSV |
US10188667 | 22 | 11 | HGNC:4591 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | Allergan Inc | 05/25/19 | 2D 3D TSV |
US10188642 | 104 | 103 | HGNC:12401 | Pharmacologically active compounds | Cancer Research Technology Limited | 05/25/19 | 2D 3D TSV |
US10189809 | 198 | 191 | HGNC:4685 | SGC stimulators | Ironwood Pharmaceuticals, Inc. | 05/25/19 | 2D 3D TSV |
US10189788 | 90 | 73 | HGNC:9600 | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | Bayer Pharma Aktiengesellschaft | 05/25/19 | 2D 3D TSV |
US10189816 | 194 | 162 | Substituted pyridines as inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 05/25/19 | 2D 3D TSV | |
US10189807 | 7 | 7 | HGNC:23 | Tetrahydrothiophene-based GABA aminotransferase inactivators | Northwestern University | 05/25/19 | 2D 3D TSV |
US9630945 | 80 | 80 | HGNC:10555 | Autotaxin inhibitors | Novartis AG | 05/20/19 | 2D 3D TSV |
US9630929 | 138 | 57 | HGNC:10593 HGNC:10597 | Benzenesulfonamide compounds and their use as therapeutic agents | Xenon Pharmaceuticals Inc | 05/20/19 | 2D 3D TSV |
US9629836 | 101 | 100 | Compounds and compositions as inhibitors of MEK | Novartis AG | 05/20/19 | 2D 3D TSV | |
US9630956 | 151 | 149 | HGNC:882 | Compounds useful as inhibitors of ATR kinase | Vertex Pharmaceuticals Inc | 05/20/19 | 2D 3D TSV |
US9630965 | 73 | 63 | HGNC:5253 HGNC:1735 | Fused amino pyridine as HSP90 inhibitors | Curis Inc | 05/20/19 | 2D 3D TSV |
US9630914 | 86 | 19 | HGNC:3553 HGNC:9605 | Multitarget FAAH and COX inhibitors and therapeutical uses thereof | Fondazione Istituto Italiano di Tecnologia | 05/20/19 | 2D 3D TSV |
US9630949 | 143 | 77 | HGNC:6932 HGNC:6929 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | Galderma Research & Development | 05/20/19 | 2D 3D TSV |
US9630931 | 29 | 29 | HGNC:1925 | Pharmaceutically active pyrazine derivatives | Sentinel Oncology Limited | 05/20/19 | 2D 3D TSV |
US10183937 | 838 | 407 | HGNC:15459 HGNC:8534 | 1,3-thiazol-2-yl substituted benzamides | Bayer Aktiengesellschaft | 05/16/19 | 2D 3D TSV |
US10179123 | 89 | 74 | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors | Bayer Pharma Aktiengesellschaft | 05/16/19 | 2D 3D TSV | |
US10174024 | 77 | 60 | HGNC:13575 | 5H-pyrido[3,2-B]indole compounds as anticancer agents | Bristol-Myers Squibb Co. | 05/16/19 | 2D 3D TSV |
US10174035 | 234 | 135 | HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 | 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors | Daiichi Sankyo Company, Limited | 05/16/19 | 2D 3D TSV |
US10183940 | 124 | 78 | HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists | Boehringer Ingelheim International GmbH | 05/16/19 | 2D 3D TSV |
US10183025 | 206 | 200 | HGNC:3357 | Autotaxin inhibitors | Novartis AG | 05/16/19 | 2D 3D TSV |
US10174049 | 36 | 36 | HGNC:2843 | Compounds as diacylglycerol acyltransferase inhibitors | GlaxoSmithKline | 05/16/19 | 2D 3D TSV |
US10179761 | 52 | 28 | HGNC:8157 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE | 05/16/19 | 2D 3D TSV |
US10174030 | 116 | 116 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 05/16/19 | 2D 3D TSV |
US10174037 | 579 | 205 | Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | Merck Sharp & Dohme Corp | 05/16/19 | 2D 3D TSV | |
US10183939 | 56 | 21 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | Redx Pharma PLC | 05/16/19 | 2D 3D TSV | |
US10174044 | 63 | 62 | HGNC:19679 | Fused pyridines as kinase inhibitors | Bristol-Myers Squibb Co. | 05/16/19 | 2D 3D TSV |
US10183938 | 448 | 300 | HGNC:5297 HGNC:1960 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | Axovant Sciences GmbH | 05/16/19 | 2D 3D TSV |
US10174023 | 22 | 22 | HGNC:270 | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD | 05/16/19 | 2D 3D TSV |
US10174026 | 297 | 93 | HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 05/16/19 | 2D 3D TSV |
US10179769 | 211 | 103 | HGNC:9886 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 05/16/19 | 2D 3D TSV |
US10183928 | 8 | 4 | HGNC:9967 | Inhibitors of RET | BLUEPRINT MEDICINES CORPORATION | 05/16/19 | 2D 3D TSV |
US10179773 | 10 | 10 | Isoxazole carboxamides as irreversible SMYD inhibitors | Epizyme Inc | 05/16/19 | 2D 3D TSV | |
US10183942 | 112 | 16 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC | 05/16/19 | 2D 3D TSV |
US10179804 | 132 | 132 | HGNC:6932 | Melanocortin receptor-specific peptides | Palatin Technologies Inc | 05/16/19 | 2D 3D TSV |
US10183954 | 14 | 14 | HGNC:15631 | Oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection | Hoffmann-La Roche Inc | 05/16/19 | 2D 3D TSV |
US10183913 | 128 | 64 | HGNC:11050 HGNC:5295 | Pyrazole compound | Sumitomo Dainippon Pharma Co., Ltd | 05/16/19 | 2D 3D TSV |
US10183947 | 51 | 49 | HGNC:435 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | AstraZeneca AB | 05/16/19 | 2D 3D TSV |
US10174020 | 10 | 10 | HGNC:3529 | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. | 05/16/19 | 2D 3D TSV |
US10183944 | 614 | 335 | HGNC:6192 HGNC:11491 | Pyrimido-pyridazinone compounds and methods of use thereof | Asana BioSciences, LLC | 05/16/19 | 2D 3D TSV |
US10174040 | 143 | 110 | HGNC:1373 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 05/16/19 | 2D 3D TSV |
US10183931 | 91 | 36 | HGNC:10251 HGNC:10252 | Rho kinase inhibitors | Kadmon Corporation LLC | 05/16/19 | 2D 3D TSV |
US10179791 | 122 | 42 | HGNC:3167 HGNC:3165 HGNC:14299 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie B.V. | 05/16/19 | 2D 3D TSV |
US10183953 | 990 | 258 | HGNC:4849 HGNC:4848 | Substituted 2-azabicycles and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 05/16/19 | 2D 3D TSV |
US10183932 | 357 | 143 | HGNC:3529 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | Bayer Pharma Aktiengesellschaft | 05/16/19 | 2D 3D TSV |
US10174028 | 1162 | 716 | HGNC:9967 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc | 05/16/19 | 2D 3D TSV |
US10174027 | 1162 | 716 | HGNC:9967 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc | 05/16/19 | 2D 3D TSV |
US10183009 | 122 | 121 | Therapeutic compounds and uses thereof | Genentech Inc | 05/16/19 | 2D 3D TSV | |
US10183946 | 92 | 45 | HGNC:2160 HGNC:2159 | Triazolo[4,5-D]pyrimidines | Hoffmann-La Roche Inc | 05/16/19 | 2D 3D TSV |
US10183917 | 18 | 17 | HGNC:7967 | Tricyclic compounds and uses thereof in medicine | Sunshine Lake Pharma Co., Ltd | 05/16/19 | 2D 3D TSV |
US10183021 | 388 | 384 | HGNC:4685 | sGC stimulators | Ironwood Pharmaceuticals, Inc. | 05/16/19 | 2D 3D TSV |
US10174016 | 873 | 411 | HGNC:2596 HGNC:2637 HGNC:15459 HGNC:2625 HGNC:8534 HGNC:2622 HGNC:2623 | 1,3-thiazol-2-yl substituted benzamides | BEYER AKTIENGESELLSCHAFT | 05/15/19 | 2D 3D TSV |
US9624197 | 30 | 15 | HGNC:4849 HGNC:4848 | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists | Merck Sharp & Dohme Corp | 05/15/19 | 2D 3D TSV |
US9624210 | 3 | 3 | HGNC:11491 | Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors | Merck Sharp & Dohme Corp | 05/15/19 | 2D 3D TSV |
US10173985 | 34 | 18 | HGNC:10593 HGNC:10597 | Aminoindazole derivatives as sodium channel inhibitors | Almirall, S.A. | 05/15/19 | 2D 3D TSV |
US9624159 | 8 | 8 | HGNC:9596 | Aniline derivatives, their preparation and their therapeutic application | Sanofi | 05/15/19 | 2D 3D TSV |
US10174013 | 42 | 27 | HGNC:6251 HGNC:3765 | Benzimidazole derivatives as kinase inhibitors | Selvita S.A. | 05/15/19 | 2D 3D TSV |
US10174000 | 62 | 32 | HGNC:17967 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | Pfizer Inc | 05/15/19 | 2D 3D TSV |
US9624235 | 20 | 15 | HGNC:587 | Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity | University of Pittsburgh | 05/15/19 | 2D 3D TSV |
US9624213 | 207 | 207 | Compounds and methods for kinase modulation, and indications therefor | Plexxikon Inc. | 05/15/19 | 2D 3D TSV | |
US9624217 | 159 | 156 | Dihydropyrrolopyridine inhibitors of ROR-gamma | Vitae Pharmaceuticals Inc | 05/15/19 | 2D 3D TSV | |
US9624175 | 82 | 61 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | Forma Therapeutics Inc | 05/15/19 | 2D 3D TSV | |
US9624194 | 25 | 22 | HGNC:10597 | Heteroaryl compounds as sodium channel blockers | Purdue Pharma LP | 05/15/19 | 2D 3D TSV |
US9624234 | 25 | 24 | HGNC:338 | Heterocyclic compounds and methods for their use | Novartis AG | 05/15/19 | 2D 3D TSV |
US9624243 | 85 | 83 | HGNC:338 | Heterocyclic compounds and methods of their use | Novartis AG | 05/15/19 | 2D 3D TSV |
US10174011 | 307 | 98 | HGNC:3023 HGNC:5286 | Heterocyclic compounds, process for preparation of the same and use thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 05/15/19 | 2D 3D TSV |
US10173996 | 511 | 154 | HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 05/15/19 | 2D 3D TSV |
US10174003 | 329 | 106 | HGNC:29012 HGNC:13606 HGNC:17071 HGNC:18039 HGNC:20672 HGNC:13610 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 05/15/19 | 2D 3D TSV |
US9624188 | 12 | 12 | HGNC:6059 | IDO inhibitors | Bristol-Myers Squibb Co. | 05/15/19 | 2D 3D TSV |
US9624228 | 377 | 370 | HGNC:6871 | Inhibitors of ERK and methods of use | Kura Oncology Inc | 05/15/19 | 2D 3D TSV |
US9624201 | 20 | 20 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | F. Hoffmann-La Roche Inc | 05/15/19 | 2D 3D TSV |
US9623028 | 67 | 28 | HGNC:2068 HGNC:2069 HGNC:1470 HGNC:12401 | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof | Signal Pharmaceuticals, LLC | 05/15/19 | 2D 3D TSV |
US10173988 | 15 | 5 | HGNC:7889 HGNC:7891 HGNC:2578 | N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine | GLUCOX BIOTECH AB | 05/15/19 | 2D 3D TSV |
US9623021 | 24 | 12 | HGNC:3467 HGNC:3468 | Nuclear receptor binding agents | GTX Inc | 05/15/19 | 2D 3D TSV |
US9624247 | 107 | 27 | HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease | Novartis AG | 05/15/19 | 2D 3D TSV |
US9624246 | 30 | 15 | HGNC:17967 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | Merck Patent GmbH | 05/15/19 | 2D 3D TSV |
US10173995 | 7 | 6 | HGNC:8979 | Pyridine compounds used as PI3 kinase inhibitors | Teligene Ltd | 05/15/19 | 2D 3D TSV |
US9624218 | 112 | 32 | HGNC:270 HGNC:11941 HGNC:15677 | Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors | Eli Lilly and Company | 05/15/19 | 2D 3D TSV |
US10174007 | 40 | 18 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | Pfizer Inc | 05/15/19 | 2D 3D TSV | |
US9624205 | 12 | 6 | HGNC:3527 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme Inc | 05/15/19 | 2D 3D TSV |
US9624199 | 21 | 21 | HGNC:277 | Substituted bipiperidinyl derivatives | Bayer Pharma Aktiengesellschaft | 05/15/19 | 2D 3D TSV |
US10174015 | 92 | 46 | HGNC:3553 HGNC:736 | Substituted heterocyclic derivative, preparation method and use thereof | Xiamen University | 05/15/19 | 2D 3D TSV |
US9624198 | 15 | 14 | HGNC:277 | Substituted piperidinyltetrahydroquinolines | Bayer Pharma Aktiengesellschaft | 05/15/19 | 2D 3D TSV |
US10172868 | 103 | 52 | HGNC:6307 HGNC:1133 HGNC:6193 HGNC:3689 HGNC:3236 HGNC:3688 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. | 05/15/19 | 2D 3D TSV |
US10173991 | 590 | 589 | HGNC:6623 | Sulfone amide linked benzothiazole inhibitors of endothelial lipase | Bristol-Myers Squibb Co. | 05/15/19 | 2D 3D TSV |
US9624241 | 574 | 277 | Tricyclic heterocycles as BET protein inhibitors | Incyte Corporation | 05/15/19 | 2D 3D TSV | |
US10173990 | 17 | 17 | HGNC:17989 | URAT1 inhibitor | Nippon Chemiphar Co., Ltd | 05/15/19 | 2D 3D TSV |
US9617246 | 74 | 36 | HGNC:4849 HGNC:4848 | Thioether-piperidinyl orexin receptor antagonists | Merck Sharp & Dohme Corp | 05/10/19 | 2D 3D TSV |
US9617225 | 165 | 150 | HGNC:1780 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | VIROSTATICS SRL | 05/08/19 | 2D 3D TSV |
US9617262 | 62 | 62 | Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | Janssen Ireland | 05/08/19 | 2D 3D TSV | |
US9617267 | 761 | 86 | HGNC:2596 HGNC:9829 HGNC:1097 HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2621 | Compounds and methods for kinase modulation, and indications therefor | Plexxikon Inc. | 05/08/19 | 2D 3D TSV |
US9617226 | 45 | 44 | HGNC:895 | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG | 05/08/19 | 2D 3D TSV |
US9617273 | 122 | 68 | HGNC:270 HGNC:272 HGNC:15677 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors | BeiGene, Ltd | 05/08/19 | 2D 3D TSV |
US9617259 | 45 | 45 | HGNC:14063 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation Inc | 05/08/19 | 2D 3D TSV |
US9617242 | 237 | 77 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 05/08/19 | 2D 3D TSV |
US9617281 | 8 | 8 | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE S.A. | 05/08/19 | 2D 3D TSV | |
US9617260 | 34 | 34 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Hoffmann-La Roche Inc | 05/08/19 | 2D 3D TSV |
US9617282 | 218 | 216 | HGNC:17967 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. | 05/08/19 | 2D 3D TSV |
US9617269 | 97 | 96 | HGNC:8795 | N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof | Sun Yat-sen University | 05/08/19 | 2D 3D TSV |
US9617239 | 89 | 88 | HGNC:4696 | Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase | North Carolina Central University | 05/08/19 | 2D 3D TSV |
US9617250 | 26 | 13 | HGNC:3167 HGNC:3165 | Pyridin-4-yl derivatives | Actelion Pharmaceuticals Ltd | 05/08/19 | 2D 3D TSV |
US9617258 | 611 | 315 | HGNC:6193 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | Pfizer Inc | 05/08/19 | 2D 3D TSV |
US9617261 | 11 | 11 | HGNC:6840 | Substituted pyridinone compounds as MEK inhibitors | CMG PHARMACEUTICAL CO., LTD. | 05/08/19 | 2D 3D TSV |
US9617271 | 72 | 72 | HGNC:8772 | Triazolo compounds | Hoffmann-La Roche Inc | 05/08/19 | 2D 3D TSV |
US9617272 | 20 | 10 | HGNC:11708 HGNC:6059 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NewLink Genetics Corporation | 05/08/19 | 2D 3D TSV |
US9616063 | 30 | 15 | HGNC:7218 HGNC:12015 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | AstraZeneca AB | 05/07/19 | 2D 3D TSV |
US9617222 | 48 | 48 | HGNC:6307 | Alkynyl indazole derivative and use thereof | Senju Pharmaceutical Co., Ltd | 05/07/19 | 2D 3D TSV |
US9616064 | 137 | 77 | HGNC:10251 HGNC:10252 | Rho kinase inhibitors and methods of use | H. Lee Moffitt Cancer Center and Research Institute Inc | 05/07/19 | 2D 3D TSV |
US9616059 | 12 | 4 | HGNC:5465 HGNC:11393 HGNC:427 | Substituted indazole derivatives active as kinase inhibitors | Nerviano Medical Sciences srl | 05/07/19 | 2D 3D TSV |
US10172856 | 122 | 122 | HGNC:17383 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | Janssen Pharmaceutica NV | 04/30/19 | 2D 3D TSV |
US10172859 | 919 | 330 | HGNC:6251 HGNC:9413 | Arylquinazolines | Merck Patent GmbH | 04/30/19 | 2D 3D TSV |
US9611269 | 84 | 42 | HGNC:6190 HGNC:6192 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | Incyte Corporation | 04/30/19 | 2D 3D TSV |
US10172858 | 368 | 95 | HGNC:8979 HGNC:8978 HGNC:8980 HGNC:3942 HGNC:8977 | Combination pharmaceutical compositions and uses thereof | Intellikine LLC | 04/30/19 | 2D 3D TSV |
US9611270 | 21 | 14 | HGNC:2593 HGNC:2600 | Inhibitors of CYP17A1 | University of Kansas | 04/30/19 | 2D 3D TSV |
US10172837 | 11 | 11 | HGNC:1368 | Insulin sensitisers and methods of treatment | Naia Metabolic, Inc. | 04/30/19 | 2D 3D TSV |
US9611275 | 61 | 59 | HGNC:7056 | Permeable glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 04/30/19 | 2D 3D TSV |
US10172843 | 81 | 79 | HGNC:2545 | Piperidine derivatives | Hoffmann-La Roche Inc | 04/30/19 | 2D 3D TSV |
US9611277 | 990 | 259 | HGNC:4849 HGNC:4848 | Substituted 2-azabicycles and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 04/30/19 | 2D 3D TSV |
US10172845 | 2116 | 814 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc | 04/30/19 | 2D 3D TSV | |
US10172851 | 1229 | 556 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc | 04/30/19 | 2D 3D TSV | |
US10172814 | 213 | 157 | HGNC:9605 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | Bayer Pharma Aktiengesellschaft | 04/30/19 | 2D 3D TSV |
US10172864 | 1070 | 389 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals Inc | 04/30/19 | 2D 3D TSV | |
US9611229 | 39 | 39 | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders | LABORATORIOS DEL DR. ESTEVE S.A. | 04/29/19 | 2D 3D TSV | |
US9611249 | 35 | 34 | HGNC:4617 | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. | 04/29/19 | 2D 3D TSV |
US9611224 | 350 | 177 | HGNC:590 HGNC:591 | Antiproliferative benzo [B] azepin-2-ones | Hoffmann-La Roche Inc | 04/29/19 | 2D 3D TSV |
US9610264 | 16 | 15 | HGNC:6162 | Compounds for the treatment and prevention of retroviral infections | KFLP BIOTECH, LLC | 04/29/19 | 2D 3D TSV |
US9610299 | 42 | 12 | HGNC:6833 HGNC:6834 HGNC:404 | Compounds for the treatment of addiction | Gilead Sciences Inc | 04/29/19 | 2D 3D TSV |
US9611221 | 199 | 93 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 04/29/19 | 2D 3D TSV |
US9610322 | 10 | 10 | HGNC:5381 | Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof | President and Fellows of Harvard College | 04/29/19 | 2D 3D TSV |
US9611232 | 8 | 8 | HGNC:6293 | Oxazolidinone and imidazolidinone compounds | Hoffmann-La Roche Inc | 04/29/19 | 2D 3D TSV |
US9611261 | 846 | 397 | HGNC:2529 HGNC:933 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | Amgen Inc | 04/29/19 | 2D 3D TSV |
US9611222 | 152 | 151 | HGNC:10597 | Pyridine compounds and the uses thereof | Purdue Pharma LP | 04/29/19 | 2D 3D TSV |
US9611262 | 489 | 129 | HGNC:4849 HGNC:4848 | Substituted 2-azabicycles and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 04/29/19 | 2D 3D TSV |
US9611251 | 546 | 192 | HGNC:4849 HGNC:4848 | Substituted piperidine compounds and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 04/29/19 | 2D 3D TSV |
US9611259 | 3 | 3 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | Janssen Pharmaceutica NV | 04/29/19 | 2D 3D TSV | |
US9611267 | 699 | 232 | HGNC:3690 HGNC:3689 HGNC:3688 | Substituted tricyclic compounds as FGFR inhibitors | Incyte Holdings Corporation | 04/29/19 | 2D 3D TSV |
US9611252 | 146 | 145 | HGNC:6371 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. | 04/29/19 | 2D 3D TSV |
US9611265 | 241 | 79 | HGNC:8031 HGNC:8032 HGNC:8033 | Tropomyosin-related kinase (TRK) inhibitors | Genzyme Corporation | 04/29/19 | 2D 3D TSV |
US10167299 | 125 | 111 | HGNC:1606 HGNC:6251 | 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 04/24/19 | 2D 3D TSV |
US10167282 | 14 | 5 | HGNC:6251 | 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer | Cancer Research Technology Limited | 04/24/19 | 2D 3D TSV |
US9605007 | 135 | 118 | HGNC:6251 HGNC:933 HGNC:2625 | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | Pfizer Inc | 04/24/19 | 2D 3D TSV |
US10167261 | 20 | 9 | 2-oxo-3,4-dihydroquinolin-6-yl sulphonamide CPDS and their use as plant growth regulators | University of California | 04/24/19 | 2D 3D TSV | |
US9605006 | 15 | 15 | HGNC:933 | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines | Hoffmann-La Roche Inc | 04/24/19 | 2D 3D TSV |
US9605005 | 199 | 198 | HGNC:5960 | Alkynyl alcohols and methods of use | Genentech Inc | 04/24/19 | 2D 3D TSV |
US10167292 | 172 | 37 | Benzodiazepines as bromodomain inhibitors | Catalyst Therapeutics Pty Ltd. | 04/24/19 | 2D 3D TSV | |
US9605008 | 21 | 21 | HGNC:8784 | Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof | Bayer Pharma Aktiengesellschaft | 04/24/19 | 2D 3D TSV |
US10167279 | 409 | 305 | HGNC:9829 | Compounds and compositions as RAF kinase inhibitors | Novartis AG | 04/24/19 | 2D 3D TSV |
US10167276 | 207 | 69 | Compounds and methods for inhibiting JAK | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | 04/24/19 | 2D 3D TSV | |
US9604998 | 109 | 95 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 04/24/19 | 2D 3D TSV |
US9605022 | 39 | 20 | HGNC:592 | Macrocyclic compounds for inhibition of inhibitors of apoptosis | Ensemble Therapeutics Corp | 04/24/19 | 2D 3D TSV |
US9605024 | 9 | 9 | HGNC:3540 | PAR4 agonist peptides | Bristol-Myers Squibb Co. | 04/24/19 | 2D 3D TSV |
US10167256 | 8 | 4 | HGNC:3023 | Psychotrophic agents and uses thereof | LB PHARMACEUTICALS INC. | 04/24/19 | 2D 3D TSV |
US10167313 | 102 | 25 | HGNC:1506 HGNC:1508 HGNC:1504 HGNC:1499 HGNC:1511 | Selective caspase inhibitors and uses thereof | Genesis Technologies Limited | 04/24/19 | 2D 3D TSV |
US10167285 | 48 | 16 | HGNC:3430 HGNC:5253 | Small-molecule HSP90 inhibitors | Memorial Sloan-Kettering Cancer Center | 04/24/19 | 2D 3D TSV |
US10166249 | 952 | 228 | HGNC:3167 HGNC:10817 | Substituted bicyclic compounds | Bristol-Myers Squibb Co. | 04/24/19 | 2D 3D TSV |
US10167280 | 108 | 47 | HGNC:3529 | Substituted oxopyridine derivatives | Bayer Pharma Aktiengesellschaft | 04/24/19 | 2D 3D TSV |
US10167264 | 10 | 5 | HGNC:3236 | Substituted pyrimidines useful as EGFR-T790M kinase inhibitors | Jiangsu Medolution Ltd | 04/24/19 | 2D 3D TSV |
US10167270 | 175 | 127 | HGNC:4177 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | Northwestern University | 04/24/19 | 2D 3D TSV |
US10167281 | 213 | 119 | HGNC:8537 | Substituted thiazole or oxazole P2X7 receptor antagonists | Axxam S.P.A. | 04/24/19 | 2D 3D TSV |
US10166216 | 151 | 151 | Substituted triazoles useful as Axl inhibitors | Rigel Pharmaceuticals, Inc | 04/24/19 | 2D 3D TSV | |
US10167273 | 111 | 107 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | Takeda Pharmaceutical Co., Ltd | 04/24/19 | 2D 3D TSV | |
US10167296 | 99 | 67 | HGNC:7110 HGNC:7111 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATIONAL GMBH | 04/24/19 | 2D 3D TSV |
US10166239 | 241 | 78 | HGNC:8031 HGNC:8032 HGNC:8033 | Tropomyosin-related kinase (Trk) inhibitors | Genzyme Corporation | 04/24/19 | 2D 3D TSV |
US10167293 | 76 | 76 | HGNC:386 | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones | Bayer Pharma Aktiengesellschaft | 04/24/19 | 2D 3D TSV |
US9603834 | 27 | 26 | HGNC:1603 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | Allergan Inc | 04/23/19 | 2D 3D TSV |
US9604984 | 934 | 465 | HGNC:6190 HGNC:6192 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | Genentech Inc | 04/23/19 | 2D 3D TSV |
US9604960 | 81 | 27 | HGNC:11050 HGNC:11048 HGNC:11049 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | Albany Molecular Research, Inc. | 04/23/19 | 2D 3D TSV |
US9604944 | 6 | 2 | HGNC:5286 | Arylpiperazine derivatives and methods of utilizing same | Reviva Pharmaceuticals Inc | 04/23/19 | 2D 3D TSV |
US9603833 | 88 | 42 | HGNC:6833 HGNC:6834 HGNC:550 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-Tech Ueno, Ltd. | 04/23/19 | 2D 3D TSV |
US9604977 | 516 | 251 | HGNC:3560 HGNC:3559 | Bicyclic thiophenylamide compounds | Hoffman-La Roche Inc | 04/23/19 | 2D 3D TSV |
US9604926 | 226 | 99 | HGNC:3023 HGNC:4584 HGNC:11050 HGNC:8156 HGNC:11048 HGNC:11049 | Highly selective sigma receptor radioligands | The University of Mississippi | 04/23/19 | 2D 3D TSV |
US9604961 | 509 | 153 | HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 04/23/19 | 2D 3D TSV |
US9603889 | 86 | 43 | HGNC:592 | IAP antagonists | Bristol-Myers Squibb Co. | 04/23/19 | 2D 3D TSV |
US9604989 | 159 | 80 | HGNC:391 HGNC:392 | Imidazopyridazines as Akt kinase inhibitors | Bayer Intellectual Property GmbH | 04/23/19 | 2D 3D TSV |
US9603854 | 119 | 113 | HGNC:990 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier | 04/23/19 | 2D 3D TSV |
US9604931 | 24 | 12 | HGNC:3473 HGNC:3471 | Nuclear receptor binding agents | GTX Inc | 04/23/19 | 2D 3D TSV |
US9604982 | 678 | 116 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 04/23/19 | 2D 3D TSV |
US9603836 | 28 | 27 | HGNC:6059 | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | iTeos Therapeutics | 04/23/19 | 2D 3D TSV |
US9603819 | 13 | 13 | HGNC:7154 | Substituted aminobutyric derivatives as neprilysin inhibitors | Novartis AG | 04/23/19 | 2D 3D TSV |
US9604945 | 7 | 7 | HGNC:11049 | Sydnonimines-specific dopamine reuptake inhibitors and their use in treating dopamine related disorders | Caliper Life Sciences, Inc. | 04/23/19 | 2D 3D TSV |
US10166226 | 9 | 9 | CGRP receptor antagonists | Heptares Therapeutics Limited | 04/11/19 | 2D 3D TSV | |
US10166229 | 10 | 10 | HGNC:1504 | Compounds and methods for the treatment of cancer | University of Illinois | 04/11/19 | 2D 3D TSV |
US10155763 | 7 | 7 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | TIUMBIO CO., LTD. | 04/10/19 | 2D 3D TSV | |
US10155750 | 76 | 38 | HGNC:4849 HGNC:4848 | Amidoethyl azole orexin receptor antagonists | Merck Sharp & Dohme Corp | 04/10/19 | 2D 3D TSV |
US10155760 | 237 | 233 | HGNC:19679 | Biaryl kinase inhibitors | Bristol-Myers Squibb Co. | 04/10/19 | 2D 3D TSV |
US10155765 | 66 | 66 | HGNC:17967 | Carboxamide inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 04/10/19 | 2D 3D TSV |
US10155769 | 91 | 91 | HGNC:1406 | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | Janssen Pharmaceutica NV | 04/10/19 | 2D 3D TSV |
US10155768 | 520 | 197 | HGNC:9967 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 04/10/19 | 2D 3D TSV |
US10155752 | 16 | 12 | HGNC:10597 | Indazoles and use thereof | Purdue Pharma LP | 04/10/19 | 2D 3D TSV |
US10155733 | 27 | 27 | HGNC:1952 | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same | Conopco, Inc. | 04/10/19 | 2D 3D TSV |
US10155731 | 131 | 127 | HGNC:9958 | Nitrogen-containing saturated heterocyclic compound | Mitsubishi Tanabe Pharma Corporation | 04/10/19 | 2D 3D TSV |
US10155751 | 81 | 27 | Pyrazolyl-substituted heteroaryls and their use as medicaments | Boehringer Ingelheim International GmbH | 04/10/19 | 2D 3D TSV | |
US10155732 | 5 | 5 | HGNC:10452 | Ribonucleotide reductase inhibitors and methods of use | City of Hope | 04/10/19 | 2D 3D TSV |
US10155972 | 10 | 6 | HGNC:11708 | Screening method | Iomet Pharma Ltd. | 04/10/19 | 2D 3D TSV |
US10166214 | 284 | 169 | HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | Somatostatin receptor subtype 4 (SSTR4) agonists | Centrexion Therapeutics Corporation | 04/10/19 | 2D 3D TSV |
US10155775 | 8 | 8 | HGNC:3009 | Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors | Centaurus BioPharma Co., Ltd | 04/10/19 | 2D 3D TSV |
US10155764 | 114 | 111 | Therapeutic compounds and uses thereof | Genentech Inc | 04/10/19 | 2D 3D TSV | |
US10150759 | 3 | 3 | HGNC:3527 | 1,4-pyridone bicycic heteroaryl compounds | Epizyme Inc | 04/09/19 | 2D 3D TSV |
US10150755 | 127 | 89 | HGNC:6857 HGNC:7590 HGNC:11892 | ASK1 inhibitor compounds and uses thereof | SEAL ROCK THERAPEUTICS, INC. | 04/09/19 | 2D 3D TSV |
US9657003 | 40 | 20 | Androgen receptor modulating compounds | ORION CORPORATION | 04/09/19 | 2D 3D TSV | |
US10155722 | 20 | 20 | HGNC:5383 | Antitumor compound targeting IDH2 mutation and method of use thereof | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | 04/09/19 | 2D 3D TSV |
US10155002 | 334 | 185 | HGNC:3527 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme Inc | 04/09/19 | 2D 3D TSV |
US9657001 | 65 | 65 | HGNC:6719 | Compounds and uses | AstraZeneca AB | 04/09/19 | 2D 3D TSV |
US10150760 | 390 | 224 | HGNC:339 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | Amgen Inc | 04/09/19 | 2D 3D TSV |
US9656996 | 17 | 17 | HGNC:11892 | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | Shanghai Yingli Pharmaceutical Co., Ltd | 04/09/19 | 2D 3D TSV |
US9657009 | 168 | 150 | HGNC:17967 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | Bristol-Myers Squibb Co. | 04/09/19 | 2D 3D TSV |
US10150763 | 76 | 38 | HGNC:4852 HGNC:14064 | Histone deacetylase inhibitors and their use in therapy | Karus Therapeutics Limited | 04/09/19 | 2D 3D TSV |
US9656988 | 1351 | 352 | HGNC:1133 HGNC:6193 HGNC:3236 HGNC:6524 | Inhibitors of Bruton's tyrosine kinase | Pharmacyclics LLC | 04/09/19 | 2D 3D TSV |
US9656991 | 121 | 70 | HGNC:9753 | Inhibitors of glutaminyl cyclase | Probiodrug AG | 04/09/19 | 2D 3D TSV |
US10150765 | 843 | 286 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 04/09/19 | 2D 3D TSV |
US10150766 | 102 | 62 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 04/09/19 | 2D 3D TSV |
US10150758 | 30 | 29 | HGNC:10894 | PRMT5 inhibitors and uses thereof | Epizyme Inc | 04/09/19 | 2D 3D TSV |
US10155727 | 217 | 103 | HGNC:4586 HGNC:6251 | Pyrazoles | JANSSEN PHARMACEUTICALS, INC. | 04/09/19 | 2D 3D TSV |
US9657007 | 36 | 18 | HGNC:8979 HGNC:8978 HGNC:8977 HGNC:8976 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC | 04/09/19 | 2D 3D TSV |
US10150764 | 139 | 70 | HGNC:3527 | Substituted benzene compounds | Epizyme Inc | 04/09/19 | 2D 3D TSV |
US9657015 | 73 | 49 | HGNC:3309 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 04/09/19 | 2D 3D TSV |
US10150787 | 10 | 10 | HGNC:9650 | TC-PTP inhibitors as APC activators for immunotherapy | TBA | 04/09/19 | 2D 3D TSV |
US9657033 | 112 | 92 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | Lycera Corporation | 04/09/19 | 2D 3D TSV | |
US10150767 | 46 | 45 | Therapeutic compounds and uses thereof | Genentech Inc | 04/09/19 | 2D 3D TSV | |
US10150762 | 178 | 86 | Trifluoromethyl alcohols as modulators of RORγt | Janssen Pharmaceutica NV | 04/09/19 | 2D 3D TSV | |
US9656975 | 20 | 10 | HGNC:4579 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. Lundbeck A/S | 04/08/19 | 2D 3D TSV |
US9655879 | 188 | 94 | HGNC:9490 HGNC:9475 | Heteroarylcarboxylic acid ester derivative | EA Pharma Co., Ltd. | 04/08/19 | 2D 3D TSV |
US9656961 | 158 | 54 | HGNC:8156 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED | 04/08/19 | 2D 3D TSV |
US9656968 | 122 | 102 | HGNC:10597 | Pyrimidines as sodium channel blockers | TBA | 04/08/19 | 2D 3D TSV |
US9656955 | 808 | 790 | HGNC:7044 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Inc | 04/08/19 | 2D 3D TSV |
US9656962 | 87 | 47 | HGNC:8153 HGNC:8154 HGNC:8155 HGNC:8156 | Ring-contracted morphinans and the use thereof | Purdue Pharma LP | 04/08/19 | 2D 3D TSV |
US9656959 | 90 | 77 | HGNC:10597 | Substituted pyridines as sodium channel blockers | Purdue Pharma LP | 04/08/19 | 2D 3D TSV |
US9649308 | 246 | 175 | HGNC:8537 | Benzamide-containing compounds and their use in the treatment of pain | H. Lundbeck A/S | 04/03/19 | 2D 3D TSV |
US9650377 | 368 | 161 | HGNC:4597 HGNC:4593 | Diazepinone derivatives | Novartis AG | 04/03/19 | 2D 3D TSV |
US9650366 | 16 | 13 | HGNC:6307 HGNC:8804 HGNC:9437 | Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors | Allergan Inc | 04/03/19 | 2D 3D TSV |
US9650362 | 20 | 10 | HGNC:9753 | Inhibitors | Probiodrug AG | 04/03/19 | 2D 3D TSV |
US9650336 | 11 | 11 | Mono-fluoro beta-secretase inhibitors | AstraZeneca AB | 04/03/19 | 2D 3D TSV | |
US9650358 | 339 | 335 | HGNC:1780 | Pyridine CDK9 kinase inhibitors | AbbVie Inc | 04/03/19 | 2D 3D TSV |
US9650371 | 37 | 37 | HGNC:933 | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity | Shionogi & Co., Ltd | 04/03/19 | 2D 3D TSV |
US9649309 | 1394 | 400 | HGNC:7027 HGNC:12446 HGNC:3765 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | University of North Carolina at Chapel Hill | 04/03/19 | 2D 3D TSV |
US10150740 | 15 | 15 | 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection | Hoffmann-La Roche Inc | 03/31/19 | 2D 3D TSV | |
US10150728 | 704 | 701 | HGNC:85 | Alkylene derivatives | Shionogi & Co., Ltd | 03/31/19 | 2D 3D TSV |
US10144746 | 350 | 344 | HGNC:6371 | Bridged bicyclic kallikrein inhibitors | Global Blood Therapeutics, Inc. | 03/31/19 | 2D 3D TSV |
US10150743 | 28 | 13 | HGNC:15631 HGNC:15632 | Carboxylic acid compounds | Sumitomo Dainippon Pharma Co., Ltd | 03/31/19 | 2D 3D TSV |
US10149839 | 156 | 72 | HGNC:3467 | Chemical compounds | AstraZeneca AB | 03/31/19 | 2D 3D TSV |
US10149841 | 6 | 6 | HGNC:1232 | Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. | 03/31/19 | 2D 3D TSV |
US10150747 | 65 | 31 | Compounds for the treatment of hepatitis C | Bristol-Myers Squibb Co. | 03/31/19 | 2D 3D TSV | |
US10149835 | 7 | 7 | HGNC:7967 | Isoxazole derivatives as FXR agonists and methods of use thereof | Elmore Patent Law Group, P.C. | 03/31/19 | 2D 3D TSV |
US10149840 | 3 | 3 | HGNC:9221 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | 03/31/19 | 2D 3D TSV |
US10150751 | 82 | 41 | HGNC:4849 HGNC:4848 | Pyrrolidine orexin receptor antagonists | Merck Sharp & Dohme Corp | 03/31/19 | 2D 3D TSV |
US10143681 | 183 | 71 | HGNC:6371 HGNC:3529 | Factor XIa inhibitors | Merck Sharp & Dohme Corp | 03/30/19 | 2D 3D TSV |
US10138245 | 14 | 14 | HGNC:8772 | Fused triazole derivatives as phosphodiesterase 10A inhibitors | Celon Pharma S.A. | 03/30/19 | 2D 3D TSV |
US10143668 | 5 | 5 | HGNC:4879 | Hydroxy-substituted amino and ammonium derivatives and their medical use | GRI BIO, INC. | 03/30/19 | 2D 3D TSV |
US10138253 | 38 | 28 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 03/30/19 | 2D 3D TSV | |
US10143746 | 28 | 28 | Immunomodulators | Bristol-Myers Squibb Co. | 03/30/19 | 2D 3D TSV | |
US10144729 | 8 | 8 | HGNC:7967 | Isoxazole analogs as FXR agonists and methods of use thereof | Enanta Pharmaceuticals Inc | 03/30/19 | 2D 3D TSV |
US10143704 | 1 | 1 | Methods for treating cancer | Epizyme Inc | 03/30/19 | 2D 3D TSV | |
USRE47141 | 78 | 78 | Methods of treating fibrosis, cancer and vascular injuries | EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION | 03/30/19 | 2D 3D TSV | |
US10144731 | 519 | 257 | HGNC:7782 | Nrf2 regulators | GlaxoSmithKline | 03/30/19 | 2D 3D TSV |
US10144715 | 925 | 407 | HGNC:7966 HGNC:7965 | Piperazine derivatives as liver X receptor modulators | Vitae Pharmaceuticals Inc | 03/30/19 | 2D 3D TSV |
US10144738 | 148 | 35 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | Pfizer Inc | 03/30/19 | 2D 3D TSV |
US10138242 | 229 | 112 | HGNC:8856 | Pyrazolopyridine derivatives and their use in therapy | TBA | 03/30/19 | 2D 3D TSV |
US10143695 | 130 | 26 | HGNC:3430 | Pyrrolobenzodiazepines and conjugates thereof | Mersana Therapeutics, Inc. | 03/30/19 | 2D 3D TSV |
US10144742 | 520 | 520 | HGNC:30092 | Quinoxaline compounds and uses thereof | Millennium Pharmaceuticals Inc | 03/30/19 | 2D 3D TSV |
US10144734 | 2116 | 812 | HGNC:9967 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc | 03/30/19 | 2D 3D TSV |
US10138249 | 20 | 20 | HGNC:29079 | Triazolopyridines and triazolopyrazines as LSD1 inhibitors | Incyte Corporation | 03/30/19 | 2D 3D TSV |
US10137110 | 81 | 46 | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors | Bayer Pharma Aktiengesellschaft | 03/29/19 | 2D 3D TSV | |
US9597318 | 7 | 7 | HGNC:9035 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | Avexxin AS | 03/29/19 | 2D 3D TSV |
US9598446 | 65 | 65 | HGNC:2771 | Amino compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 03/29/19 | 2D 3D TSV |
US10138212 | 111 | 111 | HGNC:263 | Aminoquinazoline compounds as A2A antagonist | Merck Sharp & Dohme Corp | 03/29/19 | 2D 3D TSV |
US9598407 | 41 | 41 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | Janssen Ireland | 03/29/19 | 2D 3D TSV | |
US10137202 | 11 | 6 | HGNC:3590 | Antibody-drug conjugates and immunotoxins | Oncomatryx Biopharma, S.L. | 03/29/19 | 2D 3D TSV |
US10138230 | 125 | 123 | HGNC:3357 | Autotaxin inhibitors | Cancer Research Technology Limited | 03/29/19 | 2D 3D TSV |
US9597333 | 160 | 79 | HGNC:15631 HGNC:15632 | Benzazepine dicarboxamide compounds | Hoffmann-La Roche Inc | 03/29/19 | 2D 3D TSV |
US10138226 | 44 | 35 | Benzimidazol-2-amines as MIDH1 inhibitors | Bayer Pharma Aktiengesellschaft | 03/29/19 | 2D 3D TSV | |
US9597326 | 26 | 26 | HGNC:15631 | Benzonapthyridine compositions and uses thereof | GlaxoSmithKline | 03/29/19 | 2D 3D TSV |
US10131670 | 108 | 36 | HGNC:1884 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. | 03/29/19 | 2D 3D TSV |
US10131663 | 194 | 70 | HGNC:6251 HGNC:3467 | Chemical compounds | AstraZeneca AB | 03/29/19 | 2D 3D TSV |
US9598415 | 265 | 261 | Compounds as modulators of RORγ | Boehringer Ingelheim International GmbH | 03/29/19 | 2D 3D TSV | |
US9598431 | 15 | 4 | HGNC:10259 HGNC:10258 | Compounds useful for inhibiting ROR-gamma-t | Eli Lilly and Company | 03/29/19 | 2D 3D TSV |
US10138240 | 2 | 2 | Crystal of 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative | Daiichi Sankyo Company, Limited | 03/29/19 | 2D 3D TSV | |
US9597330 | 60 | 48 | HGNC:10597 | Drugs for treating respiratory diseases | Daiichi Sankyo Company, Limited | 03/29/19 | 2D 3D TSV |
US10138236 | 66 | 33 | HGNC:6371 HGNC:3529 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | Bayer Pharma Aktiengesellschaft | 03/29/19 | 2D 3D TSV |
US10138229 | 156 | 149 | HGNC:1133 | Heteroaromatic compounds as BTK inhibitors | Boehringer Ingelheim International GmbH | 03/29/19 | 2D 3D TSV |
US9598421 | 372 | 103 | HGNC:8780 HGNC:8781 HGNC:8783 | Imidazopyridazine compounds | Pfizer Inc | 03/29/19 | 2D 3D TSV |
US9597310 | 65 | 65 | HGNC:4498 | Indanyloxydihydrobenzofuranylacetic acids | Boehringer Ingelheim International GmbH | 03/29/19 | 2D 3D TSV |
US9598440 | 159 | 158 | HGNC:17967 | Inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 03/29/19 | 2D 3D TSV |
US10131664 | 178 | 174 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research Inc | 03/29/19 | 2D 3D TSV |
US10138228 | 4 | 4 | HGNC:7967 | Isoxazole derivatives as FXR agonists and methods of use therof | Enanta Pharmaceuticals Inc | 03/29/19 | 2D 3D TSV |
US10137122 | 244 | 116 | HGNC:2452 HGNC:4617 HGNC:4616 | Kinase inhibitors and methods of use thereof | The Broad Institute, Inc. | 03/29/19 | 2D 3D TSV |
US9598426 | 8 | 4 | HGNC:8775 HGNC:8774 | Organic compounds | Intra-Cellular Therapies Inc | 03/29/19 | 2D 3D TSV |
US9598447 | 72 | 14 | HGNC:8153 HGNC:8154 HGNC:8155 HGNC:8156 | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof | Purdue Pharma LP | 03/29/19 | 2D 3D TSV |
US10131673 | 42 | 41 | Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | Janssen Ireland | 03/29/19 | 2D 3D TSV | |
US9598370 | 55 | 24 | HGNC:1232 HGNC:12680 HGNC:14661 | Prolyl hydroxylase inhibitors and methods of use | Akebia Therapeutics, Inc. | 03/29/19 | 2D 3D TSV |
US9598381 | 18 | 17 | HGNC:20982 | SMYD2 inhibitors | AbbVie Inc | 03/29/19 | 2D 3D TSV |
US9598410 | 68 | 64 | HGNC:6278 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them | Sanofi | 03/29/19 | 2D 3D TSV |
US9598423 | 827 | 421 | HGNC:2453 HGNC:2452 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | Bristol-Myers Squibb Co. | 03/29/19 | 2D 3D TSV |
US10138222 | 122 | 120 | HGNC:10020 | Substituted benzamides as RIPK2 inhibitors | Boehringer Ingelheim International GmbH | 03/29/19 | 2D 3D TSV |
US10138241 | 97 | 97 | HGNC:10020 | Substituted benzamides as RIPK2 inhibitors | Boehringer Ingelheim International GmbH | 03/29/19 | 2D 3D TSV |
US9598411 | 172 | 73 | HGNC:8153 HGNC:8154 HGNC:8155 HGNC:8156 | Substituted benzimidazole-type piperidine compounds and uses thereof | Purdue Pharma LP | 03/29/19 | 2D 3D TSV |
US9598416 | 159 | 83 | HGNC:3690 HGNC:3688 | Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer | Bayer Intellectual Property GmbH | 03/29/19 | 2D 3D TSV |
US9598436 | 18 | 18 | HGNC:2593 | Substituted bicyclic heteroaryl compounds | Bristol-Myers Squibb Co. | 03/29/19 | 2D 3D TSV |
US9598401 | 63 | 46 | HGNC:5286 | Substituted heteroaryl compounds and methods of use thereof | Sunshine Lake Pharma Co., Ltd | 03/29/19 | 2D 3D TSV |
US9597317 | 74 | 37 | HGNC:6342 HGNC:3765 | Substituted indazole derivatives active as kinase inhibitiors | Nerviano Medical Sciences srl | 03/29/19 | 2D 3D TSV |
US10137124 | 1229 | 557 | HGNC:9967 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc | 03/29/19 | 2D 3D TSV |
US10131667 | 699 | 231 | HGNC:3690 HGNC:3689 HGNC:3688 | Substituted tricyclic compounds as FGFR inhibitors | Incyte Corporation | 03/29/19 | 2D 3D TSV |
US9598396 | 39 | 19 | HGNC:270 HGNC:15677 | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors | Janssen Pharmaceutica NV | 03/29/19 | 2D 3D TSV |
US9598405 | 52 | 44 | HGNC:11491 | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors | Merck Sharp & Dohme Corp | 03/29/19 | 2D 3D TSV |
US10137210 | 9 | 9 | HGNC:620 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | The University of Pittsburgh—Of the Commonwealth System of Higher Education | 03/29/19 | 2D 3D TSV |
US10131675 | 153 | 152 | HGNC:6851 | Tricyclic DLK inhibitors and uses thereof | Genentech Inc | 03/29/19 | 2D 3D TSV |
US9598387 | 260 | 129 | HGNC:3023 HGNC:3024 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | Southern Research Institute | 03/29/19 | 2D 3D TSV |
US10131692 | 88 | 43 | HGNC:897 HGNC:896 | Vasopressin-2 receptor agonists | Ferring B.V. | 03/29/19 | 2D 3D TSV |
US10130619 | 70 | 70 | HGNC:7889 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA | 03/28/19 | 2D 3D TSV |
US10131658 | 37 | 34 | HGNC:6141 | Anti-alphavbeta1 integrin compounds and methods | The Regents of the University of California | 03/28/19 | 2D 3D TSV |
US10131645 | 33 | 33 | Benzofurans substituted with primary benzamide as HCV inhibitors | Bristol-Myers Squibb Co. | 03/28/19 | 2D 3D TSV | |
US10130617 | 18 | 9 | HGNC:3467 | Chemical compounds | AstraZeneca AB | 03/28/19 | 2D 3D TSV |
US10130633 | 700 | 254 | HGNC:15983 | Compounds | Bayer Pharma Aktiengesellschaft | 03/28/19 | 2D 3D TSV |
US10130622 | 11 | 4 | HGNC:1884 | Compounds for treatment of cystic fibrosis | AbbVie S.á.r.l. | 03/28/19 | 2D 3D TSV |
US10130642 | 65 | 64 | HGNC:7154 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 03/28/19 | 2D 3D TSV |
US10131648 | 98 | 97 | HGNC:4498 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | Janssen Pharmaceutica NV | 03/28/19 | 2D 3D TSV |
US10131651 | 13 | 9 | HGNC:4498 | [7,6]-fused bicyclic antidiabetic compounds | Merck Sharp & Dohme Corp | 03/28/19 | 2D 3D TSV |
US9593097 | 435 | 405 | Axl inhibitors | Pfizer Inc | 03/15/19 | 2D 3D TSV | |
US9593099 | 22 | 22 | HGNC:1097 | Compounds and compositions as protein kinase inhibitors | Array BioPharma Inc | 03/15/19 | 2D 3D TSV |
US9593100 | 23 | 23 | HGNC:1097 | Compounds and compositions as protein kinase inhibitors | Array BioPharma Inc | 03/15/19 | 2D 3D TSV |
US9593127 | 20 | 20 | HGNC:4597 | Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors | RECORDATI IRELAND LTD. | 03/15/19 | 2D 3D TSV |
US9593123 | 194 | 97 | HGNC:2160 HGNC:2159 | Triazolo[4,5-D]pyrimidine derivatives | Hoffmann-La Roche Inc | 03/15/19 | 2D 3D TSV |
US9592235 | 219 | 214 | HGNC:6866 | Aminoquinazoline and pyridopyrimidine derivatives | Genentech Inc | 03/14/19 | 2D 3D TSV |
US9593105 | 223 | 144 | HGNC:8537 | Cyclic amines | H. Lundbeck A/S | 03/14/19 | 2D 3D TSV |
US9593110 | 201 | 168 | HGNC:7154 | Neprilysin inhibitors | Theravence Biopharma R&D IP, LLC | 03/14/19 | 2D 3D TSV |
US9592230 | 125 | 125 | HGNC:8772 | Substituted imidazoles as PDE10A inhibitors | H. Lundbeck A/S | 03/14/19 | 2D 3D TSV |
US10125145 | 31 | 29 | HGNC:5297 | 5-HT3 receptor antagonists | Takeda Pharmaceutical Co., Ltd | 03/12/19 | 2D 3D TSV |
US10125150 | 26 | 26 | HGNC:6190 | Crystalline forms of a PI3K inhibitor | Incyte Corporation | 03/12/19 | 2D 3D TSV |
US9593113 | 85 | 83 | HGNC:7978 | Imide and acylurea derivatives as modulators of the glucocorticoid receptor | Bristol-Myers Squibb Co. | 03/12/19 | 2D 3D TSV |
US9593121 | 14 | 14 | HGNC:25581 | Indole substituted pyrrolopyrimidinyl inhibitors of Uba6 | Millennium Pharmaceuticals Inc | 03/12/19 | 2D 3D TSV |
US9593129 | 497 | 406 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | Amgen Inc | 03/12/19 | 2D 3D TSV | |
US10125148 | 28 | 27 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 03/12/19 | 2D 3D TSV | |
US10125097 | 18 | 18 | HGNC:9358 | 1- [1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | Universitat de Barcelona | 03/11/19 | 2D 3D TSV |
US10125111 | 99 | 97 | Benzofuran compounds for the treatment of hepatitis C | Bristol-Myers Squibb Co. | 03/11/19 | 2D 3D TSV | |
US10125137 | 10 | 10 | Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors | Bristol-Myers Squibb Co. | 03/11/19 | 2D 3D TSV | |
US10124009 | 14 | 7 | HGNC:13575 | Bromodomain inhibitors | Tensha Therapeutics, Inc. | 03/11/19 | 2D 3D TSV |
US10125135 | 51 | 47 | HGNC:3467 | Chemical compounds | AstraZeneca AB | 03/11/19 | 2D 3D TSV |
US10123995 | 32 | 20 | HGNC:3529 | Factor XIa inhibitors | Merck Sharp & Dohme Corp | 03/11/19 | 2D 3D TSV |
US10125118 | 458 | 450 | HGNC:7027 | Heteroaryl compounds and their use as therapeutic drugs | Dong-A Socio Holdings Co., Ltd. | 03/11/19 | 2D 3D TSV |
US10117875 | 20 | 20 | HGNC:15633 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. | 03/11/19 | 2D 3D TSV |
US10125101 | 123 | 45 | HGNC:4498 HGNC:2622 HGNC:2623 | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 03/11/19 | 2D 3D TSV |
US10112968 | 7 | 7 | Inhibitors of protein methyltransferase DOT1L and methods of use thereof | Epizyme Inc | 03/11/19 | 2D 3D TSV | |
US10112955 | 73 | 53 | HGNC:7110 HGNC:7111 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | eFFECTOR Therapeutics Inc | 03/11/19 | 2D 3D TSV |
US10118894 | 7 | 7 | Isoindolinone derivatives useful as antiviral agents | ViiV HEALTHCARE UK LIMITED | 03/11/19 | 2D 3D TSV | |
US10118915 | 563 | 548 | HGNC:8154 | Kappa opioid ligands | The Scripps Research Institute | 03/11/19 | 2D 3D TSV |
US10125100 | 197 | 73 | HGNC:11491 HGNC:11283 HGNC:6251 HGNC:4616 HGNC:6876 | Kinase inhibitors | Topivert Pharma Limited | 03/11/19 | 2D 3D TSV |
US10125125 | 58 | 58 | HGNC:10499 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | Active Biotech AB | 03/11/19 | 2D 3D TSV |
US10123984 | 50 | 47 | HGNC:7154 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 03/11/19 | 2D 3D TSV |
US10118929 | 6 | 3 | HGNC:6161 HGNC:6163 | Nonanoic and decanoic acid derivatives and uses thereof | SciFluor Life Sciences, Inc. | 03/11/19 | 2D 3D TSV |
US10118918 | 49 | 48 | HGNC:10894 | PRMT5 inhibitors and uses thereof | Epizyme Inc | 03/11/19 | 2D 3D TSV |
US10118930 | 465 | 459 | HGNC:9051 | Piperidinylpyrazolopyrimidinones and their use | Bayer Pharma Aktiengesellschaft | 03/11/19 | 2D 3D TSV |
US10117858 | 15 | 13 | HGNC:1884 | Pyridine and pyrazine derivative for the treatment of CF | Novartis AG | 03/11/19 | 2D 3D TSV |
US10125144 | 60 | 30 | HGNC:10251 HGNC:10252 | Rho kinase inhibitors | Kadmon Corporation LLC | 03/11/19 | 2D 3D TSV |
US10118902 | 223 | 210 | HGNC:8039 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute | 03/11/19 | 2D 3D TSV |
US10117864 | 67 | 62 | HGNC:9600 | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | Bayer Pharma Aktiengesellschaft | 03/11/19 | 2D 3D TSV |
US10125133 | 13 | 13 | HGNC:29079 | Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors | Incyte Corporation | 03/11/19 | 2D 3D TSV |
US10117944 | 14 | 14 | HGNC:3430 | Targeted therapeutics | Madrigal Pharmaceuticals Inc | 03/11/19 | 2D 3D TSV |
US10124003 | 52 | 49 | HGNC:3689 | Therapeutic agent for FGFR inhibitor-resistant cancer | Taiho Pharmaceutical Co., Ltd | 03/11/19 | 2D 3D TSV |
US10112941 | 441 | 334 | HGNC:13575 | Tricyclic compounds as anticancer agents | Bristol-Myers Squibb Co. | 03/11/19 | 2D 3D TSV |
US10111866 | 2 | 2 | Compounds as rearranged during transfection (RET) inhibitors | GlaxoSmithKline | 03/10/19 | 2D 3D TSV | |
US10112934 | 40 | 20 | HGNC:2160 HGNC:2159 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | Centrexion Therapeutics Corporation | 03/04/19 | 2D 3D TSV |
US10112931 | 783 | 397 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | Novartis AG | 03/04/19 | 2D 3D TSV | |
US10112932 | 62 | 20 | HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 | Benzoxazepin oxazolidinone compounds and methods of use | Genentech Inc | 03/04/19 | 2D 3D TSV |
US10112944 | 41 | 37 | HGNC:11892 | Heterocyclic compounds useful as inhibitors of TNF | Bristol-Myers Squibb Co. | 03/04/19 | 2D 3D TSV |
US10112940 | 116 | 115 | HGNC:17071 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 03/04/19 | 2D 3D TSV |
US10112935 | 516 | 247 | HGNC:10251 HGNC:10252 | Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | Lycera Corporation | 03/04/19 | 2D 3D TSV |
US10112928 | 32 | 32 | Inhibitors of SYK | Hoffmann-La Roche Inc | 03/04/19 | 2D 3D TSV | |
US10112929 | 379 | 248 | HGNC:10252 | Lactams as inhibitors of rock | Bristol-Myers Squibb Co. | 03/04/19 | 2D 3D TSV |
US10112937 | 1877 | 363 | HGNC:8537 | P2X7 modulators and methods of use | Janssen Pharmaceutica NV | 03/04/19 | 2D 3D TSV |
US10112950 | 116 | 116 | HGNC:29079 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | Incyte Corporation | 03/04/19 | 2D 3D TSV |
US10112942 | 1229 | 555 | HGNC:9967 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc | 03/04/19 | 2D 3D TSV |
US10112939 | 112 | 103 | HGNC:10252 | Tied-back benzamide derivatives as potent rock inhibitors | Bristol-Myers Squibb Co. | 03/04/19 | 2D 3D TSV |
US9586925 | 22 | 11 | HGNC:108 HGNC:983 | 1-(dimethylamino)ethyl-substituted 6H-benzo[C]chromen-6-ones against senile dementia | NOBEL ILAÇ | 03/02/19 | 2D 3D TSV |
US9586950 | 104 | 25 | HGNC:4849 HGNC:4848 | 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists | Merck Sharp & Dohme Corp | 03/02/19 | 2D 3D TSV |
US10112926 | 1455 | 226 | HGNC:8979 HGNC:8978 HGNC:8984 HGNC:3942 HGNC:8974 HGNC:8977 HGNC:8976 | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors | Novartis AG | 03/02/19 | 2D 3D TSV |
US9586945 | 38 | 35 | HGNC:7044 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG | 03/02/19 | 2D 3D TSV |
US9586942 | 17 | 17 | HGNC:7044 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG | 03/02/19 | 2D 3D TSV |
US10112895 | 14 | 14 | Antivirals against molluscum contagiosum virus | University of Pennsylvania | 03/02/19 | 2D 3D TSV | |
US9586949 | 157 | 78 | HGNC:8978 HGNC:8977 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | Incyte Corporation | 03/02/19 | 2D 3D TSV |
US9586962 | 903 | 449 | HGNC:4849 HGNC:4848 | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV | 03/02/19 | 2D 3D TSV |
US9585879 | 28 | 28 | HGNC:4617 | Heterocyclic GSK-3 allosteric modulators | Consejo Superior de Investigaciones Cientificas (CSIC) | 03/02/19 | 2D 3D TSV |
US9586970 | 27 | 27 | HGNC:8772 | Imidazole derivatives | Hoffmann-La Roche Inc | 03/02/19 | 2D 3D TSV |
US10112922 | 40 | 19 | HGNC:1133 HGNC:6171 | Inhibitor of bruton's tyrosine kinase | Centaurus BioPharma Co., Ltd | 03/02/19 | 2D 3D TSV |
US9586948 | 51 | 51 | HGNC:17967 | Inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 03/02/19 | 2D 3D TSV |
US10112899 | 326 | 315 | Isoindoline derivatives for use in the treatment of a viral infection | ViiV HEALTHCARE UK LIMITED | 03/02/19 | 2D 3D TSV | |
US9586965 | 16 | 4 | HGNC:6190 HGNC:6192 HGNC:1133 HGNC:6193 | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases | ACEA BIOSCIENCES INC. | 03/02/19 | 2D 3D TSV |
US9586900 | 121 | 121 | HGNC:4479 | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Co. | 03/02/19 | 2D 3D TSV |
US10111875 | 18 | 6 | HGNC:6190 HGNC:6192 HGNC:6193 | Pyrrolopyrimidine compounds and uses thereof | HUTCHINSON MEDIPHARMA LIMITED | 03/02/19 | 2D 3D TSV |
US10112911 | 75 | 75 | Substituted cyanoguanidines as oral anti-virals | AbbVie Inc | 03/02/19 | 2D 3D TSV | |
US10112907 | 52 | 13 | Substituted indazoles for treating tendon and/or ligament injuries | Novartis AG | 03/02/19 | 2D 3D TSV | |
US9585881 | 56 | 19 | HGNC:3528 HGNC:3529 HGNC:3535 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | Ono Pharmaceutical Co., Ltd | 03/02/19 | 2D 3D TSV |
US9586959 | 169 | 110 | HGNC:5297 HGNC:17383 HGNC:5184 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES | 03/02/19 | 2D 3D TSV |
US10106550 | 6 | 6 | HGNC:270 | Aza-phenalene-3-ketone derivative, preparation method thereof, and its application as PARP inhibitor | SUZHOU KANGRUN PHARMACEUTICALS INC. | 02/24/19 | 2D 3D TSV |
US10106522 | 12 | 12 | HGNC:5182 | Benzimidazole derivatives as antihistamine agents | Faes Farma SA | 02/24/19 | 2D 3D TSV |
US10106552 | 43 | 43 | HGNC:24615 | Compounds inhibiting eukaryotic elongation factor 2 kinase activity | Longevica Pharmaceuticals, Inc. | 02/24/19 | 2D 3D TSV |
US10106521 | 18 | 9 | HGNC:108 HGNC:983 | Eckol derivatives, methods of synthesis and uses thereof | Phloronol, Inc. | 02/24/19 | 2D 3D TSV |
US10106571 | 23 | 22 | HCV polymerase inhibitors | Medivir AB | 02/24/19 | 2D 3D TSV | |
US10106535 | 45 | 45 | HGNC:14063 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation Inc | 02/24/19 | 2D 3D TSV |
US10106534 | 274 | 216 | HGNC:29012 HGNC:17071 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 02/24/19 | 2D 3D TSV |
US10106527 | 488 | 237 | HGNC:4617 HGNC:3091 | Isoquinolin-3-yl carboxamides and preparation and use thereof | Samumed, LLC | 02/24/19 | 2D 3D TSV |
US10106501 | 428 | 416 | Nuclear receptor modulators | AbbVie Inc | 02/24/19 | 2D 3D TSV | |
US10106557 | 26 | 6 | HGNC:9475 HGNC:3528 HGNC:3535 | Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof | NORTH CHINA PHARMACEUTICAL NEW DRUG R&D CO., LTD. | 02/24/19 | 2D 3D TSV |
US10106504 | 83 | 68 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 02/24/19 | 2D 3D TSV | |
US10106508 | 94 | 47 | HGNC:3236 | Quinazoline heterocyclic compound as EGFR kinase inhibitor and preparation and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED | 02/24/19 | 2D 3D TSV |
US10106553 | 70 | 70 | HGNC:4498 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | Janssen Pharmaceutica NV | 02/24/19 | 2D 3D TSV |
US10106510 | 60 | 59 | Substituted isoxazoles for treating cancer | Epizyme Inc | 02/24/19 | 2D 3D TSV | |
US10106559 | 152 | 43 | HGNC:6192 HGNC:1133 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | Bristol-Myers Squibb Co. | 02/24/19 | 2D 3D TSV |
US10100045 | 36 | 36 | HGNC:1406 | 3-aryl-2H-pyrazolo[4,3-b]pyridine compounds and their use as AMPA receptor modulators | Janssen Pharmaceutica NV | 02/21/19 | 2D 3D TSV |
US10100030 | 25 | 13 | HGNC:11526 HGNC:2637 | Carboxymethyl piperidine derivative | Kissei Pharmaceutical Co., Ltd | 02/21/19 | 2D 3D TSV |
US10100051 | 14 | 14 | HGNC:1232 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. | 02/21/19 | 2D 3D TSV |
US10100058 | 717 | 364 | HGNC:1462 | Fused heterocyclic compounds as CaM kinase inhibitors | Gilead Sciences Inc | 02/21/19 | 2D 3D TSV |
US10100048 | 7 | 7 | HGNC:4617 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG | 02/21/19 | 2D 3D TSV |
US10100057 | 199 | 198 | HGNC:4597 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK Biopharmaceuticals Co. Ltd | 02/21/19 | 2D 3D TSV |
US10100046 | 31 | 30 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research Inc | 02/21/19 | 2D 3D TSV |
US10100049 | 112 | 27 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC | 02/21/19 | 2D 3D TSV |
US10100019 | 177 | 72 | HGNC:6091 HGNC:427 | N2-(2-methoxyphenyl)pyrimidine derivative, method for preparing same, and pharmaceutical composition for cancer prevention or treatment containing same as active ingredient | Korea Research Institute of Chemical Technology | 02/21/19 | 2D 3D TSV |
US10105349 | 6 | 6 | Organic compounds | Intra-Cellular Therapies Inc | 02/21/19 | 2D 3D TSV | |
US10105367 | 304 | 300 | HGNC:8775 | Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones | Dart NeuroScience (Cayman) Ltd | 02/21/19 | 2D 3D TSV |
US9580437 | 709 | 243 | HGNC:17101 | Triazolopyrimidine compounds and uses thereof | Novartis AG | 02/21/19 | 2D 3D TSV |
US10100042 | 12 | 10 | HGNC:4498 | [5,6]—fused bicyclic antidiabetic compounds | Merck Sharp & Dohme Corp | 02/21/19 | 2D 3D TSV |
US9580418 | 156 | 52 | HGNC:19310 HGNC:8987 | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors | Incyte Corporation | 02/19/19 | 2D 3D TSV |
US9580423 | 200 | 37 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 02/19/19 | 2D 3D TSV |
US9580396 | 112 | 56 | HGNC:934 HGNC:933 | C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 02/19/19 | 2D 3D TSV |
US9580449 | 298 | 295 | HGNC:1133 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH | 02/19/19 | 2D 3D TSV |
US9580415 | 36 | 21 | HGNC:6251 HGNC:550 | Compounds | Proximagen Limited | 02/19/19 | 2D 3D TSV |
US9580412 | 102 | 21 | HGNC:4540 HGNC:1605 HGNC:1607 HGNC:6026 HGNC:6027 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | Galderma Research & Development | 02/19/19 | 2D 3D TSV |
US9580432 | 134 | 84 | HGNC:1133 HGNC:3236 | Fused pyrimidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 02/19/19 | 2D 3D TSV |
US9579320 | 492 | 473 | HGNC:11491 | Inhibitors of syk and JAK protein kinases | Portola Pharmaceuticals Inc | 02/19/19 | 2D 3D TSV |
US9579407 | 4 | 4 | HGNC:8772 | Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals | Takeda Pharmaceutical Co., Ltd | 02/19/19 | 2D 3D TSV |
US9580411 | 11 | 10 | HGNC:497 | Substituted sulfonamide compounds | Hoffmann-La Roche Inc | 02/19/19 | 2D 3D TSV |
US9580442 | 52 | 13 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | Karus Therapeutics Limited | 02/19/19 | 2D 3D TSV |
US10098883 | 105 | 101 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | Bayer Pharma Aktiengesellschaft | 02/18/19 | 2D 3D TSV | |
US10100018 | 136 | 83 | HGNC:3166 | Amide derivatives as lysophosphatidic acid receptor antagonists | Takeda Pharmaceutical Co., Ltd | 02/18/19 | 2D 3D TSV |
US10098902 | 131 | 66 | HGNC:663 HGNC:664 | Arginase inhibitors as therapeutics | Mars, Incorporated | 02/18/19 | 2D 3D TSV |
US10100016 | 53 | 53 | HGNC:17989 | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | Shanghai Yingli Pharmaceutical Co., Ltd | 02/18/19 | 2D 3D TSV |
US10099993 | 358 | 176 | HGNC:4595 HGNC:4594 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | Sanford-Burnham Medical Research Institute | 02/18/19 | 2D 3D TSV |
US10098900 | 5 | 5 | HGNC:1133 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | Zhejiang DTRM Biopharma Co. Ltd | 02/18/19 | 2D 3D TSV |
US10098888 | 22 | 3 | HGNC:2625 HGNC:3527 HGNC:2622 HGNC:2623 HGNC:2621 | Substituted benzene compounds | Epizyme Inc | 02/18/19 | 2D 3D TSV |
US10093671 | 40 | 37 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | Hoffmann-La Roche Inc | 01/23/19 | 2D 3D TSV | |
US9573958 | 74 | 73 | HGNC:6171 | Benzimidazole derivatives as ITK inhibitors | Principia Biopharma Inc | 01/23/19 | 2D 3D TSV |
US9572792 | 5 | 5 | HGNC:3165 | Coumarin compounds as receptor modulators with therapeutic utility | Allergan Inc | 01/23/19 | 2D 3D TSV |
US9572802 | 96 | 92 | HGNC:1952 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | Theravance Respiratory Company LLC | 01/23/19 | 2D 3D TSV |
US10093683 | 74 | 58 | HGNC:3529 | Factor XIa inhibitors | Merck Sharp & Dohme Corp | 01/23/19 | 2D 3D TSV |
US10093697 | 12 | 11 | HGNC:10906 | IBAT inhibitors for the treatment of liver diseases | TBA | 01/23/19 | 2D 3D TSV |
US9573957 | 151 | 151 | HGNC:6710 | Inhibitors of leukotriene production | Boehringer Ingelheim International GmbH | 01/23/19 | 2D 3D TSV |
US9573930 | 122 | 119 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research Inc | 01/23/19 | 2D 3D TSV |
US9573961 | 95 | 88 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 01/23/19 | 2D 3D TSV |
US9573943 | 86 | 29 | HGNC:19310 HGNC:8987 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | Genentech Inc | 01/23/19 | 2D 3D TSV |
US10092575 | 221 | 217 | HGNC:8775 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | Dart NeuroScience (Cayman) Ltd | 01/23/19 | 2D 3D TSV |
US10093673 | 15 | 13 | Tetracyclic pyridone compounds as antivirals | Novartis AG | 01/23/19 | 2D 3D TSV | |
US9572811 | 103 | 89 | HGNC:1133 | Treatment of dry eye | Principia Biopharma Inc | 01/23/19 | 2D 3D TSV |
US10093646 | 286 | 292 | HGNC:6943 HGNC:936 HGNC:992 HGNC:9644 | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | Novartis AG | 01/22/19 | 2D 3D TSV |
US10093664 | 74 | 72 | HGNC:6851 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | The University of Texas System | 01/22/19 | 2D 3D TSV |
US10093631 | 12 | 6 | HGNC:12805 HGNC:17989 | Bifunctional compounds and use for reducing uric acid levels | Acquist LLC | 01/22/19 | 2D 3D TSV |
US10093658 | 29 | 14 | HGNC:12805 HGNC:17989 | Bifunctional compounds and use for reducing uric acid levels | Acquist LLC | 01/22/19 | 2D 3D TSV |
US10093651 | 5 | 5 | HGNC:32311 | Ghrelin O-acyl transferase inhibitors | Eli Lilly and Company | 01/22/19 | 2D 3D TSV |
US10093655 | 81 | 77 | HGNC:3020 | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc | 01/22/19 | 2D 3D TSV |
US10093635 | 56 | 56 | HGNC:17038 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. | 01/22/19 | 2D 3D TSV |
US10093663 | 110 | 89 | HGNC:1037 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | Novartis AG | 01/22/19 | 2D 3D TSV |
US10093660 | 261 | 220 | HGNC:7110 HGNC:7111 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATONAL GMBH | 01/22/19 | 2D 3D TSV |
US10093650 | 24 | 23 | HGNC:7045 | Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors | Bristol-Myers Squibb Co. | 01/22/19 | 2D 3D TSV |
US10092570 | 368 | 340 | HGNC:8977 | Heterocyclylamines as PI3K inhibitors | Incyte Holdings Corporation | 01/18/19 | 2D 3D TSV |
US10092529 | 7 | 7 | Necrosis inhibitors | National Institute of Biological Sciences, Beijing | 01/18/19 | 2D 3D TSV | |
US10092563 | 408 | 133 | HGNC:8978 HGNC:8980 HGNC:8977 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences Inc | 01/18/19 | 2D 3D TSV |
US10092556 | 28 | 14 | HGNC:11393 HGNC:11390 | Piperidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 01/18/19 | 2D 3D TSV |
US10087191 | 87 | 87 | HGNC:4485 | Piperidine derivative and preparation method and pharmaceutical use thereof | Jiangsu Hengrui Medicine Co., Ltd. | 01/18/19 | 2D 3D TSV |
US10092551 | 173 | 167 | HGNC:895 | Spiro-thiazolones | Hoffmann-La Roche Inc | 01/18/19 | 2D 3D TSV |
US10087144 | 18 | 18 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | UCL Business PLC | 01/17/19 | 2D 3D TSV | |
US10085988 | 5 | 5 | Aglaroxin C and derivatives as HCV entry inhibitors | SRI International | 01/17/19 | 2D 3D TSV | |
US10085983 | 38 | 19 | HGNC:3236 | Azabicyclo derivatives, process for preparation thereof and medical use thereof | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 01/17/19 | 2D 3D TSV |
US10087188 | 204 | 192 | HGNC:1133 | Benzamide imidazopyrazine Btk inhibitors | Merck Sharp & Dohme Corp | 01/17/19 | 2D 3D TSV |
US10087167 | 32 | 32 | Benzofurans substituted with secondary benzamide as HCV inhibitors | Bristol-Myers Squibb Co. | 01/17/19 | 2D 3D TSV | |
US10087181 | 30 | 30 | HGNC:15983 | Compound as WNT signaling inhibitor, composition, and use thereof | CUREGENIX, INC. | 01/17/19 | 2D 3D TSV |
US10087185 | 125 | 122 | HGNC:13628 | Fused bicylic pyridine compounds and their use as AMPA receptor modulators | Janssen Pharmaceutica NV | 01/17/19 | 2D 3D TSV |
US10087187 | 510 | 91 | HGNC:8978 HGNC:8971 HGNC:8972 HGNC:3942 HGNC:8977 | Imidazopyridazine derivatives as PI3KB inhibitors | Janssen Pharmaceutica NV | 01/17/19 | 2D 3D TSV |
US10085984 | 272 | 135 | HGNC:2592 HGNC:2591 | Metalloenzyme inhibitor compounds | Viamet Pharmaceuticals (Bermuda), Ltd. | 01/17/19 | 2D 3D TSV |
US10087143 | 160 | 158 | HGNC:10582 | Pyridone amides as modulators of sodium channels | Vertex Pharmaceuticals Inc | 01/17/19 | 2D 3D TSV |
US10085986 | 20 | 20 | HGNC:2671 | Pyrimidinone compounds and their use | Takeda Pharmaceutical Co., Ltd | 01/17/19 | 2D 3D TSV |
US9567341 | 72 | 22 | HGNC:4586 HGNC:6251 HGNC:2625 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | Rugen Holdings (Cayman) Limited | 01/17/19 | 2D 3D TSV |
US10087148 | 49 | 49 | HGNC:11049 | Quinazolines as biogenic amine transport modulators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTE OF HEALTH | 01/17/19 | 2D 3D TSV |
US9567334 | 150 | 147 | HGNC:3688 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | Principia Biopharma Inc | 01/17/19 | 2D 3D TSV |
US9567324 | 34 | 25 | HGNC:6307 HGNC:8804 | Substituted nicotinamide derivatives as kinase inhibitors | Allergan Inc | 01/17/19 | 2D 3D TSV |
US10087178 | 163 | 160 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | Japan Tobacco Inc | 01/17/19 | 2D 3D TSV | |
US10086000 | 131 | 124 | Tricyclic compounds as inhibitors of mutant IDH enzymes | Merck Sharp & Dohme Corp | 01/17/19 | 2D 3D TSV | |
US10085990 | 88 | 64 | HGNC:8781 HGNC:8783 HGNC:16841 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | vTv Therapeutics LLC | 01/17/19 | 2D 3D TSV |
US9518026 | 206 | 103 | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum | University of Washington Through its Center for Commercialization | 01/14/19 | 2D 3D TSV | |
US9518000 | 100 | 98 | HGNC:19061 | Bicyclo [2.2.1] acid GPR120 modulators | Bristol-Myers Squibb Co. | 01/14/19 | 2D 3D TSV |
US9517228 | 8 | 8 | HGNC:2159 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | Jenrin Discovery Inc | 01/14/19 | 2D 3D TSV |
US9566312 | 321 | 105 | HGNC:9253 HGNC:9255 HGNC:9259 | Cyclic peptides and use as medicines | Novartis AG | 01/14/19 | 2D 3D TSV |
US9567327 | 3 | 3 | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals Inc | 01/14/19 | 2D 3D TSV | |
US9518055 | 38 | 19 | HGNC:2592 HGNC:2591 | Imidazopyridyl compounds as aldosterone synthase inhibitors | Merck Sharp & Dohme | 01/14/19 | 2D 3D TSV |
US9518064 | 131 | 113 | HGNC:3540 HGNC:3537 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | Bristol-Myers Squibb Co. | 01/14/19 | 2D 3D TSV |
US9566277 | 5 | 5 | HGNC:270 | Methods of using phthalazinone ketone derivatives | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 01/14/19 | 2D 3D TSV |
US9567339 | 358 | 354 | Primary carboxamides as BTK inhibitors | AbbVie Inc | 01/14/19 | 2D 3D TSV | |
US9567338 | 61 | 60 | Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands | LABORATORIOS DEL DR. ESTEVE S.A. | 01/14/19 | 2D 3D TSV | |
US9518052 | 676 | 168 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrazolopyridines and pyrazolopyrimidines | Pfizer Inc | 01/14/19 | 2D 3D TSV |
US9567320 | 29 | 17 | HGNC:6112 HGNC:17967 | Pyridazinone-amides derivatives | Merck Patent GmbH | 01/14/19 | 2D 3D TSV |
US9567304 | 358 | 356 | HGNC:2730 | Quinazolinedione derivative | Chugai Seiyaku Kabushiki Kaisha | 01/14/19 | 2D 3D TSV |
US9518060 | 98 | 94 | HGNC:9612 | Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors | Pfizer Inc | 01/14/19 | 2D 3D TSV |
US9567333 | 14 | 7 | HGNC:2592 HGNC:2591 | Triazolopyridyl compounds as aldosterone synthase inhibitors | Merck Sharp & Dohme Corp | 01/14/19 | 2D 3D TSV |
US10081635 | 20 | 5 | HGNC:6190 HGNC:6193 HGNC:12440 | Substituted N-(pyrrolidine-3-yl)-7H-pyrrolo[2,3-D]pyrimidine-4-amine as janus kinase inhibitor | YANG JI CHEMICAL CO., LTD. | 01/13/19 | 2D 3D TSV |
US10081632 | 21 | 19 | HGNC:10432 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGNS | 01/13/19 | 2D 3D TSV |
US10081629 | 107 | 49 | HGNC:9599 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | Jiangsu Hengrui Medicine Co., Ltd. | 01/12/19 | 2D 3D TSV |
US10081623 | 35 | 35 | HGNC:3529 | Diamide macrocycles that are FXIa inhibitors | Bristol-Myers Squibb Co. | 01/12/19 | 2D 3D TSV |
US10081617 | 134 | 94 | HGNC:3529 | Factor XIa inhibitors | Merck Sharp & Dohme Corp | 01/12/19 | 2D 3D TSV |
US10081606 | 46 | 23 | HGNC:3236 | Heteroaryl compounds and uses thereof | Celgene CAR LLC | 01/12/19 | 2D 3D TSV |
US10081602 | 42 | 12 | HGNC:8154 HGNC:8156 | Opioid agonists and uses thereof | Nektar Therapeutics | 01/12/19 | 2D 3D TSV |
US10081622 | 12 | 4 | HGNC:5465 HGNC:11393 HGNC:427 | Substituted indazole derivatives active as kinase inhibitors | Nerviano Medical Sciences srl | 01/12/19 | 2D 3D TSV |
US10080750 | 243 | 243 | Aminopyrimidine derivatives for use as modulators of kinase activity | Merck Patent GmbH | 01/11/19 | 2D 3D TSV | |
US10077277 | 38 | 26 | HGNC:6190 HGNC:8977 | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors | Incyte Corporation | 01/11/19 | 2D 3D TSV |
US10023583 | 56 | 28 | HGNC:6656 | Bicyclic pyridine compound | Astellas Pharma Inc | 01/11/19 | 2D 3D TSV |
US10023592 | 505 | 494 | HGNC:13575 | Bromodomain inhibitors | Celgene Quanticel Research Inc | 01/11/19 | 2D 3D TSV |
US10077289 | 76 | 38 | HGNC:9253 HGNC:9316 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | Allergan Inc | 01/11/19 | 2D 3D TSV |
US10081601 | 41 | 31 | HGNC:4177 | Glucocerebrosidase modulators and uses thereof | Alectos Therapeutics Inc | 01/11/19 | 2D 3D TSV |
US10077272 | 23 | 23 | HGNC:3020 | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc | 01/11/19 | 2D 3D TSV |
US10023576 | 117 | 115 | HGNC:8977 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | Bristol-Myers Squibb Co. | 01/11/19 | 2D 3D TSV |
US10077269 | 372 | 104 | Imidazopyridazine compounds | Pfizer Inc | 01/11/19 | 2D 3D TSV | |
US10077273 | 54 | 33 | HGNC:10852 HGNC:10850 | SHMT inhibitors | The Trustees of Princeton University | 01/11/19 | 2D 3D TSV |
US10077265 | 28 | 13 | HGNC:6371 HGNC:3529 | Substituted oxopyridine derivatives | Bayer Pharma Aktiengesellschaft | 01/11/19 | 2D 3D TSV |
US10077266 | 142 | 140 | HGNC:4515 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | Takeda Pharmaceutical Co., Ltd | 01/11/19 | 2D 3D TSV |
US10080744 | 176 | 85 | Thiazoles as modulators of RORγt | Janssen Pharmaceutica NV | 01/11/19 | 2D 3D TSV | |
US10077247 | 54 | 54 | HGNC:9596 | Tricyclic spiro compound | Ono Pharmaceutical Co., Ltd | 01/11/19 | 2D 3D TSV |
US10023575 | 202 | 66 | HGNC:8772 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | Boehringer Ingelheim International GmbH | 01/10/19 | 2D 3D TSV |
US10023564 | 139 | 39 | HGNC:4544 HGNC:10251 HGNC:289 HGNC:10013 | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | The Regents of the University of Michigan | 01/10/19 | 2D 3D TSV |
US10023562 | 168 | 150 | HGNC:17967 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | Bristol-Myers Squibb Co. | 01/10/19 | 2D 3D TSV |
US10023570 | 1162 | 715 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc | 01/10/19 | 2D 3D TSV | |
US10023539 | 107 | 59 | HGNC:20982 | Aryl-cyanoguanidine compounds | Bayer Pharma Aktiengesellschaft | 01/06/19 | 2D 3D TSV |
US10023561 | 74 | 74 | HGNC:16672 | Fumagillol heterocyclic compounds and methods of making and using same | Zafgen, Inc. | 01/06/19 | 2D 3D TSV |
US10023543 | 122 | 119 | HGNC:29079 | Inhibitors of lysine specific demethylase-1 | Celgene Quanticel Research Inc | 01/06/19 | 2D 3D TSV |
US10023559 | 262 | 131 | Substituted azetidine derivatives | Hoffman-La Roche Inc | 01/06/19 | 2D 3D TSV | |
US10023557 | 451 | 312 | HGNC:6371 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. | 01/06/19 | 2D 3D TSV |
US9884865 | 4 | 4 | HGNC:10597 | Azaspiro[4.5] decane derivatives and use thereof | Purdue Pharma LP | 01/05/19 | 2D 3D TSV |
US9884874 | 18 | 18 | HGNC:13575 | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer | KAINOS MEDICINE, INC. | 01/05/19 | 2D 3D TSV |
US9884843 | 140 | 112 | HGNC:12680 | Cyclic sulfone and sulfoximine analogs and uses thereof | PELOTON THERAPEUTICS, INC. | 01/05/19 | 2D 3D TSV |
US9884878 | 845 | 837 | HGNC:436 | FLAP modulators | Janssen Pharmaceutica NV | 01/05/19 | 2D 3D TSV |
US9884860 | 365 | 353 | HGNC:6278 | Fused pyrroledicarboxamides and their use as pharmaceuticals | Sanofi | 01/05/19 | 2D 3D TSV |
US9884850 | 16 | 4 | HGNC:4852 HGNC:14064 HGNC:4853 | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors | Acetylon Pharmaceuticals Inc | 01/05/19 | 2D 3D TSV |
US9884828 | 117 | 117 | HGNC:18618 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | Imago Pharmaceuticals Inc | 01/05/19 | 2D 3D TSV |
US9884868 | 605 | 303 | HGNC:11773 | TGF-beta inhibitors | Rigel Pharmaceuticals, Inc | 01/05/19 | 2D 3D TSV |
US10022387 | 157 | 76 | HGNC:8978 HGNC:8977 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | Incyte Corporation | 12/31/18 | 2D 3D TSV |
US10023528 | 16 | 14 | HGNC:4685 | Branched 3-phenylpropionic acid derivatives and their use | Bayer Pharma Aktiengesellschaft | 12/31/18 | 2D 3D TSV |
US10023534 | 22 | 18 | HGNC:1133 | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | Bristol-Myers Squibb Co. | 12/31/18 | 2D 3D TSV |
US10023519 | 68 | 66 | HGNC:23693 | Cyclobutane containing carboxylic acid GPR120 modulators | Bristol-Myers Squibb Co. | 12/31/18 | 2D 3D TSV |
US10030026 | 52 | 17 | HGNC:4586 HGNC:6251 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | Rugen Holdings (Cayman) Limited | 12/31/18 | 2D 3D TSV |
US10030016 | 798 | 774 | Heterocyclic compounds useful as PDK1 inhibitors | Sunesis Pharmaceuticals Inc | 12/31/18 | 2D 3D TSV | |
US10022352 | 15 | 14 | HGNC:1884 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Inc | 12/31/18 | 2D 3D TSV |
US10030047 | 55 | 55 | Peptide macrocycles against acinetobacter baumannii | Hoffmann-La Roche Inc | 12/31/18 | 2D 3D TSV | |
US10022376 | 676 | 168 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrazolopyridines and pyrazolopyrimidines | Pfizer Inc | 12/31/18 | 2D 3D TSV |
US10022354 | 246 | 243 | HGNC:9886 | Pyrrolidine amide compounds as histone demethylase inhibitors | Genentech Inc | 12/31/18 | 2D 3D TSV |
US10022461 | 105 | 105 | HGNC:6893 | Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrilary tangles | Merck Sharp & Dohme Corp | 12/31/18 | 2D 3D TSV |
US10030027 | 248 | 233 | HGNC:4685 | Soluble guanylate cyclase stimulators | Merck Sharp & Dohme Corp | 12/31/18 | 2D 3D TSV |
US10030020 | 677 | 265 | HGNC:17038 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. | 12/31/18 | 2D 3D TSV |
US10030025 | 205 | 47 | HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Ogeda SA | 12/31/18 | 2D 3D TSV |
US10030004 | 207 | 36 | HGNC:171 HGNC:1076 HGNC:172 HGNC:175 | Compounds and methods of use | Medivation Technologies LLC | 12/30/18 | 2D 3D TSV |
US10029993 | 68 | 68 | HGNC:2592 | Disubstituted 1, 2, 4-triazine compound | Mitsubishi Tanabe Pharma Corporation | 12/30/18 | 2D 3D TSV |
US10030012 | 100 | 85 | HGNC:1953 HGNC:1951 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | Heptares Therapeutics Limited | 12/30/18 | 2D 3D TSV |
US10028961 | 1070 | 390 | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals Inc | 12/30/18 | 2D 3D TSV | |
US10034864 | 21 | 21 | HGNC:6059 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | Incyte Holdings Corporation | 12/25/18 | 2D 3D TSV |
US10034861 | 606 | 190 | HGNC:8775 HGNC:8774 HGNC:8776 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. Lundbeck A/S | 12/25/18 | 2D 3D TSV |
US10035761 | 33 | 11 | HGNC:11050 HGNC:11048 HGNC:11049 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | Revivia Pharmaceuticals, Inc. | 12/25/18 | 2D 3D TSV |
US10035797 | 73 | 61 | HGNC:5253 | Fused amino pyridine as HSP90 inhibitors | Curis Inc | 12/25/18 | 2D 3D TSV |
US10035814 | 18 | 18 | HGNC:11726 | Guanine analogs as telomerase substrates and telomere length affectors | Geron Corporation | 12/25/18 | 2D 3D TSV |
US10035794 | 139 | 47 | HGNC:934 HGNC:933 | Heterocyclic derivatives and their use in the treatment of neurological disorders | Novartis AG | 12/25/18 | 2D 3D TSV |
US10035777 | 109 | 108 | HGNC:19679 | Heterocyclic kinase inhibitors | Bristol-Myers Squibb Co. | 12/25/18 | 2D 3D TSV |
US10035760 | 349 | 273 | Inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 12/25/18 | 2D 3D TSV | |
US10035778 | 119 | 17 | HGNC:6160 HGNC:6161 HGNC:6163 HGNC:6153 HGNC:6156 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | Saint Louis University | 12/25/18 | 2D 3D TSV |
US10028960 | 106 | 42 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrimidine compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 12/25/18 | 2D 3D TSV |
US10035780 | 9 | 9 | Quinazoline scaffold based compounds, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | 12/25/18 | 2D 3D TSV | |
US10035792 | 71 | 71 | HGNC:5253 | Resorcinol derivative as HSP90 inhibitor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | 12/25/18 | 2D 3D TSV |
US10035804 | 122 | 61 | HGNC:2592 HGNC:2591 | Spirodiamine derivatives as aldosterone synthase inhibitors | Hoffman-La Roche Inc | 12/25/18 | 2D 3D TSV |
US10028934 | 74 | 37 | HGNC:6342 HGNC:3765 | Substituted indazole derivatives active as kinase inhibitiors | Nerviano Medical Sciences srl | 12/25/18 | 2D 3D TSV |
US10034939 | 22 | 22 | HGNC:6059 | Synergistic combination of immunologic inhibitors for the treatment of cancer | The University of Chicago | 12/25/18 | 2D 3D TSV |
US10040788 | 63 | 57 | 1,3,4-thiadiazole compounds and their use in treating cancer | AstraZeneca AB | 12/22/18 | 2D 3D TSV | |
US10040789 | 28 | 17 | 1,3,4-thiadiazole compounds and their use in treating cancer | AstraZeneca AB | 12/22/18 | 2D 3D TSV | |
US10040815 | 21 | 20 | HGNC:15631 | 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | Hoffmann-La Roche Inc | 12/22/18 | 2D 3D TSV |
US10040790 | 162 | 54 | HGNC:3690 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR inhibitors | Incyte Holdings Corporation | 12/22/18 | 2D 3D TSV |
US10040791 | 334 | 167 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | Daiichi Sankyo Company, Limited | 12/22/18 | 2D 3D TSV | |
US10040798 | 117 | 115 | HGNC:17967 | Pyrrolopyridazine inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 12/22/18 | 2D 3D TSV |
US10040805 | 19 | 17 | HGNC:1133 | Substituted imidazo[1,5-a]pyrazines as Btk inhibitors | Merck Sharp & Dohme Corp | 12/22/18 | 2D 3D TSV |
US10040802 | 109 | 109 | HGNC:17967 | Thienopyrazine inhibitors of IRAK4 activity | Merck Sharp & Dohme Corp | 12/22/18 | 2D 3D TSV |
US10071086 | 115 | 105 | HGNC:16913 HGNC:583 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | Samumed, LLC | 12/21/18 | 2D 3D TSV |
US10072005 | 105 | 103 | HGNC:1950 | 4-azaindole derivatives | Eisai R&D Management Co., Ltd | 12/21/18 | 2D 3D TSV |
US10072026 | 1144 | 279 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile | THERAVANCE BIOPHARMA R&D IP, LLC | 12/21/18 | 2D 3D TSV |
US10071992 | 17 | 13 | HGNC:16940 | Diacylglycerol acyl transferase 2 inhibitors | Pfizer Inc | 12/21/18 | 2D 3D TSV |
US10072025 | 140 | 62 | HGNC:6190 HGNC:6192 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | Merck Sharp & Dohme Corp | 12/21/18 | 2D 3D TSV |
US10071984 | 129 | 55 | HGNC:13606 HGNC:13610 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 12/21/18 | 2D 3D TSV |
US10040779 | 237 | 79 | HGNC:9886 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 12/21/18 | 2D 3D TSV |
US10071998 | 58 | 29 | HGNC:934 HGNC:933 | Iminothiadiazine dioxides bearing an amine-linked substituent as BACE inhibitors, compositions, and their use | TBA | 12/21/18 | 2D 3D TSV |
US10072034 | 37 | 27 | HGNC:11491 HGNC:11283 HGNC:11892 HGNC:6025 HGNC:5439 | Kinase inhibitors | Respivert Limited | 12/21/18 | 2D 3D TSV |
US10071974 | 169 | 85 | HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | Boehringer Ingelheim International GmbH | 12/21/18 | 2D 3D TSV |
US10071957 | 138 | 98 | HGNC:10593 HGNC:10597 | N-substituted benzamides and methods of use thereof | Genentech Inc | 12/21/18 | 2D 3D TSV |
US10071994 | 3 | 3 | N-sulfonyl homoserine lactone derivatives, preparation method and use thereof | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | 12/21/18 | 2D 3D TSV | |
US10071110 | 33 | 17 | HGNC:3688 | Phosphonate compounds | The Regents of the University of California | 12/21/18 | 2D 3D TSV |
US10071965 | 42 | 15 | Pyridone FabI inhibitors and uses thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 12/21/18 | 2D 3D TSV | |
US10072008 | 7 | 7 | HGNC:8157 | Spiro-isoquinoline-3,4′-piperidine compounds having activity against pain | ESTEVE PHARMACEUTICALS S.A. | 12/21/18 | 2D 3D TSV |
US10071988 | 647 | 640 | HGNC:10477 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | Janssen Pharmaceutica NV | 12/21/18 | 2D 3D TSV |
US10072016 | 247 | 111 | HGNC:12405 HGNC:9922 | Substituted 4-phenylpiperidines, their preparation and use | Columbia University | 12/21/18 | 2D 3D TSV |
US10071995 | 38 | 14 | HGNC:6371 | Substituted oxopyridine derivatives | Bayer Pharma Aktiengesellschaft | 12/21/18 | 2D 3D TSV |
US10071991 | 18 | 7 | Substituted pyridine derivatives useful as c-fms kinase inhibitors | Janssen Pharmaceutica NV | 12/21/18 | 2D 3D TSV | |
US10072001 | 527 | 262 | HGNC:11584 HGNC:14552 | Tank-binding kinase inhibitor compounds | Gilead Sciences Inc | 12/21/18 | 2D 3D TSV |
US10040781 | 1854 | 611 | HGNC:6192 HGNC:11584 HGNC:14552 | Tank-binding kinase inhibitor compounds | Gilead Sciences Inc | 12/21/18 | 2D 3D TSV |
US10072003 | 130 | 109 | HGNC:4594 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | TBA | 12/21/18 | 2D 3D TSV |
US9878996 | 42 | 14 | HGNC:7872 HGNC:7873 | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase | Northwestern University | 12/12/18 | 2D 3D TSV |
US9884814 | 277 | 277 | HGNC:2529 | Acylguanidines for treating osteoarthritis | Merck Patent GmbH | 12/12/18 | 2D 3D TSV |
US10065972 | 193 | 189 | HGNC:17929 | Bicyclic or tricyclic heterocyclic compound | Mitsubishi Tanabe Pharma Corporation | 12/12/18 | 2D 3D TSV |
US9884048 | 326 | 314 | HGNC:6871 | ERK inhibitors | Merck Sharp & Dohme Corp | 12/12/18 | 2D 3D TSV |
US9556117 | 95 | 95 | HGNC:8537 | Indole carboxamide derivatives as P2X7 receptor antagonists | Actelion Pharmaceuticals Ltd | 12/12/18 | 2D 3D TSV |
US9556190 | 94 | 45 | HGNC:4849 HGNC:4848 | Piperidinyloxy lactone orexin receptor antagonists | Merck Sharp & Dohme Corp | 12/12/18 | 2D 3D TSV |
US9879013 | 12 | 4 | HGNC:4037 HGNC:6735 HGNC:6524 | Purinone derivative | Ono Pharmaceutical Co., Ltd | 12/12/18 | 2D 3D TSV |
US9879032 | 46 | 45 | HGNC:438 | Pyridine compounds | Daiichi Sankyo Company, Limited | 12/12/18 | 2D 3D TSV |
US9550796 | 455 | 128 | HGNC:2348 HGNC:1104 | Pyrrolopyrrolone derivatives and their use as BET inhibitors | Novartis AG | 12/12/18 | 2D 3D TSV |
US9951047 | 4 | 1 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Salt of monocyclic pyridine derivative and crystal thereof | Eisai R&D Management Co., Ltd | 12/12/18 | 2D 3D TSV |
US9556188 | 218 | 214 | HGNC:1133 | Substituted imidazo[1,2-b]pyrazoles as bruton'S tyrosine kinase modulators | BeiGene, Ltd | 12/12/18 | 2D 3D TSV |
US9556179 | 949 | 469 | HGNC:2453 HGNC:2452 | Substituted imidazoles as casein kinase 1 D/E inhibitors | Bristol-Myers Squibb Co. | 12/12/18 | 2D 3D TSV |
US9556187 | 1933 | 467 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | Nissan Chemical Industries, Ltd | 12/12/18 | 2D 3D TSV |
US9879026 | 27 | 27 | HGNC:2528 | Substituted spirocycles | Boehringer Ingelheim International GmbH | 12/12/18 | 2D 3D TSV |
US9878991 | 226 | 137 | HGNC:12716 | TRPV1 antagonists including dihydroxy substituent and uses thereof | Purdue Pharma LP | 12/12/18 | 2D 3D TSV |
US9877957 | 81 | 78 | HGNC:16940 | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | Merck Sharp & Dohme Corp | 12/12/18 | 2D 3D TSV |
US10059669 | 24 | 21 | HGNC:933 | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease | H. Lundbeck A/S | 12/11/18 | 2D 3D TSV |
US10058540 | 19 | 18 | HGNC:933 | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors | H. Lundbeck A/S | 12/11/18 | 2D 3D TSV |
US10059713 | 296 | 296 | HGNC:4501 | 3-substituted 2-amino-indole derivatives | Takeda Pharmaceutical Co., Ltd | 12/11/18 | 2D 3D TSV |
US10059705 | 452 | 174 | HGNC:6190 HGNC:6192 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | Merck Sharp & Dohme Corp | 12/11/18 | 2D 3D TSV |
US10065941 | 574 | 554 | HGNC:8534 | Aminotriazine derivative and pharmaceutical composition comprising the same | Shionogi & Co., Ltd | 12/11/18 | 2D 3D TSV |
US10059667 | 216 | 144 | HGNC:4498 | Antidiabetic compounds | Merck Sharp & Dohme Corp | 12/11/18 | 2D 3D TSV |
US10058534 | 230 | 137 | HGNC:3467 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | Novartis AG | 12/11/18 | 2D 3D TSV |
US10065961 | 90 | 31 | HGNC:11526 HGNC:11527 HGNC:11528 HGNC:3446 | Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | Ogeda SA | 12/11/18 | 2D 3D TSV |
US10059709 | 84 | 28 | HGNC:6190 HGNC:6192 HGNC:12440 | Compounds | Elanco Tiergesundheit AG | 12/11/18 | 2D 3D TSV |
US10064873 | 147 | 74 | Compounds and compositions for treating HIV with derivatives of Betulin | GlaxoSmithKline | 12/11/18 | 2D 3D TSV | |
US10064853 | 26 | 13 | HGNC:8548 | Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase | Beth Israel Deaconess Medical Center, Inc. | 12/11/18 | 2D 3D TSV |
US10065967 | 43 | 43 | HGNC:6871 | Compounds that are ERK inhibitors | Merck Sharp & Dohme Corp | 12/11/18 | 2D 3D TSV |
US10059695 | 67 | 37 | HGNC:3236 | Cot modulators and methods of use thereof | Gilead Sciences Inc | 12/11/18 | 2D 3D TSV |
US10065963 | 620 | 239 | HGNC:6190 HGNC:8978 HGNC:8977 | Heterocyclic compounds as PI3K-γ inhibitors | Incyte Corporation | 12/11/18 | 2D 3D TSV |
US10065948 | 96 | 88 | HGNC:14065 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation Inc | 12/11/18 | 2D 3D TSV |
US10059687 | 128 | 44 | HGNC:29012 HGNC:17071 HGNC:18039 | Histone demethylase inhibitors | Celgene Quanticel Research Inc | 12/11/18 | 2D 3D TSV |
US10058549 | 3 | 3 | Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals Inc | 12/11/18 | 2D 3D TSV | |
US10065953 | 19 | 17 | Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication | ViiV HEALTHCARE UK (NO. 5) LIMITED | 12/11/18 | 2D 3D TSV | |
US10065945 | 9 | 9 | HGNC:7045 | Isoquinoline derivatives as MGAT2 inhibitors | Merck Sharp & Dohme Corp | 12/11/18 | 2D 3D TSV |
US10059668 | 41 | 35 | HGNC:29079 | LSD1 inhibitors | Mirati Therapeutics Inc | 12/11/18 | 2D 3D TSV |
US10064861 | 81 | 41 | HGNC:6112 HGNC:17967 | Macrocyclic pyridazinone derivatives | Merck Patent GmbH | 12/11/18 | 2D 3D TSV |
US10058550 | 788 | 582 | HGNC:339 | Methods of treating heart failure | Amgen Inc | 12/11/18 | 2D 3D TSV |
US10059688 | 43 | 9 | HGNC:427 HGNC:3236 | Protein tyrosine kinase modulators and methods of use | Betta Pharmaceuticals Co., Ltd | 12/11/18 | 2D 3D TSV |
US10059720 | 288 | 148 | HGNC:6656 | Pyridine derivative | Astellas Pharma Inc | 12/11/18 | 2D 3D TSV |
US10065928 | 42 | 42 | HGNC:4910 | Quinolinone compound and use thereof | Sunshine Lake Pharma Co., Ltd | 12/11/18 | 2D 3D TSV |
US10065973 | 23 | 20 | HGNC:15631 | Substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection | Hoffmann-La Roche Inc | 12/11/18 | 2D 3D TSV |
US10065950 | 358 | 353 | Substituted thiazoles as HIV integrase inhibitors | Japan Tobacco Inc | 12/11/18 | 2D 3D TSV | |
US10065970 | 215 | 210 | HGNC:8975 | Tricyclic PI3K inhibitor compounds and methods of use | Genentech Inc | 12/11/18 | 2D 3D TSV |
US10071079 | 2922 | 952 | HGNC:15633 HGNC:15631 HGNC:15632 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | Bristol-Myers Squibb Co. | 12/11/18 | 2D 3D TSV |
US9718813 | 168 | 97 | HGNC:23437 HGNC:3594 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | Janssen Pharmaceutica NV | 12/10/18 | 2D 3D TSV |
US9718825 | 648 | 629 | HGNC:10810 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | Sanofi | 12/10/18 | 2D 3D TSV |
US9549932 | 488 | 431 | HGNC:882 | 2-(morpholin-4-yl)-1,7-naphthyridines | Bayer Pharma Aktiengesellschaft | 11/29/18 | 2D 3D TSV |
US9718828 | 489 | 483 | HGNC:1133 | BTK Inhibitors | Merck Sharp & Dohme Corp | 11/29/18 | 2D 3D TSV |
US9550771 | 93 | 91 | Keto-imidazopyridine derivatives as RORc modulators | Genentech Inc | 11/29/18 | 2D 3D TSV | |
US9718822 | 68 | 48 | HGNC:8031 | Macrocyclic compounds as Trk kinase inhibitors | Array BioPharma Inc | 11/29/18 | 2D 3D TSV |
US9718854 | 20 | 20 | HGNC:25155 | Selective glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 11/29/18 | 2D 3D TSV |
US9718820 | 90 | 86 | Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators | Janssen Pharmaceutica NV | 11/29/18 | 2D 3D TSV | |
US9550775 | 130 | 95 | HGNC:10597 | Substituted triazolopyridines and methods of use thereof | Genentech Inc | 11/29/18 | 2D 3D TSV |
US9718814 | 375 | 111 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Co., Ltd | 11/28/18 | 2D 3D TSV |
US9718819 | 182 | 181 | Non-nucleoside reverse transcriptase inhibitors | Merck Sharp & Dohme Corp | 11/28/18 | 2D 3D TSV | |
US9718812 | 213 | 123 | HGNC:8537 | Substituted thiazole or oxazole P2X7 receptor antagonists | Axxam S.P.A. | 11/28/18 | 2D 3D TSV |
US9718809 | 87 | 82 | HGNC:8875 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | Kancera AB | 11/27/18 | 2D 3D TSV |
US9718800 | 115 | 111 | HGNC:8976 | Chromenone derivatives | AstraZeneca AB | 11/27/18 | 2D 3D TSV |
US9718808 | 144 | 140 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 11/27/18 | 2D 3D TSV |
US9718793 | 138 | 136 | HGNC:5253 | Isoxazole compounds as inhibitors of heat shock proteins | The Institute of Cancer Research | 11/27/18 | 2D 3D TSV |
US9718792 | 101 | 99 | Isoxazoline hydroxamic acid derivatives as LpxC inhibitors | Novartis AG | 11/27/18 | 2D 3D TSV | |
US9718790 | 2250 | 2236 | HGNC:8534 | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same | Shionogi & Co., Ltd | 11/27/18 | 2D 3D TSV |
US9718803 | 375 | 373 | HGNC:8772 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | Amgen Inc | 11/27/18 | 2D 3D TSV |
US9718771 | 48 | 48 | HGNC:3165 | Aniline derivative, pharmaceutical composition containing same, and use thereof | Kissei Pharmaceutical Co., Ltd | 11/16/18 | 2D 3D TSV |
US9718787 | 9 | 9 | HGNC:270 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DIAO PHARMACEUTICAL GROUP CO., LTD. | 11/16/18 | 2D 3D TSV |
US9718780 | 6 | 6 | HGNC:10597 | Substituted pyridines as sodium channel blockers | TBA | 11/16/18 | 2D 3D TSV |
US9714242 | 13 | 7 | HGNC:5297 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | Bayer Intellectual Property GmbH | 11/15/18 | 2D 3D TSV |
US9714234 | 70 | 33 | HGNC:6192 HGNC:1133 | Carbazole carboxamide compounds | Bristol-Myers Squibb Co. | 11/15/18 | 2D 3D TSV |
US9713651 | 56 | 55 | Compositions, methods, and systems for the synthesis and use of imaging agents | Lantheus Medical Imaging, Inc. | 11/15/18 | 2D 3D TSV | |
US9714236 | 207 | 69 | Compounds and methods for inhibiting JAK | AstraZeneca AB | 11/15/18 | 2D 3D TSV | |
US9713612 | 30 | 30 | HGNC:15983 | Compounds for treatment of cancer | CUREGENIX, INC. | 11/15/18 | 2D 3D TSV |
US9714252 | 7 | 7 | HGNC:10597 | Cyclic sulfonamides as sodium channel blockers | Purdue Pharma LP | 11/15/18 | 2D 3D TSV |
US9714241 | 375 | 110 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Co., Ltd | 11/15/18 | 2D 3D TSV |
US9714266 | 46 | 46 | HGNC:386 | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) | Bayer Pharma Aktiengesellschaft | 11/15/18 | 2D 3D TSV |
US9714224 | 8 | 7 | HGNC:338 | Heterocyclic compounds and methods of their use | Novartis AG | 11/15/18 | 2D 3D TSV |
US9714230 | 511 | 153 | HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. | 11/15/18 | 2D 3D TSV |
US9713606 | 584 | 356 | HGNC:2528 HGNC:2536 | Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C | Boehringer Ingelheim International GmbH | 11/15/18 | 2D 3D TSV |
US9714247 | 452 | 147 | HGNC:6735 HGNC:1133 HGNC:11283 | Multiple kinase pathway inhibitors | Tolero Pharmaceuticals Inc | 11/15/18 | 2D 3D TSV |
US9717745 | 5 | 5 | HGNC:1133 | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | Zhejiang DTRM Biopharma Co. Ltd | 11/15/18 | 2D 3D TSV |
US9718760 | 257 | 133 | HGNC:8583 HGNC:775 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof | University of Michigan | 11/15/18 | 2D 3D TSV |
US9714249 | 134 | 33 | HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease | Novartis AG | 11/15/18 | 2D 3D TSV |
US9714235 | 40 | 20 | HGNC:3430 HGNC:3236 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | Shanghai Fochon Pharmaceutical Co., Ltd. | 11/15/18 | 2D 3D TSV |
US9717714 | 14 | 14 | HGNC:1869 | Spirocyclic CETP inhibitors | Merck Sharp & Dohme Corp | 11/15/18 | 2D 3D TSV |
US9714221 | 654 | 217 | HGNC:3467 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | Sanofi | 11/15/18 | 2D 3D TSV |
US9714232 | 72 | 38 | HGNC:5286 | Substituted piperazine compounds and methods of use thereof | Sunshine Lake Pharma Co., Ltd | 11/15/18 | 2D 3D TSV |
US9714244 | 46 | 33 | HGNC:6251 HGNC:12761 | Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors | ALMAC DISCOVERY LIMITED | 11/15/18 | 2D 3D TSV |
US9556130 | 73 | 73 | HGNC:19995 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 | Takeda Pharmaceutical Co., Ltd | 11/08/18 | 2D 3D TSV |
US9550741 | 612 | 77 | HGNC:3023 HGNC:12679 HGNC:5286 | Benzoisothiazole compounds and methods of treating schizophrenia | Shanghai Institute of Pharmaceutical Industry | 11/08/18 | 2D 3D TSV |
US9556150 | 59 | 59 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | F. Hoffmann-La Roche Inc | 11/08/18 | 2D 3D TSV |
US9708370 | 88 | 51 | Azapeptides as CD36 binding compounds | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP | 11/07/18 | 2D 3D TSV | |
US9546162 | 91 | 24 | HGNC:9594 HGNC:9596 | Compounds and methods for skin repair | Allergan Inc | 11/07/18 | 2D 3D TSV |
US9533987 | 230 | 114 | HGNC:6371 HGNC:6357 | Heterocyclic derivates | Kalvista Pharmaceuticals Limited | 11/07/18 | 2D 3D TSV |
US9546164 | 648 | 527 | HGNC:10593 HGNC:10597 | Substituted benzamides and methods of use thereof | Genentech Inc | 11/07/18 | 2D 3D TSV |
US9708337 | 36 | 36 | HGNC:19679 | Aryl amide-based kinase inhibitors | Bristol-Myers Squibb Co. | 11/05/18 | 2D 3D TSV |
US9708336 | 2511 | 825 | Metallo-beta-lactamase inhibitors | Merck Sharp & Dohme Corp | 11/05/18 | 2D 3D TSV | |
US9708359 | 143 | 131 | Pyrrolopyrimidine nucleosides and analogs thereof | Chimerix, Inc. | 11/05/18 | 2D 3D TSV | |
US9708340 | 96 | 48 | HGNC:3560 HGNC:3559 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | Hoffmann-La Roche Inc | 11/05/18 | 2D 3D TSV |
US9708333 | 86 | 34 | HGNC:6190 HGNC:7027 HGNC:12446 HGNC:8977 | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors | Incyte Corporation | 11/01/18 | 2D 3D TSV |
US9708309 | 24 | 8 | HGNC:6833 HGNC:6834 HGNC:29079 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | Oryzon Genomics, S.A. | 10/31/18 | 2D 3D TSV |
US9708311 | 143 | 143 | HGNC:9596 | Benzimidazole derivatives as EP4 antagonists | Bayer Pharma Aktiengesellschaft | 10/31/18 | 2D 3D TSV |
US9708318 | 856 | 187 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Bicyclic heterocycles as FGFR4 inhibitors | Incyte Corporation | 10/31/18 | 2D 3D TSV |
US9708302 | 46 | 23 | HGNC:1950 | Flouro-naphthyl derivatives | Hoffmann-La Roche Inc | 10/31/18 | 2D 3D TSV |
US9708313 | 142 | 139 | HGNC:4515 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | Takeda Pharmaceutical Co., Ltd | 10/31/18 | 2D 3D TSV |
US9708325 | 62 | 45 | HGNC:15631 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | Hoffmann-La Roche Inc | 10/31/18 | 2D 3D TSV |
US9708279 | 100 | 50 | HGNC:427 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ | 10/30/18 | 2D 3D TSV |
US10053471 | 17 | 17 | HGNC:9385 | Azabenzimidazole derivatives | Boehringer Ingelheim International GmbH | 10/30/18 | 2D 3D TSV |
US9708266 | 40 | 21 | HGNC:11526 HGNC:2637 | Cyclohexyl pyridine derivative | Kissei Pharmaceutical Co., Ltd | 10/30/18 | 2D 3D TSV |
US9708253 | 135 | 123 | Cyclohexyl sulfone RORγ modulators | Bristol-Myers Squibb Co. | 10/30/18 | 2D 3D TSV | |
US9701672 | 77 | 73 | HGNC:7045 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | Bristol-Myers Squibb Co. | 10/30/18 | 2D 3D TSV |
US9708275 | 12 | 11 | HGNC:338 | Heterocyclic compounds and methods for their use | Novartis AG | 10/30/18 | 2D 3D TSV |
US9707233 | 368 | 352 | HGNC:8977 | Heterocyclylamines as PI3K inhibitors | Incyte Holdings Corporation | 10/30/18 | 2D 3D TSV |
US9708272 | 22 | 22 | HGNC:19288 | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase | TES Pharma S.r.l. | 10/30/18 | 2D 3D TSV |
US9700563 | 3 | 3 | HGNC:8154 | Kappa opioid receptor compounds | MediSynergies, LLC | 10/30/18 | 2D 3D TSV |
US10053462 | 195 | 56 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 10/30/18 | 2D 3D TSV |
US9701669 | 34 | 19 | HGNC:3332 HGNC:6251 | Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists | Merck Sharp & Dohme Corp | 10/30/18 | 2D 3D TSV |
US9708269 | 7 | 7 | HGNC:1232 | Process for making isoquinoline compounds | FibroGen Inc | 10/30/18 | 2D 3D TSV |
US9701670 | 374 | 91 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 | Pyrazolyl-ureas as kinase inhibitors | Respivert Limited | 10/30/18 | 2D 3D TSV |
US10053465 | 286 | 93 | HGNC:6190 HGNC:7027 HGNC:12446 HGNC:8977 | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation | 10/30/18 | 2D 3D TSV |
US9708268 | 42 | 12 | HGNC:14901 HGNC:5981 HGNC:16404 | ROR modulators and their uses | INNOV17 LLC | 10/30/18 | 2D 3D TSV |
US9707205 | 16 | 15 | HGNC:3167 HGNC:3165 | S1P receptors modulators and their use thereof | Akaal Pharma PTY Ltd | 10/30/18 | 2D 3D TSV |
US9701693 | 4 | 4 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 10/30/18 | 2D 3D TSV |
US9701685 | 18 | 13 | HGNC:6973 | Spiropyrrolidines as MDM2 inhibitors | Hudson Biopharma Inc. | 10/30/18 | 2D 3D TSV |
US9708295 | 51 | 41 | HGNC:427 | Substituted 2-aminopyridine protein kinase inhibitor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | 10/30/18 | 2D 3D TSV |
US10053463 | 422 | 125 | HGNC:8537 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | Janssen Pharmaceutica NV | 10/30/18 | 2D 3D TSV |
US9708270 | 91 | 89 | HGNC:19061 | Substituted spiropiperidinyl compounds useful as GPR120 agonists | Merck Sharp & Dohme Corp | 10/30/18 | 2D 3D TSV |
US9701663 | 37 | 11 | HGNC:14900 HGNC:5981 HGNC:16404 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC | 10/30/18 | 2D 3D TSV |
US9708274 | 328 | 298 | HGNC:7110 HGNC:7111 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATIONAL GMBH | 10/30/18 | 2D 3D TSV |
US10053461 | 41 | 40 | Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | Hoffmann-La Roche Inc | 10/30/18 | 2D 3D TSV | |
US9701638 | 16 | 16 | Therapeutic hydroxyquinolones | Rutgers, The State University of New Jersey | 10/30/18 | 2D 3D TSV | |
US9701691 | 25 | 25 | HGNC:11491 | Thienopyrimidine compounds | Hoffman-La Roche Inc | 10/30/18 | 2D 3D TSV |
US9550763 | 437 | 434 | HGNC:8534 | Heterocyclic ring and carbocyclic derivative | Shionogi & Co., Ltd | 10/19/18 | 2D 3D TSV |
US9546173 | 190 | 151 | HGNC:6871 HGNC:10430 HGNC:10432 | Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors | Novartis AG | 10/19/18 | 2D 3D TSV |
US10053433 | 20 | 10 | HGNC:644 | Androgen receptor antagonists | The Regents of the University of California | 10/18/18 | 2D 3D TSV |
US10053454 | 88 | 88 | HGNC:13575 | Carbazole compounds useful as bromodomain inhibitors | Bristol-Myers Squibb Co. | 10/18/18 | 2D 3D TSV |
US10053456 | 375 | 111 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Co., Ltd | 10/18/18 | 2D 3D TSV |
US10053455 | 22 | 22 | HGNC:11491 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE | 10/18/18 | 2D 3D TSV |
US10053434 | 24 | 22 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation Inc | 10/18/18 | 2D 3D TSV | |
US10053458 | 216 | 107 | HGNC:427 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | Korea Research Institute of Chemical Technology | 10/18/18 | 2D 3D TSV |
US10053431 | 514 | 247 | Tetrahydro-benzodiazepinones | Hoffmann-La Roche Inc | 10/18/18 | 2D 3D TSV | |
US9556139 | 260 | 245 | HGNC:4502 | 6-substituted phenoxychroman carboxylic acid derivatives | Array BioPharma Inc | 10/17/18 | 2D 3D TSV |
US9556135 | 339 | 168 | HGNC:2529 HGNC:933 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | Amgen Inc | 10/17/18 | 2D 3D TSV |
US10047118 | 7 | 7 | C17-aryl substituted betulinic acid analogs | ViiV HEALTHCARE UK (NO. 5) LIMITED | 10/17/18 | 2D 3D TSV | |
US10047086 | 158 | 158 | HGNC:29079 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | Incyte Corporation | 10/17/18 | 2D 3D TSV |
US9556143 | 18 | 5 | HGNC:2637 HGNC:2623 HGNC:2621 | Metalloenzyme inhibitor compounds | Viamet Pharmaceuticals Inc | 10/17/18 | 2D 3D TSV |
US9556168 | 60 | 60 | N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp | 10/17/18 | 2D 3D TSV | |
US9556148 | 86 | 29 | HGNC:6190 HGNC:6192 HGNC:6193 | N-cyanomethylamides as inhibitors of janus kinase | Cadila Healthcare Limited | 10/17/18 | 2D 3D TSV |
US10052306 | 333 | 328 | HGNC:4586 | Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC. | 10/17/18 | 2D 3D TSV |
US9555024 | 35 | 26 | HGNC:6833 HGNC:6834 HGNC:29079 | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors | University of Utah Research Foundation | 10/17/18 | 2D 3D TSV |
US9555022 | 102 | 101 | HGNC:12401 | Substituted triazolopyridines | Bayer Intellectual Property GmbH | 10/17/18 | 2D 3D TSV |
US10047080 | 42 | 21 | HGNC:4540 | (R)-2-methyl-piperazine derivatives as CXCR3 receptor modulators | IDORSIA PHARMACEUTICALS Ltd | 10/10/18 | 2D 3D TSV |
US10045974 | 14 | 12 | HGNC:933 | 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors | H. Lundbeck A/S | 10/10/18 | 2D 3D TSV |
US9556175 | 46 | 46 | HGNC:3009 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions | Boehringer Ingelheim International GmbH | 10/10/18 | 2D 3D TSV |
US10047073 | 12 | 11 | HGNC:14063 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation Inc | 10/10/18 | 2D 3D TSV |
US10047084 | 43 | 37 | HGNC:8979 HGNC:3942 | Imidazolone derivatives, pharmaceutical compositions and uses thereof | BEIJING FORELANDPHARMA CO. LTD. | 10/10/18 | 2D 3D TSV |
US10047093 | 120 | 102 | HGNC:6251 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | Tolero Pharmaceuticals Inc | 10/10/18 | 2D 3D TSV |
US9556191 | 8 | 30 | HGNC:3430 HGNC:8975 HGNC:3236 | Aminoquinazoline derivatives and their salts and methods of use thereof | Sunshine Lake Pharma Co., Ltd | 10/05/18 | 2D 3D TSV |
US9556160 | 76 | 37 | HGNC:550 | Guanidine compound | Astellas Pharma Inc | 10/03/18 | 2D 3D TSV |
US9562012 | 23 | 23 | PPAR-sparing compounds for the treatment of metabolic diseases | Metabolic Solutions Development Company, LLC | 10/03/18 | 2D 3D TSV | |
US9561238 | 6 | 3 | HGNC:3467 HGNC:3468 | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy | Donesta Bioscience B.V. | 10/03/18 | 2D 3D TSV |
US10047098 | 188 | 90 | HGNC:934 HGNC:933 | C5-C6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 10/02/18 | 2D 3D TSV |
US10047103 | 384 | 313 | HGNC:3540 HGNC:3535 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | Bristol-Myers Squibb Co. | 10/02/18 | 2D 3D TSV |
US10047097 | 105 | 105 | HGNC:8031 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Array BioPharma Inc | 10/02/18 | 2D 3D TSV |
US10047092 | 276 | 91 | HGNC:8537 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | Janssen Pharmaceutica NV | 10/02/18 | 2D 3D TSV |
US10047096 | 454 | 216 | HGNC:6307 HGNC:8804 | Substituted pyridobenzodiazepinone-derivatives and use thereof | Bayer Pharma Aktiengesellschaft | 10/02/18 | 2D 3D TSV |
US9556181 | 21 | 11 | Substituted pyrazolopyrimidinylamino-indazoles | Bayer Pharma Aktiengesellschaft | 09/30/18 | 2D 3D TSV | |
US9540377 | 1285 | 1155 | 2,6,7,8 substituted purines as HDM2 inhibitors | Merck Sharp & Dohme Corp | 09/26/18 | 2D 3D TSV | |
US9556157 | 6 | 4 | HGNC:3527 | Enhancer of zeste homolog 2 inhibitors | GlaxoSmithKline | 09/26/18 | 2D 3D TSV |
US9556170 | 3 | 3 | HGNC:29079 | Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors | University of Utah Research Foundation | 09/26/18 | 2D 3D TSV |
US9546152 | 448 | 115 | HGNC:4849 HGNC:4848 | 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists | Merck Sharp & Dohme Corp | 09/18/18 | 2D 3D TSV |
US9546153 | 514 | 427 | HGNC:17967 | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | Bristol-Myers Squibb Co. | 09/18/18 | 2D 3D TSV |
US9533992 | 75 | 71 | HGNC:8795 | PDE9 inhibitors with imidazo triazinone backbone | TBA | 09/18/18 | 2D 3D TSV |
US9550778 | 52 | 52 | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 | Vanderbilt University | 09/18/18 | 2D 3D TSV | |
US9556111 | 23 | 23 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO | 09/18/18 | 2D 3D TSV | |
US9556145 | 22 | 10 | HGNC:4849 HGNC:4848 | 2-pyridyloxy-4-ester orexin receptor antagonists | Merck Sharp & Dohme Corp | 09/07/18 | 2D 3D TSV |
US9540359 | 15 | 15 | HGNC:933 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | Shionogi & Co., Ltd | 09/07/18 | 2D 3D TSV |
US9556147 | 7 | 7 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA INC. | 09/07/18 | 2D 3D TSV |
US9550781 | 26 | 26 | Kinase modulating compounds, compositions containing the same and use thereof | Centaurus BioPharma Co., Ltd | 09/07/18 | 2D 3D TSV | |
US9556132 | 41 | 39 | HGNC:6293 | Tetrazole derivatives and their use as potassium channel modulators | Saniona A/S | 09/07/18 | 2D 3D TSV |
US9540396 | 38 | 38 | HGNC:6840 | 6-arylamino pyridone carboxamide as MEK inhibitors | Centaurus BioPharma Co., Ltd | 08/28/18 | 2D 3D TSV |
US9550755 | 5 | 5 | HGNC:2771 | Complement pathway modulators and uses thereof | Novartis AG | 08/28/18 | 2D 3D TSV |
US9546168 | 29 | 28 | HGNC:6871 | ERK inhibitors | Merck Sharp & Dohme Corp | 08/28/18 | 2D 3D TSV |
US9550774 | 2 | 2 | HGNC:3357 | Dihydropyrido pyrimidine compounds as autotaxin inhibitors | Eli Lilly and Company | 08/25/18 | 2D 3D TSV |
US9527857 | 211 | 76 | HGNC:1771 HGNC:1773 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | GI Therapeutics, Inc. | 08/25/18 | 2D 3D TSV |
US9540379 | 222 | 110 | HGNC:8772 | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases | Boehringer Ingelheim International GmbH | 08/24/18 | 2D 3D TSV |
US9539260 | 567 | 272 | HGNC:8975 HGNC:8977 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | Novartis AG | 08/24/18 | 2D 3D TSV |
US9540357 | 74 | 19 | HGNC:9594 HGNC:9596 | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof | Allergan Inc | 08/16/18 | 2D 3D TSV |
US9540323 | 274 | 267 | HGNC:8539 | 7-hydroxy-indolinyl antagonists of P2Y1 receptor | Bristol-Myers Squibb Co. | 08/16/18 | 2D 3D TSV |
US9540388 | 197 | 56 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 08/16/18 | 2D 3D TSV |
US9527851 | 130 | 79 | HGNC:6190 HGNC:6192 HGNC:6193 | Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof | Jiangsu Hengrui Medicine Co., Ltd. | 08/16/18 | 2D 3D TSV |
US9540352 | 14 | 14 | HGNC:3020 | Substituted 1,7-naphthyridines as dopamine D1 ligands | Pfizer Inc | 08/16/18 | 2D 3D TSV |
US9670229 | 31 | 29 | HGNC:5297 | 5-HT3 receptor antagonists | Takeda Pharmaceutical Co., Ltd | 08/07/18 | 2D 3D TSV |
US9522914 | 174 | 174 | HGNC:896 | Azole derivative | Taisho Pharmaceutical Co., Ltd | 08/07/18 | 2D 3D TSV |
US9540364 | 19 | 19 | HGNC:9376 | Benzimidazole tetrahydrofuran derivatives | Merck Sharp & Dohme Corp | 08/07/18 | 2D 3D TSV |
US9676777 | 3 | 3 | Compounds useful for producing an optically active diazabicyclooctane compound | Meiji Seika Pharma Co., Ltd | 08/07/18 | 2D 3D TSV | |
US9533999 | 64 | 64 | HGNC:6293 | Fused thiazin-3-ones as KCA3.1 inhibitors | Boehringer Ingelheim International GmbH | 08/07/18 | 2D 3D TSV |
US9670231 | 368 | 84 | HGNC:9829 HGNC:3236 | Fused tricyclic amide compounds as multiple kinase inhibitors | BeiGene, Ltd | 08/07/18 | 2D 3D TSV |
US9670230 | 12 | 12 | HGNC:8772 | Heteroaryl compounds and methods of use thereof | Sunovion Pharmaceuticals Inc | 08/07/18 | 2D 3D TSV |
US9676783 | 105 | 105 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | Array BioPharma Inc | 08/07/18 | 2D 3D TSV | |
US9670255 | 3 | 2 | Modified biotin, mutant streptavidin, and use thereof | SAVID THERAPEUTICS INC. | 08/07/18 | 2D 3D TSV | |
US9676786 | 4 | 4 | HGNC:4326 | Pharmacologically active compounds | The University of Liverpool | 08/07/18 | 2D 3D TSV |
US9676792 | 4 | 2 | HGNC:6880 | Pyrimido-diazepinone compounds and methods of treating disorders | Dana-Farber Cancer Institute Inc | 08/07/18 | 2D 3D TSV |
US9540384 | 58 | 58 | HGNC:8772 | Pyrrolidino heterocycles | Hoffmann-La Roche Inc | 08/07/18 | 2D 3D TSV |
US9533995 | 14 | 14 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | Sanofi | 08/07/18 | 2D 3D TSV | |
US9676782 | 342 | 166 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of metabotropic glutamate receptor 3 | Vanderbilt University | 08/07/18 | 2D 3D TSV | |
US9540373 | 27 | 27 | HGNC:2528 | Substituted spirocycles | Boehringer Ingelheim International GmbH | 08/07/18 | 2D 3D TSV |
US9676818 | 32 | 32 | HGNC:11848 | Toll-like receptor 2-agonistic lipopeptides, and method of making the same | University of Kansas | 08/07/18 | 2D 3D TSV |
US9670211 | 45 | 45 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | Hoffmann-La Roche Inc | 07/07/18 | 2D 3D TSV | |
US9670216 | 58 | 33 | HGNC:2160 HGNC:2159 | Cannabinoid-2 agonists | Allergan Inc | 07/07/18 | 2D 3D TSV |
US9670204 | 211 | 208 | HGNC:3357 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | Galapagos NV | 07/07/18 | 2D 3D TSV |
US9670210 | 116 | 116 | HGNC:29079 | Cyclopropylamines as LSD1 inhibitors | Incyte Corporation | 07/07/18 | 2D 3D TSV |
US9670220 | 66 | 21 | HGNC:3167 HGNC:3165 HGNC:14299 | Fused heterocyclic derivatives as S1P modulators | AbbVie B.V. | 07/07/18 | 2D 3D TSV |
US9670203 | 142 | 101 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BeiGene, Ltd | 07/07/18 | 2D 3D TSV | |
US9670212 | 191 | 188 | HGNC:8977 | Inhibitors of PI3K-delta and methods of their use and manufacture | Exelixis Inc | 07/07/18 | 2D 3D TSV |
US9670209 | 69 | 24 | HGNC:1950 HGNC:1952 HGNC:1951 | Muscarinic agonists | ACADIA Pharmaceuticals Inc | 07/07/18 | 2D 3D TSV |
US9670213 | 175 | 34 | HGNC:1057 HGNC:3236 HGNC:3765 | Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor | East China University of Science and Technology | 07/07/18 | 2D 3D TSV |
US9670208 | 48 | 48 | Serine/threonine kinase inhibitors | Array BioPharma Inc | 07/07/18 | 2D 3D TSV | |
US9670214 | 404 | 200 | Small molecule myristate inhibitors of Bcr-abl and methods of use | Dana-Farber Cancer Institute Inc | 07/07/18 | 2D 3D TSV | |
US9670136 | 210 | 57 | HGNC:6833 HGNC:6834 HGNC:29079 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | Oryzon Genomics, S.A. | 05/19/18 | 2D 3D TSV |
US9670142 | 171 | 170 | HGNC:3594 | 1,3-diaminocyclopentane carboxamide derivatives | Merck Patent GmbH | 05/19/18 | 2D 3D TSV |
US9669034 | 227 | 84 | HGNC:1780 HGNC:1771 | 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group | Bayer Intellectual Property GmbH | 05/19/18 | 2D 3D TSV |
US9670161 | 20 | 5 | HGNC:1780 HGNC:1771 | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group | Bayer Pharma Aktiengesellschaft | 05/19/18 | 2D 3D TSV |
US9670157 | 271 | 121 | HGNC:3530 HGNC:6371 HGNC:9475 HGNC:3535 HGNC:6357 HGNC:9071 | Benzylamine derivatives | Kalvista Pharmaceuticals Limited | 05/19/18 | 2D 3D TSV |
US9669035 | 66 | 32 | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders | Janssen Pharmaceutica NV | 05/19/18 | 2D 3D TSV | |
US9669095 | 13 | 13 | Cyclosporin analogues for preventing or treating hepatitis C infection | Enanta Pharmaceuticals Inc | 05/19/18 | 2D 3D TSV | |
US9670195 | 3 | 3 | HGNC:7056 | Glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 05/19/18 | 2D 3D TSV |
US9669029 | 114 | 110 | Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors | H. Lundbeck A/S | 05/19/18 | 2D 3D TSV | |
US9669031 | 313 | 182 | HGNC:7110 HGNC:7111 | MNK inhibitors and methods related thereto | eFFECTOR Therapeutics Inc | 05/19/18 | 2D 3D TSV |
US9670201 | 104 | 104 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | Pfizer Inc | 05/19/18 | 2D 3D TSV | |
US9670191 | 116 | 115 | HGNC:17364 | Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors | Nerviano Medical Sciences srl | 05/19/18 | 2D 3D TSV |
US9669028 | 175 | 65 | HGNC:18618 HGNC:3091 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC | 05/19/18 | 2D 3D TSV |
US9670181 | 87 | 83 | HGNC:8772 HGNC:8783 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | Allergan Inc | 05/19/18 | 2D 3D TSV |
US9670194 | 71 | 39 | HGNC:8979 HGNC:8978 HGNC:8977 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC | 05/19/18 | 2D 3D TSV |
US9670166 | 297 | 273 | HGNC:3309 HGNC:2622 HGNC:2623 HGNC:2621 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 05/19/18 | 2D 3D TSV |
US9670202 | 22 | 21 | HGNC:12401 | Substituted triazolopyridines | Bayer Pharma Aktiengesellschaft | 05/19/18 | 2D 3D TSV |
US9670196 | 13 | 12 | HGNC:11491 | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors | Merck Sharp & Dohme Corp | 05/19/18 | 2D 3D TSV |
US9670193 | 138 | 46 | HGNC:4852 HGNC:14064 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | Novartis AG | 05/19/18 | 2D 3D TSV |
US9676728 | 19 | 17 | HGNC:1037 | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof | Novartis AG | 04/16/18 | 2D 3D TSV |
US9675697 | 203 | 33 | BET bromodomain inhibitors and therapeutic methods using the same | The Regents of the University of Michigan | 04/16/18 | 2D 3D TSV | |
US9676721 | 112 | 111 | HGNC:30092 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC | 04/16/18 | 2D 3D TSV |
US9676701 | 287 | 95 | HGNC:6833 HGNC:6834 HGNC:29079 | Cyclopropylamine derivatives useful as LSD1 inhibitors | Oryzon Genomics, S.A. | 04/16/18 | 2D 3D TSV |
US9676732 | 74 | 74 | HGNC:4596 | Ethynyl derivatives | Hoffmann-La Roche Inc | 04/16/18 | 2D 3D TSV |
US9676712 | 15 | 6 | HGNC:9594 HGNC:9596 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Cayman Chemical Company Inc | 04/16/18 | 2D 3D TSV |
US9676720 | 29 | 29 | HGNC:9594 | Substituted biaryl compound | Ube Industries, Ltd | 04/16/18 | 2D 3D TSV |
US9675616 | 13 | 7 | HGNC:8979 | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines | Bayer Intellectual Property GmbH | 04/12/18 | 2D 3D TSV |
US9688710 | 328 | 160 | HGNC:11037 HGNC:11036 | Inhibitors of sodium glucose cotransporter 1 | Lexicon Pharmaceuticals, Inc. | 04/12/18 | 2D 3D TSV |
US9675614 | 334 | 329 | PRMT5 inhibitors and uses thereof | Epizyme Inc | 04/12/18 | 2D 3D TSV | |
US9688696 | 116 | 115 | HGNC:2843 | Piperidine/piperazine derivatives | Janssen Pharmaceutica NV | 04/12/18 | 2D 3D TSV |
US9688816 | 46 | 21 | HGNC:3467 HGNC:3468 | Polyetherimide compositions and methods for the manufacture and use thereof | SABIC GLOBAL TECHNOLOGIES B.V. | 04/12/18 | 2D 3D TSV |
US9675612 | 45 | 45 | Substituted thiazolopyrimidines | Bayer Pharma Aktiengesellschaft | 04/12/18 | 2D 3D TSV | |
US9688680 | 950 | 313 | HGNC:6342 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION | 03/27/18 | 2D 3D TSV |
US9688695 | 384 | 312 | HGNC:3540 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | Bristol-Myers Squibb Co. | 03/27/18 | 2D 3D TSV |
US9688678 | 37 | 36 | HGNC:896 | Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG | 03/27/18 | 2D 3D TSV |
US9688683 | 31 | 30 | HGNC:8781 | Substituted condensed pyrimidine compounds | GRÜNENTHAL GMBH | 03/27/18 | 2D 3D TSV |
US9688684 | 278 | 162 | Substituted tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors | Merck Patent GmbH | 03/27/18 | 2D 3D TSV | |
US9688676 | 65 | 64 | HGNC:1133 | Tyrosine kinase inhibitors | Principia Biopharma Inc | 03/27/18 | 2D 3D TSV |
US9688672 | 450 | 375 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | Novartis AG | 03/19/18 | 2D 3D TSV | |
US9688668 | 150 | 72 | HGNC:18859 HGNC:11240 | Long chain base sphingosine kinase inhibitors | University of Virginia Patent Foundation | 03/19/18 | 2D 3D TSV |
US9688664 | 8 | 2 | HGNC:3553 HGNC:2625 | Modulators of fatty acid amide hydrolase | Janssen Pharmaceutica NV | 03/19/18 | 2D 3D TSV |
US9688669 | 125 | 113 | Oxazolidinones as modulators of mGluR5 | Bristol-Myers Squibb Co. | 03/19/18 | 2D 3D TSV | |
US9688661 | 139 | 50 | HGNC:6192 | Substituted pyrroles active as kinases inhibitors | Nerviano Medical Sciences srl | 03/19/18 | 2D 3D TSV |
US9675593 | 518 | 518 | HGNC:3176 | Anti-fibrotic pyridinones | INTERMUNE, Inc. | 03/16/18 | 2D 3D TSV |
US9675594 | 46 | 23 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. Lundbeck A/S | 03/16/18 | 2D 3D TSV | |
US9675539 | 2 | 2 | HGNC:9600 | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives | Duke University | 03/16/18 | 2D 3D TSV |
US9675571 | 28 | 28 | HGNC:6059 | Inhibitors of indoleamine 2,3-dioxygenase (IDO) | Bristol-Myers Squibb Co. | 03/16/18 | 2D 3D TSV |
US9688645 | 25 | 25 | HGNC:2300 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | Sanofi | 03/16/18 | 2D 3D TSV |
US9675591 | 9 | 1 | HGNC:6290 HGNC:10588 HGNC:10590 HGNC:6231 HGNC:10591 HGNC:10593 HGNC:10585 | Methods for treating seizure disorders and pain | The Regents of the University of California | 03/16/18 | 2D 3D TSV |
US9675605 | 83 | 83 | HGNC:6834 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | Dart NeuroScience (Cayman) Ltd | 03/16/18 | 2D 3D TSV |
US9688642 | 96 | 47 | HGNC:4498 | Substituted pyrazines as GPR40 agonists | Janssen Pharmaceutica NV | 03/12/18 | 2D 3D TSV |
US9688643 | 325 | 325 | HGNC:8534 | Triazine derivative and pharmaceutical composition comprising the same | Shionogi & Co., Ltd | 03/12/18 | 2D 3D TSV |
US9688638 | 35 | 8 | HGNC:8154 HGNC:8156 | Opioid agonists and uses thereof | Nektar Therapeutics | 03/11/18 | 2D 3D TSV |
US9682995 | 359 | 122 | HGNC:1771 HGNC:12401 | Amino-substituted isothiazoles | Bayer Pharma Aktiengesellschaft | 03/10/18 | 2D 3D TSV |
US9682993 | 22 | 11 | HGNC:6973 | Anticancer compounds | St. Jude Children's Research Hospital | 03/10/18 | 2D 3D TSV |
US9682983 | 326 | 66 | HGNC:171 HGNC:1076 HGNC:172 HGNC:175 | BMP inhibitors and methods of use thereof | The Brigham and Women's Hospital, Inc. | 03/10/18 | 2D 3D TSV |
US9688615 | 706 | 99 | HGNC:1395 HGNC:1394 HGNC:1390 HGNC:10593 HGNC:1389 | Benzimidazole inhibitors of the sodium channel | DEGIACOMO, INTERIM TRUSTEE, MARK G. | 03/10/18 | 2D 3D TSV |
US9688624 | 12 | 6 | HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2621 | DP2 antagonist and uses thereof | Brickell Biotech, Inc. | 03/10/18 | 2D 3D TSV |
US9687494 | 21 | 11 | HGNC:934 HGNC:933 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | Ambit Biosciences | 03/10/18 | 2D 3D TSV |
US9688629 | 262 | 223 | HGNC:1133 | Indole carboxamide compounds | Bristol-Myers Squibb Co. | 03/10/18 | 2D 3D TSV |
US9687479 | 520 | 391 | HGNC:6371 HGNC:3535 HGNC:6357 | Multisubstituted aromatic compounds as serine protease inhibitors | VERSEON CORPORATION | 03/10/18 | 2D 3D TSV |
US9687478 | 34 | 34 | HGNC:1952 | Quinuclidine derivatives and medicinal compositions containing the same | Almirall, S.A. | 03/10/18 | 2D 3D TSV |
US9687483 | 5 | 2 | Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors | BIOAXONE BIOSCIENCES, INC. | 03/10/18 | 2D 3D TSV | |
US9682991 | 198 | 91 | HGNC:19310 HGNC:8987 | Tricyclic compounds for use as kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III | 03/10/18 | 2D 3D TSV |
US9682971 | 220 | 216 | HGNC:436 | 1,2,5-Substituted benzimidazoles as flap modulators | Janssen Pharmaceutica NV | 02/14/18 | 2D 3D TSV |
US9682980 | 85 | 83 | HGNC:4594 | Positive allosteric modulators of mGluR2 | Bristol-Myers Squibb Co. | 02/14/18 | 2D 3D TSV |
US9682976 | 324 | 296 | HGNC:6001 | Protein kinase C inhibitors and uses thereof | Rigel Pharmaceuticals, Inc | 02/14/18 | 2D 3D TSV |
US9682959 | 6 | 6 | HGNC:4597 | Ethynyl derivatives | Hoffmann-La Roche Inc | 02/13/18 | 2D 3D TSV |
US9682965 | 75 | 75 | HGNC:16672 | Fumagillol heterocyclic compounds and methods of making and using same | Zafgen, Inc. | 02/13/18 | 2D 3D TSV |
US9682966 | 563 | 547 | HGNC:8154 | Kappa opioid ligands | The Scripps Research Institute | 02/13/18 | 2D 3D TSV |
US9682967 | 50 | 49 | HGNC:11186 | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | H. Lundbeck A/S | 02/13/18 | 2D 3D TSV |
US9682960 | 137 | 127 | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety | ENDORECHERCHE, INC. | 02/13/18 | 2D 3D TSV | |
US9682969 | 31 | 26 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | Flatley Discovery Lab LLC | 02/13/18 | 2D 3D TSV | |
US9682968 | 110 | 98 | HGNC:1037 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | Novartis AG | 02/13/18 | 2D 3D TSV |
US9682963 | 28 | 16 | HGNC:10252 | Pyridine derivatives as soft rock inhibitors | Redx Pharma PLC | 02/13/18 | 2D 3D TSV |
US9682961 | 26 | 26 | HGNC:15983 | Quinazoline derivative | Carna Biosciences, Inc | 02/13/18 | 2D 3D TSV |
US9682953 | 166 | 95 | HGNC:3553 | Amide compounds, compositions and applications thereof | Advinus Therapeutics Ltd | 02/07/18 | 2D 3D TSV |
US9687476 | 60 | 30 | HGNC:897 HGNC:895 | Bisaryl-bonded aryltriazolones and use thereof | Bayer Intellectual Property GmbH | 02/07/18 | 2D 3D TSV |
US9682141 | 2516 | 586 | HGNC:8979 HGNC:8978 HGNC:8980 HGNC:3942 HGNC:8977 | Combination of kinase inhibitors and uses thereof | Intellikine LLC | 02/07/18 | 2D 3D TSV |
US9682957 | 192 | 95 | HGNC:286 HGNC:1952 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | Theravance Respiratory Company LLC | 02/07/18 | 2D 3D TSV |
US9682940 | 502 | 236 | HGNC:2160 HGNC:2159 | Indazole derivatives useful as CB-1 inverse agonists | Janssen Pharmaceutica NV | 02/07/18 | 2D 3D TSV |
US9682955 | 280 | 140 | HGNC:2160 HGNC:2159 | Quinazoline derivatives useful as CB-1 inverse agonists | Janssen Pharmaceutica NV | 02/07/18 | 2D 3D TSV |
US9682910 | 35 | 35 | Series of skin-whitening (lightening) compounds | Unigen, Inc. | 02/07/18 | 2D 3D TSV | |
US9695195 | 162 | 151 | HGNC:5297 | 5-HT3 receptor antagonists | Takeda Pharmaceutical Co., Ltd | 02/06/18 | 2D 3D TSV |
US9695205 | 53 | 53 | HGNC:2771 | Amide compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals Inc | 02/06/18 | 2D 3D TSV |
US9695197 | 11 | 6 | HGNC:7056 | Glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 02/06/18 | 2D 3D TSV |
US9695200 | 175 | 92 | HGNC:6171 HGNC:9065 | Heterocyclic ITK inhibitors for treating inflammation and cancer | Confluence Life Sciences Inc | 02/06/18 | 2D 3D TSV |
US9695151 | 90 | 41 | HGNC:2592 HGNC:2591 | 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds | Hoffmann-La Roche Inc | 01/26/18 | 2D 3D TSV |
US9695152 | 84 | 38 | HGNC:2592 HGNC:2591 | 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds | Hoffmann-La Roche Inc | 01/26/18 | 2D 3D TSV |
US9695194 | 126 | 18 | HGNC:9475 HGNC:6362 HGNC:3535 HGNC:2523 HGNC:6368 HGNC:2532 | Benzoxazinone derivatives for treatment of skin diseases | SIXERA Pharma AB | 01/26/18 | 2D 3D TSV |
US9695172 | 15 | 5 | HGNC:11393 HGNC:18618 HGNC:11390 HGNC:11391 HGNC:13575 HGNC:1105 | Diazepane derivatives and uses thereof | Dana-Farber Cancer Institute Inc | 01/26/18 | 2D 3D TSV |
US9695175 | 51 | 51 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. | 01/26/18 | 2D 3D TSV | |
US9695181 | 15 | 6 | HGNC:4852 HGNC:6307 HGNC:8804 | Hydroximic acid derivatives and medical applications therof | DOUBLE RIDER MEDICINE CO., LTD. | 01/26/18 | 2D 3D TSV |
US9695174 | 21 | 8 | HGNC:74 HGNC:40 HGNC:2638 HGNC:2625 HGNC:2622 HGNC:2623 HGNC:2621 | Inhibitor of breast cancer resistance protein (BCRP) | Millennium Pharmaceuticals Inc | 01/26/18 | 2D 3D TSV |
US9695165 | 82 | 55 | HGNC:3255 HGNC:3691 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION | 01/26/18 | 2D 3D TSV |
US9695179 | 17 | 17 | HGNC:30193 | Methods and compositions for inhibition of bromodomain-containing proteins | ConverGene LLC | 01/26/18 | 2D 3D TSV |
US9695170 | 217 | 199 | HGNC:1232 | Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase | FibroGen Inc | 01/26/18 | 2D 3D TSV |
US9695160 | 36 | 36 | HGNC:11305 | Piperazine derivatives for treating disorders | The University of Nottingham | 01/26/18 | 2D 3D TSV |
US9695183 | 702 | 266 | HGNC:4849 HGNC:4848 | Substituted 7-azabicycles and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 01/26/18 | 2D 3D TSV |
US9695180 | 119 | 119 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | Incyte Corporation | 01/26/18 | 2D 3D TSV | |
US9695168 | 158 | 158 | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors | Incyte Corporation | 01/26/18 | 2D 3D TSV | |
US9695176 | 4 | 4 | HGNC:16709 | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | Bristol-Myers Squibb Co. | 01/26/18 | 2D 3D TSV |
US9695167 | 13 | 13 | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors | Incyte Corporation | 01/26/18 | 2D 3D TSV | |
US9695185 | 5 | 5 | HGNC:10597 | Synthetic methods for spiro-oxindole compounds | Xenon Pharmaceuticals Inc | 01/26/18 | 2D 3D TSV |
US9695163 | 76 | 38 | HGNC:4849 HGNC:4848 | Thiazole orexin receptor antagonists | Merck Sharp & Dohme Corp | 01/26/18 | 2D 3D TSV |
US9695149 | 235 | 217 | HGNC:436 | 1,2,6-substituted benzimidazoles as flap modulators | Janssen Pharmaceutica NV | 01/19/18 | 2D 3D TSV |
US9695118 | 394 | 382 | HGNC:2730 | Benzamide derivative | Chugai Seiyaku Kabushiki Kaisha | 01/19/18 | 2D 3D TSV |
US9694016 | 2555 | 1061 | Biaryl amide compounds as kinase inhibitors | Novartis AG | 01/19/18 | 2D 3D TSV | |
US9695128 | 13 | 13 | HGNC:4596 | Ethynyl derivatives | Hoffmann-La Roche Inc | 01/19/18 | 2D 3D TSV |
US9695132 | 194 | 190 | HGNC:3691 | Heteroaryl compounds and uses thereof | Celgene CAR LLC | 01/19/18 | 2D 3D TSV |
US9694018 | 12 | 12 | HGNC:7967 | IBAT inhibitors for the treatment of liver disease | Albireo AB | 01/19/18 | 2D 3D TSV |
US9694015 | 59 | 10 | HGNC:5992 HGNC:10627 HGNC:21163 HGNC:11892 HGNC:6018 HGNC:2434 HGNC:10630 | Methods for the treatment of locally advanced breast cancer | Celgene Corporation | 01/19/18 | 2D 3D TSV |
US9694024 | 17 | 7 | Methods of treating retroviral infections and related dosage regimes | Chimerix, Inc. | 01/19/18 | 2D 3D TSV | |
US9694012 | 76 | 38 | HGNC:2160 HGNC:2159 | Pyrazol derivatives | Hoffmann-La Roche Inc | 01/19/18 | 2D 3D TSV |
US9694011 | 6 | 2 | HGNC:1133 | Substituted pyrazolopyrimidines as kinases inhibitors | Jiangsu Medolution Ltd | 01/19/18 | 2D 3D TSV |
US9695131 | 56 | 50 | Substituted uracils as chymase inhibitors | Bayer Pharma Aktiengesellschaft | 01/19/18 | 2D 3D TSV | |
US9693997 | 356 | 293 | Antiviral compounds | Hoffmann-La Roche Inc | 01/14/18 | 2D 3D TSV | |
US9693992 | 251 | 249 | HGNC:3449 | IRE-1α inhibitors | MannKind Corporation | 01/14/18 | 2D 3D TSV |
US9694002 | 648 | 574 | HGNC:10583 HGNC:10593 HGNC:10597 | Substituted benzamides and methods of use thereof | Genentech Inc | 01/14/18 | 2D 3D TSV |
US9527838 | 54 | 54 | HGNC:4195 | 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment | Merck Sharp & Dohme Corp | 12/04/17 | 2D 3D TSV |
US9527839 | 25 | 25 | HGNC:9385 | Benzimidazole tetrahydropyran derivatives | Merck Sharp & Dohme Corp | 12/04/17 | 2D 3D TSV |
US9533969 | 6 | 6 | HGNC:10289 | Materials and method for inhibiting replication protein A and uses thereof | Indiana University Research and Technology Corporation | 12/04/17 | 2D 3D TSV |
US9532990 | 119 | 119 | HGNC:1133 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd | 12/04/17 | 2D 3D TSV |
US9504692 | 48 | 45 | HGNC:6819 | Selective inhibition of MALT1 protease by phenothiazine derivatives | HELMHOLTZ ZENTRUM MUNCHEN, DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) | 12/04/17 | 2D 3D TSV |
US9533989 | 123 | 116 | HGNC:11491 | Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors | Ziarco Pharma Ltd. | 12/04/17 | 2D 3D TSV |
US9533985 | 193 | 104 | HGNC:6162 HGNC:12663 | Sulfonamide derivative and medicinal use thereof | EA Pharma Co., Ltd. | 12/04/17 | 2D 3D TSV |
US9522881 | 71 | 48 | HGNC:6080 HGNC:9671 HGNC:1718 HGNC:9651 HGNC:3069 HGNC:3065 HGNC:21480 HGNC:28110 HGNC:9642 HGNC:9675 HGNC:9652 HGNC:9655 HGNC:9657 HGNC:9659 HGNC:25016 HGNC:9658 HGNC:122 HGNC:9669 HGNC:9647 | Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) | Indiana University Research and Technology Corporation | 11/27/17 | 2D 3D TSV |
US9512115 | 58 | 29 | HGNC:9753 | Inhibitors | Probiodrug AG | 11/27/17 | 2D 3D TSV |
US9505766 | 158 | 77 | HGNC:1133 HGNC:9077 HGNC:11283 | Kinase inhibitors | The Regents of the University of California | 11/27/17 | 2D 3D TSV |
US9522910 | 16 | 8 | HGNC:76 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU “FUSION PHARMA” | 11/27/17 | 2D 3D TSV |
US9505762 | 338 | 169 | HGNC:2160 HGNC:2159 | Purine derivatives as CB2 receptor agonists | Hoffmann-La Roche Inc | 11/27/17 | 2D 3D TSV |
US9512141 | 84 | 42 | HGNC:2160 HGNC:2159 | Pyrazine derivatives as CB2 receptor agonists | Hoffmann-La Roche Inc | 11/27/17 | 2D 3D TSV |
US9512132 | 76 | 37 | HGNC:2160 HGNC:2159 | Pyrazole compounds as CB2 agonists | Hoffmann-La Roche Inc | 11/27/17 | 2D 3D TSV |
US9522886 | 195 | 90 | HGNC:2160 HGNC:2159 | Pyridine derivatives | Hoffmann-La Roche Inc | 11/27/17 | 2D 3D TSV |
US9505749 | 527 | 145 | HGNC:270 HGNC:272 | Quinazolinone compounds and derivatives thereof | Amgen Inc | 11/27/17 | 2D 3D TSV |
US9505780 | 114 | 28 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Thienopyranones as kinase and epigenetic inhibitors | Signal Rx Pharmaceuticals Inc | 11/27/17 | 2D 3D TSV |
US9512121 | 47 | 47 | HGNC:7029 | [1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 11/27/17 | 2D 3D TSV |
US9499492 | 130 | 42 | HGNC:1373 HGNC:1780 HGNC:4638 HGNC:1368 | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group | Bayer Pharma Aktiengesellschaft | 11/20/17 | 2D 3D TSV |
US9499502 | 733 | 363 | HGNC:934 HGNC:933 | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 11/20/17 | 2D 3D TSV |
US9512084 | 40 | 40 | HGNC:1133 | Amino pyrimidine derivatives | Novartis AG | 11/20/17 | 2D 3D TSV |
US9499547 | 110 | 64 | HGNC:4638 | Amino-substituted imidazopyridazines | Bayer Intellectual Property GmbH | 11/20/17 | 2D 3D TSV |
US9493490 | 60 | 10 | HGNC:391 HGNC:9380 HGNC:9393 HGNC:289 HGNC:4638 HGNC:10430 | Boron-containing small molecules | Anacor Pharmaceuticals Inc | 11/20/17 | 2D 3D TSV |
US9493486 | 113 | 112 | HGNC:3357 | Diazaspirocycloalkane and azaspirocycloalkane | Hoffmann-La Roches Inc. | 11/20/17 | 2D 3D TSV |
US9505745 | 110 | 76 | Enhancer of zeste homolog 2 inhibitors | GlaxoSmithKline | 11/20/17 | 2D 3D TSV | |
US9526727 | 30 | 29 | HGNC:6251 | Inhibitors of beta-secretase | Vitae Pharmaceutical, Inc. | 11/20/17 | 2D 3D TSV |
US9499482 | 247 | 247 | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Co. | 11/20/17 | 2D 3D TSV | |
US9512114 | 52 | 22 | HGNC:8979 HGNC:8978 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC | 11/20/17 | 2D 3D TSV |
US9512126 | 25 | 25 | HGNC:12401 | Substituted imidazopyridazines | Bayer Intellectual Property GmbH | 11/20/17 | 2D 3D TSV |
US9512169 | 23 | 19 | HGNC:4638 | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments | Bayer Pharma Aktiengesellschaft | 11/13/17 | 2D 3D TSV |
US9512068 | 14 | 14 | Augmenting moieties for anti-inflammatory compounds | Rutgers, The State University of New Jersey | 11/13/17 | 2D 3D TSV | |
US9493448 | 168 | 150 | HGNC:10597 | Cycloalkane derivatives | Daiichi Sankyo Company, Limited | 11/13/17 | 2D 3D TSV |
US9511061 | 6 | 1 | HGNC:5302 HGNC:5297 HGNC:5295 HGNC:5294 | Incontinence treatment methods | IXALTIS | 11/13/17 | 2D 3D TSV |
US9505753 | 69 | 68 | HGNC:2671 | Inhibitors of D-amino acid oxidase | The Johns Hopkins University | 11/13/17 | 2D 3D TSV |
US9512082 | 7 | 7 | HGNC:9753 | Inhibitors of glutaminyl cyclase | Probiodrug AG | 11/13/17 | 2D 3D TSV |
US9493446 | 1134 | 565 | HGNC:4849 HGNC:4848 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | Actelion Pharmaceuticals Ltd | 11/13/17 | 2D 3D TSV |
US9512065 | 5 | 1 | HGNC:9475 HGNC:3528 HGNC:3535 HGNC:9071 | Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride | Kalvista Pharmaceuticals Limited | 11/13/17 | 2D 3D TSV |
US9493485 | 178 | 65 | HGNC:2529 HGNC:933 | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof | Imago Pharmaceuticals Inc | 11/13/17 | 2D 3D TSV |
US9505786 | 59 | 59 | HGNC:8784 | Substituted annulated triazines and use thereof | Bayer Pharma Aktiengesellschaft | 11/13/17 | 2D 3D TSV |
US9522888 | 952 | 242 | HGNC:3167 HGNC:3165 | Substituted bicyclic compounds | Bristol-Myers Squibb Co. | 11/13/17 | 2D 3D TSV |
US9512130 | 4 | 4 | HGNC:2637 | Substituted imidazopyridazines | Bayer Pharma Aktiengesellschaft | 11/13/17 | 2D 3D TSV |
US9493441 | 222 | 108 | HGNC:6190 HGNC:6192 | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | Merck Sharp & Dohme Corp | 11/06/17 | 2D 3D TSV |
US9489013 | 194 | 97 | HGNC:934 HGNC:933 | C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 11/06/17 | 2D 3D TSV |
US9493440 | 239 | 223 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | Merck Sharp & Dohme Corp | 11/06/17 | 2D 3D TSV | |
US9493432 | 214 | 104 | HGNC:4849 HGNC:4848 | Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders | Takeda Pharmaceutical Co., Ltd | 11/06/17 | 2D 3D TSV |
US9487511 | 375 | 113 | HGNC:6833 HGNC:6834 HGNC:4638 | Cyclopropanamine compound and use thereof | Takeda Pharmaceutical Co., Ltd | 11/06/17 | 2D 3D TSV |
US9522883 | 1 | 1 | HGNC:7056 | Glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 11/06/17 | 2D 3D TSV |
US9505736 | 16 | 16 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI Foundation Inc | 11/06/17 | 2D 3D TSV | |
US9493435 | 182 | 174 | HGNC:4638 | IRE-1α inhibitors | MannKing Corporation | 11/06/17 | 2D 3D TSV |
US9492453 | 77 | 76 | HGNC:391 | Protein kinase B inhibitors | AstraZeneca AB | 11/06/17 | 2D 3D TSV |
US9505773 | 18 | 18 | HGNC:3711 | Rapamycin analogues and their pharmaceutical use | Isomerase Therapeutics Ltd. | 11/06/17 | 2D 3D TSV |
US9504684 | 11 | 11 | HGNC:11491 | Syk inhibitors | Gilead Sciences Inc | 11/06/17 | 2D 3D TSV |
US9487512 | 159 | 44 | HGNC:6833 HGNC:6834 HGNC:4638 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | Oryzon Genomics, S.A. | 10/30/17 | 2D 3D TSV |
US9487490 | 63 | 63 | 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof | Merck Sharp & Dohme Corp | 10/30/17 | 2D 3D TSV | |
US9481672 | 253 | 246 | Bicyclically substituted uracils and the use thereof | Bayer Pharma Aktiengesellschaft | 10/30/17 | 2D 3D TSV | |
US9487483 | 128 | 128 | HGNC:2771 | Complement pathway modulators and uses thereof | Novartis AG | 10/30/17 | 2D 3D TSV |
US9505754 | 4 | 1 | Compound useful for the treatment of degenerative and inflammatory diseases | Galapagos NV | 10/30/17 | 2D 3D TSV | |
US9487462 | 114 | 29 | HGNC:7176 HGNC:7155 HGNC:7166 HGNC:7159 | Inhibitors of matrix metalloproteinases | PharmaHungary 2000 Kft. | 10/30/17 | 2D 3D TSV |
US9481648 | 347 | 120 | HGNC:11491 HGNC:11283 HGNC:6251 HGNC:2637 HGNC:4616 HGNC:2623 HGNC:6876 | Kinase inhibitors | Respivert Limited | 10/30/17 | 2D 3D TSV |
US9505743 | 3 | 2 | HGNC:7159 | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases | TBA | 10/30/17 | 2D 3D TSV |
US9487501 | 114 | 57 | Pyrazole carboxamide compounds and uses thereof | Hoffmann-La Roche Inc | 10/30/17 | 2D 3D TSV | |
US9475815 | 228 | 130 | HGNC:4638 | Substituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLETUAL PROPERTY GMBH | 10/30/17 | 2D 3D TSV |
US9487488 | 60 | 60 | HGNC:17961 | Sulfonamide compound | Mitsubishi Tanabe Pharma Corporation | 10/30/17 | 2D 3D TSV |
US9481688 | 24 | 1 | HGNC:5295 HGNC:5294 HGNC:5182 HGNC:5302 HGNC:281 HGNC:5301 HGNC:3023 HGNC:282 HGNC:3024 HGNC:5289 HGNC:5300 HGNC:283 HGNC:5287 HGNC:4075 HGNC:3020 HGNC:277 HGNC:278 | (Thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT2A antagonists | Eli Lilly and Company | 10/23/17 | 2D 3D TSV |
US9499493 | 51 | 50 | HGNC:11491 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmaceuticals, Inc | 10/23/17 | 2D 3D TSV |
US9499570 | 14 | 14 | HGNC:8781 | Boron containing small molecules | Anacor Pharmaceuticals Inc | 10/23/17 | 2D 3D TSV |
US9499561 | 46 | 23 | HGNC:8975 HGNC:8977 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | Shanghai Yingli Pharmaceutical Co., Ltd | 10/23/17 | 2D 3D TSV |
US9499486 | 7 | 1 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6524 HGNC:6876 | Kinase inhibitor | Respivert Limited | 10/23/17 | 2D 3D TSV |
US9499523 | 63 | 21 | HGNC:8978 HGNC:8977 HGNC:8976 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences Inc | 10/23/17 | 2D 3D TSV |
US9475817 | 402 | 200 | HGNC:2453 HGNC:2452 | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors | Bristol-Myers Squibb Co. | 10/23/17 | 2D 3D TSV |
US9475819 | 702 | 282 | HGNC:4849 HGNC:4848 | Substituted 7-azabicycles and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 10/23/17 | 2D 3D TSV |
US9481682 | 221 | 220 | HGNC:1133 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | Merck Sharp & Dohme Corp | 10/23/17 | 2D 3D TSV |
US9499534 | 42 | 42 | HGNC:11491 | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors | Merck Sharp & Dohme Corp | 10/23/17 | 2D 3D TSV |
US9475813 | 268 | 67 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | Nissan Chemical Industries, Ltd | 10/23/17 | 2D 3D TSV |
US9469597 | 210 | 59 | HGNC:6833 HGNC:6834 HGNC:4638 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | Oryzon Genomics, S.A. | 10/16/17 | 2D 3D TSV |
US9505765 | 36 | 36 | HGNC:18157 | 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment | Confluence Life Sciences Inc | 10/16/17 | 2D 3D TSV |
US9499542 | 46 | 23 | HGNC:18618 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. Lundbeck A/S | 10/16/17 | 2D 3D TSV |
US9475775 | 160 | 78 | HGNC:15631 HGNC:15632 | Benzazepine dicarboxamide compounds | Hoffmann-La Roche Inc | 10/16/17 | 2D 3D TSV |
US9493483 | 6 | 5 | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof | Constellation Pharmaceuticals, Inc. | 10/16/17 | 2D 3D TSV | |
US9487554 | 62 | 31 | HGNC:2593 HGNC:4638 | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments | Bayer Intellectual Property GmbH | 10/16/17 | 2D 3D TSV |
US9469631 | 130 | 130 | HGNC:19060 | N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof | Boehringer Ingelheim International GmbH | 10/16/17 | 2D 3D TSV |
US9464084 | 843 | 293 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 10/16/17 | 2D 3D TSV |
US9505734 | 2 | 1 | HGNC:11037 HGNC:11036 | Phenyl C-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | Tianjin Institute of Pharmaceutical Research | 10/16/17 | 2D 3D TSV |
US9468661 | 123 | 116 | HGNC:2771 | Pyrrolidine derivatives and their use as complement pathway modulators | Novartis AG | 10/16/17 | 2D 3D TSV |
US9493412 | 34 | 34 | HGNC:6623 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | Bristol-Myers Squibb Co. | 10/16/17 | 2D 3D TSV |
US9493472 | 34 | 31 | HGNC:3535 | Substituted benzoxazoles | Bayer Pharma Aktiengesellschaft | 10/16/17 | 2D 3D TSV |
US9481677 | 37 | 37 | HGNC:10597 | Biaryl ether sulfonamides and their use as therapeutic agents | Xenon Pharmaceuticals Inc | 10/10/17 | 2D 3D TSV |
US9493457 | 3 | 3 | HGNC:550 | 4,5,6,7-tetrahyroimidazo[4,5-c]pyridine compounds | Proximagen Limited | 10/09/17 | 2D 3D TSV |
US9481673 | 141 | 22 | HGNC:2637 HGNC:2625 HGNC:2622 HGNC:2623 HGNC:2621 | 6-alkynyl-pyridine derivatives | Boehringer Ingelheim International GmbH | 10/09/17 | 2D 3D TSV |
US9493431 | 44 | 44 | HGNC:4638 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc | 10/09/17 | 2D 3D TSV |
US9493430 | 41 | 41 | HGNC:1869 | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors | Chong Kun Dang Pharmaceutical Corp. | 10/09/17 | 2D 3D TSV |
US9493474 | 60 | 34 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 10/09/17 | 2D 3D TSV |
US9458201 | 162 | 125 | HGNC:6932 HGNC:6929 | Melanocortin receptor-specific heptapeptides | Palatin Technologies Inc | 10/09/17 | 2D 3D TSV |
US9458171 | 572 | 568 | Pyrrolidinyl sulfone RORγ modulators | Bristol-Myers Squibb Co. | 10/09/17 | 2D 3D TSV | |
US9505739 | 11 | 11 | HGNC:933 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck Sharp & Dohme Corp | 10/09/17 | 2D 3D TSV |
US9464092 | 229 | 76 | HGNC:1771 HGNC:1773 | Transient protection of normal cells during chemotherapy | G1 Therapeutics, Inc. | 10/09/17 | 2D 3D TSV |
US9459250 | 254 | 250 | HGNC:15661 | Use of T1R3 venus flytrap region polypeptide to screen for taste modulators | Senomyx Inc | 10/09/17 | 2D 3D TSV |
US9464076 | 131 | 94 | Benzothiophene derivative | Daiichi Sankyo Company, Limited | 10/02/17 | 2D 3D TSV | |
US9487494 | 9 | 9 | HGNC:2625 | Cyclic hydrocarbon compounds for the treatment of diseases | Leo Pharma A/S | 10/02/17 | 2D 3D TSV |
US9481685 | 8 | 8 | Imaging neuroinflammation | GE Healthcare Limited | 10/02/17 | 2D 3D TSV | |
US9493447 | 14 | 3 | HGNC:8791 HGNC:8793 HGNC:8784 HGNC:8773 HGNC:8772 HGNC:8778 | Optically active PDE10 inhibitor | Omeros Corporation | 10/02/17 | 2D 3D TSV |
US9480684 | 35 | 11 | HGNC:8154 HGNC:8155 | Orvinol and thevinol derivatives useful in the treatment of anxiety or a compulsive disorder | The University of Bath | 10/02/17 | 2D 3D TSV |
US9458110 | 632 | 285 | HGNC:10251 HGNC:10252 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | Bristol-Myers Squibb Co. | 10/02/17 | 2D 3D TSV |
US9458172 | 180 | 168 | HGNC:30092 | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives | TBA | 10/02/17 | 2D 3D TSV |
US9493429 | 9 | 9 | HGNC:10597 | Substituted benzoxazoles and methods of use thereof | Genentech Inc | 10/02/17 | 2D 3D TSV |
US9458113 | 187 | 184 | HGNC:3309 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 10/02/17 | 2D 3D TSV |
US9458176 | 245 | 244 | HGNC:4594 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | Eisai R&D Management Co., Ltd | 10/02/17 | 2D 3D TSV |
US9469608 | 44 | 43 | HGNC:3535 | Thrombin inhibitors | Merck Sharp & Dohme Corp | 10/02/17 | 2D 3D TSV |
US9452986 | 683 | 619 | HGNC:10582 HGNC:10597 | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use | AbbVie Inc | 09/25/17 | 2D 3D TSV |
US9453031 | 272 | 87 | HGNC:8979 HGNC:6251 HGNC:2637 HGNC:9413 HGNC:2625 HGNC:2623 HGNC:2621 | Chemical entities | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | 09/25/17 | 2D 3D TSV |
US9475814 | 83 | 31 | HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof | Euroscreen SA | 09/25/17 | 2D 3D TSV |
US9475806 | 21 | 21 | HGNC:1037 | Complement factor B inhibitors and uses there of | Novartis AG | 09/25/17 | 2D 3D TSV |
US9452990 | 131 | 130 | HGNC:2771 | Complement pathway modulators and uses thereof | Novartis AG | 09/25/17 | 2D 3D TSV |
US9464060 | 136 | 83 | HGNC:13307 HGNC:3166 | Compounds | Takeda Pharmaceutical Co., Ltd | 09/25/17 | 2D 3D TSV |
US9468642 | 46 | 46 | HGNC:12401 | Imidazopyrazines | Bayer Intellectual Property GmbH | 09/25/17 | 2D 3D TSV |
US9447148 | 197 | 54 | HGNC:6932 HGNC:6929 | Melanocortin-1 receptor-specific cyclic peptides | Palatin Technologies Inc | 09/25/17 | 2D 3D TSV |
US9469653 | 23 | 23 | HGNC:6834 | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same | Korea Institute of Science and Technology | 09/25/17 | 2D 3D TSV |
US9452998 | 274 | 116 | HGNC:9393 HGNC:4617 HGNC:9410 HGNC:8987 | Protein kinase C inhibitors and methods of their use | Novartis AG | 09/25/17 | 2D 3D TSV |
US9481668 | 1 | 1 | Quinoline inhibitor of the macrophage stimulating 1 receptor MSTR1 | Merck Patent GmbH | 09/25/17 | 2D 3D TSV | |
US9475779 | 63 | 55 | HGNC:6251 HGNC:3309 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 09/25/17 | 2D 3D TSV |
US9475809 | 16 | 16 | HGNC:3529 | Substituted oxopyridine derivatives and use thereof as factor xia/plasma | Bayer Pharma Aktiengesellschaft | 09/25/17 | 2D 3D TSV |
US9469613 | 4 | 1 | HGNC:171 HGNC:1076 | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide | Gilead Sciences Inc | 09/18/17 | 2D 3D TSV |
US9464044 | 101 | 98 | HGNC:5208 | Compound having ability to inhibit 11Beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | Ahn-Gook Pharmaceutical Co. Ltd | 09/18/17 | 2D 3D TSV |
US9447087 | 91 | 88 | HGNC:4118 | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders | University of Utah Research Foundation | 09/18/17 | 2D 3D TSV |
US9469644 | 7 | 7 | HGNC:1133 | Inhibitors of Bruton's tyrosine kinase | Hoffmann-La Roche Inc | 09/18/17 | 2D 3D TSV |
US9469639 | 14 | 7 | HGNC:6307 HGNC:8804 | Naphthylurea derivatives and medical applications thereof | Radiant Pharma & Tech. Co., Ltd. | 09/18/17 | 2D 3D TSV |
US9469627 | 3 | 3 | HGNC:17890 | Phenyloxadiazole derivatives as PGDS inhibitors | Sanofi | 09/18/17 | 2D 3D TSV |
US9434697 | 144 | 66 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | Pyrimidine FGFR4 inhibitors | Eisai R&D Management Co., Ltd | 09/18/17 | 2D 3D TSV |
US9464103 | 12 | 12 | Spirocyclic sulfones as gamma secretase inhibitors | Merck Sharp & Dohme Corp | 09/18/17 | 2D 3D TSV | |
US9434727 | 247 | 112 | HGNC:9922 | Substituted 4-phenylpiperidines, their preparation and use | Columbia University | 09/18/17 | 2D 3D TSV |
US9447038 | 205 | 203 | HGNC:10637 | Substituted B-amino acid derivatives as CXCR3 receptor antagonists | Sanofi | 09/18/17 | 2D 3D TSV |
US9452980 | 625 | 321 | Substituted benzamides | Hoffmann-La Roche Inc | 09/18/17 | 2D 3D TSV | |
US9447106 | 218 | 217 | HGNC:1133 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BeiGene, Ltd | 09/18/17 | 2D 3D TSV |
US9475795 | 111 | 107 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | Takeda Pharmaceutical Co., Ltd | 09/18/17 | 2D 3D TSV | |
US9457039 | 24 | 19 | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | Merck Sharp & Dohme Corp | 09/11/17 | 2D 3D TSV | |
US9434725 | 762 | 199 | HGNC:19310 HGNC:8987 | 5-azaindazole compounds and methods of use | F. Hoffmann-La Roche Inc | 09/11/17 | 2D 3D TSV |
US9458145 | 111 | 42 | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences Inc | 09/11/17 | 2D 3D TSV | |
US9453034 | 72 | 36 | HGNC:934 HGNC:933 | C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 09/11/17 | 2D 3D TSV |
US9458136 | 1 | 1 | HGNC:2160 | Crystalline forms and processes for the preparation of cannabinoid receptor modulators | Arena Pharmaceuticals Inc | 09/11/17 | 2D 3D TSV |
US9458135 | 60 | 30 | HGNC:2592 HGNC:2591 | Dihydroquinoline-2-one derivatives | Hoffmann-La Roche Inc | 09/11/17 | 2D 3D TSV |
US9464062 | 6 | 6 | HGNC:5294 | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators | Temple University | 09/11/17 | 2D 3D TSV |
US9458140 | 29 | 29 | Furanone compounds as kinase inhibitors | Eternity Bioscience Inc. | 09/11/17 | 2D 3D TSV | |
US9453038 | 42 | 34 | HGNC:4195 | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment | Merck Sharp & Dohme Corp | 09/11/17 | 2D 3D TSV |
US9453048 | 38 | 17 | IAP antagonists | Bristol-Myers Squibb Co. | 09/11/17 | 2D 3D TSV | |
US9458105 | 10 | 10 | HGNC:1133 | Inhibitors of Bruton's tyrosine kinase | Hoffmann-La Roche Inc | 09/11/17 | 2D 3D TSV |
US9464073 | 16 | 4 | HGNC:4852 HGNC:14064 HGNC:4854 HGNC:4853 | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors | Acetylon Pharmaceuticals Inc | 09/11/17 | 2D 3D TSV |
US9464081 | 23 | 23 | HGNC:2771 | Pyrrolidine derivatives and their use as complement pathway modulators | Novartis AG | 09/11/17 | 2D 3D TSV |
US9434711 | 709 | 701 | HGNC:17961 | Sulfonamides as TRPM8 modulators | Janssen Pharmaceutica NV | 09/11/17 | 2D 3D TSV |
US9463192 | 43 | 43 | HGNC:8031 | Trk-inhibiting compound | Ono Pharmaceutical Co., Ltd | 09/11/17 | 2D 3D TSV |
US9434719 | 783 | 471 | HGNC:5382 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | Novartis AG | 09/05/17 | 2D 3D TSV |
US9453017 | 12 | 3 | HGNC:9068 HGNC:9067 | Antiviral therapies with phospholipase D inhibitors | Vanderbilt University | 09/05/17 | 2D 3D TSV |
US9447029 | 38 | 28 | HGNC:2625 HGNC:1389 | Fluorinated arylalkylaminocarboxamide derivatives | Newron Pharmaceuticals S.P.A. | 09/05/17 | 2D 3D TSV |
US9447090 | 34 | 34 | Imidazopyridine compounds | Astellas Pharma Inc | 09/05/17 | 2D 3D TSV | |
US9447085 | 33 | 17 | HGNC:934 HGNC:933 | Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 09/05/17 | 2D 3D TSV |
US9446026 | 20 | 1 | HGNC:6091 HGNC:12680 HGNC:11390 HGNC:8803 HGNC:3763 HGNC:11724 HGNC:4037 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3767 HGNC:3236 HGNC:9967 HGNC:3688 HGNC:3765 | Ocular formulations for drug-delivery to the posterior segment of the eye | PanOptica, Inc. | 09/05/17 | 2D 3D TSV |
US9434733 | 75 | 71 | HGNC:8795 | PDE9 inhibitors with imidazo triazinone backbone | H. Lundbeck A/S | 09/05/17 | 2D 3D TSV |
US9447092 | 48 | 5 | HGNC:11393 HGNC:6251 HGNC:11390 HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2621 HGNC:2610 HGNC:3765 | Pharmaceutically active compounds | Cancer Research Technology Limited | 09/05/17 | 2D 3D TSV |
US9447091 | 40 | 40 | HGNC:3688 | Protein kinase inhibitors | ORION CORPORATION | 09/05/17 | 2D 3D TSV |
US9447095 | 30 | 30 | HGNC:8772 | Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10) | Palobiofarma, S.L. | 09/05/17 | 2D 3D TSV |
US9453018 | 22 | 8 | HGNC:6371 HGNC:3529 | Pyrimidinones as factor XIa inhibitors | Bristol-Myers Squibb Co. | 09/05/17 | 2D 3D TSV |
US9453021 | 17 | 17 | Pyrimidodiazepinone compound | Kyowa Hakko Kirin Co., Ltd | 09/05/17 | 2D 3D TSV | |
US9434724 | 377 | 84 | HGNC:6251 HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2621 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC | 09/05/17 | 2D 3D TSV |
US9453023 | 39 | 39 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | Sanofi | 09/05/17 | 2D 3D TSV | |
US9452985 | 8 | 8 | HGNC:6893 | Tau imaging probe | GE Healthcare Limited | 09/05/17 | 2D 3D TSV |
US9428508 | 324 | 161 | HGNC:9611 HGNC:9612 | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | Centaurus BioPharma Co., Ltd | 08/28/17 | 2D 3D TSV |
US9446130 | 25 | 25 | HGNC:1133 | BTK inhibitors | Merck Sharp & Dohme Corp | 08/28/17 | 2D 3D TSV |
US9433609 | 144 | 20 | Benzimidazole-imidazole derivatives | Janssen Ireland | 08/28/17 | 2D 3D TSV | |
US9428514 | 208 | 104 | Bromodomain inhibitors | AbbVie Inc | 08/28/17 | 2D 3D TSV | |
US9446044 | 107 | 65 | HGNC:3092 HGNC:3091 | DYRK1 inhibitors and uses thereof | DIAXONHIT | 08/28/17 | 2D 3D TSV |
US9447132 | 2 | 2 | Highly active nucleoside derivative for the treatment of HCV | Achillion Pharmaceuticals Inc | 08/28/17 | 2D 3D TSV | |
US9428503 | 315 | 79 | HGNC:882 HGNC:795 HGNC:8975 HGNC:3942 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer | AstraZeneca AB | 08/28/17 | 2D 3D TSV |
US9428511 | 152 | 73 | HGNC:6190 HGNC:6193 | Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | Bristol-Myers Squibb Co. | 08/28/17 | 2D 3D TSV |
US9434692 | 4 | 4 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals Inc | 08/28/17 | 2D 3D TSV | |
US9433622 | 330 | 165 | HGNC:11584 HGNC:14552 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | Case Western Reserve University | 08/28/17 | 2D 3D TSV |
US9447057 | 29 | 29 | Schiff bases of thiazoles: a new class of ureases inhibitors | TBA | 08/28/17 | 2D 3D TSV | |
US9434690 | 357 | 143 | HGNC:6371 HGNC:3529 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | Bayer Pharma Aktiengesellschaft | 08/28/17 | 2D 3D TSV |
US9434693 | 45 | 45 | HGNC:1403 | Substituted pyrazoles as N-type calcium channel blockers | Janssen Pharmaceutica NV | 08/28/17 | 2D 3D TSV |
US9447114 | 29 | 23 | HGNC:12337 | Thieno- and furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives | Hydra Biosciences Inc | 08/28/17 | 2D 3D TSV |
US9428513 | 29 | 29 | Triazolopyrazine | Boehringer Ingelheim International GmbH | 08/28/17 | 2D 3D TSV | |
US9428505 | 22 | 17 | Hydantoin derivative | Chugai Seiyaku Kabushiki Kaisha | 08/24/17 | 2D 3D TSV | |
US9428469 | 30 | 29 | Antiviral compounds | F. Hoffmann-La Roche Inc | 08/22/17 | 2D 3D TSV | |
US9447055 | 2 | 2 | HGNC:9600 | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | Merck Serono | 08/21/17 | 2D 3D TSV |
US9428456 | 501 | 498 | HGNC:23692 | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | Actelion Pharmaceuticals Ltd | 08/21/17 | 2D 3D TSV |
US9428504 | 172 | 169 | HGNC:8539 | 7-hydroxy-spiropipiperidine indolinyl antagonists of P2Y1 receptor | Bristol-Myers Squibb Co. | 08/21/17 | 2D 3D TSV |
US9428500 | 117 | 57 | HGNC:427 | Alpha-carbolines for the treatment of cancer | UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA | 08/21/17 | 2D 3D TSV |
US9427428 | 138 | 20 | Benzimidazole-imidazole derivatives | Janssen Ireland | 08/21/17 | 2D 3D TSV | |
US9428501 | 53 | 19 | HGNC:9377 HGNC:8975 | Bicyclic nitrogen-containing aromatic heterocyclic amide compound | Astellas Pharma Inc | 08/21/17 | 2D 3D TSV |
US9446064 | 9 | 9 | Combination therapy for treating cancer | Epizyme Inc | 08/21/17 | 2D 3D TSV | |
US9428502 | 338 | 335 | HGNC:3594 | Heterocyclic modulators of lipid synthesis | 3-V Biosciences, Inc. | 08/21/17 | 2D 3D TSV |
US9427440 | 69 | 27 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | Janssen Ireland | 08/21/17 | 2D 3D TSV | |
US9428460 | 40 | 32 | N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | Bayer Pharma Aktiengesellschaft | 08/21/17 | 2D 3D TSV | |
US9428478 | 66 | 41 | HGNC:12805 HGNC:2578 | Piperazine derivatives, compositions, and uses related thereto | Emory University | 08/21/17 | 2D 3D TSV |
US9428476 | 17 | 9 | HGNC:934 HGNC:933 | S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 08/21/17 | 2D 3D TSV |
US9428492 | 54 | 24 | HGNC:2623 | Secondary alcohol substituted triazoles as PDE10 inhibitors | Merck Sharp & Dohme Corp | 08/21/17 | 2D 3D TSV |
US9428491 | 12 | 10 | Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof | TBA | 08/21/17 | 2D 3D TSV | |
US9422293 | 771 | 377 | HGNC:12716 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | Janssen Pharmaceutica NV | 08/21/17 | 2D 3D TSV |
US9422331 | 108 | 54 | 2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer | Hoffmann-La Roche Inc | 08/14/17 | 2D 3D TSV | |
US9422332 | 92 | 47 | Azaheterocycles as BIR2 and/or BIR3 inhibitors | Hoffmann-La Roche Inc | 08/14/17 | 2D 3D TSV | |
US9428447 | 29 | 21 | HGNC:14064 HGNC:4854 | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer | The Royal Institution for the Advancement of Learning/McGill University | 08/14/17 | 2D 3D TSV |
US9415055 | 223 | 223 | HGNC:8537 | Cyclic amines | H. Lundbeck A/S | 08/14/17 | 2D 3D TSV |
US9422318 | 37 | 35 | HGNC:3402 | Epoxyeicosatrienoic acid analogs and methods of making and using the same | The Medical College of Wisconsin, Inc. | 08/14/17 | 2D 3D TSV |
US9427442 | 58 | 29 | HGNC:5724 | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds | Bristol-Myers Squibb Co. | 08/14/17 | 2D 3D TSV |
US9422240 | 52 | 51 | HGNC:1232 | Partially saturated nitrogen-containing heterocyclic compound | Taisho Pharmaceutical Co., Ltd | 08/14/17 | 2D 3D TSV |
US9422255 | 40 | 20 | HGNC:934 HGNC:933 | S-imino-S-oxo-iminothiazine compounds as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 08/14/17 | 2D 3D TSV |
US9422299 | 205 | 46 | HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Euroscreen SA | 08/14/17 | 2D 3D TSV |
US9416132 | 120 | 103 | HGNC:6251 | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors | Tolero Pharmaceuticals Inc | 08/14/17 | 2D 3D TSV |
US9422235 | 171 | 95 | HGNC:2160 HGNC:2159 | Sulfonamide derivatives with therapeutic indications | Pharmos Corporation | 08/14/17 | 2D 3D TSV |
US9422290 | 38 | 36 | Triazolopyridazine | Boehringer Ingelheim International GmbH | 08/14/17 | 2D 3D TSV | |
US9422297 | 65 | 27 | HGNC:6307 HGNC:8804 HGNC:12441 HGNC:3236 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | Duquesne University of the Holy Ghost | 08/14/17 | 2D 3D TSV |
US9416129 | 244 | 120 | HGNC:934 HGNC:2529 HGNC:933 | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use | Merck Sharp & Dohme Corp | 08/14/17 | 2D 3D TSV |
US9422277 | 170 | 83 | HGNC:934 HGNC:933 | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use | Merck Sharp & Dohme Corp | 08/14/17 | 2D 3D TSV |
US9394331 | 44 | 30 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | Gilead Pharmasset LLC | 08/07/17 | 2D 3D TSV | |
US9409892 | 368 | 183 | HGNC:1232 HGNC:14660 | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors | FibroGen Inc | 08/07/17 | 2D 3D TSV |
US9416154 | 45 | 44 | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | Merck Sharp & Dohme Corp | 08/07/17 | 2D 3D TSV | |
US9428465 | 17 | 15 | HGNC:735 | Acid ceramidase inhibitors and their use as medicaments | Fondazione Istituto Italiano Di Technologia | 08/07/17 | 2D 3D TSV |
US9409895 | 69 | 69 | HGNC:3357 | Autotaxin inhibitors | Novartis AG | 08/07/17 | 2D 3D TSV |
US9409908 | 443 | 216 | HGNC:3551 HGNC:6371 | Dihydropyridone p1 as factor XIa inhibitors | Bristol-Myers Squibb Co. | 08/07/17 | 2D 3D TSV |
US9409888 | 53 | 27 | Dimeric compounds | Hoffmann-La Roche Inc | 08/07/17 | 2D 3D TSV | |
US9422333 | 28 | 4 | HCV protease inhibitors and uses thereof | Celgene Avilomics Research, Inc. | 08/07/17 | 2D 3D TSV | |
US9409917 | 118 | 86 | HGNC:8537 | Heterocyclic amide derivatives as P2X7 receptor antagonists | Actelion Pharmaceuticals Ltd | 08/07/17 | 2D 3D TSV |
US9421177 | 72 | 36 | HGNC:11240 | Imidamide sphingosine kinase inhibitors | University of Virginia Patent Foundation | 08/07/17 | 2D 3D TSV |
US9409907 | 205 | 204 | HGNC:12401 | Inhibitor compounds | Cancer Research Technology Limited | 08/07/17 | 2D 3D TSV |
US9416123 | 85 | 16 | HGNC:9617 HGNC:6307 HGNC:19297 HGNC:11283 HGNC:1097 HGNC:10020 HGNC:3236 | Kinase modulators for the treatment of cancer | Synovo GmbH | 08/07/17 | 2D 3D TSV |
US9428466 | 9 | 5 | HGNC:12805 HGNC:17989 | Methods for reducing uric acid levels using barbiturate derivatives | TBA | 08/07/17 | 2D 3D TSV |
US9416139 | 72 | 34 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | Sunshine Lake Pharma Co., Ltd | 08/07/17 | 2D 3D TSV | |
US9409915 | 90 | 90 | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | Janssen Pharmaceutica NV | 08/07/17 | 2D 3D TSV | |
US9422307 | 17 | 17 | HGNC:9611 | 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors | Korea Institute of Science and Technology | 08/01/17 | 2D 3D TSV |
US9422324 | 8 | 4 | HGNC:3467 HGNC:3468 | 6-substituted demethyl-estradiol derivatives as selective ER-β agonists | Endece LLC | 08/01/17 | 2D 3D TSV |
US9422312 | 21 | 21 | HGNC:9385 | Azabenzimidazole derivatives | Boehringer Ingelheim International GmbH | 08/01/17 | 2D 3D TSV |
US9422273 | 40 | 5 | HGNC:9591 HGNC:9594 HGNC:9593 HGNC:9596 HGNC:9595 HGNC:11608 HGNC:9600 HGNC:9602 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | Allergan Inc | 08/01/17 | 2D 3D TSV |
US9422243 | 55 | 19 | HGNC:270 HGNC:272 | 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | Nerviano Medical Sciences srl | 07/31/17 | 2D 3D TSV |
US9403813 | 270 | 135 | HGNC:4849 HGNC:4848 | Azetidine amide derivatives as orexin receptor antagonists | Actelion Pharmaceuticals Ltd | 07/31/17 | 2D 3D TSV |
US9403843 | 72 | 54 | HGNC:1476 | Cysteine protease inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 07/31/17 | 2D 3D TSV |
US9422263 | 19 | 10 | HGNC:7029 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | Bayer Pharma Aktiengesellschaft | 07/31/17 | 2D 3D TSV |
US9422261 | 11 | 11 | Heterocyclic resorcinol derivatives, preparation of same and cosmetic uses thereof | PIERRE FABRE DERMO-COSMETIQUE | 07/31/17 | 2D 3D TSV | |
US9422231 | 5 | 5 | Method for inhibiting Trypanosoma cruzi | Howard University | 07/31/17 | 2D 3D TSV | |
US9403808 | 195 | 105 | HGNC:2160 HGNC:2159 | Pyrazine derivatives | Hoffmann-La Roche Inc | 07/31/17 | 2D 3D TSV |
US9409882 | 96 | 48 | HGNC:2537 HGNC:2545 | Pyridine derivatives | Hoffmann-La Roche Inc | 07/31/17 | 2D 3D TSV |
US9409866 | 620 | 222 | HGNC:2160 HGNC:2159 | Pyridine-2-amides useful as CB2 agonists | Hoffmann-La Roche Inc | 07/31/17 | 2D 3D TSV |
US9409924 | 26 | 19 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 07/31/17 | 2D 3D TSV |
US9403767 | 182 | 71 | HGNC:8154 HGNC:8155 HGNC:8156 | Substituted 4-aminocyclohexane derivatives | Gruenenthal GmbH | 07/31/17 | 2D 3D TSV |
US9403801 | 81 | 40 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11393 HGNC:12440 HGNC:3765 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC | 07/31/17 | 2D 3D TSV |
US9394309 | 198 | 170 | Substituted phenylimidazopyrazoles and their use | Bayer Pharma Aktiengesellschaft | 07/31/17 | 2D 3D TSV | |
US9416127 | 72 | 32 | Triazole carboxamides and uses thereof | Hoffmann-La Roche Inc | 07/31/17 | 2D 3D TSV | |
US9394311 | 136 | 134 | HGNC:8772 | Triazolo compounds as PDE10 inhibitors | Hoffmann-La Roche Inc | 07/31/17 | 2D 3D TSV |
US9403810 | 48 | 48 | Carboxamide derivatives | Novartis AG | 07/25/17 | 2D 3D TSV | |
US9409931 | 8 | 4 | HGNC:9399 | 3-O-acyl-ingenol analogues | LEO LABORATORIES LIMITED | 07/24/17 | 2D 3D TSV |
US9408863 | 13 | 13 | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases | Merck Sharp & Dohme Corp | 07/24/17 | 2D 3D TSV | |
US9409845 | 22 | 22 | HGNC:3236 | Alpha-(3,5-dimethoxybenzylidene)-alpha′-hydrocarbyl methylene cyclic ketone and preparation method thereof | PHARMAXYN LABORATORIES LTD. | 07/24/17 | 2D 3D TSV |
US9394297 | 934 | 430 | HGNC:8987 | Amides as pim inhibitors | Amgen Inc | 07/24/17 | 2D 3D TSV |
US9403846 | 28 | 25 | HGNC:933 | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | Pfizer Inc | 07/24/17 | 2D 3D TSV |
US9403833 | 17 | 16 | Carboxamide derivatives | Novartis AG | 07/24/17 | 2D 3D TSV | |
US9409900 | 4 | 4 | Compound for increasing kinase active and application thereof | FUJIAN HAIXI PHARMACEUTICALS, INC. | 07/24/17 | 2D 3D TSV | |
US9416126 | 394 | 366 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | Merck Sharp & Dohme Corp | 07/24/17 | 2D 3D TSV | |
US9403803 | 15 | 10 | HGNC:6307 HGNC:8804 | Indole-3-carboxamides as kinase inhibitors | Allergan Inc | 07/24/17 | 2D 3D TSV |
US9403768 | 24 | 12 | Indolines | Hoffmann-La Roche Inc | 07/24/17 | 2D 3D TSV | |
US9409868 | 44 | 22 | Inhibitors of rho associated protein kinases (ROCK) and methods of use | H. Lee Moffin Cancer Center and Research Institute, Inc. | 07/24/17 | 2D 3D TSV | |
US9409858 | 37 | 19 | HGNC:4852 HGNC:14064 | Selective histone deactylase 6 inhibitors | H. Lee Moffitt Cancer Center and Research Institute Inc | 07/24/17 | 2D 3D TSV |
US9408850 | 74 | 37 | Substituted indazole derivatives active as kinase inhibitors | Nerviano Medical Sciences srl | 07/24/17 | 2D 3D TSV | |
US9403827 | 32 | 25 | Substituted purinone compounds | Novartis AG | 07/24/17 | 2D 3D TSV | |
US9403831 | 42 | 41 | HGNC:7029 | Triazolopyrazine derivative and use thereof | Korea Research Institute of Chemical Technology | 07/24/17 | 2D 3D TSV |
US9416103 | 25 | 11 | HGNC:2160 | Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases | University of Arkansas | 07/24/17 | 2D 3D TSV |
US9394275 | 191 | 93 | HGNC:286 HGNC:1952 | Diamide compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | Theravance Respiratory Company LLC | 07/18/17 | 2D 3D TSV |
US9394273 | 118 | 16 | HGNC:9594 HGNC:9596 HGNC:9595 HGNC:11608 | Therapeutic prostaglandin receptor agonists | Allergan Inc | 07/18/17 | 2D 3D TSV |
US9403797 | 2 | 2 | HGNC:1925 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | Cancer Research Technology Limited | 07/17/17 | 2D 3D TSV |
US9394291 | 20 | 10 | Benzoxazinone amides as mineralocorticoid receptor modulators | AstraZeneca AB | 07/17/17 | 2D 3D TSV | |
US9403774 | 6 | 6 | HGNC:3529 | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors | Bristol-Myers Squibb Co. | 07/17/17 | 2D 3D TSV |
US9394285 | 186 | 177 | HGNC:9385 | Indole and indazole compounds that activate AMPK | Pfizer Inc | 07/17/17 | 2D 3D TSV |
US9394289 | 44 | 44 | Inhibitors of c-fms kinase | Janssen Pharmaceutica NV | 07/17/17 | 2D 3D TSV | |
US9403804 | 10 | 10 | Inhibitors of c-fms kinase | Janssen Pharmaceutica NV | 07/17/17 | 2D 3D TSV | |
US9388165 | 22 | 9 | HGNC:8803 HGNC:3430 HGNC:6307 HGNC:8804 HGNC:5465 HGNC:11283 HGNC:1097 HGNC:76 HGNC:3689 HGNC:3236 HGNC:3688 HGNC:3765 | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | Hanmi Pharm. Co., Ltd | 07/17/17 | 2D 3D TSV |
US9402837 | 20 | 20 | HGNC:4177 | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | Amicus Therapeutics, Inc | 07/17/17 | 2D 3D TSV |
US9409887 | 14 | 5 | Mutant-selective EGFR inhibitors and uses thereof | Celgene Avilomics Research, Inc. | 07/17/17 | 2D 3D TSV | |
US9388210 | 17 | 13 | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | Washington University | 07/17/17 | 2D 3D TSV | |
US9394282 | 406 | 196 | HGNC:6190 HGNC:6192 | Pyrazole carboxamides as Janus kinase inhibitors | Merck Sharp & Dohme Corp | 07/17/17 | 2D 3D TSV |
US9394290 | 90 | 46 | HGNC:2592 HGNC:2591 | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases | UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN | 07/17/17 | 2D 3D TSV |
US9394303 | 31 | 23 | Small molecule inhibitors of MCL-1 and uses thereof | The Regents of the University of Michigan | 07/17/17 | 2D 3D TSV | |
US9393232 | 171 | 122 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BeiGene, Ltd | 07/17/17 | 2D 3D TSV | |
US9394263 | 237 | 131 | Substituted hetero-azepinones | F. Hoffmann-La Roche Inc | 07/17/17 | 2D 3D TSV | |
US9394250 | 56 | 19 | HGNC:3528 HGNC:3529 HGNC:3535 | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | Ono Pharmaceutical Co., Ltd | 07/17/17 | 2D 3D TSV |
US9402842 | 12 | 12 | HGNC:18884 | Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (Tdp1)—topoisomerase I (Top1) inhibitors | Purdue Research Foundation | 07/17/17 | 2D 3D TSV |
US9394293 | 17 | 6 | HGNC:12716 | TRPV1 antagonists including dihydroxy substituent and uses thereof | Purdue Pharma LP | 07/17/17 | 2D 3D TSV |
US9394254 | 6 | 4 | Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase | The University of Denver and Regis University | 07/10/17 | 2D 3D TSV | |
US9403822 | 5 | 5 | HGNC:990 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc | 07/10/17 | 2D 3D TSV |
US9365589 | 82 | 37 | HGNC:934 HGNC:933 | C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 07/10/17 | 2D 3D TSV |
US9402878 | 2 | 2 | HGNC:6251 | Depsipeptide and uses thereof | NovoBiotic Pharmaceuticals, LLC | 07/10/17 | 2D 3D TSV |
US9388139 | 97 | 28 | HGNC:9605 HGNC:8784 HGNC:8795 HGNC:8772 HGNC:8774 HGNC:8779 HGNC:9604 HGNC:8778 | Derivatives of celeboxib, use thereof and preparation thereof | German University | 07/10/17 | 2D 3D TSV |
US9388149 | 69 | 25 | HGNC:6026 HGNC:6027 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | Galderma Research & Development | 07/10/17 | 2D 3D TSV |
US9394307 | 6 | 5 | HGNC:2637 HGNC:2623 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | ChemoCentryx, Inc. | 07/10/17 | 2D 3D TSV |
US9388197 | 76 | 75 | HGNC:8537 | Heterocyclic amide derivatives as P2X7 receptor antagonists | Actelion Pharmaceuticals Ltd | 07/10/17 | 2D 3D TSV |
US9388198 | 17 | 16 | HGNC:8537 | Heterocyclic amide derivatives as P2X7 receptor antagonists | Actelion Pharmaceuticals Ltd | 07/10/17 | 2D 3D TSV |
US9394304 | 18 | 18 | HGNC:497 | Imidazopyridine derivatives | Hoffmann-La Roche Inc | 07/10/17 | 2D 3D TSV |
US9365582 | 24 | 12 | Macrocyclic inhibitors of hepatitis C virus | Janssen Ireland | 07/10/17 | 2D 3D TSV | |
US9388176 | 119 | 87 | HGNC:6307 HGNC:8804 | Method of treating conditiions with kinase inhibitors | Allergan Inc | 07/10/17 | 2D 3D TSV |
US9365572 | 65 | 6 | HGNC:9393 HGNC:17967 HGNC:10252 HGNC:16835 HGNC:3091 HGNC:10810 HGNC:391 HGNC:8816 HGNC:5465 HGNC:1460 HGNC:6871 HGNC:8975 HGNC:3688 HGNC:6876 HGNC:3765 HGNC:9380 HGNC:6192 HGNC:6193 HGNC:11393 HGNC:6307 HGNC:8804 HGNC:1771 HGNC:6342 HGNC:3236 HGNC:1925 HGNC:11283 HGNC:9376 HGNC:10432 HGNC:11724 HGNC:10434 HGNC:9407 HGNC:6735 HGNC:10436 HGNC:5960 HGNC:2452 HGNC:3385 HGNC:12858 HGNC:11406 HGNC:3942 HGNC:6896 HGNC:7029 HGNC:7745 HGNC:8591 HGNC:11491 HGNC:427 HGNC:76 HGNC:3657 HGNC:6886 HGNC:2444 HGNC:6524 HGNC:6887 | PI3K and/or mTOR inhibitor | Xuanzhu Pharma Co., Ltd | 07/10/17 | 2D 3D TSV |
US9403799 | 14 | 2 | HGNC:7029 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | Merck Patent GmbH | 07/10/17 | 2D 3D TSV |
US9388199 | 44 | 44 | HGNC:2771 | Pyrrolidine derivatives and their use as complement pathway modulators | Novartis AG | 07/10/17 | 2D 3D TSV |
US9388189 | 81 | 81 | HGNC:8977 | Pyrrolotriazinone derivatives as PI3K inhibitors | Almirall, S.A. | 07/10/17 | 2D 3D TSV |
US9388171 | 28 | 14 | HGNC:10430 | Serine/threonine kinase inhibitors | Genetech, Inc | 07/10/17 | 2D 3D TSV |
US9394276 | 16 | 16 | HGNC:3529 | Substituted 1,2,3,4-tetrahydro-2,6-naphthyridines as factor XIa inhibitors | Bristol-Myers Squibb Co. | 07/10/17 | 2D 3D TSV |
US9388181 | 15 | 7 | HGNC:6307 HGNC:8804 | Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase | Allergan Inc | 07/10/17 | 2D 3D TSV |
US9388140 | 120 | 117 | HGNC:12401 | Substituted benzimidazoles | Bayer Intellectual Property GmbH | 07/10/17 | 2D 3D TSV |
US9388162 | 146 | 60 | HGNC:8154 HGNC:8156 | Substituted morphinans and the use thereof | Purdue Pharma LP | 07/10/17 | 2D 3D TSV |
US9388136 | 35 | 19 | HGNC:6876 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof | Chroma Therapeutics Ltd | 07/10/17 | 2D 3D TSV |
USRE46024 | 22 | 22 | Thyroid hormone analogs | Hoffmann-La Roche Inc | 07/10/17 | 2D 3D TSV | |
US9365562 | 126 | 126 | 1,3 substituted azetidine PDE10 inhibitors | Merck Sharp & Dohme Corp | 07/03/17 | 2D 3D TSV | |
US9364459 | 43 | 15 | HGNC:6307 HGNC:4617 HGNC:3765 | 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz | 07/03/17 | 2D 3D TSV |
US9365508 | 26 | 13 | HGNC:10886 HGNC:14929 | Aroyl thiourea derivatives | University Court of the University of St Andrews | 07/03/17 | 2D 3D TSV |
US9365534 | 43 | 19 | HGNC:2160 HGNC:2159 | Arylated camphenes, processes for their preparation and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. | 07/03/17 | 2D 3D TSV |
US9365529 | 68 | 20 | HGNC:195 HGNC:7173 HGNC:216 HGNC:7176 HGNC:7155 HGNC:188 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVLOPMENT | 07/03/17 | 2D 3D TSV |
US9359371 | 77 | 34 | HGNC:8773 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd | 07/03/17 | 2D 3D TSV |
US9365511 | 26 | 26 | HGNC:5184 | Biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders | Arena Pharmaceuticals Inc | 07/03/17 | 2D 3D TSV |
US9359372 | 60 | 29 | HGNC:3023 HGNC:5286 HGNC:3020 | Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 07/03/17 | 2D 3D TSV |
US9359361 | 20 | 20 | HGNC:15633 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. | 07/03/17 | 2D 3D TSV |
US9365575 | 25 | 25 | HGNC:6307 | Kinase inhibitors | Allergan Inc | 07/03/17 | 2D 3D TSV |
US9365853 | 7 | 7 | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | TBA | 07/03/17 | 2D 3D TSV | |
US9365502 | 18 | 18 | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors | Washington University | 07/03/17 | 2D 3D TSV | |
US9365539 | 11 | 11 | HGNC:9344 | Prolylcarboxypeptidase inhibitors | Merck Sharp & Dohme Corp | 07/03/17 | 2D 3D TSV |
US9365576 | 279 | 238 | Pyrrolopyrrolidinone compounds | Novartis AG | 07/03/17 | 2D 3D TSV | |
US9388137 | 9 | 8 | HGNC:10597 | Quaternized amines as sodium channel blockers | Purdue Pharma LP | 07/03/17 | 2D 3D TSV |
US9394283 | 2 | 1 | HGNC:3527 | Salt form of a human histone methyltransferase EZH2 inhibitor | Epizyme Inc | 07/03/17 | 2D 3D TSV |
US9364482 | 134 | 67 | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases | Merck Sharp & Dohme Corp | 07/03/17 | 2D 3D TSV | |
US9394281 | 12 | 5 | HGNC:6190 HGNC:6192 HGNC:11390 HGNC:3765 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC | 07/03/17 | 2D 3D TSV |
US9365546 | 8 | 2 | HGNC:6887 | Substituted pyridinone-pyridinyl compounds | Confluence Life Sciences Inc | 07/03/17 | 2D 3D TSV |
US9359399 | 71 | 36 | HGNC:8154 | Synthetic peptide amides | Cara Therapeutics, Inc. | 07/03/17 | 2D 3D TSV |
US9365563 | 228 | 137 | HGNC:12716 | TRPV1 antagonists including dihydroxy substituent and uses thereof | Purdue Pharma LP | 07/03/17 | 2D 3D TSV |
US9359338 | 366 | 240 | HGNC:1097 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (Taiwan) | 06/27/17 | 2D 3D TSV |
US9388160 | 4 | 2 | Quinazoline derivatives as kinases inhibitors and methods of use thereof | Teligene Ltd | 06/27/17 | 2D 3D TSV | |
US9388170 | 7 | 3 | Substituted aminoquinazolines useful as kinases inhibitors | TBA | 06/27/17 | 2D 3D TSV | |
US9353084 | 49 | 49 | HGNC:933 | 2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease | H. Lundbeck A/S | 06/26/17 | 2D 3D TSV |
US9359337 | 12 | 12 | HGNC:497 | Acetamide derivatives | Hoffmann-La Roche Inc | 06/26/17 | 2D 3D TSV |
US9359341 | 11 | 2 | HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2634 HGNC:2621 | Aldehyde derivative of substitute oxazolidinones | WANBURY LTD. | 06/26/17 | 2D 3D TSV |
US9353089 | 180 | 82 | HGNC:2529 HGNC:933 HGNC:2637 HGNC:2625 HGNC:2621 | Compositions and methods for the treatment of malaria | Saint Louis University | 06/26/17 | 2D 3D TSV |
US9353101 | 64 | 64 | HGNC:1869 | Cyclic amine substituted heterocyclic CETP inhibitors | Merck Sharp & Dohme Corp | 06/26/17 | 2D 3D TSV |
US9359348 | 11 | 11 | Cyclopropyl imidazopyridine PDE10 inhibitors | Merck Sharp & Dohme Corp | 06/26/17 | 2D 3D TSV | |
US9365558 | 99 | 94 | HGNC:7045 | Dihydropyridinone MGAT2 inhibitors | Bristol-Myers Squibb Co. | 06/26/17 | 2D 3D TSV |
US9359339 | 19 | 19 | HGNC:4192 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | Merck Sharp & Dohme Corp | 06/26/17 | 2D 3D TSV |
US9353093 | 63 | 26 | HGNC:6307 HGNC:8800 | Indole-1-carboxamides as kinase inhibitors | Allergan Inc | 06/26/17 | 2D 3D TSV |
US9353116 | 62 | 27 | HGNC:18618 | Methods and compositions for kinase inhibition | The Regents of the University of California | 06/26/17 | 2D 3D TSV |
US9353102 | 88 | 42 | HGNC:3560 HGNC:3559 | Non-annulated thiophenylamides | Hoffmann-La Roche Inc | 06/26/17 | 2D 3D TSV |
US9353104 | 130 | 130 | Substituted pyridizinone derivatives as PDE10 inhibitors | Merck Sharp & Dohme Corp | 06/26/17 | 2D 3D TSV | |
US9359345 | 12 | 12 | HGNC:1133 | Thiazole derivatives as inhibitors of Bruton's tyrosine kinase | Hoffmann-La Roche Inc | 06/26/17 | 2D 3D TSV |
US9393245 | 88 | 64 | HGNC:11892 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | vTv Therapeutics LLC | 06/26/17 | 2D 3D TSV |
US9353061 | 28 | 7 | HGNC:4852 HGNC:5006 HGNC:14064 HGNC:4853 | 3,5,N-trihydroxy-alkanamide and derivatives: method for making same and use thereof | National Taiwan University | 06/19/17 | 2D 3D TSV |
US9346829 | 31 | 29 | HGNC:5297 | 5-HT3 receptor antagonists | Takeda Pharmaceutical Co., Ltd | 06/19/17 | 2D 3D TSV |
US9353081 | 132 | 46 | HGNC:2592 HGNC:2591 | Bicyclic dihydroquinoline-2-one derivatives | Hoffmann-La Roche Inc | 06/19/17 | 2D 3D TSV |
US9353075 | 66 | 55 | HGNC:736 | Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) | University of California | 06/19/17 | 2D 3D TSV |
US9359301 | 14 | 6 | Ethynyl derivatives | Hoffmann-La Roche Inc | 06/19/17 | 2D 3D TSV | |
US9346814 | 250 | 49 | HGNC:18648 HGNC:3009 HGNC:9358 HGNC:14892 | FAP inhibitors | Universiteit Antwerp | 06/19/17 | 2D 3D TSV |
US9346821 | 66 | 33 | HGNC:9490 HGNC:9475 | Heterocyclic carboxylic acid ester derivative | Ajinomoto Co. Inc | 06/19/17 | 2D 3D TSV |
US9353090 | 331 | 323 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | Boehringer Ingelheim International GmbH | 06/19/17 | 2D 3D TSV | |
US9351965 | 152 | 123 | Indazole derivatives useful as ERK inhibitors | Merck Sharp & Dohme Corp | 06/19/17 | 2D 3D TSV | |
US9359293 | 24 | 4 | HGNC:14935 HGNC:14934 HGNC:10886 HGNC:14933 HGNC:14929 HGNC:14931 | Methods of treatment using modulators of SIRT2 | Cornell University | 06/19/17 | 2D 3D TSV |
US9346786 | 123 | 122 | HGNC:11528 | Pyrrolidine compounds | Hoffmann-La Roche Inc | 06/19/17 | 2D 3D TSV |
US9353066 | 228 | 225 | HGNC:11491 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | Merck Sharp & Dohme Corp | 06/19/17 | 2D 3D TSV |
US9359330 | 25 | 23 | HGNC:10597 | Substituted piperidines as sodium channel blockers | Purdue Pharma LP | 06/19/17 | 2D 3D TSV |
US9346815 | 934 | 465 | HGNC:6190 HGNC:6192 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | Genentech Inc | 06/12/17 | 2D 3D TSV |
US9345742 | 42 | 42 | HGNC:2529 | Aminostatin derivatives for the treatment of arthrosis | Merck Patent GmbH | 06/12/17 | 2D 3D TSV |
US9346770 | 29 | 10 | HGNC:9232 HGNC:9235 HGNC:9236 | Compounds having activating effect on subtypes of peroxisome proliferator-activated receptors and its preparation method and uses | Zhejiang Hisun Pharmaceutical Co., Ltd | 06/12/17 | 2D 3D TSV |
US9353067 | 3 | 3 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR Holding S.A. | 06/12/17 | 2D 3D TSV | |
US9353115 | 11 | 11 | HGNC:15633 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. | 06/12/17 | 2D 3D TSV |
US9353083 | 4 | 2 | HGNC:6932 HGNC:6929 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | Galderma Research & Development | 06/12/17 | 2D 3D TSV |
US9358227 | 12 | 7 | HGNC:3236 | Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives | Jiangsu Hengrui Medicine Co., Ltd. | 06/12/17 | 2D 3D TSV |
US9346839 | 11 | 9 | HGNC:4800 | Phosphonate derivatives and methods of use thereof in the treatment of Alzheimer's disease | University of Kansas | 06/12/17 | 2D 3D TSV |
US9351973 | 15 | 9 | HGNC:2592 HGNC:2591 | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | Merck Sharp & Dohme Corp | 06/12/17 | 2D 3D TSV |
US9346794 | 85 | 64 | HGNC:3309 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 06/12/17 | 2D 3D TSV |
US9346795 | 186 | 93 | HGNC:992 HGNC:990 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | Bristol-Myers Squibb Co. | 06/12/17 | 2D 3D TSV |
US9353113 | 13 | 13 | HGNC:3357 | Tetrahydrocarboline derivative | Ono Pharmaceutical Co., Ltd | 06/12/17 | 2D 3D TSV |
US9346827 | 11 | 10 | HGNC:933 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | Amgen Inc | 06/05/17 | 2D 3D TSV |
US9346782 | 60 | 16 | Alkyl linked quinolinyl modulators of RORγt | Janssen Pharmaceutica NV | 06/05/17 | 2D 3D TSV | |
US9346818 | 42 | 39 | Benzodioxole derivative and preparation method and use thereof | Zhejiang Hisun Pharmaceutical Co., Ltd | 06/05/17 | 2D 3D TSV | |
US9345700 | 53 | 53 | HGNC:6943 | Compositions and methods useful for treating diseases | Eutropics Pharmaceuticals, Inc. | 06/05/17 | 2D 3D TSV |
US9346798 | 678 | 258 | HGNC:10593 HGNC:10597 | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors | Amgen Inc | 06/05/17 | 2D 3D TSV |
US9346803 | 44 | 11 | HGNC:387 HGNC:384 HGNC:385 HGNC:386 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | Vanderbilt University | 06/05/17 | 2D 3D TSV |
US9340574 | 25 | 3 | HGNC:16077 HGNC:9671 HGNC:9670 HGNC:9673 HGNC:9650 HGNC:3069 HGNC:9642 HGNC:9675 HGNC:9652 HGNC:9644 HGNC:9655 HGNC:9665 HGNC:9646 HGNC:9656 HGNC:9645 HGNC:9659 HGNC:9658 HGNC:9669 | Inhibitors of protein tyrosine phosphatases | Indiana University Research and Technology Corporation | 06/05/17 | 2D 3D TSV |
US9340549 | 193 | 178 | Oxazolidinone compounds and derivatives thereof | Amgen Inc | 06/05/17 | 2D 3D TSV | |
US9346787 | 28 | 14 | HGNC:11393 HGNC:11390 | Piperidine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 06/05/17 | 2D 3D TSV |
US9339501 | 54 | 50 | HGNC:2593 | 17a-hydroxylase/C17,20-lyase inhibitors | Novartis AG | 05/31/17 | 2D 3D TSV |
US9346797 | 14 | 12 | HGNC:933 | 2-amino 6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors | H. Lundbeck A/S | 05/31/17 | 2D 3D TSV |
US9340500 | 154 | 129 | HGNC:18083 | Aromatic heterocyclic derivative having TRPV4-inhibiting activity | Shionogi & Co., Ltd | 05/31/17 | 2D 3D TSV |
US9340537 | 173 | 102 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVATIS AG | 05/31/17 | 2D 3D TSV | |
US9334269 | 337 | 327 | HGNC:10597 | Carboxamides as inhibitors of voltage-gated sodium channels | Amgen Inc | 05/31/17 | 2D 3D TSV |
US9346793 | 15 | 15 | HGNC:3827 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | Actelion Pharmaceuticals Ltd | 05/31/17 | 2D 3D TSV |
US9340517 | 531 | 489 | HGNC:6932 HGNC:6933 HGNC:6929 HGNC:6931 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | Mimetica PTY LTD | 05/31/17 | 2D 3D TSV |
US9334286 | 108 | 107 | HGNC:12401 | Pharmacologically active compounds | Cancer Research Technology Limited | 05/31/17 | 2D 3D TSV |
US9340530 | 84 | 76 | HGNC:3537 | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists | Merck Sharp & Dohme Corp | 05/31/17 | 2D 3D TSV |
US9340507 | 111 | 109 | HGNC:3309 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 05/31/17 | 2D 3D TSV |
US9353062 | 2 | 2 | HGNC:1133 | Substituted quinolines as bruton's tyrosine kinases inhibitors | HangzhouDeRenYuCheng Biotechnology Ltd | 05/31/17 | 2D 3D TSV |
US9334290 | 152 | 60 | HGNC:6192 HGNC:1133 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | Bristol-Myers Squibb Co. | 05/31/17 | 2D 3D TSV |
US9340510 | 245 | 245 | HGNC:85 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 05/31/17 | 2D 3D TSV |
US9346822 | 4 | 2 | HGNC:4421 | Thienopyrimidine compounds and use thereof | Takeda Pharmaceutical Co., Ltd | 05/31/17 | 2D 3D TSV |
US9340506 | 38 | 34 | HGNC:4195 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | Advinus Therapeutics Ltd | 05/22/17 | 2D 3D TSV |
US9340573 | 28 | 14 | Azaindolines | Hoffmann-La Roche Inc | 05/22/17 | 2D 3D TSV | |
US9340555 | 180 | 69 | HGNC:3763 HGNC:6307 | Compounds as tyrosine kinase modulators | Allergan Inc | 05/22/17 | 2D 3D TSV |
US9345793 | 20 | 20 | HGNC:6156 | Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi | PIRAMAL IMAGING SA | 05/22/17 | 2D 3D TSV |
US9334279 | 129 | 65 | Hepatitis C virus inhibitors | Bristol-Myers Squibb Co. | 05/22/17 | 2D 3D TSV | |
US9345740 | 24 | 12 | IAP antagonists | Bristol-Myers Squibb Co. | 05/22/17 | 2D 3D TSV | |
US9340521 | 130 | 65 | HGNC:11037 HGNC:11036 | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives | Green Cross Corporation | 05/22/17 | 2D 3D TSV |
US9340542 | 20 | 7 | HGNC:8154 HGNC:8156 | Propellane-based compounds and the use thereof | Purdue Pharma LP | 05/22/17 | 2D 3D TSV |
US9340504 | 6 | 6 | HGNC:10597 | Pyridine and piperidine derivatives as novel sodium channel blockers | Purdue Pharma LP | 05/22/17 | 2D 3D TSV |
US9346810 | 249 | 144 | Pyrrolopyrimidine compounds and uses thereof | Hutchison MediPharma Limited | 05/22/17 | 2D 3D TSV | |
US9334288 | 34 | 9 | HGNC:4696 | Selective β-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents | University of North Carolina at Chapel Hill | 05/22/17 | 2D 3D TSV |
US9345789 | 13 | 5 | HGNC:9472 HGNC:2527 HGNC:1504 HGNC:2537 | Specific inhibitors and active site probes for legumain | The Board of Trustees of the Leland Stanford Junior University | 05/22/17 | 2D 3D TSV |
US9328099 | 1336 | 661 | HGNC:6190 HGNC:6192 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | Merck Sharp & Dohme Corp | 05/18/17 | 2D 3D TSV |
US9333195 | 34 | 34 | HGNC:1952 | Quinuclidine derivatives and medicinal compositions containing the same | Almirall, S.A. | 05/18/17 | 2D 3D TSV |
US9334268 | 25 | 13 | HGNC:15631 HGNC:15632 | 4-amino-imidazoquinoline compounds | Hoffman-La Roche Inc | 05/15/17 | 2D 3D TSV |
US9340534 | 4 | 1 | HGNC:9594 HGNC:9596 | Compounds and methods for treating ocular diseases | Allergan Inc | 05/15/17 | 2D 3D TSV |
US9328106 | 297 | 284 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | Genentech Inc | 05/15/17 | 2D 3D TSV | |
US9339486 | 15 | 4 | HGNC:2160 HGNC:2159 | Heterocyclic modulators of cannabinoid receptors | The Cleveland Clinic Foundation | 05/15/17 | 2D 3D TSV |
US9333217 | 10 | 2 | HGNC:3527 | Inhibitors of human EZH2, and methods of use thereof | Epizyme Inc | 05/15/17 | 2D 3D TSV |
US9333205 | 6 | 3 | HGNC:3255 HGNC:12401 | Isoxazolo-quinazolines as modulators of protein kinase activity | Nerviano Medical Sciences srl | 05/15/17 | 2D 3D TSV |
US9333199 | 13 | 7 | HGNC:17383 HGNC:5182 | Methods of treatment of histamine H-4 receptor-related pruritus associated with nerve disorders | BRIDGE PHARMA, INC. | 05/15/17 | 2D 3D TSV |
US9340511 | 7 | 7 | HGNC:1232 | Process for making isoquinoline compounds | FibroGen Inc | 05/15/17 | 2D 3D TSV |
US9334271 | 32 | 32 | HGNC:3942 | Purine derivatives and their use in the treatment of disease | Novarits AG | 05/15/17 | 2D 3D TSV |
US9321790 | 119 | 119 | HGNC:8979 | Pyrimidinone derivatives as antimalarial agents | Sanofi | 05/15/17 | 2D 3D TSV |
US9334278 | 38 | 38 | Pyrrolo[2,3-B]pyrazines as SYK inhibitors | Hoffmann-La Roche Inc | 05/15/17 | 2D 3D TSV | |
US9328096 | 800 | 794 | Tropomyosin-related kinase inhibitors | Pfizer Inc | 05/15/17 | 2D 3D TSV | |
US9328120 | 34 | 28 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | Boehringer Ingelheim International GmbH | 05/08/17 | 2D 3D TSV | |
US9321791 | 46 | 46 | HGNC:3009 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | Boehringer Ingelheim International GmbH | 05/08/17 | 2D 3D TSV |
US9326978 | 16 | 5 | HGNC:268 HGNC:262 HGNC:263 | A3 adenosine receptor allosteric modulators | The United States of America, Represented by the Secretary, Dept. of Health and Human Services | 05/08/17 | 2D 3D TSV |
US9321760 | 243 | 242 | HGNC:10436 | Aminopyrimidine derivatives for use as modulators of kinase activity | Merck Patent GmbH | 05/08/17 | 2D 3D TSV |
US9333197 | 9 | 9 | HGNC:2595 HGNC:2637 HGNC:2615 HGNC:2625 HGNC:2622 HGNC:2623 HGNC:2621 | Apoptosis signal-regulating kinase inhibitor | Gilead Sciences Inc | 05/08/17 | 2D 3D TSV |
US9321756 | 823 | 293 | HGNC:19310 HGNC:8987 | Azole compounds as PIM inhibitors | Amgen Inc | 05/08/17 | 2D 3D TSV |
US9328124 | 3 | 3 | BACE inhibitors | Eli Lilly and Company | 05/08/17 | 2D 3D TSV | |
US9321773 | 21 | 7 | HGNC:8979 HGNC:8978 HGNC:8977 | Compounds | Respivert Ltd | 05/08/17 | 2D 3D TSV |
US9328070 | 8 | 5 | Ethynyl derivatives | Hoffmann-La Roche Inc | 05/08/17 | 2D 3D TSV | |
US9328118 | 159 | 123 | HGNC:2545 | Nitrogen-containing bicyclic aromatic heterocyclic compound | Astellas Pharma Inc | 05/08/17 | 2D 3D TSV |
US9328123 | 5 | 4 | Rotenone derivatives and a use thereof | Korea Atomic Energy Research Institute | 05/08/17 | 2D 3D TSV | |
US9328111 | 39 | 18 | HGNC:270 HGNC:272 HGNC:15677 | Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors | BeiGene, Ltd | 05/08/17 | 2D 3D TSV |
US9328112 | 193 | 193 | HGNC:1780 | Tetracyclic CDK9 kinase inhibitors | AbbVie Inc | 05/03/17 | 2D 3D TSV |
US9315520 | 135 | 115 | HGNC:6251 HGNC:2625 | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | Pfizer Inc | 05/01/17 | 2D 3D TSV |
US9321748 | 59 | 30 | Aminopyridine derived compounds as LRRK2 inhibitors | H. Lundbeck A/S | 05/01/17 | 2D 3D TSV | |
US9321728 | 33 | 33 | HGNC:2843 | Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient | Korea Research Institute of Chemical Technology | 05/01/17 | 2D 3D TSV |
US9320741 | 14 | 7 | HGNC:13575 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | Dana-Farber Cancer Institute Inc | 05/01/17 | 2D 3D TSV |
US9321743 | 25 | 25 | Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase | University of California | 05/01/17 | 2D 3D TSV | |
US9321766 | 10 | 5 | HGNC:6307 HGNC:8804 | Kinase inhibitors | Allergan Inc | 05/01/17 | 2D 3D TSV |
US9321738 | 28 | 14 | HGNC:3166 HGNC:14298 | N-alkyltriazole compounds as LPAR antagonists | Hoffman-La Roche Inc | 05/01/17 | 2D 3D TSV |
US9321752 | 10 | 10 | HGNC:6893 | Pyrazole derivative | GREEN TECH CO., LTD. | 05/01/17 | 2D 3D TSV |
US9321750 | 5 | 5 | ROR modulators and their uses | INNOV17 LLC | 05/01/17 | 2D 3D TSV | |
US9320722 | 81 | 55 | HGNC:402 HGNC:404 HGNC:405 | Regulators of aldehyde dehydrogenase ALDH3A1 and related therapeutic methods | Indiana University Research and Technology Corporation | 05/01/17 | 2D 3D TSV |
US9320734 | 110 | 44 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | The University of Texas System | 05/01/17 | 2D 3D TSV | |
US20160326143 | 65 | 64 | HGNC:6719 | Compounds and uses | AstraZeneca AB | 04/27/17 | 2D 3D TSV |
US9320732 | 21 | 20 | HGNC:6059 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | Incyte Corporation | 04/24/17 | 2D 3D TSV |
US9315514 | 32 | 9 | HGNC:8154 HGNC:8156 | 1,3-dioxanomorphides and 1,3-dioxanocodides | Rhodes Technologies | 04/24/17 | 2D 3D TSV |
US9321747 | 21 | 7 | HGNC:1869 | Acid addition salt of substituted pyridine compound | Daiichi Sankyo Company, Limited | 04/24/17 | 2D 3D TSV |
US9315498 | 174 | 173 | Arlethynyl derivatives | Hoffman-La Roche Inc | 04/24/17 | 2D 3D TSV | |
US9315500 | 26 | 26 | Bicyclic heteroaryl cycloalkyldiamine derivatives | Novartis AG | 04/24/17 | 2D 3D TSV | |
US9315489 | 98 | 80 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | Novartis AG | 04/24/17 | 2D 3D TSV | |
US9315499 | 41 | 41 | Cytomegalovirus inhibitor compounds | Boehringer Ingelheim International GmbH | 04/24/17 | 2D 3D TSV | |
US9315519 | 6 | 6 | HGNC:3529 | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | Bristol-Myers Squibb Co. | 04/24/17 | 2D 3D TSV |
US9315518 | 40 | 25 | HGNC:4594 | Imidazopyridin-2-one derivatives | Merck Sharp & Dohme Corp | 04/24/17 | 2D 3D TSV |
US9321721 | 8 | 7 | HGNC:6307 | Kinase inhibitors | Allergan Inc | 04/24/17 | 2D 3D TSV |
US9315493 | 18 | 18 | Phenylpyridine derivative and drug containing same | KOWA COMPANY, LTD. | 04/24/17 | 2D 3D TSV | |
US9315491 | 129 | 129 | HGNC:3942 | Pyrimidine compounds as mTOR and PI3K inhibitors | Development Center for Biotechnology | 04/24/17 | 2D 3D TSV |
US9320737 | 32 | 32 | Substituted imidazopyridazines | Bayer Intellectual Property GmbH | 04/24/17 | 2D 3D TSV | |
US9315508 | 3 | 3 | HGNC:3009 | Treating diabetes with dipeptidyl peptidase-IV inhibitors | Merck Sharp & Dohme Corp | 04/24/17 | 2D 3D TSV |
US9303017 | 131 | 12 | 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof | Georgetown University | 04/10/17 | 2D 3D TSV | |
US9303045 | 162 | 153 | HGNC:5297 | 5-HT3 receptor antagonists | Takeda Pharmaceutical Co., Ltd | 04/10/17 | 2D 3D TSV |
US9303025 | 407 | 404 | HGNC:990 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc | 04/10/17 | 2D 3D TSV |
US9314468 | 140 | 122 | HGNC:2561 HGNC:6251 | Chemokine receptor modulators | Altiris Therapeutics, Inc. | 04/10/17 | 2D 3D TSV |
US9314464 | 22 | 22 | HGNC:1097 | Compounds and compositions as protein kinase inhibitors | Novartis AG | 04/10/17 | 2D 3D TSV |
US9315463 | 30 | 15 | HGNC:286 HGNC:1952 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | Almirall, S.A. | 04/10/17 | 2D 3D TSV |
US9303015 | 151 | 44 | Heteroaryl linked quinolinyl modulators of RORγt | Janssen Pharmaceutica NV | 04/10/17 | 2D 3D TSV | |
US9315492 | 29 | 19 | HGNC:3165 | Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof | Beijing Foreland Biopharma Co., Ltd. | 04/10/17 | 2D 3D TSV |
US9315438 | 10 | 5 | HGNC:11037 HGNC:11036 | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative | Xuanzhu Pharma Co., Ltd | 04/10/17 | 2D 3D TSV |
US9303023 | 145 | 145 | HGNC:4849 | Pyrazole and imidazole derivatives useful as orexin antagonists | Actelion Pharmaceuticals Ltd | 04/10/17 | 2D 3D TSV |
US9303012 | 304 | 152 | HGNC:2160 HGNC:2159 | Pyridine-2-amides useful as CB2 agonists | Hoffman-La Roche Inc | 04/10/17 | 2D 3D TSV |
US9303035 | 36 | 34 | Substituted pyrazino[1′,2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel | Novartis AG | 04/10/17 | 2D 3D TSV | |
US9284322 | 30 | 16 | Nicotinic receptor compounds | Research Triangle Institute | 04/04/17 | 2D 3D TSV | |
US9296759 | 188 | 93 | HGNC:2529 HGNC:933 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | Amgen Inc | 04/03/17 | 2D 3D TSV |
US9290488 | 165 | 39 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Azetidine-substituted quinoxalines as opioid receptor like-1 modulators | Purdue Pharma LP | 04/03/17 | 2D 3D TSV |
US9271961 | 119 | 27 | HGNC:9605 HGNC:381 HGNC:382 HGNC:387 HGNC:384 HGNC:385 HGNC:9604 HGNC:386 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | University of Pennsylvania | 04/03/17 | 2D 3D TSV |
US9296741 | 698 | 348 | Bromodomain inhibitors | AbbVie Inc | 04/03/17 | 2D 3D TSV | |
US9296708 | 17 | 17 | HGNC:2843 | Chimeric small molecules for the recruitment of antibodies to cancer cells | Yale University | 04/03/17 | 2D 3D TSV |
US9302996 | 148 | 145 | HGNC:2843 | Continuous arycyclic compound | Mitsubishi Tanabe Pharma Corporation | 04/03/17 | 2D 3D TSV |
US9278100 | 149 | 25 | HGNC:6193 HGNC:6171 HGNC:11491 HGNC:11283 HGNC:12841 HGNC:9617 HGNC:3432 HGNC:4840 HGNC:6735 HGNC:3697 HGNC:4037 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:76 HGNC:11719 HGNC:3236 HGNC:2444 HGNC:6524 HGNC:3655 | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | Pharmacyclics LLC | 04/03/17 | 2D 3D TSV |
US9290476 | 160 | 94 | Methylene linked quinolinyl modulators of RORγt | Janssen Pharmaceutica NV | 04/03/17 | 2D 3D TSV | |
US9271963 | 95 | 27 | HGNC:2594 HGNC:2592 HGNC:2593 HGNC:2591 | Selective inhibitors of human corticosteroid synthases | Universitat des Saarlandes | 04/03/17 | 2D 3D TSV |
US9278925 | 146 | 10 | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | Bayer Intellectual Property GmbH | 04/03/17 | 2D 3D TSV | |
US9302986 | 97 | 26 | HGNC:6834 HGNC:80 HGNC:550 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | Boehringer Ingelheim International GmbH | 04/03/17 | 2D 3D TSV |
US9303033 | 2239 | 1176 | HGNC:2460 HGNC:2457 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. | 03/30/17 | 2D 3D TSV |
US9302985 | 17 | 17 | Benzyl sulfonamide derivatives as RORc modulators | Genentech Inc | 03/21/17 | 2D 3D TSV | |
US9212182 | 776 | 650 | HGNC:10593 HGNC:10597 | Bicyclic sulfonamide compounds as sodium channel inhibitors | Amgen Inc | 03/21/17 | 2D 3D TSV |
US9296681 | 36 | 12 | HGNC:11050 HGNC:11048 HGNC:11049 | Cycloalkylmethylamines | Reviva Pharmaceuticals Inc | 03/21/17 | 2D 3D TSV |
US9289400 | 6 | 2 | HGNC:11050 HGNC:11048 HGNC:11049 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | Drexel University | 03/21/17 | 2D 3D TSV |
US9284333 | 390 | 363 | HGNC:6251 HGNC:6278 | Fused pyrroledicarboxamides and their use as pharmaceuticals | Sanofi | 03/21/17 | 2D 3D TSV |
US9249087 | 156 | 50 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:1014 HGNC:4853 HGNC:18128 | HDAC inhibitors and therapeutic methods using the same | University of Illinois | 03/21/17 | 2D 3D TSV |
US9290501 | 16 | 10 | Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase | Albert Einstein College of Medicine, Inc | 03/21/17 | 2D 3D TSV | |
US9296757 | 92 | 89 | HGNC:4626 | Substituted benzothienopyrimidines | Bayer Pharma Aktiengesellschaft | 03/21/17 | 2D 3D TSV |
US9260435 | 16 | 8 | HGNC:391 HGNC:392 | Substituted imidazopyrazines as Akt kinase inhibitors | Bayer Pharma Aktiengesellschaft | 03/21/17 | 2D 3D TSV |
US9303018 | 23 | 23 | HGNC:6710 | Inhibitors of leukotriene production | Boehringer Ingelheim International GmbH | 03/13/17 | 2D 3D TSV |
US9302989 | 1657 | 1518 | HGNC:30092 HGNC:10252 | NAMPT and rock inhibitors | AbbVie Inc | 03/13/17 | 2D 3D TSV |
US9303019 | 12 | 6 | HGNC:283 HGNC:18006 | Amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome | Universite de Strasbourg | 03/06/17 | 2D 3D TSV |
US9296745 | 236 | 213 | HGNC:16940 | Diacylglycerol acyltransferase 2 inhibitors | Pfizer Inc | 03/06/17 | 2D 3D TSV |
US9296734 | 722 | 242 | HGNC:2529 HGNC:933 | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | Amgen Inc | 03/06/17 | 2D 3D TSV |
US9296736 | 497 | 405 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | Amgen Inc | 03/06/17 | 2D 3D TSV | |
US9296748 | 113 | 112 | Pyridinones | Boehringer Ingelheim International GmbH | 03/06/17 | 2D 3D TSV | |
US9302981 | 6 | 2 | HGNC:11050 HGNC:11048 HGNC:11049 | Synthesis, methods of using, and compositions of cycloalkylmethylamines | Reviva Pharmaceuticals Inc | 03/06/17 | 2D 3D TSV |
US9303005 | 4 | 4 | HGNC:2457 | Use of dibenzofuranone derivatives to inhibit kinases | TBA | 03/06/17 | 2D 3D TSV |
US9296747 | 30 | 17 | HGNC:6307 HGNC:8804 | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 | Allergan Inc | 02/28/17 | 2D 3D TSV |
US9296703 | 2 | 2 | HGNC:1133 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | University of Utah Research Foundation | 02/28/17 | 2D 3D TSV |
US9296728 | 26 | 26 | Therapeutic compounds | Regents of the University of Minnesota | 02/28/17 | 2D 3D TSV | |
US9284330 | 29 | 29 | HGNC:108 | 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof | Jiangsu Simovay Pharmaceutical Co., Ltd. | 02/27/17 | 2D 3D TSV |
US9296693 | 133 | 66 | HGNC:3402 | Acyl piperidine inhibitors of soluble epoxide hydrolase | The Regents of the University of California | 02/27/17 | 2D 3D TSV |
US9284319 | 34 | 18 | HGNC:4626 | Heterocyclyl aminoimidazopyridazines | Bayer Intellectual Property GmbH | 02/27/17 | 2D 3D TSV |
US9283222 | 773 | 725 | HGNC:270 | Inhibitors of poly(ADP-ribose)polymerase | AbbVie Inc | 02/27/17 | 2D 3D TSV |
US9295672 | 37 | 3 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:2637 HGNC:2615 HGNC:268 HGNC:2625 HGNC:12440 HGNC:2622 HGNC:2623 HGNC:2621 | Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof | Ambit Biosciences Corporation | 02/27/17 | 2D 3D TSV |
US9278978 | 83 | 42 | 6-Alkynyl Pyridine | Boehringer Ingelheim International GmbH | 02/21/17 | 2D 3D TSV | |
US9278976 | 8 | 8 | HGNC:3009 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | Merck Sharp & Dohme Corp | 02/21/17 | 2D 3D TSV |
US9278981 | 551 | 297 | HGNC:76 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | Novartis AG | 02/21/17 | 2D 3D TSV |
US9284302 | 4 | 4 | Cyclobutyl benzimidazoles as PDE 10 inhibitors | Merck Sharp & Dohme Corp | 02/21/17 | 2D 3D TSV | |
US9278968 | 106 | 106 | Imidazopyridine compounds | Astellas Pharma Inc | 02/21/17 | 2D 3D TSV | |
US9284284 | 64 | 32 | HGNC:934 HGNC:933 | Oxazine derivatives and their use in the treatment of disease | Novartis AG | 02/21/17 | 2D 3D TSV |
US9296775 | 3 | 1 | HGNC:11037 HGNC:11036 | Pyrazole compounds | Eli Lilly and Company | 02/21/17 | 2D 3D TSV |
US9284298 | 8 | 6 | HGNC:6192 HGNC:8987 | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | Nerviano Medical Sciences srl | 02/21/17 | 2D 3D TSV |
US9283225 | 2 | 2 | Pyrido-pyrimidine derivatives | Merck Patent GmbH | 02/21/17 | 2D 3D TSV | |
US9284299 | 58 | 25 | Substituted 1H-indazol-1-ol analogs as inhibitors of beta catenin/Tcf protein-protein interactions | University of Utah Research Foundation | 02/21/17 | 2D 3D TSV | |
US9284317 | 29 | 29 | HGNC:12401 | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors | Bayer Intellectual Property GmbH | 02/21/17 | 2D 3D TSV |
US9284315 | 32 | 16 | HGNC:8975 HGNC:3942 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. | 02/21/17 | 2D 3D TSV |
US9290517 | 25 | 25 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | Merck Sharp & Dohme Corp | 02/14/17 | 2D 3D TSV | |
US9278963 | 124 | 31 | HGNC:4852 HGNC:14064 HGNC:4854 HGNC:4853 | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors | Acetylon Pharmaceuticals Inc | 02/14/17 | 2D 3D TSV |
US9278960 | 315 | 290 | HGNC:4594 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | Merck Sharp & Dohme Corp | 02/14/17 | 2D 3D TSV |
US9278093 | 8 | 4 | HGNC:2592 HGNC:2591 | Aldosterone synthase inhibitors | Merck Sharp & Dohme Corp | 02/13/17 | 2D 3D TSV |
US9278953 | 14 | 14 | HGNC:9595 | Antagonists of prostaglandin EP3 receptor | Pfizer Inc | 02/13/17 | 2D 3D TSV |
US9278930 | 32 | 16 | HGNC:12680 | Methods for increasing the stabilization of hypoxia inducible factor-α | Aerpio Therapeutics Inc | 02/13/17 | 2D 3D TSV |
US9278944 | 131 | 128 | HGNC:9958 | Nitrogen-containing saturated heterocyclic compound | Mitsubishi Tanabe Pharma Corporation | 02/13/17 | 2D 3D TSV |
US8772490 | 5 | 4 | Optically active diazabicyclooctane derivatives and process for preparing the same | Meiji Seika Pharma Co., Ltd | 02/13/17 | 2D 3D TSV | |
US9278954 | 172 | 149 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 02/13/17 | 2D 3D TSV | |
US9278914 | 5 | 1 | HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2621 | SARMs and method of use thereof | University of Tennessee Research Foundation | 02/13/17 | 2D 3D TSV |
US9278918 | 32 | 16 | HGNC:3560 HGNC:3559 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | Hoffmann-La Roche Inc | 02/13/17 | 2D 3D TSV |
US9290482 | 8 | 8 | Amino-substituted imidazopyridazines | Bayer Pharma Aktiengesellschaft | 02/06/17 | 2D 3D TSV | |
US9290490 | 33 | 33 | HGNC:11491 | Aminopyrimidines as Syk inhibitors | Merck Sharp & Dohme Corp | 02/06/17 | 2D 3D TSV |
US9290507 | 137 | 137 | HGNC:1097 | B-RAF kinase inhibitors | Boehringer Ingelheim International GmbH | 02/06/17 | 2D 3D TSV |
US9290481 | 13 | 13 | Monocyclic heteroaryl cycloalkyldiamine derivatives | Novartis AG | 02/06/17 | 2D 3D TSV | |
US9290485 | 183 | 182 | HGNC:6371 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | Novartis AG | 02/06/17 | 2D 3D TSV |
US9290487 | 74 | 74 | HGNC:4706 | Pharmaceutical composition for treating diabetes | Ajinomoto Co. Inc | 02/06/17 | 2D 3D TSV |
US9290459 | 353 | 270 | HGNC:3309 HGNC:2622 HGNC:2623 HGNC:2621 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 02/06/17 | 2D 3D TSV |
US9290457 | 215 | 211 | HGNC:3309 | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | Boehringer Ingelheim International GmbH | 02/06/17 | 2D 3D TSV |
US9290505 | 22 | 11 | HGNC:1692 HGNC:11491 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | Gilead Sciences Inc | 02/06/17 | 2D 3D TSV |
US9247759 | 464 | 422 | HGNC:14915 HGNC:14920 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof | Senomyx Inc | 02/02/17 | 2D 3D TSV |
US9290467 | 51 | 49 | HGNC:2537 | Cyclic amides | Hoffmann-La Roche Inc | 01/30/17 | 2D 3D TSV |
US9273046 | 116 | 58 | HGNC:9829 HGNC:1097 | Fused tricyclic compounds as Raf kinase inhibitors | BeiGene, Ltd | 01/30/17 | 2D 3D TSV |
US9290477 | 7 | 7 | Inhibitors of β-secretase | Vitae Pharmaceuticals Inc | 01/30/17 | 2D 3D TSV | |
US9290456 | 68 | 66 | HGNC:2671 | Pyridazinone compounds and their use as DAAO inhibitors | Takeda Pharmaceutical Co., Ltd | 01/30/17 | 2D 3D TSV |
US9290451 | 758 | 382 | HGNC:2160 HGNC:2159 | Pyridine derivatives as agonists of the CB2 receptor | Hoffmann-La Roche Inc | 01/30/17 | 2D 3D TSV |
US9290463 | 5 | 5 | HGNC:5295 | Radiolabeled compounds and uses thereof | Columbia University | 01/30/17 | 2D 3D TSV |
US9290454 | 27 | 26 | HGNC:4502 | Substituted isoquinolines as CRTH2 receptor modulators | Merck Sharp & Dohme Corp | 01/30/17 | 2D 3D TSV |
US9273053 | 82 | 79 | HGNC:933 | Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity | Shionogi & Co., Ltd | 01/30/17 | 2D 3D TSV |
US9273043 | 82 | 34 | HGNC:12716 | TRPV1 antagonists including dihydroxy substituent and uses thereof | Purdue Pharma LP | 01/30/17 | 2D 3D TSV |
US9249124 | 141 | 83 | HGNC:11393 | Aurora kinase inhibitors and methods of making and using thereof | H. Lee Moffitt Cancer Center and Research Institute Inc | 01/27/17 | 2D 3D TSV |
US9273042 | 9 | 9 | HGNC:933 | 5-amino[1,4]thiazines as BACE 1 inhibitors | Hoffmann-La Roche Inc | 01/25/17 | 2D 3D TSV |
US9273014 | 82 | 39 | HGNC:7881 HGNC:7883 HGNC:5724 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof | Bristol-Myers Squibb Co. | 01/24/17 | 2D 3D TSV |
US9266877 | 359 | 187 | HGNC:992 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc | 01/23/17 | 2D 3D TSV |
US9271969 | 134 | 67 | HGNC:2843 | Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | KAINOS MEDICINE, INC. | 01/23/17 | 2D 3D TSV |
US9273021 | 6 | 3 | HGNC:3606 | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof | Boston College | 01/23/17 | 2D 3D TSV |
US9273052 | 5 | 5 | HGNC:270 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 01/23/17 | 2D 3D TSV |
US9273029 | 119 | 58 | HGNC:11584 HGNC:14552 | Pyridine-and pyrazine derivatives | Merck Patent GmbH | 01/23/17 | 2D 3D TSV |
US9266890 | 24 | 19 | HGNC:9077 HGNC:6880 HGNC:12401 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | Dana-Farber Cancer Institute Inc | 01/23/17 | 2D 3D TSV |
US9271981 | 7 | 2 | Pyrrolo[2,3-D]pyrimidine compounds | Zoetis Services LLC | 01/23/17 | 2D 3D TSV | |
US9266883 | 144 | 143 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | Novartis AG | 01/23/17 | 2D 3D TSV | |
US9266891 | 61 | 61 | HGNC:29607 | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors | Boehringer Ingelheim International GmbH | 01/23/17 | 2D 3D TSV |
US9273011 | 14 | 14 | HGNC:3357 | Substituted pyridazines for the treatment of pain | Inhibitaxin Limited | 01/23/17 | 2D 3D TSV |
US9273033 | 142 | 135 | HGNC:8772 | Substituted pyridone derivatives as PDE10 inhibitors | Merck Sharp & Dohme Corp | 01/23/17 | 2D 3D TSV |
US9243038 | 35 | 29 | HGNC:5381 | Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof | President and Fellows of Harvard College | 01/18/17 | 2D 3D TSV |
US9233167 | 124 | 36 | HGNC:8153 HGNC:8154 HGNC:8156 | Oligomer-opioid agonist conjugates | Nektar Therapeutics | 01/18/17 | 2D 3D TSV |
US9233947 | 11 | 11 | Sulfamides as TRPM8 modulators | Janssen Pharmaceutica NV | 01/18/17 | 2D 3D TSV | |
US9266876 | 244 | 243 | HGNC:4383 | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | Actelion Pharmaceuticals Ltd | 01/17/17 | 2D 3D TSV |
US9266870 | 96 | 45 | HGNC:4849 HGNC:4848 | Heteroaromatic methyl cyclic amine derivative | Taisho Pharmaceutical Co., Ltd | 01/17/17 | 2D 3D TSV |
US9266878 | 656 | 163 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga LLC | 01/17/17 | 2D 3D TSV |
US9266880 | 8 | 8 | HGNC:2593 | Substituted azaindazole compounds | Bristol-Myers Squibb Co. | 01/17/17 | 2D 3D TSV |
US9266869 | 118 | 42 | HGNC:6307 HGNC:8804 | Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors | Allergan Inc | 01/17/17 | 2D 3D TSV |
US9266895 | 33 | 33 | HGNC:1133 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | Principia Biopharma Inc | 01/17/17 | 2D 3D TSV |
US9266881 | 22 | 22 | HGNC:8772 | Triazolopyridinone PDE10 inhibitors | Merck Sharp & Dohme Corp | 01/17/17 | 2D 3D TSV |
US9266835 | 362 | 171 | HGNC:2160 HGNC:2159 | Quinoline derivatives useful as CB-1 inverse agonists | Janssen Pharmaceutica NV | 01/16/17 | 2D 3D TSV |
US9265773 | 422 | 195 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | Merck Sharp & Dohme Corp | 01/16/17 | 2D 3D TSV | |
US9233921 | 34 | 34 | Potent poxvirus inhibitor | University of Pennsylvania | 01/14/17 | 2D 3D TSV | |
US9266848 | 37 | 12 | HGNC:195 HGNC:7173 HGNC:216 HGNC:7176 HGNC:7155 HGNC:188 | 4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases | Galderma Research & Development | 01/09/17 | 2D 3D TSV |
US9260455 | 15 | 8 | HGNC:934 | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | Pfizer Inc | 01/09/17 | 2D 3D TSV |
US9265734 | 416 | 206 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BioMarin Pharmaceutical Inc | 01/09/17 | 2D 3D TSV |
US9266832 | 90 | 89 | HGNC:11138 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun | 01/09/17 | 2D 3D TSV |
US9260439 | 575 | 509 | HGNC:8979 HGNC:8975 | Dihydropyrrolopyrimidine derivatives | Pfizer Inc | 01/09/17 | 2D 3D TSV |
US9260440 | 123 | 68 | HGNC:270 HGNC:272 HGNC:15677 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors | BeiGene, Ltd | 01/09/17 | 2D 3D TSV |
US9266828 | 5 | 5 | HGNC:8568 | Inhibitors of Furin and other pro-protein convertases | Sanford-Burnham Medical Research Institute | 01/09/17 | 2D 3D TSV |
US9266853 | 8 | 2 | HGNC:2637 HGNC:2623 | Orally available viridiofungin derivative possessing anti-HCV activity | Chugai Seiyaku Kabushiki Kaisha | 01/09/17 | 2D 3D TSV |
US9260450 | 18 | 9 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. | 01/09/17 | 2D 3D TSV | |
US9266839 | 2 | 2 | HGNC:2625 | Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | Lycera Corporation | 01/09/17 | 2D 3D TSV |
US9233965 | 111 | 110 | HGNC:2453 HGNC:2452 | 3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta | Sanofi | 01/07/17 | 2D 3D TSV |
US9249163 | 241 | 117 | HGNC:8772 | PDE10a inhibitors for the treatment of type II diabetes | Janssen Pharmaceutica NV | 12/31/16 | 2D 3D TSV |
US9492405 | 97 | 35 | HGNC:286 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | The United States of America, as represented by the Secretary, Department of Health and Human Services | 12/31/16 | 2D 3D TSV |
US9260415 | 17 | 17 | HGNC:1133 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | Genentech Inc | 12/28/16 | 2D 3D TSV |
US9260413 | 5 | 5 | HGNC:2228 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | Merck Sharp & Dohme Corp | 12/28/16 | 2D 3D TSV |
US9259422 | 35 | 11 | HGNC:8154 HGNC:8155 | Orvinol and thevinol derivatives useful in the treatment of depression | The University of Bath | 12/28/16 | 2D 3D TSV |
US9260410 | 8 | 3 | HGNC:11283 HGNC:6874 HGNC:6876 | P38 MAP kinase inhibitors | Respivert Ltd | 12/28/16 | 2D 3D TSV |
US9260425 | 412 | 405 | Pyrazolo[3,4-c]pyridine compounds and methods of use | Genetech, Inc | 12/28/16 | 2D 3D TSV | |
US9259470 | 42 | 42 | HGNC:6871 | Serine/threonine kinase inhibitors | Array BioPharma Inc | 12/28/16 | 2D 3D TSV |
US9260446 | 5 | 5 | HGNC:10597 | Synthetic methods for spiro-oxindole compounds | Xenon Pharmaceuticals Inc | 12/28/16 | 2D 3D TSV |
US9260448 | 11 | 11 | HGNC:4593 | Thienopyrimidinone derivatives as mGluR1 antagonists | Korea Institute of Science and Technology | 12/28/16 | 2D 3D TSV |
US9253997 | 33 | 33 | Alkylamine derivative | Ajinomoto Co. Inc | 12/20/16 | 2D 3D TSV | |
US9255091 | 15 | 5 | HGNC:108 HGNC:983 | Benzothiazole-based pyridinium compounds | The University of Montana | 12/20/16 | 2D 3D TSV |
US9255107 | 8 | 8 | Heteroaryl alkyne compound and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. | 12/20/16 | 2D 3D TSV | |
US9255090 | 449 | 432 | HGNC:4502 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | Actelion Pharmaceuticals Ltd | 12/20/16 | 2D 3D TSV |
US9255110 | 229 | 176 | HGNC:11491 HGNC:6112 HGNC:17967 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | Roche Palo Alto LLC | 12/20/16 | 2D 3D TSV |
US9255096 | 26 | 8 | HGNC:6307 HGNC:8804 | Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors | Allergan Inc | 12/20/16 | 2D 3D TSV |
US9255106 | 46 | 25 | HGNC:270 HGNC:11941 HGNC:272 HGNC:15677 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 12/20/16 | 2D 3D TSV |
US9255103 | 59 | 52 | HGNC:4597 | Substituted pyrazolo[1,5-a]pyrazines as mGluR5 receptor modulators | Vanderbilt University | 12/20/16 | 2D 3D TSV |
US9255098 | 6 | 4 | HGNC:3009 | Xanthine derivative | Chengdu Easton Pharmaceutical Co., Ltd. | 12/20/16 | 2D 3D TSV |
US9260417 | 14 | 1 | HGNC:8803 HGNC:6307 HGNC:8590 HGNC:8804 HGNC:1782 HGNC:1097 HGNC:76 HGNC:6342 HGNC:3689 HGNC:9967 HGNC:6876 HGNC:3765 | Therapeutic methods and compositions involving allosteric kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 12/15/16 | 2D 3D TSV |
US9249085 | 61 | 52 | HGNC:9594 HGNC:9596 | Aniline derivatives, their preparation and their therapeutic application | FOVEA PHARMACEUTICALS | 12/12/16 | 2D 3D TSV |
US9249151 | 126 | 60 | Bis-amido pyridines | Boehringer Ingelheim International GmbH | 12/12/16 | 2D 3D TSV | |
US9248140 | 66 | 32 | Chemical compounds | AstraZeneca AB | 12/12/16 | 2D 3D TSV | |
US9249139 | 9 | 9 | HGNC:8779 | Indolizinone based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | Council of Scientific & Industrial Research | 12/12/16 | 2D 3D TSV |
US9249125 | 371 | 93 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 | Pyrazole derivatives as p38 MAP inhibitors | Respivert Limited | 12/12/16 | 2D 3D TSV |
US9249123 | 8 | 7 | HGNC:1133 | Pyridinones/pyrazinones, method of making, and method of use thereof | Genentech Inc | 12/12/16 | 2D 3D TSV |
US9249096 | 30 | 30 | HGNC:6623 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | Bristol-Myers Squibb Co. | 12/12/16 | 2D 3D TSV |
US9243020 | 20 | 12 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 12/12/16 | 2D 3D TSV |
US9255087 | 12 | 4 | HGNC:5465 HGNC:11393 HGNC:427 | Substituted indazole derivatives active as kinase inhibitors | Nerviano Medical Sciences srl | 12/12/16 | 2D 3D TSV |
US9249114 | 74 | 47 | HGNC:11584 HGNC:14552 | Thiazole derivatives | Merck Patent GmbH | 12/12/16 | 2D 3D TSV |
US9227979 | 64 | 30 | HGNC:268 HGNC:262 HGNC:263 | Fluorescent antagonists of the A3 adenosine receptor | The United States of America, as represented by the Secretary, Department of Health and Human Services | 12/08/16 | 2D 3D TSV |
US9260454 | 41 | 40 | HGNC:11778 | Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals | Sanofi | 12/08/16 | 2D 3D TSV |
US9242977 | 42 | 24 | Trk-inhibiting compound | Ono Pharmaceutical Co., Ltd | 12/06/16 | 2D 3D TSV | |
US9242988 | 7 | 7 | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | Merck Sharp & Dohme Corp | 12/05/16 | 2D 3D TSV | |
US9242996 | 573 | 459 | HGNC:6871 | Aminoheteroaryl benzamides as kinase inhibitors | Novartis AG | 12/05/16 | 2D 3D TSV |
US9242973 | 532 | 211 | HGNC:6251 HGNC:933 | Chromane compounds | CoMentis Inc | 12/05/16 | 2D 3D TSV |
US9242998 | 118 | 59 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C | Merck Sharp & Dohme Corp | 12/05/16 | 2D 3D TSV | |
US9243002 | 192 | 84 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C | Merck Sharp & Dohme Corp | 12/05/16 | 2D 3D TSV | |
US9221809 | 356 | 349 | HGNC:17967 | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | Merck Sharp & Dohme Corp | 11/29/16 | 2D 3D TSV |
US9242943 | 66 | 36 | HGNC:934 HGNC:2529 HGNC:933 HGNC:2637 HGNC:2625 HGNC:2623 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | Siena Biotech SpA | 11/28/16 | 2D 3D TSV |
US9242969 | 416 | 202 | HGNC:1097 | Biaryl amide compounds as kinase inhibitors | Novartis AG | 11/28/16 | 2D 3D TSV |
US9238625 | 33 | 11 | HGNC:11050 HGNC:11048 HGNC:11049 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | Reviva Pharmaceuticals Inc | 11/28/16 | 2D 3D TSV |
US9242981 | 44 | 24 | Fused pyrazole derivatives as novel ERK inhibitors | Merck Sharp & Dohme Corp | 11/28/16 | 2D 3D TSV | |
US9242975 | 27 | 26 | HGNC:17967 | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors | Bristol-Myers Squibb Co. | 11/28/16 | 2D 3D TSV |
US9242995 | 3 | 3 | HGNC:4849 | Isoxazolopyridine orexin receptor antagonists | Merck Sharp & Dohme Corp | 11/28/16 | 2D 3D TSV |
US9242970 | 930 | 464 | HGNC:4849 HGNC:4848 | Lactam derivatives useful as orexin receptor antagonists | Actelion Pharmaceuticals Ltd | 11/28/16 | 2D 3D TSV |
US9242960 | 4 | 2 | HGNC:6874 HGNC:6876 | P38MAP kinase inhibitors | Respivert Ltd | 11/28/16 | 2D 3D TSV |
US9242982 | 7 | 7 | HGNC:8779 | Pyridopyrimidine based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof | Council of Scientific & Industrial Research | 11/28/16 | 2D 3D TSV |
US9242957 | 72 | 24 | Thiophene-2-carboximidamide based selective neuronal nitric oxide inhibitors | Northwestern University | 11/28/16 | 2D 3D TSV | |
US9238651 | 72 | 36 | HGNC:8816 | 1-H-pyrrolo[2,3-b]pyridine derivatives | Merck Patent GmbH | 11/21/16 | 2D 3D TSV |
US9238626 | 42 | 11 | HGNC:108 HGNC:933 HGNC:983 | Beta-amyloid-directed multitarget compounds for the treatment of alzheimer's disease | Universitat de Barcelona | 11/21/16 | 2D 3D TSV |
US9233979 | 458 | 446 | HGNC:6871 | Compounds that are ERK inhibitors | Merck Sharp & Dohme Corp | 11/21/16 | 2D 3D TSV |
US9238629 | 88 | 22 | HGNC:3236 | Heteroaryl compounds and uses thereof | Celgene Avilomics Research, Inc. | 11/21/16 | 2D 3D TSV |
US9241942 | 494 | 278 | HGNC:3449 | IRE-1α inhibitors | MannKind Corporation | 11/21/16 | 2D 3D TSV |
US9238619 | 76 | 76 | HGNC:11056 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG | 11/21/16 | 2D 3D TSV |
US9233983 | 152 | 147 | HGNC:1133 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | Advinus Therapeutics Ltd | 11/21/16 | 2D 3D TSV |
US9233981 | 33 | 32 | HGNC:933 | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | Pfizer Inc | 11/21/16 | 2D 3D TSV |
US9238658 | 49 | 44 | Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors | Janssen Pharmaceutica NV | 11/21/16 | 2D 3D TSV | |
US9238644 | 143 | 81 | HGNC:6307 HGNC:3767 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED | 11/21/16 | 2D 3D TSV |
US9187424 | 434 | 289 | HGNC:7045 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | Bristol-Myers Squibb Co. | 11/15/16 | 2D 3D TSV |
US9227969 | 101 | 99 | HGNC:6871 | Compounds and compositions as inhibitors of MEK | Novartis AG | 11/14/16 | 2D 3D TSV |
US9233108 | 30 | 15 | HGNC:286 HGNC:1952 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | Almirall, S.A. | 11/14/16 | 2D 3D TSV |
US9233953 | 161 | 160 | HGNC:11056 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | Boehringer Ingelheim International GmbH | 11/14/16 | 2D 3D TSV |
US9226927 | 15 | 15 | HGNC:620 | Gamma secretase inhibitors | Merck Sharp & Dohme Corp | 11/14/16 | 2D 3D TSV |
US9233086 | 100 | 100 | Inhibition of WDR5 interaction with its binding partners | The Regents of the University of Michigan | 11/14/16 | 2D 3D TSV | |
US9233968 | 97 | 30 | HGNC:6307 HGNC:8804 | Kinase inhibitors | Allergan Inc | 11/14/16 | 2D 3D TSV |
US9227975 | 60 | 60 | HGNC:8031 | Method of treatment using substituted imidazo[1,2B]pyridazine compounds | Array BioPharma Inc | 11/14/16 | 2D 3D TSV |
US9227977 | 14 | 4 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Phosphoinositide 3-kinase inhibitors | Respivert Ltd | 11/14/16 | 2D 3D TSV |
US9227973 | 16 | 11 | HGNC:16709 | Pyridine CGRP receptor antagonists | Merck Sharp & Dohme Corp | 11/14/16 | 2D 3D TSV |
US9233111 | 72 | 67 | HGNC:1133 | Pyrrolo pyrimidine derivatives | Novartis AG | 11/14/16 | 2D 3D TSV |
US9227956 | 98 | 41 | HGNC:20001 | Substituted amide compounds | Pfizer Inc | 11/14/16 | 2D 3D TSV |
US9233946 | 59 | 57 | HGNC:8874 HGNC:8875 | Sulfonamide compounds | Kancera AB | 11/14/16 | 2D 3D TSV |
US9227970 | 43 | 42 | HGNC:8772 | Triazolopyridine compounds | Hoffmann-La Roche Inc | 11/14/16 | 2D 3D TSV |
US9227982 | 56 | 26 | HGNC:270 | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors | Novartis AG | 11/08/16 | 2D 3D TSV |
US9227930 | 16 | 15 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Inc | 11/08/16 | 2D 3D TSV | |
US9234000 | 417 | 198 | HGNC:3530 HGNC:6371 HGNC:9475 HGNC:3528 HGNC:3535 HGNC:6357 HGNC:9071 | Benzylamine derivatives as inhibitors of plasma kallikrein | Kalvista Pharmaceuticals Limited | 11/08/16 | 2D 3D TSV |
US9221831 | 451 | 97 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Buprenorphine analogs | Purdue Pharma LP | 11/08/16 | 2D 3D TSV |
US9226922 | 476 | 458 | HGNC:6871 | Compounds that are ERK inhibitors | Merck Sharp & Dohme Corp | 11/08/16 | 2D 3D TSV |
US9227959 | 8 | 6 | Ethynyl derivatives | Hoffman-La Roche Inc | 11/08/16 | 2D 3D TSV | |
US9227949 | 188 | 94 | HGNC:9490 HGNC:9475 | Heteroarylcarboxylic acid ester derivative | Ajinomoto Co. Inc | 11/08/16 | 2D 3D TSV |
US9221808 | 178 | 88 | HGNC:10251 HGNC:10252 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. Lee Moffitt Cancer Center and Research Institute Inc | 11/08/16 | 2D 3D TSV |
US9226923 | 19 | 6 | HGNC:427 HGNC:7029 | Spirocyclic molecules as protein kinase inhibitors | Nanjing Allgen Pharma Co. Ltd. | 11/08/16 | 2D 3D TSV |
US9216998 | 56 | 27 | HGNC:6623 | Tricyclic indole derivatives useful endothelial lipase inhibitors | Janssen Pharmaceutica NV | 11/08/16 | 2D 3D TSV |
US9217012 | 22 | 4 | HGNC:16077 HGNC:9670 HGNC:1718 HGNC:9650 HGNC:9661 HGNC:3069 HGNC:9308 HGNC:9642 HGNC:9652 HGNC:9644 HGNC:9646 HGNC:9659 HGNC:122 | Inhibitors of protein tyrosine phosphatases | Indiana University Research and Technology Corporation | 11/02/16 | 2D 3D TSV |
US9221802 | 10 | 10 | Arylethynyl derivatives | Hoffman-La Roche Inc | 10/31/16 | 2D 3D TSV | |
US9221839 | 30 | 15 | HGNC:934 HGNC:933 | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 10/31/16 | 2D 3D TSV |
US9221832 | 152 | 120 | HGNC:8537 | Heterocyclic amide derivatives as P2X7 receptor antagonists | Actelion Pharmaceuticals Ltd | 10/31/16 | 2D 3D TSV |
US9221824 | 5 | 5 | HGNC:7029 | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors | Incyte Holdings Corporation | 10/31/16 | 2D 3D TSV |
US9221797 | 93 | 85 | Inhibitors of c-fms kinase | Janssen Pharmaceutica NV | 10/31/16 | 2D 3D TSV | |
US9221791 | 18 | 6 | HGNC:2637 HGNC:2623 HGNC:2621 | Metalloenzyme inhibitor compounds | Viamet Pharmaceuticals Inc | 10/31/16 | 2D 3D TSV |
US9221828 | 21 | 21 | HGNC:10810 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides as pharmaceuticals | Sanofi | 10/31/16 | 2D 3D TSV |
US9221796 | 174 | 137 | Selective NR2B antagonists | Bristol-Myers Squibb Co. | 10/31/16 | 2D 3D TSV | |
US9216999 | 1840 | 459 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | Nissan Chemical Industries, Ltd | 10/31/16 | 2D 3D TSV |
US9216984 | 12 | 2 | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors | Incyte Corporation | 10/24/16 | 2D 3D TSV | |
US9216985 | 41 | 12 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones | SciFluor Life Sciences, Inc. | 10/24/16 | 2D 3D TSV |
US9221790 | 16 | 16 | HGNC:5299 | Benzamide derivatives | Dong-A Pharm. Co., Ltd | 10/24/16 | 2D 3D TSV |
US9216988 | 210 | 203 | Benzyl sulfonamide derivatives as RORc modulators | Genentech Inc | 10/24/16 | 2D 3D TSV | |
US9216968 | 239 | 237 | HGNC:9599 | Heterocyclic derivative and pharmaceutical drug | Nippon Shinyaku Co. Ltd | 10/24/16 | 2D 3D TSV |
US9221795 | 143 | 95 | HGNC:8977 HGNC:8976 | Phosphatidylinositol 3-kinase inhibitors | Gilead Sciences Inc | 10/24/16 | 2D 3D TSV |
US9216981 | 88 | 44 | HGNC:1097 | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient | Medpacto, Inc. | 10/24/16 | 2D 3D TSV |
US9216986 | 52 | 50 | Quinoline derivatives as PDE10A enzyme inhibitors | H. Lundbeck A/S | 10/24/16 | 2D 3D TSV | |
US9221767 | 26 | 13 | HGNC:10251 HGNC:10252 | Substituted phthalazinones as rock inhibitors | Bristol-Myers Squibb Co. | 10/24/16 | 2D 3D TSV |
US9216962 | 216 | 75 | HGNC:4852 HGNC:14064 HGNC:4854 | Thiazole compounds, methods for preparation and use thereof | Shanghai Puyi Chemical Co., Ltd. | 10/24/16 | 2D 3D TSV |
US9216997 | 21 | 21 | HGNC:3765 | Tri-heterocyclic derivatives, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd | 10/24/16 | 2D 3D TSV |
US9216972 | 69 | 23 | HGNC:3167 HGNC:3165 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Co. | 10/24/16 | 2D 3D TSV |
US9090621 | 104 | 99 | HGNC:1133 | Tyrosine kinase inhibitors | Principia Biopharma Inc | 10/19/16 | 2D 3D TSV |
US9212206 | 8 | 4 | HGNC:12823 HGNC:2707 | 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use | TBA | 10/18/16 | 2D 3D TSV |
US9216182 | 192 | 102 | HGNC:5184 | Carbamate/urea derivatives containing piperidin and piperazin rings as H3 receptor inhibitors | Novartis AG | 10/18/16 | 2D 3D TSV |
US9206164 | 111 | 109 | HGNC:4502 | Pyrazole compounds as CRTH2 antagonists | Boehringer Ingelheim International GmbH | 10/18/16 | 2D 3D TSV |
US9212144 | 43 | 16 | HGNC:7872 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | Northwestern University | 10/17/16 | 2D 3D TSV |
US9212184 | 4 | 4 | HGNC:12401 | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors | Bayer Intellectual Property GmbH | 10/17/16 | 2D 3D TSV |
US9212192 | 59 | 59 | HGNC:427 | Bicyclic carboxamide inhibitors of kinases | AbbVie Inc | 10/17/16 | 2D 3D TSV |
US9212186 | 25 | 19 | HGNC:18618 | Bicyclic pyrazole LRRK2 small molecule inhibitors | Genentech Inc | 10/17/16 | 2D 3D TSV |
US9212147 | 64 | 34 | HGNC:2671 | Dihydroxy aromatic heterocyclic compound | Takeda Pharmaceutical Co., Ltd | 10/17/16 | 2D 3D TSV |
US9212171 | 46 | 43 | Ethynyl compounds | Hoffmann-La Roche Inc | 10/17/16 | 2D 3D TSV | |
US9212196 | 105 | 33 | Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof | Universite Paris Descartes | 10/17/16 | 2D 3D TSV | |
US9212187 | 13 | 13 | HGNC:6224 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | Otsuka Pharmaceutical Co., Ltd | 10/17/16 | 2D 3D TSV |
US9212173 | 37 | 36 | HGNC:18618 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | Genentech Inc | 10/17/16 | 2D 3D TSV |
US9212178 | 35 | 32 | HGNC:11491 | Substituted pyrimidine compounds and their use as SYK inhibitors | Genosco | 10/17/16 | 2D 3D TSV |
US9212145 | 3 | 3 | HGNC:6307 | Urea derivatives and uses thereof | Kala Pharmaceuticals, Inc. | 10/17/16 | 2D 3D TSV |
US9212140 | 12 | 3 | (5s,8s)-3-(4′-chlor-3′-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one (compound A) for treatment | Bayer Intellectual Property GmbH | 10/11/16 | 2D 3D TSV | |
US9212139 | 88 | 67 | HGNC:10597 | Aryl substituted indoles and their use as blockers of sodium channels | Purdue Pharma LP | 10/11/16 | 2D 3D TSV |
US9212165 | 28 | 25 | HGNC:4597 | Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same | H. Lundbeck A/S | 10/11/16 | 2D 3D TSV |
US9206201 | 4 | 1 | HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 | Boronic acid bearing liphagane compounds as inhibitors of P13K-α and/or β | Counsel of Scientific & Industrial Research | 10/11/16 | 2D 3D TSV |
US9212130 | 181 | 179 | HGNC:8534 | Heterocyclic derivative and pharmaceutical composition comprising the same | Shionogi & Co., Ltd | 10/11/16 | 2D 3D TSV |
US9206199 | 217 | 196 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 10/11/16 | 2D 3D TSV |
US9206232 | 203 | 201 | Organic compounds and their uses | Novartis AG | 10/11/16 | 2D 3D TSV | |
US9206188 | 228 | 54 | HGNC:6190 HGNC:6192 HGNC:1133 HGNC:6193 HGNC:6171 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC | 10/11/16 | 2D 3D TSV |
US9211296 | 35 | 35 | Therapeutic compounds for blocking DNA synthesis of POX viruses | University of Pennsylvania | 10/11/16 | 2D 3D TSV | |
US9206173 | 137 | 88 | HGNC:4464 | Heterocyclic compounds for the treatment of stress-related conditions | Otsuka Pharmaceutical Co., Ltd | 10/10/16 | 2D 3D TSV |
US9216974 | 16 | 15 | HGNC:620 | Phenoxazine derivatives and methods of use thereof | Washington University | 10/04/16 | 2D 3D TSV |
US9206129 | 53 | 53 | Agent for treatment of eye diseases | Daito Chemix Corporation | 10/03/16 | 2D 3D TSV | |
US9206139 | 65 | 5 | HGNC:7160 HGNC:7173 HGNC:7174 HGNC:7175 HGNC:7176 HGNC:7155 HGNC:7166 HGNC:7158 HGNC:7159 HGNC:220 HGNC:221 | Aggrecanase inhibitors | Eli Lilly and Company | 10/03/16 | 2D 3D TSV |
US9206184 | 219 | 115 | HGNC:3690 HGNC:3688 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | Bayer Intellectual Property GmbH | 10/03/16 | 2D 3D TSV |
US9212153 | 549 | 541 | Inhibitors of beta-secretase | Vitae Pharmaceuticals Inc | 10/03/16 | 2D 3D TSV | |
US9206198 | 113 | 76 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 10/03/16 | 2D 3D TSV |
US9206167 | 122 | 65 | Piperazine-substituted benzothiophenes for treatment of mental disorders | Otsuka Pharmaceutical Co., Ltd | 10/03/16 | 2D 3D TSV | |
US9206162 | 53 | 50 | HGNC:5258 | Triazole compounds that modulate Hsp90 activity | Synta Pharmaceuticals Corp. | 10/03/16 | 2D 3D TSV |
US9205085 | 73 | 72 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | Emory University | 10/03/16 | 2D 3D TSV | |
US9200020 | 75 | 27 | HGNC:5157 | 6-oxopurine phosphoribosyltransferase inhibitors | The University of Queensland | 09/27/16 | 2D 3D TSV |
US9199981 | 176 | 168 | HGNC:6342 | Compounds and compositions as C-kit kinase inhibitors | Novartis AG | 09/27/16 | 2D 3D TSV |
US9200268 | 5 | 5 | HGNC:3528 | Compounds and methods for purification of serine proteases | Portola Pharmaceuticals Inc | 09/27/16 | 2D 3D TSV |
US9199976 | 17 | 17 | HGNC:17890 | Haematopoietic-prostaglandin D2 synthase inhibitors | The University of Queensland | 09/27/16 | 2D 3D TSV |
US9205078 | 4 | 1 | HGNC:76 | N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia | Pfizer Inc | 09/27/16 | 2D 3D TSV |
US9200006 | 26 | 6 | HGNC:2536 HGNC:2537 HGNC:2545 | Protease inhibitors | Medivir AB | 09/27/16 | 2D 3D TSV |
US9199997 | 3 | 1 | HGNC:4037 HGNC:6735 HGNC:6524 | Purinone derivative hydrochloride | Ono Pharmaceutical Co., Ltd | 09/27/16 | 2D 3D TSV |
US9200016 | 173 | 167 | HGNC:8772 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | Allergan Inc | 09/27/16 | 2D 3D TSV |
US9199999 | 76 | 73 | HGNC:12401 | Substituted imidazopyrazines | Bayer Intellectual Property GmbH | 09/27/16 | 2D 3D TSV |
US9200001 | 119 | 117 | Triazolyl PDE10 inhibitors | Merck Sharp & Dohme Corp | 09/27/16 | 2D 3D TSV | |
US9199947 | 140 | 139 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | Sanofi | 09/20/16 | 2D 3D TSV | |
US9199927 | 112 | 55 | HGNC:9475 | Guanidinobenzoic acid compound | Astellas Pharma Inc | 09/20/16 | 2D 3D TSV |
US9199944 | 157 | 90 | HGNC:427 | N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer | Korea Research Institute of Chemical Technology | 09/20/16 | 2D 3D TSV |
US9199949 | 11 | 7 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Alectos Therapeutics Inc | 09/20/16 | 2D 3D TSV |
US9193689 | 18 | 18 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | Institute of Cancer Research | 09/19/16 | 2D 3D TSV | |
US9187487 | 46 | 46 | Azaindole derivatives as tyrosine kinase inhibitors | Principia Biopharma Inc | 09/19/16 | 2D 3D TSV | |
US9192603 | 67 | 66 | HGNC:4596 | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | Vanderbilt University | 09/19/16 | 2D 3D TSV |
US9193697 | 39 | 38 | HGNC:3553 | Oxazole derivatives useful as modulators of FAAH | Merck Sharp & Dohme Corp | 09/19/16 | 2D 3D TSV |
US9193736 | 311 | 166 | PDE 10a inhibitors for the treatment of type II diabetes | Janssen Pharmaceutica NV | 09/19/16 | 2D 3D TSV | |
US9193762 | 57 | 32 | HGNC:9344 | Selective inhibitors of prolylcarboxypeptidase | University of Mississippi | 09/19/16 | 2D 3D TSV |
US9193726 | 73 | 72 | HGNC:9508 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | Pfizer Inc | 09/19/16 | 2D 3D TSV |
US9187470 | 12 | 9 | HGNC:6875 | Anti-mucus drugs and uses therefor | Washington University | 09/12/16 | 2D 3D TSV |
US9187477 | 16 | 15 | HGNC:9376 | Azabenzimidazole derivatives | Boehringer Ingelheim International GmbH | 09/12/16 | 2D 3D TSV |
US9187486 | 205 | 101 | HGNC:8987 | Bicyclic pyridazine compounds as Pim inhibitors | Amgen Inc | 09/12/16 | 2D 3D TSV |
US9187466 | 60 | 30 | HGNC:897 HGNC:895 | Bisaryl-bonded aryltriazolones and use thereof | Bayer Intellectual Property GmbH | 09/12/16 | 2D 3D TSV |
US9187469 | 20 | 17 | HGNC:9413 | Morpholinylbenzotriazines for use in cancer therapy | Merck Patent GmbH | 09/12/16 | 2D 3D TSV |
US9187480 | 48 | 22 | HGNC:2160 HGNC:2159 | Peripherally restricted diphenyl purine derivatives | Research Triangle Institute | 09/12/16 | 2D 3D TSV |
US9187459 | 10 | 5 | HGNC:3430 HGNC:3236 | Quinazoline-7-ether compounds and methods of use | NewGen Therapeutics, Inc. | 09/12/16 | 2D 3D TSV |
US9187474 | 8 | 2 | HGNC:9829 HGNC:1097 HGNC:646 | Raf inhibitor compounds | Deciphera Pharmaceuticals LLC | 09/12/16 | 2D 3D TSV |
US9187437 | 45 | 24 | HGNC:3167 HGNC:3165 | Substituted oxadiazole compounds | Bristol-Myers Squibb Co. | 09/12/16 | 2D 3D TSV |
US9187450 | 56 | 56 | HGNC:1869 | Substituted pyridine compound | Daiichi Sankyo Company, Limited | 09/12/16 | 2D 3D TSV |
US9187462 | 122 | 118 | Substituted quinazolines as serine/threonine kinase inhibitors | Array BioPharma Inc | 09/12/16 | 2D 3D TSV | |
US9187441 | 88 | 84 | HGNC:6973 | p53-Mdm2 antagonists | University of Pittsburgh | 09/12/16 | 2D 3D TSV |
US9187406 | 25 | 9 | HGNC:7175 HGNC:7176 HGNC:7166 HGNC:7159 | Curcumin analogues as zinc chelators and their uses | The Research Foundation of State University of New York | 09/06/16 | 2D 3D TSV |
US9182402 | 47 | 16 | HGNC:5155 | Hepsin inhibitors | Fred Hutchinson Cancer Research Center | 09/06/16 | 2D 3D TSV |
US9181263 | 149 | 25 | HGNC:6193 HGNC:6171 HGNC:11491 HGNC:11283 HGNC:12841 HGNC:9617 HGNC:3432 HGNC:4840 HGNC:6735 HGNC:3697 HGNC:4037 HGNC:3430 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:76 HGNC:11719 HGNC:3236 HGNC:2444 HGNC:6524 HGNC:3655 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics LLC | 09/06/16 | 2D 3D TSV |
US9187413 | 6 | 6 | Peripherally restricted FAAH inhibitors | University of California | 09/06/16 | 2D 3D TSV | |
US9187429 | 211 | 72 | HGNC:2592 HGNC:2591 | Phenyl-tetrahydroisoquinoline derivatives | Hoffmann-La Roche Inc | 09/06/16 | 2D 3D TSV |
US9187430 | 9 | 9 | HGNC:270 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. | 09/06/16 | 2D 3D TSV |
US9186318 | 31 | 2 | HGNC:11283 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:427 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:18128 HGNC:4852 HGNC:6307 HGNC:8804 HGNC:6342 HGNC:4854 HGNC:7029 HGNC:9967 HGNC:4853 HGNC:3765 | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof | Beijing Konruns Pharmaceutical Co., Ltd | 09/06/16 | 2D 3D TSV |
US9187428 | 150 | 49 | HGNC:262 HGNC:263 HGNC:264 | Substituted dicyanopyridines and use thereof | Bayer Intellectual Property GmbH | 09/06/16 | 2D 3D TSV |
US9187397 | 23 | 11 | HGNC:7794 HGNC:6204 | Therapeutic curcumin derivatives | STC.UNM | 09/06/16 | 2D 3D TSV |
US9186360 | 490 | 103 | HGNC:12716 HGNC:497 HGNC:18084 HGNC:18083 HGNC:17961 | Treatment of respiratory disorders using TRPA1 antagonists | GLENMARK PHARMACEUTICALS S.A. | 09/06/16 | 2D 3D TSV |
US9181266 | 321 | 98 | HGNC:270 HGNC:11941 HGNC:272 HGNC:15677 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | Novartis AG | 08/29/16 | 2D 3D TSV |
US9181236 | 290 | 174 | HGNC:934 HGNC:933 | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use | Merck Sharp & Dohme Corp | 08/29/16 | 2D 3D TSV |
US9181253 | 52 | 22 | HGNC:262 HGNC:263 | Adenosine receptor agonists, partial agonists, and antagonists | The United States of America, as represented by the Secretary, Department of Health and Human Services | 08/29/16 | 2D 3D TSV |
US9181272 | 300 | 265 | Aldosterone synthase inhibitors | Boehringer Ingelheim International GmbH | 08/29/16 | 2D 3D TSV | |
US9181279 | 16 | 15 | HGNC:9596 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. | 08/29/16 | 2D 3D TSV |
US9181233 | 28 | 28 | HGNC:25952 | Inhibitors of glutaminyl cyclase | Probiodrug AG | 08/29/16 | 2D 3D TSV |
US9181275 | 4 | 4 | Mercaptoamidine derivatives and methods of use | AbbVie Inc | 08/29/16 | 2D 3D TSV | |
US9181258 | 130 | 64 | HGNC:8987 | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors | Nerviano Medical Sciences srl | 08/29/16 | 2D 3D TSV |
US9181249 | 142 | 140 | HGNC:4515 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | Takeda Pharmaceutical Co., Ltd | 08/29/16 | 2D 3D TSV |
US9181261 | 10 | 10 | HGNC:8031 | TrkA kinase inhibitors, compositions and methods thereof | Merck Sharp & Dohme Corp | 08/29/16 | 2D 3D TSV |
US9181181 | 77 | 41 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | Albireo AB | 08/15/16 | 2D 3D TSV | |
US9180122 | 35 | 35 | HGNC:2671 | 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain | Takeda Pharmaceutical Co., Ltd | 08/15/16 | 2D 3D TSV |
US9181219 | 48 | 20 | HGNC:10588 HGNC:6251 HGNC:12716 HGNC:18084 | Compounds of modulating TRPV3 function | Hydra Biosciences Inc | 08/15/16 | 2D 3D TSV |
US9180116 | 72 | 31 | HGNC:9594 HGNC:9596 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Cayman Chemical Company Inc | 08/15/16 | 2D 3D TSV |
US9175357 | 23 | 23 | HGNC:9077 | Fragment ligated inhibitors selective for the polo box domain of PLK1 | University of South Carolina | 08/15/16 | 2D 3D TSV |
US9181185 | 25 | 22 | HGNC:10597 | Heteroaryl compounds as sodium channel blockers | Purdue Pharma LP | 08/15/16 | 2D 3D TSV |
US9181184 | 18 | 17 | Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives | Amicus Therapeutics, Inc | 08/15/16 | 2D 3D TSV | |
US9181230 | 110 | 54 | Morpholine compounds and uses thereof | Hoffmann-La Roche Inc | 08/15/16 | 2D 3D TSV | |
US9180183 | 18 | 8 | HGNC:2637 HGNC:2615 HGNC:2638 HGNC:2625 HGNC:2622 HGNC:2623 HGNC:2631 HGNC:2621 | Phospholipid drug analogs | Telormedix SA | 08/15/16 | 2D 3D TSV |
US9181182 | 40 | 35 | HGNC:3167 HGNC:3165 HGNC:433 | S1P receptors modulators | Akaal Pharma PTY Ltd | 08/15/16 | 2D 3D TSV |
US9180120 | 38 | 19 | HGNC:897 HGNC:895 | Substituted N-phenethyltriazoloneacetamides and use thereof | Bayer Intellectual Property GmbH | 08/15/16 | 2D 3D TSV |
US9181187 | 12 | 12 | Therapeutic agent for urinary excretion disorder | Ono Pharmaceutical Co., Ltd | 08/15/16 | 2D 3D TSV | |
US9180192 | 46 | 46 | HGNC:4596 | mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | Vanderbilt University | 08/15/16 | 2D 3D TSV |
US9174997 | 29 | 29 | HGNC:3309 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | Bayer Intellectual Property GmbH | 08/08/16 | 2D 3D TSV |
US9174982 | 360 | 346 | HGNC:990 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc | 08/08/16 | 2D 3D TSV |
US9175000 | 27 | 7 | HGNC:8154 HGNC:8156 | Buprenorphine analogs | Purdue Pharma LP | 08/08/16 | 2D 3D TSV |
US9174969 | 73 | 68 | HGNC:9644 HGNC:9659 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | University of South Florida | 08/08/16 | 2D 3D TSV |
US9175331 | 256 | 63 | HGNC:3527 | Inhibitors of human EZH2, and methods of use thereof | Epizyme Inc | 08/08/16 | 2D 3D TSV |
US9174974 | 85 | 43 | HGNC:3544 | Macrocyclic factor VIIa inhibitors | Bristol-Myers Squibb Co. | 08/08/16 | 2D 3D TSV |
US9174999 | 20 | 11 | Methods and compositions for studying, imaging, and treating pain | The Board of Trustees of the Leland Stanford Junior University | 08/08/16 | 2D 3D TSV | |
US9174993 | 27 | 27 | HGNC:10810 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | Sanofi | 08/08/16 | 2D 3D TSV |
US9175320 | 1 | 1 | HGNC:3165 | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | Arena Pharmaceuticals Inc | 08/08/16 | 2D 3D TSV |
US9175003 | 234 | 233 | HGNC:4324 | Substituted azoanthracene derivatives and intermediates for preparation thereof | vTv Therapeutics LLC | 08/08/16 | 2D 3D TSV |
US9173884 | 107 | 25 | HGNC:8791 HGNC:8793 HGNC:8784 HGNC:8795 HGNC:8773 HGNC:8772 HGNC:8775 HGNC:8787 HGNC:8778 | Inhibitors of phosphodiesterase 11 (PDE11) | Boston College | 08/02/16 | 2D 3D TSV |
US9173935 | 18 | 8 | HGNC:2637 HGNC:2615 HGNC:2638 HGNC:2625 HGNC:2622 HGNC:2623 HGNC:2631 HGNC:2621 | Phospholipid drug analogs | Telormedix SA | 08/02/16 | 2D 3D TSV |
US9174965 | 6 | 6 | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators | Bristol-Myers Squibb Co. | 08/02/16 | 2D 3D TSV | |
US9174940 | 29 | 24 | HGNC:12373 | TSH receptor antagonizing tetrahydroquinoline compounds | Merck Sharp & Dohme B.V. | 08/02/16 | 2D 3D TSV |
US9169270 | 120 | 120 | HGNC:4502 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | Actelion Pharmaceuticals Ltd | 08/01/16 | 2D 3D TSV |
US9169260 | 399 | 394 | HGNC:17967 | Amidopyrazole inhibitors of interleukin receptor-associated kinases | Merck Sharp & Dohme Corp | 08/01/16 | 2D 3D TSV |
US9173879 | 6 | 1 | HGNC:11050 HGNC:11048 HGNC:11049 | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof | Bristol-Myers Squibb Co. | 08/01/16 | 2D 3D TSV |
US9173869 | 43 | 43 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | Curis Inc | 08/01/16 | 2D 3D TSV | |
US9169246 | 207 | 205 | HGNC:16672 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | Sanofi | 08/01/16 | 2D 3D TSV |
US9073941 | 179 | 134 | Compounds and methods for treating tuberculosis infection | Academia Sinica | 07/26/16 | 2D 3D TSV | |
US9169224 | 209 | 155 | HGNC:3553 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | Janssen Pharmaceutica NV | 07/26/16 | 2D 3D TSV |
US9169243 | 45 | 45 | HGNC:391 | Apoptosis signal-regulating kinase inhibitors | Gilead Sciences Inc | 07/25/16 | 2D 3D TSV |
US9169209 | 118 | 118 | HGNC:30092 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC | 07/25/16 | 2D 3D TSV |
US9169252 | 645 | 585 | HGNC:17967 | Heteroaryl substituted nicotinamide compounds | Bristol-Myers Squibb Co. | 07/25/16 | 2D 3D TSV |
US9169259 | 92 | 91 | Imidazopyridazine compounds | Hoffmann-La Roche Inc | 07/25/16 | 2D 3D TSV | |
US9169240 | 92 | 83 | HGNC:6623 | Ketone linked benzothiazole inhibitors of endothelial lipase | Bristol-Myers Squibb Co. | 07/25/16 | 2D 3D TSV |
US9079895 | 129 | 35 | Morpholino compounds, uses and methods | University of Dundee | 07/25/16 | 2D 3D TSV | |
US9169234 | 24 | 12 | HGNC:11257 | Sepiapterin reductase inhibitors for the treatment of pain | Children's Medical Center Corporation | 07/25/16 | 2D 3D TSV |
US9163017 | 17 | 17 | Anti-viral compounds | AbbVie Inc | 07/18/16 | 2D 3D TSV | |
US9168247 | 6 | 6 | HGNC:3091 | Beta carboline derivatives useful in the treatment of proliferative disorders | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX | 07/18/16 | 2D 3D TSV |
US9163012 | 94 | 74 | HGNC:5208 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | Vitae Pharmaceuticals Inc | 07/18/16 | 2D 3D TSV |
US9163011 | 106 | 37 | HGNC:934 HGNC:933 HGNC:620 | Oxazine derivatives and their use in the treatment of disease | Novartis AG | 07/18/16 | 2D 3D TSV |
US9163042 | 24 | 24 | Prodrugs of pyridone amides useful as modulators of sodium channels | Vertex Pharmaceuticals Inc | 07/18/16 | 2D 3D TSV | |
US9163015 | 90 | 90 | HGNC:4596 | Pyrazolopyridine, pyrarolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | Vanderbilt University | 07/18/16 | 2D 3D TSV |
US9169205 | 200 | 197 | HGNC:85 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 07/18/16 | 2D 3D TSV |
US9163021 | 236 | 210 | HGNC:8031 | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | Pfizer Inc | 07/18/16 | 2D 3D TSV |
US9168248 | 27 | 26 | HGNC:10571 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | Merck Canada Inc. | 07/18/16 | 2D 3D TSV |
US9163040 | 1 | 1 | HGNC:7154 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | Novartis AG | 07/18/16 | 2D 3D TSV |
US9163013 | 34 | 31 | HGNC:1771 HGNC:8749 HGNC:4617 HGNC:3091 | Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. | 07/18/16 | 2D 3D TSV |
US9162979 | 50 | 47 | HGNC:9605 | 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors | ROTTAPHARM BIOTECH S.R.L. | 07/11/16 | 2D 3D TSV |
US9161945 | 2 | 1 | HGNC:11037 HGNC:11036 | 4-isopropyl-6-methoxyphenyl glucitol compound | Taisho Pharmaceutical Co., Ltd | 07/11/16 | 2D 3D TSV |
US9163003 | 106 | 38 | HGNC:270 HGNC:11941 HGNC:272 HGNC:15677 | 4-piperidinyl compounds for use as tankyrase inhibitors | Novartis AG | 07/11/16 | 2D 3D TSV |
US9163007 | 94 | 87 | HGNC:1745 | 5-substituted indazoles as kinase inhibitors | AbbVie Inc | 07/11/16 | 2D 3D TSV |
US9169182 | 4 | 2 | Chrysophaentin analogs that inhibit FtsZ protein | The United States of America, as represented by the Secretary, Department of Health and Human Services | 07/11/16 | 2D 3D TSV | |
US9162991 | 55 | 53 | Cinnamoyl inhibitors of transglutaminase | University of Ottawa | 07/11/16 | 2D 3D TSV | |
US9156822 | 144 | 44 | HGNC:3026 HGNC:3023 HGNC:3024 HGNC:5286 HGNC:3020 HGNC:5295 HGNC:5294 | Functionally selective ligands of dopamine D2 receptors | University of North Carolina at Chapel Hill | 07/11/16 | 2D 3D TSV |
US9163010 | 3 | 2 | HGNC:3763 HGNC:6307 | Indolinone protein kinase inhibitors | Beta Pharma, Inc. | 07/11/16 | 2D 3D TSV |
US9163008 | 122 | 103 | HGNC:10597 | Pyrimidines as sodium channel blockers | Purdue Pharma LP | 07/11/16 | 2D 3D TSV |
US9161939 | 7 | 2 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrrolo[2,3-d]pyrimidine compounds | Zoetis Services LLC | 07/11/16 | 2D 3D TSV |
US9168255 | 39 | 30 | HGNC:10597 | Quinazoline compounds as sodium channel blockers | Purdue Pharma LP | 07/11/16 | 2D 3D TSV |
US9162983 | 5 | 5 | HGNC:108 | Reactivators of organophosphorous inhibited acetylcholinesterase | Southwest Research Institute | 07/11/16 | 2D 3D TSV |
US9156845 | 422 | 204 | HGNC:18618 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | Pfizer Inc | 06/30/16 | 2D 3D TSV |
US9161922 | 34 | 26 | Amine oxidase inhibitors | Case Western Reserve University | 06/30/16 | 2D 3D TSV | |
US9156856 | 44 | 44 | HGNC:992 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc | 06/30/16 | 2D 3D TSV |
US9156831 | 41 | 10 | HGNC:882 HGNC:8975 HGNC:8977 HGNC:8976 | Chemical compounds | AstraZeneca AB | 06/30/16 | 2D 3D TSV |
US9156829 | 308 | 148 | HGNC:4849 HGNC:4848 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | Takeda Pharmaceutical Co., Ltd | 06/30/16 | 2D 3D TSV |
US9161924 | 6 | 5 | HGNC:3551 | Factor IXa inhibitors | Merck Sharp & Dohme Corp | 06/30/16 | 2D 3D TSV |
US9156830 | 87 | 52 | HGNC:12716 | Heterocyclic compounds | Shionogi & Co., Ltd | 06/30/16 | 2D 3D TSV |
US9156852 | 39 | 8 | HGNC:9829 HGNC:1097 HGNC:2730 HGNC:2731 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | Hanmi Pharm. Co., Ltd | 06/30/16 | 2D 3D TSV |
US9156848 | 4 | 4 | HGNC:3009 | Treating diabetes with dipeptidyl peptidase-IV inhibitors | Merck Sharp & Dohme Corp | 06/30/16 | 2D 3D TSV |
US9156836 | 5 | 5 | HGNC:5258 | Tricyclic triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. | 06/30/16 | 2D 3D TSV |
US9150566 | 561 | 198 | HGNC:2637 HGNC:4849 HGNC:4848 | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists | Actelion Pharmaceuticals Ltd | 06/20/16 | 2D 3D TSV |
US9150578 | 174 | 171 | 5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors | Boehringer Ingelheim International GmbH | 06/20/16 | 2D 3D TSV | |
US9150526 | 208 | 208 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | Sanofi | 06/20/16 | 2D 3D TSV | |
US9155743 | 90 | 44 | HGNC:590 HGNC:592 | Bicyclic heterocycle compounds and their uses in therapy | Astex Therapeutics Limited | 06/20/16 | 2D 3D TSV |
US9150583 | 8 | 8 | HGNC:1869 | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation | Boehringer Ingelheim International GmbH | 06/20/16 | 2D 3D TSV |
US9150577 | 239 | 237 | HGNC:10431 | Heterocyclic compounds containing an indole core | Boehringer Ingelheim International GmbH | 06/20/16 | 2D 3D TSV |
US9156811 | 829 | 505 | HGNC:7857 | N-myristoyl transferase inhibitors | Univeristy of Dundee | 06/20/16 | 2D 3D TSV |
US9150581 | 30 | 11 | Nicotinic receptor compounds | Research Triangle Institute | 06/20/16 | 2D 3D TSV | |
US9150579 | 6 | 6 | HGNC:8977 | Selective PI3K delta inhibitors | Rhizen Pharmaceuticals SA | 06/20/16 | 2D 3D TSV |
US9156810 | 66 | 22 | HGNC:9594 HGNC:9593 HGNC:9596 HGNC:9595 | Treatment of inflammatory bowel disease | Allergan Inc | 06/20/16 | 2D 3D TSV |
US9150519 | 242 | 154 | HGNC:3167 HGNC:3165 | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis | Merck Serono | 06/14/16 | 2D 3D TSV |
US9145414 | 77 | 68 | HGNC:6307 HGNC:11491 HGNC:11390 | 1,2,4-triazine-6-carboxamide derivative | Taiho Pharmaceutical Co., Ltd | 06/13/16 | 2D 3D TSV |
US9149477 | 5 | 5 | HGNC:8977 | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS Corporation | 06/13/16 | 2D 3D TSV |
US9145402 | 38 | 37 | HGNC:18618 | Aminopyrimidine derivatives as LRRK2 modulators | Genentech Inc | 06/13/16 | 2D 3D TSV |
US9145391 | 266 | 242 | HGNC:11491 | Bipyridylaminopyridines as Syk inhibitors | Merck Sharp & Dohme Corp | 06/13/16 | 2D 3D TSV |
US9145380 | 240 | 239 | HGNC:17822 | Bis-(sulfonylamino) derivatives for use in therapy | AstraZeneca AB | 06/13/16 | 2D 3D TSV |
US9144538 | 75 | 68 | HGNC:2637 | Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin | The Procter & Gamble Company | 06/13/16 | 2D 3D TSV |
US9145392 | 772 | 399 | HGNC:391 HGNC:10436 | Imidazole amines as modulators of kinase activity | Merck Patent GmbH | 06/13/16 | 2D 3D TSV |
US9145419 | 10 | 10 | HGNC:2593 | Imidazopyridazinyl compounds | Bristol-Myers Squibb Co. | 06/13/16 | 2D 3D TSV |
US9150527 | 8 | 2 | HGNC:2593 HGNC:2637 HGNC:2623 HGNC:2621 | Metalloenzyme inhibitor compounds | Innocrin Pharmaceuticals, Inc. | 06/13/16 | 2D 3D TSV |
US9149492 | 26 | 13 | HGNC:11177 HGNC:11178 | Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease | Dartmouth College | 06/13/16 | 2D 3D TSV |
US9145354 | 231 | 217 | Pharmaceutical compounds | Astex Therapeutics Limited | 06/13/16 | 2D 3D TSV | |
US9145426 | 38 | 19 | HGNC:934 HGNC:933 | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 06/13/16 | 2D 3D TSV |
US9145412 | 77 | 26 | HGNC:4852 HGNC:4854 HGNC:4853 | Selective HDAC1 and HDAC2 inhibitors | Acetylon Pharmaceuticals Inc | 06/13/16 | 2D 3D TSV |
US9145418 | 10 | 5 | HGNC:8987 | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors | Nerviano Medical Sciences srl | 06/13/16 | 2D 3D TSV |
US9145408 | 44 | 7 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | Purdue Pharma LP | 06/13/16 | 2D 3D TSV |
US9150544 | 176 | 91 | HGNC:3551 HGNC:3528 | Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application | Sanofi | 06/13/16 | 2D 3D TSV |
US9150546 | 325 | 325 | HGNC:8534 | Triazine derivative and pharmaceutical composition comprising the same | Shionogi & Co., Ltd | 06/13/16 | 2D 3D TSV |
US9139578 | 26 | 24 | HGNC:6623 | Amide or urea containing benzothiazole inhibitors of endothelial lipase | Bristol-Myers Squibb Co. | 06/06/16 | 2D 3D TSV |
US9139593 | 21 | 21 | HGNC:3402 | Azetidine compounds, compositions and methods of use | Hoffmann-La Roche Inc | 06/06/16 | 2D 3D TSV |
US9138393 | 75 | 68 | HGNC:2637 | Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin | The Procter & Gamble Company | 06/06/16 | 2D 3D TSV |
US9139568 | 167 | 119 | HGNC:391 HGNC:10436 | Heterocyclic carboxamides as modulators of kinase activity | Merck Patent GmbH | 06/06/16 | 2D 3D TSV |
US9139585 | 51 | 49 | HGNC:6255 | Inhibitors of the Renal Outer Medullary Potassium channel | Merck Sharp & Dohme Corp | 06/06/16 | 2D 3D TSV |
US9138431 | 13 | 7 | HGNC:17383 HGNC:5182 | Methods of treatment of histamine H-4 receptor-related pruritus | BRIDGE PHARMA, INC. | 06/06/16 | 2D 3D TSV |
US9138494 | 8 | 8 | HGNC:8772 | Radiolabeled PDE10A ligands | AbbVie Inc | 06/06/16 | 2D 3D TSV |
US9139529 | 80 | 80 | Substituted quinoxalines as sodium channel modulators | Vertex Pharmaceuticals Inc | 06/06/16 | 2D 3D TSV | |
US9139577 | 328 | 295 | HGNC:7110 HGNC:7111 | Sulfoximine substituted quinazolines for pharmaceutical compositions | Boehringer Ingelheim International GmbH | 06/06/16 | 2D 3D TSV |
US9139546 | 32 | 16 | HGNC:2160 HGNC:2159 | Tri-aryl/heteroaromatic cannabinoids and use thereof | The University of Tennessee Research Foundation | 06/06/16 | 2D 3D TSV |
US9138423 | 2 | 2 | HGNC:4982 | Use of inhibitors of porphobilinogen deaminase in the treatment of congenital erythropoietic porphyria | Asociación Centro de Investigación Cooperativa en Biociencias—CIC Biogune | 06/06/16 | 2D 3D TSV |
US9133180 | 33 | 11 | HGNC:11393 HGNC:11390 HGNC:3765 | Aurora and FLT3 kinases modulators | SAREUM LIMITED | 05/23/16 | 2D 3D TSV |
US8772323 | 260 | 259 | HGNC:19060 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | Boehringer Ingelheim International GmbH | 05/23/16 | 2D 3D TSV |
US9133171 | 193 | 39 | HGNC:1780 HGNC:1373 HGNC:1771 HGNC:1368 | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group | Bayer Intellectual Property GmbH | 05/23/16 | 2D 3D TSV |
US8829029 | 164 | 82 | HGNC:3024 | Dual modulators of 5HT2A and D3 receptors | Hoffmann-La Roche Inc | 05/23/16 | 2D 3D TSV |
US9133183 | 27 | 9 | HGNC:6307 HGNC:7029 | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | Deciphera Pharmaceuticals LLC | 05/23/16 | 2D 3D TSV |
US9133201 | 12 | 10 | HGNC:1133 | Inhibitors of Bruton's tyrosine kinase | Pharmacyclics Inc | 05/23/16 | 2D 3D TSV |
US9133197 | 12 | 7 | HGNC:262 HGNC:263 | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments | Sigma-Tau Industrie Farmaceutiche Riunite SpA | 05/23/16 | 2D 3D TSV |
US8865745 | 19 | 19 | HGNC:8781 | Pyrazolone derivatives as PDE4 inhibitors | Takeda GmbH | 05/23/16 | 2D 3D TSV |
US9133199 | 2 | 2 | HGNC:9077 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited | 05/23/16 | 2D 3D TSV |
US9133182 | 37 | 37 | Selective androgen receptor modulators | Radius Health, Inc. | 05/23/16 | 2D 3D TSV | |
US9133187 | 85 | 85 | HGNC:6871 | Serine/threonine kinase inhibitors | Array BioPharma Inc | 05/23/16 | 2D 3D TSV |
US9132129 | 8 | 6 | HGNC:9527 | Antiviral compounds | Katholieke Universiteit Leuven | 05/16/16 | 2D 3D TSV |
US9133148 | 91 | 91 | Carbamate compounds and of making and using same | The Scripps Research Institute | 05/16/16 | 2D 3D TSV | |
US9133157 | 134 | 130 | HIV protease inhibitors | Merck Canada Inc. | 05/16/16 | 2D 3D TSV | |
US9133134 | 1 | 1 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics LLC | 05/16/16 | 2D 3D TSV |
US9132134 | 10 | 4 | HGNC:3023 HGNC:3024 HGNC:5182 | Methods for treating GI tract disorders | Neurogastrx, Inc. | 05/16/16 | 2D 3D TSV |
US9133125 | 72 | 38 | HGNC:8156 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED | 05/16/16 | 2D 3D TSV |
US9133168 | 168 | 117 | HGNC:391 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | Sanofi | 05/16/16 | 2D 3D TSV |
US9133131 | 27 | 19 | HGNC:10597 | Pyrimidine diol amides as sodium channel blockers | Purdue Pharma LP | 05/16/16 | 2D 3D TSV |
US9133160 | 15 | 15 | HGNC:2593 | Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators | Bristol-Meyers Squibb Company | 05/16/16 | 2D 3D TSV |
US9133162 | 13 | 7 | HGNC:6307 HGNC:7029 | Substituted quinoline compounds and methods of use | Sunshine Lake Pharma Co., Ltd | 05/16/16 | 2D 3D TSV |
US9133105 | 4 | 4 | HGNC:6997 | Transcription factor modulators | C&C BIOPHARMA, LLC | 05/16/16 | 2D 3D TSV |
US9126978 | 10 | 5 | HGNC:10251 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties | The Regents of the University of Michigan | 05/09/16 | 2D 3D TSV |
US9126979 | 24 | 12 | HGNC:990 | Compounds for inhibiting the interaction of BCL2 with binding partners | Novartis AG | 05/09/16 | 2D 3D TSV |
US9126980 | 90 | 45 | HGNC:990 | Compounds for inhibiting the interaction of BCL2 with binding partners | Novartis AG | 05/09/16 | 2D 3D TSV |
US9127027 | 37 | 36 | HGNC:3402 | Epoxyeicosatrienoic acid analogs and methods of making and using the same | The Medical College of Wisconsin, Inc. | 05/09/16 | 2D 3D TSV |
US9126987 | 25 | 25 | HGNC:9753 | Inhibitors of glutaminyl cyclase | Probiodrug AG | 05/09/16 | 2D 3D TSV |
US9127005 | 20 | 9 | HGNC:9067 | Isoform selective phospholipase D inhibitors | Vanderbilt University | 05/09/16 | 2D 3D TSV |
US9126952 | 67 | 67 | HGNC:9413 | Morpholinylquinazolines | Merck Patent GmbH | 05/09/16 | 2D 3D TSV |
US9126973 | 76 | 57 | HGNC:17890 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | CAYMAN CHEMICAL COMPANY, INCORPORATED | 05/09/16 | 2D 3D TSV |
US9126957 | 10 | 10 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Merck Sharp & Dohme Corp | 05/09/16 | 2D 3D TSV |
US9127001 | 68 | 63 | HGNC:6278 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them | Sanofi | 05/09/16 | 2D 3D TSV |
US9126976 | 41 | 41 | HGNC:1869 | Substituted benzopiperazines as CETP inhibitors | Merck Sharp & Dohme Corp | 05/09/16 | 2D 3D TSV |
US9125915 | 17 | 17 | HGNC:29607 | Antitumor agent | Mitsubishi Tanabe Pharma Corporation | 05/02/16 | 2D 3D TSV |
US9125913 | 853 | 431 | HGNC:990 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | AbbVie Inc | 05/02/16 | 2D 3D TSV |
US9126948 | 14 | 14 | HGNC:8977 | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors | Incyte Holdings Corporation | 05/02/16 | 2D 3D TSV |
US9120812 | 515 | 260 | HGNC:8979 HGNC:3942 | Pyrimidooxazocine derivatives as mTOR-inhibitors | Sanofi | 05/02/16 | 2D 3D TSV |
US9120838 | 4 | 4 | HGNC:11892 | Saccharide conjugates | Curators of the University of Missouri | 05/02/16 | 2D 3D TSV |
US9120808 | 141 | 42 | Substituted clavulanic acid | NABRIVA THERAPEUTICS AG | 05/02/16 | 2D 3D TSV | |
US9126947 | 6 | 6 | HGNC:427 | Substituted pyridazine carboxamide compounds | Xcovery Holding Company LLC | 05/02/16 | 2D 3D TSV |
US9126931 | 266 | 262 | HGNC:427 | Tetracyclic compound | Chugai Seiyaku Kabushiki Kaisha | 05/02/16 | 2D 3D TSV |
US9126941 | 39 | 39 | HGNC:644 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | The Regents of the University of California | 05/02/16 | 2D 3D TSV |
US9120798 | 50 | 50 | HGNC:8539 | Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor | Bristol-Myers Squibb Co. | 04/25/16 | 2D 3D TSV |
US9120769 | 172 | 171 | HGNC:5208 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | Boehringer Ingelheim International GmbH | 04/25/16 | 2D 3D TSV |
US9120771 | 46 | 17 | HGNC:11050 HGNC:11048 HGNC:11049 | Azetidine derivative and antidepressant composition including the same | Korea Institute of Science and Technology | 04/25/16 | 2D 3D TSV |
US9120772 | 6 | 3 | HGNC:6026 HGNC:6027 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | Galderma Research & Development | 04/25/16 | 2D 3D TSV |
US9120780 | 37 | 37 | HGNC:5253 | Indole or indazole derivative or salt thereof | Taiho Pharmaceutical Co., Ltd | 04/25/16 | 2D 3D TSV |
US9120791 | 119 | 115 | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier | 04/25/16 | 2D 3D TSV | |
US9120797 | 66 | 27 | HGNC:8156 HGNC:21378 | Process for preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds | Gruenenthal GmbH | 04/25/16 | 2D 3D TSV |
US9120785 | 12 | 11 | HGNC:11491 | Pyridyl aminopyridines as Syk inhibitors | Merck Sharp & Dohme Corp | 04/25/16 | 2D 3D TSV |
US9120781 | 7 | 7 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Simon Fraser University | 04/25/16 | 2D 3D TSV |
US9120807 | 28 | 7 | HGNC:262 HGNC:263 HGNC:264 | Thienopyrimidine compounds | Vernalis (R&D) Ltd | 04/25/16 | 2D 3D TSV |
US9120786 | 14 | 14 | HGNC:10597 | Triazine carboxamides as sodium channel blockers | Purdue Pharma LP | 04/25/16 | 2D 3D TSV |
US9115121 | 70 | 70 | HGNC:2160 | 1,3,5-triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof | Sanofi | 04/18/16 | 2D 3D TSV |
US9119845 | 20 | 20 | Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase | Amicus Therapeutics, Inc | 04/18/16 | 2D 3D TSV | |
US9115122 | 39 | 8 | Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK) | University of Maryland, Baltimore | 04/18/16 | 2D 3D TSV | |
US9120744 | 43 | 38 | HGNC:8583 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | University of Michigan | 04/18/16 | 2D 3D TSV |
US9120752 | 40 | 40 | HGNC:10597 | Pyridine compounds as sodium channel blockers | Purdue Pharma LP | 04/18/16 | 2D 3D TSV |
US9120749 | 650 | 612 | HGNC:16870 | Quinoline derivatives and MELK inhibitors containing the same | OncoTherapy Science Inc | 04/18/16 | 2D 3D TSV |
US9120761 | 34 | 13 | Selective FAK inhibitors | Cancer Therapeutics CRC Pty Ltd | 04/18/16 | 2D 3D TSV | |
US9120756 | 63 | 40 | HGNC:12716 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | Gruenenthal GmbH | 04/18/16 | 2D 3D TSV |
US9120745 | 4 | 4 | HGNC:5258 | Triazole compounds that modualte HSP90 activity | Synta Pharmaceuticals Corp. | 04/18/16 | 2D 3D TSV |
US9115089 | 2 | 1 | HGNC:6889 HGNC:6887 | Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds | Confluence Life Sciences Inc | 04/12/16 | 2D 3D TSV |
US9115140 | 33 | 20 | HGNC:427 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | Sanofi | 04/12/16 | 2D 3D TSV |
US9115126 | 10 | 10 | HGNC:2545 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | Merck Sharp & Dohme B.V. | 04/11/16 | 2D 3D TSV |
US9096593 | 403 | 61 | HGNC:2637 HGNC:6342 HGNC:2625 HGNC:2623 HGNC:2621 HGNC:3765 | Compounds and methods for kinase modulation, and indications therefor | Plexxikon Inc. | 04/11/16 | 2D 3D TSV |
US9115083 | 75 | 70 | Compounds from Antrodia cinnamomea and use thereof | SIMPSON BIOTECH CO., LTD. | 04/11/16 | 2D 3D TSV | |
US9115085 | 1 | 1 | HGNC:1232 | Crystalline forms of a prolyl hydroxylase inhibitor | FibroGen Inc | 04/11/16 | 2D 3D TSV |
US9115082 | 9 | 7 | HGNC:3009 HGNC:285 HGNC:286 | Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension | TBA | 04/11/16 | 2D 3D TSV |
US9115116 | 27 | 7 | HGNC:4852 HGNC:5006 HGNC:14064 HGNC:4853 | Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase | National Taiwan University | 04/11/16 | 2D 3D TSV |
US9115144 | 5 | 5 | Fused heterocyclic derivative and pharmaceutical use thereof | Kissei Pharmaceutical Co., Ltd | 04/11/16 | 2D 3D TSV | |
US9115102 | 45 | 21 | HGNC:195 HGNC:7173 HGNC:216 HGNC:7176 HGNC:7155 HGNC:188 | N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors | Galderma Research & Development | 04/11/16 | 2D 3D TSV |
US9115117 | 280 | 98 | HGNC:4849 HGNC:4848 | Substituted piperidine compounds and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 04/11/16 | 2D 3D TSV |
US9102669 | 100 | 84 | Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors | Janssen Pharmaceutica NV | 04/05/16 | 2D 3D TSV | |
US9102686 | 152 | 45 | HGNC:8537 | 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators | Janssen Pharmaceutica NV | 04/04/16 | 2D 3D TSV |
US9102591 | 244 | 180 | HGNC:8537 | Benzamides | H. Lundbeck A/S | 04/04/16 | 2D 3D TSV |
US9102637 | 93 | 93 | HGNC:30765 | Bicyclic thiazole compounds | Carna Biosciences, Inc | 04/04/16 | 2D 3D TSV |
US9102622 | 63 | 59 | Fatty acid amide hydrolase inhibitors | University of Connecticut | 04/04/16 | 2D 3D TSV | |
US9096627 | 6 | 1 | HGNC:4852 HGNC:14064 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Hydroxamic acid derivatives | Purdue Pharmaceutical Products L.P. | 04/04/16 | 2D 3D TSV |
US9102599 | 15 | 15 | HGNC:1869 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | Bristol-Myers Squibb Co. | 04/04/16 | 2D 3D TSV |
US9114126 | 10 | 10 | Na/K-ATPase ligands, ouabain antagonists, assays and uses thereof | The University of Toledo | 04/04/16 | 2D 3D TSV | |
US9115061 | 17 | 13 | HGNC:992 | Naphthalene-based inhibitors of anti-apoptotic proteins | Burnham Institute for Medical Research | 04/04/16 | 2D 3D TSV |
US9102670 | 445 | 440 | HGNC:391 HGNC:3942 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED | 04/04/16 | 2D 3D TSV |
US9102656 | 12 | 12 | HGNC:5006 | Use of rosuvastatin lactols as medicaments | RedX Pharma Limited | 04/04/16 | 2D 3D TSV |
US9096559 | 134 | 125 | HGNC:4852 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | Merck Sharp & Dohme Corp | 03/28/16 | 2D 3D TSV |
US9096595 | 51 | 51 | HGNC:4502 | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators | Actelion Pharmaceuticals Ltd | 03/28/16 | 2D 3D TSV |
US9096579 | 258 | 175 | HGNC:11491 | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | Boehringer Ingelheim International GmbH | 03/28/16 | 2D 3D TSV |
US9238653 | 54 | 53 | Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 03/28/16 | 2D 3D TSV | |
US9096601 | 108 | 26 | HGNC:6307 HGNC:3236 | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 03/28/16 | 2D 3D TSV |
US9096580 | 5 | 5 | Benzofuran derivatives for the treatment of hepatitis C | Bristol-Myers Squibb Co. | 03/28/16 | 2D 3D TSV | |
US9096589 | 112 | 111 | HGNC:8772 | Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors | H. Lundbeck A/S | 03/28/16 | 2D 3D TSV |
US9096541 | 28 | 22 | HGNC:934 HGNC:933 | Inhibition of memapsin 1 cleavage in the treatment of diabetes | Oklahoma Medical Research Foundation | 03/28/16 | 2D 3D TSV |
US9096594 | 15 | 5 | HGNC:2453 HGNC:2451 HGNC:2452 HGNC:1771 HGNC:4617 HGNC:4616 HGNC:1774 | Kinase inhibitors and methods of use thereof | The Broad Institute, Inc. | 03/28/16 | 2D 3D TSV |
US9096515 | 36 | 12 | HGNC:11048 HGNC:11049 | Methods of using cycloalkylmethylamine derivatives | Reviva Pharmaceuticals Inc | 03/28/16 | 2D 3D TSV |
US9096596 | 332 | 111 | HGNC:8537 | P2X7 modulators | Janssen Pharmaceutica NV | 03/28/16 | 2D 3D TSV |
US9096606 | 64 | 24 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Quarternized buprenorphine analogs | Purdue Pharma LP | 03/28/16 | 2D 3D TSV |
US9096549 | 46 | 17 | HGNC:4852 HGNC:4854 HGNC:4853 | Selective HDAC3 inhibitors | Acetylon Pharmaceuticals Inc | 03/28/16 | 2D 3D TSV |
US9089569 | 190 | 174 | HGNC:436 | 1,2,6-substituted benzimidazoles as flap modulators | Janssen Pharmaceutica NV | 03/21/16 | 2D 3D TSV |
US9090564 | 130 | 130 | HGNC:3942 | 5-alkynyl-pyridines | Boehringer Ingelheim International GmbH | 03/21/16 | 2D 3D TSV |
US9090562 | 334 | 184 | HGNC:3527 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme Inc | 03/21/16 | 2D 3D TSV |
US9090628 | 126 | 89 | HGNC:8977 | Benzoxazepin compounds selective for PI3K P110 delta and methods of use | Genentech Inc | 03/21/16 | 2D 3D TSV |
US9090657 | 22 | 4 | HGNC:40 HGNC:9253 HGNC:53 HGNC:42 HGNC:10959 HGNC:10961 | Compound and methods for its production | NEUROVIVE PHARMACEUTICAL AB | 03/21/16 | 2D 3D TSV |
US9090596 | 84 | 36 | HGNC:4540 HGNC:1605 HGNC:1607 HGNC:6026 HGNC:6027 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | Galderma Research & Development | 03/21/16 | 2D 3D TSV |
US9090589 | 25 | 9 | HGNC:7872 HGNC:7873 | Specific nNOS inhibitors for the therapy and prevention of human melanoma | Northwestern University | 03/21/16 | 2D 3D TSV |
US9090618 | 172 | 73 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Substituted benzimidazole-type piperidine compounds and uses thereof | Purdue Pharma LP | 03/21/16 | 2D 3D TSV |
US9085584 | 356 | 121 | HGNC:8772 | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders | Boehringer Ingelheim International GmbH | 03/21/16 | 2D 3D TSV |
US9090625 | 9 | 9 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. | 03/21/16 | 2D 3D TSV | |
US9085572 | 10 | 10 | HGNC:12687 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | Bayer Intellectual Property GmbH | 03/16/16 | 2D 3D TSV |
US9085531 | 117 | 36 | HGNC:11050 HGNC:11048 HGNC:11049 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | Albany Molecular Research, Inc. | 03/14/16 | 2D 3D TSV |
US9085555 | 773 | 768 | HGNC:2771 | Complement pathway modulators and uses thereof | Novartis AG | 03/14/16 | 2D 3D TSV |
US9085549 | 48 | 33 | HGNC:11138 HGNC:6893 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC | 03/14/16 | 2D 3D TSV |
US9079902 | 124 | 65 | HGNC:10593 HGNC:10597 | Heteroaryl sodium channel inhibitors | Amgen Inc | 03/14/16 | 2D 3D TSV |
US9085571 | 30 | 30 | Nonpeptide HIV-1 protease inhibitors | Purdue Research Foundation | 03/14/16 | 2D 3D TSV | |
US9085576 | 846 | 396 | HGNC:2529 HGNC:933 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | Amgen Inc | 03/14/16 | 2D 3D TSV |
US9085540 | 31 | 17 | HGNC:3236 | Pyrazinecarboxamide compound | Astellas Pharma Inc | 03/14/16 | 2D 3D TSV |
US9079913 | 185 | 172 | HGNC:6973 | Spiro-oxindole MDM2 antagonists | The Regents of the University of Michigan | 03/14/16 | 2D 3D TSV |
US9079929 | 29 | 28 | HGNC:3529 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | Bristol-Myers Squibb Co. | 03/14/16 | 2D 3D TSV |
US9073940 | 429 | 428 | HGNC:8978 | Tricyclic pyrazol amine derivatives | Merck Serono | 03/09/16 | 2D 3D TSV |
US9079866 | 833 | 818 | HGNC:436 | Flap modulators | Janssen Pharmaceutica NV | 03/07/16 | 2D 3D TSV |
US9079834 | 11 | 10 | HIV protease inhibitors | Merck Canada Inc. | 03/07/16 | 2D 3D TSV | |
US9073926 | 105 | 105 | HGNC:10432 | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core | Boehringer Ingelheim International GmbH | 03/07/16 | 2D 3D TSV |
US9073939 | 7 | 5 | HGNC:7029 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | Bayer Intellectual Property GmbH | 03/07/16 | 2D 3D TSV |
US9073931 | 108 | 43 | HGNC:7966 HGNC:7965 | Liver X receptor modulators | Vitae Pharmaceuticals Inc | 03/07/16 | 2D 3D TSV |
US9079852 | 20 | 10 | HGNC:6251 | NMDA receptor antagonists for neuroprotection | Emory University | 03/07/16 | 2D 3D TSV |
US9073936 | 8 | 4 | HGNC:8774 | Organic compounds | Intra-Cellular Therapies Inc | 03/07/16 | 2D 3D TSV |
US9079880 | 163 | 112 | HGNC:10252 | Rho kinase inhibitors | Boehringer Ingelheim International GmbH | 03/07/16 | 2D 3D TSV |
US9079868 | 1 | 1 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Simon Fraser University | 03/07/16 | 2D 3D TSV |
US9079906 | 27 | 27 | HGNC:3537 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | Sanofi | 03/07/16 | 2D 3D TSV |
US9073893 | 60 | 24 | HGNC:270 HGNC:272 | 3-Oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives as PARP-1 inhibitors | Nerviano Medical Sciences srl | 02/29/16 | 2D 3D TSV |
US9073870 | 181 | 181 | HGNC:5208 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use | Boehringer Ingelheim International GmbH | 02/29/16 | 2D 3D TSV |
US9073917 | 27 | 12 | HGNC:11393 HGNC:6058 HGNC:8778 | Anti-cancer compound and pharmaceutical composition containing the same | Sanofi | 02/29/16 | 2D 3D TSV |
US9073925 | 10 | 10 | HGNC:4479 | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof | Albany Molecular Research, Inc. | 02/29/16 | 2D 3D TSV |
US9073881 | 153 | 149 | HGNC:3287 | Benzoic acid derivatives | Hoffmann-La Roche Inc | 02/29/16 | 2D 3D TSV |
US9073876 | 335 | 332 | HGNC:436 | Flap modulators | Janssen Pharmaceutica NV | 02/29/16 | 2D 3D TSV |
US9073882 | 9 | 9 | HGNC:6255 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 02/29/16 | 2D 3D TSV |
US9073869 | 37 | 25 | HGNC:2528 HGNC:2536 | Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C | Boehringer Ingelheim International GmbH | 02/29/16 | 2D 3D TSV |
US9073911 | 108 | 54 | Pyrazole derivatives | Hoffmann-La Roche Inc | 02/29/16 | 2D 3D TSV | |
US9073922 | 368 | 368 | HGNC:1780 HGNC:8153 HGNC:8154 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | AbbVie Inc | 02/29/16 | 2D 3D TSV |
US9073906 | 44 | 23 | HGNC:5209 HGNC:5208 | Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt | Korea Research Institute of Chemical Technology | 02/29/16 | 2D 3D TSV |
US9067924 | 24 | 14 | 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors | Hoffmann-La Roche Inc | 02/22/16 | 2D 3D TSV | |
US9067937 | 113 | 113 | HGNC:16870 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | OncoTherapy Science Inc | 02/22/16 | 2D 3D TSV |
US9067931 | 20 | 19 | 2-heteroaryl carboxamides | Bayer Intellectual Property GmbH | 02/22/16 | 2D 3D TSV | |
US9067949 | 216 | 201 | HGNC:5301 | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia | Albany Molecular Research, Inc. | 02/22/16 | 2D 3D TSV |
US9067922 | 243 | 241 | HGNC:17989 | Chemical compounds | Pfizer Inc | 02/22/16 | 2D 3D TSV |
US9073853 | 157 | 157 | HGNC:4540 | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists | Sanofi | 02/22/16 | 2D 3D TSV |
US9062043 | 371 | 240 | HGNC:270 HGNC:2457 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. | 02/22/16 | 2D 3D TSV |
US9073821 | 60 | 47 | Hydroxamic acid derivative | Taisho Pharmaceutical Co., Ltd | 02/22/16 | 2D 3D TSV | |
US9067935 | 114 | 109 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | Janssen Pharmaceutica NV | 02/22/16 | 2D 3D TSV | |
US9073833 | 17 | 8 | HGNC:3309 | Oxime-based compound, pharmaceutical composition containing the same and method for preparing the same | Chang Gung University | 02/22/16 | 2D 3D TSV |
US9067945 | 10 | 1 | HGNC:8793 HGNC:8781 HGNC:8792 HGNC:8784 HGNC:8795 HGNC:8773 HGNC:8772 HGNC:8776 HGNC:8779 | Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes | Boehringer Ingehleim International GmbH | 02/22/16 | 2D 3D TSV |
US9067917 | 220 | 215 | HGNC:436 | 1,2,5-substituted benzimidazoles as FLAP modulators | Janssen Pharmaceutica NV | 02/16/16 | 2D 3D TSV |
US9067871 | 405 | 302 | HGNC:11056 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG | 02/16/16 | 2D 3D TSV |
US9062066 | 13 | 1 | HGNC:4840 HGNC:6735 HGNC:3697 HGNC:6307 HGNC:1133 HGNC:3387 HGNC:11491 HGNC:11283 HGNC:12841 HGNC:6524 HGNC:3765 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same | Korea Institute of Science and Technology | 02/16/16 | 2D 3D TSV |
US9066954 | 107 | 107 | HGNC:7029 | Fused heterocyclic derivatives and methods of use | Amgen Inc | 02/16/16 | 2D 3D TSV |
US9067888 | 20 | 2 | HGNC:1780 HGNC:1772 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:1777 HGNC:4617 HGNC:4616 HGNC:6112 HGNC:1774 | Inhibitors of protein kinases | AstraZeneca AB | 02/16/16 | 2D 3D TSV |
US9062070 | 238 | 89 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 02/16/16 | 2D 3D TSV | |
US9062059 | 20 | 20 | HGNC:8772 | Pyrimidine PDE10 inhibitors | Merck Sharp & Dohme Corp | 02/16/16 | 2D 3D TSV |
US9062078 | 702 | 274 | HGNC:4849 HGNC:4848 | Substituted 7-azabicyles and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 02/16/16 | 2D 3D TSV |
US9062060 | 11 | 11 | HGNC:8772 | Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors | H. Lundbeck A/S | 02/16/16 | 2D 3D TSV |
US9067914 | 241 | 79 | HGNC:8031 HGNC:8032 HGNC:8033 | Tropomyosin-related kinase (TRK) inhibitors | Genzyme Corporation | 02/16/16 | 2D 3D TSV |
US9061041 | 6 | 6 | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | Merck Sharp & Dohme Corp | 02/09/16 | 2D 3D TSV | |
US9062004 | 58 | 36 | HGNC:2160 HGNC:2159 | Cannabinoid-2 agonists | Allergan Inc | 02/09/16 | 2D 3D TSV |
US9062048 | 173 | 160 | HGNC:1612 | Cyclohexyl-azetidinyl antagonists of CCR2 | Janssen Pharmaceutica NV | 02/09/16 | 2D 3D TSV |
US9062026 | 89 | 88 | HGNC:12666 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | Cleave Biosciences, Inc. | 02/09/16 | 2D 3D TSV |
US9056859 | 11 | 11 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 02/09/16 | 2D 3D TSV | |
US9061023 | 2 | 2 | HGNC:11285 | Management and treatment of benign prostatic hyperplasia | CSIR, Pretoria (ZA) | 02/09/16 | 2D 3D TSV |
US9056865 | 149 | 149 | HGNC:11119 | Pyridine-2-derivatives as smoothened receptor modulators | Pfizer Inc | 02/09/16 | 2D 3D TSV |
US9056863 | 3 | 3 | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof | H. Lundbeck A/S | 02/09/16 | 2D 3D TSV | |
US9062045 | 143 | 92 | HGNC:7029 HGNC:8779 | Triazolopyridine compounds | Novartis AG | 02/09/16 | 2D 3D TSV |
US9056843 | 460 | 155 | HGNC:4852 HGNC:14064 HGNC:14063 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | Novartis AG | 02/09/16 | 2D 3D TSV |
US9056847 | 4 | 4 | HGNC:4177 | Activity based probes (ABPs) interacting with glycosidases | ACADEMISCH MEDISCH CENTRUM BIJ UNIVERSITEIT VAN AMSTERDAM | 01/25/16 | 2D 3D TSV |
US9051313 | 18 | 18 | HGNC:6857 | Apoptosis signal-regulating kinase inhibitors | Gildead Sciences, Inc. | 01/25/16 | 2D 3D TSV |
US9056836 | 11 | 5 | HGNC:8154 HGNC:8156 | Benzomorphan analogs and the use thereof | Purdue Pharma LP | 01/25/16 | 2D 3D TSV |
US9051321 | 28 | 27 | Heterocyclic acrylamides and their use as pharmaceuticals | Fab Pharma S.A.S. | 01/25/16 | 2D 3D TSV | |
US9056857 | 7 | 7 | HGNC:620 | Methods for treating or preventing cancer and neurodegenerative diseases | Sloan-Kettering Institute for Cancer Research | 01/25/16 | 2D 3D TSV |
US9056832 | 152 | 152 | HGNC:10597 | Pyridine compounds and the users thereof | Purdue Pharma LP | 01/25/16 | 2D 3D TSV |
US9051279 | 174 | 98 | HGNC:6973 HGNC:6974 | Substituted isoquinolinones and quinazolinones | Novartis AG | 01/25/16 | 2D 3D TSV |
US9051311 | 173 | 64 | HGNC:10593 HGNC:10597 | Sulfamide sodium channel inhibitors | Amgen Inc | 01/25/16 | 2D 3D TSV |
US9051280 | 10 | 10 | HGNC:11056 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG | 01/25/16 | 2D 3D TSV |
US9051329 | 8 | 8 | HGNC:3009 | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors | Merck Sharp & Dohme Corp | 01/25/16 | 2D 3D TSV |
US9108973 | 73 | 51 | HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 | 3,5-disubstituted alkynylbenzene compound and salt thereof | Taiho Pharmaceutical Co., Ltd | 01/19/16 | 2D 3D TSV |
US9108978 | 16 | 6 | Antimicrobial compounds | Monash University | 01/19/16 | 2D 3D TSV | |
US9108983 | 174 | 169 | HGNC:990 | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier | 01/19/16 | 2D 3D TSV |
US9108984 | 2 | 2 | HGNC:8977 | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors | Incyte Corporation | 01/19/16 | 2D 3D TSV |
US9108950 | 12 | 1 | HGNC:4840 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:6874 HGNC:6876 | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors | Respivert Ltd | 01/18/16 | 2D 3D TSV |
US9108956 | 11 | 4 | HGNC:2843 | Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors | Novartis AG | 01/18/16 | 2D 3D TSV |
US9051265 | 89 | 85 | HGNC:9236 | N-benzylindole modulators of PPARG | The Scripps Research Institute | 01/18/16 | 2D 3D TSV |
US9051270 | 160 | 157 | Pyridone amides as modulators of sodium channels | Vertex Pharmaceuticals Inc | 01/18/16 | 2D 3D TSV | |
US9051240 | 7 | 7 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | Newron Pharmaceuticals S.P.A. | 01/18/16 | 2D 3D TSV | |
US9045501 | 28 | 26 | HGNC:5297 | 5-HT3 receptor modulators, methods of making, and use thereof | Albany Molecular Research, Inc. | 01/11/16 | 2D 3D TSV |
US9108903 | 76 | 74 | Amides as modulators of sodium channels | Vertex Pharmaceuticals Inc | 01/11/16 | 2D 3D TSV | |
US9107954 | 14 | 6 | HGNC:1606 HGNC:8156 | Bivalent ligands for the treatment of neurological disorders | Virginia Commonwealth University | 01/11/16 | 2D 3D TSV |
US9107923 | 81 | 74 | HGNC:3020 | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc | 01/11/16 | 2D 3D TSV |
US9045498 | 25 | 20 | HGNC:934 HGNC:933 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | Pfizer Inc | 01/11/16 | 2D 3D TSV |
US9045500 | 32 | 32 | HGNC:933 | Inhibitors of beta-secretase | Vitae Pharmaceuticals Inc | 01/11/16 | 2D 3D TSV |
US9108947 | 18 | 17 | HGNC:6255 | Inhibitors of the Renal Outer Medullary Potassium channel | Merck Sharp & Dohme Corp | 01/11/16 | 2D 3D TSV |
US9045524 | 160 | 28 | HGNC:1507 HGNC:1506 HGNC:1509 HGNC:1508 HGNC:1503 HGNC:1505 HGNC:1504 HGNC:1499 HGNC:1511 HGNC:1500 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION | 01/11/16 | 2D 3D TSV |
US9108951 | 16 | 16 | HGNC:3529 | Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors | Bristol-Myers Squibb Co. | 01/11/16 | 2D 3D TSV |
US9108905 | 19 | 19 | HGNC:497 | TRPA1 antagonists | AbbVie Inc | 01/11/16 | 2D 3D TSV |
US9045468 | 186 | 55 | HGNC:11050 HGNC:11048 HGNC:11049 | 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | Albany Molecular Research, Inc. | 12/21/15 | 2D 3D TSV |
US9045389 | 9 | 9 | HGNC:4191 | Biphenyl derivatives useful as glucagon receptor antagonists | Janssen Pharmaceutica NV | 12/21/15 | 2D 3D TSV |
US9040694 | 20 | 6 | HGNC:171 HGNC:6307 HGNC:9378 | Compounds and methods useful for directing stem cell differentiation | Vanderbilt University | 12/21/15 | 2D 3D TSV |
US9040693 | 15 | 15 | HGNC:4421 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | Kissei Pharmaceutical Co., Ltd | 12/21/15 | 2D 3D TSV |
US9040727 | 36 | 18 | HGNC:4853 | Histone deacetylase inhibitor of benzamides and use thereof | Shanghai Institute of Pharmaceutical Industry | 12/21/15 | 2D 3D TSV |
US9040691 | 47 | 40 | HGNC:175 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | Bayer Intellectual Property GmbH | 12/21/15 | 2D 3D TSV |
US9040714 | 139 | 137 | HGNC:3449 | IRE-1α inhibitors | MannKind Corporation | 12/21/15 | 2D 3D TSV |
US9045483 | 13 | 13 | HGNC:30661 | Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines | City of Hope | 12/21/15 | 2D 3D TSV |
US9045459 | 3 | 3 | HGNC:11056 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG | 12/21/15 | 2D 3D TSV |
US9040717 | 10 | 6 | HGNC:8809 HGNC:8810 | Pyrazole-amide compounds and pharmaceutical use thereof | Japan Tobacco Inc | 12/21/15 | 2D 3D TSV |
US9040518 | 72 | 72 | HGNC:10906 | Chemical compounds | GlaxoSmithKline | 12/14/15 | 2D 3D TSV |
US9040528 | 203 | 190 | Chemical compounds 542 | AstraZeneca AB | 12/14/15 | 2D 3D TSV | |
US9040501 | 5 | 5 | HGNC:1712 | Compositions and methods for treating cancer | Otsuka Pharmaceutical Co., Ltd | 12/14/15 | 2D 3D TSV |
US9040663 | 202 | 116 | HGNC:6932 HGNC:6929 | Melanocortin receptor-specific peptides | AstraZeneca AB | 12/14/15 | 2D 3D TSV |
US9040509 | 6 | 3 | HGNC:3467 HGNC:3468 | Method of treating human skin and a skin care composition for use in such a method | Pantarhei Bioscience B.V. | 12/14/15 | 2D 3D TSV |
US9035059 | 157 | 143 | HGNC:23248 | Nitrogen-containing condensed heterocyclic compound | Taisho Pharmaceutical Co., Ltd | 12/14/15 | 2D 3D TSV |
US9035074 | 168 | 42 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrrolo[2,3-D]pyrimidine derivatives | Pfizer Inc | 12/14/15 | 2D 3D TSV |
US9040542 | 2 | 1 | Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pryimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea | Vertex Pharmaceuticals Inc | 12/14/15 | 2D 3D TSV | |
US9040534 | 279 | 90 | HGNC:8537 | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | Janssen Pharmaceutica NV | 12/14/15 | 2D 3D TSV |
US9034921 | 203 | 202 | HGNC:11037 | Diphenylmethane derivatives as SGLT2 inhibitors | Green Cross Corporation | 12/08/15 | 2D 3D TSV |
US9035066 | 3 | 3 | HGNC:550 | Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds | Proximagen Limited | 12/08/15 | 2D 3D TSV |
US9035062 | 3 | 3 | Process for preparing a compound useful for producing an optically active diazabicyclooctane compound | Meiji Seika Pharma Co., Ltd | 12/08/15 | 2D 3D TSV | |
US9034856 | 51 | 14 | HGNC:644 HGNC:8910 | 17-(1′propenyl)-17-3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | Bayer Intellectual Property GmbH | 12/07/15 | 2D 3D TSV |
US9034886 | 5 | 5 | HGNC:4852 | 4-aminoquinazoline derivatives and uses thereof | Shanghai Institute of Pharmaceutical Industry | 12/07/15 | 2D 3D TSV |
US9034574 | 20 | 12 | HGNC:6917 HGNC:6990 | Agents for reversing epigenetic silencing of genes | The Johns Hopkins University | 12/07/15 | 2D 3D TSV |
US9034899 | 81 | 26 | HGNC:11050 HGNC:11048 HGNC:11049 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | Albany Molecular Research, Inc. | 12/07/15 | 2D 3D TSV |
US9034874 | 20 | 10 | HGNC:5184 | Carbamate/urea derivatives | Novartis AG | 12/07/15 | 2D 3D TSV |
US9034897 | 44 | 44 | HGNC:6278 | Indanyl-substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them | Sanofi | 12/07/15 | 2D 3D TSV |
US9034907 | 36 | 36 | HGNC:9753 | Inhibitors of glutaminyl cyclase | Probiodrug AG | 12/07/15 | 2D 3D TSV |
US9034866 | 815 | 608 | HGNC:6853 | Tricyclic compounds and methods of use therefor | Genentech Inc | 12/07/15 | 2D 3D TSV |
US9029399 | 54 | 50 | HGNC:2593 | 17α-hydroxylase/C17,20-lyase inhibitors | Novartis AG | 11/23/15 | 2D 3D TSV |
US9029364 | 34 | 17 | HGNC:4849 HGNC:4848 | 2,5-disubstituted thiomorpholine orexin receptor antagonists | Merck Sharp & Dohme Corp | 11/23/15 | 2D 3D TSV |
US9029393 | 22 | 22 | HGNC:263 | Adenosine receptor ligands and uses thereof | Kaldi Pharma, SAS | 11/23/15 | 2D 3D TSV |
US9029381 | 55 | 32 | HGNC:5184 | Cyclopropyl amide derivatives | AstraZeneca AB | 11/23/15 | 2D 3D TSV |
US9029362 | 23 | 10 | HGNC:934 HGNC:933 | Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 11/23/15 | 2D 3D TSV |
US9034303 | 10 | 5 | HGNC:6833 HGNC:6834 | Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof | TBA | 11/23/15 | 2D 3D TSV |
US9034854 | 6 | 3 | HGNC:3467 HGNC:3468 | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy | Pantarhei Bioscience B.V. | 11/23/15 | 2D 3D TSV |
US9029401 | 58 | 30 | HGNC:9829 HGNC:3402 | Sorafenib derivatives as sEH inhibitors | The Regents of the University of California | 11/23/15 | 2D 3D TSV |
US9029370 | 276 | 138 | Substituted benzamide derivatives | Hoffmann-La Roche Inc | 11/23/15 | 2D 3D TSV | |
US9023767 | 2 | 2 | HGNC:28042 | γ-Secretase substrates and methods of use | Memorial Sloan-Kettering Cancer Center | 11/16/15 | 2D 3D TSV |
US9023882 | 212 | 212 | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same | Kissei Pharmaceutical Co., Ltd | 11/16/15 | 2D 3D TSV | |
US9029367 | 5 | 5 | HGNC:933 | BACE inhibitors | Eli Lilly and Company | 11/16/15 | 2D 3D TSV |
US9023865 | 687 | 655 | HGNC:6871 | Compounds that are ERK inhibitors | Merck Sharp & Dohme Corp | 11/16/15 | 2D 3D TSV |
US9024044 | 162 | 81 | HGNC:9490 HGNC:9475 | Heteroarylcarboxylic acid ester derivative | Ajinomoto Co. Inc | 11/16/15 | 2D 3D TSV |
US9029360 | 36 | 19 | HGNC:4597 HGNC:5208 | Pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists | Boehringer Ingelheim International GmbH | 11/16/15 | 2D 3D TSV |
US9023849 | 22 | 22 | HGNC:8784 | Substituted fused imidazoles and pyrazoles and use thereof | Bayer Intellectual Property GmbH | 11/16/15 | 2D 3D TSV |
US9029356 | 12 | 4 | HGNC:5465 HGNC:11390 HGNC:427 | Substituted indazole derivatives active as kinase inhibitors | Nerviano Medical Sciences srl | 11/16/15 | 2D 3D TSV |
US9018371 | 27 | 15 | HGNC:262 HGNC:263 | Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient | FM Therapeutics Co., Ltd. | 11/11/15 | 2D 3D TSV |
US9018381 | 66 | 32 | HGNC:992 HGNC:990 | Chemical compounds | AstraZeneca AB | 11/11/15 | 2D 3D TSV |
US9023354 | 43 | 42 | HGNC:6973 | Combination therapy with MDM2 and EFGR inhibitors | TBA | 11/11/15 | 2D 3D TSV |
US9018217 | 124 | 124 | HGNC:8772 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. Lundbeck A/S | 11/11/15 | 2D 3D TSV |
US9029559 | 503 | 500 | HGNC:9251 | Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | Sanofi | 11/11/15 | 2D 3D TSV |
US9018213 | 12 | 6 | Alicyclic[c] benzopyrone derivatives and uses thereof | Huazhong University of Science & Technology | 11/02/15 | 2D 3D TSV | |
US9018214 | 370 | 217 | HGNC:590 HGNC:592 | Bicyclic heterocycle compounds and their uses in therapy | Astex Therapeutics Limited | 11/02/15 | 2D 3D TSV |
US9011882 | 20 | 20 | HGNC:2715 | Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof | The Board of Trustees of the Leland Stanford Junior University | 11/02/15 | 2D 3D TSV |
US9018255 | 7 | 7 | HGNC:12437 | Esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them, and their use as inhibitors of the thioredoxin—thioredoxin reductase system | Instytut Chemii Organicznej Polskiej Akademii Nauk | 11/02/15 | 2D 3D TSV |
US9012461 | 132 | 38 | HGNC:9611 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd | 11/02/15 | 2D 3D TSV |
US9018234 | 8 | 7 | HGNC:7029 | Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof | Bayer Intellectual Property GmbH | 11/02/15 | 2D 3D TSV |
US9018391 | 16 | 16 | HGNC:933 | Inhibitors of beta-secretase | Boehringer Ingelheim International GmbH | 11/02/15 | 2D 3D TSV |
US9018211 | 9 | 9 | Inhibitors of the renal outer medullary potassium channel | Merck Sharp & Dohme Corp | 11/02/15 | 2D 3D TSV | |
US9012475 | 26 | 13 | HGNC:11393 HGNC:11390 | Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor | Taiho Pharmaceutical Co., Ltd | 11/02/15 | 2D 3D TSV |
US9012651 | 291 | 291 | HGNC:18084 | TRPV3 modulators | AbbVie Inc | 11/02/15 | 2D 3D TSV |
US9006269 | 19 | 19 | HGNC:3553 | Azetidine derivatives | Vernalis (R&D) Ltd | 10/26/15 | 2D 3D TSV |
US9006454 | 111 | 110 | HGNC:2867 | Dihydroorotate dehydrogenase inhibitors | Merck Serono | 10/26/15 | 2D 3D TSV |
US9006244 | 14 | 7 | HGNC:7966 HGNC:7965 | Liver X receptor modulators | Vitae Pharmaceuticals Inc | 10/26/15 | 2D 3D TSV |
US9006283 | 6 | 6 | Methods of modifying amyloid β oligomers using non-peptidic compounds | Acumen Pharmaceuticals, Inc. | 10/26/15 | 2D 3D TSV | |
US9006268 | 10 | 10 | HGNC:9344 | Prolylcarboxypeptidase inhibitors | Merck Sharp & Dohme Corp | 10/26/15 | 2D 3D TSV |
US9006232 | 98 | 98 | Pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation | 10/26/15 | 2D 3D TSV | |
US9006282 | 20 | 20 | Rosuvastatin and atorvastatin derivatives | RedX Pharma Limited | 10/26/15 | 2D 3D TSV | |
US9006249 | 13 | 13 | HGNC:7154 | Substituted aminobutyric derivatives as neprilysin inhibitors | Novartis AG | 10/26/15 | 2D 3D TSV |
US9006242 | 15 | 3 | HGNC:2595 HGNC:2625 HGNC:2622 HGNC:2623 HGNC:2621 | Substituted benzene compounds | Epizyme Inc | 10/26/15 | 2D 3D TSV |
US9006246 | 15 | 15 | HGNC:3357 | Tetrahydrocarboline derivative | Ono Pharmaceutical Co., Ltd | 10/26/15 | 2D 3D TSV |
US9000182 | 41 | 24 | HGNC:933 HGNC:620 | 2H-imidazol-4-amine compounds and their use as BACE inhibitors | AstraZeneca AB | 10/19/15 | 2D 3D TSV |
US9000185 | 18 | 10 | HGNC:933 HGNC:620 | Cycloalkyl ether compounds and their use as BACE inhibitors | AstraZeneca AB | 10/19/15 | 2D 3D TSV |
US9000183 | 21 | 12 | HGNC:933 HGNC:620 | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors | AstraZeneca AB | 10/19/15 | 2D 3D TSV |
US9000184 | 31 | 17 | HGNC:933 HGNC:620 | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors | AstraZeneca AB | 10/19/15 | 2D 3D TSV |
US8999957 | 459 | 315 | Heterocyclic compounds as ERK inhibitors | Merck Sharp & Dohme Corp | 10/19/15 | 2D 3D TSV | |
US9000153 | 43 | 43 | HGNC:9413 | Imidazo[4,5-c]quinolines as DNA-PK inhibitors | Merck Patent GmbH | 10/19/15 | 2D 3D TSV |
US9000043 | 4 | 1 | HGNC:9594 HGNC:9593 HGNC:9596 HGNC:9595 | Phenoxyethoxy compounds | Eli Lilly and Company | 10/19/15 | 2D 3D TSV |
US9000029 | 118 | 59 | HGNC:4849 HGNC:4848 | Proline sulfonamide derivatives as orexin receptor antagonists | Actelion Pharmaceuticals Ltd | 10/19/15 | 2D 3D TSV |
US9000044 | 67 | 61 | HGNC:4502 | Substituted naphthylacetic acids | Hoffmann-La Roche Inc | 10/19/15 | 2D 3D TSV |
US9006187 | 34 | 34 | HGNC:11037 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | Green Cross Corporation | 10/19/15 | 2D 3D TSV |
US8999981 | 252 | 240 | HGNC:9395 | 3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives | Pfizer Inc | 10/12/15 | 2D 3D TSV |
US9012443 | 827 | 500 | HGNC:10593 HGNC:10597 | Bicyclic aryl and heteroaryl sodium channel inhibitors | Amgen Inc | 10/12/15 | 2D 3D TSV |
US9000008 | 5 | 5 | Amides of acetic and propionic acids | Bayer Intellectual Property GmbH | 10/05/15 | 2D 3D TSV | |
US9000015 | 42 | 14 | HGNC:6833 HGNC:6834 HGNC:404 | Compounds for the treatment of addiction | Gilead Sciences Inc | 10/05/15 | 2D 3D TSV |
US8999994 | 36 | 9 | Derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimer's and Parkinson's diseases | Consejo Superior de Investigaciones Cientificas | 10/05/15 | 2D 3D TSV | |
US8999980 | 19 | 19 | HGNC:933 | Oxazine derivatives | Shionogi & Co., Ltd | 10/05/15 | 2D 3D TSV |
US8999982 | 16 | 16 | Pharmaceutically active compounds as Axl inhibitors | Lead Discovery Center GmbH | 10/05/15 | 2D 3D TSV | |
US8993808 | 181 | 65 | HGNC:6833 HGNC:6834 HGNC:29079 | Phenylcyclopropylamine derivatives and their medical use | Oryzon Genomics, S.A. | 10/05/15 | 2D 3D TSV |
US8999998 | 95 | 24 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrazolopyrimidine JAK inhibitor compounds and methods | Genentech Inc | 10/05/15 | 2D 3D TSV |
US8999975 | 140 | 138 | HGNC:2528 | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C | Boehringer Ingelheim International GmbH | 10/05/15 | 2D 3D TSV |
US8999955 | 14 | 5 | HGNC:1722 HGNC:1774 | Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological | Centre National de la Recherche Scientifique | 10/05/15 | 2D 3D TSV |
US8993616 | 113 | 113 | (aza)indole derivative and use thereof for medical purposes | Kissei Pharmaceutical Co., Ltd | 09/28/15 | 2D 3D TSV | |
US8993596 | 3 | 3 | 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics | Galderma Research & Development | 09/28/15 | 2D 3D TSV | |
US8993631 | 43 | 42 | HGNC:14668 | Method of treating contrast-induced nephropathy | Novartis AG | 09/28/15 | 2D 3D TSV |
US8993612 | 10 | 10 | HGNC:25896 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | Rhizen Pharmaceuticals SA | 09/28/15 | 2D 3D TSV |
US8993568 | 6 | 5 | HGNC:23248 | Morpholinyl derivatives useful as MOGAT-2 inhibitors | Eli Lilly and Company | 09/28/15 | 2D 3D TSV |
US8993586 | 248 | 124 | HGNC:85 HGNC:84 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | Pfizer Inc | 09/28/15 | 2D 3D TSV |
US8993756 | 226 | 112 | HGNC:6192 HGNC:6193 | Pyrrolopyrimidines as janus kinase inhibitors | Merck Sharp & Dohme Corp | 09/28/15 | 2D 3D TSV |
US8993614 | 52 | 48 | HGNC:6973 | Substituted pyrrolidine-2-carboxamides | F. Hoffmann-La Roche Inc | 09/28/15 | 2D 3D TSV |
US8993765 | 26 | 26 | HGNC:4479 | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof | Albany Molecular Research, Inc. | 09/28/15 | 2D 3D TSV |
US8993575 | 12 | 6 | [1,3,4] oxadiazole derivative and application thereof | Huazhong University of Science & Technology | 09/28/15 | 2D 3D TSV | |
US8993565 | 161 | 153 | HGNC:391 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | Sanofi | 09/03/15 | 2D 3D TSV |
US8993552 | 72 | 64 | HGNC:7010 | Compositions and methods for treatment of leukemia | University of Michigan | 09/03/15 | 2D 3D TSV |
US8987474 | 133 | 124 | HGNC:9670 HGNC:9673 HGNC:9642 HGNC:9644 HGNC:9659 HGNC:9658 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | University of South Florida | 09/03/15 | 2D 3D TSV |
US8993557 | 10 | 10 | HGNC:6623 | Pyridinedione carboxamide inhibitors of endothelial lipase | Bristol-Myers Squibb Co. | 09/03/15 | 2D 3D TSV |
US8993556 | 18 | 18 | HGNC:5253 | Resorcinol derivatives as HSP90 inhibitors | Nerviano Medical Sciences srl | 09/03/15 | 2D 3D TSV |
US8987473 | 72 | 72 | HGNC:17989 | Ring-fused compound | Sato Pharmaceutical Co., Ltd. | 09/03/15 | 2D 3D TSV |
US8987457 | 595 | 202 | HGNC:19310 HGNC:8987 | Ring-substituted N-pyridinyl amides as kinase inhibitors | Novartis AG | 09/03/15 | 2D 3D TSV |
US8987319 | 37 | 37 | HGNC:644 | Selective androgen receptor modulators | Radius Health, Inc. | 09/03/15 | 2D 3D TSV |
US8987335 | 35 | 26 | HGNC:6833 HGNC:6834 HGNC:29079 | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors | University of Utah Research Foundation | 09/03/15 | 2D 3D TSV |
US8987445 | 181 | 180 | HGNC:17961 | Sulfonamide compounds having TRPM8 antagonistic activity | Mitsubishi Tanabe Pharma Corporation | 09/03/15 | 2D 3D TSV |
US8987314 | 725 | 375 | HGNC:6619 HGNC:6623 | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase | Bristol-Myers Squibb Co. | 08/25/15 | 2D 3D TSV |
US8987272 | 3 | 3 | Compounds and method for treatment of HIV | Critical Outcome Technologies Inc. | 08/25/15 | 2D 3D TSV | |
US8987257 | 68 | 38 | HGNC:8975 HGNC:3942 | Heterocyclic derivatives | Novartis AG | 08/25/15 | 2D 3D TSV |
US8987313 | 34 | 17 | HGNC:2637 | Inhibitors of cytochrome P450 | Gilead Sciences Inc | 08/25/15 | 2D 3D TSV |
US8987315 | 20 | 5 | HGNC:2593 HGNC:2637 HGNC:2623 HGNC:2621 | Metalloenzyme inhibitor compounds | Innocrin Pharmaceuticals, Inc. | 08/25/15 | 2D 3D TSV |
US8981106 | 177 | 177 | HGNC:6027 | Pyrimidinecarboxamides as CXCR2 modulators | Syntrix Biosystems, Inc. | 08/25/15 | 2D 3D TSV |
US8987268 | 121 | 60 | HGNC:6190 HGNC:6193 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | Bristol-Myers Squibb Co. | 08/25/15 | 2D 3D TSV |
US8987287 | 25 | 12 | HGNC:8153 HGNC:8154 HGNC:8156 | Spirocyclic morphinans and their use | Purdue Pharma LP | 08/25/15 | 2D 3D TSV |
US8987273 | 75 | 38 | HGNC:391 HGNC:392 | Substituted imidazo[1,2-B]pyridazines | Bayer Intellectual Property GmbH | 08/25/15 | 2D 3D TSV |
US8987286 | 45 | 45 | HGNC:391 | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway | Bayer Intellectual Property GmbH | 08/25/15 | 2D 3D TSV |
US8987239 | 20 | 10 | HGNC:644 HGNC:8910 | 19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives | Bayer Intellectual Property GbmH | 08/19/15 | 2D 3D TSV |
US8980938 | 7 | 7 | HGNC:6027 | CXCR2 inhibitors | Sanofi | 08/19/15 | 2D 3D TSV |
US8980932 | 40 | 10 | HGNC:1373 HGNC:1383 HGNC:1371 HGNC:1368 | Cancer targeting using carbonic anhydrase isoform IX inhibitors | Maastro-Clinic | 08/19/15 | 2D 3D TSV |
US8981112 | 25 | 25 | HGNC:933 | Inhibitors of β-secretase | Vitae Pharmaceuticals Inc | 08/19/15 | 2D 3D TSV |
US8987247 | 3 | 1 | HGNC:17038 | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders | Janssen Pharmaceutica NV | 08/19/15 | 2D 3D TSV |
US8987242 | 15 | 15 | HGNC:3551 | Morpholinone compounds as factor IXA inhibitors | Merck Sharp & Dohme Corp | 08/19/15 | 2D 3D TSV |
US8987249 | 358 | 357 | HGNC:2528 | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C | Boehringer Ingelheim International GmbH | 08/19/15 | 2D 3D TSV |
US8980954 | 13 | 13 | HGNC:9955 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM | 08/19/15 | 2D 3D TSV |
US8987248 | 26 | 25 | HGNC:3537 | Substituted piperidines as Par-1 antagonists | Bayer Intellectual Property GmbH | 08/19/15 | 2D 3D TSV |
US8987254 | 8 | 8 | HGNC:933 | Tetrahydropyrrolothiazine compounds | Eli Lilly and Company | 08/19/15 | 2D 3D TSV |
US8980887 | 7 | 7 | 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof | Toxicology Academy of Military Medical Sciences P.L.A. | 08/10/15 | 2D 3D TSV | |
US8980901 | 5 | 5 | HGNC:8977 | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS Corporation | 08/10/15 | 2D 3D TSV |
US8980829 | 56 | 25 | HGNC:11037 HGNC:11036 | Aryl glycoside compound, preparation method and use thereof | Shanghai Yingli Science and Technology Co., Ltd | 08/10/15 | 2D 3D TSV |
US8980905 | 10 | 10 | HGNC:8780 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | Leo Pharma A/S | 08/10/15 | 2D 3D TSV |
US8975415 | 367 | 211 | HGNC:6251 HGNC:933 | Chromane compounds | CoMentis Inc | 08/10/15 | 2D 3D TSV |
US8980916 | 3 | 3 | HGNC:3551 | Factor IXa inhibitors | Merck Sharp & Dohme Corp | 08/10/15 | 2D 3D TSV |
US8980904 | 18 | 18 | HGNC:8784 | Heterocyclic substituted pyrimidine compound | Xuanzhu Pharma Co., Ltd | 08/10/15 | 2D 3D TSV |
US8975409 | 18 | 9 | HGNC:3169 | Phenyl derivative | Ono Pharmaceutical Co., Ltd | 08/10/15 | 2D 3D TSV |
US8975417 | 716 | 189 | HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | Novartis AG | 08/10/15 | 2D 3D TSV |
US8980906 | 50 | 27 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Pyridonemorphinan analogs and biological activity on opioid receptors | Purdue Pharma LP | 08/10/15 | 2D 3D TSV |
US8980929 | 14 | 13 | HGNC:3009 | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes | Merck Sharp & Dohme Corp | 08/10/15 | 2D 3D TSV |
US8975250 | 13 | 13 | HGNC:1462 | 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases | Sanofi | 08/03/15 | 2D 3D TSV |
US8975261 | 14 | 14 | HGNC:8772 | Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors | Merck Sharp & Dohme Corp | 08/03/15 | 2D 3D TSV |
US8975249 | 94 | 45 | HGNC:3236 | Heterocyclic compounds and uses thereof | Celgene Avilomics Research, Inc. | 08/03/15 | 2D 3D TSV |
US8975276 | 8 | 8 | HGNC:8772 | Inhibitors of PDE10 | Bristol-Myers Squibb Co. | 08/03/15 | 2D 3D TSV |
US8962860 | 19 | 19 | HGNC:9753 | Inhibitors of glutaminyl cyclase | Probiodrug AG | 08/03/15 | 2D 3D TSV |
US8975247 | 27 | 27 | HGNC:6251 | Methods and compositions of treating a flaviviridae family viral infection | The Board of Trustees of the Leland Stanford Junion University | 08/03/15 | 2D 3D TSV |
US8975252 | 2 | 2 | HGNC:9958 | Morpholine derivative | Shanghai Pharmaceuticals Holding Co., Ltd. | 08/03/15 | 2D 3D TSV |
US8975260 | 12 | 12 | HGNC:1133 | Pyridazinones, method of making, and method of use thereof | Genetech, Inc | 08/03/15 | 2D 3D TSV |
US8975265 | 371 | 189 | HGNC:391 HGNC:392 | Substituted imidazo[1,2-a]pyrimidines and —pyridines | Bayer Intellectual Property GmbH | 08/03/15 | 2D 3D TSV |
US8975282 | 8 | 4 | HGNC:6307 HGNC:7029 | Substituted pyrazolone compounds and methods of use | Sunshine Lake Pharma Co., Ltd | 08/03/15 | 2D 3D TSV |
US8975267 | 51 | 17 | HGNC:12401 HGNC:8987 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | Nerviano Medical Sciences srl | 08/03/15 | 2D 3D TSV |
US8962637 | 76 | 42 | HGNC:6190 HGNC:6192 HGNC:11283 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | Debiopharm S.A. | 07/22/15 | 2D 3D TSV |
US8962651 | 8 | 8 | Compounds for the treatment of hepatitis C | Bristol-Myers Squibb Co. | 07/22/15 | 2D 3D TSV | |
US8962674 | 93 | 92 | HGNC:933 | Curcumin derivative | Tokyo Institute of Technology | 07/22/15 | 2D 3D TSV |
US8962837 | 24 | 24 | HGNC:10571 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | Pierre Fabre Medicament | 07/22/15 | 2D 3D TSV |
US8962646 | 38 | 13 | HGNC:8153 HGNC:8154 HGNC:8156 | Peripherally acting opioid compounds | Alkermes, Inc. | 07/22/15 | 2D 3D TSV |
US8962659 | 4 | 1 | HGNC:9594 HGNC:9593 HGNC:9596 HGNC:9595 | Phenoxyethyl piperidine compounds | Eli Lilly and Company | 07/22/15 | 2D 3D TSV |
US8962641 | 490 | 483 | HGNC:85 | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 07/22/15 | 2D 3D TSV |
US8962630 | 205 | 97 | HGNC:1771 HGNC:1722 HGNC:1773 | Pyrrolopyrimidine compounds and their uses | Novartis AG | 07/22/15 | 2D 3D TSV |
US8962664 | 3 | 3 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Simon Fraser University | 07/22/15 | 2D 3D TSV |
US8962859 | 12 | 11 | HGNC:933 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | Amgen Inc | 07/22/15 | 2D 3D TSV |
US8962648 | 231 | 223 | HGNC:18282 | Tricyclic compounds and PBK inhibitors containing the same | OncoTherapy Science Inc | 07/22/15 | 2D 3D TSV |
US8957084 | 9 | 5 | HGNC:8154 HGNC:8156 | 7,8-cyclicmorphinan analogs | Purdue Pharma LP | 07/15/15 | 2D 3D TSV |
US8957219 | 12 | 12 | HGNC:6623 | Acetic acid amide derivative having inhibitory activity on endothelial lipase | Shionogi & Co., Ltd | 07/15/15 | 2D 3D TSV |
US8957103 | 18 | 5 | HGNC:6307 HGNC:4617 HGNC:3765 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz | 07/15/15 | 2D 3D TSV |
US8962608 | 1192 | 563 | HGNC:6190 HGNC:6192 | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors | Merck Sharp & Dohme Corp | 07/15/15 | 2D 3D TSV |
US8962616 | 41 | 22 | HGNC:934 HGNC:933 | Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | Pfizer Inc | 07/15/15 | 2D 3D TSV |
US8957093 | 262 | 261 | HGNC:9236 | N-biphenylmethylindole modulators of PPARG | The Scripps Research Institute | 07/15/15 | 2D 3D TSV |
US8962609 | 129 | 72 | HGNC:11584 HGNC:14552 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | Domainex Limited | 07/15/15 | 2D 3D TSV |
US8962611 | 356 | 270 | HGNC:6973 | Substituted imidazopyridines as HDM2 inhibitors | Merck Sharp & Dohme Corp | 07/15/15 | 2D 3D TSV |
US8962619 | 36 | 20 | HGNC:391 | Substituted imidazopyridinyl-aminopyridine compounds | ArQule Inc | 07/15/15 | 2D 3D TSV |
US8962612 | 20 | 20 | HGNC:5300 | Tetrahydroisoquinoline derivative | Astellas Pharma Inc | 07/15/15 | 2D 3D TSV |
US8957075 | 28 | 26 | HGNC:8127 | O-GlcNAc transferase inhibitors and uses thereof | President and Fellows of Harvard College | 07/10/15 | 2D 3D TSV |
US8957077 | 14 | 14 | HGNC:8772 | Pyrazolopyrimidine PDE 10 inhibitors | Merck Sharp & Dohme Corp | 07/10/15 | 2D 3D TSV |
US8957074 | 298 | 144 | HGNC:1722 HGNC:1773 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | Novartis AG | 07/10/15 | 2D 3D TSV |
US8957083 | 31 | 29 | HGNC:933 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | Amgen Inc | 07/10/15 | 2D 3D TSV |
US8957068 | 870 | 504 | HGNC:5382 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | Novartis AG | 07/09/15 | 2D 3D TSV |
US8957064 | 185 | 91 | HGNC:391 HGNC:392 | Fused pyrimidines | Bayer Intellectual Property GmbH | 07/09/15 | 2D 3D TSV |
US8957059 | 66 | 66 | Modulators of serotonin receptors | Janssen Pharmaceutica NV | 07/09/15 | 2D 3D TSV | |
US8957073 | 378 | 372 | HGNC:8772 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | Amgen Inc | 07/09/15 | 2D 3D TSV |
US8957057 | 4 | 1 | HGNC:7978 HGNC:644 HGNC:3467 HGNC:8910 | Use of azaphilone compounds for the modulation of the activity of a nuclear hormone receptor | Food Industry Research and Development Institute | 07/09/15 | 2D 3D TSV |
US8952177 | 191 | 177 | HGNC:436 | 1,2,6-substituted benzimidazoles as FLAP modulators | Janssen Pharmaceutica NV | 06/29/15 | 2D 3D TSV |
US8952157 | 407 | 404 | HGNC:990 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc | 06/29/15 | 2D 3D TSV |
US8952036 | 5 | 5 | HGNC:2637 | Benzoic acid derivative MDM2 inhibitor for the treatment of cancer | Amgen Inc | 06/29/15 | 2D 3D TSV |
US8952037 | 98 | 93 | HGNC:8772 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | Amgen Inc | 06/29/15 | 2D 3D TSV |
US8956589 | 22 | 22 | HGNC:620 | Imaging diagnostic agent and extracorporeal diagnostic agent for incurable neurological diseases | Shiga University of Medical Science | 06/29/15 | 2D 3D TSV |
US8952027 | 12 | 3 | HGNC:15916 HGNC:6735 HGNC:3697 HGNC:11491 HGNC:11283 HGNC:6861 HGNC:12841 HGNC:6524 HGNC:3765 | Inhibitors of syk and JAK protein kinases | Portola Pharmaceuticals Inc | 06/29/15 | 2D 3D TSV |
US8952025 | 3 | 3 | Multifunctional radical quenchers and their uses | Arizona Board of Regents, A Body Corporate of the State of Arizona Acting for and on Behalf of Arizona State University | 06/29/15 | 2D 3D TSV | |
US8952169 | 708 | 407 | HGNC:10593 HGNC:10597 | N-substituted benzamides and methods of use thereof | Xenon Pharmaceuticals Inc | 06/29/15 | 2D 3D TSV |
US8952150 | 30 | 28 | Prostaglandin transporter inhibitors and uses thereof | Albert Einstein College of Medicine of Yeshiva University | 06/29/15 | 2D 3D TSV | |
US8952128 | 168 | 49 | HGNC:3023 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 | Somatostatin-dopamine chimeric analogs | Ipsen Pharma S.A.S. | 06/29/15 | 2D 3D TSV |
US8969583 | 55 | 29 | HGNC:3763 HGNC:6307 HGNC:8804 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | Allergan Inc | 06/22/15 | 2D 3D TSV |
US8952002 | 3 | 3 | HGNC:7029 | Aminoheteroaryl compounds and preparation method and use thereof | Shanghai Allist Pharmaceuticals, Inc. | 06/22/15 | 2D 3D TSV |
US8969358 | 54 | 38 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Buprenorphine analogs | Purdue Pharma LP | 06/22/15 | 2D 3D TSV |
US8952008 | 50 | 50 | HGNC:4076 | Chemical compounds | Pfizer Inc | 06/22/15 | 2D 3D TSV |
US8969348 | 10 | 10 | HGNC:2097 | Chymase inhibitors | Boehringer Ingelheim International GmbH | 06/22/15 | 2D 3D TSV |
US8969336 | 95 | 50 | HGNC:10261 HGNC:9967 HGNC:3765 | Diamino heterocyclic carboxamide compound | Astellas Pharma Inc | 06/22/15 | 2D 3D TSV |
US8969578 | 13 | 13 | HGNC:11364 | Inhibitors of STAT3 | University of Central Florida Research Foundation, Inc. | 06/22/15 | 2D 3D TSV |
US8969376 | 43 | 43 | HGNC:8772 | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors | Mitsubishi Tanabe Pharma Corporation | 06/22/15 | 2D 3D TSV |
US8969586 | 18 | 18 | HGNC:2593 | Substituted bicyclic heteroaryl compounds | Bristol-Myers Squibb Co. | 06/22/15 | 2D 3D TSV |
US8969568 | 125 | 115 | HGNC:11491 | Substituted naphthyridines and their use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG | 06/22/15 | 2D 3D TSV |
US8969333 | 6 | 6 | HGNC:20449 | Therapeutic compositions and methods | The Penn State Research Foundation | 06/22/15 | 2D 3D TSV |
US8969394 | 24 | 24 | HGNC:9596 | Thiophenecarboxamide derivatives as EP4 receptor ligands | Merck Frosst Canada Ltd | 06/22/15 | 2D 3D TSV |
US8969335 | 189 | 95 | HGNC:11584 HGNC:14552 | Benzonitrile derivatives as kinase inhibitors | Merck Patent GmbH | 06/16/15 | 2D 3D TSV |
US8940739 | 190 | 187 | HGNC:2637 | Compound of a reverse-turn mimetic and a production method and use therefor | JW Pharmaceutical Corporation | 06/16/15 | 2D 3D TSV |
US8940893 | 17 | 17 | HGNC:1133 | Heteroaromatic compounds as BTK inhibitors | Boehringer Ingelheim International GmbH | 06/16/15 | 2D 3D TSV |
US8940748 | 21 | 11 | HGNC:934 HGNC:933 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 06/16/15 | 2D 3D TSV |
US8940720 | 77 | 77 | HGNC:3529 | Macrocycles as factor XIa inhibitors | Bristol-Myers Squibb Co. | 06/16/15 | 2D 3D TSV |
US8940771 | 29 | 29 | HGNC:8975 | Organic compounds | Novartis AG | 06/16/15 | 2D 3D TSV |
US8940744 | 33 | 33 | HGNC:1133 | Pyrazolopyrimidine compounds as kinase inhibitors | Principia Biopharma Inc | 06/16/15 | 2D 3D TSV |
US8969341 | 345 | 199 | HGNC:6973 HGNC:6974 | Pyrazolopyrrolidine compounds | Novartis AG | 06/16/15 | 2D 3D TSV |
US8969352 | 164 | 47 | HGNC:4849 HGNC:4848 | Substituted 2-azabicycles and their use as orexin receptor modulators | Janssen Pharmaceutica NV | 06/16/15 | 2D 3D TSV |
US8969325 | 333 | 331 | HGNC:12716 | TRPV1 antagonists | AbbVie Inc | 06/16/15 | 2D 3D TSV |
US8937070 | 24 | 4 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11491 | Inhibitors of protein kinases | Portola Pharmaceuticals Inc | 06/15/15 | 2D 3D TSV |
US8937058 | 38 | 19 | HGNC:644 HGNC:8910 | 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivative, use thereof, and medicament containing the derivative | TBA | 06/08/15 | 2D 3D TSV |
US8937095 | 12 | 6 | HGNC:6840 | Anticancer compounds | Boehringer Ingelheim International GmbH | 06/08/15 | 2D 3D TSV |
US8937193 | 50 | 12 | HGNC:6943 HGNC:992 HGNC:990 HGNC:991 | Apogossypolone derivatives as anticancer agents | Sanford-Burnham Medical Research Institute | 06/08/15 | 2D 3D TSV |
US8937092 | 22 | 22 | HGNC:12716 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | Gruenenthal GmbH | 06/08/15 | 2D 3D TSV |
US8940736 | 142 | 71 | HGNC:2459 HGNC:2457 | Imidazotriazinecarbonitriles useful as kinase inhibitors | Bristol-Myers Squibb Co. | 06/08/15 | 2D 3D TSV |
US8940719 | 16 | 16 | Lithocholic acid analogues that inhibit sialyltransferase | Academia Sinica | 06/08/15 | 2D 3D TSV | |
US8937084 | 27 | 15 | HGNC:8153 HGNC:8154 HGNC:8156 | Nitrogen containing morphinan derivatives and the use thereof | Purdue Pharma LP | 06/08/15 | 2D 3D TSV |
US8937068 | 220 | 51 | HGNC:6871 HGNC:8975 HGNC:6886 HGNC:6876 | Pyridopyrazine derivatives and their use | Zentaris GmbH | 06/08/15 | 2D 3D TSV |
US8940738 | 11 | 11 | Pyrimidone compounds | Mitsubishi Tanabe Pharma Corporation | 06/08/15 | 2D 3D TSV | |
US8933228 | 147 | 36 | HGNC:4840 HGNC:11283 HGNC:6874 HGNC:6876 | Respiratory formulations and compounds for use therein | Respivert Ltd | 06/08/15 | 2D 3D TSV |
US8933224 | 248 | 169 | HGNC:8772 | Triazine derivatives | Pfizer Inc | 06/08/15 | 2D 3D TSV |
US8927738 | 26 | 26 | HGNC:8772 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. Lundbeck A/S | 06/01/15 | 2D 3D TSV |
US8933024 | 22 | 22 | HGNC:6623 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | Sanofi | 06/01/15 | 2D 3D TSV |
US8933098 | 4 | 1 | HGNC:9594 HGNC:9593 HGNC:9596 HGNC:9595 | Dimethyl-benzoic acid compounds | Eli Lilly and Company | 06/01/15 | 2D 3D TSV |
US8933221 | 31 | 29 | HGNC:933 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | Pfizer Inc | 06/01/15 | 2D 3D TSV |
US8927730 | 16 | 8 | Intramolecular hydrogen-bonded nitric oxide synthase inhibitors | Northwestern University | 06/01/15 | 2D 3D TSV | |
US8933095 | 29 | 29 | HGNC:17929 | KAT II inhibitors | Pfizer Inc | 06/01/15 | 2D 3D TSV |
US8927563 | 4 | 1 | HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 | Kinase inhibitor | Respivert Limited | 06/01/15 | 2D 3D TSV |
US8933099 | 139 | 128 | HGNC:3690 HGNC:3691 HGNC:3676 HGNC:3688 | Monocyclic pyridine derivative | Eisai R&D Management Co., Ltd | 06/01/15 | 2D 3D TSV |
US8933079 | 121 | 119 | HGNC:4479 | Pyridone and pyridazinone derivatives as anti-obesity agents | Boehringer Ingelheim International GmbH | 06/01/15 | 2D 3D TSV |
US8927577 | 27 | 23 | HGNC:4191 | Quinolinyl glucagon receptor modulators | Pfizer Inc | 06/01/15 | 2D 3D TSV |
US8933040 | 7 | 7 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | TBA | 06/01/15 | 2D 3D TSV |
US8933056 | 55 | 27 | HGNC:3009 | Soft protease inhibitors and pro-soft forms thereof | Trustees of Tufts College | 06/01/15 | 2D 3D TSV |
US8921559 | 61 | 53 | HGNC:1603 | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 | Janssen Pharmaceutica NV | 05/26/15 | 2D 3D TSV |
US8927520 | 6 | 3 | Antibacterial compounds | Institut Curie | 05/26/15 | 2D 3D TSV | |
US8921397 | 263 | 88 | HGNC:3023 HGNC:3024 | Benzofurane-piperidine compounds | Hoffmann-La Roche Inc | 05/26/15 | 2D 3D TSV |
US8921412 | 16 | 16 | HGNC:11037 | C-aryl ansa SGLT2 inhibitors | Green Cross Corporation | 05/26/15 | 2D 3D TSV |
US8927534 | 24 | 12 | HGNC:6141 HGNC:6138 | Compounds for the inhibition of integrins and use thereof | Shire Orphan Therapies GmbH | 05/26/15 | 2D 3D TSV |
US8927539 | 10 | 10 | HGNC:5208 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure | Vitae Pharmaceuticals Inc | 05/26/15 | 2D 3D TSV |
US8921424 | 13 | 13 | HGNC:14064 | Histone deacetylase inhibitors, process for preparation and uses thereof | Zhejiang Hisun Pharmaceutical Co., Ltd | 05/26/15 | 2D 3D TSV |
US8921421 | 2 | 2 | HGNC:2715 | Inhibitors of dimethylarginine dimethylaminohydrolase | Christian-Albrechts-Universitaet Zu Kiel | 05/26/15 | 2D 3D TSV |
US8921389 | 217 | 217 | HGNC:1232 | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FibroGen Inc | 05/26/15 | 2D 3D TSV |
US8921410 | 175 | 79 | HGNC:1958 | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes | Targacept Inc | 05/26/15 | 2D 3D TSV |
US8927507 | 8 | 8 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | TBA | 05/26/15 | 2D 3D TSV |
US8927536 | 14 | 14 | HGNC:5208 | Tetrahydrothiazepine derivative | Daiichi Sankyo Company, Limited | 05/26/15 | 2D 3D TSV |
US8653304 | 10 | 9 | HGNC:6876 | 2,3-dihydro-1H-indene-2-yl urea derivative and pharmaceutical application of same | Toray Industries Inc | 05/18/15 | 2D 3D TSV |
US8916594 | 27 | 25 | HGNC:7958 | 5-membered ring heteroaromatic derivatives having NPY Y5 receptor antagonistic activity | Shionogi & Co., Ltd | 05/18/15 | 2D 3D TSV |
US8921404 | 9 | 9 | Azole derivatives in the form of lipase and phospholipase inhibitors | Sanofi | 05/18/15 | 2D 3D TSV | |
US8921370 | 20 | 10 | HGNC:4597 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. Lundbeck A/S | 05/18/15 | 2D 3D TSV |
US8921373 | 25 | 22 | HGNC:12716 | Compounds having TRPV1 antagonistic activity and uses thereof | Shionogi & Co., Ltd | 05/18/15 | 2D 3D TSV |
US8653257 | 5 | 5 | HGNC:3023 | Dibenzothiazepine derivatives and uses thereof—424 | AstraZeneca AB | 05/18/15 | 2D 3D TSV |
US8921364 | 56 | 56 | HGNC:28657 | Modulators of calcium release-activated calcium channel | Rhizen Pharmaceuticals SA | 05/18/15 | 2D 3D TSV |
US8916600 | 20 | 17 | HGNC:7978 | Phenyl and benzodioxinyl substituted indazoles derivatives | AstraZeneca AB | 05/18/15 | 2D 3D TSV |
US8921368 | 103 | 53 | HGNC:6190 HGNC:6193 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | Bristol-Myers Squibb Co. | 05/18/15 | 2D 3D TSV |
US8921319 | 60 | 15 | HGNC:6371 HGNC:3528 HGNC:3535 HGNC:9071 | Serine protease inhibitors | The Medicines Company (Leipzig) GmbH | 05/18/15 | 2D 3D TSV |
US8653100 | 267 | 180 | HGNC:11056 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | AbbVie Inc | 05/18/15 | 2D 3D TSV |
US8916577 | 22 | 16 | HGNC:12401 HGNC:8987 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | Nerviano Medical Sciences srl | 05/18/15 | 2D 3D TSV |
US8912208 | 4 | 4 | HGNC:2843 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | Novartis AG | 05/11/15 | 2D 3D TSV |
US8916574 | 6 | 6 | HGNC:3236 | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors | Qilu Pharmaceutical Co., Ltd | 05/11/15 | 2D 3D TSV |
US8912219 | 10 | 10 | Aryl sulfamide and sulfamate derivatives as RORc modulators | Genentech Inc | 05/11/15 | 2D 3D TSV | |
US8912221 | 44 | 44 | HGNC:1029 | Biaryl amide derivatives | Hoffmann-La Roche Inc | 05/11/15 | 2D 3D TSV |
US8912181 | 115 | 115 | HGNC:5253 | Bicyclic compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 05/11/15 | 2D 3D TSV |
US8907086 | 8 | 8 | HGNC:3009 | Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors | Merck Sharp & Dohme Corp | 05/11/15 | 2D 3D TSV |
US8916576 | 100 | 51 | HGNC:10251 HGNC:10252 | Pharmacokinetically improved compounds | Surface Logix, Inc. | 05/11/15 | 2D 3D TSV |
US8912224 | 390 | 360 | HGNC:11068 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | Sanofi | 05/11/15 | 2D 3D TSV |
US8912173 | 121 | 119 | HGNC:11491 | Substituted quinolines and their use as medicaments | Boehringer Ingelheim International GmbH | 05/11/15 | 2D 3D TSV |
US8916553 | 45 | 45 | HGNC:2593 | Sulfonamide compounds useful as CYP17 inhibitors | Bristol-Myers Squibb Co. | 05/11/15 | 2D 3D TSV |
US8912213 | 12 | 12 | HGNC:18884 | Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors | Purdue Research Foundation | 05/11/15 | 2D 3D TSV |
US8906943 | 19 | 10 | HGNC:2615 HGNC:2610 | Synthetic compounds and methods to decrease nicotine self-administration | TBA | 05/11/15 | 2D 3D TSV |
US8895581 | 96 | 94 | HGNC:8816 | 1H-imidazo[4,5-c]quinolines | Boehringer Ingelheim International GmbH | 05/04/15 | 2D 3D TSV |
US8901140 | 7 | 7 | HGNC:3236 | 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof | Jiangsu Hengrui Medicine Co., Ltd. | 05/04/15 | 2D 3D TSV |
US8895745 | 17 | 17 | HGNC:3690 | Bicyclic heterocyclic compounds as FGFR inhibitors | Astex Therapeutics Limited | 05/04/15 | 2D 3D TSV |
US8906911 | 68 | 68 | HGNC:1603 | Chemokine receptor antagonists | AbbVie Inc | 05/04/15 | 2D 3D TSV |
US8895592 | 76 | 38 | HGNC:2160 | Compounds as cannabinoid receptor ligands | AbbVie Inc | 05/04/15 | 2D 3D TSV |
US8901115 | 25 | 24 | HGNC:3529 | Cyclic P1 linkers as factor XIa inhibitors | Bristol-Myers Squibb Co. | 05/04/15 | 2D 3D TSV |
US8906933 | 30 | 20 | HGNC:11528 HGNC:253 | Dihydropyrimidin-2(1H)-one compounds as neurokinin-3 receptor antagonists | N30 Pharmaceuticals, Inc. | 05/04/15 | 2D 3D TSV |
US8901295 | 31 | 16 | HGNC:9255 HGNC:9257 HGNC:14650 | Inhibitors of cyclophilins and uses thereof | University of Montpellier | 05/04/15 | 2D 3D TSV |
US8901087 | 39 | 39 | HGNC:7056 | Selective glycosidase inhibitors and uses thereof | Merck Sharp & Dohme Corp | 05/04/15 | 2D 3D TSV |
US8901315 | 337 | 165 | HGNC:8791 | Thienopyrazole derivative having PDE7 inhibitory activity | Daiichi Sankyo Company, Limited | 05/04/15 | 2D 3D TSV |
US8901310 | 29 | 14 | HGNC:7978 HGNC:195 HGNC:6018 | Tricyclic compounds, compositions, and methods | Pfizer Inc | 05/04/15 | 2D 3D TSV |
US8614223 | 561 | 138 | HGNC:4852 HGNC:14064 HGNC:4854 HGNC:4853 | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | Acetylon Pharmaceuticals Inc | 05/03/15 | 2D 3D TSV |
US8895549 | 35 | 35 | HGNC:8976 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Bayer Intellectual Property GmbH | 04/27/15 | 2D 3D TSV |
US8889684 | 10 | 10 | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | Boehringer Ingelheim International GmbH | 04/27/15 | 2D 3D TSV | |
US8889671 | 80 | 77 | Compounds and methods for treating bacterial infections | AstraZeneca AB | 04/27/15 | 2D 3D TSV | |
US8889672 | 29 | 26 | HGNC:9412 | Compounds, formulations, and methods of protein kinase C inhibition | University of Michigan | 04/27/15 | 2D 3D TSV |
US8614195 | 22 | 11 | HGNC:11037 HGNC:11036 | Glycoside derivatives and uses thereof | Novartis AG | 04/27/15 | 2D 3D TSV |
US8895544 | 57 | 28 | HGNC:6190 HGNC:6193 | Indazoles | Pfizer Inc | 04/27/15 | 2D 3D TSV |
US8895245 | 10 | 2 | HGNC:3527 | Inhibitors of human EZH2 and methods of use thereof | Epizyme Inc | 04/27/15 | 2D 3D TSV |
US8889870 | 111 | 88 | HGNC:6307 HGNC:8804 | Kinase inhibitors | Allergan Inc | 04/27/15 | 2D 3D TSV |
US8894989 | 59 | 57 | HGNC:270 | PARP inhibitor compounds, compositions and methods of use | Eisai Inc. | 04/27/15 | 2D 3D TSV |
US8889708 | 42 | 30 | HGNC:2528 HGNC:2536 | Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C | Boehringer Ingelheim International GmbH | 04/27/15 | 2D 3D TSV |
US8889696 | 65 | 2 | HGNC:6190 HGNC:6192 HGNC:19310 HGNC:9077 HGNC:11283 HGNC:14542 HGNC:10430 HGNC:19699 HGNC:2453 HGNC:11724 HGNC:6735 HGNC:6307 HGNC:1057 HGNC:12858 HGNC:76 HGNC:3690 HGNC:6342 HGNC:1777 HGNC:9412 HGNC:7744 HGNC:6524 HGNC:3688 HGNC:3765 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof | Temple University | 04/27/15 | 2D 3D TSV |
US8889724 | 7 | 7 | HGNC:17989 | Tetrazole compounds for reducing uric acid | Wellstat Therapeutics Corporation | 04/27/15 | 2D 3D TSV |
US8877733 | 2 | 2 | 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment | Gilead Sciences Inc | 04/20/15 | 2D 3D TSV | |
US8884017 | 21 | 21 | HGNC:1960 | 2-heteroarylcarboxylic acid amides | Bayer Intellectual Property GmbH | 04/20/15 | 2D 3D TSV |
US8883759 | 20 | 20 | HGNC:3078 | Anti-tumor effect potentiator | Taiho Pharmaceutical Co., Ltd | 04/20/15 | 2D 3D TSV |
US8883784 | 15 | 15 | HGNC:992 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | AbbVie Inc | 04/20/15 | 2D 3D TSV |
US8883771 | 150 | 50 | HGNC:590 HGNC:591 HGNC:592 | Bivalent inhibitors of IAP proteins and therapeutic methods using the same | The Regents of the University of Michigan | 04/20/15 | 2D 3D TSV |
US8614213 | 83 | 82 | HGNC:2357 | Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists | Novartis AG | 04/20/15 | 2D 3D TSV |
US8883797 | 12 | 4 | HGNC:2637 HGNC:2623 HGNC:2621 | Metalloenzyme inhibitor compounds | Viamet Pharmaceuticals Inc | 04/20/15 | 2D 3D TSV |
US8889668 | 31 | 31 | HGNC:3165 | Oxadiazole diaryl compounds | Merck Serono | 04/20/15 | 2D 3D TSV |
US8877741 | 485 | 478 | HGNC:85 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 04/20/15 | 2D 3D TSV |
US8614220 | 15 | 15 | HGNC:9077 | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | Nerviano Medical Sciences srl | 04/20/15 | 2D 3D TSV |
US8883846 | 5 | 4 | Synthesis of bicyclic compounds and method for their use as therapeutic agents | UVic Industry Partnerships Inc. | 04/20/15 | 2D 3D TSV | |
US8877798 | 71 | 26 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | Neurovance, Inc. | 04/13/15 | 2D 3D TSV | |
US8877944 | 96 | 53 | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors | Nerviano Medical Sciences srl | 04/13/15 | 2D 3D TSV | |
US8877778 | 285 | 95 | HGNC:3023 HGNC:3024 | Benzofurane compounds | Hoffmann-La Roche Inc | 04/13/15 | 2D 3D TSV |
US8877967 | 42 | 13 | HGNC:2527 HGNC:2536 HGNC:2537 | Compositions and methods for inhibition of cathepsins | OXiGENE, Inc. | 04/13/15 | 2D 3D TSV |
US8871738 | 76 | 74 | HGNC:1869 | Fused bicyclic oxazolidinone CETP inhibitor | Merck Sharp & Dohme Corp | 04/13/15 | 2D 3D TSV |
US8877795 | 33 | 33 | HGNC:12405 | Identification of stabilizers of multimeric proteins | The Board of Trustees of the Leland Stanford Junior University | 04/13/15 | 2D 3D TSV |
US8877791 | 8 | 8 | HGNC:9021 | Inhibitors of pyruvate kinase and methods of treating disease | Beth Israel Deaconess Medical Center, Inc. | 04/13/15 | 2D 3D TSV |
US8871728 | 49 | 28 | HGNC:14064 HGNC:13315 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | Georgia Tech Research Corporation | 04/13/15 | 2D 3D TSV |
US8877757 | 7 | 7 | HGNC:8977 | Pyrazine derivatives and use as PI3K inhibitors | Merck Serono | 04/13/15 | 2D 3D TSV |
US8877775 | 37 | 25 | HGNC:2528 HGNC:2536 | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C | Boehringer Ingelheim International GmbH | 04/13/15 | 2D 3D TSV |
US8877786 | 7 | 7 | HGNC:7154 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | Novartis AG | 04/13/15 | 2D 3D TSV |
US8871778 | 44 | 22 | HGNC:6307 HGNC:11491 | Substituted pyrimidine compounds and their use as SYK inhibitors | Genosco | 04/13/15 | 2D 3D TSV |
US8865911 | 180 | 153 | HGNC:933 | Compounds and their use as BACE inhibitors | AstraZeneca AB | 04/06/15 | 2D 3D TSV |
US8865655 | 4 | 4 | HGNC:4852 | Depsipeptides and their therapeutic use | Karus Therapeutics Limited | 04/06/15 | 2D 3D TSV |
US8871934 | 680 | 653 | HGNC:8810 | Fluorene compound and pharmaceutical use thereof | Japan Tobacco Inc | 04/06/15 | 2D 3D TSV |
US8865706 | 30 | 30 | HGNC:933 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | Pfizer Inc | 04/06/15 | 2D 3D TSV |
US8871790 | 475 | 472 | HGNC:3594 | Heterocyclic modulators of lipid synthesis | 3-V Biosciences, Inc. | 04/06/15 | 2D 3D TSV |
US8865662 | 5 | 5 | HGNC:8780 | Macrolides and their use | Basilea Pharmaceutica AG | 04/06/15 | 2D 3D TSV |
US8865698 | 105 | 105 | HGNC:8031 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | Array BioPharma Inc | 04/06/15 | 2D 3D TSV |
US8865714 | 35 | 35 | HGNC:17890 | Piperazine compound capable of inhibiting prostaglandin D synthase | Taiho Pharmaceutical Co., Ltd | 04/06/15 | 2D 3D TSV |
US8865701 | 11 | 11 | HGNC:933 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease | Merck Sharp & Dohme Corp | 04/06/15 | 2D 3D TSV |
US8871783 | 26 | 26 | HGNC:2528 | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C | Boehringer Ingelheim International GmbH | 04/06/15 | 2D 3D TSV |
US8865726 | 144 | 143 | HGNC:3942 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | Array BioPharma Inc | 04/06/15 | 2D 3D TSV |
US8865686 | 8 | 8 | HGNC:18884 | Tetracycline compounds as tyrosyl-DNA phosphodiesterase I inhibitors | The United States of America, as Represented by the Secretary, Dept. of Health and Human Services | 04/06/15 | 2D 3D TSV |
US8859534 | 106 | 53 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB | 03/16/15 | 2D 3D TSV | |
US8853224 | 62 | 31 | HGNC:7892 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | Industrial Research Limited | 03/16/15 | 2D 3D TSV |
US8859596 | 128 | 64 | HGNC:2160 | Compounds as cannabinoid receptor ligands | AbbVie Inc | 03/16/15 | 2D 3D TSV |
US8859586 | 50 | 32 | HGNC:6973 HGNC:6974 | Cyclohexyl isoquinolinone compounds | Novartis AG | 03/16/15 | 2D 3D TSV |
US8853215 | 17 | 17 | HGNC:9922 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | Takeda Pharmaceutical Co., Ltd | 03/16/15 | 2D 3D TSV |
US8853203 | 366 | 185 | HGNC:4597 HGNC:4593 | Diazepinone derivatives | Novartis AG | 03/16/15 | 2D 3D TSV |
US8853227 | 9 | 9 | HGNC:12576 | Methotrexate adjuvants to reduce toxicity and methods for using the same | Tosk, Incorporated | 03/16/15 | 2D 3D TSV |
US8865750 | 10 | 4 | HGNC:13735 HGNC:16810 HGNC:10000 HGNC:9997 | Small molecule inhibitors of RGS proteins | University of Michigan | 03/16/15 | 2D 3D TSV |
US8853212 | 17 | 16 | HGNC:3009 | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | Merck Sharp & Dohme Corp | 03/16/15 | 2D 3D TSV |
US8853193 | 170 | 165 | HGNC:7111 | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions | Boehringer Ingelheim International GmbH | 03/16/15 | 2D 3D TSV |
US8853206 | 11 | 11 | HGNC:3537 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | Sanofi | 03/16/15 | 2D 3D TSV |
US8853226 | 26 | 13 | HGNC:8781 HGNC:8783 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | High Point Pharmaceuticals, LLC | 03/16/15 | 2D 3D TSV |
US8853258 | 197 | 197 | C-linked hydroxamic acid derivatives useful as antibacterial agents | Pfizer Inc | 03/09/15 | 2D 3D TSV | |
US8853228 | 67 | 26 | HGNC:2861 | Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase | University of Connecticut | 03/09/15 | 2D 3D TSV |
US8853207 | 12 | 6 | HGNC:8804 HGNC:6342 | Heterocyclic pyrazole compounds, method for preparing the same and use thereof | Development Center for Biotechnology | 03/09/15 | 2D 3D TSV |
US8846601 | 142 | 126 | HGNC:6932 HGNC:6929 | Melanocortin receptor-specific peptides | Palatin Technologies Inc | 03/09/15 | 2D 3D TSV |
US8853242 | 18 | 18 | HGNC:5300 | Nitrogenous-ring acylguanidine derivative | Astellas Pharma Inc | 03/09/15 | 2D 3D TSV |
US8846658 | 184 | 180 | HGNC:933 | Oxazine derivatives and their use in the treatment of neurological disorders | Novartis AG | 03/09/15 | 2D 3D TSV |
US8846698 | 511 | 506 | HGNC:8031 | Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors | Pfizer Inc | 03/09/15 | 2D 3D TSV |
US8846000 | 35 | 35 | HGNC:8772 | Radiolabeled PDE10 inhibitors | Merck Sharp & Dohme Corp | 03/09/15 | 2D 3D TSV |
US8846657 | 356 | 282 | HGNC:6973 | Substituted imidazopyridines as HDM2 inhibitors | Merck Sharp & Dohme Corp | 03/09/15 | 2D 3D TSV |
US8846656 | 146 | 143 | HGNC:1338 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators | Novartis AG | 03/09/15 | 2D 3D TSV |
US8846654 | 11 | 8 | HGNC:8791 HGNC:8793 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | Sanofi | 03/09/15 | 2D 3D TSV |
US8846673 | 38 | 38 | HGNC:1133 | Azaindazoles as kinase inhibitors and use thereof | Bristol-Myers Squibb Co. | 03/03/15 | 2D 3D TSV |
US8846730 | 132 | 65 | HGNC:2160 | Compounds as cannabinoid receptor ligands | AbbVie Inc | 03/03/15 | 2D 3D TSV |
US8846711 | 28 | 28 | Heterocyclic acrylamides and their use as pharmaceuticals | Fab Pharma S.A.S. | 03/03/15 | 2D 3D TSV | |
US8846719 | 372 | 371 | HGNC:4079 | Isoxazolo-pyridine derivatives | Roche Palo Alto LLC | 03/03/15 | 2D 3D TSV |
US8846741 | 9 | 8 | HGNC:11056 | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Inc | 03/03/15 | 2D 3D TSV |
US8846696 | 60 | 10 | HGNC:9380 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:6871 HGNC:1773 | Purine derivatives | Cyclacel Limited | 03/03/15 | 2D 3D TSV |
US8846746 | 520 | 511 | HGNC:11036 | Pyrazole compound and pharmaceutical use thereof | Japan Tobacco Inc | 03/03/15 | 2D 3D TSV |
US8846699 | 346 | 170 | HGNC:6307 HGNC:3236 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | Hanmi Pharm. Co., Ltd | 03/03/15 | 2D 3D TSV |
US8846660 | 29 | 29 | HGNC:2097 | Seven-membered ring compound and pharmaceutical use therefor | Daiichi Sankyo Company, Ltd. | 03/03/15 | 2D 3D TSV |
US8846689 | 212 | 211 | HGNC:9611 | Substituted pyrimidines for the treatment of diseases such as cancer | Boehringer Ingelheim International GmbH | 03/03/15 | 2D 3D TSV |
US8846929 | 836 | 251 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | Purdue Pharma LP | 03/03/15 | 2D 3D TSV |
US8835436 | 169 | 60 | HGNC:11050 HGNC:5295 | Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | Green Cross Corporation | 02/23/15 | 2D 3D TSV |
US8841450 | 2 | 2 | HGNC:882 | Compounds useful as inhibitors of ATR kinase | Vertex Pharmaceuticals Inc | 02/23/15 | 2D 3D TSV |
US8846917 | 1 | 1 | HGNC:882 | Compounds useful as inhibitors of ATR kinase | Vertex Pharmaceuticals Inc | 02/23/15 | 2D 3D TSV |
US8835444 | 36 | 28 | HGNC:2358 HGNC:2357 | Cyclohexyl amide derivatives as CRF receptor antagonists | Novartis AG | 02/23/15 | 2D 3D TSV |
US8835445 | 82 | 40 | HGNC:2861 | Dihydrofolate reductase inhibitors | Trius Therapeutics Inc | 02/23/15 | 2D 3D TSV |
US8841312 | 749 | 480 | HGNC:1777 HGNC:1773 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | Amgen Inc | 02/23/15 | 2D 3D TSV |
US8841453 | 36 | 18 | HGNC:108 HGNC:983 | Hybrid cholinesterase inhibitors | Uniwersytet Warszawski | 02/23/15 | 2D 3D TSV |
USRE45173 | 173 | 146 | HGNC:2593 | Inhibitors of CYP 17 | Novartis AG | 02/23/15 | 2D 3D TSV |
US8841288 | 10 | 10 | HGNC:8975 | Quinolin-4 (1H)-one derivatives as inhibitors of phosphatidylinositol 3-kinases | Universtà Degli Studi di Torino; Università Degli Studi del Piemonte Orientale “Amedeo Avogadro” | 02/23/15 | 2D 3D TSV |
US8841455 | 165 | 165 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors | Array BioPharma Inc | 02/23/15 | 2D 3D TSV | |
US8835464 | 53 | 50 | HGNC:5258 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. | 02/23/15 | 2D 3D TSV |
US8835472 | 664 | 663 | HGNC:85 | Compounds, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 02/16/15 | 2D 3D TSV |
US8828983 | 13 | 12 | HGNC:3529 | Macrocycles as factor XIa inhibitors | Bristol-Myers Squibb Co. | 02/16/15 | 2D 3D TSV |
US8835470 | 25 | 25 | HGNC:3165 | Mandelamide heterocyclic compounds | Bristol-Myers Squibb Co. | 02/16/15 | 2D 3D TSV |
US8829193 | 162 | 54 | HGNC:19310 HGNC:8987 | PIM kinase inhibitors and methods of their use | Novartis AG | 02/16/15 | 2D 3D TSV |
US8835659 | 7 | 7 | HGNC:14929 | Polysubstituted benzofurans and medicinal applications thereof | Ikerchem, S.L. | 02/16/15 | 2D 3D TSV |
US8829010 | 57 | 55 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | Pfizer Inc | 02/16/15 | 2D 3D TSV | |
US8835465 | 3 | 3 | HGNC:8031 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB | 02/16/15 | 2D 3D TSV |
US8829009 | 6 | 6 | HGNC:5301 | Substituted 2-amino-3-(sulfonyl)pyrazolo[1,5-a]pyrimidines - serotonin 5-HT6 receptor antagonists, method for use thereof | TBA | 02/16/15 | 2D 3D TSV |
US8829000 | 22 | 11 | HGNC:8784 HGNC:8795 | Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors | ASKA Pharmaceutical Co., Ltd | 02/16/15 | 2D 3D TSV |
US8829190 | 28 | 28 | HGNC:8780 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | Leo Pharma A/S | 02/16/15 | 2D 3D TSV |
US8822479 | 7 | 7 | HGNC:8795 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | Boehringer Ingelheim International GmbH | 02/02/15 | 2D 3D TSV |
US8829199 | 333 | 111 | HGNC:3690 HGNC:3689 HGNC:3688 | Aminopyrazole derivative | Chugai Seiyaku Kabushiki Kaisha | 02/02/15 | 2D 3D TSV |
US8822505 | 100 | 40 | HGNC:2537 HGNC:2545 | Azetidine derivatives | Genentech Inc | 02/02/15 | 2D 3D TSV |
US8829200 | 30 | 30 | HGNC:436 | Benzimidazole inhibitors of leukotriene production | Boehringer Ingelheim International GmbH | 02/02/15 | 2D 3D TSV |
US8822460 | 15 | 10 | HGNC:1603 | Fused cyclopentyl antagonists of CCR2 | Janssen Pharmaceutica NV | 02/02/15 | 2D 3D TSV |
US8822494 | 47 | 42 | HGNC:3020 | Heteroaromatic compounds and their use as dopamine D1 ligands | Pfizer Inc | 02/02/15 | 2D 3D TSV |
US8822447 | 155 | 154 | Indazole compounds useful as ketohexokinase inhibitors | Janssen Pharmaceutica NV | 02/02/15 | 2D 3D TSV | |
US8822457 | 4 | 4 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto LLC | 02/02/15 | 2D 3D TSV |
US8822448 | 100 | 100 | Pyrazoloquinoline compound | Astellas Pharma Inc | 02/02/15 | 2D 3D TSV | |
US8822510 | 15 | 15 | HGNC:3165 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | Bristol-Myers Squibb Co. | 02/02/15 | 2D 3D TSV |
US8822458 | 61 | 60 | HGNC:3528 | Substituted oxazolidinones and their use in the field of blood coagulation | Bayer Intellectual Property GmbH | 02/02/15 | 2D 3D TSV |
US8822500 | 55 | 14 | HGNC:6091 HGNC:5465 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:10261 HGNC:175 HGNC:7029 HGNC:9967 | Tyrosine kinase inhibitors | ChemBridge Corporation | 02/02/15 | 2D 3D TSV |
US8815881 | 20 | 20 | HGNC:934 | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds | Hoffmann-La Roche Inc | 01/26/15 | 2D 3D TSV |
US8815845 | 10 | 5 | HGNC:10251 HGNC:10252 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties | The Regents of the University of Michigan | 01/26/15 | 2D 3D TSV |
US8815927 | 11 | 6 | HGNC:591 | Bivalent diazo bicyclic Smac mimetics and the uses thereof | The Regents of the University of Michigan | 01/26/15 | 2D 3D TSV |
US8815852 | 34 | 17 | Carbamoyloxy arylalkan arylpiperazine analgesics | SK Biopharmaceuticals Co. Ltd | 01/26/15 | 2D 3D TSV | |
US8815840 | 94 | 94 | HGNC:6192 | Carbazole and carboline kinase inhibitors | Bristol-Myers Squibb Co. | 01/26/15 | 2D 3D TSV |
US8815918 | 14 | 14 | HGNC:8975 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | Centro Nacional de Investigaciones Oncologicas (CNIO) | 01/26/15 | 2D 3D TSV |
US8815901 | 52 | 51 | HGNC:3690 | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors | Novartis AG | 01/26/15 | 2D 3D TSV |
US8822534 | 22 | 20 | HGNC:14668 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG | 01/26/15 | 2D 3D TSV |
US8815854 | 24 | 24 | HGNC:391 | Substituted imidazopyridinyl compounds | ArQule Inc | 01/26/15 | 2D 3D TSV |
US8815926 | 334 | 310 | HGNC:6973 HGNC:6974 | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | Novartis AG | 01/26/15 | 2D 3D TSV |
US8815891 | 114 | 112 | HGNC:270 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | Jeil Pharmaceutical Co., Ltd | 01/26/15 | 2D 3D TSV |
US8815934 | 54 | 53 | HGNC:3467 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | Wyeth LLC | 01/19/15 | 2D 3D TSV |
US8802674 | 212 | 207 | HGNC:18618 | Aminopyrimidine derivatives as LRRK2 modulators | Genentech Inc | 01/19/15 | 2D 3D TSV |
US8816088 | 96 | 94 | HGNC:1952 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | Theravance Respiratory Company LLC | 01/19/15 | 2D 3D TSV |
US8802679 | 44 | 22 | HGNC:550 | Glycine compound | Astellas Pharma Inc | 01/19/15 | 2D 3D TSV |
US8802673 | 421 | 210 | Heterocyclic amine derivatives | Hoffmann-La Roche Inc | 01/19/15 | 2D 3D TSV | |
US8815951 | 300 | 150 | HGNC:3401 | Inhibitors of epoxide hydrolases for the treatment of inflammation | The Regents of the University of California | 01/19/15 | 2D 3D TSV |
US8802663 | 45 | 42 | HGNC:3165 | Pyrazole oxadiazole derivatives as S1P1 agonists | Merck Serono | 01/19/15 | 2D 3D TSV |
US8802712 | 80 | 80 | HGNC:9413 | Pyrazoloquinolines | Merck Patent GmbH | 01/19/15 | 2D 3D TSV |
US8802672 | 27 | 9 | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands | Richter Gedeon Nyrt. | 01/19/15 | 2D 3D TSV | |
US8802665 | 48 | 48 | HGNC:2545 | Pyrrolidine derivatives | Genentech Inc | 01/19/15 | 2D 3D TSV |
US8802686 | 63 | 16 | HGNC:6307 HGNC:1771 HGNC:1722 HGNC:1773 | Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine | Bayer Intellectual Property GmbH | 01/19/15 | 2D 3D TSV |
US8802711 | 155 | 155 | HGNC:12716 | TRPV1 antagonists | AbbVie Inc | 01/19/15 | 2D 3D TSV |
US8796280 | 46 | 46 | HGNC:4502 | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors | Merck Serono | 01/12/15 | 2D 3D TSV |
US8796284 | 21 | 17 | HGNC:263 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | Palobiofarma, S.L. | 01/12/15 | 2D 3D TSV |
US8796296 | 33 | 32 | HGNC:18618 | Aminopyrimidine derivatives as LRRK2 modulators | Genentech Inc | 01/12/15 | 2D 3D TSV |
US8802695 | 41 | 24 | HGNC:6857 | Apoptosis signal-regulating kinase 1 inhibitors | Takeda Pharmaceutical Co., Ltd | 01/12/15 | 2D 3D TSV |
US8796244 | 586 | 312 | HGNC:6307 HGNC:3690 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | Astex Therapeutics Ltd | 01/12/15 | 2D 3D TSV |
US8802724 | 5 | 3 | Processes and intermediates for preparing substituted hexahydrofuro [2,3-b] furans | Purdue Research Foundation | 01/12/15 | 2D 3D TSV | |
US8796293 | 9 | 9 | HGNC:10252 | Purine and deazapurine derivatives as pharmaceutical compounds | The Institute of Cancer Research | 01/12/15 | 2D 3D TSV |
US8796295 | 30 | 15 | HGNC:4597 | Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | Vanderbilt University | 01/12/15 | 2D 3D TSV |
US8802861 | 17 | 17 | HGNC:8978 | Thiazole derivatives and use thereof | Merck Serono | 01/12/15 | 2D 3D TSV |
US8802721 | 9 | 9 | HGNC:6001 | Thiophene compounds for inflammation and immune-related uses | Synta Pharmaceuticals Corp. | 01/12/15 | 2D 3D TSV |
US8802864 | 12 | 12 | HGNC:3594 | Triazolones as fatty acid synthase inhibitors | GlaxoSmithKline | 01/12/15 | 2D 3D TSV |
US8796297 | 46 | 23 | HGNC:5184 | 4-substituted-2-amino-pyrimidine derivatives | AbbVie Inc | 12/22/14 | 2D 3D TSV |
US8796310 | 83 | 79 | HGNC:11491 | Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors | Merck Sharp & Dohme Corp | 12/22/14 | 2D 3D TSV |
US8791130 | 46 | 46 | HGNC:18618 | Aminopyrimidine derivatives as LRRK2 modulators | Genentech Inc | 12/22/14 | 2D 3D TSV |
US8791100 | 79 | 77 | HGNC:3165 | Aryl benzylamine compounds | Novartis AG | 12/22/14 | 2D 3D TSV |
US8796457 | 1 | 1 | HGNC:6190 | Compound useful for the treatment of degenerative and inflammatory diseases | Galapagos NV | 12/22/14 | 2D 3D TSV |
US8796330 | 80 | 74 | HGNC:4852 HGNC:13315 | Inhibitors of histone deacetylase and prodrugs thereof | MethylGene Inc | 12/22/14 | 2D 3D TSV |
US8791118 | 38 | 38 | HGNC:6871 | Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors | Aeterna Zentaris GmbH | 12/22/14 | 2D 3D TSV |
US8791123 | 504 | 233 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:12440 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharma Inc | 12/22/14 | 2D 3D TSV |
US8796328 | 44 | 44 | HGNC:12716 | TRPV1 antagonists | TBA | 12/22/14 | 2D 3D TSV |
US8796304 | 19 | 18 | HGNC:8772 | Tricyclic imidazole compounds as PDE10 inhibitors | H. Lundbeck A/S | 12/22/14 | 2D 3D TSV |
US8785467 | 20 | 20 | HGNC:8772 | Alkoxy pyrimidine PDE10 inhibitors | Merck Sharp & Dohme Corp | 12/16/14 | 2D 3D TSV |
US8785489 | 97 | 97 | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors | Boehringer Ingelheim International GmbH | 12/16/14 | 2D 3D TSV | |
US8785477 | 9 | 9 | Hexahydropyrrolo[3,4-b]pyrrole derivatives, preparation methods and pharmaceutical uses thereof | Shanghai Sun-Sail Pharmaceutical Science & Technology Co., Ltd. | 12/16/14 | 2D 3D TSV | |
US8791131 | 292 | 152 | HGNC:8975 HGNC:3942 | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions | Pfizer Inc | 12/16/14 | 2D 3D TSV |
US8791272 | 215 | 214 | HGNC:4502 | Pyrazole compounds as CRTH2 antagonists | Boehringer Ingelheim International GmbH | 12/16/14 | 2D 3D TSV |
US8785464 | 81 | 80 | HGNC:9611 | Pyrimidine derivatives that inhibit FAK/PTK2 | Boehringer Ingelheim International GmbH | 12/16/14 | 2D 3D TSV |
US8785459 | 386 | 128 | HGNC:9829 HGNC:1097 | Quinazoline compounds as kinase inhibitors | Development Center for Biotechnology | 12/16/14 | 2D 3D TSV |
US8791257 | 60 | 30 | HGNC:2459 HGNC:2457 | Substituted pyrrolotriazines as protein kinase inhibitors | Bristol-Myers Squibb Co. | 12/16/14 | 2D 3D TSV |
US8791268 | 22 | 15 | HGNC:12716 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | Gruenenthal GmbH | 12/16/14 | 2D 3D TSV |
US8778932 | 5 | 5 | HGNC:4079 | Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them | Les Laboratoires Servier | 12/15/14 | 2D 3D TSV |
US8785634 | 9 | 9 | HGNC:9344 | Spiropiperidine prolylcarboxypeptidase inhibitors | Merck Sharp & Dohme Corp | 12/15/14 | 2D 3D TSV |
US8785499 | 8 | 8 | Targeting NAD biosynthesis in bacterial pathogens | University of Maryland, Baltimore | 12/15/14 | 2D 3D TSV | |
US8779142 | 157 | 157 | HGNC:5253 | Azabicyclo compound and salt thereof | Taiho Pharmaceutical Co., Ltd | 12/08/14 | 2D 3D TSV |
US8772304 | 33 | 33 | HGNC:436 | Benzimidazole inhibitors of leukotriene production | Boehringer Ingelheim International GmbH | 12/08/14 | 2D 3D TSV |
US8772285 | 2 | 2 | HGNC:5184 | Benzothiazoles having histamine H3 receptor activity | High Point Pharmaceuticals, LLC | 12/08/14 | 2D 3D TSV |
US8778970 | 55 | 18 | HGNC:5286 HGNC:11050 HGNC:2625 | Benzyl piperidine compound | Dainippon Sumitomo Pharma Co., Ltd | 12/08/14 | 2D 3D TSV |
US8778957 | 21 | 20 | CGRP receptor antagonists | Merck Sharp & Dohme Corp | 12/08/14 | 2D 3D TSV | |
US8778951 | 352 | 350 | HGNC:1599 | Heteroaryl compounds and their uses | Novartis AG | 12/08/14 | 2D 3D TSV |
US8772283 | 128 | 64 | HGNC:391 HGNC:392 | Imidazo-oxazine compound or salt thereof | Taiho Pharmaceutical Co., Ltd | 12/08/14 | 2D 3D TSV |
US8778412 | 32 | 16 | HGNC:1232 HGNC:12680 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | Aerpio Therapeutics Inc | 12/08/14 | 2D 3D TSV |
US8772288 | 36 | 36 | HGNC:6876 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | Almirall, S.A. | 12/08/14 | 2D 3D TSV |
US8772297 | 20 | 20 | TGF-β signal transduction inhibitor | Kyoto University | 12/08/14 | 2D 3D TSV | |
US8772282 | 6 | 6 | HGNC:933 | Tetrahydropyrrolothiazine compounds | Eli Lilly and Company | 12/08/14 | 2D 3D TSV |
US8785638 | 71 | 70 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | Katholieke Universiteit Leuven | 12/08/14 | 2D 3D TSV | |
US8772495 | 1 | 1 | HGNC:436 | 5-lipoxygenase-activating protein inhibitor | Panmira Pharmaceuticals, LLC | 11/24/14 | 2D 3D TSV |
US8765733 | 21 | 21 | HGNC:12716 | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands | Gruenenthal GmbH | 11/24/14 | 2D 3D TSV |
US8772481 | 21 | 21 | HGNC:6876 | Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof | Amgen Inc | 11/24/14 | 2D 3D TSV |
US8772511 | 7 | 7 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | Bayer Intellectual Property GmbH | 11/24/14 | 2D 3D TSV | |
US8765744 | 129 | 128 | HGNC:5208 | Azaspirohexanones | Boehringer Ingelheim International GmbH | 11/24/14 | 2D 3D TSV |
US8772478 | 21 | 9 | HGNC:7173 HGNC:216 HGNC:7176 HGNC:7155 HGNC:188 HGNC:15478 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | Galderma Research & Development | 11/24/14 | 2D 3D TSV |
US8772480 | 690 | 343 | HGNC:8975 HGNC:3942 | Inhibitors of PI3 kinase and/or mTOR | Amgen Inc | 11/24/14 | 2D 3D TSV |
US8772508 | 17 | 17 | HGNC:25952 | Inhibitors of glutaminyl cyclase | Probiodrug AG | 11/24/14 | 2D 3D TSV |
US8765727 | 95 | 19 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:427 HGNC:12440 | Macrocyclic compounds and their use as kinase inhibitors | Incyte Corporation | 11/24/14 | 2D 3D TSV |
US8772510 | 65 | 65 | HGNC:8772 | PDE10 modulators | Hoffmann-La Roche Inc | 11/24/14 | 2D 3D TSV |
US8772316 | 84 | 84 | HGNC:8772 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) | Allergan Inc | 11/24/14 | 2D 3D TSV |
US8772305 | 292 | 292 | HGNC:11491 | Substituted pyridinyl-pyrimidines and their use as medicaments | Boehringer Ingelheim International GmbH | 11/24/14 | 2D 3D TSV |
US8765972 | 19 | 19 | HGNC:270 | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides with selective PARP-1 inhibition | Nerviano Medical Sciences srl | 11/18/14 | 2D 3D TSV |
US8759537 | 85 | 85 | HGNC:9599 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | Boehringer Ingelheim International GmbH | 11/18/14 | 2D 3D TSV |
US8759366 | 48 | 46 | HGNC:11491 | Aminopyrimidines as SYK inhibitors | Merck Sharp & Dohme Corp | 11/18/14 | 2D 3D TSV |
US8759341 | 15 | 11 | HGNC:7029 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | Bayer Intellectual Property GmbH | 11/18/14 | 2D 3D TSV |
US8765747 | 21 | 1 | HGNC:19006 HGNC:11388 HGNC:8803 HGNC:3763 HGNC:11724 HGNC:6307 HGNC:1772 HGNC:1771 HGNC:1097 HGNC:76 HGNC:1778 HGNC:6342 HGNC:1774 HGNC:3767 HGNC:6874 HGNC:2730 HGNC:9967 HGNC:3765 | Fused 2-aminothiazole compounds | Dana-Farber Cancer Institute Inc | 11/18/14 | 2D 3D TSV |
US8765940 | 162 | 162 | HGNC:8975 | Heterocyclic compounds and their uses | Amgen Inc | 11/18/14 | 2D 3D TSV |
US8759338 | 57 | 19 | HGNC:19310 HGNC:8987 | Heterocyclic kinase inhibitors | Novartis AG | 11/18/14 | 2D 3D TSV |
US8759365 | 23 | 22 | HGNC:1869 | Organic compounds | Novartis AG | 11/18/14 | 2D 3D TSV |
US8765750 | 27 | 27 | HGNC:17890 | Piperazine compound having a PGDS inhibitory effect | Taiho Pharmaceutical Co., Ltd | 11/18/14 | 2D 3D TSV |
US8759386 | 59 | 59 | HGNC:4502 | Pyrazole compounds as CRTH2 antagonists | Boehringer Ingelheim International GmbH | 11/18/14 | 2D 3D TSV |
US8759532 | 266 | 253 | HGNC:8772 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | Amgen Inc | 11/18/14 | 2D 3D TSV |
US8765820 | 21 | 8 | HGNC:6833 HGNC:6834 HGNC:29079 | Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2 | Sapienza University of Rome | 11/18/14 | 2D 3D TSV |
US8754075 | 87 | 52 | HGNC:934 HGNC:933 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | Hoffmann-La Roche Inc | 11/11/14 | 2D 3D TSV |
US8748418 | 53 | 26 | HGNC:934 HGNC:933 | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors | Hoffmann-La Roche Inc | 11/11/14 | 2D 3D TSV |
US8748608 | 39 | 29 | HGNC:3023 HGNC:3024 | 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use | The United States of America as Represented by the Secretary of the Department of Health and Human Services | 11/11/14 | 2D 3D TSV |
US8748451 | 35 | 12 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | HDAC inhibitors and therapeutic methods of using same | University of Illinois | 11/11/14 | 2D 3D TSV |
US8754089 | 32 | 32 | HGNC:8977 | Heterocyclic compounds and their uses | Amgen Inc | 11/11/14 | 2D 3D TSV |
US8754106 | 9 | 8 | Macrocyclic inhibitors of hepatitis C virus | Janssen Ireland | 11/11/14 | 2D 3D TSV | |
US8754105 | 6 | 6 | Macrocyclic inhibitors of hepatitis C virus | Medivir AB | 11/11/14 | 2D 3D TSV | |
US8754227 | 15 | 5 | HGNC:2637 HGNC:2623 HGNC:2621 | Metalloenzyme inhibitor compounds | Viamet Pharmaceuticals Inc | 11/11/14 | 2D 3D TSV |
US8754099 | 5 | 5 | HGNC:11332 | Oxadiazole beta carboline derivatives as antidiabetic compounds | Merck Sharp & Dohme Corp | 11/11/14 | 2D 3D TSV |
US8754113 | 39 | 39 | HGNC:6623 | Oxadiazole derivative having endothelial lipase inhibitory activity | Shionogi & Co., Ltd | 11/11/14 | 2D 3D TSV |
US8754233 | 151 | 151 | HGNC:6040 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | Dermira (Canada), Inc. | 11/11/14 | 2D 3D TSV |
US8748458 | 41 | 10 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Scriptaid isosteres and their use in therapy | Karus Therapeutics Limited | 11/11/14 | 2D 3D TSV |
US8741907 | 16 | 7 | HGNC:8793 HGNC:8781 HGNC:8792 HGNC:8784 HGNC:8795 HGNC:8772 HGNC:8776 HGNC:8779 | Alkyl-substituted pyrazolopyrimidines | Boehringer Ingelheim International GmbH | 11/05/14 | 2D 3D TSV |
US8741944 | 37 | 37 | HGNC:8816 | Anti-infective agents against intracellular pathogens | The Ohio State University Research Foundation | 11/05/14 | 2D 3D TSV |
US8741915 | 24 | 23 | HGNC:253 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | N30 Pharmaceuticals, Inc. | 11/05/14 | 2D 3D TSV |
US8742106 | 172 | 79 | HGNC:4849 HGNC:4848 | Disubstituted heteroaryl-fused pyridines | Novartis AG | 11/05/14 | 2D 3D TSV |
US8748618 | 36 | 34 | HGNC:1539 | Inhibitors of inv(16) leukemia | University of Virginia Patent Foundation | 11/05/14 | 2D 3D TSV |
US8741926 | 10 | 10 | Macrocyclic inhibitors of hepatitis C virus | Janssen Ireland | 11/05/14 | 2D 3D TSV | |
US8741923 | 19 | 19 | HGNC:3165 | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis | Merck Serono | 11/05/14 | 2D 3D TSV |
US8748626 | 8 | 8 | HGNC:6388 | Oxazole and thiazole compounds as KSP inhibitors | Novartis AG | 11/05/14 | 2D 3D TSV |
US8748624 | 138 | 138 | HGNC:4192 | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists | Janssen Pharmaceutica NV | 11/05/14 | 2D 3D TSV |
US8748435 | 37 | 37 | HGNC:4497 | Pyrazolo pyrimidine derivatives | Novartis AG | 11/05/14 | 2D 3D TSV |
US8742113 | 21 | 21 | HGNC:1745 | Furanone derivative | SBI Biotech Co., Ltd. | 11/04/14 | 2D 3D TSV |
US8742110 | 170 | 169 | HGNC:11334 | Spiroxazolidinone compounds | Merck Sharp & Dohme Corp | 11/04/14 | 2D 3D TSV |
US8729113 | 97 | 97 | 4,5-dihydro-oxazol-2yl derivatives | Hoffmann-La Roche Inc | 10/28/14 | 2D 3D TSV | |
US8742134 | 8 | 4 | HGNC:1952 | 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof | Theron Pharmaceuticals, Inc. | 10/28/14 | 2D 3D TSV |
US8735386 | 429 | 422 | HGNC:5465 | Aminopyrazoloquinazolines | Boehringer Ingelheim International GmbH | 10/28/14 | 2D 3D TSV |
US8735593 | 10 | 5 | HGNC:4617 HGNC:4616 | Aminopyridines useful as inhibitors of protein kinases | Vertex Pharmaceuticals Inc | 10/28/14 | 2D 3D TSV |
US8742115 | 35 | 35 | HGNC:1604 | Co-crystals and salts of CCR3-inhibitors | Boehringer Ingelheim International GmbH | 10/28/14 | 2D 3D TSV |
US8722692 | 731 | 722 | HGNC:11491 | Compounds and compositions as Syk kinase inhibitors | TBA | 10/28/14 | 2D 3D TSV |
US8742138 | 35 | 34 | Compounds as hypoxia mimetics, and compositions and uses thereof | Betta Pharmaceuticals Co., Ltd | 10/28/14 | 2D 3D TSV | |
US8729074 | 47 | 25 | HGNC:8975 HGNC:3942 | Inhibitors of PI3 kinase | Amgen Inc | 10/28/14 | 2D 3D TSV |
US8729078 | 50 | 50 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Hoffmann-La Roche Inc | 10/28/14 | 2D 3D TSV |
US8735395 | 13 | 5 | HGNC:2536 HGNC:2537 HGNC:2545 | Protease inhibitors | Medivir AB | 10/28/14 | 2D 3D TSV |
US8742158 | 44 | 43 | Protease inhibitors | TaiMed Biologies, Inc. | 10/28/14 | 2D 3D TSV | |
US8729061 | 248 | 62 | HGNC:2527 HGNC:2536 HGNC:2537 HGNC:2545 | Pyrrolidine derivatives | Hoffmann-La Roche Inc | 10/28/14 | 2D 3D TSV |
US8722877 | 5 | 5 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme Inc | 10/20/14 | 2D 3D TSV | |
US8722683 | 231 | 77 | HGNC:3023 HGNC:3024 | Benzodioxole piperazine compounds | Hoffmann-La Roche Inc | 10/20/14 | 2D 3D TSV |
US8716478 | 12 | 12 | HGNC:8780 | Boron-containing small molecules | Anacor Pharmaceuticals Inc | 10/20/14 | 2D 3D TSV |
US8729273 | 31 | 31 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG Life Sciences Ltd | 10/20/14 | 2D 3D TSV | |
US8722718 | 2 | 2 | Inhibitors of C-FMS kinase | Janssen Pharmaceutica NV | 10/20/14 | 2D 3D TSV | |
US8716296 | 11 | 10 | HGNC:1780 | Inhibitors of protein kinases | Ingenium Pharmaceuticals GmbH | 10/20/14 | 2D 3D TSV |
US8722709 | 57 | 57 | Mineralocorticoid receptor antagonists | Boehringer Ingelheim International GmbH | 10/20/14 | 2D 3D TSV | |
US8716285 | 65 | 65 | HGNC:13315 | N-hydroxy-benzamids for the treatment of cancer | Hoffmann-La Roche Inc | 10/20/14 | 2D 3D TSV |
US8716287 | 65 | 65 | HGNC:1925 | Pharmaceutical compounds | Sentinel Oncology Limited | 10/20/14 | 2D 3D TSV |
US8722896 | 588 | 315 | Prokineticin receptor antagonists and uses thereof | The Regents of the University of California | 10/20/14 | 2D 3D TSV | |
US8722895 | 34 | 24 | HGNC:1232 HGNC:14661 | Prolyl hydroxylase inhibitors and method of use | Akebia Therapeutics, Inc. | 10/20/14 | 2D 3D TSV |
US8722721 | 18 | 17 | HGNC:6621 | SEC-hydroxycyclohexyl derivatives | Hoffmann-La Roche Inc | 10/20/14 | 2D 3D TSV |
US8722890 | 54 | 5 | HGNC:3763 HGNC:6307 HGNC:11393 HGNC:11390 HGNC:2637 HGNC:6342 HGNC:3765 | Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile | AbbVie Inc | 10/20/14 | 2D 3D TSV |
US8710076 | 8 | 4 | HGNC:4849 | 2,5-disubstituted piperidine orexin receptor antagonists | Merck Sharp & Dohme Corp | 10/14/14 | 2D 3D TSV |
US8703785 | 9 | 9 | HGNC:933 | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity | Shionogi & Co., Ltd | 10/14/14 | 2D 3D TSV |
US8703807 | 12 | 12 | HGNC:6621 | Azaspirodecanone compounds | Hoffmann-La Roche Inc | 10/14/14 | 2D 3D TSV |
US8703947 | 11 | 10 | HGNC:933 | Compounds for treatment of Alzheimer's disease | Purdue Research Foundation | 10/14/14 | 2D 3D TSV |
US8703720 | 17 | 9 | HGNC:6561 HGNC:6563 | Galactoside inhibitors of galectins | Galecto Biotech AB | 10/14/14 | 2D 3D TSV |
US8710232 | 17 | 17 | HGNC:2299 | Imidazole derivatives used as TAFIa inhibitors | Sanofi-Aventis Deutschland GmbH | 10/14/14 | 2D 3D TSV |
US8703768 | 340 | 329 | HGNC:8772 | Nitrogen containing heteroaryl compounds | Hoffmann-La Roche Inc | 10/14/14 | 2D 3D TSV |
US8703761 | 15 | 15 | Organic compounds | Novartis AG | 10/14/14 | 2D 3D TSV | |
US8703771 | 45 | 12 | HGNC:8804 HGNC:76 HGNC:6342 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor | Harbin Gloria Pharmaceuticals Co., Ltd. | 10/14/14 | 2D 3D TSV |
US8703770 | 2 | 2 | HGNC:4849 | Pyridazine carboxamide orexin receptor antagonists | Merck Sharp & Dohme Corp | 10/14/14 | 2D 3D TSV |
US8703811 | 138 | 95 | HGNC:2867 | Small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase | Genzyme Corporation | 10/14/14 | 2D 3D TSV |
US8703767 | 18 | 12 | HGNC:1133 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | University of Utah Research Foundation | 10/14/14 | 2D 3D TSV |
US8716482 | 17 | 17 | HGNC:3009 | Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | Merck Sharp & Dohme Corp | 10/14/14 | 2D 3D TSV |
US8697869 | 57 | 56 | HGNC:4502 | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators | Actelion Pharmaceuticals Ltd | 10/06/14 | 2D 3D TSV |
US8697868 | 10 | 10 | HGNC:3009 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | Boehringer Ingelheim International GmbH | 10/06/14 | 2D 3D TSV |
US8697708 | 16 | 16 | HGNC:12440 | Azabenzothiazole compounds, compositions and methods of use | F. Hoffmann-La Roche Inc | 10/06/14 | 2D 3D TSV |
US8697716 | 17 | 17 | HGNC:6342 | Method of inhibiting C-KIT kinase | Janssen Pharmaceutica NV | 10/06/14 | 2D 3D TSV |
US8691753 | 866 | 103 | HGNC:7173 HGNC:7174 HGNC:7175 HGNC:7176 HGNC:7155 HGNC:7166 HGNC:7156 HGNC:7158 HGNC:7159 | Pseudodipeptides as MMP inhibitors | Commissariat A l'Energie Atomique et Aux Energies Alternatives | 10/06/14 | 2D 3D TSV |
US8697911 | 172 | 116 | HGNC:10252 | Rho kinase inhibitors | Boehringer Ingelheim International GmbH | 10/06/14 | 2D 3D TSV |
US8697715 | 42 | 42 | HGNC:6871 | Serine/threonine kinase inhibitors | Array BioPharma Inc | 10/06/14 | 2D 3D TSV |
US8697696 | 11 | 11 | HGNC:4079 | Triazole compounds II | Roche Palo Alto LLC | 10/06/14 | 2D 3D TSV |
US8691852 | 26 | 26 | HGNC:2867 | Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors | Amirall, S.A. | 09/30/14 | 2D 3D TSV |
US8691827 | 9 | 9 | HGNC:8772 | Amino tetrahydro-pyridopyrimidine PDE10 inhibitors | Merck Sharp & Dohme Corp | 09/30/14 | 2D 3D TSV |
US8691986 | 34 | 17 | HGNC:8772 | Azetidine and piperidine compounds useful as PDE10 inhibitors | Amgen Inc | 09/30/14 | 2D 3D TSV |
US8691856 | 2 | 2 | HGNC:4192 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly and Company | 09/30/14 | 2D 3D TSV |
US8691840 | 5 | 5 | N-biarylamides | Bayer Intellectual Property GmbH | 09/30/14 | 2D 3D TSV | |
US8691993 | 13 | 13 | HGNC:4502 | Piperidinyl naphthylacetic acids | Hoffmann-La Roche Inc | 09/30/14 | 2D 3D TSV |
US8685958 | 20 | 16 | HGNC:4479 | Therapeutic agents | AstraZeneca AB | 09/30/14 | 2D 3D TSV |
US8691829 | 4 | 4 | HGNC:8977 | Treatment of liver disorders with PI3K inhibitors | Gilead Calistoga LLC | 09/30/14 | 2D 3D TSV |
US8691832 | 20 | 20 | HGNC:3009 | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors | Merck Sharp & Dohme Corp | 09/30/14 | 2D 3D TSV |
US8680119 | 4 | 4 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals Inc | 09/16/14 | 2D 3D TSV | |
US8680275 | 351 | 173 | HGNC:4849 HGNC:4848 | Fused heterocyclic compounds as orexin receptor modulators | Janssen Pharmaceutica NV | 09/16/14 | 2D 3D TSV |
US8686042 | 2 | 2 | HGNC:4617 | GSK-3 inhibitors | Neuropharma, S.A. | 09/16/14 | 2D 3D TSV |
US8685992 | 120 | 18 | HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 | Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers | Universidad del País Vasco | 09/16/14 | 2D 3D TSV |
US8680120 | 31 | 31 | Indole derivative or pharmaceutically acceptable salt thereof | Kissei Pharmaceutical Co., Ltd | 09/16/14 | 2D 3D TSV | |
US8685986 | 12 | 12 | HGNC:9594 | Medical composition for treatment or prophylaxis of glaucoma | Ube Industries, Ltd | 09/16/14 | 2D 3D TSV |
US8686018 | 9 | 9 | HGNC:9596 | Pharmaceutical composition | Eisai R&D Management Co., Ltd | 09/16/14 | 2D 3D TSV |
US8680116 | 9 | 9 | Quinolinone PDE2 inhibitors | Merck Sharp & Dohme Corp | 09/16/14 | 2D 3D TSV | |
US8680132 | 72 | 48 | HGNC:6973 | Spiro-oxindole MDM2 antagonists | University of Michigan | 09/16/14 | 2D 3D TSV |
US8673938 | 23 | 23 | HGNC:5208 | Chemical compounds | AstraZeneca AB | 09/08/14 | 2D 3D TSV |
US8673906 | 102 | 93 | HGNC:8976 | Chromenone derivatives | AstraZeneca AB | 09/08/14 | 2D 3D TSV |
US8673950 | 149 | 75 | Dihydrooxazol-2-amine derivatives | Hoffmann-La Roche Inc | 09/08/14 | 2D 3D TSV | |
US8669380 | 8 | 5 | HGNC:11037 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | Pfizer Inc | 09/08/14 | 2D 3D TSV |
US8673905 | 42 | 42 | HGNC:3765 | Imidazo pyrazines | Hoffmann-La Roche Inc | 09/08/14 | 2D 3D TSV |
US8669252 | 14 | 14 | HGNC:9344 | Prolylcarboxypeptidase inhibitors | Merck Sharp & Dohme Corp | 09/08/14 | 2D 3D TSV |
US8669361 | 86 | 29 | HGNC:19310 HGNC:8987 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. Hoffmann-La Roche Inc | 09/08/14 | 2D 3D TSV |
US8669266 | 17 | 17 | HGNC:18124 | Quinoline-carboxamide derivatives as P2Y12 antagonists | Sanofi | 09/08/14 | 2D 3D TSV |
US8673966 | 123 | 41 | HGNC:6833 HGNC:6834 HGNC:404 | ALDH-2 inhibitors in the treatment of addiction | Gilead Sciences Inc | 09/03/14 | 2D 3D TSV |
US8674113 | 185 | 180 | HGNC:9599 | Compounds | Boehringer Ingelheim International GmbH | 09/03/14 | 2D 3D TSV |
US8653125 | 23 | 23 | Cyclohexane derivative having NPY Y5 receptor antagonism | Shionogi Co., Ltd. | 09/03/14 | 2D 3D TSV | |
US8653263 | 733 | 377 | HGNC:4849 HGNC:4848 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV | 09/03/14 | 2D 3D TSV |
US8674100 | 93 | 85 | Inhibitors of C-FMS kinase | Janssen Pharmaceutica NV | 09/03/14 | 2D 3D TSV | |
US8653111 | 20 | 20 | HGNC:14660 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | Bayer Intellectual Property GmbH | 09/03/14 | 2D 3D TSV |
US8653092 | 188 | 94 | HGNC:8975 HGNC:8977 | Tetrahydro-pyrido-pyrimidine derivatives | Novartis AG | 09/03/14 | 2D 3D TSV |
US8664236 | 35 | 35 | HGNC:8816 | 1H-pyrrolo[2,3 b]-pyridine derivatives | Merck Patent GmbH | 08/26/14 | 2D 3D TSV |
US8664219 | 26 | 12 | HGNC:4617 HGNC:4616 | Aminopyrimidines useful as inhibitors of protein kinases | Vertex Pharmaceuticals Inc | 08/26/14 | 2D 3D TSV |
US8648092 | 144 | 141 | HGNC:4852 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | Mei Pharma Inc | 08/26/14 | 2D 3D TSV |
US8664258 | 5 | 5 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals Inc | 08/26/14 | 2D 3D TSV | |
US8653091 | 46 | 46 | HGNC:8534 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | Evotec AG | 08/26/14 | 2D 3D TSV |
US8653087 | 741 | 737 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | Boehringer Ingelheim International GmbH | 08/26/14 | 2D 3D TSV | |
US8664230 | 18 | 6 | HGNC:8979 HGNC:8978 HGNC:8977 | Pyridopyrimidine derivatives and use thereof | The Asan Foundation | 08/26/14 | 2D 3D TSV |
US8637558 | 130 | 124 | HGNC:5154 | Thiazolidinedione derivative and use thereof | Industry-Academic Cooperation Foundation, Chosun University | 08/26/14 | 2D 3D TSV |
US8637502 | 75 | 31 | HGNC:8153 HGNC:8154 HGNC:8155 HGNC:8156 | 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain | Purde Pharma L.P. | 08/22/14 | 2D 3D TSV |
US8633183 | 1192 | 574 | HGNC:8975 HGNC:3942 | 5-alkynyl-pyrimidines | Boehringer Ingelheim International GmbH | 08/22/14 | 2D 3D TSV |
US8637532 | 1511 | 692 | HGNC:8816 HGNC:10436 HGNC:11393 HGNC:11390 | Amino azaheterocyclic carboxamides | Merck Patent GmbH | 08/22/14 | 2D 3D TSV |
US8637500 | 360 | 351 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | Amgen Inc | 08/22/14 | 2D 3D TSV | |
US8637508 | 90 | 45 | HGNC:934 HGNC:933 | Heterocyclic derivatives and their use in the treatment of neurological disorders | Novartis AG | 08/22/14 | 2D 3D TSV |
US8637526 | 40 | 10 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Pyrazolopyrimidine JAK inhibitor compounds and methods | Genentech Inc | 08/22/14 | 2D 3D TSV |
US8637504 | 37 | 37 | HGNC:933 | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity | Shionogi & Co., Ltd | 08/22/14 | 2D 3D TSV |
US8637528 | 8 | 4 | HGNC:8791 HGNC:8792 | Use of PDE7 inhibitors for the treatment of movement disorders | Omeros Corporation | 08/22/14 | 2D 3D TSV |
US8633204 | 174 | 173 | HGNC:8975 | 4-methylpyridopyrimidinone compounds | Pfizer Inc | 08/06/14 | 2D 3D TSV |
US8633208 | 48 | 24 | HGNC:6833 HGNC:6834 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | Rottapharm S.p.A | 08/06/14 | 2D 3D TSV |
US8633188 | 60 | 60 | HGNC:933 | Aminodihydrothiazine derivatives | Shionogi & Co., Ltd | 08/06/14 | 2D 3D TSV |
US8637501 | 113 | 111 | HGNC:4479 | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof | Albany Molecular Research, Inc. | 08/06/14 | 2D 3D TSV |
US8633196 | 19 | 18 | HGNC:195 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | Galderma Research & Development | 08/06/14 | 2D 3D TSV |
US8637507 | 15 | 14 | HGNC:2843 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | Merck Sharp & Dohme Corp | 08/06/14 | 2D 3D TSV |
US8633212 | 166 | 163 | Inhibitors of beta-secretase | Vitae Pharmaceuticals Inc | 08/06/14 | 2D 3D TSV | |
US8633226 | 5 | 5 | HGNC:1602 | Piperidinyl derivative as a modulator of chemokine receptor activity | Bristol-Myers Squibb Co. | 08/06/14 | 2D 3D TSV |
US8633206 | 417 | 139 | HGNC:6190 HGNC:6192 HGNC:6193 | Pyrrolo[2,3-D]pyrimidine compounds | Pfizer Inc | 08/06/14 | 2D 3D TSV |
US8633231 | 20 | 20 | HGNC:4192 | Substituted imidazolones, compositions containing such compounds and methods of use | Merck Sharp & Dohme Corp | 08/05/14 | 2D 3D TSV |
US8629158 | 46 | 40 | HGNC:4479 | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof | Albany Molecular Research, Inc. | 07/28/14 | 2D 3D TSV |
US8623860 | 151 | 150 | HGNC:85 | Azetidine derivatives, pharmaceutical compositions and uses thereof | Boehringer Ingelheim International GmbH | 07/28/14 | 2D 3D TSV |
US8623863 | 24 | 12 | HGNC:4849 | Disubstituted azepan orexin receptor antagonists | Merck Sharp & Dohme Corp | 07/28/14 | 2D 3D TSV |
US8629282 | 13 | 13 | HGNC:3165 | Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases | Bristol-Myers Squibb Co. | 07/28/14 | 2D 3D TSV |
US8629135 | 14 | 13 | HGNC:9967 | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer | Queen's University at Kingston | 07/28/14 | 2D 3D TSV |
US8629167 | 93 | 93 | Selective androgen receptor modulators | Radius Health, Inc. | 07/28/14 | 2D 3D TSV | |
US8628961 | 13 | 7 | HGNC:391 HGNC:8816 HGNC:9504 | Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (PIP3) and uses thereof | Tufts University | 07/28/14 | 2D 3D TSV |
US8629141 | 39 | 39 | HGNC:6973 | Spiro-oxindole MDM2 antagonists | University of Michigan | 07/28/14 | 2D 3D TSV |
US8629154 | 10 | 5 | HGNC:5301 | Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-HT6 receptors and methods for production and the use thereof | TBA | 07/28/14 | 2D 3D TSV |
US8623883 | 20 | 7 | HGNC:3432 HGNC:3430 HGNC:3236 | 4-phenylamino-quinazolin-6-yl-amides | Warner-Lambert Company LLC | 07/22/14 | 2D 3D TSV |
US8623865 | 3 | 3 | Acylpiperazinones and their use as pharmaceuticals | Fab Pharma S.A.S. | 07/22/14 | 2D 3D TSV | |
US8623901 | 43 | 43 | HGNC:8795 | Compounds for the treatment of CNS disorders | Boehringer Ingelheim International GmbH | 07/22/14 | 2D 3D TSV |
US8623885 | 48 | 26 | HGNC:1773 HGNC:3765 | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 | Amgen Inc | 07/22/14 | 2D 3D TSV |
US8618103 | 236 | 119 | HGNC:6192 HGNC:6193 | Inhibitors of JAK | Hoffmann-La Roche Inc | 07/22/14 | 2D 3D TSV |
US8623892 | 13 | 4 | HGNC:2593 HGNC:2637 HGNC:2623 HGNC:2621 | Metalloenzyme inhibitor compounds | Viamet Pharmaceuticals Inc | 07/22/14 | 2D 3D TSV |
US8618107 | 64 | 64 | HGNC:1133 | Pyridone and aza-pyridone compounds and methods of use | Gilead Connecticut, Inc. | 07/22/14 | 2D 3D TSV |
US8623889 | 490 | 427 | HGNC:76 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | Genentech Inc | 07/22/14 | 2D 3D TSV |
US8623906 | 70 | 67 | HGNC:9644 | Carboxy isatin hydrazones and their esters as Shp2 inhibitors | H. Lee Moffitt Cancer Center and Research Institute Inc | 07/21/14 | 2D 3D TSV |
US8618114 | 79 | 55 | HGNC:5301 | Substituted 3-arylsulfonyl-pyrazolo[1,5-A]pyrimidines, serotonin 5-HT6 receptor antagonists and methods for the production and use thereof | TBA | 07/09/14 | 2D 3D TSV |
US8618111 | 284 | 141 | HGNC:8975 HGNC:3942 | 5-alkynyl-pyrimidines | Boehringer Ingelheim International GmbH | 07/08/14 | 2D 3D TSV |
US8618286 | 87 | 29 | HGNC:7872 HGNC:7873 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NeurAxon Inc | 07/08/14 | 2D 3D TSV |
US8618075 | 9 | 9 | HGNC:1712 | Certain compounds, compositions and methods | Eisai Inc. | 07/08/14 | 2D 3D TSV |
US8623903 | 17 | 17 | HGNC:4502 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | Shionogi & Co., Ltd | 07/08/14 | 2D 3D TSV |
US8618098 | 4 | 4 | HGNC:1133 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto LLC | 07/08/14 | 2D 3D TSV |
US8618147 | 16 | 16 | Modified macrophage migration inhibitory factor inhibitors | The Feinstein Institute for Medical Research | 07/08/14 | 2D 3D TSV | |
US8624022 | 14 | 7 | Substituted aniline derivatives | UCB Pharma SA | 07/08/14 | 2D 3D TSV | |
US8618158 | 80 | 78 | HGNC:6973 | Therapeutic agents | Cancer Research Technology Limited | 07/08/14 | 2D 3D TSV |
US8614253 | 302 | 272 | HGNC:3449 | IRE-1α inhibitors | MannKind Corporation | 06/25/14 | 2D 3D TSV |
US8614234 | 165 | 146 | HGNC:3763 HGNC:6307 | Compounds as tyrosine kinase modulators | Allergan Inc | 06/24/14 | 2D 3D TSV |
US8618290 | 17 | 17 | HGNC:5253 | HSP90 inhibitors | Takeda Pharmaceutical Co., Ltd | 06/24/14 | 2D 3D TSV |
US8613914 | 197 | 197 | Peptidomimetic sulfamide compounds and antiviral uses thereof | Novartis AG | 06/24/14 | 2D 3D TSV | |
US8614206 | 289 | 215 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. Hoffmann-La Roche Inc | 06/24/14 | 2D 3D TSV | |
US8614215 | 103 | 103 | HGNC:8978 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | Merck Serono | 06/24/14 | 2D 3D TSV |
US8618299 | 55 | 52 | HGNC:4479 | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof | Albany Molecular Research, Inc. | 06/16/14 | 2D 3D TSV |
US8609647 | 91 | 67 | HGNC:6192 HGNC:6193 | Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof | Japan Tobacco Inc | 06/16/14 | 2D 3D TSV |
US8618303 | 36 | 35 | HGNC:11528 | Pyrrolidine derivatives | Hoffmann-La Roche Inc | 06/16/14 | 2D 3D TSV |
US8609678 | 365 | 176 | HGNC:14064 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | Acetylon Pharmaceuticals Inc | 06/16/14 | 2D 3D TSV |
US8609681 | 72 | 24 | HGNC:2527 HGNC:2536 HGNC:2545 | Spirocyclic nitriles as protease inhibitors | Sanofi | 06/16/14 | 2D 3D TSV |
US8609708 | 141 | 89 | HGNC:2637 HGNC:2610 | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer | Human BioMolecular Research Institute | 06/16/14 | 2D 3D TSV |
US8604061 | 221 | 221 | 2-aminooxazolines as TAAR1 ligands | Hoffmann-La Roche Inc | 06/04/14 | 2D 3D TSV | |
US8609666 | 67 | 67 | HGNC:8975 | 2-morpholino-pyrido[3,2-D]pyrimidines | Merck Serono | 06/04/14 | 2D 3D TSV |
US8609622 | 20 | 7 | C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof | Shanghai Hengrui Pharmaceutical Co., Ltd | 06/04/14 | 2D 3D TSV | |
US8609710 | 29 | 29 | HGNC:2300 | Cycloalkyl-substituted imidazole derivative | Daiichi Sankyo Company, Limited | 06/04/14 | 2D 3D TSV |
US8609715 | 258 | 129 | HGNC:9490 HGNC:9475 | Heteroarylcarboxylic acid ester derivative | Ajinomoto Co. Inc | 06/04/14 | 2D 3D TSV |
US8609698 | 8 | 8 | HGNC:28858 | Substituted dipyridyl-dihydropyrazolones and use thereof | Bayer Intellectual Property GmbH | 06/04/14 | 2D 3D TSV |
US8604028 | 6 | 6 | HGNC:7029 | Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof | Bayer Intellectual Property GmbH | 05/13/14 | 2D 3D TSV |
US8609852 | 103 | 102 | Thiazolyl mGluR5 antagonists and methods for their use | Merck Sharp & Dohme Corp | 05/13/14 | 2D 3D TSV | |
US8604206 | 18 | 7 | HGNC:4177 | Compositions for preventing and/or treating degenerative disorders of the central nervous system | Amicus Therapeutics, Inc | 05/12/14 | 2D 3D TSV |
US8604016 | 694 | 665 | Heterocyclic inhibitors of glutaminase | Calithera Biosciences Inc | 05/12/14 | 2D 3D TSV | |
US8609688 | 36 | 20 | HGNC:391 | Substituted imidazopyridinyl-aminopyridine compounds | ArQule Inc | 05/12/14 | 2D 3D TSV |
US8604217 | 78 | 78 | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent | Selvita S.A. | 05/05/14 | 2D 3D TSV | |
US8609892 | 2 | 2 | HGNC:4191 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly and Company | 05/05/14 | 2D 3D TSV |
US8598119 | 47 | 11 | HGNC:3023 HGNC:11050 HGNC:5295 HGNC:277 HGNC:4714 | Methods and compositions for sleep disorders and other disorders | Intra-Cellular Therapies Inc | 05/05/14 | 2D 3D TSV |
US8609833 | 18 | 6 | HGNC:268 HGNC:262 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | Inotek Pharmaceuticals Corporation | 05/05/14 | 2D 3D TSV |
US8604046 | 69 | 69 | Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | Sanofi | 05/05/14 | 2D 3D TSV | |
US8598157 | 90 | 89 | HGNC:8975 | 5-alkynyl-pyridines | Boehringer Ingelheim International GmbH | 04/28/14 | 2D 3D TSV |
US8598163 | 45 | 24 | HGNC:5208 | Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders | Vitae Pharmaceuticals Inc | 04/28/14 | 2D 3D TSV |
US8598184 | 5 | 5 | HGNC:7029 | Protein kinase inhibitors | Tiger Pharmatech | 04/28/14 | 2D 3D TSV |
US8598172 | 6 | 2 | HGNC:2154 HGNC:9077 HGNC:19699 | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | Nerviano Medical Sciences srl | 04/28/14 | 2D 3D TSV |
US8598206 | 241 | 23 | HGNC:9051 HGNC:3530 HGNC:9451 HGNC:6371 HGNC:3528 HGNC:3529 HGNC:1246 HGNC:4646 HGNC:9071 HGNC:1247 | Trypsin-like serine protease inhibitors, and their preparation and use | The Medicines Company (Leipzig) GmbH | 04/28/14 | 2D 3D TSV |
US8604218 | 166 | 165 | HGNC:10252 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | Inspire Pharmaceuticals, Inc. | 04/18/14 | 2D 3D TSV |
US8598155 | 86 | 84 | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | Pfizer Inc | 04/18/14 | 2D 3D TSV | |
US8598217 | 20 | 20 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | Astex Therapeutics Ltd | 04/18/14 | 2D 3D TSV | |
US8598200 | 29 | 29 | HGNC:17929 | KAT II inhibitors | Pfizer Inc | 04/18/14 | 2D 3D TSV |
US8598210 | 55 | 24 | HGNC:1232 HGNC:12680 HGNC:14661 | Prolyl hydroxylase inhibitors and methods of use | Akebia Therapeutics, Inc. | 04/18/14 | 2D 3D TSV |
US8592371 | 8 | 8 | HGNC:3009 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | Merck Sharpe & Dohme Corp. | 04/14/14 | 2D 3D TSV |
US8592426 | 124 | 60 | HGNC:6383 | Aryl-benzocycloalkyl amide derivatives | Hoffmann-La Roche Inc | 04/14/14 | 2D 3D TSV |
US8598357 | 237 | 79 | HGNC:3023 HGNC:3024 | Benzodioxole piperidine compounds | Hoffmann-La Roche Inc | 04/14/14 | 2D 3D TSV |
US8592432 | 61 | 61 | HGNC:427 | Compounds and compositions as protein kinase inhibitors | TBA | 04/14/14 | 2D 3D TSV |
US8592410 | 135 | 34 | HGNC:2637 HGNC:5208 HGNC:2623 HGNC:2621 | Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1 | Vitae Pharmaceuticals Inc | 04/14/14 | 2D 3D TSV |
US8575157 | 341 | 109 | HGNC:2637 HGNC:5208 HGNC:2623 HGNC:2621 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | Vitae Pharmaceuticals Inc | 04/14/14 | 2D 3D TSV |
US8592431 | 151 | 145 | HGNC:95 | Fused ring compound and use thereof | Takeda Pharmaceutical Co., Ltd | 04/14/14 | 2D 3D TSV |
US8592425 | 5 | 5 | Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors | Merck Sharp & Dohme Corp | 04/14/14 | 2D 3D TSV | |
US8592423 | 3 | 3 | HGNC:8772 | Inhibitors of PDE10 | Bristol-Myers Squibb Co. | 04/14/14 | 2D 3D TSV |
US8592379 | 11 | 9 | HGNC:4510 | Metastin derivative and use thereof | Kyoto University | 04/14/14 | 2D 3D TSV |
US8592415 | 144 | 36 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Selective kinase inhibitors | Reaction Biology Corp | 04/14/14 | 2D 3D TSV |
US8598345 | 91 | 77 | HGNC:4597 | Substituted heteroarylamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | Vanderbilt University | 04/14/14 | 2D 3D TSV |
US8592468 | 14 | 14 | Bacterial thioredoxin reductase inhibitors and methods for use thereof | Thioredoxin Systems AB | 03/17/14 | 2D 3D TSV | |
US8592457 | 5 | 5 | HGNC:4849 | Isonicotinamide orexin receptor antagonists | Merck Sharp & Dohme Corp | 03/17/14 | 2D 3D TSV |
US8592455 | 417 | 139 | HGNC:19310 HGNC:8987 | Kinase inhibitors and methods of their use | Novartis AG | 03/17/14 | 2D 3D TSV |
US8592454 | 32 | 12 | HGNC:11526 HGNC:11527 HGNC:11528 | Nitrogen-containing heterocyclic compound and use of same | Takeda Pharmaceutical Co., Ltd | 03/17/14 | 2D 3D TSV |
US8592579 | 45 | 45 | HGNC:5465 | Pyrrolotriazine kinase inhibitors | Bristol-Myers Squibb Co. | 03/17/14 | 2D 3D TSV |
US8592581 | 36 | 16 | HGNC:1780 HGNC:1771 | Trisubstituted purine derivatives | Cyclacel Limited | 03/17/14 | 2D 3D TSV |
US8586580 | 8 | 8 | HGNC:9611 | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors | Korea Institute of Science and Technology | 03/12/14 | 2D 3D TSV |
US8586617 | 104 | 103 | Aminomethyl-4-imidazoles | Hoffmann-La Roche Inc | 03/12/14 | 2D 3D TSV | |
US8586579 | 423 | 141 | HGNC:3023 HGNC:3024 | Anellated pyridine compounds | Hoffmann-La Roche Inc | 03/12/14 | 2D 3D TSV |
US8586571 | 15 | 15 | HGNC:9922 | Heterocyclic compound | Takeda Pharmaceutical Co., Ltd | 03/12/14 | 2D 3D TSV |
US8586600 | 34 | 14 | HGNC:8803 HGNC:6307 HGNC:6342 | Heterocyclic compounds and uses thereof | Celgene Avilomics Research, Inc. | 03/12/14 | 2D 3D TSV |
US8586620 | 134 | 53 | HGNC:7872 HGNC:7873 | Substituted indole compounds having NOS inhibitory activity | NeurAxon Inc | 03/12/14 | 2D 3D TSV |
US8580800 | 9 | 9 | HGNC:3309 | 1,4-diaryl-pyrimidopyridazine-2,5-diones and their use | Bayer Intellectual Property GmbH | 03/06/14 | 2D 3D TSV |
US8586597 | 5 | 5 | HGNC:8977 | 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS Corporation | 03/06/14 | 2D 3D TSV |
US8575203 | 258 | 253 | HGNC:8816 | Chemical compounds | Boehringer Ingelheim International GmbH | 03/06/14 | 2D 3D TSV |
US8580788 | 21 | 7 | HGNC:8153 HGNC:8154 HGNC:8156 | Opioid antagonists | Adolor Corporation | 03/06/14 | 2D 3D TSV |
US8575197 | 752 | 750 | HGNC:8534 | Pyrolinone derivative and pharmaceutical composition comprising the same | Shionogi & Co., Ltd | 03/06/14 | 2D 3D TSV |
US8580778 | 9 | 9 | HGNC:28858 | Substituted dihydropyrazolones and their use | Bayer Intellectual Property GmbH | 03/06/14 | 2D 3D TSV |
US8580782 | 16 | 12 | HGNC:1771 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | Merck Sharp & Dohme Corp | 03/06/14 | 2D 3D TSV |
US8575391 | 31 | 31 | HGNC:6840 | 5-substituted-2-phenylamino benzamides as MEK inhibitors | Chugai Seiyaku Kabushiki Kaisha | 02/24/14 | 2D 3D TSV |
US8575375 | 5 | 5 | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties | Research Triangle Institute | 02/24/14 | 2D 3D TSV | |
US8569291 | 11 | 10 | HGNC:16709 | Bicyclic dihydroimidazolone CGRP receptor antagonists | Merck Sharp & Dohme Corp | 02/24/14 | 2D 3D TSV |
US8569281 | 119 | 119 | HGNC:18618 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | Medical Research Council Technology | 02/24/14 | 2D 3D TSV |
US8580815 | 16 | 4 | HGNC:76 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | OriBase Pharma | 02/24/14 | 2D 3D TSV |
US8575186 | 219 | 152 | HGNC:5301 | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof | Albany Molecular Research, Inc. | 02/24/14 | 2D 3D TSV |
US8569306 | 18 | 11 | HGNC:6881 HGNC:6886 | JNK modulators | Hoffmann-La Roche Inc | 02/24/14 | 2D 3D TSV |
US8569313 | 47 | 47 | HGNC:11344 | Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors | The Medicines Company (Leipzig) GmbH | 02/24/14 | 2D 3D TSV |
US8575364 | 66 | 66 | Modulators of serotonin receptor | Janssen Pharmaceutica NV | 02/24/14 | 2D 3D TSV | |
US8575201 | 175 | 173 | HGNC:436 | Oxadiazole inhibitors of leukotriene production | Boehringer Ingelheim International GmbH | 02/24/14 | 2D 3D TSV |
US8569299 | 10 | 10 | HGNC:9344 | Prolylcarboxypeptidase inhibitors | Merck Sharp & Dohme Corp | 02/24/14 | 2D 3D TSV |
US8569311 | 48 | 24 | Pyridyl piperidine orexin receptor antagonists | Merch Sharp & Dohme Corp. | 02/24/14 | 2D 3D TSV | |
US8569316 | 64 | 64 | Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases | Boehringer Ingelheim International GmbH | 02/24/14 | 2D 3D TSV | |
USRE44599 | 5 | 5 | HGNC:8977 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS Corporation | 02/24/14 | 2D 3D TSV |
US8575114 | 43 | 22 | HGNC:11037 HGNC:11036 | SGLT-2 inhibitors, methods of making them, and uses thereof | Albany Molecular Research, Inc. | 02/24/14 | 2D 3D TSV |
US8569308 | 118 | 87 | HGNC:4597 | Substituted heteroarylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | Vanderbilt University | 02/24/14 | 2D 3D TSV |
US8569314 | 10 | 10 | HGNC:3309 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | Bayer Intellectual Property GmbH | 02/24/14 | 2D 3D TSV |
US8575145 | 329 | 116 | HGNC:8987 | Triazolopyridine compounds as PIM kinase inhibitors | Array BioPharma Inc | 02/24/14 | 2D 3D TSV |
US8569521 | 10 | 10 | HGNC:620 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | Merck Sharp & Dohme Corp | 01/21/14 | 2D 3D TSV |
US8569318 | 7 | 7 | HGNC:5301 | Tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5-HT6 receptors, methods for the production and use thereof | TBA | 01/21/14 | 2D 3D TSV |
US8569338 | 3 | 3 | HGNC:550 | Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds | Proximagen Ltd. | 01/20/14 | 2D 3D TSV |
US8563583 | 6 | 6 | HGNC:4479 | Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Co. | 01/20/14 | 2D 3D TSV |
US8569511 | 40 | 21 | HGNC:8816 | Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase | University of Utah Research Foundation | 01/20/14 | 2D 3D TSV |
US8562945 | 22 | 11 | HGNC:1373 HGNC:1383 HGNC:3590 HGNC:3009 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | Molecular Insight Pharmaceuticals, Inc. | 01/20/14 | 2D 3D TSV |
US8551988 | 144 | 97 | HGNC:4852 HGNC:13315 | Benzimidazole derivatives: preparation and pharmaceutical applications | Mei Pharma Inc | 01/14/14 | 2D 3D TSV |
US8563545 | 42 | 11 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 | Compound useful for the treatment of degenerative and inflammatory diseases | Galapagos NV | 01/14/14 | 2D 3D TSV |
US8563553 | 103 | 103 | Compounds and compositions as protein kinase inhibitors | Novartis AG | 01/14/14 | 2D 3D TSV | |
US8551978 | 95 | 93 | HGNC:1952 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | Theravance, Inc. | 01/14/14 | 2D 3D TSV |
US8551963 | 10 | 2 | HGNC:3765 | Imidazolothiazole compounds and methods of use thereof | Ambit Biosciences Corporation | 01/14/14 | 2D 3D TSV |
US8563594 | 17 | 16 | HGNC:3167 | S1P3 receptor inhibitors for treating pain | Allergan Inc | 01/14/14 | 2D 3D TSV |
US8552005 | 16 | 13 | HGNC:5301 | (EN) 3-sulfonyl-pyrazolo[1,5-a] pyrimidines / antagonists of serotonin 5-HT6 receptors, methods for the production and the use thereof | Avincuro Pharmaceuticals, Inc. | 01/03/14 | 2D 3D TSV |
US8552017 | 4 | 4 | HGNC:5301 | 2-amino-3-sulphonyl-tetrahydro-pyrazolo[1,5-A]pyrido-pyrimidine antagonists of serotonin 5-HT6 receptors, methods for the production and use thereof | TBA | 01/03/14 | 2D 3D TSV |
US8552004 | 30 | 27 | HGNC:882 | Chemical compounds | AstraZeneca AB | 01/03/14 | 2D 3D TSV |
US8546370 | 24 | 23 | HGNC:12858 | Compounds and compositions as kinase inhibitors | IRM LLC | 01/03/14 | 2D 3D TSV |
US8552023 | 5 | 5 | HGNC:16709 | Non-amidic linkers with branched termini as CGRP receptor antagonists | Merck Sharp & Dohme Corp | 01/03/14 | 2D 3D TSV |
US8551989 | 12 | 8 | HGNC:7029 | Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof | Bayer Intellectual Property GmbH | 01/03/14 | 2D 3D TSV |
US8546380 | 61 | 60 | HGNC:933 | Aminodihydrothiazine derivatives | Shionogi & Co., Ltd | 12/22/13 | 2D 3D TSV |
US8552202 | 105 | 21 | HGNC:2538 HGNC:2527 HGNC:2536 HGNC:2537 HGNC:2545 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | Amura Therapeutics Limited | 12/22/13 | 2D 3D TSV |
US8552033 | 2 | 2 | HGNC:6027 | Inhibitors of CXCR2 | Sanofi | 12/22/13 | 2D 3D TSV |
US8552057 | 12 | 8 | HGNC:3467 HGNC:3468 | Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases | University of Southern California | 12/22/13 | 2D 3D TSV |
US8552037 | 42 | 21 | HGNC:7463 HGNC:7464 | Tricyclic compound and pharmaceutical use thereof | Takeda Pharmaceutical Co., Ltd | 12/22/13 | 2D 3D TSV |
US8546392 | 59 | 17 | HGNC:5211 HGNC:5210 HGNC:2637 HGNC:2625 HGNC:2623 HGNC:2621 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | Universitaet des Saarlandes | 12/09/13 | 2D 3D TSV |
US8546404 | 17 | 14 | Compounds that are ERK inhibitors | Merck Sharp & Dohme | 12/09/13 | 2D 3D TSV | |
US8552199 | 24 | 24 | HGNC:4479 | Substituted indanes, method for the production thereof, and use thereof as drugs | Sanofi | 12/09/13 | 2D 3D TSV |
US8546434 | 14 | 14 | HGNC:6388 | Triazole compounds as KSP inhibitors | Novartis AG | 12/09/13 | 2D 3D TSV |
US8546389 | 76 | 38 | Viral polymerase inhibitors | Biota Scientific Management Pty Ltd | 12/09/13 | 2D 3D TSV | |
US8541380 | 97 | 97 | HGNC:11037 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | Green Cross Corporation | 12/03/13 | 2D 3D TSV |
US8546451 | 20 | 10 | HGNC:3467 HGNC:3468 | Estrogen receptor ligands and methods of use thereof | GTX Inc | 12/03/13 | 2D 3D TSV |
US8541363 | 4 | 4 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | St George's Hosptial Medical School | 12/03/13 | 2D 3D TSV | |
US8541407 | 230 | 230 | HGNC:391 | Substituted benzo-pyrido-triazolo-diazepine compounds | ArQule Inc | 12/03/13 | 2D 3D TSV |
US8546435 | 9 | 9 | HGNC:4267 | Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors | AEterna Zentaris GmbH | 12/03/13 | 2D 3D TSV |
US8541447 | 6 | 6 | HGNC:1960 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | Targacept Inc | 11/26/13 | 2D 3D TSV |
US8541408 | 48 | 48 | HGNC:933 | Aminodihydrothiazine derivatives substituted with a cyclic group | Shionogi & Co., Ltd | 11/26/13 | 2D 3D TSV |
US8541572 | 292 | 289 | HGNC:11892 | Compounds for the treatment of inflammatory disorders | Merck Sharp & Dohme Corp | 11/26/13 | 2D 3D TSV |
US8541596 | 10 | 10 | HGNC:9753 | Inhibitors | Probiodrug AG | 11/26/13 | 2D 3D TSV |
US8541427 | 45 | 43 | HGNC:933 | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use | Merck Sharp & Dohme Corp | 11/26/13 | 2D 3D TSV |
US8536165 | 55 | 55 | HGNC:2867 | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | Almirall, S.A. | 11/18/13 | 2D 3D TSV |
US8536158 | 8 | 8 | HGNC:4502 | Compounds having CRTH2 antagonist activity | Atopix Therapeutics Limited | 11/18/13 | 2D 3D TSV |
US8536166 | 4 | 4 | HGNC:1133 | Inhibitors of Burton's tyrosine kinase | Roche Palo Alto LLC | 11/18/13 | 2D 3D TSV |
US8536172 | 106 | 66 | HGNC:6881 | Inhibitors of JNK | Roche Palo Alto LLC | 11/18/13 | 2D 3D TSV |
US8536175 | 50 | 50 | HGNC:3690 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | Novartis AG | 11/18/13 | 2D 3D TSV |
US8536173 | 10 | 10 | HGNC:5208 | Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I | Sanofi | 11/18/13 | 2D 3D TSV |
US8536192 | 53 | 31 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | Shionogi & Co., Ltd | 11/11/13 | 2D 3D TSV | |
US8536210 | 19 | 19 | HGNC:550 | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases | Semmelweis Egyetem | 11/11/13 | 2D 3D TSV |
US8536193 | 14 | 8 | HGNC:391 HGNC:392 | Inhibitors of AKT activity | Merck Sharp & Dohme Corp | 11/11/13 | 2D 3D TSV |
US8536198 | 23 | 23 | HGNC:1602 | Piperidine derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Co. | 11/11/13 | 2D 3D TSV |
US8536181 | 32 | 16 | HGNC:1232 HGNC:12680 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc | 11/11/13 | 2D 3D TSV |
US8530460 | 200 | 199 | Azetidine derivatives | Boehringer Ingelheim International GmbH | 11/04/13 | 2D 3D TSV | |
US8530648 | 404 | 155 | HGNC:4849 HGNC:4848 | Diaza-spiro[5.5]undecanes | Novartis AG | 11/04/13 | 2D 3D TSV |
US8536227 | 10 | 10 | HGNC:5465 | Modulators of protein kinase signaling | Novotyr Therapeutics Ltd. | 11/04/13 | 2D 3D TSV |
US8530504 | 83 | 82 | HGNC:2357 | Pyrazolothiazole compound | Eisai R&D Management Co., Ltd | 11/04/13 | 2D 3D TSV |
US8530490 | 143 | 141 | HGNC:3078 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | Taiho Pharmaceutical Co., Ltd | 11/04/13 | 2D 3D TSV |
US8530494 | 94 | 31 | HGNC:8153 HGNC:8154 HGNC:8156 HGNC:21378 | Buprenophine analogs | Purdue Pharma LP | 10/25/13 | 2D 3D TSV |
US8530670 | 5 | 5 | HGNC:9753 | Inhibitors | Probiodrug AG | 10/25/13 | 2D 3D TSV |
US8524716 | 27 | 26 | Macrocyclic indoles as hepatitis C virus inhibitors | Janssen Ireland | 10/25/13 | 2D 3D TSV | |
US8524710 | 86 | 83 | HGNC:2545 | Pyrrolidine derivatives | Hoffmann-La Roche Inc | 10/25/13 | 2D 3D TSV |
US8530652 | 86 | 82 | HGNC:16059 | Pyrrolopyrazoles, potent kinase inhibitors | Agouron Pharmaceuticals Inc | 10/25/13 | 2D 3D TSV |
US8524699 | 11 | 11 | HGNC:28858 | Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors | Bayer Intellectual Property GmbH | 10/25/13 | 2D 3D TSV |
US8507477 | 10 | 10 | HGNC:16709 | 3- and 6-quinolines with N-attached heterocyclic CGRP receptor antagonists | Merck Sharp & Dohme Corp | 10/18/13 | 2D 3D TSV |
US8524917 | 157 | 154 | HGNC:3167 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | Allergan Inc | 10/18/13 | 2D 3D TSV |
US8507479 | 48 | 48 | HGNC:933 | Aminodihydrothiazine derivatives substituted with a cyclic group | Shionogi & Co., Ltd | 10/18/13 | 2D 3D TSV |
US8524717 | 175 | 59 | HGNC:6833 HGNC:6834 HGNC:29079 | Oxidase inhibitors and their use | Oryzon Genomics, S.A. | 10/18/13 | 2D 3D TSV |
US8524722 | 21 | 21 | HGNC:3236 | Substituted tricyclic compounds and methods of use thereof | Bayer Intellectual Property GmbH | 10/18/13 | 2D 3D TSV |
US8507510 | 190 | 60 | HGNC:6307 HGNC:1771 HGNC:1722 | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents | Bayer Intellectual Property GmbH | 10/18/13 | 2D 3D TSV |
US8524909 | 65 | 50 | Tetrahydro-pyran derivatives | Hoffmann-La Roche Inc | 10/18/13 | 2D 3D TSV | |
US8507714 | 18 | 17 | HGNC:2097 | 7-membered ring compound and method of production and pharmaceutical application thereof | Daiichi Sankyo Company, Limited | 10/07/13 | 2D 3D TSV |
US8501732 | 211 | 210 | HGNC:6881 | Aminomethyl quinolone compounds | Hoffmann-La Roche Inc | 10/07/13 | 2D 3D TSV |
US8507683 | 7 | 7 | Compounds for the treatment of hepatitis C | Bristol-Myers Squibb Co. | 10/07/13 | 2D 3D TSV | |
US8507533 | 84 | 74 | HGNC:4191 | Glucagon receptor modulators | Pfizer Inc | 10/07/13 | 2D 3D TSV |
US8507676 | 92 | 88 | HGNC:7029 | Heterocyclic oxime compounds | Novartis AG | 10/07/13 | 2D 3D TSV |
US8507535 | 25 | 25 | HGNC:11528 | Methyl-pyrrolidine ether derivatives | Hoffmann-La Roche Inc | 10/07/13 | 2D 3D TSV |
US8501749 | 31 | 31 | HGNC:2097 | Azaquinazolinediones chymase inhibitors | Boehringer Ingelheim International GmbH | 09/30/13 | 2D 3D TSV |
US8501981 | 6 | 6 | HGNC:6027 | CXCR2 inhibitors | Sanofi | 09/30/13 | 2D 3D TSV |
US8501783 | 79 | 76 | HGNC:3401 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | The Regents of the University of California | 09/30/13 | 2D 3D TSV |
US8501944 | 20 | 4 | HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11491 | Inhibitors of protein kinases | Portola Pharmaceuticals Inc | 09/30/13 | 2D 3D TSV |
US8501744 | 22 | 22 | HGNC:2536 | Piperazine compounds | Amura Therapeutics Limited | 09/30/13 | 2D 3D TSV |
US8501729 | 34 | 34 | HGNC:5297 | 5-HT3 receptor modulators, methods of making, and use thereof | Albany Molecular Research, Inc. | 09/16/13 | 2D 3D TSV |
US8501961 | 20 | 20 | HIV protease inhibitors and methods for using | Purdue Research Foundation | 09/16/13 | 2D 3D TSV | |
US8501750 | 52 | 52 | HGNC:336 | Heterocyclic compound and use thereof | Takeda Pharmaceutical Co., Ltd | 09/16/13 | 2D 3D TSV |
US8501767 | 18 | 18 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR, Pretoria (ZA) | 09/16/13 | 2D 3D TSV | |
US8501991 | 6 | 6 | HGNC:14929 | P53 activating compounds | University Court of the University of Dundee | 09/16/13 | 2D 3D TSV |
US8501936 | 1030 | 365 | HGNC:6192 HGNC:6193 HGNC:9611 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | Cephalon Inc | 09/16/13 | 2D 3D TSV |
US8497281 | 179 | 176 | HGNC:5208 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | Vitae Pharmaceuticals Inc | 09/10/13 | 2D 3D TSV |
US8497274 | 6 | 6 | HGNC:6840 | Heterocyclic compound and use thereof | Takeda Pharmaceutical Co., Ltd | 09/10/13 | 2D 3D TSV |
US8497368 | 81 | 80 | HGNC:7029 | Heterocyclic hydrazone compounds | Novartis AG | 09/10/13 | 2D 3D TSV |
US8501768 | 36 | 36 | HGNC:6621 | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds | Hoffmann-La Roche Inc | 09/10/13 | 2D 3D TSV |
US8501708 | 57 | 18 | Adenosine compounds and their use thereof | Inotek Pharmaceuticals Corporation | 09/09/13 | 2D 3D TSV | |
US8497265 | 327 | 320 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | Amgen Inc | 09/09/13 | 2D 3D TSV | |
US8497385 | 6 | 6 | Bryostatin analogues, synthetic methods and uses | The Board of Trustees of the Leland Stanford Junior University | 09/03/13 | 2D 3D TSV | |
US8497288 | 40 | 40 | HGNC:6621 | Hexahydropyrroloimidazolone compounds | Hoffmann-La Roche Inc | 09/03/13 | 2D 3D TSV |
US8497277 | 12 | 9 | HGNC:1133 | Inhibitors of Bruton's tyrosine kinase | Pharmacyclics Inc | 09/03/13 | 2D 3D TSV |
US8497376 | 27 | 27 | Inhibitors of c-fms kinase | Janssen Pharmaceutica NV | 09/03/13 | 2D 3D TSV | |
US8497270 | 8 | 8 | Macrocyclic integrase inhibitors | Elanco Animal Health Ireland Limited | 09/03/13 | 2D 3D TSV | |
US8497286 | 18 | 17 | HGNC:9958 | Organic compounds | Novartis AG | 09/03/13 | 2D 3D TSV |
US8487093 | 224 | 111 | ß-lactamase inhibitors | Merck Sharp & Dohme Corp | 09/03/13 | 2D 3D TSV | |
US8470847 | 15 | 14 | HGNC:3767 | Derivatives of 7-alkynyl-1,8-Naphthyridones, Preparation Method Therefore and Use of Same in Therapeutics | Sanofi | 08/29/13 | 2D 3D TSV |
US8476306 | 120 | 29 | Urokinase inhibitors, production and use thereof | The Medicines Company | 08/29/13 | 2D 3D TSV | |
US8492394 | 16 | 15 | HGNC:8772 | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors | H. Lundbeck A/S | 08/28/13 | 2D 3D TSV |
US8492387 | 9 | 9 | HGNC:933 | 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease | Merck Sharp & Dohme Corp | 08/28/13 | 2D 3D TSV |
US8492392 | 17 | 17 | HGNC:8772 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | Merck Sharp & Dohme Corp | 08/28/13 | 2D 3D TSV |
US8492408 | 4 | 4 | HGNC:4075 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | Aniona APS | 08/28/13 | 2D 3D TSV |
US8492568 | 1 | 1 | HGNC:18084 | Chromane derivatives as TRPV3 modulators | Glenmark Pharamceuticals S.A. | 08/28/13 | 2D 3D TSV |
US8492564 | 11 | 11 | HGNC:8154 | Salvinorin derivatives and uses thereof | The McLean Hospital Corporation | 08/28/13 | 2D 3D TSV |
US8486940 | 185 | 184 | HGNC:9753 | Inhibitors | Probiodrug AG | 08/19/13 | 2D 3D TSV |
US8486989 | 1 | 1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | Vertex Pharmaceuticals Inc | 08/19/13 | 2D 3D TSV | |
US8481733 | 348 | 346 | HGNC:19297 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals LLC | 08/19/13 | 2D 3D TSV |
US8487111 | 8 | 4 | HGNC:3528 HGNC:3535 | Substituted oxazolidinones and their use | Bayer Intellectual Property GmbH | 08/19/13 | 2D 3D TSV |
US8492379 | 10 | 10 | Translocator protein ligands | The University of Sydney | 08/19/13 | 2D 3D TSV | |
US8486966 | 24 | 22 | HGNC:6192 HGNC:8031 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | AstraZeneca AB | 08/12/13 | 2D 3D TSV |
US8481536 | 323 | 262 | HGNC:8804 HGNC:3395 HGNC:11283 HGNC:12841 | Benzotriazine inhibitors of kinases | TargeGen Inc | 08/12/13 | 2D 3D TSV |
US8487096 | 5 | 5 | HGNC:7029 | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors | Incyte Corporation | 08/12/13 | 2D 3D TSV |
US8481743 | 8 | 4 | HGNC:8155 HGNC:8156 | Phenylpropionamide compounds and the use thereof | Purdue Pharma LP | 08/12/13 | 2D 3D TSV |
US8481586 | 11 | 6 | HGNC:19310 HGNC:8987 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | Centre National de la Recherche Scientifique | 08/12/13 | 2D 3D TSV |
US8486953 | 20 | 10 | HGNC:7110 HGNC:7111 | Thienopyrimidines for pharmaceutical compositions | Boehringer Ingelheim International GmbH | 08/12/13 | 2D 3D TSV |
US8476225 | 66 | 66 | Antiviral compounds | Gilead Sciences Inc | 08/05/13 | 2D 3D TSV | |
US8486964 | 9 | 3 | HGNC:5208 | Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | Merck Patent GmbH | 08/05/13 | 2D 3D TSV |
US8476267 | 8 | 8 | HGNC:4617 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | Bayer Intellectual Property GmbH | 08/05/13 | 2D 3D TSV |
US8481564 | 14 | 14 | Inhibitors of c-fms kinase | Janssen Pharmaceutica NV | 08/05/13 | 2D 3D TSV | |
US8476271 | 28 | 7 | HGNC:8154 HGNC:8155 HGNC:8156 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | Purdue Pharma LP | 08/05/13 | 2D 3D TSV |
US8476295 | 12 | 6 | Bridged bicyclic RHO kinase inhibitor compounds, composition and use | Inspire | 07/29/13 | 2D 3D TSV | |
US8476255 | 38 | 30 | Histone deacetylase inhibitors | Orchid Chemicals & Pharmaceuticals Limited | 07/29/13 | 2D 3D TSV | |
US8476284 | 14 | 12 | HGNC:6735 HGNC:1133 HGNC:6524 | Inhibitors of Bruton's tyrosine kinase | Pharmacyclics Inc | 07/29/13 | 2D 3D TSV |
US8470843 | 15 | 14 | HGNC:6621 | Azacyclic compounds | Hoffmann-La Roche Inc | 07/24/13 | 2D 3D TSV |
US8470888 | 8 | 6 | HGNC:74 | Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer | The United States of America, as represented by the Secretary, Department of Health and Human Services | 07/24/13 | 2D 3D TSV |
US8470836 | 40 | 22 | HGNC:16490 HGNC:18648 HGNC:3009 HGNC:14892 | Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent | LG Life Sciences Ltd | 07/24/13 | 2D 3D TSV |
US8470841 | 39 | 33 | HGNC:84 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | Sanofi | 07/24/13 | 2D 3D TSV |
US8470837 | 44 | 44 | MAPK/ERK kinase inhibitors | Takeda Pharmaceutical Co., Ltd | 07/24/13 | 2D 3D TSV | |
US8470835 | 3 | 1 | HGNC:6307 HGNC:11491 | Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase | Glaxo Group Limited | 07/24/13 | 2D 3D TSV |
US8470825 | 17 | 17 | HGNC:270 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | Eisai Inc. | 07/08/13 | 2D 3D TSV |
US8470800 | 10 | 10 | HGNC:262 | Method of reducing intraocular pressure in humans | Inotek Pharmaceuticals Corporation | 07/08/13 | 2D 3D TSV |
US8470820 | 64 | 63 | HGNC:8772 | Nitrogen-containing heteroaryl derivatives | Hoffman-La Roche Inc | 07/08/13 | 2D 3D TSV |
US8470816 | 43 | 20 | HGNC:11526 HGNC:11527 HGNC:11521 | Nitrogen-containing heterocyclic compound and use thereof | Takeda Pharmaceutical Co., Ltd | 07/08/13 | 2D 3D TSV |
US20130102619 | 122 | 38 | HGNC:4849 HGNC:4848 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | TBA | 06/25/13 | 2D 3D TSV |
US20130089624 | 1 | 1 | HGNC:882 | Compounds useful as inhibitors of atr kinase | Vertex Pharmaceuticals Inc | 06/24/13 | 2D 3D TSV |